ID   TMPS2_HUMAN             Reviewed;         492 AA.
AC   O15393; A8K6Z8; B2R8E5; B7Z459; D3DSJ2; F8WES1; Q6GTK7; Q9BXX1;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 3.
DT   12-AUG-2020, entry version 190.
DE   RecName: Full=Transmembrane protease serine 2 {ECO:0000305};
DE            EC=3.4.21.-;
DE   AltName: Full=Serine protease 10 {ECO:0000305};
DE   Contains:
DE     RecName: Full=Transmembrane protease serine 2 non-catalytic chain;
DE   Contains:
DE     RecName: Full=Transmembrane protease serine 2 catalytic chain;
DE   Flags: Precursor;
GN   Name=TMPRSS2 {ECO:0000312|HGNC:HGNC:11876}; Synonyms=PRSS10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS MET-160 AND GLN-329.
RX   PubMed=9325052; DOI=10.1006/geno.1997.4845;
RA   Paoloni-Giacobino A., Chen H., Peitsch M.C., Rossier C., Antonarakis S.E.;
RT   "Cloning of the TMPRSS2 gene, which encodes a novel serine protease with
RT   transmembrane, LDLRA, and SRCR domains and maps to 21q22.3.";
RL   Genomics 44:309-320(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-160.
RX   PubMed=11414763; DOI=10.1006/geno.2001.6551;
RA   Teng D.-H., Chen Y., Lian L., Ha P.C., Tavtigian S.V., Wong A.K.C.;
RT   "Mutation analyses of 268 candidate genes in human tumor cell lines.";
RL   Genomics 74:352-364(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), MUTAGENESIS OF SER-441, FUNCTION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=11245484;
RA   Afar D.E.H., Vivanco I., Hubert R.S., Kuo J., Chen E., Saffran D.C.,
RA   Raitano A.B., Jakobovits A.;
RT   "Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in
RT   its secretion by prostate and prostate cancer epithelia.";
RL   Cancer Res. 61:1686-1692(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Prostate, Testis, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.-S.,
RA   Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y., Soeda E., Ohki M.,
RA   Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U.,
RA   Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A.,
RA   Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J.,
RA   Shibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K.,
RA   Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G.,
RA   Hornischer K., Brandt P., Scharfe M., Schoen O., Desario A., Reichelt J.,
RA   Kauer G., Bloecker H., Ramser J., Beck A., Klages S., Hennig S.,
RA   Riesselmann L., Dagand E., Wehrmeyer S., Borzym K., Gardiner K.,
RA   Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=PNS;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=11169526;
RX   DOI=10.1002/1096-9896(2000)9999:9999<::aid-path743>3.0.co;2-t;
RA   Vaarala M.H., Porvari K.S., Kellokumpu S., Kyllonen A.P., Vihko P.T.;
RT   "Expression of transmembrane serine protease TMPRSS2 in mouse and human
RT   tissues.";
RL   J. Pathol. 193:134-140(2001).
RN   [10]
RP   FUNCTION.
RX   PubMed=15537383; DOI=10.1042/bj20041066;
RA   Wilson S., Greer B., Hooper J., Zijlstra A., Walker B., Quigley J.,
RA   Hawthorne S.;
RT   "The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in
RT   prostate cancer cells.";
RL   Biochem. J. 388:967-972(2005).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND GLYCOSYLATION.
RX   PubMed=20382709; DOI=10.2353/ajpath.2010.090665;
RA   Chen Y.W., Lee M.S., Lucht A., Chou F.P., Huang W., Havighurst T.C.,
RA   Kim K., Wang J.K., Antalis T.M., Johnson M.D., Lin C.Y.;
RT   "TMPRSS2, a serine protease expressed in the prostate on the apical surface
RT   of luminal epithelial cells and released into semen in prostasomes, is
RT   misregulated in prostate cancer cells.";
RL   Am. J. Pathol. 176:2986-2996(2010).
RN   [12]
RP   FUNCTION (MICROBIAL INFECTION), SUBCELLULAR LOCATION, AUTOCATALYTIC
RP   CLEAVAGE, AND INTERACTION WITH ACE2.
RX   PubMed=21068237; DOI=10.1128/jvi.02062-10;
RA   Shulla A., Heald-Sargent T., Subramanya G., Zhao J., Perlman S.,
RA   Gallagher T.;
RT   "A transmembrane serine protease is linked to the severe acute respiratory
RT   syndrome coronavirus receptor and activates virus entry.";
RL   J. Virol. 85:873-882(2011).
RN   [13]
RP   FUNCTION (MICROBIAL INFECTION), AND TISSUE SPECIFICITY.
RX   PubMed=21325420; DOI=10.1128/jvi.02232-10;
RA   Glowacka I., Bertram S., Muller M.A., Allen P., Soilleux E., Pfefferle S.,
RA   Steffen I., Tsegaye T.S., He Y., Gnirss K., Niemeyer D., Schneider H.,
RA   Drosten C., Pohlmann S.;
RT   "Evidence that TMPRSS2 activates the severe acute respiratory syndrome
RT   coronavirus spike protein for membrane fusion and reduces viral control by
RT   the humoral immune response.";
RL   J. Virol. 85:4122-4134(2011).
RN   [14]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=23536651; DOI=10.1128/jvi.03372-12;
RA   Bertram S., Dijkman R., Habjan M., Heurich A., Gierer S., Glowacka I.,
RA   Welsch K., Winkler M., Schneider H., Hofmann-Winkler H., Thiel V.,
RA   Pohlmann S.;
RT   "TMPRSS2 activates the human coronavirus 229E for cathepsin-independent
RT   host cell entry and is expressed in viral target cells in the respiratory
RT   epithelium.";
RL   J. Virol. 87:6150-6160(2013).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=23966399; DOI=10.1128/jvi.01490-13;
RA   Abe M., Tahara M., Sakai K., Yamaguchi H., Kanou K., Shirato K., Kawase M.,
RA   Noda M., Kimura H., Matsuyama S., Fukuhara H., Mizuta K., Maenaka K.,
RA   Ami Y., Esumi M., Kato A., Takeda M.;
RT   "TMPRSS2 is an activating protease for respiratory parainfluenza viruses.";
RL   J. Virol. 87:11930-11935(2013).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=24027332; DOI=10.1128/jvi.01890-13;
RA   Shirato K., Kawase M., Matsuyama S.;
RT   "Middle East respiratory syndrome coronavirus infection mediated by the
RT   transmembrane serine protease TMPRSS2.";
RL   J. Virol. 87:12552-12561(2013).
RN   [17]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=24227843; DOI=10.1128/jvi.02202-13;
RA   Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O.,
RA   Poehlmann S.;
RT   "TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by
RT   TMPRSS2 augments entry driven by the severe acute respiratory syndrome
RT   coronavirus spike protein.";
RL   J. Virol. 88:1293-1307(2014).
RN   [18]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=25122198; DOI=10.1158/2159-8290.cd-13-1010;
RA   Lucas J.M., Heinlein C., Kim T., Hernandez S.A., Malik M.S., True L.D.,
RA   Morrissey C., Corey E., Montgomery B., Mostaghel E., Clegg N., Coleman I.,
RA   Brown C.M., Schneider E.L., Craik C., Simon J.A., Bedalov A., Nelson P.S.;
RT   "The androgen-regulated protease TMPRSS2 activates a proteolytic cascade
RT   involving components of the tumor microenvironment and promotes prostate
RT   cancer metastasis.";
RL   Cancer Discov. 4:1310-1325(2014).
RN   [19]
RP   FUNCTION.
RX   PubMed=26018085; DOI=10.1158/0008-5472.can-14-3297;
RA   Ko C.J., Huang C.C., Lin H.Y., Juan C.P., Lan S.W., Shyu H.Y., Wu S.R.,
RA   Hsiao P.W., Huang H.P., Shun C.T., Lee M.S.;
RT   "Androgen-Induced TMPRSS2 activates matriptase and promotes extracellular
RT   matrix degradation, prostate cancer cell invasion, tumor growth, and
RT   metastasis.";
RL   Cancer Res. 75:2949-2960(2015).
RN   [20]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor.";
RL   Cell 181:1-10(2020).
RN   [21]
RP   TISSUE SPECIFICITY.
RX   DOI=10.1016/j.cell.2020.04.035;
RA   Ziegler C.G.K., Allon S.J., Nyquist S.K., Mbano I.M., Miao V.N.,
RA   Tzouanas C.N., Cao Y., Yousif A.S., Bals J., Hauser B.M., Feldman J.,
RA   Muus C., Wadsworth M.H., Kazer S.W., Hughes T.K., Doran B., Gatter G.J.,
RA   Vukovic M., Taliaferro F., Mead B.E., Guo Z., Wang J.P., Gras D.,
RA   Plaisant M., Ansari M., Angelidis I., Adler H., Sucre J.M.S., Taylor C.J.,
RA   Lin B., Waghray A., Mitsialis V., Dwyer D.F., Buchheit K.M., Boyce J.A.,
RA   Barrett N.A., Laidlaw T.M., Carroll S.L., Colonna L., Tkachev V.,
RA   Peterson C.W., Yu A., Zheng H.B., Gideon H.P., Winchell C.G., Lin P.L.,
RA   Bingle C.D., Snapper S.B., Kropski J.A., Theis F.J., Schiller H.B.,
RA   Zaragosi L.E., Barbry P., Leslie A., Kiem H.P., Flynn J.L., Fortune S.M.,
RA   Berger B., Finberg R.W., Kean L.S., Garber M., Schmidt A.G., Lingwood D.,
RA   Shalek A.K., Ordovas-Montanes J.;
RT   "SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway
RT   epithelial cells and is detected in specific cell subsets across tissues.";
RL   Cell 0:0-0(2020).
RN   [22]
RP   TISSUE SPECIFICITY.
RX   PubMed=32327758; DOI=10.1038/s41591-020-0868-6;
RG   HCA Lung Biological Network;
RA   Sungnak W., Huang N., Becavin C., Berg M., Queen R., Litvinukova M.,
RA   Talavera-Lopez C., Maatz H., Reichart D., Sampaziotis F., Worlock K.B.,
RA   Yoshida M., Barnes J.L.;
RT   "SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells
RT   together with innate immune genes.";
RL   Nat. Med. 0:0-0(2020).
RN   [23]
RP   VARIANTS MET-160; CYS-254; GLN-329 AND ASN-491.
RX   PubMed=17918732; DOI=10.1002/humu.20617;
RA   Guipponi M., Toh M.-Y., Tan J., Park D., Hanson K., Ballana E., Kwong D.,
RA   Cannon P.Z.F., Wu Q., Gout A., Delorenzi M., Speed T.P., Smith R.J.H.,
RA   Dahl H.-H.M., Petersen M., Teasdale R.D., Estivill X., Park W.J.,
RA   Scott H.S.;
RT   "An integrated genetic and functional analysis of the role of type II
RT   transmembrane serine proteases (TMPRSSs) in hearing loss.";
RL   Hum. Mutat. 29:130-141(2008).
CC   -!- FUNCTION: Plasma membrane-anchored serine protease that participates in
CC       proteolytic cascades of relevance for the normal physiologic function
CC       of the prostate (PubMed:25122198). Androgen-induced TMPRSS2 activates
CC       several substrates that include pro-hepatocyte growth factor/HGF, the
CC       protease activated receptor-2/F2RL1 or matriptase/ST14 leading to
CC       extracellular matrix disruption and metastasis of prostate cancer cells
CC       (PubMed:15537383, PubMed:26018085, PubMed:25122198). In addition,
CC       activates trigeminal neurons and contribute to both spontaneous pain
CC       and mechanical allodynia (By similarity).
CC       {ECO:0000250|UniProtKB:Q9JIQ8, ECO:0000269|PubMed:15537383,
CC       ECO:0000269|PubMed:25122198, ECO:0000269|PubMed:26018085}.
CC   -!- FUNCTION: (Microbial infection) Facilitates human coronaviruses SARS-
CC       CoV and SARS-CoV-2 infections via two independent mechanisms,
CC       proteolytic cleavage of ACE2 receptor which promotes viral uptake, and
CC       cleavage of coronavirus spike glycoproteins which activates the
CC       glycoprotein for host cell entry (PubMed:24227843, PubMed:32142651).
CC       Proteolytically cleaves and activates the spike glycoproteins of human
CC       coronavirus 229E (HCoV-229E) and human coronavirus EMC (HCoV-EMC) and
CC       the fusion glycoproteins F0 of Sendai virus (SeV), human
CC       metapneumovirus (HMPV), human parainfluenza 1, 2, 3, 4a and 4b viruses
CC       (HPIV). Essential for spread and pathogenesis of influenza A virus
CC       (strains H1N1, H3N2 and H7N9); involved in proteolytic cleavage and
CC       activation of hemagglutinin (HA) protein which is essential for viral
CC       infectivity. {ECO:0000269|PubMed:21068237, ECO:0000269|PubMed:21325420,
CC       ECO:0000269|PubMed:23536651, ECO:0000269|PubMed:23966399,
CC       ECO:0000269|PubMed:24027332, ECO:0000269|PubMed:24227843,
CC       ECO:0000269|PubMed:32142651}.
CC   -!- SUBUNIT: The catalytically active form interacts with ACE2.
CC       {ECO:0000269|PubMed:21068237}.
CC   -!- INTERACTION:
CC       O15393; Q9BYF1: ACE2; NbExp=3; IntAct=EBI-12549863, EBI-7730807;
CC       O15393-2; Q15848: ADIPOQ; NbExp=3; IntAct=EBI-12345267, EBI-10827839;
CC       O15393-2; Q86W74-2: ANKRD46; NbExp=3; IntAct=EBI-12345267, EBI-12109402;
CC       O15393-2; P29972: AQP1; NbExp=3; IntAct=EBI-12345267, EBI-745213;
CC       O15393-2; O95393: BMP10; NbExp=3; IntAct=EBI-12345267, EBI-3922513;
CC       O15393-2; Q12982: BNIP2; NbExp=3; IntAct=EBI-12345267, EBI-752094;
CC       O15393-2; Q12983: BNIP3; NbExp=3; IntAct=EBI-12345267, EBI-749464;
CC       O15393-2; Q6PL45-2: BRICD5; NbExp=3; IntAct=EBI-12345267, EBI-12244618;
CC       O15393-2; Q86Z23: C1QL4; NbExp=3; IntAct=EBI-12345267, EBI-12062109;
CC       O15393-2; O14523: C2CD2L; NbExp=3; IntAct=EBI-12345267, EBI-12822627;
CC       O15393-2; Q9BXR6: CFHR5; NbExp=3; IntAct=EBI-12345267, EBI-11579371;
CC       O15393-2; Q9BXN2-6: CLEC7A; NbExp=3; IntAct=EBI-12345267, EBI-11989440;
CC       O15393-2; Q9NWW5: CLN6; NbExp=3; IntAct=EBI-12345267, EBI-6165897;
CC       O15393-2; Q96FZ5: CMTM7; NbExp=3; IntAct=EBI-12345267, EBI-2807956;
CC       O15393-2; Q6PI25: CNIH2; NbExp=3; IntAct=EBI-12345267, EBI-12815321;
CC       O15393-2; Q8TBE1: CNIH3; NbExp=3; IntAct=EBI-12345267, EBI-12208021;
CC       O15393-2; Q4LDR2: CTXN3; NbExp=3; IntAct=EBI-12345267, EBI-12019274;
CC       O15393-2; Q07325: CXCL9; NbExp=3; IntAct=EBI-12345267, EBI-3911467;
CC       O15393-2; Q9BQA9: CYBC1; NbExp=3; IntAct=EBI-12345267, EBI-2680384;
CC       O15393-2; P81534: DEFB103B; NbExp=3; IntAct=EBI-12345267, EBI-12074168;
CC       O15393-2; P56851: EDDM3B; NbExp=3; IntAct=EBI-12345267, EBI-10215665;
CC       O15393-2; Q9UKR5: ERG28; NbExp=3; IntAct=EBI-12345267, EBI-711490;
CC       O15393-2; Q92520: FAM3C; NbExp=3; IntAct=EBI-12345267, EBI-2876774;
CC       O15393-2; Q96IV6: FAXDC2; NbExp=3; IntAct=EBI-12345267, EBI-12142299;
CC       O15393-2; P24593: IGFBP5; NbExp=3; IntAct=EBI-12345267, EBI-720480;
CC       O15393-2; Q6ZSS7: MFSD6; NbExp=3; IntAct=EBI-12345267, EBI-2858252;
CC       O15393-2; O75425: MOSPD3; NbExp=3; IntAct=EBI-12345267, EBI-12179105;
CC       O15393-2; Q9NZG7: NINJ2; NbExp=3; IntAct=EBI-12345267, EBI-10317425;
CC       O15393-2; Q9UHJ9-5: PGAP2; NbExp=3; IntAct=EBI-12345267, EBI-12092917;
CC       O15393-2; Q9Y342: PLLP; NbExp=3; IntAct=EBI-12345267, EBI-3919291;
CC       O15393-2; P26678: PLN; NbExp=3; IntAct=EBI-12345267, EBI-692836;
CC       O15393-2; P60201-2: PLP1; NbExp=3; IntAct=EBI-12345267, EBI-12188331;
CC       O15393-2; Q04941: PLP2; NbExp=4; IntAct=EBI-12345267, EBI-608347;
CC       O15393-2; Q13635-3: PTCH1; NbExp=3; IntAct=EBI-12345267, EBI-14199621;
CC       O15393-2; P53801: PTTG1IP; NbExp=3; IntAct=EBI-12345267, EBI-3906138;
CC       O15393-2; O00767: SCD; NbExp=4; IntAct=EBI-12345267, EBI-2684237;
CC       O15393-2; Q96IW7: SEC22A; NbExp=3; IntAct=EBI-12345267, EBI-8652744;
CC       O15393-2; Q9Y6D0: SELENOK; NbExp=3; IntAct=EBI-12345267, EBI-9679163;
CC       O15393-2; P11686: SFTPC; NbExp=3; IntAct=EBI-12345267, EBI-10197617;
CC       O15393-2; P78382: SLC35A1; NbExp=3; IntAct=EBI-12345267, EBI-12870360;
CC       O15393-2; Q9NVC3: SLC38A7; NbExp=3; IntAct=EBI-12345267, EBI-10314552;
CC       O15393-2; B2RUZ4: SMIM1; NbExp=3; IntAct=EBI-12345267, EBI-12188413;
CC       O15393-2; O15400: STX7; NbExp=4; IntAct=EBI-12345267, EBI-3221827;
CC       O15393-2; Q9UNK0: STX8; NbExp=3; IntAct=EBI-12345267, EBI-727240;
CC       O15393-2; P17152: TMEM11; NbExp=3; IntAct=EBI-12345267, EBI-723946;
CC       O15393-2; A0PK00: TMEM120B; NbExp=3; IntAct=EBI-12345267, EBI-10171534;
CC       O15393-2; Q5BJH2-2: TMEM128; NbExp=3; IntAct=EBI-12345267, EBI-10694905;
CC       O15393-2; A2RU14: TMEM218; NbExp=3; IntAct=EBI-12345267, EBI-10173151;
CC       O15393-2; Q9H0R3: TMEM222; NbExp=3; IntAct=EBI-12345267, EBI-347385;
CC       O15393-2; Q8NBD8: TMEM229B; NbExp=3; IntAct=EBI-12345267, EBI-12195227;
CC       O15393-2; Q9BU79: TMEM243; NbExp=3; IntAct=EBI-12345267, EBI-12887458;
CC       O15393-2; Q9H2L4: TMEM60; NbExp=3; IntAct=EBI-12345267, EBI-2852148;
CC       O15393-2; Q9BSE2: TMEM79; NbExp=3; IntAct=EBI-12345267, EBI-8649725;
CC       O15393-2; Q8N2M4: TMEM86A; NbExp=3; IntAct=EBI-12345267, EBI-12015604;
CC       O15393-2; Q8N661: TMEM86B; NbExp=3; IntAct=EBI-12345267, EBI-2548832;
CC       O15393-2; P01375: TNF; NbExp=3; IntAct=EBI-12345267, EBI-359977;
CC       O15393-2; Q5BVD1: TTMP; NbExp=5; IntAct=EBI-12345267, EBI-10243654;
CC       O15393-2; O00526: UPK2; NbExp=3; IntAct=EBI-12345267, EBI-10179682;
CC       O15393-2; O95183: VAMP5; NbExp=3; IntAct=EBI-12345267, EBI-10191195;
CC       O15393-2; Q9BQB6: VKORC1; NbExp=3; IntAct=EBI-12345267, EBI-6256462;
CC       O15393-2; O95159: ZFPL1; NbExp=3; IntAct=EBI-12345267, EBI-718439;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20382709,
CC       ECO:0000269|PubMed:21068237}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:20382709, ECO:0000269|PubMed:21068237}.
CC   -!- SUBCELLULAR LOCATION: [Transmembrane protease serine 2 catalytic
CC       chain]: Secreted {ECO:0000269|PubMed:20382709}. Note=Activated by
CC       cleavage and secreted. {ECO:0000269|PubMed:11245484,
CC       ECO:0000269|PubMed:20382709}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15393-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15393-2; Sequence=VSP_045083;
CC   -!- TISSUE SPECIFICITY: Expressed in several tissues that comprise large
CC       populations of epithelial cells with the highest level of transcripts
CC       measured in the prostate gland. Expressed in type II pneumocytes in the
CC       lung (at protein level). Expressed strongly in small intestine. Also
CC       expressed in colon, stomach and salivary gland. Coexpressed with ACE2
CC       within lung type II pneumocytes, ileal absorptive enterocytes,
CC       intestinal epithelial cells, cornea, gallbladder and nasal goblet
CC       secretory cells (Ref.21). {ECO:0000269|PubMed:11169526,
CC       ECO:0000269|PubMed:20382709, ECO:0000269|PubMed:21325420,
CC       ECO:0000269|Ref.21}.
CC   -!- INDUCTION: By androgenic hormones in vivo.
CC       {ECO:0000269|PubMed:25122198}.
CC   -!- PTM: Proteolytically processed; by an autocatalytic mechanism.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00274}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TMPRSS2ID42592ch21q22.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U75329; AAC51784.1; -; mRNA.
DR   EMBL; AF123453; AAD37117.1; -; mRNA.
DR   EMBL; AF270487; AAK29280.1; -; mRNA.
DR   EMBL; AK291813; BAF84502.1; -; mRNA.
DR   EMBL; AK296860; BAH12445.1; -; mRNA.
DR   EMBL; AK313338; BAG36142.1; -; mRNA.
DR   EMBL; AK222784; BAD96504.1; -; mRNA.
DR   EMBL; AP001610; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471079; EAX09597.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09598.1; -; Genomic_DNA.
DR   EMBL; BC051839; AAH51839.1; -; mRNA.
DR   CCDS; CCDS33564.1; -. [O15393-1]
DR   CCDS; CCDS54486.1; -. [O15393-2]
DR   RefSeq; NP_001128571.1; NM_001135099.1. [O15393-2]
DR   RefSeq; NP_005647.3; NM_005656.3. [O15393-1]
DR   RefSeq; XP_011528033.1; XM_011529731.2.
DR   SMR; O15393; -.
DR   BioGRID; 112968; 6.
DR   IntAct; O15393; 61.
DR   STRING; 9606.ENSP00000381588; -.
DR   BindingDB; O15393; -.
DR   ChEMBL; CHEMBL1795140; -.
DR   GuidetoPHARMACOLOGY; 2421; -.
DR   MEROPS; S01.247; -.
DR   GlyConnect; 1848; 4 N-Linked glycans (2 sites).
DR   GlyGen; O15393; 2 sites.
DR   iPTMnet; O15393; -.
DR   PhosphoSitePlus; O15393; -.
DR   SwissPalm; O15393; -.
DR   BioMuta; TMPRSS2; -.
DR   jPOST; O15393; -.
DR   MassIVE; O15393; -.
DR   MaxQB; O15393; -.
DR   PaxDb; O15393; -.
DR   PeptideAtlas; O15393; -.
DR   PRIDE; O15393; -.
DR   ProteomicsDB; 31938; -.
DR   ProteomicsDB; 48634; -. [O15393-1]
DR   ABCD; O15393; 1 sequenced antibody.
DR   Antibodypedia; 2685; 293 antibodies.
DR   DNASU; 7113; -.
DR   Ensembl; ENST00000332149; ENSP00000330330; ENSG00000184012. [O15393-1]
DR   Ensembl; ENST00000398585; ENSP00000381588; ENSG00000184012. [O15393-2]
DR   Ensembl; ENST00000458356; ENSP00000391216; ENSG00000184012. [O15393-1]
DR   GeneID; 7113; -.
DR   KEGG; hsa:7113; -.
DR   UCSC; uc002yzj.4; human. [O15393-1]
DR   CTD; 7113; -.
DR   DisGeNET; 7113; -.
DR   EuPathDB; HostDB:ENSG00000184012.11; -.
DR   GeneCards; TMPRSS2; -.
DR   HGNC; HGNC:11876; TMPRSS2.
DR   HPA; ENSG00000184012; Tissue enhanced (intestine, pancreas, prostate).
DR   MIM; 602060; gene.
DR   neXtProt; NX_O15393; -.
DR   OpenTargets; ENSG00000184012; -.
DR   PharmGKB; PA36577; -.
DR   eggNOG; KOG3627; Eukaryota.
DR   GeneTree; ENSGT00940000155207; -.
DR   InParanoid; O15393; -.
DR   KO; K09633; -.
DR   OMA; YQPESLY; -.
DR   OrthoDB; 1314811at2759; -.
DR   PhylomeDB; O15393; -.
DR   TreeFam; TF351678; -.
DR   PathwayCommons; O15393; -.
DR   SIGNOR; O15393; -.
DR   BioGRID-ORCS; 7113; 2 hits in 872 CRISPR screens.
DR   ChiTaRS; TMPRSS2; human.
DR   GeneWiki; TMPRSS2; -.
DR   GenomeRNAi; 7113; -.
DR   Pharos; O15393; Tchem.
DR   PRO; PR:O15393; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   RNAct; O15393; protein.
DR   Bgee; ENSG00000184012; Expressed in prostate gland and 166 other tissues.
DR   ExpressionAtlas; O15393; baseline and differential.
DR   Genevisible; O15393; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005044; F:scavenger receptor activity; IEA:InterPro.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0008236; F:serine-type peptidase activity; TAS:ProtInc.
DR   GO; GO:0046598; P:positive regulation of viral entry into host cell; IDA:UniProtKB.
DR   GO; GO:0016540; P:protein autoprocessing; IMP:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   CDD; cd00112; LDLa; 1.
DR   CDD; cd00190; Tryp_SPc; 1.
DR   Gene3D; 2.40.10.10; -; 1.
DR   Gene3D; 3.10.250.10; -; 1.
DR   Gene3D; 4.10.400.10; -; 1.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR001190; SRCR.
DR   InterPro; IPR017448; SRCR-like_dom.
DR   InterPro; IPR036772; SRCR-like_dom_sf.
DR   InterPro; IPR001254; Trypsin_dom.
DR   InterPro; IPR018114; TRYPSIN_HIS.
DR   InterPro; IPR033116; TRYPSIN_SER.
DR   Pfam; PF15494; SRCR_2; 1.
DR   Pfam; PF00089; Trypsin; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00202; SR; 1.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF56487; SSF56487; 1.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS50287; SRCR_2; 1.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Autocatalytic cleavage; Cell membrane;
KW   Disulfide bond; Glycoprotein; Hydrolase; Membrane; Polymorphism; Protease;
KW   Reference proteome; Secreted; Serine protease; Signal-anchor;
KW   Transmembrane; Transmembrane helix; Zymogen.
FT   CHAIN           1..255
FT                   /note="Transmembrane protease serine 2 non-catalytic chain"
FT                   /id="PRO_0000027855"
FT   CHAIN           256..492
FT                   /note="Transmembrane protease serine 2 catalytic chain"
FT                   /id="PRO_0000027856"
FT   TOPO_DOM        1..84
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        85..105
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        106..492
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          112..149
FT                   /note="LDL-receptor class A"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00124"
FT   DOMAIN          150..242
FT                   /note="SRCR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DOMAIN          256..489
FT                   /note="Peptidase S1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00274"
FT   ACT_SITE        296
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        345
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        441
FT                   /note="Charge relay system"
FT   SITE            255..256
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000269|PubMed:11245484"
FT   CARBOHYD        213
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        249
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        113..126
FT                   /evidence="ECO:0000250"
FT   DISULFID        120..139
FT                   /evidence="ECO:0000250"
FT   DISULFID        133..148
FT                   /evidence="ECO:0000250"
FT   DISULFID        172..231
FT                   /evidence="ECO:0000250"
FT   DISULFID        185..241
FT                   /evidence="ECO:0000250"
FT   DISULFID        244..365
FT                   /note="Interchain (between non-catalytic and catalytic
FT                   chains)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00124,
FT                   ECO:0000255|PROSITE-ProRule:PRU00196, ECO:0000255|PROSITE-
FT                   ProRule:PRU00274"
FT   DISULFID        281..297
FT                   /evidence="ECO:0000250"
FT   DISULFID        410..426
FT                   /evidence="ECO:0000250"
FT   DISULFID        437..465
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1
FT                   /note="M -> MPPAPPGGESGCEERGAAGHIEHSRYLSLLDAVDNSKM (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045083"
FT   VARIANT         160
FT                   /note="V -> M (in dbSNP:rs12329760)"
FT                   /evidence="ECO:0000269|PubMed:11414763,
FT                   ECO:0000269|PubMed:17918732, ECO:0000269|PubMed:9325052"
FT                   /id="VAR_027674"
FT   VARIANT         254
FT                   /note="S -> C"
FT                   /evidence="ECO:0000269|PubMed:17918732"
FT                   /id="VAR_038002"
FT   VARIANT         329
FT                   /note="E -> Q (in dbSNP:rs775137340)"
FT                   /evidence="ECO:0000269|PubMed:17918732,
FT                   ECO:0000269|PubMed:9325052"
FT                   /id="VAR_038003"
FT   VARIANT         449
FT                   /note="K -> N (in dbSNP:rs1056602)"
FT                   /id="VAR_011692"
FT   VARIANT         491
FT                   /note="D -> N (in dbSNP:rs779875214)"
FT                   /evidence="ECO:0000269|PubMed:17918732"
FT                   /id="VAR_038004"
FT   MUTAGEN         255
FT                   /note="R->Q: Loss of cleavage."
FT                   /evidence="ECO:0000269|PubMed:11245484"
FT   MUTAGEN         441
FT                   /note="S->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11245484"
FT   CONFLICT        26
FT                   /note="Y -> H (in Ref. 4; BAF84502)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        62
FT                   /note="N -> S (in Ref. 4; BAH12445)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        163
FT                   /note="S -> P (in Ref. 4; BAF84502)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        242
FT                   /note="I -> L (in Ref. 1; AAC51784)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        489..491
FT                   /note="RAD -> KAN (in Ref. 1; AAC51784)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   492 AA;  53859 MW;  C05B5531C8A311C7 CRC64;
     MALNSGSPPA IGPYYENHGY QPENPYPAQP TVVPTVYEVH PAQYYPSPVP QYAPRVLTQA
     SNPVVCTQPK SPSGTVCTSK TKKALCITLT LGTFLVGAAL AAGLLWKFMG SKCSNSGIEC
     DSSGTCINPS NWCDGVSHCP GGEDENRCVR LYGPNFILQV YSSQRKSWHP VCQDDWNENY
     GRAACRDMGY KNNFYSSQGI VDDSGSTSFM KLNTSAGNVD IYKKLYHSDA CSSKAVVSLR
     CIACGVNLNS SRQSRIVGGE SALPGAWPWQ VSLHVQNVHV CGGSIITPEW IVTAAHCVEK
     PLNNPWHWTA FAGILRQSFM FYGAGYQVEK VISHPNYDSK TKNNDIALMK LQKPLTFNDL
     VKPVCLPNPG MMLQPEQLCW ISGWGATEEK GKTSEVLNAA KVLLIETQRC NSRYVYDNLI
     TPAMICAGFL QGNVDSCQGD SGGPLVTSKN NIWWLIGDTS WGSGCAKAYR PGVYGNVMVF
     TDWIYRQMRA DG
//
ID   SGTA_HUMAN              Reviewed;         313 AA.
AC   O43765; D6W610; Q6FIA9; Q9BTZ9;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   12-AUG-2020, entry version 197.
DE   RecName: Full=Small glutamine-rich tetratricopeptide repeat-containing protein alpha;
DE   AltName: Full=Alpha-SGT;
DE   AltName: Full=Vpu-binding protein;
DE            Short=UBP;
GN   Name=SGTA; Synonyms=SGT, SGT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9740675; DOI=10.1006/geno.1998.5385;
RA   Kordes E., Savelyeva L., Schwab M., Rommelaere J., Jauniaux J.-C.,
RA   Cziepluch C.;
RT   "Isolation and characterization of human SGT and identification of
RT   homologues in Saccharomyces cerevisiae and Caenorhabditis elegans.";
RL   Genomics 52:90-94(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10567422; DOI=10.1074/jbc.274.48.34425;
RA   Liu F.H., Wu S.J., Hu S.M., Hsiao C.D., Wang C.;
RT   "Specific interaction of the 70-kDa heat shock cognate protein with the
RT   tetratricopeptide repeats.";
RL   J. Biol. Chem. 274:34425-34432(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH HIV-1V PU AND GAG
RP   (MICROBIAL INFECTION).
RX   PubMed=9573291;
RA   Callahan M.A., Handley M.A., Lee Y.H., Talbot K.J., Harper J.W.,
RA   Panganiban A.T.;
RT   "Functional interaction of human immunodeficiency virus type 1 Vpu and Gag
RT   with a novel member of the tetratricopeptide repeat protein family.";
RL   J. Virol. 72:5189-5197(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Tobaben S., Stahl B.;
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, Muscle, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 138-160; 165-174 AND 185-196.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [11]
RP   SUBUNIT, AND INTERACTION WITH HSP90AA1 AND SLC2A1.
RX   PubMed=15708368; DOI=10.1016/j.abb.2004.12.020;
RA   Liou S.T., Wang C.;
RT   "Small glutamine-rich tetratricopeptide repeat-containing protein is
RT   composed of three structural units with distinct functions.";
RL   Arch. Biochem. Biophys. 435:253-263(2005).
RN   [12]
RP   INTERACTION WITH HSP90AB1, AND SUBCELLULAR LOCATION.
RX   PubMed=16580629; DOI=10.1016/j.bbrc.2006.03.090;
RA   Yin H., Wang H., Zong H., Chen X., Wang Y., Yun X., Wu Y., Wang J., Gu J.;
RT   "SGT, a Hsp90beta binding partner, is accumulated in the nucleus during
RT   cell apoptosis.";
RL   Biochem. Biophys. Res. Commun. 343:1153-1158(2006).
RN   [13]
RP   INTERACTION WITH SARS-COV ACCESSORY PROTEIN 7A (MICROBIAL INFECTION).
RX   PubMed=16580632; DOI=10.1016/j.bbrc.2006.03.091;
RA   Fielding B.C., Gunalan V., Tan T.H.P., Chou C.-F., Shen S., Khan S.,
RA   Lim S.G., Hong W., Tan Y.-J.;
RT   "Severe acute respiratory syndrome coronavirus protein 7a interacts with
RT   hSGT.";
RL   Biochem. Biophys. Res. Commun. 343:1201-1208(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-305, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [15]
RP   INTERACTION WITH DNAJC5 AND DNAJC5B.
RX   PubMed=17034881; DOI=10.1016/j.bbamcr.2006.08.054;
RA   Boal F., Le Pevelen S., Cziepluch C., Scotti P., Lang J.;
RT   "Cysteine-string protein isoform beta (Cspbeta) is targeted to the trans-
RT   Golgi network as a non-palmitoylated CSP in clonal beta-cells.";
RL   Biochim. Biophys. Acta 1773:109-119(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77; THR-81; SER-301; THR-303
RP   AND SER-305, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77; THR-81 AND SER-305, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-137, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-303, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-301 AND SER-305, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH BAG6.
RX   PubMed=23129660; DOI=10.1073/pnas.1209997109;
RA   Leznicki P., High S.;
RT   "SGTA antagonizes BAG6-mediated protein triage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:19214-19219(2012).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77; THR-81 AND SER-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH BAG6.
RX   PubMed=25179605; DOI=10.1242/jcs.155648;
RA   Wunderley L., Leznicki P., Payapilly A., High S.;
RT   "SGTA regulates the cytosolic quality control of hydrophobic substrates.";
RL   J. Cell Sci. 127:4728-4739(2014).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-81; THR-303 AND SER-305, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   FUNCTION (MICROBIAL INFECTION), IDENTIFICATION IN A COMPLEX WITH DNAJB12
RP   AND DNAJB14, AND INTERACTION WITH HSPA8.
RX   PubMed=24675744; DOI=10.1371/journal.ppat.1004007;
RA   Walczak C.P., Ravindran M.S., Inoue T., Tsai B.;
RT   "A cytosolic chaperone complexes with dynamic membrane J-proteins and
RT   mobilizes a nonenveloped virus out of the endoplasmic reticulum.";
RL   PLoS Pathog. 10:E1004007-E1004007(2014).
RN   [27]
RP   FUNCTION, AND MUTAGENESIS OF CYS-38.
RX   PubMed=25535373; DOI=10.1073/pnas.1402745112;
RA   Mock J.Y., Chartron J.W., Zaslaver M., Xu Y., Ye Y., Clemons W.M. Jr.;
RT   "Bag6 complex contains a minimal tail-anchor-targeting module and a mock
RT   BAG domain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:106-111(2015).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH BAG6.
RX   PubMed=27193484; DOI=10.1038/srep26433;
RA   Krysztofinska E.M., Martinez-Lumbreras S., Thapaliya A., Evans N.J.,
RA   High S., Isaacson R.L.;
RT   "Structural and functional insights into the E3 ligase, RNF126.";
RL   Sci. Rep. 6:26433-26433(2016).
RN   [29]
RP   FUNCTION.
RX   PubMed=28104892; DOI=10.1126/science.aah6130;
RA   Shao S., Rodrigo-Brenni M.C., Kivlen M.H., Hegde R.S.;
RT   "Mechanistic basis for a molecular triage reaction.";
RL   Science 355:298-302(2017).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 84-210, SUBUNIT (MICROBIAL
RP   INFECTION), AND FUNCTION.
RX   PubMed=18759457; DOI=10.1021/bi800758a;
RA   Dutta S., Tan Y.J.;
RT   "Structural and functional characterization of human SGT and its
RT   interaction with Vpu of the human immunodeficiency virus type 1.";
RL   Biochemistry 47:10123-10131(2008).
CC   -!- FUNCTION: Co-chaperone that binds misfolded and hydrophobic patches-
CC       containing client proteins in the cytosol. Mediates their targeting to
CC       the endoplasmic reticulum but also regulates their sorting to the
CC       proteasome when targeting fails (PubMed:28104892). Functions in tail-
CC       anchored/type II transmembrane proteins membrane insertion constituting
CC       with ASNA1 and the BAG6 complex a targeting module (PubMed:28104892).
CC       Functions upstream of the BAG6 complex and ASNA1, binding more rapidly
CC       the transmembrane domain of newly synthesized proteins
CC       (PubMed:28104892, PubMed:25535373). It is also involved in the
CC       regulation of the endoplasmic reticulum-associated misfolded protein
CC       catabolic process via its interaction with BAG6: collaborates with the
CC       BAG6 complex to maintain hydrophobic substrates in non-ubiquitinated
CC       states (PubMed:23129660, PubMed:25179605). Competes with RNF126 for
CC       interaction with BAG6, preventing the ubiquitination of client proteins
CC       associated with the BAG6 complex (PubMed:27193484). Binds directly to
CC       HSC70 and HSP70 and regulates their ATPase activity (PubMed:18759457).
CC       {ECO:0000269|PubMed:18759457, ECO:0000269|PubMed:23129660,
CC       ECO:0000269|PubMed:25179605, ECO:0000269|PubMed:25535373,
CC       ECO:0000269|PubMed:27193484, ECO:0000269|PubMed:28104892}.
CC   -!- FUNCTION: (Microbial infection) In case of infection by polyomavirus,
CC       involved in the virus endoplasmic reticulum membrane penetration and
CC       infection via interaction with DNAJB12, DNAJB14 and HSPA8/Hsc70
CC       (PubMed:24675744). {ECO:0000269|PubMed:24675744}.
CC   -!- SUBUNIT: Homodimer (PubMed:15708368). Homooligomer (By similarity).
CC       Interacts with DNAJC5 and DNAJC5B. Interacts (via TPR repeats) with
CC       HSP90AA1 (PubMed:15708368). Interacts (via Gln-rich region) with SLC2A1
CC       (PubMed:15708368). Interacts with HSP90AB1 (PubMed:16580629). Interacts
CC       (via TPR repeats) with HSPA8/Hsc70; the interaction is direct
CC       (PubMed:24675744). Interacts with BAG6 (via ubiquitin-like domain);
CC       interaction prevents interaction between BAG6 and RNF126
CC       (PubMed:23129660, PubMed:25179605, PubMed:27193484). Forms a
CC       multiprotein complex, at least composed of DNAJB12, DNAJB14,
CC       HSPA8/Hsc70 and SGTA; interaction with DNAJB14 and HSPA8/Hsc70 is
CC       direct (PubMed:24675744). {ECO:0000250|UniProtKB:O70593,
CC       ECO:0000269|PubMed:15708368, ECO:0000269|PubMed:16580629,
CC       ECO:0000269|PubMed:17034881, ECO:0000269|PubMed:18759457,
CC       ECO:0000269|PubMed:23129660, ECO:0000269|PubMed:24675744,
CC       ECO:0000269|PubMed:25179605, ECO:0000269|PubMed:27193484}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Vpu and Gag from HIV-1.
CC       {ECO:0000269|PubMed:18759457, ECO:0000269|PubMed:9573291}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV accessory
CC       protein 7a. {ECO:0000269|PubMed:16580632}.
CC   -!- INTERACTION:
CC       O43765; Q9UKJ8: ADAM21; NbExp=3; IntAct=EBI-347996, EBI-12046857;
CC       O43765; A8K660: ADIPOQ; NbExp=3; IntAct=EBI-347996, EBI-10174479;
CC       O43765; Q15848: ADIPOQ; NbExp=7; IntAct=EBI-347996, EBI-10827839;
CC       O43765; O95994: AGR2; NbExp=3; IntAct=EBI-347996, EBI-712648;
CC       O43765; Q8TD06: AGR3; NbExp=6; IntAct=EBI-347996, EBI-3925742;
CC       O43765; Q16853: AOC3; NbExp=3; IntAct=EBI-347996, EBI-3921628;
CC       O43765; O95816: BAG2; NbExp=2; IntAct=EBI-347996, EBI-355275;
CC       O43765; P46379: BAG6; NbExp=6; IntAct=EBI-347996, EBI-347552;
CC       O43765; P46379-2: BAG6; NbExp=3; IntAct=EBI-347996, EBI-10988864;
CC       O43765; P35070: BTC; NbExp=6; IntAct=EBI-347996, EBI-6590057;
CC       O43765; Q86Z23: C1QL4; NbExp=3; IntAct=EBI-347996, EBI-12062109;
CC       O43765; Q9BXJ1: C1QTNF1; NbExp=4; IntAct=EBI-347996, EBI-750200;
CC       O43765; Q9BXJ0: C1QTNF5; NbExp=3; IntAct=EBI-347996, EBI-19947914;
CC       O43765; Q9BXI9: C1QTNF6; NbExp=9; IntAct=EBI-347996, EBI-10301084;
CC       O43765; Q6UWT4: C5orf46; NbExp=3; IntAct=EBI-347996, EBI-11986083;
CC       O43765; Q8N6L0: CCDC155; NbExp=8; IntAct=EBI-347996, EBI-749265;
CC       O43765; P40259: CD79B; NbExp=6; IntAct=EBI-347996, EBI-2873732;
CC       O43765; Q8TCZ2: CD99L2; NbExp=8; IntAct=EBI-347996, EBI-2824782;
CC       O43765; P55291: CDH15; NbExp=8; IntAct=EBI-347996, EBI-10215061;
CC       O43765; P07510-2: CHRNG; NbExp=3; IntAct=EBI-347996, EBI-11979451;
CC       O43765; A0A0S2Z3K0: COL1A2; NbExp=3; IntAct=EBI-347996, EBI-16431143;
CC       O43765; P08123: COL1A2; NbExp=11; IntAct=EBI-347996, EBI-983038;
CC       O43765; Q4VAQ0: COL8A2; NbExp=3; IntAct=EBI-347996, EBI-10241815;
CC       O43765; Q68CJ9: CREB3L3; NbExp=3; IntAct=EBI-347996, EBI-852194;
CC       O43765; P09603: CSF1; NbExp=6; IntAct=EBI-347996, EBI-2872294;
CC       O43765; P01037: CST1; NbExp=3; IntAct=EBI-347996, EBI-1056240;
CC       O43765; P78358: CTAG1B; NbExp=3; IntAct=EBI-347996, EBI-1188472;
CC       O43765; P07711: CTSL; NbExp=3; IntAct=EBI-347996, EBI-1220160;
CC       O43765; Q9UHQ9: CYB5R1; NbExp=3; IntAct=EBI-347996, EBI-953870;
CC       O43765; P59861: DEFB131A; NbExp=5; IntAct=EBI-347996, EBI-12304807;
CC       O43765; Q9UBP4: DKK3; NbExp=3; IntAct=EBI-347996, EBI-954409;
CC       O43765; Q6E0U4: DMKN; NbExp=3; IntAct=EBI-347996, EBI-7943171;
CC       O43765; Q9HAV5: EDA2R; NbExp=3; IntAct=EBI-347996, EBI-526033;
CC       O43765; Q9UNE0-2: EDAR; NbExp=3; IntAct=EBI-347996, EBI-12964110;
CC       O43765; A0A0S2Z3V1: EFEMP1; NbExp=3; IntAct=EBI-347996, EBI-16434097;
CC       O43765; Q12805: EFEMP1; NbExp=14; IntAct=EBI-347996, EBI-536772;
CC       O43765; O95967: EFEMP2; NbExp=7; IntAct=EBI-347996, EBI-743414;
CC       O43765; Q96DN0: ERP27; NbExp=7; IntAct=EBI-347996, EBI-953772;
CC       O43765; P30040: ERP29; NbExp=3; IntAct=EBI-347996, EBI-946830;
CC       O43765; Q9HBU6: ETNK1; NbExp=3; IntAct=EBI-347996, EBI-2834493;
CC       O43765; Q9NVM1: EVA1B; NbExp=6; IntAct=EBI-347996, EBI-10314666;
CC       O43765; Q9Y624: F11R; NbExp=11; IntAct=EBI-347996, EBI-742600;
CC       O43765; Q96RJ6: FERD3L; NbExp=3; IntAct=EBI-347996, EBI-10183007;
CC       O43765; Q9NSA1: FGF21; NbExp=3; IntAct=EBI-347996, EBI-3909329;
CC       O43765; Q9Y680: FKBP7; NbExp=6; IntAct=EBI-347996, EBI-3918971;
CC       O43765; Q12841: FSTL1; NbExp=3; IntAct=EBI-347996, EBI-2349801;
CC       O43765; P54710-2: FXYD2; NbExp=5; IntAct=EBI-347996, EBI-13084584;
CC       O43765; P58549: FXYD7; NbExp=8; IntAct=EBI-347996, EBI-10216171;
CC       O43765; O75084: FZD7; NbExp=3; IntAct=EBI-347996, EBI-746917;
CC       O43765; P22466: GAL; NbExp=6; IntAct=EBI-347996, EBI-6624768;
CC       O43765; Q9UBC7: GALP; NbExp=3; IntAct=EBI-347996, EBI-12244186;
CC       O43765; P09681: GIP; NbExp=6; IntAct=EBI-347996, EBI-8588553;
CC       O43765; Q14440: GPErik; NbExp=3; IntAct=EBI-347996, EBI-10232920;
CC       O43765; Q96SL4: GPX7; NbExp=7; IntAct=EBI-347996, EBI-749411;
CC       O43765; P28799: GRN; NbExp=7; IntAct=EBI-347996, EBI-747754;
CC       O43765; Q02747: GUCA2A; NbExp=8; IntAct=EBI-347996, EBI-12244272;
CC       O43765; A0A0C4DFT7: GYPA; NbExp=3; IntAct=EBI-347996, EBI-12044847;
CC       O43765; B8Q183: GYPA; NbExp=4; IntAct=EBI-347996, EBI-10176190;
CC       O43765; P02724: GYPA; NbExp=3; IntAct=EBI-347996, EBI-702665;
CC       O43765; P48723: HSPA13; NbExp=8; IntAct=EBI-347996, EBI-750892;
CC       O43765; P46695: IER3; NbExp=6; IntAct=EBI-347996, EBI-1748945;
CC       O43765; P24592: IGFBP6; NbExp=3; IntAct=EBI-347996, EBI-947015;
CC       O43765; Q6PIQ7: IGL@; NbExp=3; IntAct=EBI-347996, EBI-6677651;
CC       O43765; Q8N355: IGL@; NbExp=4; IntAct=EBI-347996, EBI-748681;
CC       O43765; P40189: IL6ST; NbExp=3; IntAct=EBI-347996, EBI-1030834;
CC       O43765; Q14653: IRF3; NbExp=3; IntAct=EBI-347996, EBI-2650369;
CC       O43765; Q13568: IRF5; NbExp=3; IntAct=EBI-347996, EBI-3931258;
CC       O43765; Q6GPH6: ITPRIPL1; NbExp=3; IntAct=EBI-347996, EBI-953819;
CC       O43765; Q6GPH6-2: ITPRIPL1; NbExp=3; IntAct=EBI-347996, EBI-12337095;
CC       O43765; Q09470: KCNA1; NbExp=3; IntAct=EBI-347996, EBI-8286599;
CC       O43765; Q16322: KCNA10; NbExp=3; IntAct=EBI-347996, EBI-12265328;
CC       O43765; Q9UJ90: KCNE5; NbExp=3; IntAct=EBI-347996, EBI-11981259;
CC       O43765; P02538: KRT6A; NbExp=3; IntAct=EBI-347996, EBI-702198;
CC       O43765; Q86UP2: KTN1; NbExp=3; IntAct=EBI-347996, EBI-359761;
CC       O43765; Q86UP2-3: KTN1; NbExp=3; IntAct=EBI-347996, EBI-12007212;
CC       O43765; Q6ISS4: LAIR2; NbExp=6; IntAct=EBI-347996, EBI-10250491;
CC       O43765; O43561: LAT; NbExp=3; IntAct=EBI-347996, EBI-1222766;
CC       O43765; O43561-2: LAT; NbExp=3; IntAct=EBI-347996, EBI-8070286;
CC       O43765; P80188: LCN2; NbExp=5; IntAct=EBI-347996, EBI-11911016;
CC       O43765; O15165-2: LDLRAD4; NbExp=3; IntAct=EBI-347996, EBI-13302279;
CC       O43765; Q8N112: LSMEM2; NbExp=3; IntAct=EBI-347996, EBI-10264855;
CC       O43765; Q96G30: MRAP2; NbExp=6; IntAct=EBI-347996, EBI-9537218;
CC       O43765; Q96HJ5: MS4A3; NbExp=3; IntAct=EBI-347996, EBI-12806656;
CC       O43765; P08118: MSMB; NbExp=3; IntAct=EBI-347996, EBI-10195681;
CC       O43765; Q969H8: MYDGF; NbExp=8; IntAct=EBI-347996, EBI-718622;
CC       O43765; Q99972: MYOC; NbExp=3; IntAct=EBI-347996, EBI-11692272;
CC       O43765; Q8IW45: NAXD; NbExp=7; IntAct=EBI-347996, EBI-8650724;
CC       O43765; Q13232: NME3; NbExp=12; IntAct=EBI-347996, EBI-713684;
CC       O43765; Q9HCQ7: NPVF; NbExp=3; IntAct=EBI-347996, EBI-1753111;
CC       O43765; Q9GZP1: NRSN2; NbExp=3; IntAct=EBI-347996, EBI-724857;
CC       O43765; Q5JUK9: PAGE3; NbExp=6; IntAct=EBI-347996, EBI-10244544;
CC       O43765; C3PTT6: PAUF; NbExp=3; IntAct=EBI-347996, EBI-3505892;
CC       O43765; Q96AQ6: PBXIP1; NbExp=4; IntAct=EBI-347996, EBI-740845;
CC       O43765; Q9UN74: PCDHA4; NbExp=3; IntAct=EBI-347996, EBI-712273;
CC       O43765; Q9Y5G9: PCDHGA4; NbExp=3; IntAct=EBI-347996, EBI-12956949;
CC       O43765; Q96PD5-2: PGLYRP2; NbExp=3; IntAct=EBI-347996, EBI-12758027;
CC       O43765; Q9UL19: PLAAT4; NbExp=4; IntAct=EBI-347996, EBI-10323452;
CC       O43765; Q969W9-2: PMEPA1; NbExp=3; IntAct=EBI-347996, EBI-13318883;
CC       O43765; P23284: PPIB; NbExp=6; IntAct=EBI-347996, EBI-359252;
CC       O43765; P45877: PPIC; NbExp=6; IntAct=EBI-347996, EBI-953909;
CC       O43765; Q96NZ9: PRAP1; NbExp=9; IntAct=EBI-347996, EBI-2116102;
CC       O43765; Q8TAS3: PRRG2; NbExp=3; IntAct=EBI-347996, EBI-10272071;
CC       O43765; Q9UIG4: PSORS1C2; NbExp=5; IntAct=EBI-347996, EBI-11974061;
CC       O43765; Q15293: RCN1; NbExp=3; IntAct=EBI-347996, EBI-948278;
CC       O43765; Q5GAN6: RNASE10; NbExp=5; IntAct=EBI-347996, EBI-12423312;
CC       O43765; P50876: RNF144A; NbExp=3; IntAct=EBI-347996, EBI-2340657;
CC       O43765; Q96K19-5: RNF170; NbExp=3; IntAct=EBI-347996, EBI-12055631;
CC       O43765; P04843: RPN1; NbExp=7; IntAct=EBI-347996, EBI-355963;
CC       O43765; P31431: SDC4; NbExp=6; IntAct=EBI-347996, EBI-3913237;
CC       O43765; Q9HCN8: SDF2L1; NbExp=3; IntAct=EBI-347996, EBI-2339921;
CC       O43765; P05121: SERPINE1; NbExp=6; IntAct=EBI-347996, EBI-953978;
CC       O43765; O75830: SERPINI2; NbExp=3; IntAct=EBI-347996, EBI-750144;
CC       O43765; Q16586: SGCA; NbExp=13; IntAct=EBI-347996, EBI-5663553;
CC       O43765; Q16586-2: SGCA; NbExp=4; IntAct=EBI-347996, EBI-16434133;
CC       O43765; O43765: SGTA; NbExp=4; IntAct=EBI-347996, EBI-347996;
CC       O43765; Q96EQ0: SGTB; NbExp=3; IntAct=EBI-347996, EBI-744081;
CC       O43765; Q96DD7: SHISA4; NbExp=3; IntAct=EBI-347996, EBI-18035902;
CC       O43765; Q8N114-3: SHISA5; NbExp=3; IntAct=EBI-347996, EBI-13369834;
CC       O43765; P03973: SLPI; NbExp=6; IntAct=EBI-347996, EBI-355293;
CC       O43765; Q0VAQ4: SMAGP; NbExp=3; IntAct=EBI-347996, EBI-10226799;
CC       O43765; Q96QK8: SMIM14; NbExp=3; IntAct=EBI-347996, EBI-373430;
CC       O43765; Q71RC9: SMIM5; NbExp=9; IntAct=EBI-347996, EBI-12334905;
CC       O43765; P08294: SOD3; NbExp=3; IntAct=EBI-347996, EBI-10195782;
CC       O43765; Q5DT21: SPINK9; NbExp=3; IntAct=EBI-347996, EBI-13119580;
CC       O43765; P16150: SPN; NbExp=5; IntAct=EBI-347996, EBI-10049055;
CC       O43765; P10451: SPP1; NbExp=8; IntAct=EBI-347996, EBI-723648;
CC       O43765; Q8TCT8: SPPL2A; NbExp=7; IntAct=EBI-347996, EBI-750784;
CC       O43765; P10124: SRGN; NbExp=10; IntAct=EBI-347996, EBI-744915;
CC       O43765; Q86TD4-2: SRL; NbExp=3; IntAct=EBI-347996, EBI-12304565;
CC       O43765; E0CX11: STMP1; NbExp=3; IntAct=EBI-347996, EBI-18397783;
CC       O43765; P51687: SUOX; NbExp=3; IntAct=EBI-347996, EBI-3921347;
CC       O43765; Q9BT88: SYT11; NbExp=7; IntAct=EBI-347996, EBI-751770;
CC       O43765; Q9H2B2: SYT4; NbExp=7; IntAct=EBI-347996, EBI-751132;
CC       O43765; Q07654: TFF3; NbExp=3; IntAct=EBI-347996, EBI-10224676;
CC       O43765; P02786: TFRC; NbExp=6; IntAct=EBI-347996, EBI-355727;
CC       O43765; P01135: TGFA; NbExp=3; IntAct=EBI-347996, EBI-1034374;
CC       O43765; P01135-2: TGFA; NbExp=6; IntAct=EBI-347996, EBI-12367411;
CC       O43765; Q6P9G4: TMEM154; NbExp=3; IntAct=EBI-347996, EBI-13329239;
CC       O43765; Q8WUU8: TMEM174; NbExp=6; IntAct=EBI-347996, EBI-10276729;
CC       O43765; Q96A57-2: TMEM230; NbExp=3; IntAct=EBI-347996, EBI-17546822;
CC       O43765; Q5JXX7: TMEM31; NbExp=3; IntAct=EBI-347996, EBI-10244617;
CC       O43765; Q9Y2Y6: TMEM98; NbExp=3; IntAct=EBI-347996, EBI-7333781;
CC       O43765; O60235: TMPRSS11D; NbExp=3; IntAct=EBI-347996, EBI-7639969;
CC       O43765; Q71RG4: TMUB2; NbExp=3; IntAct=EBI-347996, EBI-2820477;
CC       O43765; O14798: TNFRSF10C; NbExp=3; IntAct=EBI-347996, EBI-717441;
CC       O43765; O14836: TNFRSF13B; NbExp=3; IntAct=EBI-347996, EBI-519160;
CC       O43765; O14836-2: TNFRSF13B; NbExp=8; IntAct=EBI-347996, EBI-12023110;
CC       O43765; Q9NS68-2: TNFRSF19; NbExp=3; IntAct=EBI-347996, EBI-12089038;
CC       O43765; O75509: TNFRSF21; NbExp=3; IntAct=EBI-347996, EBI-2313231;
CC       O43765; O43508: TNFSF12; NbExp=3; IntAct=EBI-347996, EBI-6932080;
CC       O43765; Q9C035-3: TRIM5; NbExp=3; IntAct=EBI-347996, EBI-12840050;
CC       O43765; Q5BVD1: TTMP; NbExp=6; IntAct=EBI-347996, EBI-10243654;
CC       O43765; Q9GZX9: TWSG1; NbExp=3; IntAct=EBI-347996, EBI-10304067;
CC       O43765; O95881: TXNDC12; NbExp=3; IntAct=EBI-347996, EBI-2564581;
CC       O43765; P11441: UBL4A; NbExp=5; IntAct=EBI-347996, EBI-356983;
CC       O43765; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-347996, EBI-947187;
CC       O43765; O75631: UPK3A; NbExp=3; IntAct=EBI-347996, EBI-10188907;
CC       O43765; P01282: VIP; NbExp=3; IntAct=EBI-347996, EBI-751454;
CC       O43765; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-347996, EBI-10316321;
CC       O43765; Q8WWY7: WFDC12; NbExp=3; IntAct=EBI-347996, EBI-11958577;
CC       O43765; Q8IUB5: WFDC13; NbExp=5; IntAct=EBI-347996, EBI-12041955;
CC       O43765; Q8TCV5: WFDC5; NbExp=3; IntAct=EBI-347996, EBI-12175871;
CC       O43765; Q8NAP8: ZBTB8B; NbExp=3; IntAct=EBI-347996, EBI-17494306;
CC       O43765; O60844: ZG16; NbExp=12; IntAct=EBI-347996, EBI-746479;
CC       O43765; Q96DA0: ZG16B; NbExp=3; IntAct=EBI-347996, EBI-953824;
CC       O43765; A0A1U9X8X8; NbExp=3; IntAct=EBI-347996, EBI-17234977;
CC       O43765; P59635: 7a; Xeno; NbExp=3; IntAct=EBI-347996, EBI-25492879;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16580629}. Nucleus
CC       {ECO:0000269|PubMed:16580629}. Note=Co-localizes with HSP90AB1 in the
CC       cytoplasm. Increased nuclear accumulation seen during cell apoptosis.
CC       {ECO:0000269|PubMed:16580629}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: The second tetratricopeptide repeat (TPR 2) mediates the
CC       interaction with SARS-CoV accessory protein 7a.
CC   -!- SIMILARITY: Belongs to the SGT family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ223828; CAA11565.1; -; mRNA.
DR   EMBL; AJ133129; CAB39725.1; -; mRNA.
DR   EMBL; AF408399; AAL01051.1; -; mRNA.
DR   EMBL; AF368279; AAP29457.1; -; mRNA.
DR   EMBL; AL050156; CAB43297.2; -; mRNA.
DR   EMBL; CR533517; CAG38548.1; -; mRNA.
DR   EMBL; CR542282; CAG47077.1; -; mRNA.
DR   EMBL; AC006538; AAD13117.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69366.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69367.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69368.1; -; Genomic_DNA.
DR   EMBL; BC000390; AAH00390.1; -; mRNA.
DR   EMBL; BC002989; AAH02989.2; -; mRNA.
DR   EMBL; BC005165; AAH05165.1; -; mRNA.
DR   EMBL; BC008885; AAH08885.1; -; mRNA.
DR   CCDS; CCDS12094.1; -.
DR   RefSeq; NP_003012.1; NM_003021.3.
DR   RefSeq; XP_011526480.1; XM_011528178.2.
DR   PDB; 2VYI; X-ray; 2.40 A; A/B=84-210.
DR   PDB; 4CPG; NMR; -; A/B=1-69.
DR   PDB; 4GOD; X-ray; 1.40 A; A/B=4-54.
DR   PDB; 4GOE; X-ray; 1.45 A; A/B=4-54.
DR   PDB; 4GOF; X-ray; 1.35 A; A/B=4-54.
DR   PDBsum; 2VYI; -.
DR   PDBsum; 4CPG; -.
DR   PDBsum; 4GOD; -.
DR   PDBsum; 4GOE; -.
DR   PDBsum; 4GOF; -.
DR   SMR; O43765; -.
DR   BioGRID; 112347; 162.
DR   IntAct; O43765; 209.
DR   MINT; O43765; -.
DR   STRING; 9606.ENSP00000221566; -.
DR   iPTMnet; O43765; -.
DR   PhosphoSitePlus; O43765; -.
DR   SwissPalm; O43765; -.
DR   BioMuta; SGTA; -.
DR   EPD; O43765; -.
DR   jPOST; O43765; -.
DR   MassIVE; O43765; -.
DR   MaxQB; O43765; -.
DR   PaxDb; O43765; -.
DR   PeptideAtlas; O43765; -.
DR   PRIDE; O43765; -.
DR   ProteomicsDB; 49156; -.
DR   TopDownProteomics; O43765; -.
DR   Antibodypedia; 23040; 261 antibodies.
DR   DNASU; 6449; -.
DR   Ensembl; ENST00000221566; ENSP00000221566; ENSG00000104969.
DR   GeneID; 6449; -.
DR   KEGG; hsa:6449; -.
DR   UCSC; uc002lwi.2; human.
DR   CTD; 6449; -.
DR   DisGeNET; 6449; -.
DR   EuPathDB; HostDB:ENSG00000104969.9; -.
DR   GeneCards; SGTA; -.
DR   HGNC; HGNC:10819; SGTA.
DR   HPA; ENSG00000104969; Low tissue specificity.
DR   MIM; 603419; gene.
DR   neXtProt; NX_O43765; -.
DR   OpenTargets; ENSG00000104969; -.
DR   PharmGKB; PA35727; -.
DR   eggNOG; KOG0553; Eukaryota.
DR   GeneTree; ENSGT00940000159037; -.
DR   HOGENOM; CLU_044224_0_0_1; -.
DR   InParanoid; O43765; -.
DR   KO; K16365; -.
DR   OMA; TDCKSAL; -.
DR   OrthoDB; 687493at2759; -.
DR   PhylomeDB; O43765; -.
DR   TreeFam; TF313092; -.
DR   PathwayCommons; O43765; -.
DR   Reactome; R-HSA-9609523; Insertion of tail-anchored proteins into the endoplasmic reticulum membrane.
DR   BioGRID-ORCS; 6449; 11 hits in 874 CRISPR screens.
DR   ChiTaRS; SGTA; human.
DR   EvolutionaryTrace; O43765; -.
DR   GeneWiki; SGTA; -.
DR   GenomeRNAi; 6449; -.
DR   Pharos; O43765; Tbio.
DR   PRO; PR:O43765; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O43765; protein.
DR   Bgee; ENSG00000104969; Expressed in C1 segment of cervical spinal cord and 204 other tissues.
DR   ExpressionAtlas; O43765; baseline and differential.
DR   Genevisible; O43765; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0098850; C:extrinsic component of synaptic vesicle membrane; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0072380; C:TRC complex; IBA:GO_Central.
DR   GO; GO:1904288; F:BAT3 complex binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0060090; F:molecular adaptor activity; IBA:GO_Central.
DR   GO; GO:0043621; F:protein self-association; IDA:UniProtKB.
DR   GO; GO:0061077; P:chaperone-mediated protein folding; IEA:Ensembl.
DR   GO; GO:1903070; P:negative regulation of ER-associated ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:2000059; P:negative regulation of ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:1903646; P:positive regulation of chaperone-mediated protein folding; IBA:GO_Central.
DR   GO; GO:1903071; P:positive regulation of ER-associated ubiquitin-dependent protein catabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006620; P:posttranslational protein targeting to endoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0071816; P:tail-anchored membrane protein insertion into ER membrane; IDA:UniProtKB.
DR   GO; GO:0030433; P:ubiquitin-dependent ERAD pathway; IDA:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 1.25.40.10; -; 1.
DR   InterPro; IPR032374; SGTA_dimer.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR001440; TPR_1.
DR   InterPro; IPR019734; TPR_repeat.
DR   Pfam; PF16546; SGTA_dimer; 1.
DR   Pfam; PF00515; TPR_1; 2.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00028; TPR; 3.
DR   SUPFAM; SSF48452; SSF48452; 1.
DR   PROSITE; PS50005; TPR; 3.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Chaperone; Cytoplasm; Direct protein sequencing;
KW   Host-virus interaction; Nucleus; Phosphoprotein; Reference proteome;
KW   Repeat; TPR repeat.
FT   CHAIN           1..313
FT                   /note="Small glutamine-rich tetratricopeptide repeat-
FT                   containing protein alpha"
FT                   /id="PRO_0000106365"
FT   REPEAT          91..124
FT                   /note="TPR 1"
FT   REPEAT          125..158
FT                   /note="TPR 2"
FT   REPEAT          159..192
FT                   /note="TPR 3"
FT   COMPBIAS        275..287
FT                   /note="Gln-rich"
FT   MOD_RES         77
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:23186163"
FT   MOD_RES         81
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:23186163,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         84
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O70593"
FT   MOD_RES         137
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163"
FT   MOD_RES         303
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:24275569"
FT   MOD_RES         305
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:16964243,
FT                   ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:24275569"
FT   MUTAGEN         38
FT                   /note="C->A: Reduces tail-anchored proteins transfer."
FT                   /evidence="ECO:0000269|PubMed:25535373"
FT   HELIX           5..21
FT                   /evidence="ECO:0000244|PDB:4GOF"
FT   HELIX           26..43
FT                   /evidence="ECO:0000244|PDB:4GOF"
FT   HELIX           48..51
FT                   /evidence="ECO:0000244|PDB:4CPG"
FT   HELIX           58..65
FT                   /evidence="ECO:0000244|PDB:4CPG"
FT   HELIX           87..103
FT                   /evidence="ECO:0000244|PDB:2VYI"
FT   HELIX           107..120
FT                   /evidence="ECO:0000244|PDB:2VYI"
FT   HELIX           125..137
FT                   /evidence="ECO:0000244|PDB:2VYI"
FT   HELIX           141..154
FT                   /evidence="ECO:0000244|PDB:2VYI"
FT   HELIX           159..171
FT                   /evidence="ECO:0000244|PDB:2VYI"
FT   HELIX           175..188
FT                   /evidence="ECO:0000244|PDB:2VYI"
FT   HELIX           193..206
FT                   /evidence="ECO:0000244|PDB:2VYI"
SQ   SEQUENCE   313 AA;  34063 MW;  80B3C71B41F3CB55 CRC64;
     MDNKKRLAYA IIQFLHDQLR HGGLSSDAQE SLEVAIQCLE TAFGVTVEDS DLALPQTLPE
     IFEAAATGKE MPQDLRSPAR TPPSEEDSAE AERLKTEGNE QMKVENFEAA VHFYGKAIEL
     NPANAVYFCN RAAAYSKLGN YAGAVQDCER AICIDPAYSK AYGRMGLALS SLNKHVEAVA
     YYKKALELDP DNETYKSNLK IAELKLREAP SPTGGVGSFD IAGLLNNPGF MSMASNLMNN
     PQIQQLMSGM ISGGNNPLGT PGTSPSQNDL ASLIQAGQQF AQQMQQQNPE LIEQLRSQIR
     SRTPSASNDD QQE
//
ID   IL6_HUMAN               Reviewed;         212 AA.
AC   P05231; Q9UCU2; Q9UCU3; Q9UCU4;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   12-AUG-2020, entry version 231.
DE   RecName: Full=Interleukin-6 {ECO:0000305};
DE            Short=IL-6;
DE   AltName: Full=B-cell stimulatory factor 2;
DE            Short=BSF-2;
DE   AltName: Full=CTL differentiation factor;
DE            Short=CDF;
DE   AltName: Full=Hybridoma growth factor;
DE   AltName: Full=Interferon beta-2;
DE            Short=IFN-beta-2;
DE   Flags: Precursor;
GN   Name=IL6 {ECO:0000312|HGNC:HGNC:6018}; Synonyms=IFNB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3491322; DOI=10.1038/324073a0;
RA   Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T.,
RA   Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A., Tsunasawa S.,
RA   Sakiyama F., Matsui H., Takahara Y., Taniguchi T., Kishimoto T.;
RT   "Complementary DNA for a novel human interleukin (BSF-2) that induces B
RT   lymphocytes to produce immunoglobulin.";
RL   Nature 324:73-76(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3500852; DOI=10.1002/j.1460-2075.1987.tb02598.x;
RA   Yasukawa K., Hirano T., Watanabe Y., Muratani K., Matsuda T., Nakai S.,
RA   Kishimoto T.;
RT   "Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6)
RT   gene.";
RL   EMBO J. 6:2939-2945(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3538015; DOI=10.1073/pnas.83.23.8957;
RA   May L.T., Helfgott D.C., Sehgal P.B.;
RT   "Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7
RT   mRNA in tumor necrosis factor-treated human fibroblasts: structural studies
RT   of the beta 2 interferon involved.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:8957-8961(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3023045; DOI=10.1002/j.1460-2075.1986.tb04531.x;
RA   Zilberstein A., Ruggieri R., Korn J.H., Revel M.;
RT   "Structure and expression of cDNA and genes for human interferon-beta-2, a
RT   distinct species inducible by growth-stimulatory cytokines.";
RL   EMBO J. 5:2529-2537(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3320204;
RA   Brakenhoff J.P.J., de Groot E.R., Evers R.F., Pannekoek H., Aarden L.A.;
RT   "Molecular cloning and expression of hybridoma growth factor in Escherichia
RT   coli.";
RL   J. Immunol. 139:4116-4121(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2789513; DOI=10.1016/0006-291x(89)92328-0;
RA   Tonouchi N., Miwa K., Karasuyama H., Matsui H.;
RT   "Deletion of 3' untranslated region of human BSF-2 mRNA causes
RT   stabilization of the mRNA and high-level expression in mouse NIH3T3
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 163:1056-1062(1989).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Fibroblast;
RX   PubMed=3758081; DOI=10.1111/j.1432-1033.1986.tb09931.x;
RA   Haegeman G., Content J., Volckaert G., Derynck R., Tavernier J., Fiers W.;
RT   "Structural analysis of the sequence coding for an inducible 26-kDa protein
RT   in human fibroblasts.";
RL   Eur. J. Biochem. 159:625-632(1986).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3266463;
RA   Wong G., Witek-Giannotti J., Hewick R., Clark S., Ogawa M.;
RT   "Interleukin 6: identification as a hematopoietic colony-stimulating
RT   factor.";
RL   Behring Inst. Mitt. 83:40-47(1988).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1291290;
RA   Chen Q.Y.;
RT   "Stable and efficient expression of human interleukin-6 cDNA in mammalian
RT   cells after gene transfer.";
RL   Zhonghua Zhong Liu Za Zhi 14:340-344(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-32 AND VAL-162.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PROTEIN SEQUENCE OF 30-63.
RX   PubMed=3279116;
RA   van Damme J., van Beeumen J., Decock B., van Snick J., de Ley M.,
RA   Billiau A.;
RT   "Separation and comparison of two monokines with lymphocyte-activating
RT   factor activity: IL-1 beta and hybridoma growth factor (HGF).
RT   Identification of leukocyte-derived HGF as IL-6.";
RL   J. Immunol. 140:1534-1541(1988).
RN   [13]
RP   PROTEIN SEQUENCE OF 30-50.
RX   PubMed=2610854;
RA   Ming J.E., Cernetti C., Steinman R.M., Granelli-Piperno A.;
RT   "Interleukin 6 is the principal cytolytic T lymphocyte differentiation
RT   factor for thymocytes in human leukocyte conditioned medium.";
RL   J. Mol. Cell. Immunol. 4:203-211(1989).
RN   [14]
RP   PROTEIN SEQUENCE OF 30-40, AND GLYCOSYLATION.
RX   PubMed=1883960; DOI=10.1016/1043-4666(91)90018-9;
RA   May L.T., Shaw J.E., Khanna A.K., Zabriskie J.B., Sehgal P.B.;
RT   "Marked cell-type-specific differences in glycosylation of human
RT   interleukin-6.";
RL   Cytokine 3:204-211(1991).
RN   [15]
RP   PROTEIN SEQUENCE OF 50-212.
RX   PubMed=7851440; DOI=10.1111/j.1432-1033.1995.tb20427.x;
RA   Breton J., la Fiura A., Bertolero F., Orsini G., Valsasina B., Ziliotto R.,
RA   de Filippis V., Polverino de Laureto P., Fontana A.;
RT   "Structure, stability and biological properties of a N-terminally truncated
RT   form of recombinant human interleukin-6 containing a single disulfide
RT   bond.";
RL   Eur. J. Biochem. 227:573-581(1995).
RN   [16]
RP   DISULFIDE BONDS.
RX   PubMed=2472117; DOI=10.1016/0003-9861(89)90205-1;
RA   Clogston C.L., Boone T.C., Crandall B.C., Mendiaz E.A., Lu H.S.;
RT   "Disulfide structures of human interleukin-6 are similar to those of human
RT   granulocyte colony stimulating factor.";
RL   Arch. Biochem. Biophys. 272:144-151(1989).
RN   [17]
RP   MUTAGENESIS.
RX   PubMed=2037043; DOI=10.1016/0014-5793(91)80491-k;
RA   Luetticken C., Kruettgen A., Moeller C., Heinrich P.C., Rose-John S.;
RT   "Evidence for the importance of a positive charge and an alpha-helical
RT   structure of the C-terminus for biological activity of human IL-6.";
RL   FEBS Lett. 282:265-267(1991).
RN   [18]
RP   TISSUE SPECIFICITY, INDUCTION BY EXERCISE, AND SUBCELLULAR LOCATION.
RX   PubMed=11080265; DOI=10.1111/j.1469-7793.2000.00237.x;
RA   Steensberg A., van Hall G., Osada T., Sacchetti M., Saltin B.,
RA   Klarlund Pedersen B.;
RT   "Production of interleukin-6 in contracting human skeletal muscles can
RT   account for the exercise-induced increase in plasma interleukin-6.";
RL   J. Physiol. (Lond.) 529:237-242(2000).
RN   [19]
RP   FUNCTION.
RX   PubMed=12794819; DOI=10.1002/art.11143;
RA   Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K.,
RA   Nishimoto N.;
RT   "Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial
RT   growth factor production in rheumatoid arthritis.";
RL   Arthritis Rheum. 48:1521-1529(2003).
RN   [20]
RP   FUNCTION.
RX   PubMed=15124018; DOI=10.1172/jci20945;
RA   Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K.,
RA   Ganz T.;
RT   "IL-6 mediates hypoferremia of inflammation by inducing the synthesis of
RT   the iron regulatory hormone hepcidin.";
RL   J. Clin. Invest. 113:1271-1276(2004).
RN   [21]
RP   FUNCTION.
RX   PubMed=17075861; DOI=10.1002/art.22175;
RA   De Benedetti F., Rucci N., Del Fattore A., Peruzzi B., Paro R., Longo M.,
RA   Vivarelli M., Muratori F., Berni S., Ballanti P., Ferrari S., Teti A.;
RT   "Impaired skeletal development in interleukin-6-transgenic mice: a model
RT   for the impact of chronic inflammation on the growing skeletal system.";
RL   Arthritis Rheum. 54:3551-3563(2006).
RN   [22]
RP   FUNCTION.
RX   PubMed=20823453; DOI=10.1152/ajpendo.00328.2010;
RA   Wolsk E., Mygind H., Groendahl T.S., Pedersen B.K., van Hall G.;
RT   "IL-6 selectively stimulates fat metabolism in human skeletal muscle.";
RL   Am. J. Physiol. 299:E832-E840(2010).
RN   [23]
RP   FUNCTION.
RX   PubMed=22037645; DOI=10.1038/nm.2513;
RA   Ellingsgaard H., Hauselmann I., Schuler B., Habib A.M., Baggio L.L.,
RA   Meier D.T., Eppler E., Bouzakri K., Wueest S., Muller Y.D., Hansen A.M.,
RA   Reinecke M., Konrad D., Gassmann M., Reimann F., Halban P.A., Gromada J.,
RA   Drucker D.J., Gribble F.M., Ehses J.A., Donath M.Y.;
RT   "Interleukin-6 enhances insulin secretion by increasing glucagon-like
RT   peptide-1 secretion from L cells and alpha cells.";
RL   Nat. Med. 17:1481-1489(2011).
RN   [24]
RP   PHOSPHORYLATION AT SER-81.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [25]
RP   FUNCTION.
RX   PubMed=25731159; DOI=10.1038/nature14228;
RA   Taniguchi K., Wu L.W., Grivennikov S.I., de Jong P.R., Lian I., Yu F.X.,
RA   Wang K., Ho S.B., Boland B.S., Chang J.T., Sandborn W.J., Hardiman G.,
RA   Raz E., Maehara Y., Yoshimura A., Zucman-Rossi J., Guan K.L., Karin M.;
RT   "A gp130-Src-YAP module links inflammation to epithelial regeneration.";
RL   Nature 519:57-62(2015).
RN   [26]
RP   INTERACTION WITH IL6R AND SORL1.
RX   PubMed=28265003; DOI=10.1128/mcb.00641-16;
RA   Larsen J.V., Petersen C.M.;
RT   "SorLA in Interleukin-6 Signaling and Turnover.";
RL   Mol. Cell. Biol. 37:0-0(2017).
RN   [27]
RP   REVIEW ON FUNCTION.
RX   PubMed=30995492; DOI=10.1016/j.immuni.2019.03.026;
RA   Kang S., Tanaka T., Narazaki M., Kishimoto T.;
RT   "Targeting Interleukin-6 Signaling in Clinic.";
RL   Immunity 50:1007-1023(2019).
RN   [28]
RP   STRUCTURE BY NMR.
RX   PubMed=8555185; DOI=10.1021/bi951949e;
RA   Nishimura C., Watanabe A., Gouda H., Shimada I., Arata Y.;
RT   "Folding topologies of human interleukin-6 and its mutants as studied by
RT   NMR spectroscopy.";
RL   Biochemistry 35:273-281(1996).
RN   [29]
RP   STRUCTURE BY NMR.
RX   PubMed=9159484; DOI=10.1006/jmbi.1997.0933;
RA   Xu G.-Y., Yu H.-A., Hong J., Stahl M., McDonagh T., Kay L.E., Cumming D.A.;
RT   "Solution structure of recombinant human interleukin-6.";
RL   J. Mol. Biol. 268:468-481(1997).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
RX   PubMed=9118960; DOI=10.1093/emboj/16.5.989;
RA   Somers W., Stahl M., Seehra J.S.;
RT   "1.9-A crystal structure of interleukin 6: implications for a novel mode of
RT   receptor dimerization and signaling.";
RL   EMBO J. 16:989-997(1997).
RN   [31] {ECO:0000244|PDB:1P9M}
RP   X-RAY CRYSTALLOGRAPHY (3.65 ANGSTROMS) OF 29-212 IN COMPLEX WITH IL6ST AND
RP   IL6R, AND SUBUNIT.
RX   PubMed=12829785; DOI=10.1126/science.1083901;
RA   Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C.;
RT   "Hexameric structure and assembly of the interleukin-6/IL-6 alpha-
RT   receptor/gp130 complex.";
RL   Science 300:2101-2104(2003).
RN   [32]
RP   INVOLVEMENT IN RASJ.
RX   PubMed=9769329; DOI=10.1172/jci2629;
RA   Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S.,
RA   Humphries S., Woo P.;
RT   "The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6
RT   transcription and plasma IL-6 levels, and an association with systemic-
RT   onset juvenile chronic arthritis.";
RL   J. Clin. Invest. 102:1369-1376(1998).
RN   [33]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO KAPOSI SARCOMA.
RX   PubMed=11001912;
RA   Foster C.B., Lehrnbecher T., Samuels S., Stein S., Mol F., Metcalf J.A.,
RA   Wyvill K., Steinberg S.M., Kovacs J., Blauvelt A., Yarchoan R.,
RA   Chanock S.J.;
RT   "An IL6 promoter polymorphism is associated with a lifetime risk of
RT   development of Kaposi sarcoma in men infected with human immunodeficiency
RT   virus.";
RL   Blood 96:2562-2567(2000).
RN   [34]
RP   INVOLVEMENT IN BMD.
RX   PubMed=11355017; DOI=10.1007/s100380170077;
RA   Ota N., Nakajima T., Nakazawa I., Suzuki T., Hosoi T., Orimo H., Inoue S.,
RA   Shirai Y., Emi M.;
RT   "A nucleotide variant in the promoter region of the interleukin-6 gene
RT   associated with decreased bone mineral density.";
RL   J. Hum. Genet. 46:267-272(2001).
RN   [35]
RP   INVOLVEMENT IN BMD.
RX   PubMed=12768442; DOI=10.1007/s10038-003-0020-8;
RA   Chung H.W., Seo J.-S., Hur S.E., Kim H.L., Kim J.Y., Jung J.H., Kim L.H.,
RA   Park B.L., Shin H.D.;
RT   "Association of interleukin-6 promoter variant with bone mineral density in
RT   pre-menopausal women.";
RL   J. Hum. Genet. 48:243-248(2003).
CC   -!- FUNCTION: Cytokine with a wide variety of biological functions in
CC       immunity, tissue regeneration, and metabolism. Binds to IL6R, then the
CC       complex associates to the signaling subunit IL6ST/gp130 to trigger the
CC       intracellular IL6-signaling pathway (Probable). The interaction with
CC       the membrane-bound IL6R and IL6ST stimulates 'classic signaling',
CC       whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-
CC       signaling'. Alternatively, 'cluster signaling' occurs when membrane-
CC       bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors
CC       on neighboring receiver cells (Probable).
CC       {ECO:0000305|PubMed:30995492}.
CC   -!- FUNCTION: IL6 is a potent inducer of the acute phase response. Rapid
CC       production of IL6 contributes to host defense during infection and
CC       tissue injury, but excessive IL6 synthesis is involved in disease
CC       pathology. In the innate immune response, is synthesized by myeloid
CC       cells, such as macrophages and dendritic cells, upon recognition of
CC       pathogens through toll-like receptors (TLRs) at the site of infection
CC       or tissue injury (Probable). In the adaptive immune response, is
CC       required for the differentiation of B cells into immunoglobulin-
CC       secreting cells. Plays a major role in the differentiation of CD4(+) T
CC       cell subsets. Essential factor for the development of T follicular
CC       helper (Tfh) cells that are required for the induction of germinal-
CC       center formation. Required to drive naive CD4(+) T cells to the Th17
CC       lineage. Also required for proliferation of myeloma cells and the
CC       survival of plasmablast cells (By similarity).
CC       {ECO:0000250|UniProtKB:P08505, ECO:0000305|PubMed:30995492}.
CC   -!- FUNCTION: Acts as an essential factor in bone homeostasis and on
CC       vessels directly or indirectly by induction of VEGF, resulting in
CC       increased angiogenesis activity and vascular permeability
CC       (PubMed:17075861, PubMed:12794819). Induces, through 'trans-signaling'
CC       and synergistically with IL1B and TNF, the production of VEGF
CC       (PubMed:12794819). Involved in metabolic controls, is discharged into
CC       the bloodstream after muscle contraction increasing lipolysis and
CC       improving insulin resistance (PubMed:20823453). 'Trans-signaling' in
CC       central nervous system also regulates energy and glucose homeostasis
CC       (By similarity). Mediates, through GLP-1, crosstalk between insulin-
CC       sensitive tissues, intestinal L cells and pancreatic islets to adapt to
CC       changes in insulin demand (By similarity). Also acts as a myokine
CC       (Probable). Plays a protective role during liver injury, being required
CC       for maintenance of tissue regeneration (By similarity). Also has a
CC       pivotal role in iron metabolism by regulating HAMP/hepcidin expression
CC       upon inflammation or bacterial infection (PubMed:15124018). Through
CC       activation of IL6ST-YAP-NOTCH pathway, induces inflammation-induced
CC       epithelial regeneration (By similarity). {ECO:0000250|UniProtKB:P08505,
CC       ECO:0000269|PubMed:12794819, ECO:0000269|PubMed:15124018,
CC       ECO:0000269|PubMed:17075861, ECO:0000269|PubMed:20823453,
CC       ECO:0000305|PubMed:30995492}.
CC   -!- SUBUNIT: Component of a hexamer of two molecules each of IL6, IL6R and
CC       IL6ST; first binds to IL6R to associate with the signaling subunit
CC       IL6ST (PubMed:12829785). Interacts with IL6R (via the N-terminal
CC       ectodomain); this interaction may be affected by IL6R-binding with
CC       SORL1, hence decreasing IL6 cis signaling (PubMed:28265003). Interacts
CC       with SORL1 (via the N-terminal ectodomain); this interaction leads to
CC       IL6 internalization and lysosomal degradation (PubMed:28265003). May
CC       form a trimeric complex with the soluble SORL1 ectodomain and soluble
CC       IL6R receptor; this interaction might stabilize circulating IL6, hence
CC       promoting IL6 trans signaling (PubMed:28265003).
CC       {ECO:0000269|PubMed:12829785, ECO:0000269|PubMed:28265003}.
CC   -!- INTERACTION:
CC       P05231; P08887: IL6R; NbExp=7; IntAct=EBI-720533, EBI-299383;
CC       P05231; Q92673: SORL1; NbExp=4; IntAct=EBI-720533, EBI-1171329;
CC       P05231; Q99523: SORT1; NbExp=4; IntAct=EBI-720533, EBI-1057058;
CC       P05231; Q05516: ZBTB16; NbExp=2; IntAct=EBI-720533, EBI-711925;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:11080265}.
CC   -!- TISSUE SPECIFICITY: Produced by skeletal muscle.
CC       {ECO:0000269|PubMed:11080265}.
CC   -!- INDUCTION: Plasma levels are highly increased upon exercise, due to
CC       enhanced production by contracting skeletal muscles.
CC       {ECO:0000269|PubMed:11080265}.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:1883960}.
CC   -!- POLYMORPHISM: Genetic variations in IL6 may be correlated with bone
CC       mineral density (BMD). Low BMD is a risk factor for osteoporotic
CC       fracture. Osteoporosis is characterized by reduced bone mineral
CC       density, disruption of bone microarchitecture, and the alteration of
CC       the amount and variety of non-collagenous proteins in bone.
CC       Osteoporotic bones are more at risk of fracture.
CC       {ECO:0000269|PubMed:11355017, ECO:0000269|PubMed:12768442}.
CC   -!- DISEASE: Rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]: An
CC       inflammatory articular disorder with systemic onset beginning before
CC       the age of 16. It represents a subgroup of juvenile arthritis
CC       associated with severe extraarticular features and occasionally fatal
CC       complications. During active phases of the disorder, patients display a
CC       typical daily spiking fever, an evanescent macular rash,
CC       lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
CC       {ECO:0000269|PubMed:9769329}. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A IL6 promoter polymorphism is associated with a lifetime
CC       risk of development of Kaposi sarcoma in HIV-infected men.
CC       {ECO:0000269|PubMed:11001912}.
CC   -!- SIMILARITY: Belongs to the IL-6 superfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Interleukin-6 entry;
CC       URL="https://en.wikipedia.org/wiki/Interleukin_6";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/il6/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL6";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IL6ID519ch7p15.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X04430; CAA28026.1; -; mRNA.
DR   EMBL; M14584; AAA52728.1; -; mRNA.
DR   EMBL; X04602; CAA28268.1; -; mRNA.
DR   EMBL; Y00081; CAA68278.1; -; Genomic_DNA.
DR   EMBL; M18403; AAA52729.1; -; mRNA.
DR   EMBL; M29150; AAA59154.1; -; mRNA.
DR   EMBL; X04402; CAA27990.1; -; Genomic_DNA.
DR   EMBL; X04403; CAA27991.1; -; mRNA.
DR   EMBL; M54894; AAC41704.1; -; mRNA.
DR   EMBL; S56892; AAD13886.1; -; mRNA.
DR   EMBL; AF372214; AAK48987.1; -; Genomic_DNA.
DR   EMBL; BC015511; AAH15511.1; -; mRNA.
DR   CCDS; CCDS5375.1; -.
DR   PIR; A32648; IVHUB2.
DR   RefSeq; NP_000591.1; NM_000600.4.
DR   RefSeq; XP_011513692.1; XM_011515390.2.
DR   PDB; 1ALU; X-ray; 1.90 A; A=28-212.
DR   PDB; 1IL6; NMR; -; A=28-212.
DR   PDB; 1N2Q; Model; -; E/F=30-212.
DR   PDB; 1P9M; X-ray; 3.65 A; B=29-212.
DR   PDB; 2IL6; NMR; -; A=28-212.
DR   PDB; 4CNI; X-ray; 2.20 A; C/D=42-212.
DR   PDB; 4J4L; X-ray; 2.30 A; C/D=47-212.
DR   PDB; 4NI7; X-ray; 2.40 A; A=28-212.
DR   PDB; 4NI9; X-ray; 2.55 A; A/C=28-212.
DR   PDB; 4O9H; X-ray; 2.42 A; A=28-212.
DR   PDB; 4ZS7; X-ray; 2.93 A; A=42-212.
DR   PDB; 5FUC; X-ray; 2.70 A; A/B=49-212.
DR   PDBsum; 1ALU; -.
DR   PDBsum; 1IL6; -.
DR   PDBsum; 1N2Q; -.
DR   PDBsum; 1P9M; -.
DR   PDBsum; 2IL6; -.
DR   PDBsum; 4CNI; -.
DR   PDBsum; 4J4L; -.
DR   PDBsum; 4NI7; -.
DR   PDBsum; 4NI9; -.
DR   PDBsum; 4O9H; -.
DR   PDBsum; 4ZS7; -.
DR   PDBsum; 5FUC; -.
DR   SMR; P05231; -.
DR   BioGRID; 109783; 5.
DR   DIP; DIP-482N; -.
DR   IntAct; P05231; 8.
DR   STRING; 9606.ENSP00000385675; -.
DR   BindingDB; P05231; -.
DR   ChEMBL; CHEMBL1795129; -.
DR   DrugBank; DB05767; Andrographolide.
DR   DrugBank; DB05513; Atiprimod.
DR   DrugBank; DB11967; Binimetinib.
DR   DrugBank; DB05744; CRx-139.
DR   DrugBank; DB12140; Dilmapimod.
DR   DrugBank; DB10770; Foreskin fibroblast (neonatal).
DR   DrugBank; DB10772; Foreskin keratinocyte (neonatal).
DR   DrugBank; DB01404; Ginseng.
DR   DrugBank; DB09221; Polaprezinc.
DR   DrugBank; DB09036; Siltuximab.
DR   DrugBank; DB06083; Tapinarof.
DR   DrugBank; DB05470; VX-702.
DR   DrugBank; DB05017; YSIL6.
DR   DrugCentral; P05231; -.
DR   GlyGen; P05231; 1 site.
DR   iPTMnet; P05231; -.
DR   MetOSite; P05231; -.
DR   PhosphoSitePlus; P05231; -.
DR   BioMuta; IL6; -.
DR   DMDM; 124347; -.
DR   MassIVE; P05231; -.
DR   PaxDb; P05231; -.
DR   PeptideAtlas; P05231; -.
DR   PRIDE; P05231; -.
DR   ProteomicsDB; 51828; -.
DR   ABCD; P05231; 181 sequenced antibodies.
DR   Antibodypedia; 12025; 2741 antibodies.
DR   DNASU; 3569; -.
DR   Ensembl; ENST00000258743; ENSP00000258743; ENSG00000136244.
DR   Ensembl; ENST00000404625; ENSP00000385675; ENSG00000136244.
DR   GeneID; 3569; -.
DR   KEGG; hsa:3569; -.
DR   CTD; 3569; -.
DR   DisGeNET; 3569; -.
DR   EuPathDB; HostDB:ENSG00000136244.11; -.
DR   GeneCards; IL6; -.
DR   HGNC; HGNC:6018; IL6.
DR   HPA; ENSG00000136244; Tissue enhanced (adipose tissue, lymphoid tissue).
DR   MalaCards; IL6; -.
DR   MIM; 147620; gene.
DR   MIM; 148000; phenotype.
DR   MIM; 604302; phenotype.
DR   neXtProt; NX_P05231; -.
DR   OpenTargets; ENSG00000136244; -.
DR   Orphanet; 206; NON RARE IN EUROPE: Crohn disease.
DR   Orphanet; 85414; Systemic-onset juvenile idiopathic arthritis.
DR   PharmGKB; PA198; -.
DR   eggNOG; ENOG502S7Q4; Eukaryota.
DR   GeneTree; ENSGT00390000000878; -.
DR   InParanoid; P05231; -.
DR   KO; K05405; -.
DR   OMA; YDKCENS; -.
DR   PhylomeDB; P05231; -.
DR   TreeFam; TF335984; -.
DR   PathwayCommons; P05231; -.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-6783783; Interleukin-10 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   Reactome; R-HSA-9662834; CD163 mediating an anti-inflammatory response.
DR   SignaLink; P05231; -.
DR   SIGNOR; P05231; -.
DR   BioGRID-ORCS; 3569; 4 hits in 872 CRISPR screens.
DR   ChiTaRS; IL6; human.
DR   EvolutionaryTrace; P05231; -.
DR   GeneWiki; Interleukin_6; -.
DR   GenomeRNAi; 3569; -.
DR   Pharos; P05231; Tclin.
DR   PRO; PR:P05231; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P05231; protein.
DR   Bgee; ENSG00000136244; Expressed in left coronary artery and 159 other tissues.
DR   ExpressionAtlas; P05231; baseline and differential.
DR   Genevisible; P05231; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005896; C:interleukin-6 receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005125; F:cytokine activity; IDA:BHF-UCL.
DR   GO; GO:0008083; F:growth factor activity; IDA:BHF-UCL.
DR   GO; GO:0005138; F:interleukin-6 receptor binding; IPI:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; TAS:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:BHF-UCL.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IMP:MGI.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; TAS:BHF-UCL.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; TAS:BHF-UCL.
DR   GO; GO:0051607; P:defense response to virus; IDA:BHF-UCL.
DR   GO; GO:0031018; P:endocrine pancreas development; ISS:BHF-UCL.
DR   GO; GO:0070091; P:glucagon secretion; ISS:BHF-UCL.
DR   GO; GO:0002384; P:hepatic immune response; IDA:BHF-UCL.
DR   GO; GO:0006959; P:humoral immune response; IC:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IDA:BHF-UCL.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035633; P:maintenance of blood-brain barrier; TAS:ARUK-UCL.
DR   GO; GO:0002548; P:monocyte chemotaxis; IC:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045779; P:negative regulation of bone resorption; ISS:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0045079; P:negative regulation of chemokine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0032966; P:negative regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; NAS:BHF-UCL.
DR   GO; GO:2000660; P:negative regulation of interleukin-1-mediated signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0010888; P:negative regulation of lipid storage; NAS:BHF-UCL.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; TAS:ARUK-UCL.
DR   GO; GO:2000635; P:negative regulation of primary miRNA processing; IGI:ARUK-UCL.
DR   GO; GO:0070050; P:neuron cellular homeostasis; TAS:ARUK-UCL.
DR   GO; GO:0031175; P:neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0001781; P:neutrophil apoptotic process; IDA:UniProtKB.
DR   GO; GO:0002446; P:neutrophil mediated immunity; TAS:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:BHF-UCL.
DR   GO; GO:0002675; P:positive regulation of acute inflammatory response; IDA:BHF-UCL.
DR   GO; GO:1902512; P:positive regulation of apoptotic DNA fragmentation; IMP:ARUK-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0050871; P:positive regulation of B cell activation; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IGI:ARUK-UCL.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IDA:ARUK-UCL.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:ARUK-UCL.
DR   GO; GO:0090091; P:positive regulation of extracellular matrix disassembly; IMP:ARUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0060252; P:positive regulation of glial cell proliferation; IDA:ARUK-UCL.
DR   GO; GO:0051024; P:positive regulation of immunoglobulin secretion; IDA:BHF-UCL.
DR   GO; GO:0045380; P:positive regulation of interleukin-17 biosynthetic process; ISS:ARUK-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:1904996; P:positive regulation of leukocyte adhesion to vascular endothelial cell; IDA:ARUK-UCL.
DR   GO; GO:0002690; P:positive regulation of leukocyte chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0150078; P:positive regulation of neuroinflammatory response; TAS:ARUK-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IDA:ARUK-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:1903800; P:positive regulation of production of miRNAs involved in gene silencing by miRNA; IDA:ARUK-UCL.
DR   GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IDA:BHF-UCL.
DR   GO; GO:1904894; P:positive regulation of receptor signaling pathway via STAT; IGI:ARUK-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IDA:BHF-UCL.
DR   GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB.
DR   GO; GO:2000676; P:positive regulation of type B pancreatic cell apoptotic process; TAS:BHF-UCL.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IDA:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:ARUK-UCL.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0045765; P:regulation of angiogenesis; IC:BHF-UCL.
DR   GO; GO:0061888; P:regulation of astrocyte activation; TAS:ARUK-UCL.
DR   GO; GO:1903978; P:regulation of microglial cell activation; TAS:ARUK-UCL.
DR   GO; GO:0150077; P:regulation of neuroinflammatory response; TAS:ARUK-UCL.
DR   GO; GO:0010574; P:regulation of vascular endothelial growth factor production; IDA:BHF-UCL.
DR   GO; GO:0051384; P:response to glucocorticoid; IDA:BHF-UCL.
DR   GO; GO:0032494; P:response to peptidoglycan; NAS:BHF-UCL.
DR   GO; GO:0072540; P:T-helper 17 cell lineage commitment; ISS:UniProtKB.
DR   InterPro; IPR009079; 4_helix_cytokine-like_core.
DR   InterPro; IPR003574; IL-6.
DR   InterPro; IPR030474; IL-6/GCSF/MGF.
DR   InterPro; IPR030473; IL6/GCSF/MGF_CS.
DR   PANTHER; PTHR10511; PTHR10511; 1.
DR   PANTHER; PTHR10511:SF3; PTHR10511:SF3; 1.
DR   Pfam; PF00489; IL6; 1.
DR   PIRSF; PIRSF001935; IL6_MGF_GCSF; 1.
DR   PRINTS; PR00433; IL6GCSFMGF.
DR   SMART; SM00126; IL6; 1.
DR   SUPFAM; SSF47266; SSF47266; 1.
DR   PROSITE; PS00254; INTERLEUKIN_6; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Cytokine; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Growth factor; Phosphoprotein; Polymorphism;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL          1..29
FT                   /evidence="ECO:0000269|PubMed:1883960,
FT                   ECO:0000269|PubMed:2610854, ECO:0000269|PubMed:3279116"
FT   CHAIN           30..212
FT                   /note="Interleukin-6"
FT                   /id="PRO_0000015582"
FT   MOD_RES         81
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039"
FT   CARBOHYD        73
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:1883960"
FT   DISULFID        72..78
FT                   /evidence="ECO:0000269|PubMed:2472117"
FT   DISULFID        101..111
FT                   /evidence="ECO:0000269|PubMed:2472117"
FT   VARIANT         32
FT                   /note="P -> S (in dbSNP:rs2069830)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_013075"
FT   VARIANT         162
FT                   /note="D -> E (in dbSNP:rs13306435)"
FT                   /id="VAR_029266"
FT   VARIANT         162
FT                   /note="D -> V (in dbSNP:rs2069860)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_013076"
FT   MUTAGEN         173
FT                   /note="A->V: Almost no loss of activity."
FT                   /evidence="ECO:0000269|PubMed:2037043"
FT   MUTAGEN         185
FT                   /note="W->R: No loss of activity."
FT                   /evidence="ECO:0000269|PubMed:2037043"
FT   MUTAGEN         204
FT                   /note="S->P: 87% loss of activity."
FT                   /evidence="ECO:0000269|PubMed:2037043"
FT   MUTAGEN         210
FT                   /note="R->K,E,Q,T,A,P: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:2037043"
FT   MUTAGEN         212
FT                   /note="M->T,N,S,R: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:2037043"
FT   HELIX           49..75
FT                   /evidence="ECO:0000244|PDB:1ALU"
FT   STRAND          76..79
FT                   /evidence="ECO:0000244|PDB:2IL6"
FT   TURN            81..83
FT                   /evidence="ECO:0000244|PDB:4CNI"
FT   HELIX           84..87
FT                   /evidence="ECO:0000244|PDB:4CNI"
FT   HELIX           97..99
FT                   /evidence="ECO:0000244|PDB:1ALU"
FT   STRAND          102..105
FT                   /evidence="ECO:0000244|PDB:4J4L"
FT   HELIX           108..132
FT                   /evidence="ECO:0000244|PDB:1ALU"
FT   STRAND          134..136
FT                   /evidence="ECO:0000244|PDB:4J4L"
FT   HELIX           137..157
FT                   /evidence="ECO:0000244|PDB:1ALU"
FT   STRAND          159..161
FT                   /evidence="ECO:0000244|PDB:1ALU"
FT   HELIX           169..180
FT                   /evidence="ECO:0000244|PDB:1ALU"
FT   HELIX           184..209
FT                   /evidence="ECO:0000244|PDB:1ALU"
SQ   SEQUENCE   212 AA;  23718 MW;  1F1ED1FE1B734079 CRC64;
     MNSFSTSAFG PVAFSLGLLL VLPAAFPAPV PPGEDSKDVA APHRQPLTSS ERIDKQIRYI
     LDGISALRKE TCNKSNMCES SKEALAENNL NLPKMAEKDG CFQSGFNEET CLVKIITGLL
     EFEVYLEYLQ NRFESSEEQA RAVQMSTKVL IQFLQKKAKN LDAITTPDPT TNASLLTKLQ
     AQNQWLQDMT THLILRSFKE FLQSSLRALR QM
//
ID   CATL1_HUMAN             Reviewed;         333 AA.
AC   P07711; Q6IAV1; Q96QJ0;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 2.
DT   12-AUG-2020, entry version 221.
DE   RecName: Full=Procathepsin L {ECO:0000305};
DE            EC=3.4.22.15 {ECO:0000269|PubMed:9468501};
DE   AltName: Full=Cathepsin L1 {ECO:0000305};
DE   AltName: Full=Major excreted protein;
DE            Short=MEP;
DE   Contains:
DE     RecName: Full=Cathepsin L;
DE   Contains:
DE     RecName: Full=Cathepsin L heavy chain;
DE   Contains:
DE     RecName: Full=Cathepsin L light chain;
DE   Flags: Precursor;
GN   Name=CTSL {ECO:0000312|HGNC:HGNC:2537}; Synonyms=CTSL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3421948; DOI=10.1042/bj2530303;
RA   Gal S., Gottesman M.M.;
RT   "Isolation and sequence of a cDNA for human pro-(cathepsin L).";
RL   Biochem. J. 253:303-306(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2835398; DOI=10.1172/jci113497;
RA   Joseph L.J., Chang L.C., Stamenkovich D., Sukhatme V.P.;
RT   "Complete nucleotide and deduced amino acid sequences of human and murine
RT   preprocathepsin L. An abundant transcript induced by transformation of
RT   fibroblasts.";
RL   J. Clin. Invest. 81:1621-1629(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 114-288 AND 292-333.
RX   PubMed=3342889; DOI=10.1016/0014-5793(88)80028-0;
RA   Ritonja A., Popovic T., Kotnik M., Machleidt W., Turk V.;
RT   "Amino acid sequences of the human kidney cathepsins H and L.";
RL   FEBS Lett. 228:341-345(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 113-154.
RX   PubMed=3550705; DOI=10.1093/nar/15.7.3186;
RA   Joseph L.J., Lapid S., Sukhatme V.P.;
RT   "The major ras induced protein in NIH3T3 cells is cathepsin L.";
RL   Nucleic Acids Res. 15:3186-3186(1987).
RN   [9]
RP   PROTEIN SEQUENCE OF 114-154 AND 292-333.
RX   PubMed=3545185; DOI=10.1042/bj2400373;
RA   Mason R.W., Walker J.E., Northrop F.D.;
RT   "The N-terminal amino acid sequences of the heavy and light chains of human
RT   cathepsin L. Relationship to a cDNA clone for a major cysteine proteinase
RT   from a mouse macrophage cell line.";
RL   Biochem. J. 240:373-377(1986).
RN   [10]
RP   FUNCTION, PROTEOLYTICAL CLEAVAGE, MUTAGENESIS OF CYS-138, CATALYTIC
RP   ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY REGULATION, AND ACTIVE
RP   SITE.
RX   PubMed=9468501; DOI=10.1074/jbc.273.8.4478;
RA   Menard R., Carmona E., Takebe S., Dufour E., Plouffe C., Mason P.,
RA   Mort J.S.;
RT   "Autocatalytic processing of recombinant human procathepsin L. Contribution
RT   of both intermolecular and unimolecular events in the processing of
RT   procathepsin L in vitro.";
RL   J. Biol. Chem. 273:4478-4484(1998).
RN   [11]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10716919; DOI=10.1093/emboj/19.6.1187;
RA   Felbor U., Dreier L., Bryant R.A., Ploegh H.L., Olsen B.R., Mothes W.;
RT   "Secreted cathepsin L generates endostatin from collagen XVIII.";
RL   EMBO J. 19:1187-1194(2000).
RN   [12]
RP   GLYCOSYLATION AT ASN-221.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15099520; DOI=10.1016/s1097-2765(04)00209-6;
RA   Goulet B., Baruch A., Moon N.S., Poirier M., Sansregret L.L., Erickson A.,
RA   Bogyo M., Nepveu A.;
RT   "A cathepsin L isoform that is devoid of a signal peptide localizes to the
RT   nucleus in S phase and processes the CDP/Cux transcription factor.";
RL   Mol. Cell 14:207-219(2004).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-221.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=16081529; DOI=10.1073/pnas.0505577102;
RA   Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L.,
RA   Bates P.;
RT   "Inhibitors of cathepsin L prevent severe acute respiratory syndrome
RT   coronavirus entry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:11876-11881(2005).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=16339146; DOI=10.1074/jbc.m508381200;
RA   Huang I.C., Bosch B.J., Li F., Li W., Lee K.H., Ghiran S., Vasilieva N.,
RA   Dermody T.S., Harrison S.C., Dormitzer P.R., Farzan M., Rottier P.J.,
RA   Choe H.;
RT   "SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to
RT   infect ACE2-expressing cells.";
RL   J. Biol. Chem. 281:3198-3203(2006).
RN   [17]
RP   FUNCTION (MICROBIAL INFECTION), AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=18562523; DOI=10.1128/jvi.00415-08;
RA   Bosch B.J., Bartelink W., Rottier P.J.;
RT   "Cathepsin L functionally cleaves the severe acute respiratory syndrome
RT   coronavirus class I fusion protein upstream of rather than adjacent to the
RT   fusion peptide.";
RL   J. Virol. 82:8887-8890(2008).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-221.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   FUNCTION (MICROBIAL INFECTION), AND ACTIVITY REGULATION.
RX   PubMed=26953343; DOI=10.1074/jbc.m116.716100;
RA   Zhou N., Pan T., Zhang J., Li Q., Zhang X., Bai C., Huang F., Peng T.,
RA   Zhang J., Liu C., Tao L., Zhang H.;
RT   "Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late
RT   Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East
RT   Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory
RT   Syndrome Coronavirus (SARS-CoV).";
RL   J. Biol. Chem. 291:9218-9232(2016).
RN   [23]
RP   ACTIVITY REGULATION.
RX   PubMed=30425301; DOI=10.1038/s41436-018-0355-3;
RA   van den Bogaard E.H.J., van Geel M., van Vlijmen-Willems I.M.J.J.,
RA   Jansen P.A.M., Peppelman M., van Erp P.E.J., Atalay S., Venselaar H.,
RA   Simon M.E.H., Joosten M., Schalkwijk J., Zeeuwen P.L.J.M.;
RT   "Deficiency of the human cysteine protease inhibitor cystatin M/E causes
RT   hypotrichosis and dry skin.";
RL   Genet. Med. 21:1559-1567(2019).
RN   [24]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor.";
RL   Cell 181:1-10(2020).
RN   [25]
RP   ACTIVITY REGULATION.
RX   PubMed=32361028; DOI=10.1016/j.ijantimicag.2020.106004;
RA   Smieszek S.P., Przychodzen B.P., Polymeropoulos M.H.;
RT   "Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19
RT   treatment.";
RL   Int. J. Antimicrob. Agents 0:0-0(2020).
RN   [26]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV.";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 18-333.
RX   PubMed=8896443; DOI=10.1002/j.1460-2075.1996.tb00934.x;
RA   Coulombe R., Grochulski P., Sivaraman J., Menard R., Mort J.S., Cygler M.;
RT   "Structure of human procathepsin L reveals the molecular basis of
RT   inhibition by the prosegment.";
RL   EMBO J. 15:5492-5503(1996).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 114-333.
RX   PubMed=9141479; DOI=10.1016/s0014-5793(97)00216-0;
RA   Fujishima A., Imai Y., Nomura T., Fujisawa Y., Yamamoto Y., Sugarawa T.;
RT   "The crystal structure of human cathepsin L complexed with E-64.";
RL   FEBS Lett. 407:47-50(1997).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 18-333.
RA   Cygler M., Coulombe R.;
RL   Submitted (AUG-1999) to the PDB data bank.
CC   -!- FUNCTION: Thiol protease important for the overall degradation of
CC       proteins in lysosomes (Probable). Plays a critical for normal cellular
CC       functions such as general protein turnover, antigen processing and bone
CC       remodeling. Involved in the solubilization of cross-linked
CC       TG/thyroglobulin and in the subsequent release of thyroid hormone
CC       thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the
CC       thyroid follicle lumen (By similarity). In neuroendocrine chromaffin
CC       cells secretory vesicles, catalyzes the prohormone proenkephalin
CC       processing to the active enkephalin peptide neurotransmitter (By
CC       similarity). In thymus, regulates CD4(+) T cell positive selection by
CC       generating the major histocompatibility complex class II (MHCII) bound
CC       peptide ligands presented by cortical thymic epithelial cells. Also
CC       mediates invariant chain processing in cortical thymic epithelial cells
CC       (By similarity). Major elastin-degrading enzyme at neutral pH.
CC       Accumulates as a mature and active enzyme in the extracellular space of
CC       antigen presenting cells (APCs) to regulate degradation of the
CC       extracellular matrix in the course of inflammation (By similarity).
CC       Secreted form generates endostatin from COL18A1 (PubMed:10716919).
CC       Critical for cardiac morphology and function. Plays an important role
CC       in hair follicle morphogenesis and cycling, as well as epidermal
CC       differentiation (By similarity). Required for maximal stimulation of
CC       steroidogenesis by TIMP1 (By similarity).
CC       {ECO:0000250|UniProtKB:P06797, ECO:0000250|UniProtKB:P07154,
CC       ECO:0000250|UniProtKB:P25975, ECO:0000269|PubMed:10716919,
CC       ECO:0000305}.
CC   -!- FUNCTION: [Isoform 2]: Functions in the regulation of cell cycle
CC       progression through proteolytic processing of the CUX1 transcription
CC       factor (PubMed:15099520). Translation initiation at downstream start
CC       sites allows the synthesis of isoforms that are devoid of a signal
CC       peptide and localize to the nucleus where they cleave the CUX1
CC       transcription factor and modify its DNA binding properties
CC       (PubMed:15099520). {ECO:0000269|PubMed:15099520}.
CC   -!- FUNCTION: (Microbial infection) Facilitates human coronaviruses SARS-
CC       CoV and SARS-CoV-2 infections via proteolysis of coronavirus spike (S)
CC       glycoproteins in lysosome for entry into host cell (PubMed:32142651,
CC       PubMed:32221306, PubMed:16339146, PubMed:18562523). Proteolysis within
CC       lysosomes is sufficient to activate membrane fusion by coronaviruses
CC       SARS-CoV and EMC (HCoV-EMC) S as well as Zaire ebolavirus glycoproteins
CC       (PubMed:16081529, PubMed:26953343, PubMed:18562523).
CC       {ECO:0000269|PubMed:16081529, ECO:0000269|PubMed:16339146,
CC       ECO:0000269|PubMed:18562523, ECO:0000269|PubMed:26953343,
CC       ECO:0000269|PubMed:32142651, ECO:0000269|PubMed:32221306}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Specificity close to that of papain. As compared to cathepsin
CC         B, cathepsin L exhibits higher activity toward protein substrates,
CC         but has little activity on Z-Arg-Arg-NHMec, and no peptidyl-
CC         dipeptidase activity.; EC=3.4.22.15;
CC         Evidence={ECO:0000269|PubMed:9468501};
CC   -!- ACTIVITY REGULATION: Inhibited by the propeptide produced by
CC       autocleavage (PubMed:9468501). Long isoform of CD74/Ii chain stabilizes
CC       the conformation of mature CTSL by binding to its active site and
CC       serving as a chaperone to help maintain a pool of mature enzyme in
CC       endocytic compartments and extracellular space of APCs. IFNG enhances
CC       the conversion into the CTSL mature and active form (By similarity).
CC       Inhibited by CST6. Inhibited by the glycopeptide antibiotic teicoplanin
CC       (PubMed:26953343). Inhibited by amantadine (PubMed:32361028).
CC       {ECO:0000250|UniProtKB:P06797, ECO:0000269|PubMed:26953343,
CC       ECO:0000269|PubMed:30425301, ECO:0000269|PubMed:32361028,
CC       ECO:0000269|PubMed:9468501}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 5.5, also active at pH 7.0 with CUX1 as substrate.
CC         {ECO:0000269|PubMed:10716919, ECO:0000269|PubMed:15099520,
CC         ECO:0000269|PubMed:18562523, ECO:0000269|PubMed:9468501};
CC   -!- SUBUNIT: Dimer of a heavy and a light chain linked by disulfide bonds.
CC       Interacts with Long isoform of CD74/Ii chain; the interaction
CC       stabilizes the conformation of mature CTSL.
CC       {ECO:0000250|UniProtKB:P06797}.
CC   -!- INTERACTION:
CC       P07711; O43765: SGTA; NbExp=3; IntAct=EBI-1220160, EBI-347996;
CC       P07711; G5EFH4: srp-6; Xeno; NbExp=2; IntAct=EBI-1220160, EBI-1549936;
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000250|UniProtKB:P06797}. Apical
CC       cell membrane {ECO:0000250|UniProtKB:P06797}; Peripheral membrane
CC       protein {ECO:0000250|UniProtKB:P06797}; Extracellular side
CC       {ECO:0000250|UniProtKB:P06797}. Cytoplasmic vesicle, secretory vesicle,
CC       chromaffin granule {ECO:0000250|UniProtKB:P25975}. Secreted,
CC       extracellular space {ECO:0000250|UniProtKB:P06797}. Secreted
CC       {ECO:0000250|UniProtKB:P06797}. Note=Localizes to the apical membrane
CC       of thyroid epithelial cells. Released at extracellular space by
CC       activated dendritic cells and macrophages.
CC       {ECO:0000250|UniProtKB:P06797}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus
CC       {ECO:0000269|PubMed:15099520}. Note=Translation initiation at
CC       downstream start sites allows the synthesis of isoforms that are devoid
CC       of a signal peptide and do not transit through the endoplasmic
CC       reticulum to localize to the nucleus (PubMed:15099520). Nuclear
CC       location varies during the cell cycle, whith higher levels during S
CC       phase (PubMed:15099520). {ECO:0000269|PubMed:15099520}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1;
CC         IsoId=P07711-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P07711-3; Sequence=VSP_060720;
CC   -!- PTM: During export along the endocytic pathway, pro-CTSL undergoes
CC       several proteolytic cleavages to generate the CTSL single-chain and
CC       two-chain mature forms, composed of a heavy chain linked to a light
CC       chain by disulfide bonds (By similarity). Autocleavage; produces the
CC       single-chain CTSL after cleavage of the propeptide. The cleavage can be
CC       intermolecular (PubMed:9468501). {ECO:0000250|UniProtKB:P06797,
CC       ECO:0000269|PubMed:9468501}.
CC   -!- SIMILARITY: Belongs to the peptidase C1 family. {ECO:0000255|PROSITE-
CC       ProRule:PRU10088, ECO:0000255|PROSITE-ProRule:PRU10089,
CC       ECO:0000255|PROSITE-ProRule:PRU10090}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CTSL1ID40208ch9q21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X12451; CAA30981.1; -; mRNA.
DR   EMBL; M20496; AAA66974.1; -; mRNA.
DR   EMBL; CR457053; CAG33334.1; -; mRNA.
DR   EMBL; BX537395; CAD97637.1; -; mRNA.
DR   EMBL; AL160279; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012612; AAH12612.1; -; mRNA.
DR   EMBL; X05256; CAA28877.1; -; mRNA.
DR   CCDS; CCDS6675.1; -.
DR   PIR; S01002; KHHUL.
DR   RefSeq; NP_001244900.1; NM_001257971.1.
DR   RefSeq; NP_001244901.1; NM_001257972.1.
DR   RefSeq; NP_001903.1; NM_001912.4.
DR   RefSeq; NP_666023.1; NM_145918.2.
DR   RefSeq; XP_005251773.1; XM_005251716.3.
DR   PDB; 1CJL; X-ray; 2.20 A; A=22-333.
DR   PDB; 1CS8; X-ray; 1.80 A; A=19-333.
DR   PDB; 1ICF; X-ray; 2.00 A; A/C=114-288, B/D=292-333.
DR   PDB; 1MHW; X-ray; 1.90 A; A/B=114-288, C/D=292-333.
DR   PDB; 2NQD; X-ray; 1.75 A; B=113-333.
DR   PDB; 2VHS; X-ray; 1.50 A; A/B/C/D=114-333.
DR   PDB; 2XU1; X-ray; 1.45 A; A/B/C/D=114-333.
DR   PDB; 2XU3; X-ray; 0.90 A; A=114-333.
DR   PDB; 2XU4; X-ray; 1.12 A; A=114-333.
DR   PDB; 2XU5; X-ray; 1.60 A; A=114-333.
DR   PDB; 2YJ2; X-ray; 1.15 A; A=114-333.
DR   PDB; 2YJ8; X-ray; 1.30 A; A=114-333.
DR   PDB; 2YJ9; X-ray; 1.35 A; A=114-333.
DR   PDB; 2YJB; X-ray; 1.40 A; A=114-333.
DR   PDB; 2YJC; X-ray; 1.14 A; A=114-333.
DR   PDB; 3BC3; X-ray; 2.20 A; A/B=114-333.
DR   PDB; 3H89; X-ray; 2.50 A; A/B/C/D/E/F=114-333.
DR   PDB; 3H8B; X-ray; 1.80 A; A/B/C/D/E/F=114-333.
DR   PDB; 3H8C; X-ray; 2.50 A; A/B=114-333.
DR   PDB; 3HHA; X-ray; 1.27 A; A/B/C/D=114-333.
DR   PDB; 3HWN; X-ray; 2.33 A; A/B/C/D=76-333.
DR   PDB; 3IV2; X-ray; 2.20 A; A/B=114-333.
DR   PDB; 3K24; X-ray; 2.50 A; A/B=114-333.
DR   PDB; 3KSE; X-ray; 1.71 A; A/B/C=114-333.
DR   PDB; 3OF8; X-ray; 2.20 A; A=113-333.
DR   PDB; 3OF9; X-ray; 1.76 A; A=113-333.
DR   PDB; 4AXL; X-ray; 1.92 A; A=114-333.
DR   PDB; 4AXM; X-ray; 2.80 A; A/B/F/I/L/O=114-333.
DR   PDB; 5F02; X-ray; 1.43 A; A=114-333.
DR   PDB; 5I4H; X-ray; 1.42 A; A=113-218, B=222-333.
DR   PDB; 5MAE; X-ray; 1.00 A; A=114-333.
DR   PDB; 5MAJ; X-ray; 1.00 A; A=114-333.
DR   PDB; 5MQY; X-ray; 1.13 A; A=114-333.
DR   PDB; 6EZP; X-ray; 1.37 A; A=114-333.
DR   PDB; 6EZX; X-ray; 2.34 A; A/B=114-333.
DR   PDB; 6F06; X-ray; 2.02 A; A/B=114-333.
DR   PDB; 6JD0; X-ray; 1.80 A; A=18-333.
DR   PDB; 6JD8; X-ray; 1.46 A; A=18-333.
DR   PDBsum; 1CJL; -.
DR   PDBsum; 1CS8; -.
DR   PDBsum; 1ICF; -.
DR   PDBsum; 1MHW; -.
DR   PDBsum; 2NQD; -.
DR   PDBsum; 2VHS; -.
DR   PDBsum; 2XU1; -.
DR   PDBsum; 2XU3; -.
DR   PDBsum; 2XU4; -.
DR   PDBsum; 2XU5; -.
DR   PDBsum; 2YJ2; -.
DR   PDBsum; 2YJ8; -.
DR   PDBsum; 2YJ9; -.
DR   PDBsum; 2YJB; -.
DR   PDBsum; 2YJC; -.
DR   PDBsum; 3BC3; -.
DR   PDBsum; 3H89; -.
DR   PDBsum; 3H8B; -.
DR   PDBsum; 3H8C; -.
DR   PDBsum; 3HHA; -.
DR   PDBsum; 3HWN; -.
DR   PDBsum; 3IV2; -.
DR   PDBsum; 3K24; -.
DR   PDBsum; 3KSE; -.
DR   PDBsum; 3OF8; -.
DR   PDBsum; 3OF9; -.
DR   PDBsum; 4AXL; -.
DR   PDBsum; 4AXM; -.
DR   PDBsum; 5F02; -.
DR   PDBsum; 5I4H; -.
DR   PDBsum; 5MAE; -.
DR   PDBsum; 5MAJ; -.
DR   PDBsum; 5MQY; -.
DR   PDBsum; 6EZP; -.
DR   PDBsum; 6EZX; -.
DR   PDBsum; 6F06; -.
DR   PDBsum; 6JD0; -.
DR   PDBsum; 6JD8; -.
DR   SMR; P07711; -.
DR   BioGRID; 107894; 26.
DR   IntAct; P07711; 22.
DR   MINT; P07711; -.
DR   STRING; 9606.ENSP00000345344; -.
DR   BindingDB; P07711; -.
DR   ChEMBL; CHEMBL3837; -.
DR   DrugBank; DB07477; Felbinac.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB03661; L-cysteic acid.
DR   DrugBank; DB14962; Trastuzumab deruxtecan.
DR   DrugCentral; P07711; -.
DR   GuidetoPHARMACOLOGY; 2351; -.
DR   MEROPS; I29.001; -.
DR   GlyConnect; 1081; 12 N-Linked glycans (1 site).
DR   GlyGen; P07711; 1 site, 1 N-linked glycan (1 site).
DR   iPTMnet; P07711; -.
DR   PhosphoSitePlus; P07711; -.
DR   BioMuta; CTSL; -.
DR   DMDM; 115741; -.
DR   EPD; P07711; -.
DR   jPOST; P07711; -.
DR   MassIVE; P07711; -.
DR   MaxQB; P07711; -.
DR   PaxDb; P07711; -.
DR   PeptideAtlas; P07711; -.
DR   PRIDE; P07711; -.
DR   ProteomicsDB; 52023; -.
DR   TopDownProteomics; P07711-1; -.
DR   ABCD; P07711; 1 sequenced antibody.
DR   Antibodypedia; 4374; 609 antibodies.
DR   DNASU; 1514; -.
DR   Ensembl; ENST00000340342; ENSP00000365061; ENSG00000135047.
DR   Ensembl; ENST00000343150; ENSP00000345344; ENSG00000135047.
DR   GeneID; 1514; -.
DR   KEGG; hsa:1514; -.
DR   UCSC; uc004aph.4; human.
DR   CTD; 1514; -.
DR   DisGeNET; 1514; -.
DR   EuPathDB; HostDB:ENSG00000135047.14; -.
DR   GeneCards; CTSL; -.
DR   HGNC; HGNC:2537; CTSL.
DR   HPA; ENSG00000135047; Tissue enhanced (placenta).
DR   MIM; 116880; gene.
DR   neXtProt; NX_P07711; -.
DR   OpenTargets; ENSG00000135047; -.
DR   PharmGKB; PA162382890; -.
DR   eggNOG; KOG1543; Eukaryota.
DR   GeneTree; ENSGT00940000154367; -.
DR   HOGENOM; CLU_012184_1_2_1; -.
DR   InParanoid; P07711; -.
DR   KO; K01365; -.
DR   OMA; GQHYRKS; -.
DR   OrthoDB; 1275401at2759; -.
DR   PhylomeDB; P07711; -.
DR   TreeFam; TF313739; -.
DR   BRENDA; 3.4.22.15; 2681.
DR   PathwayCommons; P07711; -.
DR   Reactome; R-HSA-1236977; Endosomal/Vacuolar pathway.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1679131; Trafficking and processing of endosomal TLR.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-2132295; MHC class II antigen presentation.
DR   Reactome; R-HSA-8939242; RUNX1 regulates transcription of genes involved in differentiation of keratinocytes.
DR   SIGNOR; P07711; -.
DR   BioGRID-ORCS; 1514; 7 hits in 868 CRISPR screens.
DR   ChiTaRS; CTSL; human.
DR   EvolutionaryTrace; P07711; -.
DR   GeneWiki; Cathepsin_L1; -.
DR   GenomeRNAi; 1514; -.
DR   Pharos; P07711; Tchem.
DR   PRO; PR:P07711; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P07711; protein.
DR   Bgee; ENSG00000135047; Expressed in layer of synovial tissue and 248 other tissues.
DR   ExpressionAtlas; P07711; baseline and differential.
DR   Genevisible; P07711; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0036021; C:endolysosome lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005771; C:multivesicular body; IDA:ARUK-UCL.
DR   GO; GO:0005634; C:nucleus; TAS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0005518; F:collagen binding; IDA:BHF-UCL.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; IDA:UniProtKB.
DR   GO; GO:0001968; F:fibronectin binding; IPI:BHF-UCL.
DR   GO; GO:0042393; F:histone binding; IDA:BHF-UCL.
DR   GO; GO:0043394; F:proteoglycan binding; IPI:BHF-UCL.
DR   GO; GO:0097655; F:serpin family protein binding; IPI:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEP:UniProtKB.
DR   GO; GO:0019882; P:antigen processing and presentation; TAS:UniProtKB.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IEP:UniProtKB.
DR   GO; GO:0030574; P:collagen catabolic process; IDA:BHF-UCL.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0071888; P:macrophage apoptotic process; NAS:BHF-UCL.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0051603; P:proteolysis involved in cellular protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0045616; P:regulation of keratinocyte differentiation; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   CDD; cd02248; Peptidase_C1A; 1.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR025661; Pept_asp_AS.
DR   InterPro; IPR000169; Pept_cys_AS.
DR   InterPro; IPR025660; Pept_his_AS.
DR   InterPro; IPR000668; Peptidase_C1A_C.
DR   InterPro; IPR039417; Peptidase_C1A_papain-like.
DR   InterPro; IPR013201; Prot_inhib_I29.
DR   Pfam; PF08246; Inhibitor_I29; 1.
DR   Pfam; PF00112; Peptidase_C1; 1.
DR   PRINTS; PR00705; PAPAIN.
DR   SMART; SM00848; Inhibitor_I29; 1.
DR   SMART; SM00645; Pept_C1; 1.
DR   SUPFAM; SSF54001; SSF54001; 1.
DR   PROSITE; PS00640; THIOL_PROTEASE_ASN; 1.
DR   PROSITE; PS00139; THIOL_PROTEASE_CYS; 1.
DR   PROSITE; PS00639; THIOL_PROTEASE_HIS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Cell membrane; Cytoplasmic vesicle;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Hydrolase;
KW   Lysosome; Membrane; Nucleus; Protease; Reference proteome; Secreted;
KW   Signal; Thiol protease; Zymogen.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000250|UniProtKB:P07154"
FT   PROPEP          18..113
FT                   /note="Activation peptide"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT                   /id="PRO_0000026244"
FT   CHAIN           114..333
FT                   /note="Cathepsin L"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT                   /id="PRO_0000450791"
FT   CHAIN           114..288
FT                   /note="Cathepsin L heavy chain"
FT                   /id="PRO_0000026245"
FT   PROPEP          289..291
FT                   /id="PRO_0000026246"
FT   CHAIN           292..333
FT                   /note="Cathepsin L light chain"
FT                   /evidence="ECO:0000269|PubMed:3545185"
FT                   /id="PRO_0000026247"
FT   ACT_SITE        138
FT                   /evidence="ECO:0000305|PubMed:9468501"
FT   ACT_SITE        276
FT   ACT_SITE        300
FT   SITE            106..107
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   SITE            107..108
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   SITE            112..113
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   SITE            113..114
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   CARBOHYD        221
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218"
FT   DISULFID        135..178
FT   DISULFID        169..211
FT   DISULFID        269..322
FT                   /note="Interchain (between heavy and light chains)"
FT   VAR_SEQ         1..55
FT                   /note="Missing (in isoform 2)"
FT                   /id="VSP_060720"
FT   MUTAGEN         138
FT                   /note="C->S: Catalytically inactive. Unable to autocleave
FT                   procathepsin L."
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   CONFLICT        56
FT                   /note="M -> V (in Ref. 6; AAH12612)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        268
FT                   /note="D -> N (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   HELIX           23..25
FT                   /evidence="ECO:0000244|PDB:6JD8"
FT   HELIX           26..35
FT                   /evidence="ECO:0000244|PDB:6JD8"
FT   TURN            42..44
FT                   /evidence="ECO:0000244|PDB:6JD8"
FT   HELIX           45..67
FT                   /evidence="ECO:0000244|PDB:6JD8"
FT   STRAND          72..75
FT                   /evidence="ECO:0000244|PDB:6JD8"
FT   TURN            79..82
FT                   /evidence="ECO:0000244|PDB:6JD8"
FT   HELIX           85..91
FT                   /evidence="ECO:0000244|PDB:6JD8"
FT   STRAND          103..105
FT                   /evidence="ECO:0000244|PDB:6JD8"
FT   STRAND          116..119
FT                   /evidence="ECO:0000244|PDB:6EZX"
FT   HELIX           120..123
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          134..136
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   HELIX           138..155
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   HELIX           163..169
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   TURN            171..174
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   HELIX           177..179
FT                   /evidence="ECO:0000244|PDB:2XU4"
FT   HELIX           183..193
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          196..198
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   TURN            199..201
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   HELIX           215..217
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          218..220
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          223..227
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   HELIX           232..241
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          245..249
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   HELIX           254..257
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          261..264
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          271..273
FT                   /evidence="ECO:0000244|PDB:4AXL"
FT   STRAND          276..285
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          289..291
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          294..299
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          304..306
FT                   /evidence="ECO:0000244|PDB:6EZP"
FT   STRAND          311..315
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          317..320
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   HELIX           321..323
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   TURN            324..326
FT                   /evidence="ECO:0000244|PDB:2XU3"
FT   STRAND          329..332
FT                   /evidence="ECO:0000244|PDB:2XU3"
SQ   SEQUENCE   333 AA;  37564 MW;  8CD17D00EF859D85 CRC64;
     MNPTLILAAF CLGIASATLT FDHSLEAQWT KWKAMHNRLY GMNEEGWRRA VWEKNMKMIE
     LHNQEYREGK HSFTMAMNAF GDMTSEEFRQ VMNGFQNRKP RKGKVFQEPL FYEAPRSVDW
     REKGYVTPVK NQGQCGSCWA FSATGALEGQ MFRKTGRLIS LSEQNLVDCS GPQGNEGCNG
     GLMDYAFQYV QDNGGLDSEE SYPYEATEES CKYNPKYSVA NDTGFVDIPK QEKALMKAVA
     TVGPISVAID AGHESFLFYK EGIYFEPDCS SEDMDHGVLV VGYGFESTES DNNKYWLVKN
     SWGEEWGMGG YVKMAKDRRN HCGIASAASY PTV
//
ID   IL6RA_HUMAN             Reviewed;         468 AA.
AC   P08887; A8KAE8; B2R6V4; Q16202; Q53EQ7; Q5FWG2; Q5VZ23;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   12-AUG-2020, entry version 229.
DE   RecName: Full=Interleukin-6 receptor subunit alpha {ECO:0000305};
DE            Short=IL-6 receptor subunit alpha;
DE            Short=IL-6R subunit alpha;
DE            Short=IL-6R-alpha;
DE            Short=IL-6RA;
DE   AltName: Full=IL-6R 1;
DE   AltName: Full=Membrane glycoprotein 80;
DE            Short=gp80;
DE   AltName: CD_antigen=CD126;
DE   Contains:
DE     RecName: Full=Soluble interleukin-6 receptor subunit alpha {ECO:0000305};
DE              Short=sIL6R {ECO:0000303|PubMed:12794819, ECO:0000303|PubMed:26876177, ECO:0000303|PubMed:28060820};
DE   Flags: Precursor;
GN   Name=IL6R {ECO:0000312|HGNC:HGNC:6019};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3136546; DOI=10.1126/science.3136546;
RA   Yamasaki K., Taga T., Hirata Y., Yawata H., Kawanishi Y., Seed B.,
RA   Taniguchi T., Hirano T., Kishimoto T.;
RT   "Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2)
RT   receptor.";
RL   Science 241:825-828(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Yamasaki K., Taga T., Hirata Y., Yawata H., Kawanishi Y., Seed B.,
RA   Taniguchi T., Hirano T., Kishimoto T.;
RT   "Molecular structure of interleukin 6 receptor.";
RL   Proc. Jpn. Acad., B, Phys. Biol. Sci. 64:209-211(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1872801; DOI=10.1042/bj2770659;
RA   Schooltink H., Stoyan T., Lenz D., Schmitz H., Hirano T., Kishimoto T.,
RA   Heinrich P.C., Rose-John S.;
RT   "Structural and functional studies on the human hepatic interleukin-6
RT   receptor. Molecular cloning and overexpression in HepG2 cells.";
RL   Biochem. J. 277:659-664(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ALA-358.
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 313-365 (ISOFORM 2).
RX   PubMed=8056053; DOI=10.1002/eji.1830240837;
RA   Horiuchi S., Koyanagi Y., Zhou Y., Miyamoto H., Tanaka Y., Waki M.,
RA   Matsumoto A., Yamamoto M., Yamamoto N.;
RT   "Soluble interleukin-6 receptors released from T cell or
RT   granulocyte/macrophage cell lines and human peripheral blood mononuclear
RT   cells are generated through an alternative splicing mechanism.";
RL   Eur. J. Immunol. 24:1945-1948(1994).
RN   [10]
RP   PARTIAL PROTEIN SEQUENCE, GLYCOSYLATION AT ASN-55; ASN-93 AND ASN-221, LACK
RP   OF GLYCOSYLATION AT ASN-245, AND DISULFIDE BONDS.
RX   PubMed=10066782; DOI=10.1074/jbc.274.11.7207;
RA   Cole A.R., Hall N.E., Treutlein H.R., Eddes J.S., Reid G.E., Moritz R.L.,
RA   Simpson R.J.;
RT   "Disulfide bond structure and N-glycosylation sites of the extracellular
RT   domain of the human interleukin-6 receptor.";
RL   J. Biol. Chem. 274:7207-7215(1999).
RN   [11]
RP   PROTEIN SEQUENCE OF 20-49, AND SUBCELLULAR LOCATION.
RX   PubMed=2529343; DOI=10.1084/jem.170.4.1409;
RA   Novick D., Engelmann H., Wallach D., Rubinstein M.;
RT   "Soluble cytokine receptors are present in normal human urine.";
RL   J. Exp. Med. 170:1409-1414(1989).
RN   [12]
RP   MUTAGENESIS.
RX   PubMed=8467812; DOI=10.1002/j.1460-2075.1993.tb05815.x;
RA   Yawata H., Yasukawa K., Natsuka S., Murakami M., Yamasaki K., Hibi M.,
RA   Taga T., Kishimoto T.;
RT   "Structure-function analysis of human IL-6 receptor: dissociation of amino
RT   acid residues required for IL-6-binding and for IL-6 signal transduction
RT   through gp130.";
RL   EMBO J. 12:1705-1712(1993).
RN   [13]
RP   FUNCTION.
RX   PubMed=11017875;
RA   Martens A.S., Bode J.G., Heinrich P.C., Graeve L.;
RT   "The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its
RT   basolateral sorting in polarized Madin-Darby canine kidney cells.";
RL   J. Cell Sci. 113:3593-3602(2000).
RN   [14]
RP   FUNCTION.
RX   PubMed=12794819; DOI=10.1002/art.11143;
RA   Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K.,
RA   Nishimoto N.;
RT   "Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial
RT   growth factor production in rheumatoid arthritis.";
RL   Arthritis Rheum. 48:1521-1529(2003).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16270750; DOI=10.1016/j.ejcb.2005.06.001;
RA   Buk D.M., Renner O., Graeve L.;
RT   "Increased association with detergent-resistant membranes/lipid rafts of
RT   apically targeted mutants of the interleukin-6 receptor gp80.";
RL   Eur. J. Cell Biol. 84:819-831(2005).
RN   [16]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=21990364; DOI=10.1074/jbc.m111.295758;
RA   Garbers C., Thaiss W., Jones G.W., Waetzig G.H., Lorenzen I., Guilhot F.,
RA   Lissilaa R., Ferlin W.G., Groetzinger J., Jones S.A., Rose-John S.,
RA   Scheller J.;
RT   "Inhibition of classic signaling is a novel function of soluble
RT   glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin
RT   6 and soluble interleukin 6 receptor.";
RL   J. Biol. Chem. 286:42959-42970(2011).
RN   [17]
RP   FUNCTION, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=26876177; DOI=10.1016/j.celrep.2016.01.053;
RA   Lokau J., Nitz R., Agthe M., Monhasery N., Aparicio-Siegmund S.,
RA   Schumacher N., Wolf J., Moeller-Hackbarth K., Waetzig G.H., Groetzinger J.,
RA   Mueller-Newen G., Rose-John S., Scheller J., Garbers C.;
RT   "Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.";
RL   Cell Rep. 14:1761-1773(2016).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH SORL1.
RX   PubMed=28265003; DOI=10.1128/mcb.00641-16;
RA   Larsen J.V., Petersen C.M.;
RT   "SorLA in Interleukin-6 Signaling and Turnover.";
RL   Mol. Cell. Biol. 37:0-0(2017).
RN   [19]
RP   FUNCTION, PROTEOLYTIC CLEAVAGE, TISSUE SPECIFICITY (ISOFORM 2),
RP   GLYCOSYLATION AT ASN-55; ASN-93; ASN-221; ASN-245; ASN-350 AND THR-352,
RP   MUTAGENESIS OF ASN-55; THR-57; ASN-93; ASN-221; ASN-245; ASN-350; THR-352;
RP   355-PRO-VAL-356; PRO-355 AND VAL-356, CHARACTERIZATION OF VARIANT ALA-358,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=28060820; DOI=10.1371/journal.pbio.2000080;
RA   Riethmueller S., Somasundaram P., Ehlers J.C., Hung C.W., Flynn C.M.,
RA   Lokau J., Agthe M., Duesterhoeft S., Zhu Y., Groetzinger J., Lorenzen I.,
RA   Koudelka T., Yamamoto K., Pickhinke U., Wichert R., Becker-Pauly C.,
RA   Raedisch M., Albrecht A., Hessefort M., Stahnke D., Unverzagt C.,
RA   Rose-John S., Tholey A., Garbers C.;
RT   "Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role
RT   of N-Glycosylation.";
RL   PLoS Biol. 15:e2000080-e2000080(2017).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=30995492; DOI=10.1016/j.immuni.2019.03.026;
RA   Kang S., Tanaka T., Narazaki M., Kishimoto T.;
RT   "Targeting Interleukin-6 Signaling in Clinic.";
RL   Immunity 50:1007-1023(2019).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 20-344.
RX   PubMed=12461182; DOI=10.1073/pnas.232432399;
RA   Varghese J.N., Moritz R.L., Lou M.-Z., Van Donkelaar A., Ji H., Ivancic N.,
RA   Branson K.M., Hall N.E., Simpson R.J.;
RT   "Structure of the extracellular domains of the human interleukin-6 receptor
RT   alpha-chain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:15959-15964(2002).
RN   [22] {ECO:0000244|PDB:1P9M}
RP   X-RAY CRYSTALLOGRAPHY (3.65 ANGSTROMS) OF 115-315 IN COMPLEX WITH IL6 AND
RP   IL6ST, AND SUBUNIT.
RX   PubMed=12829785; DOI=10.1126/science.1083901;
RA   Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C.;
RT   "Hexameric structure and assembly of the interleukin-6/IL-6 alpha-
RT   receptor/gp130 complex.";
RL   Science 300:2101-2104(2003).
RN   [23]
RP   POLYMORPHISM, VARIANT ALA-358, AND ASSOCIATION OF VARIANT ALA-358 WITH IL6
RP   AND SOLUBLE IL6R SERUM LEVELS.
RX   PubMed=17357077; DOI=10.1086/513206;
RG   Health, Aging and Body Composition (Health ABC) Study;
RA   Reich D., Patterson N., Ramesh V., De Jager P.L., McDonald G.J., Tandon A.,
RA   Choy E., Hu D., Tamraz B., Pawlikowska L., Wassel-Fyr C., Huntsman S.,
RA   Waliszewska A., Rossin E., Li R., Garcia M., Reiner A., Ferrell R.,
RA   Cummings S., Kwok P.Y., Harris T., Zmuda J.M., Ziv E.;
RT   "Admixture mapping of an allele affecting interleukin 6 soluble receptor
RT   and interleukin 6 levels.";
RL   Am. J. Hum. Genet. 80:716-726(2007).
CC   -!- FUNCTION: Part of the receptor for interleukin 6. Binds to IL6 with low
CC       affinity, but does not transduce a signal (PubMed:28265003). Signal
CC       activation necessitate an association with IL6ST. Activation leads to
CC       the regulation of the immune response, acute-phase reactions and
CC       hematopoiesis (Probable). The interaction with membrane-bound IL6R and
CC       IL6ST stimulates 'classic signaling', the restricted expression of the
CC       IL6R limits classic IL6 signaling to only a few tissues such as the
CC       liver and some cells of the immune system. Whereas the binding of IL6
CC       and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively,
CC       'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on
CC       transmitter cells activate IL6ST receptors on neighboring receiver
CC       cells (Probable). {ECO:0000269|PubMed:28265003,
CC       ECO:0000305|PubMed:30995492}.
CC   -!- FUNCTION: [Isoform 1]: Signaling via the membrane-bound IL6R is mostly
CC       regenerative and anti-inflammatory (Probable). Drives naive CD4(+) T
CC       cells to the Th17 lineage, through 'cluster signaling' by dendritic
CC       cells (By similarity). {ECO:0000250|UniProtKB:P22272,
CC       ECO:0000305|PubMed:30995492}.
CC   -!- FUNCTION: [Isoform 2]: Soluble form of IL6 receptor (sIL6R) that acts
CC       as an agonist of IL6 activity (PubMed:21990364). The IL6:sIL6R complex
CC       (hyper-IL6) binds to IL6ST/gp130 on cell surfaces and induces signaling
CC       also on cells that do not express membrane-bound IL6R in a process
CC       called IL6 'trans-signaling'. sIL6R is causative for the
CC       proinflammatory properties of IL6 and an important player in the
CC       development of chronic inflammatory diseases (PubMed:21990364). In
CC       complex with IL6, is required for induction of VEGF production
CC       (PubMed:12794819). Plays a protective role during liver injury, being
CC       required for maintenance of tissue regeneration (By similarity).
CC       'Trans-signaling' in central nervous system regulates energy and
CC       glucose homeostasis (By similarity). {ECO:0000250|UniProtKB:P22272,
CC       ECO:0000269|PubMed:12794819, ECO:0000269|PubMed:21990364}.
CC   -!- FUNCTION: [Soluble interleukin-6 receptor subunit alpha]: Soluble form
CC       of IL6 receptor (sIL6R) that acts as an agonist of IL6 activity
CC       (PubMed:21990364). The IL6:sIL6R complex (hyper-IL6) binds to
CC       IL6ST/gp130 on cell surfaces and induces signaling also on cells that
CC       do not express membrane-bound IL6R in a process called IL6 'trans-
CC       signaling'. sIL6R is causative for the proinflammatory properties of
CC       IL6 and an important player in the development of chronic inflammatory
CC       diseases (PubMed:21990364). In complex with IL6, is required for
CC       induction of VEGF production (PubMed:12794819). Plays a protective role
CC       during liver injury, being required for maintenance of tissue
CC       regeneration (By similarity). 'Trans-signaling' in central nervous
CC       system regulates energy and glucose homeostasis (By similarity).
CC       {ECO:0000250|UniProtKB:P22272, ECO:0000269|PubMed:12794819,
CC       ECO:0000269|PubMed:21990364}.
CC   -!- ACTIVITY REGULATION: Classic and trans-signaling are both inhibited by
CC       tocilizumab, a humanized monoclonal antibody that blocks interleukin
CC       IL6R signaling. {ECO:0000269|PubMed:21990364}.
CC   -!- SUBUNIT: Component of a hexamer of two molecules each of IL6, IL6R and
CC       IL6ST; first binds to IL6 to associate with the signaling subunit IL6ST
CC       (PubMed:12829785, PubMed:28265003). Interacts (via N-terminal
CC       ectodomain) with SORL1; this interaction may affect IL6-binding to
CC       IL6R, hence decrease IL6 'classic-signaling' (PubMed:28265003).
CC       {ECO:0000269|PubMed:12829785, ECO:0000269|PubMed:28265003}.
CC   -!- SUBUNIT: [Isoform 2]: Also interacts with SORL1; this interaction leads
CC       to soluble IL6R internalization. May form a trimeric complex with the
CC       soluble SORL1 ectodomain and circulating IL6 receptor; this interaction
CC       might stabilize circulating IL6, hence promote IL6 'trans-signaling,.
CC       {ECO:0000269|PubMed:28265003}.
CC   -!- SUBUNIT: [Soluble interleukin-6 receptor subunit alpha]: Also interacts
CC       with SORL1; this interaction leads to soluble IL6R internalization. May
CC       form a trimeric complex with the soluble SORL1 ectodomain and
CC       circulating IL6 receptor; this interaction might stabilize circulating
CC       IL6, hence promote IL6 'trans-signaling,.
CC       {ECO:0000269|PubMed:28265003}.
CC   -!- INTERACTION:
CC       P08887; P05231: IL6; NbExp=7; IntAct=EBI-299383, EBI-720533;
CC       P08887; Q96EQ0: SGTB; NbExp=3; IntAct=EBI-299383, EBI-744081;
CC       P08887; Q92673: SORL1; NbExp=7; IntAct=EBI-299383, EBI-1171329;
CC       P08887; Q2HRC7: K2; Xeno; NbExp=3; IntAct=EBI-299383, EBI-9007403;
CC       P08887-2; O00233: PSMD9; NbExp=3; IntAct=EBI-16630231, EBI-750973;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000250|UniProtKB:P22272}; Single-pass type I membrane protein
CC       {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted
CC       {ECO:0000269|PubMed:28060820}.
CC   -!- SUBCELLULAR LOCATION: [Soluble interleukin-6 receptor subunit alpha]:
CC       Secreted {ECO:0000269|PubMed:28060820}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long, mIL6R {ECO:0000303|PubMed:26876177};
CC         IsoId=P08887-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short, sIL6R {ECO:0000303|PubMed:21990364};
CC         IsoId=P08887-2; Sequence=VSP_001682, VSP_001683;
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in peripheral blood
CC       mononuclear cells and weakly found in urine and serum. 1%-20% of the
CC       total sIL6R in plasma is generated by alternative splicing
CC       (PubMed:28060820). {ECO:0000269|PubMed:28060820}.
CC   -!- DOMAIN: The two fibronectin type-III-like domains, contained in the N-
CC       terminal part, form together a cytokine-binding domain.
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-surface
CC       receptor binding.
CC   -!- PTM: A short soluble form is released from the membrane by proteolysis
CC       (PubMed:26876177). The sIL6R is formed mostly by limited proteolysis of
CC       membrane-bound receptors, a process referred to as ectodomain shedding,
CC       but is also directly secreted from the cells after alternative mRNA
CC       splicing (PubMed:26876177, PubMed:28060820). mIL6R is cleaved by the
CC       proteases ADAM10 and ADAM17 (PubMed:26876177, PubMed:28060820).
CC       {ECO:0000269|PubMed:26876177, ECO:0000269|PubMed:28060820}.
CC   -!- PTM: Glycosylated. Glycosylation is dispensable for transport,
CC       signaling, and cell-surface turnover. Glycosylation at Asn-55 is a
CC       protease-regulatory exosite. Glycosylation is required for ADAM17-
CC       mediated proteolysis. {ECO:0000269|PubMed:28060820}.
CC   -!- POLYMORPHISM: Genetic variations in IL6R determine soluble IL6R serum
CC       levels [MIM:614689].
CC   -!- POLYMORPHISM: Genetic variations in IL6R define the IL6 serum level
CC       quantitative trait locus [MIM:614752].
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 3
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X12830; CAA31312.1; -; mRNA.
DR   EMBL; X58298; CAA41231.1; -; mRNA.
DR   EMBL; AK293013; BAF85702.1; -; mRNA.
DR   EMBL; AK312730; BAG35601.1; -; mRNA.
DR   EMBL; AK223582; BAD97302.1; -; mRNA.
DR   EMBL; AL162591; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471121; EAW53200.1; -; Genomic_DNA.
DR   EMBL; BC089410; AAH89410.1; -; mRNA.
DR   EMBL; S72848; AAC60635.1; -; mRNA.
DR   CCDS; CCDS1067.1; -. [P08887-1]
DR   CCDS; CCDS1068.1; -. [P08887-2]
DR   PIR; A41242; A41242.
DR   RefSeq; NP_000556.1; NM_000565.3. [P08887-1]
DR   RefSeq; NP_001193795.1; NM_001206866.1.
DR   RefSeq; NP_852004.1; NM_181359.2. [P08887-2]
DR   PDB; 1N26; X-ray; 2.40 A; A=20-344.
DR   PDB; 1N2Q; Model; -; C/D=20-344.
DR   PDB; 1P9M; X-ray; 3.65 A; C=115-315.
DR   PDB; 2ARW; NMR; -; A=212-336.
DR   PDB; 5FUC; X-ray; 2.70 A; C/D=111-322.
DR   PDBsum; 1N26; -.
DR   PDBsum; 1N2Q; -.
DR   PDBsum; 1P9M; -.
DR   PDBsum; 2ARW; -.
DR   PDBsum; 5FUC; -.
DR   SMR; P08887; -.
DR   BioGRID; 109784; 19.
DR   DIP; DIP-162N; -.
DR   ELM; P08887; -.
DR   IntAct; P08887; 18.
DR   MINT; P08887; -.
DR   STRING; 9606.ENSP00000357470; -.
DR   ChEMBL; CHEMBL2364155; -.
DR   DrugBank; DB11767; Sarilumab.
DR   DrugBank; DB06273; Tocilizumab.
DR   DrugCentral; P08887; -.
DR   GuidetoPHARMACOLOGY; 1708; -.
DR   GlyGen; P08887; 6 sites, 2 O-linked glycans (2 sites).
DR   iPTMnet; P08887; -.
DR   PhosphoSitePlus; P08887; -.
DR   BioMuta; IL6R; -.
DR   DMDM; 124343; -.
DR   jPOST; P08887; -.
DR   MassIVE; P08887; -.
DR   MaxQB; P08887; -.
DR   PaxDb; P08887; -.
DR   PeptideAtlas; P08887; -.
DR   PRIDE; P08887; -.
DR   ProteomicsDB; 52171; -. [P08887-1]
DR   ProteomicsDB; 52172; -. [P08887-2]
DR   ABCD; P08887; 121 sequenced antibodies.
DR   Antibodypedia; 20397; 967 antibodies.
DR   DNASU; 3570; -.
DR   Ensembl; ENST00000344086; ENSP00000340589; ENSG00000160712. [P08887-2]
DR   Ensembl; ENST00000368485; ENSP00000357470; ENSG00000160712. [P08887-1]
DR   GeneID; 3570; -.
DR   KEGG; hsa:3570; -.
DR   UCSC; uc001fez.2; human. [P08887-1]
DR   CTD; 3570; -.
DR   DisGeNET; 3570; -.
DR   EuPathDB; HostDB:ENSG00000160712.12; -.
DR   GeneCards; IL6R; -.
DR   HGNC; HGNC:6019; IL6R.
DR   HPA; ENSG00000160712; Tissue enhanced (skeletal).
DR   MalaCards; IL6R; -.
DR   MIM; 147880; gene.
DR   MIM; 614689; phenotype.
DR   MIM; 614752; phenotype.
DR   neXtProt; NX_P08887; -.
DR   OpenTargets; ENSG00000160712; -.
DR   PharmGKB; PA29835; -.
DR   eggNOG; ENOG502RY0M; Eukaryota.
DR   GeneTree; ENSGT00940000161919; -.
DR   HOGENOM; CLU_051451_0_0_1; -.
DR   InParanoid; P08887; -.
DR   KO; K05055; -.
DR   OrthoDB; 783799at2759; -.
DR   PhylomeDB; P08887; -.
DR   TreeFam; TF331210; -.
DR   PathwayCommons; P08887; -.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
DR   SignaLink; P08887; -.
DR   SIGNOR; P08887; -.
DR   BioGRID-ORCS; 3570; 4 hits in 876 CRISPR screens.
DR   ChiTaRS; IL6R; human.
DR   EvolutionaryTrace; P08887; -.
DR   GeneWiki; Interleukin-6_receptor; -.
DR   GenomeRNAi; 3570; -.
DR   Pharos; P08887; Tclin.
DR   PRO; PR:P08887; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P08887; protein.
DR   Bgee; ENSG00000160712; Expressed in liver and 228 other tissues.
DR   ExpressionAtlas; P08887; baseline and differential.
DR   Genevisible; P08887; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070110; C:ciliary neurotrophic factor receptor complex; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005896; C:interleukin-6 receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0070119; F:ciliary neurotrophic factor binding; IPI:BHF-UCL.
DR   GO; GO:0019955; F:cytokine binding; IBA:GO_Central.
DR   GO; GO:0004896; F:cytokine receptor activity; IBA:GO_Central.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0019981; F:interleukin-6 binding; IPI:BHF-UCL.
DR   GO; GO:0004915; F:interleukin-6 receptor activity; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; TAS:BHF-UCL.
DR   GO; GO:0070120; P:ciliary neurotrophic factor-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; TAS:BHF-UCL.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; NAS:BHF-UCL.
DR   GO; GO:0031018; P:endocrine pancreas development; IMP:BHF-UCL.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0002384; P:hepatic immune response; TAS:BHF-UCL.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002548; P:monocyte chemotaxis; IC:BHF-UCL.
DR   GO; GO:0032966; P:negative regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0032717; P:negative regulation of interleukin-8 production; NAS:BHF-UCL.
DR   GO; GO:0002446; P:neutrophil mediated immunity; TAS:BHF-UCL.
DR   GO; GO:0010536; P:positive regulation of activation of Janus kinase activity; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
DR   GO; GO:0072126; P:positive regulation of glomerular mesangial cell proliferation; IMP:ARUK-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0002690; P:positive regulation of leukocyte chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; TAS:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:BHF-UCL.
DR   GO; GO:0034097; P:response to cytokine; IDA:BHF-UCL.
DR   CDD; cd00063; FN3; 1.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR003530; Hematopoietin_rcpt_L_F3_CS.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR015321; TypeI_recpt_CBD.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF09240; IL6Ra-bind; 1.
DR   SMART; SM00060; FN3; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS01354; HEMATOPO_REC_L_F3; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Immunoglobulin domain; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000269|PubMed:2529343"
FT   CHAIN           20..468
FT                   /note="Interleukin-6 receptor subunit alpha"
FT                   /id="PRO_0000010895"
FT   CHAIN           20..355
FT                   /note="Soluble interleukin-6 receptor subunit alpha"
FT                   /id="PRO_0000450730"
FT   TOPO_DOM        20..365
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        366..386
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        387..468
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          26..112
FT                   /note="Ig-like C2-type"
FT   DOMAIN          113..217
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          218..316
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   MOTIF           303..307
FT                   /note="WSXWS motif"
FT   SITE            245
FT                   /note="Not glycosylated"
FT                   /evidence="ECO:0000269|PubMed:10066782"
FT   SITE            355..356
FT                   /note="Cleavage; by ADAM10 and ADAM17"
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   CARBOHYD        55
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10066782,
FT                   ECO:0000269|PubMed:28060820"
FT   CARBOHYD        93
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10066782,
FT                   ECO:0000269|PubMed:28060820"
FT   CARBOHYD        221
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10066782,
FT                   ECO:0000269|PubMed:28060820"
FT   CARBOHYD        245
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   CARBOHYD        350
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   CARBOHYD        352
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   DISULFID        25..193
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:10066782"
FT   DISULFID        47..96
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:10066782"
FT   DISULFID        121..132
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:10066782"
FT   DISULFID        165..176
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:10066782"
FT   VAR_SEQ         356..365
FT                   /note="VQDSSSVPLP -> GSRRRGSCGL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8056053"
FT                   /id="VSP_001682"
FT   VAR_SEQ         366..468
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8056053"
FT                   /id="VSP_001683"
FT   VARIANT         358
FT                   /note="D -> A (significantly associated with circulating
FT                   levels of IL6 and soluble IL6R; increases cleavage by
FT                   ADAM17; dbSNP:rs2228145)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17357077, ECO:0000269|PubMed:28060820"
FT                   /id="VAR_021995"
FT   VARIANT         385
FT                   /note="V -> I (in dbSNP:rs2228146)"
FT                   /id="VAR_049166"
FT   MUTAGEN         55
FT                   /note="N->A: Strongly induces cleavage and sIL6R levels. No
FT                   effect on IL6R signaling; when associated with A-93, A-221,
FT                   A-245 and A-350. Loss of cleavage by ADAM17; when
FT                   associated with A-93, A-221, A-245 and A-350."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   MUTAGEN         57
FT                   /note="T->A: Strongly induces cleavage and sIL6R levels."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   MUTAGEN         93
FT                   /note="N->A: No effect on cleavage or sIL6R levels. No
FT                   effect on IL6R signaling; when associated with A-55, A-221,
FT                   A-245 and A-350. Loss of cleavage by ADAM17; when
FT                   associated with A-55, A-221, A-245 and A-350."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   MUTAGEN         121
FT                   /note="C->S: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         122
FT                   /note="F->A: No change of ligand-binding and IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         132
FT                   /note="C->A: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         134
FT                   /note="W->L: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         140
FT                   /note="P->G: No change of ligand-binding and IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         153
FT                   /note="F->L: No change of ligand-binding and IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         165
FT                   /note="C->L: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         174
FT                   /note="F->L: No change of ligand-binding and IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         176
FT                   /note="C->A: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         184
FT                   /note="D->T: 30% decrease of ligand-binding and IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         190
FT                   /note="V->G: 80% decrease of ligand-binding and no IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         193
FT                   /note="C->D: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         211
FT                   /note="C->A: No change of ligand-binding and IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         217
FT                   /note="D->V: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         221
FT                   /note="N->A: No effect on cleavage or sIL6R levels. No
FT                   effect on IL6R signaling; when associated with A-55, A-93,
FT                   A-245 and A-350. Loss of cleavage by ADAM17; when
FT                   associated with A-55, A-93, A-245 and A-350."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   MUTAGEN         232
FT                   /note="R->S: 30% decrease of ligand-binding and IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         233
FT                   /note="W->Q: 30% decrease of ligand-binding and increase of
FT                   IL6 signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         245
FT                   /note="N->A: Slightly induces cleavage and sIL6R levels.No
FT                   effect on IL6R signaling; when associated with A-55, A-93,
FT                   A-221 and A-350. Loss of cleavage by ADAM17; when
FT                   associated with A-55, A-93, A-221 and A-350."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   MUTAGEN         254
FT                   /note="E->A: 50% decrease of ligand-binding and IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         277
FT                   /note="C->D: 30% increase of ligand-binding and 100%
FT                   increase in IL6 signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         278
FT                   /note="V->N: 50% Decrease of ligand-binding and 50%
FT                   increase in IL6 signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         279
FT                   /note="I->D: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         280
FT                   /note="H->I: No change of ligand-binding and no IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         281
FT                   /note="D->G: 70% decrease of ligand-binding and no IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         285
FT                   /note="G->D: 80% decrease of ligand-binding and no IL6
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         291
FT                   /note="Q->K: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         293
FT                   /note="R->G: Complete loss of ligand-binding."
FT                   /evidence="ECO:0000269|PubMed:8467812"
FT   MUTAGEN         350
FT                   /note="N->A: No effect on IL6R signaling; when associated
FT                   with A-55, A-93, A-221 and A-245. Loss of cleavage by
FT                   ADAM17; when associated with A-55, A-93, A-221 and A-245."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   MUTAGEN         352
FT                   /note="T->A: No effect on IL6R signaling."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   MUTAGEN         355..356
FT                   /note="PV->IE: Abolishes cleavage by ADAM17."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   MUTAGEN         355
FT                   /note="P->I,D: Reduces cleavage by ADAM17."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   MUTAGEN         356
FT                   /note="V->E,G: Abolishes cleavage by ADAM17."
FT                   /evidence="ECO:0000269|PubMed:28060820"
FT   CONFLICT        210
FT                   /note="G -> D (in Ref. 5; BAD97302)"
FT                   /evidence="ECO:0000305"
FT   STRAND          34..37
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          43..46
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          56..63
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          65..68
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          72..83
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   HELIX           88..90
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          92..101
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          105..110
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          120..125
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          130..134
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          145..157
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          159..168
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   TURN            169..172
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          173..178
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          187..196
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          199..202
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          206..209
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   TURN            210..212
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          220..226
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          234..239
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          247..249
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          251..259
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          266..269
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   HELIX           271..273
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          275..281
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          288..296
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   TURN            297..299
FT                   /evidence="ECO:0000244|PDB:1N26"
FT   STRAND          310..312
FT                   /evidence="ECO:0000244|PDB:1N26"
SQ   SEQUENCE   468 AA;  51548 MW;  62AA239FA14F1B8B CRC64;
     MLAVGCALLA ALLAAPGAAL APRRCPAQEV ARGVLTSLPG DSVTLTCPGV EPEDNATVHW
     VLRKPAAGSH PSRWAGMGRR LLLRSVQLHD SGNYSCYRAG RPAGTVHLLV DVPPEEPQLS
     CFRKSPLSNV VCEWGPRSTP SLTTKAVLLV RKFQNSPAED FQEPCQYSQE SQKFSCQLAV
     PEGDSSFYIV SMCVASSVGS KFSKTQTFQG CGILQPDPPA NITVTAVARN PRWLSVTWQD
     PHSWNSSFYR LRFELRYRAE RSKTFTTWMV KDLQHHCVIH DAWSGLRHVV QLRAQEEFGQ
     GEWSEWSPEA MGTPWTESRS PPAENEVSTP MQALTTNKDD DNILFRDSAN ATSLPVQDSS
     SVPLPTFLVA GGSLAFGTLL CIAIVLRFKK TWKLRALKEG KTSMHPPYSL GQLVPERPRP
     TPVLVPLISP PVSPSSLGSD NTSSHNRPDA RDPRSPYDIS NTDYFFPR
//
ID   FURIN_HUMAN             Reviewed;         794 AA.
AC   P09958; Q14336; Q6LBS3; Q9UCZ5;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 2.
DT   12-AUG-2020, entry version 240.
DE   RecName: Full=Furin;
DE            EC=3.4.21.75 {ECO:0000269|PubMed:11799113, ECO:0000269|PubMed:1629222, ECO:0000269|PubMed:1713771, ECO:0000269|PubMed:2251280, ECO:0000269|PubMed:25974265, ECO:0000269|PubMed:7592877, ECO:0000269|PubMed:7690548, ECO:0000269|PubMed:9130696};
DE   AltName: Full=Dibasic-processing enzyme;
DE   AltName: Full=Paired basic amino acid residue-cleaving enzyme;
DE            Short=PACE;
DE   Flags: Precursor;
GN   Name=FURIN; Synonyms=FUR, PACE, PCSK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   PubMed=2408021; DOI=10.1093/nar/18.3.664;
RA   van den Ouweland A.M.W., van Duijnhoven H.L.P., Keizer G.D.,
RA   Dorssers L.C.J., van de Ven W.J.M.;
RT   "Structural homology between the human fur gene product and the subtilisin-
RT   like protease encoded by yeast KEX2.";
RL   Nucleic Acids Res. 18:664-664(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=2251280; DOI=10.1073/pnas.87.23.9378;
RA   Wise R.J., Barr P.J., Wong P.A., Kiefer M.C., Brake A.J., Kaufman R.J.;
RT   "Expression of a human proprotein processing enzyme: correct cleavage of
RT   the von Willebrand factor precursor at a paired basic amino acid site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9378-9382(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=1713771; DOI=10.1089/dna.1991.10.319;
RA   Barr P.J., Mason O.B., Landsberg K.E., Wong P.A., Kiefer M.C., Brake A.J.;
RT   "cDNA and gene structure for a human subtilisin-like protease with cleavage
RT   specificity for paired basic amino acid residues.";
RL   DNA Cell Biol. 10:319-328(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-280.
RX   PubMed=2674906; DOI=10.1093/nar/17.17.7101;
RA   Van den Ouweland A.M.W., van Groningen J.J.M., Roebrock A.J.M.,
RA   Onnekink C., Van de Ven W.J.M.;
RT   "Nucleotide sequence analysis of the human fur gene.";
RL   Nucleic Acids Res. 17:7101-7102(1989).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 296-794.
RX   PubMed=3023061; DOI=10.1002/j.1460-2075.1986.tb04484.x;
RA   Roebroek A.J.M., Schalken J.A., Leunissen J.A.M., Onnekink C.,
RA   Bloemers H.P.J., van de Ven W.J.M.;
RT   "Evolutionary conserved close linkage of the c-fes/fps proto-oncogene and
RT   genetic sequences encoding a receptor-like protein.";
RL   EMBO J. 5:2197-2202(1986).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 402-428, FUNCTION, AND CATALYTIC ACTIVITY.
RC   TISSUE=Colon carcinoma;
RX   PubMed=7690548; DOI=10.1006/bbrc.1993.2146;
RA   Takahashi S., Kasai K., Hatsuzawa K., Kitamura N., Misumi Y., Ikehara Y.,
RA   Murakami K., Nakayama K.;
RT   "A mutation of furin causes the lack of precursor-processing activity in
RT   human colon carcinoma LoVo cells.";
RL   Biochem. Biophys. Res. Commun. 195:1019-1026(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 527-553, FUNCTION, CATALYTIC ACTIVITY, AND
RP   VARIANT ARG-547.
RC   TISSUE=Colon carcinoma;
RX   PubMed=7592877; DOI=10.1074/jbc.270.44.26565;
RA   Takahashi S., Nakagawa T., Kasai K., Banno T., Duguay S.J.,
RA   Van de Ven W.J.M., Murakami K., Nakayama K.;
RT   "A second mutant allele of furin in the processing-incompetent cell line,
RT   LoVo. Evidence for involvement of the homo B domain in autocatalytic
RT   activation.";
RL   J. Biol. Chem. 270:26565-26569(1995).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PROTEOLYTIC PROCESSING.
RX   PubMed=1629222;
RA   Leduc R., Molloy S.S., Thorne B.A., Thomas G.;
RT   "Activation of human furin precursor processing endoprotease occurs by an
RT   intramolecular autoproteolytic cleavage.";
RL   J. Biol. Chem. 267:14304-14308(1992).
RN   [10]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=7737999; DOI=10.1074/jbc.270.18.10618;
RA   Dubois C.M., Laprise M.H., Blanchette F., Gentry L.E., Leduc R.;
RT   "Processing of transforming growth factor beta 1 precursor by human furin
RT   convertase.";
RL   J. Biol. Chem. 270:10618-10624(1995).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   3D-STRUCTURE MODELING OF CATALYTIC DOMAIN.
RX   PubMed=8020465; DOI=10.1111/j.1432-1033.1994.tb18864.x;
RA   Siezen R.J., Creemers J.W.M., van de Ven W.J.M.;
RT   "Homology modelling of the catalytic domain of human furin. A model for the
RT   eukaryotic subtilisin-like proprotein convertases.";
RL   Eur. J. Biochem. 222:255-266(1994).
RN   [13]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-773 AND SER-775, MOTIF, AND
RP   MUTAGENESIS OF SER-773 AND SER-775.
RX   PubMed=8846780; DOI=10.1002/j.1460-2075.1995.tb00275.x;
RA   Jones B.G., Thomas L., Molloy S.S., Thulin C.D., Fry M.D., Walsh K.A.,
RA   Thomas G.;
RT   "Intracellular trafficking of furin is modulated by the phosphorylation
RT   state of a casein kinase II site in its cytoplasmic tail.";
RL   EMBO J. 14:5869-5883(1995).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ACTIVITY REGULATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, PROTEOLYTIC CLEAVAGE,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF ASP-153.
RX   PubMed=9130696; DOI=10.1093/emboj/16.7.1508;
RA   Anderson E.D., VanSlyke J.K., Thulin C.D., Jean F., Thomas G.;
RT   "Activation of the furin endoprotease is a multiple-step process:
RT   requirements for acidification and internal propeptide cleavage.";
RL   EMBO J. 16:1508-1518(1997).
RN   [15]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9412467; DOI=10.1083/jcb.139.7.1719;
RA   Liu G., Thomas L., Warren R.A., Enns C.A., Cunningham C.C., Hartwig J.H.,
RA   Thomas G.;
RT   "Cytoskeletal protein ABP-280 directs the intracellular trafficking of
RT   furin and modulates proprotein processing in the endocytic pathway.";
RL   J. Cell Biol. 139:1719-1733(1997).
RN   [16]
RP   INTERACTION WITH PACS1, AND SUBCELLULAR LOCATION.
RX   PubMed=11331585; DOI=10.1093/emboj/20.9.2191;
RA   Crump C.M., Xiang Y., Thomas L., Gu F., Austin C., Tooze S.A., Thomas G.;
RT   "PACS-1 binding to adaptors is required for acidic cluster motif-mediated
RT   protein traffic.";
RL   EMBO J. 20:2191-2201(2001).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF VAL-72; ARG-75 AND ASP-153.
RX   PubMed=11799113; DOI=10.1074/jbc.m108740200;
RA   Anderson E.D., Molloy S.S., Jean F., Fei H., Shimamura S., Thomas G.;
RT   "The ordered and compartment-specfific autoproteolytic removal of the furin
RT   intramolecular chaperone is required for enzyme activation.";
RL   J. Biol. Chem. 277:12879-12890(2002).
RN   [18]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=27582320; DOI=10.1038/srep32371;
RA   Schulte T., Mikaelsson C., Beaussart A., Kikhney A., Deshmukh M.,
RA   Wolniak S., Pathak A., Ebel C., Lofling J., Fogolari F.,
RA   Henriques-Normark B., Dufrene Y.F., Svergun D., Nygren P.A., Achour A.;
RT   "The BR domain of PsrP interacts with extracellular DNA to promote
RT   bacterial aggregation; structural insights into pneumococcal biofilm
RT   formation.";
RL   Sci. Rep. 6:32371-32371(2016).
RN   [19]
RP   FUNCTION (MICROBIAL INFECTION), ACTIVITY REGULATION, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   "A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells.";
RL   Mol. Cell 0:0-0(2020).
RN   [20] {ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 108-574 IN COMPLEX WITH CALCIUM
RP   AND INHIBITOR, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND
RP   DISULFIDE BONDS.
RX   PubMed=24666235; DOI=10.1021/cb500087x;
RA   Dahms S.O., Hardes K., Becker G.L., Steinmetzer T., Brandstetter H.,
RA   Than M.E.;
RT   "X-ray structures of human furin in complex with competitive inhibitors.";
RL   ACS Chem. Biol. 9:1113-1118(2014).
RN   [21] {ECO:0000244|PDB:4RYD}
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 108-574 IN COMPLEX WITH CALCIUM
RP   AND INHIBITOR, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND
RP   DISULFIDE BONDS.
RX   PubMed=25974265; DOI=10.1002/cmdc.201500103;
RA   Hardes K., Becker G.L., Lu Y., Dahms S.O., Kohler S., Beyer W., Sandvig K.,
RA   Yamamoto H., Lindberg I., Walz L., von Messling V., Than M.E., Garten W.,
RA   Steinmetzer T.;
RT   "Novel Furin inhibitors with potent anti-infectious activity.";
RL   ChemMedChem 10:1218-1231(2015).
CC   -!- FUNCTION: Ubiquitous endoprotease within constitutive secretory
CC       pathways capable of cleavage at the RX(K/R)R consensus motif
CC       (PubMed:11799113, PubMed:1629222, PubMed:1713771, PubMed:2251280,
CC       PubMed:24666235, PubMed:25974265, PubMed:7592877, PubMed:7690548,
CC       PubMed:9130696). Mediates processing of TGFB1, an essential step in
CC       TGF-beta-1 activation (PubMed:7737999). {ECO:0000269|PubMed:11799113,
CC       ECO:0000269|PubMed:1629222, ECO:0000269|PubMed:1713771,
CC       ECO:0000269|PubMed:2251280, ECO:0000269|PubMed:24666235,
CC       ECO:0000269|PubMed:25974265, ECO:0000269|PubMed:7592877,
CC       ECO:0000269|PubMed:7690548, ECO:0000269|PubMed:7737999,
CC       ECO:0000269|PubMed:9130696}.
CC   -!- FUNCTION: (Microbial infection) Probably cleaves and activates anthrax
CC       and diphtheria toxins.
CC   -!- FUNCTION: (Microbial infection) Required for H7N1 and H5N1 influenza
CC       virus infection probably by cleaving hemagglutinin.
CC       {ECO:0000269|PubMed:25974265}.
CC   -!- FUNCTION: (Microbial infection) Able to cleave S.pneumoniae serine-rich
CC       repeat protein PsrP. {ECO:0000269|PubMed:27582320}.
CC   -!- FUNCTION: (Microbial infection) Facilitates human coronaviruses EMC and
CC       SARS-CoV-2 infections by proteolytically cleaving the spike protein at
CC       the monobasic S1/S2 cleavage site. This cleavage is essential for spike
CC       protein-mediated cell-cell fusion and entry into human lung cells.
CC       {ECO:0000269|PubMed:32362314}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Release of mature proteins from their proproteins by cleavage
CC         of -Arg-Xaa-Yaa-Arg-|-Zaa- bonds, where Xaa can be any amino acid and
CC         Yaa is Arg or Lys. Releases albumin, complement component C3 and von
CC         Willebrand factor from their respective precursors.; EC=3.4.21.75;
CC         Evidence={ECO:0000269|PubMed:11799113, ECO:0000269|PubMed:1629222,
CC         ECO:0000269|PubMed:1713771, ECO:0000269|PubMed:2251280,
CC         ECO:0000269|PubMed:24666235, ECO:0000269|PubMed:25974265,
CC         ECO:0000269|PubMed:32362314, ECO:0000269|PubMed:7592877,
CC         ECO:0000269|PubMed:7690548, ECO:0000269|PubMed:7737999,
CC         ECO:0000269|PubMed:9130696};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:24666235, ECO:0000269|PubMed:25974265,
CC         ECO:0000269|PubMed:9130696};
CC       Note=Binds 3 calcium ions per subunit. {ECO:0000269|PubMed:24666235,
CC       ECO:0000269|PubMed:25974265, ECO:0000269|PubMed:9130696};
CC   -!- ACTIVITY REGULATION: Inhibited by the not secondly cleaved propeptide
CC       (PubMed:9130696, PubMed:11799113). Inhibited by m-guanidinomethyl-
CC       phenylacetyl-Arg-Val-Arg-(amidomethyl)-benzamidine (m-guanidinomethyl-
CC       Phac-RVR-Amb) and 4-guanidinomethyl-phenylacetyl-Arg-Tle-Arg-4-
CC       amidinobenzylamide (MI-1148) (PubMed:24666235, PubMed:25974265).
CC       Inhibited by Decanoyl-Arg-Val-Lys-Arg-chloromethylketone (decanoyl-
CC       RVKR-CMK) (PubMed:32362314). {ECO:0000269|PubMed:11799113,
CC       ECO:0000269|PubMed:24666235, ECO:0000269|PubMed:25974265,
CC       ECO:0000269|PubMed:32362314, ECO:0000269|PubMed:9130696}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 6.0. {ECO:0000269|PubMed:9130696};
CC   -!- SUBUNIT: Interacts with FLNA (By similarity). Binds to PACS1 which
CC       mediates TGN localization and connection to clathrin adapters
CC       (PubMed:11331585). {ECO:0000250|UniProtKB:P23188,
CC       ECO:0000269|PubMed:11331585}.
CC   -!- INTERACTION:
CC       P09958; P50281: MMP14; NbExp=3; IntAct=EBI-1056807, EBI-992788;
CC       P09958; Q9H239: MMP28; NbExp=3; IntAct=EBI-1056807, EBI-20858485;
CC       P09958; O14793: MSTN; NbExp=2; IntAct=EBI-1056807, EBI-8542977;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi network membrane
CC       {ECO:0000269|PubMed:11331585, ECO:0000269|PubMed:11799113,
CC       ECO:0000269|PubMed:8846780, ECO:0000269|PubMed:9130696,
CC       ECO:0000269|PubMed:9412467}; Single-pass type I membrane protein
CC       {ECO:0000305}. Cell membrane {ECO:0000269|PubMed:11799113,
CC       ECO:0000269|PubMed:9130696, ECO:0000269|PubMed:9412467}; Single-pass
CC       type I membrane protein {ECO:0000305}. Secreted
CC       {ECO:0000305|PubMed:11799113}. Endosome membrane
CC       {ECO:0000269|PubMed:9412467}; Single-pass type I membrane protein
CC       {ECO:0000305}. Note=Shuttles between the trans-Golgi network and the
CC       cell surface (PubMed:9412467, PubMed:11799113). Propeptide cleavage is
CC       a prerequisite for exit of furin molecules out of the endoplasmic
CC       reticulum (ER). A second cleavage within the propeptide occurs in the
CC       trans Golgi network (TGN), followed by the release of the propeptide
CC       and the activation of furin (PubMed:11799113).
CC       {ECO:0000269|PubMed:11799113, ECO:0000269|PubMed:9412467}.
CC   -!- TISSUE SPECIFICITY: Seems to be expressed ubiquitously.
CC       {ECO:0000269|PubMed:1713771}.
CC   -!- DOMAIN: Contains a cytoplasmic domain responsible for its TGN
CC       localization and recycling from the cell surface.
CC       {ECO:0000269|PubMed:8846780}.
CC   -!- PTM: The inhibition peptide, which plays the role of an intramolecular
CC       chaperone, is autocatalytically removed in the endoplasmic reticulum
CC       (ER) and remains non-covalently bound to furin as a potent
CC       autoinhibitor. Following transport to the trans Golgi, a second
CC       cleavage within the inhibition propeptide results in propeptide
CC       dissociation and furin activation. {ECO:0000269|PubMed:1629222,
CC       ECO:0000269|PubMed:9130696}.
CC   -!- PTM: Phosphorylation is required for TGN localization of the
CC       endoprotease. In vivo, exists as di-, mono- and non-phosphorylated
CC       forms. {ECO:0000269|PubMed:8846780}.
CC   -!- SIMILARITY: Belongs to the peptidase S8 family. Furin subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FURINID40646ch15q26.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X17094; CAA34948.1; -; mRNA.
DR   EMBL; BC012181; AAH12181.1; -; mRNA.
DR   EMBL; X15723; CAA33745.1; -; Genomic_DNA.
DR   EMBL; X04329; CAA27860.1; -; Genomic_DNA.
DR   CCDS; CCDS10364.1; -.
DR   PIR; A39552; KXHUF.
DR   RefSeq; NP_001276752.1; NM_001289823.1.
DR   RefSeq; NP_001276753.1; NM_001289824.1.
DR   RefSeq; NP_002560.1; NM_002569.3.
DR   PDB; 4OMC; X-ray; 2.30 A; A/B/C/D/E/F=108-574.
DR   PDB; 4OMD; X-ray; 2.70 A; A/B/C/D/E/F=108-574.
DR   PDB; 4RYD; X-ray; 2.15 A; A/B/C/D/E/F=108-574.
DR   PDB; 4Z2A; X-ray; 1.89 A; A=110-574.
DR   PDB; 5JMO; X-ray; 2.00 A; A/B=108-574.
DR   PDB; 5JXG; X-ray; 1.80 A; A=108-574.
DR   PDB; 5JXH; X-ray; 2.00 A; A=108-574.
DR   PDB; 5JXI; X-ray; 2.00 A; A=108-574.
DR   PDB; 5JXJ; X-ray; 2.00 A; A=108-574.
DR   PDB; 5MIM; X-ray; 1.90 A; A=108-574.
DR   PDB; 6A8Y; NMR; -; A=64-89.
DR   PDB; 6EQV; X-ray; 1.90 A; A=108-574.
DR   PDB; 6EQW; X-ray; 1.99 A; A=108-574.
DR   PDB; 6EQX; X-ray; 1.99 A; A=108-567.
DR   PDB; 6HLB; X-ray; 2.00 A; A=108-574.
DR   PDB; 6HLD; X-ray; 2.10 A; A=108-574.
DR   PDB; 6HLE; X-ray; 1.99 A; A=108-574.
DR   PDB; 6HZA; X-ray; 1.90 A; A=108-574.
DR   PDB; 6HZB; X-ray; 1.90 A; A=108-574.
DR   PDB; 6HZC; X-ray; 1.90 A; A=108-574.
DR   PDB; 6HZD; X-ray; 1.90 A; A=108-574.
DR   PDBsum; 4OMC; -.
DR   PDBsum; 4OMD; -.
DR   PDBsum; 4RYD; -.
DR   PDBsum; 4Z2A; -.
DR   PDBsum; 5JMO; -.
DR   PDBsum; 5JXG; -.
DR   PDBsum; 5JXH; -.
DR   PDBsum; 5JXI; -.
DR   PDBsum; 5JXJ; -.
DR   PDBsum; 5MIM; -.
DR   PDBsum; 6A8Y; -.
DR   PDBsum; 6EQV; -.
DR   PDBsum; 6EQW; -.
DR   PDBsum; 6EQX; -.
DR   PDBsum; 6HLB; -.
DR   PDBsum; 6HLD; -.
DR   PDBsum; 6HLE; -.
DR   PDBsum; 6HZA; -.
DR   PDBsum; 6HZB; -.
DR   PDBsum; 6HZC; -.
DR   PDBsum; 6HZD; -.
DR   SMR; P09958; -.
DR   BioGRID; 111082; 44.
DR   CORUM; P09958; -.
DR   DIP; DIP-29904N; -.
DR   ELM; P09958; -.
DR   IntAct; P09958; 20.
DR   MINT; P09958; -.
DR   STRING; 9606.ENSP00000483552; -.
DR   BindingDB; P09958; -.
DR   ChEMBL; CHEMBL2611; -.
DR   DrugBank; DB03600; Capric acid.
DR   DrugBank; DB04951; Pirfenidone.
DR   GuidetoPHARMACOLOGY; 2366; -.
DR   MEROPS; S08.071; -.
DR   GlyGen; P09958; 3 sites.
DR   iPTMnet; P09958; -.
DR   PhosphoSitePlus; P09958; -.
DR   SwissPalm; P09958; -.
DR   BioMuta; FURIN; -.
DR   DMDM; 120611; -.
DR   OGP; P09958; -.
DR   EPD; P09958; -.
DR   jPOST; P09958; -.
DR   MassIVE; P09958; -.
DR   MaxQB; P09958; -.
DR   PaxDb; P09958; -.
DR   PeptideAtlas; P09958; -.
DR   PRIDE; P09958; -.
DR   ProteomicsDB; 52283; -.
DR   ABCD; P09958; 1 sequenced antibody.
DR   Antibodypedia; 4013; 421 antibodies.
DR   Ensembl; ENST00000268171; ENSP00000268171; ENSG00000140564.
DR   Ensembl; ENST00000610579; ENSP00000484952; ENSG00000140564.
DR   Ensembl; ENST00000618099; ENSP00000483552; ENSG00000140564.
DR   GeneID; 5045; -.
DR   KEGG; hsa:5045; -.
DR   UCSC; uc002bpu.2; human.
DR   CTD; 5045; -.
DR   DisGeNET; 5045; -.
DR   EuPathDB; HostDB:ENSG00000140564.10; -.
DR   GeneCards; FURIN; -.
DR   HGNC; HGNC:8568; FURIN.
DR   HPA; ENSG00000140564; Group enriched (liver, placenta, salivary gland).
DR   MIM; 136950; gene.
DR   neXtProt; NX_P09958; -.
DR   OpenTargets; ENSG00000140564; -.
DR   PharmGKB; PA32894; -.
DR   eggNOG; KOG3525; Eukaryota.
DR   GeneTree; ENSGT00940000157220; -.
DR   HOGENOM; CLU_002976_4_0_1; -.
DR   InParanoid; P09958; -.
DR   KO; K01349; -.
DR   OMA; CLGEPTH; -.
DR   OrthoDB; 473018at2759; -.
DR   PhylomeDB; P09958; -.
DR   TreeFam; TF314277; -.
DR   PathwayCommons; P09958; -.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1566948; Elastic fibre formation.
DR   Reactome; R-HSA-1592389; Activation of Matrix Metalloproteinases.
DR   Reactome; R-HSA-159782; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   Reactome; R-HSA-167060; NGF processing.
DR   Reactome; R-HSA-171286; Synthesis and processing of ENV and VPU.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-6809371; Formation of the cornified envelope.
DR   Reactome; R-HSA-8963889; Assembly of active LPL and LIPC lipase complexes.
DR   Reactome; R-HSA-9662834; CD163 mediating an anti-inflammatory response.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SignaLink; P09958; -.
DR   SIGNOR; P09958; -.
DR   BioGRID-ORCS; 5045; 121 hits in 878 CRISPR screens.
DR   ChiTaRS; FURIN; human.
DR   GeneWiki; Furin; -.
DR   GenomeRNAi; 5045; -.
DR   Pharos; P09958; Tchem.
DR   PRO; PR:P09958; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P09958; protein.
DR   Bgee; ENSG00000140564; Expressed in saliva-secreting gland and 236 other tissues.
DR   ExpressionAtlas; P09958; baseline and differential.
DR   Genevisible; P09958; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IGI:BHF-UCL.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; IMP:UniProtKB.
DR   GO; GO:0030173; C:integral component of Golgi membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:BHF-UCL.
DR   GO; GO:0030140; C:trans-Golgi network transport vesicle; IDA:MGI.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0048406; F:nerve growth factor binding; IDA:BHF-UCL.
DR   GO; GO:0008233; F:peptidase activity; IDA:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; IDA:BHF-UCL.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0001825; P:blastocyst formation; IEA:Ensembl.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0070268; P:cornification; TAS:Reactome.
DR   GO; GO:0090472; P:dibasic protein processing; IMP:UniProtKB.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0032804; P:negative regulation of low-density lipoprotein particle receptor catabolic process; IDA:HGNC-UCL.
DR   GO; GO:0032911; P:negative regulation of transforming growth factor beta1 production; IMP:BHF-UCL.
DR   GO; GO:0032455; P:nerve growth factor processing; TAS:Reactome.
DR   GO; GO:0032902; P:nerve growth factor production; IDA:BHF-UCL.
DR   GO; GO:0043043; P:peptide biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0016486; P:peptide hormone processing; IDA:BHF-UCL.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IC:BHF-UCL.
DR   GO; GO:1901394; P:positive regulation of transforming growth factor beta1 activation; IDA:UniProtKB.
DR   GO; GO:0016485; P:protein processing; IDA:UniProtKB.
DR   GO; GO:0052548; P:regulation of endopeptidase activity; IDA:BHF-UCL.
DR   GO; GO:0051004; P:regulation of lipoprotein lipase activity; TAS:Reactome.
DR   GO; GO:0045714; P:regulation of low-density lipoprotein particle receptor biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042176; P:regulation of protein catabolic process; IMP:BHF-UCL.
DR   GO; GO:0009966; P:regulation of signal transduction; IEA:Ensembl.
DR   GO; GO:0032940; P:secretion by cell; IDA:BHF-UCL.
DR   GO; GO:0006465; P:signal peptide processing; IDA:HGNC-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0019058; P:viral life cycle; IEP:BHF-UCL.
DR   GO; GO:0019082; P:viral protein processing; TAS:Reactome.
DR   GO; GO:0031638; P:zymogen activation; IMP:UniProtKB.
DR   GO; GO:0097341; P:zymogen inhibition; IMP:UniProtKB.
DR   CDD; cd00064; FU; 2.
DR   CDD; cd04059; Peptidases_S8_Protein_convertases_Kexins_Furin-like; 1.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 3.30.70.850; -; 1.
DR   Gene3D; 3.40.50.200; -; 1.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR034182; Kexin/furin.
DR   InterPro; IPR002884; P_dom.
DR   InterPro; IPR000209; Peptidase_S8/S53_dom.
DR   InterPro; IPR036852; Peptidase_S8/S53_dom_sf.
DR   InterPro; IPR023827; Peptidase_S8_Asp-AS.
DR   InterPro; IPR022398; Peptidase_S8_His-AS.
DR   InterPro; IPR023828; Peptidase_S8_Ser-AS.
DR   InterPro; IPR015500; Peptidase_S8_subtilisin-rel.
DR   InterPro; IPR032815; S8_pro-domain.
DR   InterPro; IPR038466; S8_pro-domain_sf.
DR   Pfam; PF01483; P_proprotein; 1.
DR   Pfam; PF00082; Peptidase_S8; 1.
DR   Pfam; PF16470; S8_pro-domain; 1.
DR   PRINTS; PR00723; SUBTILISIN.
DR   SMART; SM00261; FU; 2.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF52743; SSF52743; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS51829; P_HOMO_B; 1.
DR   PROSITE; PS51892; SUBTILASE; 1.
DR   PROSITE; PS00136; SUBTILASE_ASP; 1.
DR   PROSITE; PS00137; SUBTILASE_HIS; 1.
DR   PROSITE; PS00138; SUBTILASE_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Autocatalytic cleavage; Calcium; Cell membrane;
KW   Cleavage on pair of basic residues; Disulfide bond; Endosome; Glycoprotein;
KW   Golgi apparatus; Host-virus interaction; Hydrolase; Membrane;
KW   Metal-binding; Phosphoprotein; Polymorphism; Protease; Reference proteome;
KW   Repeat; Secreted; Serine protease; Signal; Transmembrane;
KW   Transmembrane helix; Zymogen.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255"
FT   PROPEP          27..107
FT                   /note="Inhibition peptide"
FT                   /evidence="ECO:0000269|PubMed:9130696"
FT                   /id="PRO_0000027028"
FT   CHAIN           108..794
FT                   /note="Furin"
FT                   /id="PRO_0000027029"
FT   TOPO_DOM        108..715
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        716..738
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        739..794
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          121..435
FT                   /note="Peptidase S8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   DOMAIN          444..576
FT                   /note="P/Homo B"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01173"
FT   REPEAT          577..620
FT                   /note="FU 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          638..681
FT                   /note="FU 2"
FT                   /evidence="ECO:0000255"
FT   REGION          191..192
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000305|PubMed:24666235,
FT                   ECO:0000305|PubMed:25974265"
FT   REGION          253..258
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000305|PubMed:24666235,
FT                   ECO:0000305|PubMed:25974265"
FT   REGION          292..295
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000305|PubMed:24666235,
FT                   ECO:0000305|PubMed:25974265"
FT   REGION          759..762
FT                   /note="Cell surface signal"
FT                   /evidence="ECO:0000303|PubMed:9412467"
FT   MOTIF           498..500
FT                   /note="Cell attachment site"
FT                   /evidence="ECO:0000255"
FT   MOTIF           773..779
FT                   /note="Trans Golgi network signal"
FT                   /evidence="ECO:0000269|PubMed:8846780"
FT   ACT_SITE        153
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   ACT_SITE        194
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   ACT_SITE        368
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   METAL           115
FT                   /note="Calcium 1"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           162
FT                   /note="Calcium 1"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           174
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           179
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           181
FT                   /note="Calcium 2; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           205
FT                   /note="Calcium 1; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           208
FT                   /note="Calcium 1"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           210
FT                   /note="Calcium 1; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           212
FT                   /note="Calcium 1; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           258
FT                   /note="Calcium 3"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           301
FT                   /note="Calcium 3"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   METAL           331
FT                   /note="Calcium 3"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   BINDING         154
FT                   /note="Substrate"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000305|PubMed:24666235,
FT                   ECO:0000305|PubMed:25974265"
FT   BINDING         236
FT                   /note="Substrate"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000305|PubMed:24666235,
FT                   ECO:0000305|PubMed:25974265"
FT   BINDING         264
FT                   /note="Substrate"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000305|PubMed:24666235,
FT                   ECO:0000305|PubMed:25974265"
FT   BINDING         306
FT                   /note="Substrate"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000305|PubMed:24666235,
FT                   ECO:0000305|PubMed:25974265"
FT   BINDING         308
FT                   /note="Substrate"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000305|PubMed:24666235,
FT                   ECO:0000305|PubMed:25974265"
FT   BINDING         368
FT                   /note="Substrate"
FT                   /evidence="ECO:0000244|PDB:4OMC, ECO:0000244|PDB:4OMD,
FT                   ECO:0000244|PDB:4RYD, ECO:0000305|PubMed:24666235,
FT                   ECO:0000305|PubMed:25974265"
FT   SITE            75..76
FT                   /note="Cleavage, second; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:9130696"
FT   SITE            107..108
FT                   /note="Cleavage, first; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:1629222,
FT                   ECO:0000269|PubMed:9130696"
FT   MOD_RES         773
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:8846780"
FT   MOD_RES         775
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:8846780"
FT   CARBOHYD        387
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        440
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        553
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        211..360
FT                   /evidence="ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   DISULFID        303..333
FT                   /evidence="ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   DISULFID        450..474
FT                   /evidence="ECO:0000269|PubMed:24666235,
FT                   ECO:0000269|PubMed:25974265"
FT   VARIANT         43
FT                   /note="A -> V (in dbSNP:rs16944971)"
FT                   /id="VAR_051821"
FT   VARIANT         547
FT                   /note="W -> R (in cell line LoVo; does not undergo
FT                   autocatalytic activation and is not transported to the
FT                   Golgi apparatus)"
FT                   /evidence="ECO:0000269|PubMed:7592877"
FT                   /id="VAR_055343"
FT   MUTAGEN         72
FT                   /note="V->R: Loss of catalytic activity and propeptide
FT                   second cleavage and removal. Abnormal accumulation in the
FT                   early secretory pathway."
FT                   /evidence="ECO:0000269|PubMed:11799113"
FT   MUTAGEN         75
FT                   /note="R->A: Loss of catalytic activity and, propeptide
FT                   second cleavage and removal. Normal trafficking to the
FT                   Golgi."
FT                   /evidence="ECO:0000269|PubMed:11799113"
FT   MUTAGEN         153
FT                   /note="D->N: Loss of catalytic activity and propeptide
FT                   first cleavage. Abnormal accumulation in the early
FT                   secretory pathway."
FT                   /evidence="ECO:0000269|PubMed:11799113,
FT                   ECO:0000269|PubMed:9130696"
FT   MUTAGEN         773..775
FT                   /note="SDS->DDD: Phosphomimetic mutant. Localization in
FT                   early endosome is increased."
FT                   /evidence="ECO:0000269|PubMed:8846780"
FT   MUTAGEN         773
FT                   /note="S->A: Slight reduction in phosphorylation. Loss of
FT                   phosphorylation and abnormal accumulation in the early
FT                   secretory pathway; when associated with A-775."
FT                   /evidence="ECO:0000269|PubMed:8846780"
FT   MUTAGEN         775
FT                   /note="S->A: Slight reduction in phosphorylation. Loss of
FT                   phosphorylation and abnormal accumulation in the early
FT                   secretory pathway; when associated with A-773."
FT                   /evidence="ECO:0000269|PubMed:8846780"
FT   HELIX           66..68
FT                   /evidence="ECO:0000244|PDB:6A8Y"
FT   HELIX           73..77
FT                   /evidence="ECO:0000244|PDB:6A8Y"
FT   STRAND          78..80
FT                   /evidence="ECO:0000244|PDB:6A8Y"
FT   TURN            82..84
FT                   /evidence="ECO:0000244|PDB:6A8Y"
FT   HELIX           85..88
FT                   /evidence="ECO:0000244|PDB:6A8Y"
FT   HELIX           118..120
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   TURN            122..124
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          127..129
FT                   /evidence="ECO:0000244|PDB:5MIM"
FT   HELIX           134..139
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          148..154
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   TURN            161..166
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           169..171
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   TURN            175..178
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           191..193
FT                   /evidence="ECO:0000244|PDB:6EQV"
FT   HELIX           194..203
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          206..211
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   TURN            215..218
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          219..225
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          227..229
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           233..240
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   TURN            244..246
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          249..252
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          259..261
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           268..280
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           282..284
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          288..292
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           297..299
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           303..305
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   TURN            307..310
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          314..320
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          338..341
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          351..355
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   TURN            356..358
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          359..364
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           367..384
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           390..400
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          419..421
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   TURN            422..424
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           431..438
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          448..453
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          464..471
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          482..496
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   HELIX           498..500
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          501..506
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          512..516
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          528..535
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   TURN            537..540
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          545..553
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          555..557
FT                   /evidence="ECO:0000244|PDB:5JXG"
FT   STRAND          561..574
FT                   /evidence="ECO:0000244|PDB:5JXG"
SQ   SEQUENCE   794 AA;  86678 MW;  10C44DD5892EF85D CRC64;
     MELRPWLLWV VAATGTLVLL AADAQGQKVF TNTWAVRIPG GPAVANSVAR KHGFLNLGQI
     FGDYYHFWHR GVTKRSLSPH RPRHSRLQRE PQVQWLEQQV AKRRTKRDVY QEPTDPKFPQ
     QWYLSGVTQR DLNVKAAWAQ GYTGHGIVVS ILDDGIEKNH PDLAGNYDPG ASFDVNDQDP
     DPQPRYTQMN DNRHGTRCAG EVAAVANNGV CGVGVAYNAR IGGVRMLDGE VTDAVEARSL
     GLNPNHIHIY SASWGPEDDG KTVDGPARLA EEAFFRGVSQ GRGGLGSIFV WASGNGGREH
     DSCNCDGYTN SIYTLSISSA TQFGNVPWYS EACSSTLATT YSSGNQNEKQ IVTTDLRQKC
     TESHTGTSAS APLAAGIIAL TLEANKNLTW RDMQHLVVQT SKPAHLNAND WATNGVGRKV
     SHSYGYGLLD AGAMVALAQN WTTVAPQRKC IIDILTEPKD IGKRLEVRKT VTACLGEPNH
     ITRLEHAQAR LTLSYNRRGD LAIHLVSPMG TRSTLLAARP HDYSADGFND WAFMTTHSWD
     EDPSGEWVLE IENTSEANNY GTLTKFTLVL YGTAPEGLPV PPESSGCKTL TSSQACVVCE
     EGFSLHQKSC VQHCPPGFAP QVLDTHYSTE NDVETIRASV CAPCHASCAT CQGPALTDCL
     SCPSHASLDP VEQTCSRQSQ SSRESPPQQQ PPRLPPEVEA GQRLRAGLLP SHLPEVVAGL
     SCAFIVLVFV TVFLVLQLRS GFSFRGVKVY TMDRGLISYK GLPPEAWQEE CPSDSEEDEG
     RGERTAFIKD QSAL
//
ID   R1A_SARS                Reviewed;        4382 AA.
AC   P0C6U8; P59641;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   12-AUG-2020, entry version 101.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE     AltName: Full=Leader protein;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE              EC=3.4.19.12;
DE              EC=3.4.22.-;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69;
DE     AltName: Full=Main protease;
DE              Short=Mpro;
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
GN   ORFNames=1a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, Isolate SZ16, and Isolate SZ3;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   "Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China.";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   "Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection.";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   "Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization.";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RX   PubMed=14645828; DOI=10.1126/science.302.5650.1504b;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.H.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "Phylogeny of the SARS coronavirus.";
RL   Science 302:1504-1505(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt-1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   "Genomic sequence of SARS isolate from the first fatal case in Taiwan.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   "Analysis of SARS coronavirus genome in Shanghai isolates.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RA   Wang Z., Cheng S., Zhang Y.;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-507 AND 1655-4382.
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   "Mechanisms and enzymes involved in SARS coronavirus genome expression.";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [22]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RX   PubMed=15331731; DOI=10.1128/jvi.78.18.9977-9986.2004;
RA   Prentice E., McAuliffe J., Lu X., Subbarao K., Denison M.R.;
RT   "Identification and characterization of severe acute respiratory syndrome
RT   coronavirus replicase proteins.";
RL   J. Virol. 78:9977-9986(2004).
RN   [23]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RC   STRAIN=Isolate Urbani;
RX   PubMed=15564471; DOI=10.1128/jvi.78.24.13600-13612.2004;
RA   Harcourt B.H., Jukneliene D., Kanjanahaluethai A., Bechill J.,
RA   Severson K.M., Smith C.M., Rota P.A., Baker S.C.;
RT   "Identification of severe acute respiratory syndrome coronavirus replicase
RT   products and characterization of papain-like protease activity.";
RL   J. Virol. 78:13600-13612(2004).
RN   [24]
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE), SUBUNIT (3C-LIKE PROTEINASE), AND
RP   BIOPHYSICOCHEMICAL PROPERTIES (3C-LIKE PROTEINASE).
RX   PubMed=14561748; DOI=10.1074/jbc.m310875200;
RA   Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., Lai B., Pei J., Liu Y.,
RA   Chen J., Lai L.;
RT   "Biosynthesis, purification, and substrate specificity of severe acute
RT   respiratory syndrome coronavirus 3C-like proteinase.";
RL   J. Biol. Chem. 279:1637-1642(2004).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17024178; DOI=10.1038/sj.emboj.7601368;
RA   Imbert I., Guillemot J.-C., Bourhis J.-M., Bussetta C., Coutard B.,
RA   Egloff M.-P., Ferron F., Gorbalenya A.E., Canard B.;
RT   "A second, non-canonical RNA-dependent RNA polymerase in SARS
RT   coronavirus.";
RL   EMBO J. 25:4933-4942(2006).
RN   [26]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=17692280; DOI=10.1016/j.abb.2007.07.006;
RA   Lindner H.A., Lytvyn V., Qi H., Lachance P., Ziomek E., Menard R.;
RT   "Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus
RT   papain-like protease.";
RL   Arch. Biochem. Biophys. 466:8-14(2007).
RN   [27]
RP   INTERACTION OF NSP10 WITH NSP14 AND NSP16.
RX   PubMed=18827877; DOI=10.1371/journal.pone.0003299;
RA   Pan J., Peng X., Gao Y., Li Z., Lu X., Chen Y., Ishaq M., Liu D.,
RA   Dediego M.L., Enjuanes L., Guo D.;
RT   "Genome-wide analysis of protein-protein interactions and involvement of
RT   viral proteins in SARS-CoV replication.";
RL   PLoS ONE 3:E3299-E3299(2008).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=19369340; DOI=10.1128/jvi.02220-08;
RA   Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S.;
RT   "Severe acute respiratory syndrome coronavirus papain-like protease
RT   ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and
RT   NF-kappaB signaling.";
RL   J. Virol. 83:6689-6705(2009).
RN   [29]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), AND INTERACTION WITH HOST PHB AND
RP   PHB2.
RX   PubMed=19640993; DOI=10.1128/jvi.00842-09;
RA   Cornillez-Ty C.T., Liao L., Yates J.R., Kuhn P., Buchmeier M.J.;
RT   "Severe acute respiratory syndrome coronavirus nonstructural protein 2
RT   interacts with a host protein complex involved in mitochondrial biogenesis
RT   and intracellular signaling.";
RL   J. Virol. 83:10314-10318(2009).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=19153232; DOI=10.1128/jvi.01505-08;
RA   Miknis Z.J., Donaldson E.F., Umland T.C., Rimmer R.A., Baric R.S.,
RA   Schultz L.W.;
RT   "Severe acute respiratory syndrome coronavirus nsp9 dimerization is
RT   essential for efficient viral growth.";
RL   J. Virol. 83:3007-3018(2009).
RN   [31]
RP   FUNCTION OF NSP1.
RX   PubMed=22174690; DOI=10.1371/journal.ppat.1002433;
RA   Huang C., Lokugamage K.G., Rozovics J.M., Narayanan K., Semler B.L.,
RA   Makino S.;
RT   "SARS coronavirus nsp1 protein induces template-dependent endonucleolytic
RT   cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA
RT   cleavage.";
RL   PLoS Pathog. 7:E1002433-E1002433(2011).
RN   [32]
RP   FUNCTION (PROTEINASE 3CL-PRO).
RX   PubMed=16226257; DOI=10.1016/j.febslet.2005.09.075;
RA   Lin C.W., Tsai F.J., Wan L., Lai C.C., Lin K.H., Hsieh T.H., Shiu S.Y.,
RA   Li J.Y.;
RT   "Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar-H+
RT   ATPase G1 subunit.";
RL   FEBS Lett. 579:6089-6094(2005).
RN   [33]
RP   HOMODIMERIZATION (3C-LIKE PROTEINASE).
RX   PubMed=15507456; DOI=10.1074/jbc.m408211200;
RA   Chen S., Chen L., Tan J., Chen J., Du L., Sun T., Shen J., Chen K.,
RA   Jiang H., Shen X.;
RT   "Severe acute respiratory syndrome coronavirus 3C-like proteinase N
RT   terminus is indispensable for proteolytic activity but not for enzyme
RT   dimerization. Biochemical and thermodynamic investigation in conjunction
RT   with molecular dynamics simulations.";
RL   J. Biol. Chem. 280:164-173(2005).
RN   [34]
RP   INTERACTION WITH ORF6 PROTEIN.
RX   PubMed=17532020; DOI=10.1016/j.virol.2007.04.029;
RA   Kumar P., Gunalan V., Liu B., Chow V.T., Druce J., Birch C., Catton M.,
RA   Fielding B.C., Tan Y.J., Lal S.K.;
RT   "The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with
RT   its ORF6 accessory protein.";
RL   Virology 366:293-303(2007).
RN   [35]
RP   INTERACTION OF NSP4 WITH PL-PRO AND NSP6, AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=21345958; DOI=10.1128/jvi.00042-11;
RA   Hagemeijer M.C., Ulasli M., Vonk A.M., Reggiori F., Rottier P.J.,
RA   de Haan C.A.;
RT   "Mobility and interactions of coronavirus nonstructural protein 4.";
RL   J. Virol. 85:4572-4577(2011).
RN   [36]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=23035226; DOI=10.1128/jvi.01958-12;
RA   Lokugamage K.G., Narayanan K., Huang C., Makino S.;
RT   "Severe acute respiratory syndrome coronavirus protein nsp1 is a novel
RT   eukaryotic translation inhibitor that represses multiple steps of
RT   translation initiation.";
RL   J. Virol. 86:13598-13608(2012).
RN   [37]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN
RP   8).
RX   PubMed=22039154; DOI=10.1093/nar/gkr893;
RA   te Velthuis A.J., van den Worm S.H., Snijder E.J.;
RT   "The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA
RT   polymerase capable of both de novo initiation and primer extension.";
RL   Nucleic Acids Res. 40:1737-1747(2012).
RN   [38]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 10), FUNCTION (GUANINE-N7
RP   METHYLTRANSFERASE), AND INTERACTION OF NSP10 AND NSP14.
RX   PubMed=22635272; DOI=10.1073/pnas.1201130109;
RA   Bouvet M., Imbert I., Subissi L., Gluais L., Canard B., Decroly E.;
RT   "RNA 3'-end mismatch excision by the severe acute respiratory syndrome
RT   coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9372-9377(2012).
RN   [39]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=23943763; DOI=10.1128/mbio.00524-13;
RA   Angelini M.M., Akhlaghpour M., Neuman B.W., Buchmeier M.J.;
RT   "Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4,
RT   and 6 induce double-membrane vesicles.";
RL   MBio 4:0-0(2013).
RN   [40]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=24991833; DOI=10.4161/auto.29309;
RA   Cottam E.M., Whelband M.C., Wileman T.;
RT   "Coronavirus NSP6 restricts autophagosome expansion.";
RL   Autophagy 10:1426-1441(2014).
RN   [41]
RP   PROTEOLYTIC CLEAVAGE (REPLICASE POLYPROTEIN 1AB), MASS SPECTROMETRY
RP   (NON-STRUCTURAL PROTEIN 8), MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 9),
RP   AND MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=32083638; DOI=10.1042/bcj20200029;
RA   Krichel B., Falke S., Hilgenfeld R., Redecke L., Uetrecht C.;
RT   "Processing of the SARS-CoV pp1a/ab nsp7-10 region.";
RL   Biochem. J. 477:1009-1019(2020).
RN   [42]
RP   REVIEW.
RX   PubMed=24410069; DOI=10.1089/dna.2013.2304;
RA   Angelini M.M., Neuman B.W., Buchmeier M.J.;
RT   "Untangling membrane rearrangement in the nidovirales.";
RL   DNA Cell Biol. 33:122-127(2014).
RN   [43]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=24622840; DOI=10.1007/s13238-014-0026-3;
RA   Chen X., Yang X., Zheng Y., Yang Y., Xing Y., Chen Z.;
RT   "SARS coronavirus papain-like protease inhibits the type I interferon
RT   signaling pathway through interaction with the STING-TRAF3-TBK1 complex.";
RL   Protein Cell 5:369-381(2014).
RN   [44]
RP   INTERACTION WITH NUP93 (HOST TRANSLATION INHIBITOR NSP1), AND FUNCTION
RP   (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=30943371; DOI=10.1139/bcb-2018-0394;
RA   Gomez G.N., Abrar F., Dodhia M.P., Gonzalez F.G., Nag A.;
RT   "SARS coronavirus protein nsp1 disrupts localization of Nup93 from the
RT   nuclear pore complex.";
RL   Biochem. Cell Biol. 97:758-766(2019).
RN   [45]
RP   3D-STRUCTURE MODELING OF 3241-3540, AND CHARACTERIZATION.
RX   PubMed=12746549; DOI=10.1126/science.1085658;
RA   Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R.;
RT   "Coronavirus main proteinase (3CLpro) structure: basis for design of anti-
RT   SARS drugs.";
RL   Science 300:1763-1767(2003).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4118-4230 (NSP9).
RC   STRAIN=Isolate Frankfurt-1;
RX   PubMed=12925794; DOI=10.1107/s0907444903016779;
RA   Campanacci V., Egloff M.-P., Longhi S., Ferron F., Rancurel C.,
RA   Salomoni A., Durousseau C., Tocque F., Bremond N., Dobbe J.C.,
RA   Snijder E.J., Canard B., Cambillau C.;
RT   "Structural genomics of the SARS coronavirus: cloning, expression,
RT   crystallization and preliminary crystallographic study of the Nsp9
RT   protein.";
RL   Acta Crystallogr. D 59:1628-1631(2003).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 4118-4230.
RX   PubMed=15007178; DOI=10.1073/pnas.0307877101;
RA   Egloff M.-P., Ferron F., Campanacci V., Longhi S., Rancurel C.,
RA   Dutartre H., Snijder E.J., Gorbalenya A.E., Cambillau C., Canard B.;
RT   "The severe acute respiratory syndrome-coronavirus replicative protein nsp9
RT   is a single-stranded RNA-binding subunit unique in the RNA virus world.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3792-3796(2004).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4107-4230.
RX   PubMed=14962394; DOI=10.1016/j.str.2004.01.016;
RA   Sutton G., Fry E., Carter L., Sainsbury S., Walter T., Nettleship J.,
RA   Berrow N., Owens R., Gilbert R., Davidson A., Siddell S., Poon L.L.M.,
RA   Diprose J., Alderton D., Walsh M., Grimes J.M., Stuart D.I.;
RT   "The nsp9 replicase protein of SARS-coronavirus, structure and functional
RT   insights.";
RL   Structure 12:341-353(2004).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 3837-4117 AND 3920-4117, AND
RP   INTERACTION OF NSP7 WITH NSP8.
RX   PubMed=16228002; DOI=10.1038/nsmb999;
RA   Zhai Y., Sun F., Li X., Pang H., Xu X., Bartlam M., Rao Z.;
RT   "Insights into SARS-CoV transcription and replication from the structure of
RT   the nsp7-nsp8 hexadecamer.";
RL   Nat. Struct. Mol. Biol. 12:980-986(2005).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1002-1176.
RX   PubMed=16271890; DOI=10.1016/j.str.2005.07.022;
RA   Saikatendu K.S., Joseph J.S., Subramanian V., Clayton T., Griffith M.,
RA   Moy K., Velasquez J., Neuman B.W., Buchmeier M.J., Stevens R.C., Kuhn P.;
RT   "Structural basis of severe acute respiratory syndrome coronavirus ADP-
RT   ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3.";
RL   Structure 13:1665-1675(2005).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1541-1854.
RX   PubMed=16581910; DOI=10.1073/pnas.0510851103;
RA   Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C.,
RA   Stevens R.C., Mesecar A.D.;
RT   "Severe acute respiratory syndrome coronavirus papain-like protease:
RT   structure of a viral deubiquitinating enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5717-5722(2006).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 4240-4362.
RC   STRAIN=Isolate Tor2;
RX   PubMed=16873246; DOI=10.1128/jvi.00467-06;
RA   Joseph J.S., Saikatendu K.S., Subramanian V., Neuman B.W., Brooun A.,
RA   Griffith M., Moy K., Yadav M.K., Velasquez J., Buchmeier M.J.,
RA   Stevens R.C., Kuhn P.;
RT   "Crystal structure of nonstructural protein 10 from the severe acute
RT   respiratory syndrome coronavirus reveals a novel fold with two zinc-binding
RT   motifs.";
RL   J. Virol. 80:7894-7901(2006).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 4231-4378.
RX   PubMed=16873247; DOI=10.1128/jvi.00483-06;
RA   Su D., Lou Z., Sun F., Zhai Y., Yang H., Zhang R., Joachimiak A.,
RA   Zhang X.C., Bartlam M., Rao Z.;
RT   "Dodecamer structure of severe acute respiratory syndrome coronavirus
RT   nonstructural protein nsp10.";
RL   J. Virol. 80:7902-7908(2006).
RN   [54]
RP   STRUCTURE BY NMR OF 13-127.
RX   PubMed=17202208; DOI=10.1128/jvi.01939-06;
RA   Almeida M.S., Johnson M.A., Herrmann T., Geralt M., Wuthrich K.;
RT   "Novel beta-barrel fold in the nuclear magnetic resonance structure of the
RT   replicase nonstructural protein 1 from the severe acute respiratory
RT   syndrome coronavirus.";
RL   J. Virol. 81:3151-3161(2007).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3241-3546.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of Sars coronavirus main proteinase(3CLPRO).";
RL   Submitted (JUL-2007) to the PDB data bank.
CC   -!- FUNCTION: [Replicase polyprotein 1a]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC   -!- FUNCTION: [Non-structural protein 1]: Inhibits host translation by
CC       interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response (PubMed:23035226). May disrupt nuclear pore function by
CC       binding and displacing host NUP93 (PubMed:30943371).
CC       {ECO:0000269|PubMed:23035226, ECO:0000269|PubMed:30943371}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2. Indeed, these two proteins play a role in maintaining the
CC       functional integrity of the mitochondria and protecting cells from
CC       various stresses. {ECO:0000269|PubMed:19640993}.
CC   -!- FUNCTION: [Non-structural protein 3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:17692280). Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication. Nsp3, nsp4 and nsp6
CC       together are sufficient to form DMV (PubMed:24410069). Antagonizes
CC       innate immune induction of type I interferon by blocking the
CC       phosphorylation, dimerization and subsequent nuclear translocation of
CC       host IRF3 (PubMed:19369340, PubMed:24622840). Prevents also host NF-
CC       kappa-B signaling. {ECO:0000269|PubMed:16271890,
CC       ECO:0000269|PubMed:17692280, ECO:0000269|PubMed:19369340,
CC       ECO:0000269|PubMed:24622840, ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication. Alone appears incapable
CC       to induce membrane curvature, but together with nsp3 is able to induce
CC       paired membranes. Nsp3, nsp4 and nsp6 together are sufficient to form
CC       DMV. {ECO:0000269|PubMed:23943763, ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [3C-like proteinase]: Cleaves the C-terminus of replicase
CC       polyprotein at 11 sites. Recognizes substrates containing the core
CC       sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). May cleave host ATP6V1G1 thereby modifying host
CC       vacuoles intracellular pH. {ECO:0000255|PROSITE-ProRule:PRU00772,
CC       ECO:0000269|PubMed:16226257}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication. Nsp3, nsp4 and nsp6
CC       together are sufficient to form DMV (PubMed:24410069). Plays a role in
CC       the initial induction of autophagosomes from host reticulum
CC       endoplasmic. Later, limits the expansion of these phagosomes that are
CC       no longer able to deliver viral components to lysosomes
CC       (PubMed:24991833). {ECO:0000269|PubMed:24991833,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [Non-structural protein 9]: May participate in viral
CC       replication by acting as a ssRNA-binding protein.
CC       {ECO:0000269|PubMed:19153232}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000269|PubMed:22635272}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=TSAVLQ-|-SGFRK-NH(2) and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:14561748};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.15 mM for peptide TSAVLQSGFRK-NH(2)
CC         {ECO:0000269|PubMed:14561748};
CC         KM=0.58 mM for peptide SGVTFQGKFKK {ECO:0000269|PubMed:14561748};
CC         KM=1.44 mM for peptide ATVRLQAGNAT {ECO:0000269|PubMed:14561748};
CC         Note=The kinetic parameters are studied for the 3C-like proteinase
CC         domain.;
CC       pH dependence:
CC         Optimum pH is 7.0 for 3C-like proteinase activity.
CC         {ECO:0000269|PubMed:14561748};
CC   -!- SUBUNIT: [Non-structural protein 2]: Interacts with host PHB and PHB2.
CC       {ECO:0000269|PubMed:19640993}.
CC   -!- SUBUNIT: [Non-structural protein 4]: Interacts with PL-PRO and nsp6.
CC       {ECO:0000269|PubMed:21345958}.
CC   -!- SUBUNIT: [3C-like proteinase]: Exists as monomer and homodimer. Only
CC       the homodimer shows catalytic activity. {ECO:0000269|PubMed:14561748,
CC       ECO:0000269|PubMed:15507456}.
CC   -!- SUBUNIT: [Non-structural protein 7]: Eight copies of nsp7 and eight
CC       copies of nsp8 assemble to form a heterohexadecamer dsRNA-encircling
CC       ring structure. {ECO:0000269|PubMed:16228002}.
CC   -!- SUBUNIT: [Non-structural protein 8]: Interacts with ORF6 protein.
CC       {ECO:0000269|PubMed:17532020}.
CC   -!- SUBUNIT: [Non-structural protein 9]: Homodimerizes.
CC       {ECO:0000269|PubMed:19153232}.
CC   -!- SUBUNIT: [Non-structural protein 10]: Forms a dodecamer and interacts
CC       with nsp14 and nsp16; these interactions enhance nsp14 and nsp16
CC       enzymatic activities. {ECO:0000269|PubMed:16873247,
CC       ECO:0000269|PubMed:18827877, ECO:0000269|PubMed:22635272}.
CC   -!- INTERACTION:
CC       PRO_0000338265; PRO_0000037310 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25492625, EBI-25474098;
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 3]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 4]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 6]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 7]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 8]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 9]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 10]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC       Name=Replicase polyprotein 1a; Synonyms=pp1a, ORF1a polyprotein;
CC         IsoId=P0C6U8-1; Sequence=Displayed;
CC       Name=Replicase polyprotein 1ab; Synonyms=pp1ab;
CC         IsoId=P0C6X7-1; Sequence=External;
CC   -!- DOMAIN: The hydrophobic domains (HD) could mediate the membrane
CC       association of the replication complex and thereby alter the
CC       architecture of the host cell membrane.
CC   -!- PTM: Specific enzymatic cleavages in vivo by its own proteases yield
CC       mature proteins. 3CL-PRO and PL-PRO proteinases are autocatalytically
CC       processed (By similarity). {ECO:0000250}.
CC   -!- MASS SPECTROMETRY: [Non-structural protein 8]: Mass=21871;
CC       Method=Electrospray; Evidence={ECO:0000269|PubMed:32083638};
CC   -!- MASS SPECTROMETRY: [Non-structural protein 9]: Mass=12403;
CC       Method=Electrospray; Evidence={ECO:0000269|PubMed:32083638};
CC   -!- MASS SPECTROMETRY: [Non-structural protein 10]: Mass=14974;
CC       Method=Electrospray; Evidence={ECO:0000269|PubMed:32083638};
CC   -!- MISCELLANEOUS: [Isoform Replicase polyprotein 1a]: Produced by
CC       conventional translation.
CC   -!- SIMILARITY: Belongs to the coronaviruses polyprotein 1ab family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Isolates SZ3 and SZ16 have been isolated from Paguma larvata
CC       and are described as SARS-like in literature. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13439.1; -; Genomic_RNA.
DR   EMBL; AY274119; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278554; AAP13575.1; -; Genomic_RNA.
DR   EMBL; AY282752; AAP30712.1; -; Genomic_RNA.
DR   EMBL; AY304495; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY304486; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY304488; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283794; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283795; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283796; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283797; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283798; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY286320; AAR16181.1; -; Genomic_RNA.
DR   EMBL; AY278488; AAP30029.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278489; AAP51226.1; -; Genomic_RNA.
DR   EMBL; AY291451; AAP37016.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50484.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33695.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72974.2; -; Genomic_RNA.
DR   EMBL; AY321118; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY338174; AAQ01595.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01607.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97880.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81347.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81361.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81375.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81389.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81403.1; -; Genomic_RNA.
DR   EMBL; AY427439; AAQ94059.1; -; Genomic_RNA.
DR   EMBL; AY322205; AAP82966.1; -; Genomic_RNA.
DR   EMBL; AY322206; AAP82976.1; -; Genomic_RNA.
DR   EMBL; AY463059; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   PDB; 1P76; Model; -; A=3241-3541, B=4225-4231.
DR   PDB; 1P9T; Model; -; A=3241-3544.
DR   PDB; 1PA5; Model; -; A=3241-3546.
DR   PDB; 1PUK; Model; -; A=3241-3550.
DR   PDB; 1Q1X; Model; -; A=3241-3542.
DR   PDB; 1Q2W; X-ray; 1.86 A; A/B=3241-3544.
DR   PDB; 1QZ8; X-ray; 2.70 A; A/B=4118-4230.
DR   PDB; 1UJ1; X-ray; 1.90 A; A/B=3241-3546.
DR   PDB; 1UK2; X-ray; 2.20 A; A/B=3241-3546.
DR   PDB; 1UK3; X-ray; 2.40 A; A/B=3241-3546.
DR   PDB; 1UK4; X-ray; 2.50 A; A/B=3241-3546.
DR   PDB; 1UW7; X-ray; 2.80 A; A=4118-4230.
DR   PDB; 1WOF; X-ray; 2.00 A; A/B=3241-3546.
DR   PDB; 1YSY; NMR; -; A=3837-3919.
DR   PDB; 1Z1I; X-ray; 2.80 A; A=3241-3546.
DR   PDB; 1Z1J; X-ray; 2.80 A; A/B=3241-3546.
DR   PDB; 2A5A; X-ray; 2.08 A; A=3241-3546.
DR   PDB; 2A5I; X-ray; 1.88 A; A=3241-3546.
DR   PDB; 2A5K; X-ray; 2.30 A; A/B=3241-3546.
DR   PDB; 2ACF; X-ray; 1.40 A; A/B/C/D=1002-1176.
DR   PDB; 2AHM; X-ray; 2.40 A; A/B/C/D=3837-3919, E/F/G/H=3920-4117.
DR   PDB; 2AJ5; Model; -; A=3241-3546.
DR   PDB; 2ALV; X-ray; 1.90 A; A=3241-3543.
DR   PDB; 2AMD; X-ray; 1.85 A; A/B=3241-3546.
DR   PDB; 2AMQ; X-ray; 2.30 A; A/B=3241-3546.
DR   PDB; 2BX3; X-ray; 2.00 A; A=3241-3546.
DR   PDB; 2BX4; X-ray; 2.79 A; A=3241-3546.
DR   PDB; 2C3S; X-ray; 1.90 A; A=3241-3546.
DR   PDB; 2D2D; X-ray; 2.70 A; A/B=3241-3546.
DR   PDB; 2DUC; X-ray; 1.70 A; A/B=3241-3546.
DR   PDB; 2FAV; X-ray; 1.80 A; A/B/C=1000-1173.
DR   PDB; 2FE8; X-ray; 1.85 A; A/B/C=1541-1854.
DR   PDB; 2FYG; X-ray; 1.80 A; A=4240-4362.
DR   PDB; 2G9T; X-ray; 2.10 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=4231-4382.
DR   PDB; 2GA6; X-ray; 2.70 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=4231-4382.
DR   PDB; 2GDT; NMR; -; A=13-127.
DR   PDB; 2GRI; NMR; -; A=819-930.
DR   PDB; 2GT7; X-ray; 1.82 A; A/B=3241-3546.
DR   PDB; 2GT8; X-ray; 2.00 A; A=3241-3546.
DR   PDB; 2GTB; X-ray; 2.00 A; A=3241-3546.
DR   PDB; 2GX4; X-ray; 1.93 A; A=3241-3546.
DR   PDB; 2GZ7; X-ray; 1.86 A; A=3241-3546.
DR   PDB; 2GZ8; X-ray; 1.97 A; A=3241-3546.
DR   PDB; 2GZ9; X-ray; 2.17 A; A=3241-3546.
DR   PDB; 2H2Z; X-ray; 1.60 A; A=3241-3546.
DR   PDB; 2HOB; X-ray; 1.95 A; A=3241-3546.
DR   PDB; 2HSX; NMR; -; A=13-127.
DR   PDB; 2IDY; NMR; -; A=819-930.
DR   PDB; 2KAF; NMR; -; A=1473-1538.
DR   PDB; 2KQV; NMR; -; A=1345-1538.
DR   PDB; 2KQW; NMR; -; A=1345-1538.
DR   PDB; 2KYS; NMR; -; A=3837-3919.
DR   PDB; 2LIZ; NMR; -; A=3427-3546.
DR   PDB; 2OP9; X-ray; 1.80 A; A/B=3241-3541.
DR   PDB; 2PWX; X-ray; 2.50 A; A=3241-3546.
DR   PDB; 2W2G; X-ray; 2.22 A; A/B=1207-1470.
DR   PDB; 2WCT; X-ray; 2.79 A; A/B/C/D=1207-1470.
DR   PDB; 2Z3C; X-ray; 1.79 A; A=3241-3546.
DR   PDB; 2Z3D; X-ray; 2.10 A; A=3241-3546.
DR   PDB; 2Z3E; X-ray; 2.32 A; A=3241-3546.
DR   PDB; 2ZU4; X-ray; 1.93 A; A=3241-3546.
DR   PDB; 2ZU5; X-ray; 1.65 A; A=3241-3546.
DR   PDB; 3ATW; X-ray; 2.36 A; A/B=3241-3546.
DR   PDB; 3AVZ; X-ray; 2.46 A; A=3241-3546.
DR   PDB; 3AW0; X-ray; 2.30 A; A=3241-3546.
DR   PDB; 3AW1; X-ray; 2.00 A; A/B=3241-3546.
DR   PDB; 3E91; X-ray; 2.55 A; A/B=3241-3546.
DR   PDB; 3EA7; X-ray; 2.65 A; A/B=3241-3546.
DR   PDB; 3EA8; X-ray; 2.25 A; A=3241-3546.
DR   PDB; 3EA9; X-ray; 2.40 A; A=3241-3546.
DR   PDB; 3EAJ; X-ray; 2.70 A; A/B=3241-3546.
DR   PDB; 3EE7; X-ray; 2.60 A; A/B/C/D=4118-4230.
DR   PDB; 3F9E; X-ray; 2.50 A; A=3241-3546.
DR   PDB; 3F9F; X-ray; 2.30 A; A/B=3241-3546.
DR   PDB; 3F9G; X-ray; 2.60 A; A/B=3241-3541.
DR   PDB; 3F9H; X-ray; 2.90 A; A/B=3241-3546.
DR   PDB; 3FZD; X-ray; 2.35 A; A=3241-3541.
DR   PDB; 3IWM; X-ray; 3.20 A; A/B/C/D=3241-3546.
DR   PDB; 3M3S; X-ray; 2.30 A; A/B=3241-3546.
DR   PDB; 3M3T; X-ray; 2.90 A; A=3241-3546.
DR   PDB; 3M3V; X-ray; 2.70 A; A/B=3241-3546.
DR   PDB; 3MJ5; X-ray; 2.63 A; A/B=1541-1855.
DR   PDB; 3R24; X-ray; 2.00 A; B=4240-4382.
DR   PDB; 3SN8; X-ray; 1.99 A; A=3241-3546.
DR   PDB; 3SNA; X-ray; 3.05 A; A=3241-3541.
DR   PDB; 3SNB; X-ray; 2.40 A; A=3241-3546.
DR   PDB; 3SNC; X-ray; 2.58 A; A=3241-3546.
DR   PDB; 3SND; X-ray; 1.89 A; A/B=3241-3546.
DR   PDB; 3SNE; X-ray; 2.60 A; A=3241-3546.
DR   PDB; 3SZN; X-ray; 1.69 A; A=3241-3546.
DR   PDB; 3TIT; X-ray; 1.99 A; A=3241-3546.
DR   PDB; 3TIU; X-ray; 2.08 A; A=3241-3546.
DR   PDB; 3TNS; X-ray; 1.99 A; A=3241-3546.
DR   PDB; 3TNT; X-ray; 1.59 A; A=3241-3546.
DR   PDB; 3V3M; X-ray; 1.96 A; A=3241-3546.
DR   PDB; 3VB3; X-ray; 2.20 A; A/B=3241-3546.
DR   PDB; 3VB4; X-ray; 2.20 A; A/B=3241-3546.
DR   PDB; 3VB5; X-ray; 1.95 A; A/B=3241-3546.
DR   PDB; 3VB6; X-ray; 2.50 A; A/B=3241-3546.
DR   PDB; 3VB7; X-ray; 1.95 A; A/B=3241-3546.
DR   PDB; 4HI3; X-ray; 2.09 A; A/B=3241-3546.
DR   PDB; 4M0W; X-ray; 1.40 A; A=1541-1858.
DR   PDB; 4MDS; X-ray; 1.60 A; A=3241-3542.
DR   PDB; 4MM3; X-ray; 2.75 A; B=1541-1855.
DR   PDB; 4OVZ; X-ray; 2.50 A; A/B=1541-1855.
DR   PDB; 4OW0; X-ray; 2.10 A; A/B=1541-1855.
DR   PDB; 5F22; X-ray; 2.15 A; A=3837-3919.
DR   PDB; 5Y3E; X-ray; 1.65 A; A=1541-1854.
DR   PDB; 5Y3Q; X-ray; 1.65 A; A=1541-1854.
DR   PDB; 6NUR; EM; 3.10 A; B/D=3920-4117.
DR   PDB; 6NUS; EM; 3.50 A; B=3920-4117.
DR   PDB; 6Y7M; X-ray; 1.90 A; AAA=3241-3546.
DR   PDBsum; 1P76; -.
DR   PDBsum; 1P9T; -.
DR   PDBsum; 1PA5; -.
DR   PDBsum; 1PUK; -.
DR   PDBsum; 1Q1X; -.
DR   PDBsum; 1Q2W; -.
DR   PDBsum; 1QZ8; -.
DR   PDBsum; 1UJ1; -.
DR   PDBsum; 1UK2; -.
DR   PDBsum; 1UK3; -.
DR   PDBsum; 1UK4; -.
DR   PDBsum; 1UW7; -.
DR   PDBsum; 1WOF; -.
DR   PDBsum; 1YSY; -.
DR   PDBsum; 1Z1I; -.
DR   PDBsum; 1Z1J; -.
DR   PDBsum; 2A5A; -.
DR   PDBsum; 2A5I; -.
DR   PDBsum; 2A5K; -.
DR   PDBsum; 2ACF; -.
DR   PDBsum; 2AHM; -.
DR   PDBsum; 2AJ5; -.
DR   PDBsum; 2ALV; -.
DR   PDBsum; 2AMD; -.
DR   PDBsum; 2AMQ; -.
DR   PDBsum; 2BX3; -.
DR   PDBsum; 2BX4; -.
DR   PDBsum; 2C3S; -.
DR   PDBsum; 2D2D; -.
DR   PDBsum; 2DUC; -.
DR   PDBsum; 2FAV; -.
DR   PDBsum; 2FE8; -.
DR   PDBsum; 2FYG; -.
DR   PDBsum; 2G9T; -.
DR   PDBsum; 2GA6; -.
DR   PDBsum; 2GDT; -.
DR   PDBsum; 2GRI; -.
DR   PDBsum; 2GT7; -.
DR   PDBsum; 2GT8; -.
DR   PDBsum; 2GTB; -.
DR   PDBsum; 2GX4; -.
DR   PDBsum; 2GZ7; -.
DR   PDBsum; 2GZ8; -.
DR   PDBsum; 2GZ9; -.
DR   PDBsum; 2H2Z; -.
DR   PDBsum; 2HOB; -.
DR   PDBsum; 2HSX; -.
DR   PDBsum; 2IDY; -.
DR   PDBsum; 2KAF; -.
DR   PDBsum; 2KQV; -.
DR   PDBsum; 2KQW; -.
DR   PDBsum; 2KYS; -.
DR   PDBsum; 2LIZ; -.
DR   PDBsum; 2OP9; -.
DR   PDBsum; 2PWX; -.
DR   PDBsum; 2W2G; -.
DR   PDBsum; 2WCT; -.
DR   PDBsum; 2Z3C; -.
DR   PDBsum; 2Z3D; -.
DR   PDBsum; 2Z3E; -.
DR   PDBsum; 2ZU4; -.
DR   PDBsum; 2ZU5; -.
DR   PDBsum; 3ATW; -.
DR   PDBsum; 3AVZ; -.
DR   PDBsum; 3AW0; -.
DR   PDBsum; 3AW1; -.
DR   PDBsum; 3E91; -.
DR   PDBsum; 3EA7; -.
DR   PDBsum; 3EA8; -.
DR   PDBsum; 3EA9; -.
DR   PDBsum; 3EAJ; -.
DR   PDBsum; 3EE7; -.
DR   PDBsum; 3F9E; -.
DR   PDBsum; 3F9F; -.
DR   PDBsum; 3F9G; -.
DR   PDBsum; 3F9H; -.
DR   PDBsum; 3FZD; -.
DR   PDBsum; 3IWM; -.
DR   PDBsum; 3M3S; -.
DR   PDBsum; 3M3T; -.
DR   PDBsum; 3M3V; -.
DR   PDBsum; 3MJ5; -.
DR   PDBsum; 3R24; -.
DR   PDBsum; 3SN8; -.
DR   PDBsum; 3SNA; -.
DR   PDBsum; 3SNB; -.
DR   PDBsum; 3SNC; -.
DR   PDBsum; 3SND; -.
DR   PDBsum; 3SNE; -.
DR   PDBsum; 3SZN; -.
DR   PDBsum; 3TIT; -.
DR   PDBsum; 3TIU; -.
DR   PDBsum; 3TNS; -.
DR   PDBsum; 3TNT; -.
DR   PDBsum; 3V3M; -.
DR   PDBsum; 3VB3; -.
DR   PDBsum; 3VB4; -.
DR   PDBsum; 3VB5; -.
DR   PDBsum; 3VB6; -.
DR   PDBsum; 3VB7; -.
DR   PDBsum; 4HI3; -.
DR   PDBsum; 4M0W; -.
DR   PDBsum; 4MDS; -.
DR   PDBsum; 4MM3; -.
DR   PDBsum; 4OVZ; -.
DR   PDBsum; 4OW0; -.
DR   PDBsum; 5F22; -.
DR   PDBsum; 5Y3E; -.
DR   PDBsum; 5Y3Q; -.
DR   PDBsum; 6NUR; -.
DR   PDBsum; 6NUS; -.
DR   PDBsum; 6Y7M; -.
DR   SMR; P0C6U8; -.
DR   BioGRID; 4383931; 1.
DR   BioGRID; 4383937; 2.
DR   DIP; DIP-48580N; -.
DR   IntAct; P0C6U8; 3.
DR   BindingDB; P0C6U8; -.
DR   ChEMBL; CHEMBL3927; -.
DR   DrugBank; DB07620; 2-[(2,4-DICHLORO-5-METHYLPHENYL)SULFONYL]-1,3-DINITRO-5-(TRIFLUOROMETHYL)BENZENE.
DR   DrugBank; DB08732; NALPHA-[(BENZYLOXY)CARBONYL]-N-[(1R)-4-HYDROXY-1-METHYL-2-OXOBUTYL]-L-PHENYLALANINAMIDE.
DR   DrugBank; DB07743; S-[5-(TRIFLUOROMETHYL)-4H-1,2,4-TRIAZOL-3-YL] 5-(PHENYLETHYNYL)FURAN-2-CARBOTHIOATE.
DR   MEROPS; C16.009; -.
DR   PRIDE; P0C6U8; -.
DR   BRENDA; 3.4.22.69; 7599.
DR   EvolutionaryTrace; P0C6U8; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000164441; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0039714; C:cytoplasmic viral factory; IDA:UniProtKB.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0008242; F:omega peptidase activity; IEA:InterPro.
DR   GO; GO:0003968; F:RNA-directed 5'-3' RNA polymerase activity; IEA:InterPro.
DR   GO; GO:0003727; F:single-stranded RNA binding; IEA:InterPro.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0039595; P:induction by virus of catabolism of host mRNA; IEA:UniProtKB-KW.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0039648; P:modulation by virus of host protein ubiquitination; IEA:UniProtKB-KW.
DR   GO; GO:0039548; P:suppression by virus of host IRF3 activity; IEA:UniProtKB-KW.
DR   GO; GO:0039579; P:suppression by virus of host ISG15 activity; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:suppression by virus of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   GO; GO:0019082; P:viral protein processing; IEA:InterPro.
DR   Gene3D; 1.10.150.420; -; 1.
DR   Gene3D; 1.10.1840.10; -; 1.
DR   Gene3D; 1.10.8.1190; -; 1.
DR   Gene3D; 1.10.8.370; -; 1.
DR   Gene3D; 2.30.30.590; -; 1.
DR   Gene3D; 2.40.10.10; -; 2.
DR   Gene3D; 2.40.10.250; -; 1.
DR   Gene3D; 2.40.10.290; -; 1.
DR   Gene3D; 3.10.20.350; -; 1.
DR   Gene3D; 3.10.20.540; -; 1.
DR   Gene3D; 3.40.220.10; -; 1.
DR   Gene3D; 3.40.220.20; -; 1.
DR   Gene3D; 3.40.220.30; -; 1.
DR   Gene3D; 3.40.50.11020; -; 1.
DR   Gene3D; 3.90.70.90; -; 1.
DR   InterPro; IPR022733; DPUP_SUD_C_bCoV.
DR   InterPro; IPR002589; Macro_dom.
DR   InterPro; IPR043472; Macro_dom-like.
DR   InterPro; IPR042570; NAR_sf.
DR   InterPro; IPR036333; NSP10_sf_CoV.
DR   InterPro; IPR021590; NSP1_bCoV.
DR   InterPro; IPR038030; NSP1_sf_bCoV.
DR   InterPro; IPR024375; NSP3_bCoV.
DR   InterPro; IPR024358; NSP3_N_bCoV.
DR   InterPro; IPR032592; NSP3_NAR_bCoV.
DR   InterPro; IPR038166; NSP3_PL2pro_sf_CoV.
DR   InterPro; IPR038400; NSP3_SUD-M_sf_bCoV.
DR   InterPro; IPR043478; NSP3_SUD-N_bCoV.
DR   InterPro; IPR038083; NSP3A-like.
DR   InterPro; IPR032505; NSP4_C_CoV.
DR   InterPro; IPR038123; NSP4_C_sf_CoV.
DR   InterPro; IPR014828; NSP7_CoV.
DR   InterPro; IPR037204; NSP7_sf_CoV.
DR   InterPro; IPR014829; NSP8_CoV-like.
DR   InterPro; IPR037230; NSP8_sf_CoV.
DR   InterPro; IPR014822; NSP9_CoV.
DR   InterPro; IPR036499; NSP9_sf_CoV.
DR   InterPro; IPR013016; Peptidase_C16_CoV.
DR   InterPro; IPR008740; Peptidase_C30_CoV.
DR   InterPro; IPR043477; Peptidase_C30_dom3_CoV.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR043177; PLpro_N_sf_CoV.
DR   InterPro; IPR043503; PLpro_palm_finger_dom_CoV.
DR   InterPro; IPR043178; PLpro_thumb_sf_CoV.
DR   InterPro; IPR018995; RNA_synth_NSP10_CoV.
DR   Pfam; PF16348; Corona_NSP4_C; 1.
DR   Pfam; PF12379; DUF3655; 1.
DR   Pfam; PF01661; Macro; 1.
DR   Pfam; PF16251; NAR; 1.
DR   Pfam; PF11501; Nsp1; 1.
DR   Pfam; PF09401; NSP10; 1.
DR   Pfam; PF12124; Nsp3_PL2pro; 1.
DR   Pfam; PF08716; nsp7; 1.
DR   Pfam; PF08717; nsp8; 1.
DR   Pfam; PF08710; nsp9; 1.
DR   Pfam; PF05409; Peptidase_C30; 1.
DR   Pfam; PF11633; SUD-M; 1.
DR   Pfam; PF08715; Viral_protease; 1.
DR   SMART; SM00506; A1pp; 1.
DR   SUPFAM; SSF101816; SSF101816; 1.
DR   SUPFAM; SSF140367; SSF140367; 1.
DR   SUPFAM; SSF143076; SSF143076; 1.
DR   SUPFAM; SSF144246; SSF144246; 1.
DR   SUPFAM; SSF159936; SSF159936; 1.
DR   SUPFAM; SSF160099; SSF160099; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF52949; SSF52949; 1.
DR   PROSITE; PS51442; M_PRO; 1.
DR   PROSITE; PS51154; MACRO; 1.
DR   PROSITE; PS51124; PEPTIDASE_C16; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host autophagy by virus;
KW   Decay of host mRNAs by virus; Endonuclease;
KW   Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Host cytoplasm;
KW   Host gene expression shutoff by virus; Host membrane;
KW   Host mRNA suppression by virus; Host-virus interaction; Hydrolase;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host IRF3 by virus; Inhibition of host ISG15 by virus;
KW   Inhibition of host RLR pathway by virus; Membrane; Metal-binding;
KW   Modulation of host ubiquitin pathway by viral deubiquitinase;
KW   Modulation of host ubiquitin pathway by virus; Nuclease; Protease;
KW   Reference proteome; Repeat; Ribosomal frameshifting; RNA-binding;
KW   Thiol protease; Transmembrane; Transmembrane helix;
KW   Ubl conjugation pathway; Viral immunoevasion; Zinc; Zinc-finger.
FT   CHAIN           1..4382
FT                   /note="Replicase polyprotein 1a"
FT                   /id="PRO_0000338254"
FT   CHAIN           1..180
FT                   /note="Non-structural protein 1"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000338255"
FT   CHAIN           181..818
FT                   /note="Non-structural protein 2"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000338256"
FT   CHAIN           819..2740
FT                   /note="Non-structural protein 3"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000338257"
FT   CHAIN           2741..3240
FT                   /note="Non-structural protein 4"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000338258"
FT   CHAIN           3241..3546
FT                   /note="3C-like proteinase"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000338259"
FT   CHAIN           3547..3836
FT                   /note="Non-structural protein 6"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000338260"
FT   CHAIN           3837..3919
FT                   /note="Non-structural protein 7"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000338261"
FT   CHAIN           3920..4117
FT                   /note="Non-structural protein 8"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000338262"
FT   CHAIN           4118..4230
FT                   /note="Non-structural protein 9"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000338263"
FT   CHAIN           4231..4369
FT                   /note="Non-structural protein 10"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000338264"
FT   CHAIN           4370..4382
FT                   /note="Non-structural protein 11"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000338265"
FT   TOPO_DOM        1..2202
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2203..2223
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2224..2303
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2304..2324
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2325..2350
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2351..2371
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2372..2754
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2755..2775
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2776..2991
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2992..3012
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3013..3021
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3022..3042
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3043..3053
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3054..3074
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3075..3076
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3077..3097
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3098..3104
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3105..3125
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3126..3141
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3142..3162
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3163..3563
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3564..3584
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3585
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3586..3606
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3607..3611
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3612..3632
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3633..3657
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3658..3678
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3679..3684
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3685..3704
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3705..3727
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3728..3748
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3749..3755
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3756..3776
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3777..4382
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          1003..1169
FT                   /note="Macro"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00490"
FT   DOMAIN          1611..1875
FT                   /note="Peptidase C16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   DOMAIN          3241..3546
FT                   /note="Peptidase C30"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772"
FT   ZN_FING         1729..1766
FT                   /note="C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ZN_FING         4304..4320
FT   ZN_FING         4347..4360
FT   REGION          2092..2371
FT                   /note="HD1"
FT   REGION          2755..3162
FT                   /note="HD2"
FT   REGION          3564..3776
FT                   /note="HD3"
FT   COMPBIAS        930..1001
FT                   /note="Glu-rich"
FT   COMPBIAS        2210..2213
FT                   /note="Poly-Leu"
FT   COMPBIAS        3766..3769
FT                   /note="Poly-Cys"
FT   ACT_SITE        1651
FT                   /note="For PL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ACT_SITE        1812
FT                   /note="For PL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ACT_SITE        3281
FT                   /note="For 3CL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772"
FT   ACT_SITE        3385
FT                   /note="For 3CL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772"
FT   METAL           4304
FT                   /note="Zinc"
FT   METAL           4307
FT                   /note="Zinc"
FT   METAL           4313
FT                   /note="Zinc"
FT   METAL           4320
FT                   /note="Zinc"
FT   METAL           4347
FT                   /note="Zinc"
FT   METAL           4350
FT                   /note="Zinc"
FT   METAL           4358
FT                   /note="Zinc"
FT   SITE            180..181
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000250"
FT   SITE            818..819
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            2740..2741
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            3240..3241
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            3546..3547
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            3836..3837
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            3919..3920
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            4117..4118
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            4230..4231
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            4369..4370
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   VARIANT         82
FT                   /note="G -> C (in strain: Isolate GD01)"
FT   VARIANT         130
FT                   /note="G -> R (in strain: Isolate GD01)"
FT   VARIANT         138
FT                   /note="I -> T (in strain: Isolate SZ16)"
FT   VARIANT         181
FT                   /note="A -> V (in strain: Isolate Shanghai LY)"
FT   VARIANT         225
FT                   /note="K -> Q (in strain: Isolate GD01)"
FT   VARIANT         249
FT                   /note="Y -> C (in strain: Isolate Shanghai LY)"
FT   VARIANT         306
FT                   /note="V -> F (in strain: Isolate BJ04)"
FT   VARIANT         549
FT                   /note="A -> S (in strain: Isolate SZ3)"
FT   VARIANT         765
FT                   /note="A -> T (in strain: Isolate FRA and Isolate
FT                   Frankfurt-1)"
FT   VARIANT         852
FT                   /note="K -> R (in strain: Isolate SZ16)"
FT   VARIANT         1004
FT                   /note="N -> H (in strain: Isolate BJ03)"
FT   VARIANT         1021
FT                   /note="V -> A (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         1023
FT                   /note="I -> T (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1121
FT                   /note="I -> T (in strain: Isolate GD01, Isolate SZ3 and
FT                   Isolate SZ16)"
FT   VARIANT         1136
FT                   /note="P -> L (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         1257
FT                   /note="K -> E (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1319
FT                   /note="K -> R (in strain: Isolate GD01)"
FT   VARIANT         1329
FT                   /note="F -> S (in strain: Isolate GD01)"
FT   VARIANT         1361
FT                   /note="T -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1385
FT                   /note="I -> V (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1538
FT                   /note="S -> T (in strain: Isolate GD01)"
FT   VARIANT         1563
FT                   /note="M -> K (in strain: Isolate BJ02)"
FT   VARIANT         1663
FT                   /note="L -> I (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         1762
FT                   /note="I -> L (in strain: Isolate BJ03)"
FT   VARIANT         1776..1777
FT                   /note="QQ -> PP (in strain: Isolate BJ03)"
FT   VARIANT         1790
FT                   /note="E -> G (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1806
FT                   /note="G -> V (in strain: Isolate BJ02)"
FT   VARIANT         1962
FT                   /note="L -> I (in strain: Isolate BJ04)"
FT   VARIANT         2116
FT                   /note="L -> F (in strain: Isolate GD01, Isolate SZ3 and
FT                   Isolate SZ16)"
FT   VARIANT         2222
FT                   /note="C -> Y (in strain: Isolate GD01, Isolate SZ3 and
FT                   Isolate SZ16)"
FT   VARIANT         2269
FT                   /note="L -> S (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         2326
FT                   /note="V -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         2392..2394
FT                   /note="RNR -> CNH (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         2480
FT                   /note="L -> P (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         2552
FT                   /note="A -> V (in strain: Isolate Urbani and Isolate Taiwan
FT                   TC2)"
FT   VARIANT         2556
FT                   /note="D -> N (in strain: Isolate HKU-39849)"
FT   VARIANT         2564
FT                   /note="S -> P (in strain: Isolate GD01)"
FT   VARIANT         2648
FT                   /note="N -> Y (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         2708
FT                   /note="S -> T (in strain: Isolate HKU-39849)"
FT   VARIANT         2718
FT                   /note="R -> T (in strain: Isolate HKU-39849)"
FT   VARIANT         2746
FT                   /note="C -> W (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         2770
FT                   /note="V -> L (in strain: Isolate BJ01 and Isolate BJ02)"
FT   VARIANT         2944
FT                   /note="T -> I (in strain: Isolate SIN2500, Isolate GD01 and
FT                   Isolate GZ50)"
FT   VARIANT         2971
FT                   /note="V -> A (in strain: Isolate GD01 and Isolate SZ16)"
FT   VARIANT         3020
FT                   /note="V -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         3047
FT                   /note="V -> A (in strain: Isolate CUHK-W1, Isolate GD01,
FT                   Isolate SZ3, Isolate SZ16, Isolate BJ01, Isolate BJ02,
FT                   Isolate BJ03 and Isolate Shanghai QXC1)"
FT   VARIANT         3072
FT                   /note="V -> A (in strain: Isolate CUHK-W1, Isolate SZ3,
FT                   Isolate SZ16 and Isolate GD01)"
FT   VARIANT         3197
FT                   /note="A -> V (in strain: Isolate BJ01, Isolate BJ02,
FT                   Isolate BJ03, Isolate BJ04 and Isolate Shanghai QXC1)"
FT   VARIANT         3429
FT                   /note="Q -> P (in strain: Isolate BJ02)"
FT   VARIANT         3488
FT                   /note="D -> E (in strain: Isolate BJ04)"
FT   VARIANT         3717
FT                   /note="V -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         3818
FT                   /note="N -> T (in strain: Isolate BJ04)"
FT   VARIANT         3903
FT                   /note="D -> N (in strain: Isolate BJ03)"
FT   VARIANT         3904
FT                   /note="I -> F (in strain: Isolate BJ02)"
FT   VARIANT         3911
FT                   /note="M -> V (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4001
FT                   /note="K -> Q (in strain: Isolate Shanghai LY)"
FT   VARIANT         4003
FT                   /note="T -> A (in strain: Isolate Shanghai LY)"
FT   VARIANT         4085
FT                   /note="I -> H (in strain: Isolate ZJ01)"
FT   VARIANT         4114
FT                   /note="V -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4202
FT                   /note="V -> M (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4240
FT                   /note="N -> H (in strain: Isolate ZJ01)"
FT   VARIANT         4296
FT                   /note="E -> G (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4377..4378
FT                   /note="LN -> FK (in strain: Isolate Shanghai QXC1)"
FT   STRAND          1208..1211
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1214..1216
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1219..1222
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   TURN            1223..1225
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1229..1233
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1241..1244
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1253..1255
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   TURN            1256..1258
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1266..1269
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1272..1276
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1280..1282
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1286..1293
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1298..1303
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1315..1324
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1325..1331
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1343..1345
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1351..1361
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1364..1368
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1372..1381
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   TURN            1382..1384
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1389..1401
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1403..1405
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1407..1417
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1421..1423
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   TURN            1429..1431
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1435..1442
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   STRAND          1449..1452
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1456..1467
FT                   /evidence="ECO:0000244|PDB:2W2G"
FT   HELIX           1473..1484
FT                   /evidence="ECO:0000244|PDB:2KAF"
FT   STRAND          1485..1487
FT                   /evidence="ECO:0000244|PDB:2KQW"
FT   STRAND          1500..1506
FT                   /evidence="ECO:0000244|PDB:2KAF"
FT   STRAND          1509..1513
FT                   /evidence="ECO:0000244|PDB:2KAF"
FT   STRAND          1515..1518
FT                   /evidence="ECO:0000244|PDB:2KAF"
FT   STRAND          1521..1523
FT                   /evidence="ECO:0000244|PDB:2KAF"
FT   STRAND          1526..1528
FT                   /evidence="ECO:0000244|PDB:2KQW"
FT   HELIX           1530..1537
FT                   /evidence="ECO:0000244|PDB:2KAF"
FT   STRAND          1544..1555
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1557..1562
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1563..1565
FT                   /evidence="ECO:0000244|PDB:4OVZ"
FT   HELIX           1567..1570
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1571..1576
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   HELIX           1581..1583
FT                   /evidence="ECO:0000244|PDB:4OW0"
FT   HELIX           1588..1590
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1594..1597
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   HELIX           1602..1612
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   HELIX           1619..1630
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   TURN            1648..1650
FT                   /evidence="ECO:0000244|PDB:4OW0"
FT   HELIX           1651..1660
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1667..1669
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   HELIX           1670..1680
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   HELIX           1685..1695
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   HELIX           1705..1713
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1722..1729
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   TURN            1730..1732
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1733..1740
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   HELIX           1741..1744
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1746..1749
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   HELIX           1753..1758
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1760..1763
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1767..1794
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1799..1806
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1811..1826
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1829..1846
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   STRAND          1848..1851
FT                   /evidence="ECO:0000244|PDB:4M0W"
FT   HELIX           3251..3254
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3257..3262
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3265..3272
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3275..3279
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   HELIX           3280..3283
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   HELIX           3288..3290
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   HELIX           3294..3299
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   HELIX           3303..3305
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3306..3310
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3313..3315
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3317..3323
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3326..3333
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3340..3343
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3351..3358
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3361..3369
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   TURN            3380..3383
FT                   /evidence="ECO:0000244|PDB:3F9F"
FT   STRAND          3388..3393
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3396..3406
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   TURN            3408..3410
FT                   /evidence="ECO:0000244|PDB:3F9E"
FT   STRAND          3412..3415
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3417..3419
FT                   /evidence="ECO:0000244|PDB:3F9G"
FT   STRAND          3421..3424
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3427..3430
FT                   /evidence="ECO:0000244|PDB:3VB5"
FT   HELIX           3441..3454
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   HELIX           3467..3476
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   HELIX           3484..3489
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   HELIX           3491..3497
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   HELIX           3501..3514
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3521..3523
FT                   /evidence="ECO:0000244|PDB:3F9E"
FT   STRAND          3524..3526
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   HELIX           3533..3540
FT                   /evidence="ECO:0000244|PDB:4MDS"
FT   STRAND          3541..3543
FT                   /evidence="ECO:0000244|PDB:2LIZ"
FT   HELIX           3838..3855
FT                   /evidence="ECO:0000244|PDB:5F22"
FT   HELIX           3858..3860
FT                   /evidence="ECO:0000244|PDB:5F22"
FT   HELIX           3862..3877
FT                   /evidence="ECO:0000244|PDB:5F22"
FT   HELIX           3881..3896
FT                   /evidence="ECO:0000244|PDB:5F22"
FT   HELIX           3904..3913
FT                   /evidence="ECO:0000244|PDB:5F22"
FT   HELIX           3997..4017
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4020..4027
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4029..4032
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4036..4038
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4040..4043
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4045..4053
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4054..4058
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4063..4068
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4071..4079
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4088..4090
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4096..4098
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4101..4109
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4127..4136
FT                   /evidence="ECO:0000244|PDB:3EE7"
FT   TURN            4137..4139
FT                   /evidence="ECO:0000244|PDB:3EE7"
FT   STRAND          4142..4150
FT                   /evidence="ECO:0000244|PDB:3EE7"
FT   STRAND          4157..4164
FT                   /evidence="ECO:0000244|PDB:3EE7"
FT   STRAND          4170..4173
FT                   /evidence="ECO:0000244|PDB:3EE7"
FT   STRAND          4180..4186
FT                   /evidence="ECO:0000244|PDB:3EE7"
FT   STRAND          4190..4194
FT                   /evidence="ECO:0000244|PDB:3EE7"
FT   STRAND          4201..4208
FT                   /evidence="ECO:0000244|PDB:3EE7"
FT   HELIX           4213..4224
FT                   /evidence="ECO:0000244|PDB:3EE7"
FT   HELIX           4240..4248
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   STRAND          4250..4252
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   HELIX           4253..4262
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   STRAND          4273..4275
FT                   /evidence="ECO:0000244|PDB:2G9T"
FT   STRAND          4284..4288
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   STRAND          4295..4299
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   HELIX           4301..4303
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   HELIX           4305..4309
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   STRAND          4314..4318
FT                   /evidence="ECO:0000244|PDB:3R24"
FT   TURN            4321..4324
FT                   /evidence="ECO:0000244|PDB:2GA6"
FT   STRAND          4325..4330
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   HELIX           4331..4333
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   HELIX           4337..4343
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   TURN            4348..4350
FT                   /evidence="ECO:0000244|PDB:2FYG"
FT   TURN            4354..4356
FT                   /evidence="ECO:0000244|PDB:2FYG"
SQ   SEQUENCE   4382 AA;  486373 MW;  E1F65D5FD5DFF828 CRC64;
     MESLVLGVNE KTHVQLSLPV LQVRDVLVRG FGDSVEEALS EAREHLKNGT CGLVELEKGV
     LPQLEQPYVF IKRSDALSTN HGHKVVELVA EMDGIQYGRS GITLGVLVPH VGETPIAYRN
     VLLRKNGNKG AGGHSYGIDL KSYDLGDELG TDPIEDYEQN WNTKHGSGAL RELTRELNGG
     AVTRYVDNNF CGPDGYPLDC IKDFLARAGK SMCTLSEQLD YIESKRGVYC CRDHEHEIAW
     FTERSDKSYE HQTPFEIKSA KKFDTFKGEC PKFVFPLNSK VKVIQPRVEK KKTEGFMGRI
     RSVYPVASPQ ECNNMHLSTL MKCNHCDEVS WQTCDFLKAT CEHCGTENLV IEGPTTCGYL
     PTNAVVKMPC PACQDPEIGP EHSVADYHNH SNIETRLRKG GRTRCFGGCV FAYVGCYNKR
     AYWVPRASAD IGSGHTGITG DNVETLNEDL LEILSRERVN INIVGDFHLN EEVAIILASF
     SASTSAFIDT IKSLDYKSFK TIVESCGNYK VTKGKPVKGA WNIGQQRSVL TPLCGFPSQA
     AGVIRSIFAR TLDAANHSIP DLQRAAVTIL DGISEQSLRL VDAMVYTSDL LTNSVIIMAY
     VTGGLVQQTS QWLSNLLGTT VEKLRPIFEW IEAKLSAGVE FLKDAWEILK FLITGVFDIV
     KGQIQVASDN IKDCVKCFID VVNKALEMCI DQVTIAGAKL RSLNLGEVFI AQSKGLYRQC
     IRGKEQLQLL MPLKAPKEVT FLEGDSHDTV LTSEEVVLKN GELEALETPV DSFTNGAIVG
     TPVCVNGLML LEIKDKEQYC ALSPGLLATN NVFRLKGGAP IKGVTFGEDT VWEVQGYKNV
     RITFELDERV DKVLNEKCSV YTVESGTEVT EFACVVAEAV VKTLQPVSDL LTNMGIDLDE
     WSVATFYLFD DAGEENFSSR MYCSFYPPDE EEEDDAECEE EEIDETCEHE YGTEDDYQGL
     PLEFGASAET VRVEEEEEED WLDDTTEQSE IEPEPEPTPE EPVNQFTGYL KLTDNVAIKC
     VDIVKEAQSA NPMVIVNAAN IHLKHGGGVA GALNKATNGA MQKESDDYIK LNGPLTVGGS
     CLLSGHNLAK KCLHVVGPNL NAGEDIQLLK AAYENFNSQD ILLAPLLSAG IFGAKPLQSL
     QVCVQTVRTQ VYIAVNDKAL YEQVVMDYLD NLKPRVEAPK QEEPPNTEDS KTEEKSVVQK
     PVDVKPKIKA CIDEVTTTLE ETKFLTNKLL LFADINGKLY HDSQNMLRGE DMSFLEKDAP
     YMVGDVITSG DITCVVIPSK KAGGTTEMLS RALKKVPVDE YITTYPGQGC AGYTLEEAKT
     ALKKCKSAFY VLPSEAPNAK EEILGTVSWN LREMLAHAEE TRKLMPICMD VRAIMATIQR
     KYKGIKIQEG IVDYGVRFFF YTSKEPVASI ITKLNSLNEP LVTMPIGYVT HGFNLEEAAR
     CMRSLKAPAV VSVSSPDAVT TYNGYLTSSS KTSEEHFVET VSLAGSYRDW SYSGQRTELG
     VEFLKRGDKI VYHTLESPVE FHLDGEVLSL DKLKSLLSLR EVKTIKVFTT VDNTNLHTQL
     VDMSMTYGQQ FGPTYLDGAD VTKIKPHVNH EGKTFFVLPS DDTLRSEAFE YYHTLDESFL
     GRYMSALNHT KKWKFPQVGG LTSIKWADNN CYLSSVLLAL QQLEVKFNAP ALQEAYYRAR
     AGDAANFCAL ILAYSNKTVG ELGDVRETMT HLLQHANLES AKRVLNVVCK HCGQKTTTLT
     GVEAVMYMGT LSYDNLKTGV SIPCVCGRDA TQYLVQQESS FVMMSAPPAE YKLQQGTFLC
     ANEYTGNYQC GHYTHITAKE TLYRIDGAHL TKMSEYKGPV TDVFYKETSY TTTIKPVSYK
     LDGVTYTEIE PKLDGYYKKD NAYYTEQPID LVPTQPLPNA SFDNFKLTCS NTKFADDLNQ
     MTGFTKPASR ELSVTFFPDL NGDVVAIDYR HYSASFKKGA KLLHKPIVWH INQATTKTTF
     KPNTWCLRCL WSTKPVDTSN SFEVLAVEDT QGMDNLACES QQPTSEEVVE NPTIQKEVIE
     CDVKTTEVVG NVILKPSDEG VKVTQELGHE DLMAAYVENT SITIKKPNEL SLALGLKTIA
     THGIAAINSV PWSKILAYVK PFLGQAAITT SNCAKRLAQR VFNNYMPYVF TLLFQLCTFT
     KSTNSRIRAS LPTTIAKNSV KSVAKLCLDA GINYVKSPKF SKLFTIAMWL LLLSICLGSL
     ICVTAAFGVL LSNFGAPSYC NGVRELYLNS SNVTTMDFCE GSFPCSICLS GLDSLDSYPA
     LETIQVTISS YKLDLTILGL AAEWVLAYML FTKFFYLLGL SAIMQVFFGY FASHFISNSW
     LMWFIISIVQ MAPVSAMVRM YIFFASFYYI WKSYVHIMDG CTSSTCMMCY KRNRATRVEC
     TTIVNGMKRS FYVYANGGRG FCKTHNWNCL NCDTFCTGST FISDEVARDL SLQFKRPINP
     TDQSSYIVDS VAVKNGALHL YFDKAGQKTY ERHPLSHFVN LDNLRANNTK GSLPINVIVF
     DGKSKCDESA SKSASVYYSQ LMCQPILLLD QALVSDVGDS TEVSVKMFDA YVDTFSATFS
     VPMEKLKALV ATAHSELAKG VALDGVLSTF VSAARQGVVD TDVDTKDVIE CLKLSHHSDL
     EVTGDSCNNF MLTYNKVENM TPRDLGACID CNARHINAQV AKSHNVSLIW NVKDYMSLSE
     QLRKQIRSAA KKNNIPFRLT CATTRQVVNV ITTKISLKGG KIVSTCFKLM LKATLLCVLA
     ALVCYIVMPV HTLSIHDGYT NEIIGYKAIQ DGVTRDIIST DDCFANKHAG FDAWFSQRGG
     SYKNDKSCPV VAAIITREIG FIVPGLPGTV LRAINGDFLH FLPRVFSAVG NICYTPSKLI
     EYSDFATSAC VLAAECTIFK DAMGKPVPYC YDTNLLEGSI SYSELRPDTR YVLMDGSIIQ
     FPNTYLEGSV RVVTTFDAEY CRHGTCERSE VGICLSTSGR WVLNNEHYRA LSGVFCGVDA
     MNLIANIFTP LVQPVGALDV SASVVAGGII AILVTCAAYY FMKFRRVFGE YNHVVAANAL
     LFLMSFTILC LVPAYSFLPG VYSVFYLYLT FYFTNDVSFL AHLQWFAMFS PIVPFWITAI
     YVFCISLKHC HWFFNNYLRK RVMFNGVTFS TFEEAALCTF LLNKEMYLKL RSETLLPLTQ
     YNRYLALYNK YKYFSGALDT TSYREAACCH LAKALNDFSN SGADVLYQPP QTSITSAVLQ
     SGFRKMAFPS GKVEGCMVQV TCGTTTLNGL WLDDTVYCPR HVICTAEDML NPNYEDLLIR
     KSNHSFLVQA GNVQLRVIGH SMQNCLLRLK VDTSNPKTPK YKFVRIQPGQ TFSVLACYNG
     SPSGVYQCAM RPNHTIKGSF LNGSCGSVGF NIDYDCVSFC YMHHMELPTG VHAGTDLEGK
     FYGPFVDRQT AQAAGTDTTI TLNVLAWLYA AVINGDRWFL NRFTTTLNDF NLVAMKYNYE
     PLTQDHVDIL GPLSAQTGIA VLDMCAALKE LLQNGMNGRT ILGSTILEDE FTPFDVVRQC
     SGVTFQGKFK KIVKGTHHWM LLTFLTSLLI LVQSTQWSLF FFVYENAFLP FTLGIMAIAA
     CAMLLVKHKH AFLCLFLLPS LATVAYFNMV YMPASWVMRI MTWLELADTS LSGYRLKDCV
     MYASALVLLI LMTARTVYDD AARRVWTLMN VITLVYKVYY GNALDQAISM WALVISVTSN
     YSGVVTTIMF LARAIVFVCV EYYPLLFITG NTLQCIMLVY CFLGYCCCCY FGLFCLLNRY
     FRLTLGVYDY LVSTQEFRYM NSQGLLPPKS SIDAFKLNIK LLGIGGKPCI KVATVQSKMS
     DVKCTSVVLL SVLQQLRVES SSKLWAQCVQ LHNDILLAKD TTEAFEKMVS LLSVLLSMQG
     AVDINRLCEE MLDNRATLQA IASEFSSLPS YAAYATAQEA YEQAVANGDS EVVLKKLKKS
     LNVAKSEFDR DAAMQRKLEK MADQAMTQMY KQARSEDKRA KVTSAMQTML FTMLRKLDND
     ALNNIINNAR DGCVPLNIIP LTTAAKLMVV VPDYGTYKNT CDGNTFTYAS ALWEIQQVVD
     ADSKIVQLSE INMDNSPNLA WPLIVTALRA NSAVKLQNNE LSPVALRQMS CAAGTTQTAC
     TDDNALAYYN NSKGGRFVLA LLSDHQDLKW ARFPKSDGTG TIYTELEPPC RFVTDTPKGP
     KVKYLYFIKG LNNLNRGMVL GSLAATVRLQ AGNATEVPAN STVLSFCAFA VDPAKAYKDY
     LASGGQPITN CVKMLCTHTG TGQAITVTPE ANMDQESFGG ASCCLYCRCH IDHPNPKGFC
     DLKGKYVQIP TTCANDPVGF TLRNTVCTVC GMWKGYGCSC DQLREPLMQS ADASTFLNGF
     AV
//
ID   R1AB_SARS               Reviewed;        7073 AA.
AC   P0C6X7; P59641; Q6WGN0; Q7T697; Q808C0; Q80BV7; Q80BV8; Q80E51;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   12-AUG-2020, entry version 112.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE              EC=3.4.19.12;
DE              EC=3.4.22.69;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.-;
DE     AltName: Full=Main protease;
DE              Short=Mpro;
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Proofreading exoribonuclease {ECO:0000303|PubMed:23966862, ECO:0000303|PubMed:29511076};
DE              Short=ExoN;
DE              EC=2.1.1.-;
DE              EC=3.1.13.-;
DE     AltName: Full=Guanine-N7 methyltransferase;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease;
DE              EC=3.1.-.-;
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase;
DE              EC=2.1.1.-;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, Isolate SZ16, and Isolate SZ3;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   "Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China.";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   "Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection.";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   "Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization.";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RX   PubMed=14645828; DOI=10.1126/science.302.5650.1504b;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.H.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "Phylogeny of the SARS coronavirus.";
RL   Science 302:1504-1505(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt-1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   "Genomic sequence of SARS isolate from the first fatal case in Taiwan.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   "Analysis of SARS coronavirus genome in Shanghai isolates.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RA   Wang Z., Cheng S., Zhang Y.;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-507; 1655-5170 AND 6903-7073.
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 4993-5127.
RC   STRAIN=Isolate Vietnam;
RA   Emery S., Erdman D.D., Peret T.C.T., Ksiazek T.G.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 4993-5136.
RC   STRAIN=Isolate Taiwan;
RA   Lin J.-H., Chiu S.-C., Yang J.-Y., Wang S.-F., Chen H.-Y.;
RT   "Detection of a novel human coronavirus in a severe acute respiratory
RT   syndrome patient in Taiwan.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [23]
RP   FUNCTION (HELICASE).
RX   PubMed=12917423; DOI=10.1074/jbc.c300328200;
RA   Tanner J.A., Watt R.M., Chai Y.-B., Lu L.-Y., Lin M.C., Peiris J.S.,
RA   Poon L.L.M., Kung H.-F., Huang J.-D.;
RT   "The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase
RT   belongs to a distinct class of 5' to 3' viral helicases.";
RL   J. Biol. Chem. 278:39578-39582(2003).
RN   [24]
RP   PROTEOLYTIC PROCESSING (REPLICASE POLYPROTEIN 1AB).
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   "Mechanisms and enzymes involved in SARS coronavirus genome expression.";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [25]
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE), SUBUNIT (3C-LIKE PROTEINASE), AND
RP   BIOPHYSICOCHEMICAL PROPERTIES (3C-LIKE PROTEINASE).
RX   PubMed=14561748; DOI=10.1074/jbc.m310875200;
RA   Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., Lai B., Pei J., Liu Y.,
RA   Chen J., Lai L.;
RT   "Biosynthesis, purification, and substrate specificity of severe acute
RT   respiratory syndrome coronavirus 3C-like proteinase.";
RL   J. Biol. Chem. 279:1637-1642(2004).
RN   [26]
RP   PROTEOLYTIC PROCESSING (REPLICASE POLYPROTEIN 1AB).
RX   PubMed=15331731; DOI=10.1128/jvi.78.18.9977-9986.2004;
RA   Prentice E., McAuliffe J., Lu X., Subbarao K., Denison M.R.;
RT   "Identification and characterization of severe acute respiratory syndrome
RT   coronavirus replicase proteins.";
RL   J. Virol. 78:9977-9986(2004).
RN   [27]
RP   PROTEOLYTIC PROCESSING (REPLICASE POLYPROTEIN 1AB).
RC   STRAIN=Isolate Urbani;
RX   PubMed=15564471; DOI=10.1128/jvi.78.24.13600-13612.2004;
RA   Harcourt B.H., Jukneliene D., Kanjanahaluethai A., Bechill J.,
RA   Severson K.M., Smith C.M., Rota P.A., Baker S.C.;
RT   "Identification of severe acute respiratory syndrome coronavirus replicase
RT   products and characterization of papain-like protease activity.";
RL   J. Virol. 78:13600-13612(2004).
RN   [28]
RP   FUNCTION (3C-LIKE PROTEINASE).
RX   PubMed=16226257; DOI=10.1016/j.febslet.2005.09.075;
RA   Lin C.W., Tsai F.J., Wan L., Lai C.C., Lin K.H., Hsieh T.H., Shiu S.Y.,
RA   Li J.Y.;
RT   "Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar-H+
RT   ATPase G1 subunit.";
RL   FEBS Lett. 579:6089-6094(2005).
RN   [29]
RP   HOMODIMERIZATION (3C-LIKE PROTEINASE).
RX   PubMed=15507456; DOI=10.1074/jbc.m408211200;
RA   Chen S., Chen L., Tan J., Chen J., Du L., Sun T., Shen J., Chen K.,
RA   Jiang H., Shen X.;
RT   "Severe acute respiratory syndrome coronavirus 3C-like proteinase N
RT   terminus is indispensable for proteolytic activity but not for enzyme
RT   dimerization. Biochemical and thermodynamic investigation in conjunction
RT   with molecular dynamics simulations.";
RL   J. Biol. Chem. 280:164-173(2005).
RN   [30]
RP   FUNCTION (GUANINE-N7 METHYLTRANSFERASE).
RC   STRAIN=Isolate Frankfurt-1;
RX   PubMed=16549795; DOI=10.1073/pnas.0508200103;
RA   Minskaia E., Hertzig T., Gorbalenya A.E., Campanacci V., Cambillau C.,
RA   Canard B., Ziebuhr J.;
RT   "Discovery of an RNA virus 3'->5' exoribonuclease that is critically
RT   involved in coronavirus RNA synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5108-5113(2006).
RN   [31]
RP   CHARACTERIZATION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE).
RX   PubMed=16882730; DOI=10.1073/pnas.0601708103;
RA   Ricagno S., Egloff M.-P., Ulferts R., Coutard B., Nurizzo D.,
RA   Campanacci V., Cambillau C., Ziebuhr J., Canard B.;
RT   "Crystal structure and mechanistic determinants of SARS coronavirus
RT   nonstructural protein 15 define an endoribonuclease family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:11892-11897(2006).
RN   [32]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17024178; DOI=10.1038/sj.emboj.7601368;
RA   Imbert I., Guillemot J.-C., Bourhis J.-M., Bussetta C., Coutard B.,
RA   Egloff M.-P., Ferron F., Gorbalenya A.E., Canard B.;
RT   "A second, non-canonical RNA-dependent RNA polymerase in SARS
RT   coronavirus.";
RL   EMBO J. 25:4933-4942(2006).
RN   [33]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=17692280; DOI=10.1016/j.abb.2007.07.006;
RA   Lindner H.A., Lytvyn V., Qi H., Lachance P., Ziomek E., Menard R.;
RT   "Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus
RT   papain-like protease.";
RL   Arch. Biochem. Biophys. 466:8-14(2007).
RN   [34]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=17855519; DOI=10.1128/jvi.01506-07;
RA   Oostra M., te Lintelo E.G., Deijs M., Verheije M.H., Rottier P.J.,
RA   de Haan C.A.;
RT   "Localization and membrane topology of coronavirus nonstructural protein 4:
RT   involvement of the early secretory pathway in replication.";
RL   J. Virol. 81:12323-12336(2007).
RN   [35]
RP   INTERACTION WITH ORF6 PROTEIN.
RX   PubMed=17532020; DOI=10.1016/j.virol.2007.04.029;
RA   Kumar P., Gunalan V., Liu B., Chow V.T., Druce J., Birch C., Catton M.,
RA   Fielding B.C., Tan Y.J., Lal S.K.;
RT   "The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with
RT   its ORF6 accessory protein.";
RL   Virology 366:293-303(2007).
RN   [36]
RP   FUNCTION (2'-O-METHYLTRANSFERASE).
RX   PubMed=18417574; DOI=10.1128/jvi.00407-08;
RA   Decroly E., Imbert I., Coutard B., Bouvet M., Selisko B., Alvarez K.,
RA   Gorbalenya A.E., Snijder E.J., Canard B.;
RT   "Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing
RT   (nucleoside-2'O)-methyltransferase activity.";
RL   J. Virol. 82:8071-8084(2008).
RN   [37]
RP   INTERACTION OF NSP10 WITH NSP14 AND NSP16.
RX   PubMed=18827877; DOI=10.1371/journal.pone.0003299;
RA   Pan J., Peng X., Gao Y., Li Z., Lu X., Chen Y., Ishaq M., Liu D.,
RA   Dediego M.L., Enjuanes L., Guo D.;
RT   "Genome-wide analysis of protein-protein interactions and involvement of
RT   viral proteins in SARS-CoV replication.";
RL   PLoS ONE 3:E3299-E3299(2008).
RN   [38]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=19369340; DOI=10.1128/jvi.02220-08;
RA   Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S.;
RT   "Severe acute respiratory syndrome coronavirus papain-like protease
RT   ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and
RT   NF-kappaB signaling.";
RL   J. Virol. 83:6689-6705(2009).
RN   [39]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), AND INTERACTION WITH HOST PHB AND
RP   PHB2.
RX   PubMed=19640993; DOI=10.1128/jvi.00842-09;
RA   Cornillez-Ty C.T., Liao L., Yates J.R., Kuhn P., Buchmeier M.J.;
RT   "Severe acute respiratory syndrome coronavirus nonstructural protein 2
RT   interacts with a host protein complex involved in mitochondrial biogenesis
RT   and intracellular signaling.";
RL   J. Virol. 83:10314-10318(2009).
RN   [40]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), AND MUTAGENESIS OF GLY-4217 AND
RP   GLY-4221.
RX   PubMed=19153232; DOI=10.1128/jvi.01505-08;
RA   Miknis Z.J., Donaldson E.F., Umland T.C., Rimmer R.A., Baric R.S.,
RA   Schultz L.W.;
RT   "Severe acute respiratory syndrome coronavirus nsp9 dimerization is
RT   essential for efficient viral growth.";
RL   J. Virol. 83:3007-3018(2009).
RN   [41]
RP   INTERACTION (PROOFREADING EXORIBONUCLEASE) WITH HOST DDX1.
RX   PubMed=20573827; DOI=10.1128/jvi.00392-10;
RA   Xu L., Khadijah S., Fang S., Wang L., Tay F.P., Liu D.X.;
RT   "The cellular RNA helicase DDX1 interacts with coronavirus nonstructural
RT   protein 14 and enhances viral replication.";
RL   J. Virol. 84:8571-8583(2010).
RN   [42]
RP   FUNCTION (GUANINE-N7 METHYLTRANSFERASE), AND FUNCTION
RP   (2'-O-METHYLTRANSFERASE).
RX   PubMed=20421945; DOI=10.1371/journal.ppat.1000863;
RA   Bouvet M., Debarnot C., Imbert I., Selisko B., Snijder E.J., Canard B.,
RA   Decroly E.;
RT   "In vitro reconstitution of SARS-coronavirus mRNA cap methylation.";
RL   PLoS Pathog. 6:E1000863-E1000863(2010).
RN   [43]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=22174690; DOI=10.1371/journal.ppat.1002433;
RA   Huang C., Lokugamage K.G., Rozovics J.M., Narayanan K., Semler B.L.,
RA   Makino S.;
RT   "SARS coronavirus nsp1 protein induces template-dependent endonucleolytic
RT   cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA
RT   cleavage.";
RL   PLoS Pathog. 7:E1002433-E1002433(2011).
RN   [44]
RP   INTERACTION OF NSP4 WITH PL-PRO AND NSP6, AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=21345958; DOI=10.1128/jvi.00042-11;
RA   Hagemeijer M.C., Ulasli M., Vonk A.M., Reggiori F., Rottier P.J.,
RA   de Haan C.A.;
RT   "Mobility and interactions of coronavirus nonstructural protein 4.";
RL   J. Virol. 85:4572-4577(2011).
RN   [45]
RP   FUNCTION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=21593585; DOI=10.4161/rna.8.2.15013;
RA   Denison M.R., Graham R.L., Donaldson E.F., Eckerle L.D., Baric R.S.;
RT   "Coronaviruses: an RNA proofreading machine regulates replication fidelity
RT   and diversity.";
RL   RNA Biol. 8:270-279(2011).
RN   [46]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN
RP   8).
RX   PubMed=22039154; DOI=10.1093/nar/gkr893;
RA   te Velthuis A.J., van den Worm S.H., Snijder E.J.;
RT   "The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA
RT   polymerase capable of both de novo initiation and primer extension.";
RL   Nucleic Acids Res. 40:1737-1747(2012).
RN   [47]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=23035226; DOI=10.1128/jvi.01958-12;
RA   Lokugamage K.G., Narayanan K., Huang C., Makino S.;
RT   "Severe acute respiratory syndrome coronavirus protein nsp1 is a novel
RT   eukaryotic translation inhibitor that represses multiple steps of
RT   translation initiation.";
RL   J. Virol. 86:13598-13608(2012).
RN   [48]
RP   FUNCTION (HELICASE).
RX   PubMed=22615777; DOI=10.1371/journal.pone.0036521;
RA   Adedeji A.O., Marchand B., Te Velthuis A.J., Snijder E.J., Weiss S.,
RA   Eoff R.L., Singh K., Sarafianos S.G.;
RT   "Mechanism of nucleic acid unwinding by SARS-CoV helicase.";
RL   PLoS ONE 7:E36521-E36521(2012).
RN   [49]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE).
RX   PubMed=22791111; DOI=10.1007/s00705-012-1404-x;
RA   Ahn D.G., Choi J.K., Taylor D.R., Oh J.W.;
RT   "Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-
RT   dependent RNA polymerase capable of copying viral RNA templates.";
RL   Arch. Virol. 157:2095-2104(2012).
RN   [50]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 10), FUNCTION (GUANINE-N7
RP   METHYLTRANSFERASE), AND INTERACTION OF NSP10 AND NSP14.
RX   PubMed=22635272; DOI=10.1073/pnas.1201130109;
RA   Bouvet M., Imbert I., Subissi L., Gluais L., Canard B., Decroly E.;
RT   "RNA 3'-end mismatch excision by the severe acute respiratory syndrome
RT   coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9372-9377(2012).
RN   [51]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=23943763; DOI=10.1128/mbio.00524-13;
RA   Angelini M.M., Akhlaghpour M., Neuman B.W., Buchmeier M.J.;
RT   "Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4,
RT   and 6 induce double-membrane vesicles.";
RL   MBio 4:0-0(2013).
RN   [52]
RP   FUNCTION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=23966862; DOI=10.1371/journal.ppat.1003565;
RA   Smith E.C., Blanc H., Surdel M.C., Vignuzzi M., Denison M.R.;
RT   "Coronaviruses lacking exoribonuclease activity are susceptible to lethal
RT   mutagenesis: evidence for proofreading and potential therapeutics.";
RL   PLoS Pathog. 9:e1003565-e1003565(2013).
RN   [53]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=24991833; DOI=10.4161/auto.29309;
RA   Cottam E.M., Whelband M.C., Wileman T.;
RT   "Coronavirus NSP6 restricts autophagosome expansion.";
RL   Autophagy 10:1426-1441(2014).
RN   [54]
RP   REVIEW.
RX   PubMed=24410069; DOI=10.1089/dna.2013.2304;
RA   Angelini M.M., Neuman B.W., Buchmeier M.J.;
RT   "Untangling membrane rearrangement in the nidovirales.";
RL   DNA Cell Biol. 33:122-127(2014).
RN   [55]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=24622840; DOI=10.1007/s13238-014-0026-3;
RA   Chen X., Yang X., Zheng Y., Yang Y., Xing Y., Chen Z.;
RT   "SARS coronavirus papain-like protease inhibits the type I interferon
RT   signaling pathway through interaction with the STING-TRAF3-TBK1 complex.";
RL   Protein Cell 5:369-381(2014).
RN   [56]
RP   FUNCTION (PROOFREADING EXORIBONUCLEASE), AND ACTIVITY REGULATION
RP   (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=29511076; DOI=10.1128/mbio.00221-18;
RA   Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X.,
RA   Smith E.C., Case J.B., Feng J.Y., Jordan R., Ray A.S., Cihlar T.,
RA   Siegel D., Mackman R.L., Clarke M.O., Baric R.S., Denison M.R.;
RT   "Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is
RT   Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.";
RL   MBio 9:0-0(2018).
RN   [57]
RP   INTERACTION WITH HOST NUP93 (HOST TRANSLATION INHIBITOR NSP1), AND FUNCTION
RP   (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=30943371; DOI=10.1139/bcb-2018-0394;
RA   Gomez G.N., Abrar F., Dodhia M.P., Gonzalez F.G., Nag A.;
RT   "SARS coronavirus protein nsp1 disrupts localization of Nup93 from the
RT   nuclear pore complex.";
RL   Biochem. Cell Biol. 97:758-766(2019).
RN   [58]
RP   PROTEOLYTIC CLEAVAGE (REPLICASE POLYPROTEIN 1AB), MASS SPECTROMETRY
RP   (NON-STRUCTURAL PROTEIN 8), MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 9),
RP   AND MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=32083638; DOI=10.1042/bcj20200029;
RA   Krichel B., Falke S., Hilgenfeld R., Redecke L., Uetrecht C.;
RT   "Processing of the SARS-CoV pp1a/ab nsp7-10 region.";
RL   Biochem. J. 477:1009-1019(2020).
RN   [59]
RP   3D-STRUCTURE MODELING OF 3241-3540, AND CHARACTERIZATION.
RX   PubMed=12746549; DOI=10.1126/science.1085658;
RA   Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R.;
RT   "Coronavirus main proteinase (3CLpro) structure: basis for design of anti-
RT   SARS drugs.";
RL   Science 300:1763-1767(2003).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4118-4230 (NSP9).
RC   STRAIN=Isolate Frankfurt-1;
RX   PubMed=12925794; DOI=10.1107/s0907444903016779;
RA   Campanacci V., Egloff M.-P., Longhi S., Ferron F., Rancurel C.,
RA   Salomoni A., Durousseau C., Tocque F., Bremond N., Dobbe J.C.,
RA   Snijder E.J., Canard B., Cambillau C.;
RT   "Structural genomics of the SARS coronavirus: cloning, expression,
RT   crystallization and preliminary crystallographic study of the Nsp9
RT   protein.";
RL   Acta Crystallogr. D 59:1628-1631(2003).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 4118-4230.
RX   PubMed=15007178; DOI=10.1073/pnas.0307877101;
RA   Egloff M.-P., Ferron F., Campanacci V., Longhi S., Rancurel C.,
RA   Dutartre H., Snijder E.J., Gorbalenya A.E., Cambillau C., Canard B.;
RT   "The severe acute respiratory syndrome-coronavirus replicative protein nsp9
RT   is a single-stranded RNA-binding subunit unique in the RNA virus world.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3792-3796(2004).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4107-4230, AND INTERACTION OF NSP8
RP   WITH NSP9.
RX   PubMed=14962394; DOI=10.1016/j.str.2004.01.016;
RA   Sutton G., Fry E., Carter L., Sainsbury S., Walter T., Nettleship J.,
RA   Berrow N., Owens R., Gilbert R., Davidson A., Siddell S., Poon L.L.M.,
RA   Diprose J., Alderton D., Walsh M., Grimes J.M., Stuart D.I.;
RT   "The nsp9 replicase protein of SARS-coronavirus, structure and functional
RT   insights.";
RL   Structure 12:341-353(2004).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 3837-4117 AND 3920-4117, AND
RP   INTERACTION OF NSP7 WITH NSP8.
RX   PubMed=16228002; DOI=10.1038/nsmb999;
RA   Zhai Y., Sun F., Li X., Pang H., Xu X., Bartlam M., Rao Z.;
RT   "Insights into SARS-CoV transcription and replication from the structure of
RT   the nsp7-nsp8 hexadecamer.";
RL   Nat. Struct. Mol. Biol. 12:980-986(2005).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1002-1176, AND FUNCTION (3C-LIKE
RP   PROTEINASE).
RX   PubMed=16271890; DOI=10.1016/j.str.2005.07.022;
RA   Saikatendu K.S., Joseph J.S., Subramanian V., Clayton T., Griffith M.,
RA   Moy K., Velasquez J., Neuman B.W., Buchmeier M.J., Stevens R.C., Kuhn P.;
RT   "Structural basis of severe acute respiratory syndrome coronavirus ADP-
RT   ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3.";
RL   Structure 13:1665-1675(2005).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1541-1854.
RX   PubMed=16581910; DOI=10.1073/pnas.0510851103;
RA   Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C.,
RA   Stevens R.C., Mesecar A.D.;
RT   "Severe acute respiratory syndrome coronavirus papain-like protease:
RT   structure of a viral deubiquitinating enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5717-5722(2006).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 4240-4362.
RC   STRAIN=Isolate Tor2;
RX   PubMed=16873246; DOI=10.1128/jvi.00467-06;
RA   Joseph J.S., Saikatendu K.S., Subramanian V., Neuman B.W., Brooun A.,
RA   Griffith M., Moy K., Yadav M.K., Velasquez J., Buchmeier M.J.,
RA   Stevens R.C., Kuhn P.;
RT   "Crystal structure of nonstructural protein 10 from the severe acute
RT   respiratory syndrome coronavirus reveals a novel fold with two zinc-binding
RT   motifs.";
RL   J. Virol. 80:7894-7901(2006).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 4231-4378, AND SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=16873247; DOI=10.1128/jvi.00483-06;
RA   Su D., Lou Z., Sun F., Zhai Y., Yang H., Zhang R., Joachimiak A.,
RA   Zhang X.C., Bartlam M., Rao Z.;
RT   "Dodecamer structure of severe acute respiratory syndrome coronavirus
RT   nonstructural protein nsp10.";
RL   J. Virol. 80:7902-7908(2006).
RN   [68]
RP   STRUCTURE BY NMR OF 13-127.
RX   PubMed=17202208; DOI=10.1128/jvi.01939-06;
RA   Almeida M.S., Johnson M.A., Herrmann T., Geralt M., Wuthrich K.;
RT   "Novel beta-barrel fold in the nuclear magnetic resonance structure of the
RT   replicase nonstructural protein 1 from the severe acute respiratory
RT   syndrome coronavirus.";
RL   J. Virol. 81:3151-3161(2007).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3241-3546.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of Sars coronavirus main proteinase(3CLPRO).";
RL   Submitted (JUL-2007) to the PDB data bank.
CC   -!- FUNCTION: [Isoform Replicase polyprotein 1ab]: Multifunctional protein
CC       involved in the transcription and replication of viral RNAs. Contains
CC       the proteinases responsible for the cleavages of the polyprotein.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response (PubMed:23035226). May disrupt nuclear pore function by
CC       binding and displacing host NUP93 (PubMed:30943371).
CC       {ECO:0000269|PubMed:23035226, ECO:0000269|PubMed:30943371}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2. Indeed, these two proteins play a role in maintaining the
CC       functional integrity of the mitochondria and protecting cells from
CC       various stresses. {ECO:0000269|PubMed:19640993}.
CC   -!- FUNCTION: [Non-structural protein 3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:17692280). Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication. Nsp3, nsp4 and nsp6
CC       together are sufficient to form DMV (PubMed:24410069). Antagonizes
CC       innate immune induction of type I interferon by blocking the
CC       phosphorylation, dimerization and subsequent nuclear translocation of
CC       host IRF3 (PubMed:19369340, PubMed:24622840). Prevents also host NF-
CC       kappa-B signaling. {ECO:0000269|PubMed:16271890,
CC       ECO:0000269|PubMed:17692280, ECO:0000269|PubMed:19369340,
CC       ECO:0000269|PubMed:24622840, ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication. Alone appears incapable
CC       to induce membrane curvature, but together with nsp3 is able to induce
CC       paired membranes. Nsp3, nsp4 and nsp6 together are sufficient to form
CC       DMV. {ECO:0000269|PubMed:23943763, ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [3C-like proteinase]: Cleaves the C-terminus of replicase
CC       polyprotein at 11 sites. Recognizes substrates containing the core
CC       sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). May cleave host ATP6V1G1 thereby modifying host
CC       vacuoles intracellular pH. {ECO:0000255|PROSITE-ProRule:PRU00772,
CC       ECO:0000269|PubMed:16226257}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication. Nsp3, nsp4 and nsp6
CC       together are sufficient to form DMV (PubMed:24410069). Plays a role in
CC       the initial induction of autophagosomes from host reticulum
CC       endoplasmic. Later, limits the expansion of these phagosomes that are
CC       no longer able to deliver viral components to lysosomes
CC       (PubMed:24991833). {ECO:0000269|PubMed:24991833,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [Non-structural protein 9]: May participate in viral
CC       replication by acting as a ssRNA-binding protein.
CC       {ECO:0000269|PubMed:19153232}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000269|PubMed:22635272}.
CC   -!- FUNCTION: [RNA-directed RNA polymerase]: Responsible for replication
CC       and transcription of the viral RNA genome.
CC       {ECO:0000269|PubMed:22791111}.
CC   -!- FUNCTION: [Helicase]: Multi-functional protein with a zinc-binding
CC       domain in N-terminus displaying RNA and DNA duplex-unwinding activities
CC       with 5' to 3' polarity. Activity of helicase is dependent on magnesium.
CC       {ECO:0000269|PubMed:12917423, ECO:0000269|PubMed:22615777}.
CC   -!- FUNCTION: [Proofreading exoribonuclease]: Enzyme possessing two
CC       different activities: an exoribonuclease activity acting on both ssRNA
CC       and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase
CC       activity (PubMed:16549795, PubMed:20421945, PubMed:22635272). Acts as a
CC       proofreading exoribonuclease for RNA replication, thereby lowering The
CC       sensitivity of the virus to RNA mutagens (PubMed:23966862,
CC       PubMed:29511076, PubMed:21593585). {ECO:0000269|PubMed:16549795,
CC       ECO:0000269|PubMed:20421945, ECO:0000269|PubMed:21593585,
CC       ECO:0000269|PubMed:22635272, ECO:0000269|PubMed:23966862,
CC       ECO:0000269|PubMed:29511076}.
CC   -!- FUNCTION: [Uridylate-specific endoribonuclease]: Mn(2+)-dependent,
CC       uridylate-specific enzyme, which leaves 2'-3'-cyclic phosphates 5' to
CC       the cleaved bond.
CC   -!- FUNCTION: [2'-O-methyltransferase]: Methyltransferase that mediates
CC       mRNA cap 2'-O-ribose methylation to the 5'-cap structure of viral
CC       mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16.
CC       Therefore plays an essential role in viral mRNAs cap methylation which
CC       is essential to evade immune system. {ECO:0000269|PubMed:18417574,
CC       ECO:0000269|PubMed:20421945, ECO:0000305}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a ribonucleoside 5'-triphosphate + RNA(n) = diphosphate +
CC         RNA(n+1); Xref=Rhea:RHEA:21248, Rhea:RHEA-COMP:11128, Rhea:RHEA-
CC         COMP:11129, ChEBI:CHEBI:33019, ChEBI:CHEBI:61557, ChEBI:CHEBI:83400;
CC         EC=2.7.7.48; Evidence={ECO:0000255|PROSITE-ProRule:PRU00539,
CC         ECO:0000269|PubMed:14561748};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.12;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=TSAVLQ-|-SGFRK-NH(2) and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:14561748};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:17692280};
CC   -!- ACTIVITY REGULATION: [Proofreading exoribonuclease]: Inhibited by
CC       Remdesivir (GS-5734). {ECO:0000269|PubMed:29511076}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.15 mM for peptide TSAVLQSGFRK-NH(2)
CC         {ECO:0000269|PubMed:14561748};
CC         KM=0.58 mM for peptide SGVTFQGKFKK {ECO:0000269|PubMed:14561748};
CC         KM=1.44 mM for peptide ATVRLQAGNAT {ECO:0000269|PubMed:14561748};
CC         Note=The kinetic parameters are studied for the 3C-like proteinase
CC         domain.;
CC       pH dependence:
CC         Optimum pH is 7.0 for 3C-like proteinase activity.
CC         {ECO:0000269|PubMed:14561748};
CC   -!- SUBUNIT: [Non-structural protein 2]: Interacts with host PHB and PHB2.
CC       {ECO:0000269|PubMed:19640993}.
CC   -!- SUBUNIT: [Non-structural protein 4]: Interacts with PL-PRO and nsp6.
CC       {ECO:0000269|PubMed:21345958}.
CC   -!- SUBUNIT: [3C-like proteinase]: Exists as monomer and homodimer. Only
CC       the homodimer shows catalytic activity. {ECO:0000269|PubMed:14561748,
CC       ECO:0000269|PubMed:15507456}.
CC   -!- SUBUNIT: [Non-structural protein 7]: Eight copies of nsp7 and eight
CC       copies of nsp8 assemble to form a heterohexadecamer dsRNA-encircling
CC       ring structure. {ECO:0000269|PubMed:16228002}.
CC   -!- SUBUNIT: [Non-structural protein 8]: Interacts with ORF6 protein.
CC       {ECO:0000269|PubMed:17532020}.
CC   -!- SUBUNIT: [Non-structural protein 9]: Homodimerizes.
CC       {ECO:0000269|PubMed:19153232}.
CC   -!- SUBUNIT: [Non-structural protein 10]: Forms a dodecamer and interacts
CC       with nsp14 and nsp16; these interactions enhance nsp14 and nsp16
CC       enzymatic activities. {ECO:0000269|PubMed:16873247,
CC       ECO:0000269|PubMed:18827877, ECO:0000269|PubMed:22635272}.
CC   -!- SUBUNIT: [Proofreading exoribonuclease]: Interacts (via N-terminus)
CC       with DDX1. {ECO:0000269|PubMed:20573827}.
CC   -!- INTERACTION:
CC       P0C6X7; P0C6X7: rep; NbExp=2; IntAct=EBI-7843867, EBI-7843867;
CC       PRO_0000037309; P59637: E; NbExp=2; IntAct=EBI-25475797, EBI-25487741;
CC       PRO_0000037309; Q9UQN3: CHMP2B; Xeno; NbExp=2; IntAct=EBI-25475797, EBI-718324;
CC       PRO_0000037309; P62942: FKBP1A; Xeno; NbExp=4; IntAct=EBI-25475797, EBI-1027571;
CC       PRO_0000037309; Q9Y4W2: LAS1L; Xeno; NbExp=2; IntAct=EBI-25475797, EBI-1051591;
CC       PRO_0000037309; P62937: PPIA; Xeno; NbExp=4; IntAct=EBI-25475797, EBI-437708;
CC       PRO_0000037309; Q13427: PPIG; Xeno; NbExp=4; IntAct=EBI-25475797, EBI-396072;
CC       PRO_0000037309; O43447: PPIH; Xeno; NbExp=4; IntAct=EBI-25475797, EBI-1055615;
CC       PRO_0000037309; Q9UKA8: RCAN3; Xeno; NbExp=2; IntAct=EBI-25475797, EBI-9091952;
CC       PRO_0000037310; PRO_0000338265 [P0C6U8]: 1a; NbExp=2; IntAct=EBI-25474098, EBI-25492625;
CC       PRO_0000037310; P59632: 3a; NbExp=2; IntAct=EBI-25474098, EBI-15595051;
CC       PRO_0000037310; PRO_0000037310 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25474098, EBI-25474098;
CC       PRO_0000037310; PRO_0000037311 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25474098, EBI-25474079;
CC       PRO_0000037310; PRO_0000037315 [P0C6X7]: rep; NbExp=4; IntAct=EBI-25474098, EBI-25487941;
CC       PRO_0000037310; P05155: SERPING1; Xeno; NbExp=2; IntAct=EBI-25474098, EBI-1223454;
CC       PRO_0000037311; PRO_0000037312 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25474079, EBI-25487250;
CC       PRO_0000037311; PRO_0000037315 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25474079, EBI-25487941;
CC       PRO_0000037311; PRO_0000037318 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25474079, EBI-25487684;
CC       PRO_0000037311; Q14653: IRF3; Xeno; NbExp=4; IntAct=EBI-25474079, EBI-2650369;
CC       PRO_0000037311; Q9H000: MKRN2; Xeno; NbExp=2; IntAct=EBI-25474079, EBI-2341005;
CC       PRO_0000037311; Q13064: MKRN3; Xeno; NbExp=2; IntAct=EBI-25474079, EBI-2340269;
CC       PRO_0000037312; PRO_0000037315 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25487250, EBI-25487941;
CC       PRO_0000037312; P62942: FKBP1A; Xeno; NbExp=2; IntAct=EBI-25487250, EBI-1027571;
CC       PRO_0000037313; PRO_0000037310 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25487192, EBI-25474098;
CC       PRO_0000037314; PRO_0000037315 [P0C6X7]: rep; NbExp=4; IntAct=EBI-25487672, EBI-25487941;
CC       PRO_0000037314; O95865: DDAH2; Xeno; NbExp=2; IntAct=EBI-25487672, EBI-749139;
CC       PRO_0000037314; A9UHW6: MIF4GD; Xeno; NbExp=2; IntAct=EBI-25487672, EBI-373498;
CC       PRO_0000037315; P59637: E; NbExp=2; IntAct=EBI-25487941, EBI-25487741;
CC       PRO_0000037315; PRO_0000037315 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25487941, EBI-25487941;
CC       PRO_0000037315; Q9P0M6: MACROH2A2; Xeno; NbExp=2; IntAct=EBI-25487941, EBI-3922608;
CC       PRO_0000037315; P69849: NOMO3; Xeno; NbExp=2; IntAct=EBI-25487941, EBI-947048;
CC       PRO_0000037315; P54274: TERF1; Xeno; NbExp=2; IntAct=EBI-25487941, EBI-710997;
CC       PRO_0000037316; PRO_0000037309 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25475825, EBI-25475797;
CC       PRO_0000037316; PRO_0000037314 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25475825, EBI-25487672;
CC       PRO_0000037316; PRO_0000037315 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25475825, EBI-25487941;
CC       PRO_0000037316; PRO_0000037320 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25475825, EBI-25487328;
CC       PRO_0000037316; Q9UQN3: CHMP2B; Xeno; NbExp=2; IntAct=EBI-25475825, EBI-718324;
CC       PRO_0000037316; Q5SQN1: SNAP47; Xeno; NbExp=2; IntAct=EBI-25475825, EBI-10244848;
CC       PRO_0000037318; PRO_0000037315 [P0C6X7]: rep; NbExp=5; IntAct=EBI-25487684, EBI-25487941;
CC       PRO_0000037319; PRO_0000037311 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25487926, EBI-25474079;
CC       PRO_0000037319; PRO_0000037315 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25487926, EBI-25487941;
CC       PRO_0000037319; PRO_0000037318 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25487926, EBI-25487684;
CC       PRO_0000037319; O96017: CHEK2; Xeno; NbExp=2; IntAct=EBI-25487926, EBI-1180783;
CC       PRO_0000037319; Q8N488: RYBP; Xeno; NbExp=2; IntAct=EBI-25487926, EBI-752324;
CC       PRO_0000037320; P59636: 9b; NbExp=3; IntAct=EBI-25487328, EBI-9021274;
CC       PRO_0000037320; PRO_0000037311 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25487328, EBI-25474079;
CC       PRO_0000037320; PRO_0000037315 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25487328, EBI-25487941;
CC       PRO_0000037320; PRO_0000037317 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25487328, EBI-25487277;
CC       PRO_0000037320; PRO_0000037318 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25487328, EBI-25487684;
CC       PRO_0000037320; P05155: SERPING1; Xeno; NbExp=2; IntAct=EBI-25487328, EBI-1223454;
CC       PRO_0000037321; PRO_0000037315 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25487301, EBI-25487941;
CC       PRO_0000037322; PRO_0000037310 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25487235, EBI-25474098;
CC       PRO_0000037322; PRO_0000037311 [P0C6X7]: rep; NbExp=3; IntAct=EBI-25487235, EBI-25474079;
CC       PRO_0000037322; P40337: VHL; Xeno; NbExp=7; IntAct=EBI-25487235, EBI-301246;
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 3]: Host membrane; Multi-
CC       pass membrane protein. Host cytoplasm {ECO:0000269|PubMed:23943763}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 4]: Host membrane; Multi-
CC       pass membrane protein. Host cytoplasm. Note=Localizes in virally-
CC       induced cytoplasmic double-membrane vesicles.
CC       {ECO:0000269|PubMed:17855519, ECO:0000269|PubMed:21345958,
CC       ECO:0000269|PubMed:23943763}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 6]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 7]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 8]: Host cytoplasm, host
CC       perinuclear region {ECO:0000269|PubMed:17532020}. Note=nsp7, nsp8, nsp9
CC       and nsp10 are localized in cytoplasmic foci, largely perinuclear. Late
CC       in infection, they merge into confluent complexes (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 9]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 10]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Helicase]: Host endoplasmic reticulum-Golgi
CC       intermediate compartment {ECO:0000305}. Note=The helicase interacts
CC       with the N protein in membranous complexes and colocalizes with sites
CC       of synthesis of new viral RNA. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Uridylate-specific endoribonuclease]: Host
CC       cytoplasm, host perinuclear region {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC       Name=Replicase polyprotein 1ab; Synonyms=pp1ab;
CC         IsoId=P0C6X7-1; Sequence=Displayed;
CC       Name=Replicase polyprotein 1a; Synonyms=pp1a, ORF1a polyprotein;
CC         IsoId=P0C6U8-1; Sequence=External;
CC   -!- DOMAIN: The hydrophobic domains (HD) could mediate the membrane
CC       association of the replication complex and thereby alter the
CC       architecture of the host cell membrane.
CC   -!- PTM: Specific enzymatic cleavages in vivo by its own proteases yield
CC       mature proteins (PubMed:32083638). 3CL-PRO and PL-PRO proteinases are
CC       autocatalytically processed (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:32083638}.
CC   -!- MASS SPECTROMETRY: [Non-structural protein 8]: Mass=21871;
CC       Method=Electrospray; Evidence={ECO:0000269|PubMed:32083638};
CC   -!- MASS SPECTROMETRY: [Non-structural protein 9]: Mass=12403;
CC       Method=Electrospray; Evidence={ECO:0000269|PubMed:32083638};
CC   -!- MASS SPECTROMETRY: [Non-structural protein 10]: Mass=14974;
CC       Method=Electrospray; Evidence={ECO:0000269|PubMed:32083638};
CC   -!- MISCELLANEOUS: [Isoform Replicase polyprotein 1ab]: Produced by -1
CC       ribosomal frameshifting at the 1a-1b genes boundary.
CC   -!- SIMILARITY: Belongs to the coronaviruses polyprotein 1ab family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Isolates SZ3 and SZ16 have been isolated from Paguma larvata
CC       and are described as SARS-like in literature. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP13440.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAP41036.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAP82975.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAP97881.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAQ01596.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAQ01608.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13442.1; -; Genomic_RNA.
DR   EMBL; AY278741; AAP13440.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; AY274119; AAP41036.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; AY278554; AAP13566.1; -; Genomic_RNA.
DR   EMBL; AY282752; AAP30711.1; -; Genomic_RNA.
DR   EMBL; AY304495; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY304486; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY304488; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283794; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283795; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283796; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283797; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283798; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY286320; AAP49011.4; -; Genomic_RNA.
DR   EMBL; AY278488; AAP30028.1; -; Genomic_RNA.
DR   EMBL; AY278489; AAP51225.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37015.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50483.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33696.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72973.2; -; Genomic_RNA.
DR   EMBL; AY321118; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY338174; AAQ01594.1; -; Genomic_RNA.
DR   EMBL; AY338174; AAQ01596.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; AY338175; AAQ01606.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01608.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; AY348314; AAP97879.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97881.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; AP006557; BAC81346.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81360.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81374.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81388.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81402.1; -; Genomic_RNA.
DR   EMBL; AY427439; AAQ94058.1; -; Genomic_RNA.
DR   EMBL; AY322205; AAP82966.1; -; Genomic_RNA.
DR   EMBL; AY322206; AAP82975.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; AY322207; AAP82967.1; -; Genomic_RNA.
DR   EMBL; AY463059; AAP82978.2; -; Genomic_RNA.
DR   EMBL; AY269391; AAP04003.1; -; Genomic_RNA.
DR   EMBL; AY268049; AAP04587.1; -; Genomic_RNA.
DR   PDB; 1O5S; Model; -; A=4745-5301.
DR   PDB; 1P76; Model; -; A=3241-3541, B=4225-4231.
DR   PDB; 1P9T; Model; -; A=3241-3544.
DR   PDB; 1PA5; Model; -; A=3241-3546.
DR   PDB; 1PUK; Model; -; A=3241-3550.
DR   PDB; 1Q1X; Model; -; A=3241-3542.
DR   PDB; 1Q2W; X-ray; 1.86 A; A/B=3241-3544.
DR   PDB; 1QZ8; X-ray; 2.70 A; A/B=4118-4230.
DR   PDB; 1SXF; Model; -; A=4765-5244.
DR   PDB; 1UJ1; X-ray; 1.90 A; A/B=3241-3546.
DR   PDB; 1UK2; X-ray; 2.20 A; A/B=3241-3546.
DR   PDB; 1UK3; X-ray; 2.40 A; A/B=3241-3546.
DR   PDB; 1UK4; X-ray; 2.50 A; A/B=3241-3546.
DR   PDB; 1UW7; X-ray; 2.80 A; A=4118-4230.
DR   PDB; 1WOF; X-ray; 2.00 A; A/B=3241-3546.
DR   PDB; 1YSY; NMR; -; A=3837-3919.
DR   PDB; 1Z1I; X-ray; 2.80 A; A=3241-3546.
DR   PDB; 1Z1J; X-ray; 2.80 A; A/B=3241-3546.
DR   PDB; 2A5A; X-ray; 2.08 A; A=3241-3546.
DR   PDB; 2A5I; X-ray; 1.88 A; A=3241-3546.
DR   PDB; 2A5K; X-ray; 2.30 A; A/B=3241-3546.
DR   PDB; 2ACF; X-ray; 1.40 A; A/B/C/D=1002-1176.
DR   PDB; 2AHM; X-ray; 2.40 A; A/B/C/D=3837-3919, E/F/G/H=3920-4117.
DR   PDB; 2AJ5; Model; -; A=3241-3546.
DR   PDB; 2ALV; X-ray; 1.90 A; A=3241-3543.
DR   PDB; 2AMD; X-ray; 1.85 A; A/B=3241-3546.
DR   PDB; 2AMQ; X-ray; 2.30 A; A/B=3241-3546.
DR   PDB; 2BX3; X-ray; 2.00 A; A=3241-3546.
DR   PDB; 2BX4; X-ray; 2.79 A; A=3241-3546.
DR   PDB; 2C3S; X-ray; 1.90 A; A=3241-3546.
DR   PDB; 2D2D; X-ray; 2.70 A; A/B=3241-3546.
DR   PDB; 2DUC; X-ray; 1.70 A; A/B=3241-3546.
DR   PDB; 2FAV; X-ray; 1.80 A; A/B/C=1000-1173.
DR   PDB; 2FE8; X-ray; 1.85 A; A/B/C=1541-1854.
DR   PDB; 2FYG; X-ray; 1.80 A; A=4240-4362.
DR   PDB; 2G1F; Model; -; A/B=5302-5877.
DR   PDB; 2G9T; X-ray; 2.10 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=4231-4378.
DR   PDB; 2GA6; X-ray; 2.70 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=4231-4378.
DR   PDB; 2GDT; NMR; -; A=13-127.
DR   PDB; 2GRI; NMR; -; A=819-930.
DR   PDB; 2GT7; X-ray; 1.82 A; A/B=3241-3546.
DR   PDB; 2GT8; X-ray; 2.00 A; A=3241-3546.
DR   PDB; 2GTB; X-ray; 2.00 A; A=3241-3546.
DR   PDB; 2GX4; X-ray; 1.93 A; A=3241-3546.
DR   PDB; 2GZ7; X-ray; 1.86 A; A=3241-3546.
DR   PDB; 2GZ8; X-ray; 1.97 A; A=3241-3546.
DR   PDB; 2GZ9; X-ray; 2.17 A; A=3241-3546.
DR   PDB; 2H2Z; X-ray; 1.60 A; A=3241-3546.
DR   PDB; 2H85; X-ray; 2.60 A; A=6429-6774.
DR   PDB; 2HOB; X-ray; 1.95 A; A=3241-3546.
DR   PDB; 2HSX; NMR; -; A=13-127.
DR   PDB; 2IDY; NMR; -; A=819-930.
DR   PDB; 2JZD; NMR; -; A=1345-1469.
DR   PDB; 2JZE; NMR; -; A=1345-1469.
DR   PDB; 2JZF; NMR; -; A=1331-1469.
DR   PDB; 2K87; NMR; -; A=1884-1998.
DR   PDB; 2OP9; X-ray; 1.80 A; A/B=3241-3541.
DR   PDB; 2OZK; X-ray; 2.90 A; A/B/C/D=6430-6775.
DR   PDB; 2PWX; X-ray; 2.50 A; A=3241-3546.
DR   PDB; 2Q6G; X-ray; 2.50 A; A/B=3241-3546.
DR   PDB; 2QC2; X-ray; 2.70 A; A/B=3241-3546.
DR   PDB; 2QCY; X-ray; 1.75 A; A=3241-3546.
DR   PDB; 2QIQ; X-ray; 1.90 A; A=3242-3541.
DR   PDB; 2RHB; X-ray; 2.80 A; A/B/C/D/E/F=6430-6775.
DR   PDB; 2RNK; NMR; -; A=1331-1469.
DR   PDB; 2V6N; X-ray; 1.98 A; A=3241-3546.
DR   PDB; 2VJ1; X-ray; 2.25 A; A/B=3242-3544.
DR   PDB; 2XYQ; X-ray; 2.00 A; A=6776-7065, B=4240-4361.
DR   PDB; 2XYR; X-ray; 2.50 A; A=6776-7067, B=4240-4361.
DR   PDB; 2XYV; X-ray; 2.06 A; A=6776-7067, B=4240-4361.
DR   PDB; 2Z3C; X-ray; 1.79 A; A=3241-3546.
DR   PDB; 2Z3D; X-ray; 2.10 A; A=3241-3546.
DR   PDB; 2Z3E; X-ray; 2.32 A; A=3241-3546.
DR   PDB; 2Z94; X-ray; 1.78 A; A=3241-3546.
DR   PDB; 2Z9G; X-ray; 1.86 A; A=3241-3546.
DR   PDB; 2Z9J; X-ray; 1.95 A; A/B=3241-3546.
DR   PDB; 2Z9K; X-ray; 1.85 A; A/B=3241-3546.
DR   PDB; 2Z9L; X-ray; 2.10 A; A/B=3241-3546.
DR   PDB; 3D62; X-ray; 2.70 A; A=3243-3541.
DR   PDB; 3E9S; X-ray; 2.50 A; A=1541-1855.
DR   PDB; 3EBN; X-ray; 2.40 A; A/B/C/D=3429-3546.
DR   PDB; 3R24; X-ray; 2.00 A; A=6776-7073, B=4240-4382.
DR   PDB; 4TWW; X-ray; 2.42 A; A/B=3241-3546.
DR   PDB; 4TWY; X-ray; 1.60 A; A=3241-3546.
DR   PDB; 4WY3; X-ray; 1.89 A; A=3241-3546.
DR   PDB; 4ZUH; X-ray; 2.39 A; C=3235-3245.
DR   PDB; 5B6O; X-ray; 2.20 A; A/B=3241-3556.
DR   PDB; 5C5N; X-ray; 1.69 A; A=3241-3546.
DR   PDB; 5C5O; X-ray; 1.50 A; A/B=3241-3546.
DR   PDB; 5C8S; X-ray; 3.33 A; A/C=4231-4369, B/D=5903-6429.
DR   PDB; 5C8T; X-ray; 3.20 A; A/C=4231-4369, B/D=5903-6429.
DR   PDB; 5C8U; X-ray; 3.40 A; A/C=4231-4369, B/D=5903-6429.
DR   PDB; 5E6J; X-ray; 2.85 A; A/D=1541-1856.
DR   PDB; 5F22; X-ray; 2.15 A; B=3989-4117.
DR   PDB; 5N19; X-ray; 1.62 A; A=3241-3546.
DR   PDB; 5N5O; X-ray; 2.00 A; A=3241-3546.
DR   PDB; 5NFY; X-ray; 3.38 A; M/N/O/P=4231-4361.
DR   PDB; 6JYT; X-ray; 2.80 A; A/B=5302-5902.
DR   PDB; 6NUR; EM; 3.10 A; A=4370-5300, C=3837-3919.
DR   PDB; 6NUS; EM; 3.50 A; A=4370-5300.
DR   PDBsum; 1O5S; -.
DR   PDBsum; 1P76; -.
DR   PDBsum; 1P9T; -.
DR   PDBsum; 1PA5; -.
DR   PDBsum; 1PUK; -.
DR   PDBsum; 1Q1X; -.
DR   PDBsum; 1Q2W; -.
DR   PDBsum; 1QZ8; -.
DR   PDBsum; 1SXF; -.
DR   PDBsum; 1UJ1; -.
DR   PDBsum; 1UK2; -.
DR   PDBsum; 1UK3; -.
DR   PDBsum; 1UK4; -.
DR   PDBsum; 1UW7; -.
DR   PDBsum; 1WOF; -.
DR   PDBsum; 1YSY; -.
DR   PDBsum; 1Z1I; -.
DR   PDBsum; 1Z1J; -.
DR   PDBsum; 2A5A; -.
DR   PDBsum; 2A5I; -.
DR   PDBsum; 2A5K; -.
DR   PDBsum; 2ACF; -.
DR   PDBsum; 2AHM; -.
DR   PDBsum; 2AJ5; -.
DR   PDBsum; 2ALV; -.
DR   PDBsum; 2AMD; -.
DR   PDBsum; 2AMQ; -.
DR   PDBsum; 2BX3; -.
DR   PDBsum; 2BX4; -.
DR   PDBsum; 2C3S; -.
DR   PDBsum; 2D2D; -.
DR   PDBsum; 2DUC; -.
DR   PDBsum; 2FAV; -.
DR   PDBsum; 2FE8; -.
DR   PDBsum; 2FYG; -.
DR   PDBsum; 2G1F; -.
DR   PDBsum; 2G9T; -.
DR   PDBsum; 2GA6; -.
DR   PDBsum; 2GDT; -.
DR   PDBsum; 2GRI; -.
DR   PDBsum; 2GT7; -.
DR   PDBsum; 2GT8; -.
DR   PDBsum; 2GTB; -.
DR   PDBsum; 2GX4; -.
DR   PDBsum; 2GZ7; -.
DR   PDBsum; 2GZ8; -.
DR   PDBsum; 2GZ9; -.
DR   PDBsum; 2H2Z; -.
DR   PDBsum; 2H85; -.
DR   PDBsum; 2HOB; -.
DR   PDBsum; 2HSX; -.
DR   PDBsum; 2IDY; -.
DR   PDBsum; 2JZD; -.
DR   PDBsum; 2JZE; -.
DR   PDBsum; 2JZF; -.
DR   PDBsum; 2K87; -.
DR   PDBsum; 2OP9; -.
DR   PDBsum; 2OZK; -.
DR   PDBsum; 2PWX; -.
DR   PDBsum; 2Q6G; -.
DR   PDBsum; 2QC2; -.
DR   PDBsum; 2QCY; -.
DR   PDBsum; 2QIQ; -.
DR   PDBsum; 2RHB; -.
DR   PDBsum; 2RNK; -.
DR   PDBsum; 2V6N; -.
DR   PDBsum; 2VJ1; -.
DR   PDBsum; 2XYQ; -.
DR   PDBsum; 2XYR; -.
DR   PDBsum; 2XYV; -.
DR   PDBsum; 2Z3C; -.
DR   PDBsum; 2Z3D; -.
DR   PDBsum; 2Z3E; -.
DR   PDBsum; 2Z94; -.
DR   PDBsum; 2Z9G; -.
DR   PDBsum; 2Z9J; -.
DR   PDBsum; 2Z9K; -.
DR   PDBsum; 2Z9L; -.
DR   PDBsum; 3D62; -.
DR   PDBsum; 3E9S; -.
DR   PDBsum; 3EBN; -.
DR   PDBsum; 3R24; -.
DR   PDBsum; 4TWW; -.
DR   PDBsum; 4TWY; -.
DR   PDBsum; 4WY3; -.
DR   PDBsum; 4ZUH; -.
DR   PDBsum; 5B6O; -.
DR   PDBsum; 5C5N; -.
DR   PDBsum; 5C5O; -.
DR   PDBsum; 5C8S; -.
DR   PDBsum; 5C8T; -.
DR   PDBsum; 5C8U; -.
DR   PDBsum; 5E6J; -.
DR   PDBsum; 5F22; -.
DR   PDBsum; 5N19; -.
DR   PDBsum; 5N5O; -.
DR   PDBsum; 5NFY; -.
DR   PDBsum; 6JYT; -.
DR   PDBsum; 6NUR; -.
DR   PDBsum; 6NUS; -.
DR   SMR; P0C6X7; -.
DR   BioGRID; 4383938; 1.
DR   BioGRID; 4383939; 9.
DR   BioGRID; 4383940; 14.
DR   BioGRID; 4383941; 17.
DR   BioGRID; 4383942; 4.
DR   BioGRID; 4383943; 16.
DR   BioGRID; 4383944; 4.
DR   BioGRID; 4383945; 17.
DR   BioGRID; 4383946; 23.
DR   BioGRID; 4383947; 12.
DR   BioGRID; 4383948; 5.
DR   BioGRID; 4383949; 18.
DR   BioGRID; 4383950; 14.
DR   BioGRID; 4383951; 7.
DR   BioGRID; 4383952; 5.
DR   BioGRID; 4383953; 4.
DR   ComplexPortal; CPX-5706; SARS-CoV main protease complex.
DR   ComplexPortal; CPX-5707; SARS-CoV 3'-5' exoribonuclease proof-reading complex.
DR   ComplexPortal; CPX-5709; SARS-CoV NSP10-NSP16 2'-O-methyltransferase complex.
DR   ComplexPortal; CPX-5710; SARS-CoV primase complex.
DR   ComplexPortal; CPX-5711; SARS-CoV NSP15 complex.
DR   ComplexPortal; CPX-5717; SARS-CoV polymerase complex.
DR   ComplexPortal; CPX-5719; SARS-CoV NSP9 complex.
DR   ComplexPortal; CPX-5721; SARS-CoV NSP3-NSP4-NSP6 complex.
DR   IntAct; P0C6X7; 98.
DR   MINT; P0C6X7; -.
DR   BindingDB; P0C6X7; -.
DR   ChEMBL; CHEMBL5118; -.
DR   DrugBank; DB07620; 2-[(2,4-DICHLORO-5-METHYLPHENYL)SULFONYL]-1,3-DINITRO-5-(TRIFLUOROMETHYL)BENZENE.
DR   DrugBank; DB08748; 4-(Dimethylamino)benzoic acid.
DR   DrugBank; DB08656; 5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide.
DR   DrugBank; DB07293; benzyl (2-oxopropyl)carbamate.
DR   DrugBank; DB08732; NALPHA-[(BENZYLOXY)CARBONYL]-N-[(1R)-4-HYDROXY-1-METHYL-2-OXOBUTYL]-L-PHENYLALANINAMIDE.
DR   DrugBank; DB14761; Remdesivir.
DR   DrugBank; DB07743; S-[5-(TRIFLUOROMETHYL)-4H-1,2,4-TRIAZOL-3-YL] 5-(PHENYLETHYNYL)FURAN-2-CARBOTHIOATE.
DR   DrugCentral; P0C6X7; -.
DR   PRIDE; P0C6X7; -.
DR   BRENDA; 2.7.7.48; 7599.
DR   BRENDA; 3.4.22.B14; 7599.
DR   BRENDA; 3.6.4.12; 7599.
DR   SABIO-RK; P0C6X7; -.
DR   EvolutionaryTrace; P0C6X7; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000164441; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0039714; C:cytoplasmic viral factory; IDA:UniProtKB.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0000175; F:3'-5'-exoribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0003678; F:DNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:UniProtKB.
DR   GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0004386; F:helicase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:1990380; F:Lys48-specific deubiquitinase activity; IDA:UniProtKB.
DR   GO; GO:0008168; F:methyltransferase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004482; F:mRNA (guanine-N7-)-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0004483; F:mRNA (nucleoside-2'-O-)-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0008242; F:omega peptidase activity; IEA:InterPro.
DR   GO; GO:0003724; F:RNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003968; F:RNA-directed 5'-3' RNA polymerase activity; IDA:UniProtKB.
DR   GO; GO:0003727; F:single-stranded RNA binding; IDA:UniProtKB.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006370; P:7-methylguanosine mRNA capping; IDA:UniProtKB.
DR   GO; GO:0039595; P:induction by virus of catabolism of host mRNA; IEA:UniProtKB-KW.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0032259; P:methylation; IEA:UniProtKB-KW.
DR   GO; GO:0039519; P:modulation by virus of host autophagy; IDA:UniProtKB.
DR   GO; GO:0039648; P:modulation by virus of host protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0080009; P:mRNA methylation; IDA:UniProtKB.
DR   GO; GO:2000158; P:positive regulation of ubiquitin-specific protease activity; IDA:UniProtKB.
DR   GO; GO:0039690; P:positive stranded viral RNA replication; IDA:UniProtKB.
DR   GO; GO:0090503; P:RNA phosphodiester bond hydrolysis, exonucleolytic; IDA:UniProtKB.
DR   GO; GO:0039548; P:suppression by virus of host IRF3 activity; IDA:UniProtKB.
DR   GO; GO:0039579; P:suppression by virus of host ISG15 activity; IDA:UniProtKB.
DR   GO; GO:0039644; P:suppression by virus of host NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0039604; P:suppression by virus of host translation; IDA:UniProtKB.
DR   GO; GO:0039502; P:suppression by virus of host type I interferon-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:InterPro.
DR   GO; GO:0001172; P:transcription, RNA-templated; IDA:UniProtKB.
DR   GO; GO:0019082; P:viral protein processing; IEA:InterPro.
DR   GO; GO:0039694; P:viral RNA genome replication; IEA:InterPro.
DR   GO; GO:0019083; P:viral transcription; IMP:CACAO.
DR   CDD; cd18808; SF1_C_Upf1; 1.
DR   Gene3D; 1.10.150.420; -; 1.
DR   Gene3D; 1.10.1840.10; -; 1.
DR   Gene3D; 1.10.8.1190; -; 1.
DR   Gene3D; 1.10.8.370; -; 1.
DR   Gene3D; 2.20.25.360; -; 1.
DR   Gene3D; 2.30.30.590; -; 1.
DR   Gene3D; 2.40.10.10; -; 2.
DR   Gene3D; 2.40.10.250; -; 1.
DR   Gene3D; 2.40.10.290; -; 1.
DR   Gene3D; 3.10.20.350; -; 1.
DR   Gene3D; 3.10.20.540; -; 1.
DR   Gene3D; 3.40.220.10; -; 1.
DR   Gene3D; 3.40.220.20; -; 1.
DR   Gene3D; 3.40.220.30; -; 1.
DR   Gene3D; 3.40.50.11020; -; 1.
DR   Gene3D; 3.40.50.11580; -; 1.
DR   Gene3D; 3.90.70.90; -; 1.
DR   InterPro; IPR027351; (+)RNA_virus_helicase_core_dom.
DR   InterPro; IPR027352; CV_ZBD.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR041679; DNA2/NAM7-like_AAA.
DR   InterPro; IPR022733; DPUP_SUD_C_bCoV.
DR   InterPro; IPR037227; EndoU-like.
DR   InterPro; IPR002589; Macro_dom.
DR   InterPro; IPR043472; Macro_dom-like.
DR   InterPro; IPR042570; NAR_sf.
DR   InterPro; IPR036333; NSP10_sf_CoV.
DR   InterPro; IPR009466; NSP11_CoV.
DR   InterPro; IPR043174; NSP15_middle_sf.
DR   InterPro; IPR042515; NSP15_N_CoV.
DR   InterPro; IPR009461; NSP16_CoV-like.
DR   InterPro; IPR021590; NSP1_bCoV.
DR   InterPro; IPR038030; NSP1_sf_bCoV.
DR   InterPro; IPR024375; NSP3_bCoV.
DR   InterPro; IPR024358; NSP3_N_bCoV.
DR   InterPro; IPR032592; NSP3_NAR_bCoV.
DR   InterPro; IPR038166; NSP3_PL2pro_sf_CoV.
DR   InterPro; IPR038400; NSP3_SUD-M_sf_bCoV.
DR   InterPro; IPR043478; NSP3_SUD-N_bCoV.
DR   InterPro; IPR038083; NSP3A-like.
DR   InterPro; IPR032505; NSP4_C_CoV.
DR   InterPro; IPR038123; NSP4_C_sf_CoV.
DR   InterPro; IPR014828; NSP7_CoV.
DR   InterPro; IPR037204; NSP7_sf_CoV.
DR   InterPro; IPR014829; NSP8_CoV-like.
DR   InterPro; IPR037230; NSP8_sf_CoV.
DR   InterPro; IPR014822; NSP9_CoV.
DR   InterPro; IPR036499; NSP9_sf_CoV.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR013016; Peptidase_C16_CoV.
DR   InterPro; IPR008740; Peptidase_C30_CoV.
DR   InterPro; IPR043477; Peptidase_C30_dom3_CoV.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR043177; PLpro_N_sf_CoV.
DR   InterPro; IPR043503; PLpro_palm_finger_dom_CoV.
DR   InterPro; IPR043178; PLpro_thumb_sf_CoV.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR009469; RNA_pol_N_coronovir.
DR   InterPro; IPR018995; RNA_synth_NSP10_CoV.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   Pfam; PF16348; Corona_NSP4_C; 1.
DR   Pfam; PF06478; Corona_RPol_N; 1.
DR   Pfam; PF12379; DUF3655; 1.
DR   Pfam; PF01661; Macro; 1.
DR   Pfam; PF16251; NAR; 1.
DR   Pfam; PF11501; Nsp1; 1.
DR   Pfam; PF09401; NSP10; 1.
DR   Pfam; PF06471; NSP11; 1.
DR   Pfam; PF06460; NSP16; 1.
DR   Pfam; PF12124; Nsp3_PL2pro; 1.
DR   Pfam; PF08716; nsp7; 1.
DR   Pfam; PF08717; nsp8; 1.
DR   Pfam; PF08710; nsp9; 1.
DR   Pfam; PF05409; Peptidase_C30; 1.
DR   Pfam; PF11633; SUD-M; 1.
DR   Pfam; PF08715; Viral_protease; 1.
DR   SMART; SM00506; A1pp; 1.
DR   SUPFAM; SSF101816; SSF101816; 1.
DR   SUPFAM; SSF140367; SSF140367; 1.
DR   SUPFAM; SSF142877; SSF142877; 1.
DR   SUPFAM; SSF143076; SSF143076; 1.
DR   SUPFAM; SSF144246; SSF144246; 1.
DR   SUPFAM; SSF159936; SSF159936; 1.
DR   SUPFAM; SSF160099; SSF160099; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF52949; SSF52949; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   SUPFAM; SSF56672; SSF56672; 1.
DR   PROSITE; PS51653; CV_ZBD; 1.
DR   PROSITE; PS51442; M_PRO; 1.
DR   PROSITE; PS51154; MACRO; 1.
DR   PROSITE; PS51124; PEPTIDASE_C16; 1.
DR   PROSITE; PS51657; PSRV_HELICASE; 1.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host autophagy by virus; ATP-binding;
KW   Decay of host mRNAs by virus; Endonuclease;
KW   Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Exonuclease; Helicase;
KW   Host cytoplasm; Host gene expression shutoff by virus; Host membrane;
KW   Host mRNA suppression by virus; Host-virus interaction; Hydrolase;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host ISG15 by virus; Inhibition of host NF-kappa-B by virus;
KW   Membrane; Metal-binding; Methyltransferase;
KW   Modulation of host ubiquitin pathway by viral deubiquitinase;
KW   Modulation of host ubiquitin pathway by virus; Nuclease;
KW   Nucleotide-binding; Nucleotidyltransferase; Protease; Reference proteome;
KW   Repeat; Ribosomal frameshifting; RNA-binding; RNA-directed RNA polymerase;
KW   Thiol protease; Transferase; Transmembrane; Transmembrane helix;
KW   Ubl conjugation pathway; Viral immunoevasion; Viral RNA replication; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..180
FT                   /note="Host translation inhibitor nsp1"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037309"
FT   CHAIN           181..818
FT                   /note="Non-structural protein 2"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037310"
FT   CHAIN           819..2740
FT                   /note="Non-structural protein 3"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037311"
FT   CHAIN           2741..3240
FT                   /note="Non-structural protein 4"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000283841"
FT   CHAIN           3241..3546
FT                   /note="3C-like proteinase"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037312"
FT   CHAIN           3547..3836
FT                   /note="Non-structural protein 6"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037313"
FT   CHAIN           3837..3919
FT                   /note="Non-structural protein 7"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037314"
FT   CHAIN           3920..4117
FT                   /note="Non-structural protein 8"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037315"
FT   CHAIN           4118..4230
FT                   /note="Non-structural protein 9"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037316"
FT   CHAIN           4231..4369
FT                   /note="Non-structural protein 10"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037317"
FT   CHAIN           4370..5301
FT                   /note="RNA-directed RNA polymerase"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037318"
FT   CHAIN           5302..5902
FT                   /note="Helicase"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037319"
FT   CHAIN           5903..6429
FT                   /note="Proofreading exoribonuclease"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037320"
FT   CHAIN           6430..6775
FT                   /note="Uridylate-specific endoribonuclease"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037321"
FT   CHAIN           6776..7073
FT                   /note="2'-O-methyltransferase"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000037322"
FT   TOPO_DOM        1..2202
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2203..2223
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2224..2303
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2304..2324
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2325..2350
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2351..2371
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2372..2754
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2755..2775
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2776..2991
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2992..3012
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3013..3021
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3022..3042
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3043..3053
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3054..3074
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3075..3076
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3077..3097
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3098..3104
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3105..3125
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3126..3141
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3142..3162
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3163..3563
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3564..3584
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3585
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3586..3606
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3607..3611
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3612..3632
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3633..3657
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3658..3678
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3679..3684
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3685..3704
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3705..3727
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3728..3748
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3749..3755
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3756..3776
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3777..7073
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          1003..1169
FT                   /note="Macro"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00490"
FT   DOMAIN          1611..1875
FT                   /note="Peptidase C16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   DOMAIN          3241..3546
FT                   /note="Peptidase C30"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772"
FT   DOMAIN          4981..5143
FT                   /note="RdRp catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00539"
FT   DOMAIN          5302..5385
FT                   /note="CV ZBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   DOMAIN          5558..5739
FT                   /note="(+)RNA virus helicase ATP-binding"
FT   DOMAIN          5740..5909
FT                   /note="(+)RNA virus helicase C-terminal"
FT   ZN_FING         1729..1766
FT                   /note="C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ZN_FING         4304..4320
FT   ZN_FING         4347..4360
FT   NP_BIND         5583..5590
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   REGION          2092..2371
FT                   /note="HD1"
FT   REGION          2755..3162
FT                   /note="HD2"
FT   REGION          3564..3776
FT                   /note="HD3"
FT   COMPBIAS        930..1001
FT                   /note="Glu-rich"
FT   COMPBIAS        2210..2213
FT                   /note="Poly-Leu"
FT   COMPBIAS        3766..3769
FT                   /note="Poly-Cys"
FT   ACT_SITE        1651
FT                   /note="For PL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ACT_SITE        1812
FT                   /note="For PL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ACT_SITE        3281
FT                   /note="For 3CL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772"
FT   ACT_SITE        3385
FT                   /note="For 3CL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772"
FT   METAL           4304
FT                   /note="Zinc"
FT   METAL           4307
FT                   /note="Zinc"
FT   METAL           4313
FT                   /note="Zinc"
FT   METAL           4320
FT                   /note="Zinc"
FT   METAL           4347
FT                   /note="Zinc"
FT   METAL           4350
FT                   /note="Zinc"
FT   METAL           4358
FT                   /note="Zinc"
FT   METAL           5306
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5309
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5317
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5320
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5327
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5330
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5334
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5340
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5351
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5356
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5373
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5376
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   SITE            180..181
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000250"
FT   SITE            818..819
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            2740..2741
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            3240..3241
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            3546..3547
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            3836..3837
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000269|PubMed:32083638"
FT   SITE            3919..3920
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000269|PubMed:32083638"
FT   SITE            4117..4118
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000269|PubMed:32083638"
FT   SITE            4230..4231
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000269|PubMed:32083638"
FT   SITE            4369..4370
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            5301..5302
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            5902..5903
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            6429..6430
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   SITE            6775..6776
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250"
FT   VARIANT         82
FT                   /note="G -> C (in strain: Isolate GD01)"
FT   VARIANT         130
FT                   /note="G -> R (in strain: Isolate GD01)"
FT   VARIANT         138
FT                   /note="I -> T (in strain: Isolate SZ16)"
FT   VARIANT         181
FT                   /note="A -> V (in strain: Isolate Shanghai LY)"
FT   VARIANT         225
FT                   /note="K -> Q (in strain: Isolate GD01)"
FT   VARIANT         249
FT                   /note="Y -> C (in strain: Isolate Shanghai LY)"
FT   VARIANT         306
FT                   /note="V -> F (in strain: Isolate BJ04)"
FT   VARIANT         549
FT                   /note="A -> S (in strain: Isolate SZ3)"
FT   VARIANT         765
FT                   /note="A -> T (in strain: Isolate FRA and Isolate
FT                   Frankfurt-1)"
FT   VARIANT         852
FT                   /note="K -> R (in strain: Isolate SZ16)"
FT   VARIANT         1004
FT                   /note="N -> H (in strain: Isolate BJ03)"
FT   VARIANT         1021
FT                   /note="V -> A (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         1023
FT                   /note="I -> T (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1121
FT                   /note="I -> T (in strain: Isolate GD01, Isolate SZ3 and
FT                   Isolate SZ16)"
FT   VARIANT         1136
FT                   /note="P -> L (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         1257
FT                   /note="K -> E (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1319
FT                   /note="K -> R (in strain: Isolate GD01)"
FT   VARIANT         1329
FT                   /note="F -> S (in strain: Isolate GD01)"
FT   VARIANT         1361
FT                   /note="T -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1385
FT                   /note="I -> V (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1538
FT                   /note="S -> T (in strain: Isolate GD01)"
FT   VARIANT         1563
FT                   /note="M -> K (in strain: Isolate BJ02)"
FT   VARIANT         1663
FT                   /note="L -> I (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         1762
FT                   /note="I -> L (in strain: Isolate BJ03)"
FT   VARIANT         1776..1777
FT                   /note="QQ -> PP (in strain: Isolate BJ03)"
FT   VARIANT         1790
FT                   /note="E -> G (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1806
FT                   /note="G -> V (in strain: Isolate BJ02)"
FT   VARIANT         1962
FT                   /note="L -> I (in strain: Isolate BJ04)"
FT   VARIANT         2116
FT                   /note="L -> F (in strain: Isolate GD01, Isolate SZ3 and
FT                   Isolate SZ16)"
FT   VARIANT         2222
FT                   /note="C -> Y (in strain: Isolate GD01, Isolate SZ3 and
FT                   Isolate SZ16)"
FT   VARIANT         2269
FT                   /note="L -> S (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         2326
FT                   /note="V -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         2392..2394
FT                   /note="RNR -> CNH (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         2480
FT                   /note="L -> P (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         2552
FT                   /note="A -> V (in strain: Isolate Urbani and Isolate Taiwan
FT                   TC2)"
FT   VARIANT         2556
FT                   /note="D -> N (in strain: Isolate HKU-39849)"
FT   VARIANT         2564
FT                   /note="S -> P (in strain: Isolate GD01)"
FT   VARIANT         2648
FT                   /note="N -> Y (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         2708
FT                   /note="S -> T (in strain: Isolate HKU-39849)"
FT   VARIANT         2718
FT                   /note="R -> T (in strain: Isolate HKU-39849)"
FT   VARIANT         2746
FT                   /note="C -> W (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         2770
FT                   /note="V -> L (in strain: Isolate BJ01 and Isolate BJ02)"
FT   VARIANT         2944
FT                   /note="T -> I (in strain: Isolate SIN2500, Isolate GD01 and
FT                   Isolate GZ50)"
FT   VARIANT         2971
FT                   /note="V -> A (in strain: Isolate GD01 and Isolate SZ16)"
FT   VARIANT         3020
FT                   /note="V -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         3047
FT                   /note="V -> A (in strain: Isolate CUHK-W1, Isolate GD01,
FT                   Isolate SZ3, Isolate SZ16, Isolate BJ01, Isolate BJ02,
FT                   Isolate BJ03 and Isolate Shanghai QXC1)"
FT   VARIANT         3072
FT                   /note="V -> A (in strain: Isolate CUHK-W1, Isolate SZ3,
FT                   Isolate SZ16 and Isolate GD01)"
FT   VARIANT         3197
FT                   /note="A -> V (in strain: Isolate BJ01, Isolate BJ02,
FT                   Isolate BJ03, Isolate BJ04 and Isolate Shanghai QXC1)"
FT   VARIANT         3429
FT                   /note="Q -> P (in strain: Isolate BJ02)"
FT   VARIANT         3488
FT                   /note="D -> E (in strain: Isolate BJ04)"
FT   VARIANT         3717
FT                   /note="V -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         3818
FT                   /note="N -> T (in strain: Isolate BJ04)"
FT   VARIANT         3903
FT                   /note="D -> N (in strain: Isolate BJ03)"
FT   VARIANT         3904
FT                   /note="I -> F (in strain: Isolate BJ02)"
FT   VARIANT         3911
FT                   /note="M -> V (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4001
FT                   /note="K -> Q (in strain: Isolate Shanghai LY)"
FT   VARIANT         4003
FT                   /note="T -> A (in strain: Isolate Shanghai LY)"
FT   VARIANT         4085
FT                   /note="I -> H (in strain: Isolate ZJ01)"
FT   VARIANT         4114
FT                   /note="V -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4202
FT                   /note="V -> M (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4240
FT                   /note="N -> H (in strain: Isolate ZJ01)"
FT   VARIANT         4296
FT                   /note="E -> G (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4377..4378
FT                   /note="LN -> FK (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4411
FT                   /note="V -> S (in strain: Isolate HKU-39849)"
FT   VARIANT         4459
FT                   /note="V -> I (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         4592
FT                   /note="V -> E (in strain: Isolate ZJ01)"
FT   VARIANT         4910
FT                   /note="Q -> L (in strain: Isolate ZJ01)"
FT   VARIANT         5112
FT                   /note="D -> G (in strain: Isolate SZ3)"
FT   VARIANT         5131
FT                   /note="A -> G (in strain: Isolate Taiwan)"
FT   VARIANT         5134..5135
FT                   /note="CY -> VL (in strain: Isolate Taiwan)"
FT   VARIANT         5623
FT                   /note="L -> S (in strain: Isolate GD01)"
FT   VARIANT         5720
FT                   /note="P -> S (in strain: Isolate GZ50 and Isolate
FT                   SIN2500)"
FT   VARIANT         5744
FT                   /note="R -> C (in strain: Isolate ZJ01)"
FT   VARIANT         5767
FT                   /note="D -> E (in strain: Isolate CUHK-W1, Isolate BJ01,
FT                   Isolate BJ02, Isolate BJ03, Isolate BJ04, Isolate SIN2500,
FT                   Isolate GD01, Isolate GZ50, Isolate SZ3, Isolate SZ16 and
FT                   Isolate Shanghai QXC1)"
FT   VARIANT         6274
FT                   /note="T -> I (in strain: Isolate FRA, Isolate Frankfurt-1
FT                   Isolate SIN2677, Isolate SIN2679 and Isolate SIN2748)"
FT   VARIANT         6474
FT                   /note="N -> S (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         6700
FT                   /note="M -> I (in strain: Isolate BJ03)"
FT   VARIANT         6721
FT                   /note="C -> R (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         6729
FT                   /note="D -> N (in strain: Isolate GD01)"
FT   VARIANT         6840
FT                   /note="M -> L (in strain: Isolate BJ02)"
FT   VARIANT         6862
FT                   /note="Q -> P (in strain: Isolate BJ04)"
FT   VARIANT         6877
FT                   /note="D -> E (in strain: Isolate GD01)"
FT   VARIANT         6910
FT                   /note="R -> K (in strain: Isolate SZ3 and Isolate SZ16)"
FT   VARIANT         6937
FT                   /note="A -> P (in strain: Isolate BJ03)"
FT   VARIANT         6992
FT                   /note="E -> D (in strain: Isolate BJ04)"
FT   VARIANT         7008
FT                   /note="N -> K (in strain: Isolate GD01)"
FT   VARIANT         7024
FT                   /note="K -> Q (in strain: Isolate BJ04)"
FT   MUTAGEN         4217
FT                   /note="G->E: Complete loss of nsp9 dimerization."
FT                   /evidence="ECO:0000269|PubMed:19153232"
FT   MUTAGEN         4221
FT                   /note="G->E: Complete loss of nsp9 dimerization."
FT                   /evidence="ECO:0000269|PubMed:19153232"
FT   STRAND          14..20
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   TURN            23..25
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   HELIX           35..48
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   STRAND          51..54
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   HELIX           61..63
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   STRAND          68..72
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   STRAND          87..93
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   TURN            95..98
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   STRAND          99..102
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   STRAND          105..109
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   STRAND          116..123
FT                   /evidence="ECO:0000244|PDB:2GDT"
FT   STRAND          827..829
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   TURN            831..833
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   STRAND          839..841
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   STRAND          848..851
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   TURN            852..856
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   STRAND          860..862
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   TURN            869..871
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   HELIX           872..882
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   HELIX           888..894
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   HELIX           898..901
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   STRAND          907..909
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   STRAND          911..915
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   STRAND          918..920
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   STRAND          922..926
FT                   /evidence="ECO:0000244|PDB:2GRI"
FT   STRAND          1013..1021
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   HELIX           1023..1030
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   STRAND          1033..1038
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   HELIX           1048..1056
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   TURN            1057..1059
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   HELIX           1060..1072
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   STRAND          1080..1084
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   TURN            1086..1088
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   STRAND          1090..1095
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   HELIX           1100..1102
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   HELIX           1108..1114
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   HELIX           1115..1118
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   STRAND          1119..1124
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   HELIX           1130..1132
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   HELIX           1136..1146
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   STRAND          1149..1156
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   HELIX           1158..1168
FT                   /evidence="ECO:0000244|PDB:2ACF"
FT   STRAND          1345..1347
FT                   /evidence="ECO:0000244|PDB:2JZF"
FT   HELIX           1351..1361
FT                   /evidence="ECO:0000244|PDB:2JZD"
FT   STRAND          1364..1368
FT                   /evidence="ECO:0000244|PDB:2JZD"
FT   HELIX           1372..1381
FT                   /evidence="ECO:0000244|PDB:2JZD"
FT   STRAND          1389..1401
FT                   /evidence="ECO:0000244|PDB:2JZD"
FT   HELIX           1407..1417
FT                   /evidence="ECO:0000244|PDB:2JZD"
FT   STRAND          1421..1424
FT                   /evidence="ECO:0000244|PDB:2JZF"
FT   STRAND          1426..1428
FT                   /evidence="ECO:0000244|PDB:2JZD"
FT   HELIX           1429..1431
FT                   /evidence="ECO:0000244|PDB:2JZD"
FT   HELIX           1435..1442
FT                   /evidence="ECO:0000244|PDB:2JZD"
FT   STRAND          1449..1452
FT                   /evidence="ECO:0000244|PDB:2JZF"
FT   HELIX           1457..1467
FT                   /evidence="ECO:0000244|PDB:2JZD"
FT   STRAND          1544..1555
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1557..1562
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   HELIX           1567..1571
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1572..1576
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1582..1584
FT                   /evidence="ECO:0000244|PDB:5E6J"
FT   HELIX           1588..1590
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1594..1597
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   HELIX           1602..1612
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   HELIX           1619..1630
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1639..1642
FT                   /evidence="ECO:0000244|PDB:5E6J"
FT   TURN            1648..1650
FT                   /evidence="ECO:0000244|PDB:5E6J"
FT   HELIX           1651..1661
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1667..1669
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   HELIX           1670..1680
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   HELIX           1685..1694
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   HELIX           1705..1713
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1722..1728
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1730..1732
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1734..1740
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   HELIX           1742..1745
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1746..1749
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   HELIX           1753..1758
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1760..1763
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1765..1785
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1790..1793
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   HELIX           1795..1797
FT                   /evidence="ECO:0000244|PDB:5E6J"
FT   STRAND          1799..1807
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1810..1826
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1829..1834
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1836..1846
FT                   /evidence="ECO:0000244|PDB:3E9S"
FT   STRAND          1904..1911
FT                   /evidence="ECO:0000244|PDB:2K87"
FT   HELIX           1912..1921
FT                   /evidence="ECO:0000244|PDB:2K87"
FT   STRAND          1929..1936
FT                   /evidence="ECO:0000244|PDB:2K87"
FT   STRAND          1942..1948
FT                   /evidence="ECO:0000244|PDB:2K87"
FT   HELIX           1949..1951
FT                   /evidence="ECO:0000244|PDB:2K87"
FT   HELIX           1954..1956
FT                   /evidence="ECO:0000244|PDB:2K87"
FT   STRAND          1963..1966
FT                   /evidence="ECO:0000244|PDB:2K87"
FT   STRAND          1969..1971
FT                   /evidence="ECO:0000244|PDB:2K87"
FT   HELIX           1977..1990
FT                   /evidence="ECO:0000244|PDB:2K87"
FT   HELIX           3251..3254
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3257..3262
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3265..3272
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3275..3279
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   HELIX           3280..3283
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   HELIX           3286..3290
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   HELIX           3294..3299
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   HELIX           3303..3305
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3307..3310
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3313..3315
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3317..3323
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3326..3333
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3340..3343
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3351..3358
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3361..3369
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   HELIX           3379..3381
FT                   /evidence="ECO:0000244|PDB:2QCY"
FT   STRAND          3388..3393
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3396..3406
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   TURN            3408..3410
FT                   /evidence="ECO:0000244|PDB:1UJ1"
FT   STRAND          3412..3415
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3421..3424
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3427..3430
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   HELIX           3441..3453
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   TURN            3458..3460
FT                   /evidence="ECO:0000244|PDB:3EBN"
FT   HELIX           3467..3476
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3477..3479
FT                   /evidence="ECO:0000244|PDB:1Z1J"
FT   HELIX           3484..3489
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   HELIX           3491..3497
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   HELIX           3501..3514
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   STRAND          3516..3518
FT                   /evidence="ECO:0000244|PDB:2BX3"
FT   STRAND          3521..3523
FT                   /evidence="ECO:0000244|PDB:1UK4"
FT   STRAND          3524..3526
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   HELIX           3533..3539
FT                   /evidence="ECO:0000244|PDB:5C5O"
FT   TURN            3540..3542
FT                   /evidence="ECO:0000244|PDB:2QC2"
FT   HELIX           3837..3855
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           3858..3860
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           3862..3876
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   STRAND          3878..3880
FT                   /evidence="ECO:0000244|PDB:1YSY"
FT   HELIX           3881..3905
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           3906..3909
FT                   /evidence="ECO:0000244|PDB:1YSY"
FT   TURN            3910..3912
FT                   /evidence="ECO:0000244|PDB:1YSY"
FT   HELIX           3913..3916
FT                   /evidence="ECO:0000244|PDB:1YSY"
FT   HELIX           3922..3924
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           3929..3946
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           3951..3956
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   TURN            3959..3963
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   TURN            3970..3972
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           3973..3987
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           3996..4017
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           4020..4030
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   STRAND          4034..4037
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   STRAND          4046..4051
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           4054..4060
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   STRAND          4065..4068
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   STRAND          4071..4079
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           4088..4090
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   TURN            4093..4095
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   HELIX           4096..4098
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   STRAND          4103..4109
FT                   /evidence="ECO:0000244|PDB:2AHM"
FT   STRAND          4120..4125
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   STRAND          4127..4131
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   STRAND          4134..4137
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   STRAND          4145..4150
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   STRAND          4153..4155
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   STRAND          4157..4164
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   STRAND          4170..4174
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   STRAND          4181..4186
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   STRAND          4191..4194
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   STRAND          4201..4208
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   HELIX           4213..4222
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   HELIX           4224..4227
FT                   /evidence="ECO:0000244|PDB:1UW7"
FT   HELIX           4238..4240
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           4243..4248
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          4250..4252
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           4253..4262
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          4284..4288
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          4295..4300
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           4301..4303
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           4305..4308
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          4314..4318
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          4325..4330
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           4331..4333
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           4337..4343
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   TURN            4348..4350
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          4351..4353
FT                   /evidence="ECO:0000244|PDB:5NFY"
FT   TURN            4354..4357
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          4490..4492
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4493..4501
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4505..4507
FT                   /evidence="ECO:0000244|PDB:6NUS"
FT   HELIX           4509..4517
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4523..4527
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            4529..4532
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4534..4537
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4540..4544
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4545..4547
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4548..4567
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4570..4573
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4576..4578
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4600..4602
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4604..4616
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            4617..4620
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4621..4624
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4645..4655
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4667..4669
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4671..4673
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4674..4686
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4687..4689
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4692..4694
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4695..4704
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4707..4717
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            4718..4720
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4721..4724
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4731..4734
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4737..4744
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4748..4751
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4754..4759
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4766..4770
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4786..4793
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            4794..4798
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4818..4822
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4823..4827
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4835..4847
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            4848..4851
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4859..4861
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4875..4877
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4881..4885
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4890..4899
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            4900..4902
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4908..4913
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4918..4920
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4925..4928
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4931..4949
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4953..4956
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            4963..4965
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4966..4975
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          4979..4985
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4991..4994
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           4997..5007
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5008..5010
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          5012..5014
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5017..5031
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          5035..5038
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          5041..5044
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          5053..5055
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5056..5077
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5081..5083
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5087..5097
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            5098..5100
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5108..5121
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          5122..5127
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          5130..5136
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5137..5140
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            5141..5143
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5148..5158
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5165..5167
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          5169..5171
FT                   /evidence="ECO:0000244|PDB:6NUS"
FT   STRAND          5184..5190
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          5192..5200
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5203..5211
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   STRAND          5217..5219
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5221..5234
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5236..5240
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5244..5263
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5278..5282
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   HELIX           5283..5285
FT                   /evidence="ECO:0000244|PDB:6NUR"
FT   TURN            5307..5309
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5312..5314
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5316..5320
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5328..5335
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5343..5349
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5361..5363
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5368..5372
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5374..5376
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5382..5386
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5393..5397
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5404..5412
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5418..5426
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5429..5446
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5447..5449
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5453..5457
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5461..5468
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5483..5488
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5493..5503
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5509..5516
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5525..5528
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5561..5566
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5567..5570
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5572..5575
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5576..5581
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5589..5599
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5605..5610
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5612..5616
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5617..5622
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5623..5626
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5630..5633
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5640..5642
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5647..5649
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5655..5660
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5661..5663
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5666..5668
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5670..5674
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5677..5679
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5682..5691
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5695..5700
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5720..5722
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5725..5730
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5743..5745
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5747..5750
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5751..5754
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5756..5759
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5791..5793
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5794..5796
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5797..5800
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5815..5818
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5819..5827
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5834..5836
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5843..5848
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   TURN            5854..5856
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5859..5866
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5873..5876
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   HELIX           5882..5884
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5893..5895
FT                   /evidence="ECO:0000244|PDB:6JYT"
FT   STRAND          5922..5924
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          5928..5931
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           5933..5935
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          5955..5957
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           5978..5983
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          5986..5997
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6000..6002
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6006..6016
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6018..6020
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6024..6028
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6033..6037
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6046..6053
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6054..6057
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6061..6076
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   TURN            6077..6079
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6084..6089
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6091..6100
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6112..6115
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6118..6120
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   TURN            6121..6124
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6125..6127
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   TURN            6129..6131
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6137..6140
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6142..6145
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6146..6149
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6155..6162
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6164..6166
FT                   /evidence="ECO:0000244|PDB:5C8U"
FT   HELIX           6172..6188
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6204..6226
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6229..6235
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6242..6245
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6247..6256
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6263..6267
FT                   /evidence="ECO:0000244|PDB:5C8S"
FT   HELIX           6272..6275
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   TURN            6276..6278
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6281..6288
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6296..6303
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6312..6314
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6320..6322
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6324..6326
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6328..6330
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6335..6338
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6341..6343
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6373..6376
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6381..6383
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6387..6405
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   STRAND          6408..6412
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6419..6425
FT                   /evidence="ECO:0000244|PDB:5C8T"
FT   HELIX           6431..6441
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6453..6456
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6459..6464
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6467..6473
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6476..6478
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   HELIX           6480..6488
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6493..6495
FT                   /evidence="ECO:0000244|PDB:2OZK"
FT   HELIX           6498..6503
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6508..6513
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   TURN            6517..6520
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6521..6530
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   TURN            6532..6534
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6535..6539
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   HELIX           6543..6545
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6550..6553
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   HELIX           6559..6565
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6567..6575
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6589..6591
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6594..6596
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6599..6601
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6606..6611
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6614..6616
FT                   /evidence="ECO:0000244|PDB:2RHB"
FT   HELIX           6629..6631
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   HELIX           6637..6644
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   HELIX           6647..6653
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   HELIX           6661..6664
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6670..6673
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6677..6679
FT                   /evidence="ECO:0000244|PDB:2OZK"
FT   HELIX           6680..6689
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6692..6698
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6703..6711
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   TURN            6712..6714
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6717..6724
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   HELIX           6728..6736
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6741..6751
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6754..6763
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   STRAND          6766..6772
FT                   /evidence="ECO:0000244|PDB:2H85"
FT   HELIX           6777..6780
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          6781..6785
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           6788..6791
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           6817..6829
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          6841..6846
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           6855..6863
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          6869..6876
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          6881..6888
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           6890..6892
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          6893..6897
FT                   /evidence="ECO:0000244|PDB:3R24"
FT   STRAND          6899..6904
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           6924..6935
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          6936..6946
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          6948..6950
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           6953..6959
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          6962..6970
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           6971..6973
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          6979..6986
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           6996..7009
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           7017..7020
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          7033..7035
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           7039..7041
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   HELIX           7044..7051
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          7055..7057
FT                   /evidence="ECO:0000244|PDB:2XYQ"
FT   STRAND          7065..7067
FT                   /evidence="ECO:0000244|PDB:3R24"
SQ   SEQUENCE   7073 AA;  790248 MW;  E6504CAFDC36BC09 CRC64;
     MESLVLGVNE KTHVQLSLPV LQVRDVLVRG FGDSVEEALS EAREHLKNGT CGLVELEKGV
     LPQLEQPYVF IKRSDALSTN HGHKVVELVA EMDGIQYGRS GITLGVLVPH VGETPIAYRN
     VLLRKNGNKG AGGHSYGIDL KSYDLGDELG TDPIEDYEQN WNTKHGSGAL RELTRELNGG
     AVTRYVDNNF CGPDGYPLDC IKDFLARAGK SMCTLSEQLD YIESKRGVYC CRDHEHEIAW
     FTERSDKSYE HQTPFEIKSA KKFDTFKGEC PKFVFPLNSK VKVIQPRVEK KKTEGFMGRI
     RSVYPVASPQ ECNNMHLSTL MKCNHCDEVS WQTCDFLKAT CEHCGTENLV IEGPTTCGYL
     PTNAVVKMPC PACQDPEIGP EHSVADYHNH SNIETRLRKG GRTRCFGGCV FAYVGCYNKR
     AYWVPRASAD IGSGHTGITG DNVETLNEDL LEILSRERVN INIVGDFHLN EEVAIILASF
     SASTSAFIDT IKSLDYKSFK TIVESCGNYK VTKGKPVKGA WNIGQQRSVL TPLCGFPSQA
     AGVIRSIFAR TLDAANHSIP DLQRAAVTIL DGISEQSLRL VDAMVYTSDL LTNSVIIMAY
     VTGGLVQQTS QWLSNLLGTT VEKLRPIFEW IEAKLSAGVE FLKDAWEILK FLITGVFDIV
     KGQIQVASDN IKDCVKCFID VVNKALEMCI DQVTIAGAKL RSLNLGEVFI AQSKGLYRQC
     IRGKEQLQLL MPLKAPKEVT FLEGDSHDTV LTSEEVVLKN GELEALETPV DSFTNGAIVG
     TPVCVNGLML LEIKDKEQYC ALSPGLLATN NVFRLKGGAP IKGVTFGEDT VWEVQGYKNV
     RITFELDERV DKVLNEKCSV YTVESGTEVT EFACVVAEAV VKTLQPVSDL LTNMGIDLDE
     WSVATFYLFD DAGEENFSSR MYCSFYPPDE EEEDDAECEE EEIDETCEHE YGTEDDYQGL
     PLEFGASAET VRVEEEEEED WLDDTTEQSE IEPEPEPTPE EPVNQFTGYL KLTDNVAIKC
     VDIVKEAQSA NPMVIVNAAN IHLKHGGGVA GALNKATNGA MQKESDDYIK LNGPLTVGGS
     CLLSGHNLAK KCLHVVGPNL NAGEDIQLLK AAYENFNSQD ILLAPLLSAG IFGAKPLQSL
     QVCVQTVRTQ VYIAVNDKAL YEQVVMDYLD NLKPRVEAPK QEEPPNTEDS KTEEKSVVQK
     PVDVKPKIKA CIDEVTTTLE ETKFLTNKLL LFADINGKLY HDSQNMLRGE DMSFLEKDAP
     YMVGDVITSG DITCVVIPSK KAGGTTEMLS RALKKVPVDE YITTYPGQGC AGYTLEEAKT
     ALKKCKSAFY VLPSEAPNAK EEILGTVSWN LREMLAHAEE TRKLMPICMD VRAIMATIQR
     KYKGIKIQEG IVDYGVRFFF YTSKEPVASI ITKLNSLNEP LVTMPIGYVT HGFNLEEAAR
     CMRSLKAPAV VSVSSPDAVT TYNGYLTSSS KTSEEHFVET VSLAGSYRDW SYSGQRTELG
     VEFLKRGDKI VYHTLESPVE FHLDGEVLSL DKLKSLLSLR EVKTIKVFTT VDNTNLHTQL
     VDMSMTYGQQ FGPTYLDGAD VTKIKPHVNH EGKTFFVLPS DDTLRSEAFE YYHTLDESFL
     GRYMSALNHT KKWKFPQVGG LTSIKWADNN CYLSSVLLAL QQLEVKFNAP ALQEAYYRAR
     AGDAANFCAL ILAYSNKTVG ELGDVRETMT HLLQHANLES AKRVLNVVCK HCGQKTTTLT
     GVEAVMYMGT LSYDNLKTGV SIPCVCGRDA TQYLVQQESS FVMMSAPPAE YKLQQGTFLC
     ANEYTGNYQC GHYTHITAKE TLYRIDGAHL TKMSEYKGPV TDVFYKETSY TTTIKPVSYK
     LDGVTYTEIE PKLDGYYKKD NAYYTEQPID LVPTQPLPNA SFDNFKLTCS NTKFADDLNQ
     MTGFTKPASR ELSVTFFPDL NGDVVAIDYR HYSASFKKGA KLLHKPIVWH INQATTKTTF
     KPNTWCLRCL WSTKPVDTSN SFEVLAVEDT QGMDNLACES QQPTSEEVVE NPTIQKEVIE
     CDVKTTEVVG NVILKPSDEG VKVTQELGHE DLMAAYVENT SITIKKPNEL SLALGLKTIA
     THGIAAINSV PWSKILAYVK PFLGQAAITT SNCAKRLAQR VFNNYMPYVF TLLFQLCTFT
     KSTNSRIRAS LPTTIAKNSV KSVAKLCLDA GINYVKSPKF SKLFTIAMWL LLLSICLGSL
     ICVTAAFGVL LSNFGAPSYC NGVRELYLNS SNVTTMDFCE GSFPCSICLS GLDSLDSYPA
     LETIQVTISS YKLDLTILGL AAEWVLAYML FTKFFYLLGL SAIMQVFFGY FASHFISNSW
     LMWFIISIVQ MAPVSAMVRM YIFFASFYYI WKSYVHIMDG CTSSTCMMCY KRNRATRVEC
     TTIVNGMKRS FYVYANGGRG FCKTHNWNCL NCDTFCTGST FISDEVARDL SLQFKRPINP
     TDQSSYIVDS VAVKNGALHL YFDKAGQKTY ERHPLSHFVN LDNLRANNTK GSLPINVIVF
     DGKSKCDESA SKSASVYYSQ LMCQPILLLD QALVSDVGDS TEVSVKMFDA YVDTFSATFS
     VPMEKLKALV ATAHSELAKG VALDGVLSTF VSAARQGVVD TDVDTKDVIE CLKLSHHSDL
     EVTGDSCNNF MLTYNKVENM TPRDLGACID CNARHINAQV AKSHNVSLIW NVKDYMSLSE
     QLRKQIRSAA KKNNIPFRLT CATTRQVVNV ITTKISLKGG KIVSTCFKLM LKATLLCVLA
     ALVCYIVMPV HTLSIHDGYT NEIIGYKAIQ DGVTRDIIST DDCFANKHAG FDAWFSQRGG
     SYKNDKSCPV VAAIITREIG FIVPGLPGTV LRAINGDFLH FLPRVFSAVG NICYTPSKLI
     EYSDFATSAC VLAAECTIFK DAMGKPVPYC YDTNLLEGSI SYSELRPDTR YVLMDGSIIQ
     FPNTYLEGSV RVVTTFDAEY CRHGTCERSE VGICLSTSGR WVLNNEHYRA LSGVFCGVDA
     MNLIANIFTP LVQPVGALDV SASVVAGGII AILVTCAAYY FMKFRRVFGE YNHVVAANAL
     LFLMSFTILC LVPAYSFLPG VYSVFYLYLT FYFTNDVSFL AHLQWFAMFS PIVPFWITAI
     YVFCISLKHC HWFFNNYLRK RVMFNGVTFS TFEEAALCTF LLNKEMYLKL RSETLLPLTQ
     YNRYLALYNK YKYFSGALDT TSYREAACCH LAKALNDFSN SGADVLYQPP QTSITSAVLQ
     SGFRKMAFPS GKVEGCMVQV TCGTTTLNGL WLDDTVYCPR HVICTAEDML NPNYEDLLIR
     KSNHSFLVQA GNVQLRVIGH SMQNCLLRLK VDTSNPKTPK YKFVRIQPGQ TFSVLACYNG
     SPSGVYQCAM RPNHTIKGSF LNGSCGSVGF NIDYDCVSFC YMHHMELPTG VHAGTDLEGK
     FYGPFVDRQT AQAAGTDTTI TLNVLAWLYA AVINGDRWFL NRFTTTLNDF NLVAMKYNYE
     PLTQDHVDIL GPLSAQTGIA VLDMCAALKE LLQNGMNGRT ILGSTILEDE FTPFDVVRQC
     SGVTFQGKFK KIVKGTHHWM LLTFLTSLLI LVQSTQWSLF FFVYENAFLP FTLGIMAIAA
     CAMLLVKHKH AFLCLFLLPS LATVAYFNMV YMPASWVMRI MTWLELADTS LSGYRLKDCV
     MYASALVLLI LMTARTVYDD AARRVWTLMN VITLVYKVYY GNALDQAISM WALVISVTSN
     YSGVVTTIMF LARAIVFVCV EYYPLLFITG NTLQCIMLVY CFLGYCCCCY FGLFCLLNRY
     FRLTLGVYDY LVSTQEFRYM NSQGLLPPKS SIDAFKLNIK LLGIGGKPCI KVATVQSKMS
     DVKCTSVVLL SVLQQLRVES SSKLWAQCVQ LHNDILLAKD TTEAFEKMVS LLSVLLSMQG
     AVDINRLCEE MLDNRATLQA IASEFSSLPS YAAYATAQEA YEQAVANGDS EVVLKKLKKS
     LNVAKSEFDR DAAMQRKLEK MADQAMTQMY KQARSEDKRA KVTSAMQTML FTMLRKLDND
     ALNNIINNAR DGCVPLNIIP LTTAAKLMVV VPDYGTYKNT CDGNTFTYAS ALWEIQQVVD
     ADSKIVQLSE INMDNSPNLA WPLIVTALRA NSAVKLQNNE LSPVALRQMS CAAGTTQTAC
     TDDNALAYYN NSKGGRFVLA LLSDHQDLKW ARFPKSDGTG TIYTELEPPC RFVTDTPKGP
     KVKYLYFIKG LNNLNRGMVL GSLAATVRLQ AGNATEVPAN STVLSFCAFA VDPAKAYKDY
     LASGGQPITN CVKMLCTHTG TGQAITVTPE ANMDQESFGG ASCCLYCRCH IDHPNPKGFC
     DLKGKYVQIP TTCANDPVGF TLRNTVCTVC GMWKGYGCSC DQLREPLMQS ADASTFLNRV
     CGVSAARLTP CGTGTSTDVV YRAFDIYNEK VAGFAKFLKT NCCRFQEKDE EGNLLDSYFV
     VKRHTMSNYQ HEETIYNLVK DCPAVAVHDF FKFRVDGDMV PHISRQRLTK YTMADLVYAL
     RHFDEGNCDT LKEILVTYNC CDDDYFNKKD WYDFVENPDI LRVYANLGER VRQSLLKTVQ
     FCDAMRDAGI VGVLTLDNQD LNGNWYDFGD FVQVAPGCGV PIVDSYYSLL MPILTLTRAL
     AAESHMDADL AKPLIKWDLL KYDFTEERLC LFDRYFKYWD QTYHPNCINC LDDRCILHCA
     NFNVLFSTVF PPTSFGPLVR KIFVDGVPFV VSTGYHFREL GVVHNQDVNL HSSRLSFKEL
     LVYAADPAMH AASGNLLLDK RTTCFSVAAL TNNVAFQTVK PGNFNKDFYD FAVSKGFFKE
     GSSVELKHFF FAQDGNAAIS DYDYYRYNLP TMCDIRQLLF VVEVVDKYFD CYDGGCINAN
     QVIVNNLDKS AGFPFNKWGK ARLYYDSMSY EDQDALFAYT KRNVIPTITQ MNLKYAISAK
     NRARTVAGVS ICSTMTNRQF HQKLLKSIAA TRGATVVIGT SKFYGGWHNM LKTVYSDVET
     PHLMGWDYPK CDRAMPNMLR IMASLVLARK HNTCCNLSHR FYRLANECAQ VLSEMVMCGG
     SLYVKPGGTS SGDATTAYAN SVFNICQAVT ANVNALLSTD GNKIADKYVR NLQHRLYECL
     YRNRDVDHEF VDEFYAYLRK HFSMMILSDD AVVCYNSNYA AQGLVASIKN FKAVLYYQNN
     VFMSEAKCWT ETDLTKGPHE FCSQHTMLVK QGDDYVYLPY PDPSRILGAG CFVDDIVKTD
     GTLMIERFVS LAIDAYPLTK HPNQEYADVF HLYLQYIRKL HDELTGHMLD MYSVMLTNDN
     TSRYWEPEFY EAMYTPHTVL QAVGACVLCN SQTSLRCGAC IRRPFLCCKC CYDHVISTSH
     KLVLSVNPYV CNAPGCDVTD VTQLYLGGMS YYCKSHKPPI SFPLCANGQV FGLYKNTCVG
     SDNVTDFNAI ATCDWTNAGD YILANTCTER LKLFAAETLK ATEETFKLSY GIATVREVLS
     DRELHLSWEV GKPRPPLNRN YVFTGYRVTK NSKVQIGEYT FEKGDYGDAV VYRGTTTYKL
     NVGDYFVLTS HTVMPLSAPT LVPQEHYVRI TGLYPTLNIS DEFSSNVANY QKVGMQKYST
     LQGPPGTGKS HFAIGLALYY PSARIVYTAC SHAAVDALCE KALKYLPIDK CSRIIPARAR
     VECFDKFKVN STLEQYVFCT VNALPETTAD IVVFDEISMA TNYDLSVVNA RLRAKHYVYI
     GDPAQLPAPR TLLTKGTLEP EYFNSVCRLM KTIGPDMFLG TCRRCPAEIV DTVSALVYDN
     KLKAHKDKSA QCFKMFYKGV ITHDVSSAIN RPQIGVVREF LTRNPAWRKA VFISPYNSQN
     AVASKILGLP TQTVDSSQGS EYDYVIFTQT TETAHSCNVN RFNVAITRAK IGILCIMSDR
     DLYDKLQFTS LEIPRRNVAT LQAENVTGLF KDCSKIITGL HPTQAPTHLS VDIKFKTEGL
     CVDIPGIPKD MTYRRLISMM GFKMNYQVNG YPNMFITREE AIRHVRAWIG FDVEGCHATR
     DAVGTNLPLQ LGFSTGVNLV AVPTGYVDTE NNTEFTRVNA KPPPGDQFKH LIPLMYKGLP
     WNVVRIKIVQ MLSDTLKGLS DRVVFVLWAH GFELTSMKYF VKIGPERTCC LCDKRATCFS
     TSSDTYACWN HSVGFDYVYN PFMIDVQQWG FTGNLQSNHD QHCQVHGNAH VASCDAIMTR
     CLAVHECFVK RVDWSVEYPI IGDELRVNSA CRKVQHMVVK SALLADKFPV LHDIGNPKAI
     KCVPQAEVEW KFYDAQPCSD KAYKIEELFY SYATHHDKFT DGVCLFWNCN VDRYPANAIV
     CRFDTRVLSN LNLPGCDGGS LYVNKHAFHT PAFDKSAFTN LKQLPFFYYS DSPCESHGKQ
     VVSDIDYVPL KSATCITRCN LGGAVCRHHA NEYRQYLDAY NMMISAGFSL WIYKQFDTYN
     LWNTFTRLQS LENVAYNVVN KGHFDGHAGE APVSIINNAV YTKVDGIDVE IFENKTTLPV
     NVAFELWAKR NIKPVPEIKI LNNLGVDIAA NTVIWDYKRE APAHVSTIGV CTMTDIAKKP
     TESACSSLTV LFDGRVEGQV DLFRNARNGV LITEGSVKGL TPSKGPAQAS VNGVTLIGES
     VKTQFNYFKK VDGIIQQLPE TYFTQSRDLE DFKPRSQMET DFLELAMDEF IQRYKLEGYA
     FEHIVYGDFS HGQLGGLHLM IGLAKRSQDS PLKLEDFIPM DSTVKNYFIT DAQTGSSKCV
     CSVIDLLLDD FVEIIKSQDL SVISKVVKVT IDYAEISFML WCKDGHVETF YPKLQASQAW
     QPGVAMPNLY KMQRMLLEKC DLQNYGENAV IPKGIMMNVA KYTQLCQYLN TLTLAVPYNM
     RVIHFGAGSD KGVAPGTAVL RQWLPTGTLL VDSDLNDFVS DADSTLIGDC ATVHTANKWD
     LIISDMYDPR TKHVTKENDS KEGFFTYLCG FIKQKLALGG SIAVKITEHS WNADLYKLMG
     HFSWWTAFVT NVNASSSEAF LIGANYLGKP KEQIDGYTMH ANYIFWRNTN PIQLSSYSLF
     DMSKFPLKLR GTAVMSLKEN QINDMIYSLL EKGRLIIREN NRVVVSSDIL VNN
//
ID   R1A_SARS2               Reviewed;        4405 AA.
AC   P0DTC1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE              EC=3.4.19.12;
DE              EC=3.4.22.-;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69;
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
RN   [2]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE AND IN COMPLEX
RP   WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   "The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3.";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE IN COMPLEX
RP   WITH ALPHA-KETOAMIDE INHIBITORS, SUBUNIT (3C-LIKE PROTEINASE), ACTIVE SITE,
RP   AND ACTIVITY REGULATION.
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   "Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors.";
RL   Science 0:0-0(2020).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE APOENZYME AND
RP   IN COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   "Structure of Mpro from COVID-19 virus and discovery of its inhibitors.";
RL   Nature 0:0-0(2020).
CC   -!- FUNCTION: [Replicase polyprotein 1a]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2. Indeed, these two proteins play a role in maintaining the
CC       functional integrity of the mitochondria and protecting cells from
CC       various stresses. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates. Participates together with nsp4 in the assembly of virally-
CC       induced cytoplasmic double-membrane vesicles necessary for viral
CC       replication. Antagonizes innate immune induction of type I interferon
CC       by blocking the phosphorylation, dimerization and subsequent nuclear
CC       translocation of host IRF3. Prevents also host NF-kappa-B signaling.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 4]: Participates in the assembly of
CC       virally-induced cytoplasmic double-membrane vesicles necessary for
CC       viral replication. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [3C-like proteinase]: Cleaves the C-terminus of replicase
CC       polyprotein at 11 sites (By similarity) (PubMed:32198291,
CC       PubMed:32272481). Recognizes substrates containing the core sequence
CC       [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-phosphate
CC       (ADRP) (By similarity). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in the initial
CC       induction of autophagosomes from host reticulum endoplasmic. Later,
CC       limits the expansion of these phagosomes that are no longer able to
CC       deliver viral components to lysosomes. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 9]: May participate in viral
CC       replication by acting as a ssRNA-binding protein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000250|UniProtKB:P0C6U8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=TSAVLQ-|-SGFRK-NH(2) and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7, ECO:0000269|PubMed:32198291,
CC         ECO:0000269|PubMed:32272481};
CC   -!- ACTIVITY REGULATION: [3C-like proteinase]: Inhibited by pyridone-
CC       containing alpha-ketoamides compounds 13a and 13b. In turn, alpha-
CC       ketoamide 13b (tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-
CC       ((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-
CC       2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate) inhibits SARS-CoV-2
CC       replication in human lung cells (PubMed:32198291). Inhibited ex vivo by
CC       michael acceptor inhibitor N3 (PubMed:32272481).
CC       {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481}.
CC   -!- SUBUNIT: [Non-structural protein 2]: Interacts with host PHB and PHB2.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [3C-like proteinase]: 3CL-PRO exists as monomer and homodimer.
CC       Only the homodimer shows catalytic activity.
CC       {ECO:0000269|PubMed:32198291}.
CC   -!- SUBUNIT: [Non-structural protein 4]: Interacts with PL-PRO and nsp6.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 7]: Eight copies of nsp7 and eight
CC       copies of nsp8 assemble to form a heterohexadecamer dsRNA-encircling
CC       ring structure. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 8]: Eight copies of nsp7 and eight
CC       copies of nsp8 assemble to form a heterohexadecamer dsRNA-encircling
CC       ring structure. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 9]: Is a dimer.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 10]: Forms a dodecamer and interacts
CC       with nsp14 and nsp16; these interactions enhance nsp14 and nsp16
CC       enzymatic activities. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 3]: Host membrane
CC       {ECO:0000250|UniProtKB:P0C6X7}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P0C6X7}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 4]: Host membrane
CC       {ECO:0000250|UniProtKB:P0C6X7}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P0C6X7}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P0C6X7}. Note=Localizes in virally-induced
CC       cytoplasmic double-membrane vesicles. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 6]: Host membrane
CC       {ECO:0000250|UniProtKB:P0C6X7}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 7]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250|UniProtKB:P0C6X9}. Note=nsp7, nsp8,
CC       nsp9 and nsp10 are localized in cytoplasmic foci, largely perinuclear.
CC       Late in infection, they merge into confluent complexes.
CC       {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 8]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250|UniProtKB:P0C6X9}. Note=nsp7, nsp8,
CC       nsp9 and nsp10 are localized in cytoplasmic foci, largely perinuclear.
CC       Late in infection, they merge into confluent complexes.
CC       {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 9]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250|UniProtKB:P0C6X9}. Note=nsp7, nsp8,
CC       nsp9 and nsp10 are localized in cytoplasmic foci, largely perinuclear.
CC       Late in infection, they merge into confluent complexes.
CC       {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 10]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250|UniProtKB:P0C6X9}. Note=nsp7, nsp8,
CC       nsp9 and nsp10 are localized in cytoplasmic foci, largely perinuclear.
CC       Late in infection, they merge into confluent complexes.
CC       {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC         Comment=Normal translation results in Replicase polyprotein 1a.
CC         Ribosomal frameshifting at the end of this protein occurs at low
CC         frequency and produces Replicase polyprotein 1ab.;
CC       Name=Replicase polyprotein 1a;
CC         IsoId=P0DTC1-1; Sequence=Displayed;
CC       Name=Replicase polyprotein 1ab;
CC         IsoId=P0DTD1-1; Sequence=External;
CC   -!- DOMAIN: The hydrophobic domains (HD) could mediate the membrane
CC       association of the replication complex and thereby alter the
CC       architecture of the host cell membrane. {ECO:0000250|UniProtKB:P0C6U8}.
CC   -!- PTM: Specific enzymatic cleavages in vivo by its own proteases yield
CC       mature proteins. 3CL-PRO and PL-PRO proteinases are autocatalytically
CC       processed. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- MISCELLANEOUS: [Replicase polyprotein 1a]: Produced by conventional
CC       translation. {ECO:0000250|UniProtKB:P0C6U8}.
CC   -!- SIMILARITY: Belongs to the coronaviruses polyprotein 1ab family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43415.1; ALT_FRAME; Genomic_RNA.
DR   RefSeq; YP_009725295.1; NC_045512.2.
DR   PDB; 6Y2E; X-ray; 1.75 A; A=3264-3569.
DR   PDB; 6Y2F; X-ray; 2.16 A; A=3264-3569.
DR   PDB; 6Y2G; X-ray; 2.16 A; A=3264-3569.
DR   PDB; 6YHU; X-ray; 2.00 A; A/C=3860-3930, B/D=4018-4134.
DR   PDBsum; 6Y2E; -.
DR   PDBsum; 6Y2F; -.
DR   PDBsum; 6Y2G; -.
DR   PDBsum; 6YHU; -.
DR   SMR; P0DTC1; -.
DR   BioGRID; 4383866; 1.
DR   IntAct; P0DTC1; 4.
DR   GeneID; 43740578; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0008242; F:omega peptidase activity; IEA:InterPro.
DR   GO; GO:0003968; F:RNA-directed 5'-3' RNA polymerase activity; IEA:InterPro.
DR   GO; GO:0003727; F:single-stranded RNA binding; IEA:InterPro.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0039595; P:induction by virus of catabolism of host mRNA; IEA:UniProtKB-KW.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0039648; P:modulation by virus of host protein ubiquitination; IEA:UniProtKB-KW.
DR   GO; GO:0039548; P:suppression by virus of host IRF3 activity; IEA:UniProtKB-KW.
DR   GO; GO:0039579; P:suppression by virus of host ISG15 activity; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:suppression by virus of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   GO; GO:0019082; P:viral protein processing; IEA:InterPro.
DR   CDD; cd15239; 7tm_YRO2_fungal-like; 1.
DR   Gene3D; 1.10.150.420; -; 1.
DR   Gene3D; 1.10.1840.10; -; 1.
DR   Gene3D; 1.10.8.1190; -; 1.
DR   Gene3D; 1.10.8.370; -; 1.
DR   Gene3D; 2.30.30.590; -; 1.
DR   Gene3D; 2.40.10.10; -; 2.
DR   Gene3D; 2.40.10.250; -; 1.
DR   Gene3D; 2.40.10.290; -; 1.
DR   Gene3D; 3.10.20.350; -; 1.
DR   Gene3D; 3.10.20.540; -; 1.
DR   Gene3D; 3.40.220.10; -; 1.
DR   Gene3D; 3.40.220.20; -; 1.
DR   Gene3D; 3.40.220.30; -; 1.
DR   Gene3D; 3.40.50.11020; -; 1.
DR   Gene3D; 3.90.70.90; -; 1.
DR   InterPro; IPR022733; DPUP_SUD_C_bCoV.
DR   InterPro; IPR002589; Macro_dom.
DR   InterPro; IPR043472; Macro_dom-like.
DR   InterPro; IPR042570; NAR_sf.
DR   InterPro; IPR036333; NSP10_sf_CoV.
DR   InterPro; IPR021590; NSP1_bCoV.
DR   InterPro; IPR038030; NSP1_sf_bCoV.
DR   InterPro; IPR024375; NSP3_bCoV.
DR   InterPro; IPR024358; NSP3_N_bCoV.
DR   InterPro; IPR032592; NSP3_NAR_bCoV.
DR   InterPro; IPR038166; NSP3_PL2pro_sf_CoV.
DR   InterPro; IPR038400; NSP3_SUD-M_sf_bCoV.
DR   InterPro; IPR043478; NSP3_SUD-N_bCoV.
DR   InterPro; IPR038083; NSP3A-like.
DR   InterPro; IPR032505; NSP4_C_CoV.
DR   InterPro; IPR038123; NSP4_C_sf_CoV.
DR   InterPro; IPR014828; NSP7_CoV.
DR   InterPro; IPR037204; NSP7_sf_CoV.
DR   InterPro; IPR014829; NSP8_CoV-like.
DR   InterPro; IPR037230; NSP8_sf_CoV.
DR   InterPro; IPR014822; NSP9_CoV.
DR   InterPro; IPR036499; NSP9_sf_CoV.
DR   InterPro; IPR013016; Peptidase_C16_CoV.
DR   InterPro; IPR008740; Peptidase_C30_CoV.
DR   InterPro; IPR043477; Peptidase_C30_dom3_CoV.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR043177; PLpro_N_sf_CoV.
DR   InterPro; IPR043503; PLpro_palm_finger_dom_CoV.
DR   InterPro; IPR043178; PLpro_thumb_sf_CoV.
DR   InterPro; IPR018995; RNA_synth_NSP10_CoV.
DR   InterPro; IPR043476; Yro2-like_7TM.
DR   Pfam; PF16348; Corona_NSP4_C; 1.
DR   Pfam; PF12379; DUF3655; 1.
DR   Pfam; PF01661; Macro; 1.
DR   Pfam; PF16251; NAR; 1.
DR   Pfam; PF11501; Nsp1; 1.
DR   Pfam; PF09401; NSP10; 1.
DR   Pfam; PF12124; Nsp3_PL2pro; 1.
DR   Pfam; PF08716; nsp7; 1.
DR   Pfam; PF08717; nsp8; 1.
DR   Pfam; PF08710; nsp9; 1.
DR   Pfam; PF05409; Peptidase_C30; 1.
DR   Pfam; PF11633; SUD-M; 1.
DR   Pfam; PF08715; Viral_protease; 1.
DR   SMART; SM00506; A1pp; 1.
DR   SUPFAM; SSF101816; SSF101816; 1.
DR   SUPFAM; SSF140367; SSF140367; 1.
DR   SUPFAM; SSF143076; SSF143076; 1.
DR   SUPFAM; SSF144246; SSF144246; 1.
DR   SUPFAM; SSF159936; SSF159936; 1.
DR   SUPFAM; SSF160099; SSF160099; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF52949; SSF52949; 1.
DR   PROSITE; PS00867; CPSASE_2; 1.
DR   PROSITE; PS51442; M_PRO; 1.
DR   PROSITE; PS51154; MACRO; 1.
DR   PROSITE; PS51124; PEPTIDASE_C16; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host autophagy by virus;
KW   Decay of host mRNAs by virus; Endonuclease;
KW   Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Host cytoplasm;
KW   Host gene expression shutoff by virus; Host membrane;
KW   Host mRNA suppression by virus; Host-virus interaction; Hydrolase;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host IRF3 by virus; Inhibition of host ISG15 by virus;
KW   Inhibition of host RLR pathway by virus; Membrane; Metal-binding;
KW   Modulation of host ubiquitin pathway by viral deubiquitinase;
KW   Modulation of host ubiquitin pathway by virus; Nuclease; Protease;
KW   Reference proteome; Repeat; Ribosomal frameshifting; RNA-binding;
KW   Thiol protease; Transmembrane; Transmembrane helix;
KW   Ubl conjugation pathway; Viral immunoevasion; Zinc; Zinc-finger.
FT   CHAIN           1..4405
FT                   /note="Replicase polyprotein 1a"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6U8"
FT                   /id="PRO_0000449634"
FT   CHAIN           1..180
FT                   /note="Host translation inhibitor nsp1"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449635"
FT   CHAIN           181..818
FT                   /note="Non-structural protein 2"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449636"
FT   CHAIN           819..2763
FT                   /note="Non-structural protein 3"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449637"
FT   CHAIN           2764..3263
FT                   /note="Non-structural protein 4"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449638"
FT   CHAIN           3264..3569
FT                   /note="3C-like proteinase"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449639"
FT   CHAIN           3570..3859
FT                   /note="Non-structural protein 6"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449640"
FT   CHAIN           3860..3942
FT                   /note="Non-structural protein 7"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449641"
FT   CHAIN           3943..4140
FT                   /note="Non-structural protein 8"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449642"
FT   CHAIN           4141..4253
FT                   /note="Non-structural protein 9"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449643"
FT   CHAIN           4254..4392
FT                   /note="Non-structural protein 10"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449644"
FT   CHAIN           4393..4405
FT                   /note="Non-structural protein 11"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449645"
FT   TRANSMEM        2226..2246
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2318..2338
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2339..2359
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2361..2381
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        2776..2796
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3045..3065
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3077..3097
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3100..3120
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3128..3148
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3165..3185
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3587..3607
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3609..3629
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3635..3655
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3674..3694
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3730..3750
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        3779..3799
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          1025..1194
FT                   /note="Macro"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00490"
FT   DOMAIN          1634..1898
FT                   /note="Peptidase C16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   DOMAIN          3264..3569
FT                   /note="Peptidase C30"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772"
FT   ZN_FING         1752..1789
FT                   /note="C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ACT_SITE        1674
FT                   /note="For PL1-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ACT_SITE        1835
FT                   /note="For PL2-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ACT_SITE        3304
FT                   /note="For 3CL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772,
FT                   ECO:0000269|PubMed:32198291"
FT   ACT_SITE        3408
FT                   /note="For 3CL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772,
FT                   ECO:0000269|PubMed:32198291"
FT   SITE            180..181
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            818..819
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            2763..2764
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            3263..3264
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            3569..3570
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            3859..3860
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            3942..3943
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            4140..4141
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            4253..4254
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            4392..4393
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   HELIX           3861..3878
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   HELIX           3881..3883
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   HELIX           3885..3899
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   HELIX           3904..3919
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   TURN            3922..3924
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   HELIX           3927..3929
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   HELIX           4019..4040
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   HELIX           4043..4053
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   STRAND          4057..4060
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   STRAND          4070..4074
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   HELIX           4077..4083
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   STRAND          4088..4091
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   STRAND          4094..4102
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   HELIX           4111..4113
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   TURN            4116..4118
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   HELIX           4119..4121
FT                   /evidence="ECO:0000244|PDB:6YHU"
FT   STRAND          4124..4132
FT                   /evidence="ECO:0000244|PDB:6YHU"
SQ   SEQUENCE   4405 AA;  489989 MW;  7F8A21148A7A7E2A CRC64;
     MESLVPGFNE KTHVQLSLPV LQVRDVLVRG FGDSVEEVLS EARQHLKDGT CGLVEVEKGV
     LPQLEQPYVF IKRSDARTAP HGHVMVELVA ELEGIQYGRS GETLGVLVPH VGEIPVAYRK
     VLLRKNGNKG AGGHSYGADL KSFDLGDELG TDPYEDFQEN WNTKHSSGVT RELMRELNGG
     AYTRYVDNNF CGPDGYPLEC IKDLLARAGK ASCTLSEQLD FIDTKRGVYC CREHEHEIAW
     YTERSEKSYE LQTPFEIKLA KKFDTFNGEC PNFVFPLNSI IKTIQPRVEK KKLDGFMGRI
     RSVYPVASPN ECNQMCLSTL MKCDHCGETS WQTGDFVKAT CEFCGTENLT KEGATTCGYL
     PQNAVVKIYC PACHNSEVGP EHSLAEYHNE SGLKTILRKG GRTIAFGGCV FSYVGCHNKC
     AYWVPRASAN IGCNHTGVVG EGSEGLNDNL LEILQKEKVN INIVGDFKLN EEIAIILASF
     SASTSAFVET VKGLDYKAFK QIVESCGNFK VTKGKAKKGA WNIGEQKSIL SPLYAFASEA
     ARVVRSIFSR TLETAQNSVR VLQKAAITIL DGISQYSLRL IDAMMFTSDL ATNNLVVMAY
     ITGGVVQLTS QWLTNIFGTV YEKLKPVLDW LEEKFKEGVE FLRDGWEIVK FISTCACEIV
     GGQIVTCAKE IKESVQTFFK LVNKFLALCA DSIIIGGAKL KALNLGETFV THSKGLYRKC
     VKSREETGLL MPLKAPKEII FLEGETLPTE VLTEEVVLKT GDLQPLEQPT SEAVEAPLVG
     TPVCINGLML LEIKDTEKYC ALAPNMMVTN NTFTLKGGAP TKVTFGDDTV IEVQGYKSVN
     ITFELDERID KVLNEKCSAY TVELGTEVNE FACVVADAVI KTLQPVSELL TPLGIDLDEW
     SMATYYLFDE SGEFKLASHM YCSFYPPDED EEEGDCEEEE FEPSTQYEYG TEDDYQGKPL
     EFGATSAALQ PEEEQEEDWL DDDSQQTVGQ QDGSEDNQTT TIQTIVEVQP QLEMELTPVV
     QTIEVNSFSG YLKLTDNVYI KNADIVEEAK KVKPTVVVNA ANVYLKHGGG VAGALNKATN
     NAMQVESDDY IATNGPLKVG GSCVLSGHNL AKHCLHVVGP NVNKGEDIQL LKSAYENFNQ
     HEVLLAPLLS AGIFGADPIH SLRVCVDTVR TNVYLAVFDK NLYDKLVSSF LEMKSEKQVE
     QKIAEIPKEE VKPFITESKP SVEQRKQDDK KIKACVEEVT TTLEETKFLT ENLLLYIDIN
     GNLHPDSATL VSDIDITFLK KDAPYIVGDV VQEGVLTAVV IPTKKAGGTT EMLAKALRKV
     PTDNYITTYP GQGLNGYTVE EAKTVLKKCK SAFYILPSII SNEKQEILGT VSWNLREMLA
     HAEETRKLMP VCVETKAIVS TIQRKYKGIK IQEGVVDYGA RFYFYTSKTT VASLINTLND
     LNETLVTMPL GYVTHGLNLE EAARYMRSLK VPATVSVSSP DAVTAYNGYL TSSSKTPEEH
     FIETISLAGS YKDWSYSGQS TQLGIEFLKR GDKSVYYTSN PTTFHLDGEV ITFDNLKTLL
     SLREVRTIKV FTTVDNINLH TQVVDMSMTY GQQFGPTYLD GADVTKIKPH NSHEGKTFYV
     LPNDDTLRVE AFEYYHTTDP SFLGRYMSAL NHTKKWKYPQ VNGLTSIKWA DNNCYLATAL
     LTLQQIELKF NPPALQDAYY RARAGEAANF CALILAYCNK TVGELGDVRE TMSYLFQHAN
     LDSCKRVLNV VCKTCGQQQT TLKGVEAVMY MGTLSYEQFK KGVQIPCTCG KQATKYLVQQ
     ESPFVMMSAP PAQYELKHGT FTCASEYTGN YQCGHYKHIT SKETLYCIDG ALLTKSSEYK
     GPITDVFYKE NSYTTTIKPV TYKLDGVVCT EIDPKLDNYY KKDNSYFTEQ PIDLVPNQPY
     PNASFDNFKF VCDNIKFADD LNQLTGYKKP ASRELKVTFF PDLNGDVVAI DYKHYTPSFK
     KGAKLLHKPI VWHVNNATNK ATYKPNTWCI RCLWSTKPVE TSNSFDVLKS EDAQGMDNLA
     CEDLKPVSEE VVENPTIQKD VLECNVKTTE VVGDIILKPA NNSLKITEEV GHTDLMAAYV
     DNSSLTIKKP NELSRVLGLK TLATHGLAAV NSVPWDTIAN YAKPFLNKVV STTTNIVTRC
     LNRVCTNYMP YFFTLLLQLC TFTRSTNSRI KASMPTTIAK NTVKSVGKFC LEASFNYLKS
     PNFSKLINII IWFLLLSVCL GSLIYSTAAL GVLMSNLGMP SYCTGYREGY LNSTNVTIAT
     YCTGSIPCSV CLSGLDSLDT YPSLETIQIT ISSFKWDLTA FGLVAEWFLA YILFTRFFYV
     LGLAAIMQLF FSYFAVHFIS NSWLMWLIIN LVQMAPISAM VRMYIFFASF YYVWKSYVHV
     VDGCNSSTCM MCYKRNRATR VECTTIVNGV RRSFYVYANG GKGFCKLHNW NCVNCDTFCA
     GSTFISDEVA RDLSLQFKRP INPTDQSSYI VDSVTVKNGS IHLYFDKAGQ KTYERHSLSH
     FVNLDNLRAN NTKGSLPINV IVFDGKSKCE ESSAKSASVY YSQLMCQPIL LLDQALVSDV
     GDSAEVAVKM FDAYVNTFSS TFNVPMEKLK TLVATAEAEL AKNVSLDNVL STFISAARQG
     FVDSDVETKD VVECLKLSHQ SDIEVTGDSC NNYMLTYNKV ENMTPRDLGA CIDCSARHIN
     AQVAKSHNIA LIWNVKDFMS LSEQLRKQIR SAAKKNNLPF KLTCATTRQV VNVVTTKIAL
     KGGKIVNNWL KQLIKVTLVF LFVAAIFYLI TPVHVMSKHT DFSSEIIGYK AIDGGVTRDI
     ASTDTCFANK HADFDTWFSQ RGGSYTNDKA CPLIAAVITR EVGFVVPGLP GTILRTTNGD
     FLHFLPRVFS AVGNICYTPS KLIEYTDFAT SACVLAAECT IFKDASGKPV PYCYDTNVLE
     GSVAYESLRP DTRYVLMDGS IIQFPNTYLE GSVRVVTTFD SEYCRHGTCE RSEAGVCVST
     SGRWVLNNDY YRSLPGVFCG VDAVNLLTNM FTPLIQPIGA LDISASIVAG GIVAIVVTCL
     AYYFMRFRRA FGEYSHVVAF NTLLFLMSFT VLCLTPVYSF LPGVYSVIYL YLTFYLTNDV
     SFLAHIQWMV MFTPLVPFWI TIAYIICIST KHFYWFFSNY LKRRVVFNGV SFSTFEEAAL
     CTFLLNKEMY LKLRSDVLLP LTQYNRYLAL YNKYKYFSGA MDTTSYREAA CCHLAKALND
     FSNSGSDVLY QPPQTSITSA VLQSGFRKMA FPSGKVEGCM VQVTCGTTTL NGLWLDDVVY
     CPRHVICTSE DMLNPNYEDL LIRKSNHNFL VQAGNVQLRV IGHSMQNCVL KLKVDTANPK
     TPKYKFVRIQ PGQTFSVLAC YNGSPSGVYQ CAMRPNFTIK GSFLNGSCGS VGFNIDYDCV
     SFCYMHHMEL PTGVHAGTDL EGNFYGPFVD RQTAQAAGTD TTITVNVLAW LYAAVINGDR
     WFLNRFTTTL NDFNLVAMKY NYEPLTQDHV DILGPLSAQT GIAVLDMCAS LKELLQNGMN
     GRTILGSALL EDEFTPFDVV RQCSGVTFQS AVKRTIKGTH HWLLLTILTS LLVLVQSTQW
     SLFFFLYENA FLPFAMGIIA MSAFAMMFVK HKHAFLCLFL LPSLATVAYF NMVYMPASWV
     MRIMTWLDMV DTSLSGFKLK DCVMYASAVV LLILMTARTV YDDGARRVWT LMNVLTLVYK
     VYYGNALDQA ISMWALIISV TSNYSGVVTT VMFLARGIVF MCVEYCPIFF ITGNTLQCIM
     LVYCFLGYFC TCYFGLFCLL NRYFRLTLGV YDYLVSTQEF RYMNSQGLLP PKNSIDAFKL
     NIKLLGVGGK PCIKVATVQS KMSDVKCTSV VLLSVLQQLR VESSSKLWAQ CVQLHNDILL
     AKDTTEAFEK MVSLLSVLLS MQGAVDINKL CEEMLDNRAT LQAIASEFSS LPSYAAFATA
     QEAYEQAVAN GDSEVVLKKL KKSLNVAKSE FDRDAAMQRK LEKMADQAMT QMYKQARSED
     KRAKVTSAMQ TMLFTMLRKL DNDALNNIIN NARDGCVPLN IIPLTTAAKL MVVIPDYNTY
     KNTCDGTTFT YASALWEIQQ VVDADSKIVQ LSEISMDNSP NLAWPLIVTA LRANSAVKLQ
     NNELSPVALR QMSCAAGTTQ TACTDDNALA YYNTTKGGRF VLALLSDLQD LKWARFPKSD
     GTGTIYTELE PPCRFVTDTP KGPKVKYLYF IKGLNNLNRG MVLGSLAATV RLQAGNATEV
     PANSTVLSFC AFAVDAAKAY KDYLASGGQP ITNCVKMLCT HTGTGQAITV TPEANMDQES
     FGGASCCLYC RCHIDHPNPK GFCDLKGKYV QIPTTCANDP VGFTLKNTVC TVCGMWKGYG
     CSCDQLREPM LQSADAQSFL NGFAV
//
ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S1 AND S2 BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor.";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   "A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells.";
RL   Mol. Cell 0:0-0(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   "Site-specific glycan analysis of the SARS-CoV-2 spike.";
RL   Science 0:0-0(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   "Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2.";
RL   Glycobiology 0:0-0(2020).
RN   [6] {ECO:0000244|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   "Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2.";
RL   Science 0:0-0(2020).
RN   [7] {ECO:0000244|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.";
RL   Science 367:1260-1263(2020).
RN   [8] {ECO:0000244|PDB:6VXX, ECO:0000244|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   "Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein.";
RL   Cell 180:1-12(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor.";
RL   Nature 0:0-0(2020).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   "Structural basis of receptor recognition by SARS-CoV-2.";
RL   Nature 0:0-0(2020).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   "A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV.";
RL   Science 0:0-0(2020).
CC   -!- FUNCTION: [Spike protein S1]: attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. Binding to
CC       human ACE2 receptor and internalization of the virus into the endosomes
CC       of the host cell induces conformational changes in the Spike
CC       glycoprotein (PubMed:32142651, PubMed:32075877, PubMed:32155444). Uses
CC       also human TMPRSS2 for priming in human lung cells which is an
CC       essential step for viral entry (PubMed:32142651). Can be alternatively
CC       processed by host furin (PubMed:32362314). Proteolysis by cathepsin
CC       CTSL may unmask the fusion peptide of S2 and activate membranes fusion
CC       within endosomes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32362314}.
CC   -!- FUNCTION: [Spike protein S2]: mediates fusion of the virion and
CC       cellular membranes by acting as a class I viral fusion protein. Under
CC       the current model, the protein has at least three conformational
CC       states: pre-fusion native state, pre-hairpin intermediate state, and
CC       post-fusion hairpin state. During viral and target cell membrane
CC       fusion, the coiled coil regions (heptad repeats) assume a trimer-of-
CC       hairpins structure, positioning the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. The formation of this
CC       structure appears to drive apposition and subsequent fusion of viral
CC       and target cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099}.
CC   -!- FUNCTION: [Spike protein S2']: Acts as a viral fusion peptide which is
CC       unmasked following S2 cleavage occurring upon virus endocytosis.
CC       {ECO:0000255|HAMAP-Rule:MF_04099}.
CC   -!- FUNCTION: [Spike glycoprotein]: May down-regulate host tetherin (BST2)
CC       by lysosomal degradation, thereby counteracting its antiviral activity.
CC       {ECO:0000250|UniProtKB:P59594}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (By similarity). Interacts with ORF3a protein and
CC       ORF7a protein. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32155444,
CC       ECO:0000269|PubMed:32245784}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2.
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32225175,
CC       ECO:0000269|PubMed:32225176}.
CC   -!- INTERACTION:
CC       P0DTC2; P0DTC2: S; NbExp=4; IntAct=EBI-25474821, EBI-25474821;
CC       P0DTC2; Q9BYF1: ACE2; Xeno; NbExp=23; IntAct=EBI-25474821, EBI-7730807;
CC       P0DTC2; P35613: BSG; Xeno; NbExp=5; IntAct=EBI-25474821, EBI-750709;
CC   -!- SUBCELLULAR LOCATION: Virion membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04099}; Single-pass type I membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_04099}. Host endoplasmic reticulum-Golgi intermediate
CC       compartment membrane {ECO:0000255|HAMAP-Rule:MF_04099}; Single-pass
CC       type I membrane protein {ECO:0000255|HAMAP-Rule:MF_04099}. Host cell
CC       membrane {ECO:0000255|HAMAP-Rule:MF_04099}; Single-pass type I membrane
CC       protein {ECO:0000255|HAMAP-Rule:MF_04099}. Note=Accumulates in the
CC       endoplasmic reticulum-Golgi intermediate compartment, where it
CC       participates in virus particle assembly. Colocalizes with S in the host
CC       endoplasmic reticulum-Golgi intermediate compartment. Some S oligomers
CC       are transported to the host plasma membrane, where they may mediate
CC       cell-cell fusion. {ECO:0000255|HAMAP-Rule:MF_04099}.
CC   -!- DOMAIN: The KxHxx motif seems to function as an ER retrieval and binds
CC       COPI in vitro. {ECO:0000250|UniProtKB:P59594}.
CC   -!- DOMAIN: Fusion peptide 1 (FP1) and fusion peptide 2 (FP2) function
CC       cooperatively and have a membrane-ordering effect on lipid headgroups
CC       and shallow hydrophobic regions of target bilayers. They are considered
CC       as two domains of an extended, bipartite FP. The membrane-ordering
CC       activity is calcium-dependent and also dependent on correct folding,
CC       which is maintained by an internal disulfide bond in FP2.
CC       {ECO:0000255|HAMAP-Rule:MF_04099}.
CC   -!- PTM: The cytoplasmic Cys-rich domain is palmitoylated. Spike
CC       glycoprotein is digested within host endosomes. {ECO:0000255|HAMAP-
CC       Rule:MF_04099}.
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins. The
CC       precursor is processed into S1 and S2 by host cell furin or another
CC       cellular protease to yield the mature S1 and S2 proteins
CC       (PubMed:32155444). Additionally, a second cleavage leads to the release
CC       of a fusion peptide after viral attachment to host cell receptor (By
CC       similarity). The presence of a furin polybasic cleavage site sets SARS-
CC       CoV-2 S apart from SARS-CoV S that possesses a monobasic S1/S2 cleavage
CC       site processed upon entry of target cells (PubMed:32155444,
CC       PubMed:32362314). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32362314}.
CC   -!- PTM: Highly decorated by heterogeneous N-linked glycans protruding from
CC       the trimer surface (PubMed:32075877, PubMed:32155444). Highly
CC       glycosylated by host both on S1 and S2 subunits, occluding many regions
CC       across the surface of the protein. This may shield viral epitopes from
CC       acquired immune response (PubMed:32366695, PubMed:32363391).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32155444,
CC       ECO:0000269|PubMed:32363391, ECO:0000269|PubMed:32366695}.
CC   -!- SIMILARITY: Belongs to the betacoronaviruses spike protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04099}.
CC   -!- CAUTION: Asn-17, Asn-603, Asn-1134, Asn-1158, and Asn-1173 are non
CC       glycosylated when S1 or S2 are expressed individually in HEK293 cells.
CC       {ECO:0000269|PubMed:32363391}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43416.1; -; Genomic_RNA.
DR   RefSeq; YP_009724390.1; NC_045512.2.
DR   PDB; 6LVN; X-ray; 2.47 A; A/B/C/D=1168-1203.
DR   PDB; 6LXT; X-ray; 2.90 A; A/B/C/D/E/F=910-988, A/B/C/D/E/F=1162-1206.
DR   PDB; 6LZG; X-ray; 2.50 A; B=319-527.
DR   PDB; 6M0J; X-ray; 2.45 A; E=319-541.
DR   PDB; 6M17; EM; 2.90 A; E/F=319-541.
DR   PDB; 6VSB; EM; 3.46 A; A/B/C=1-1208.
DR   PDB; 6VW1; X-ray; 2.68 A; E/F=455-518.
DR   PDB; 6VXX; EM; 2.80 A; A/B/C=14-1211.
DR   PDB; 6VYB; EM; 3.20 A; A/B/C=14-1211.
DR   PDB; 6W41; X-ray; 3.08 A; C=319-541.
DR   PDB; 6YLA; X-ray; 2.42 A; A/E=330-532.
DR   PDB; 6YM0; X-ray; 4.36 A; E=330-532.
DR   PDB; 6YOR; EM; 3.30 A; A/E=330-532.
DR   PDB; 7BZ5; X-ray; 1.84 A; A=319-541.
DR   PDBsum; 6LVN; -.
DR   PDBsum; 6LXT; -.
DR   PDBsum; 6LZG; -.
DR   PDBsum; 6M0J; -.
DR   PDBsum; 6M17; -.
DR   PDBsum; 6VSB; -.
DR   PDBsum; 6VW1; -.
DR   PDBsum; 6VXX; -.
DR   PDBsum; 6VYB; -.
DR   PDBsum; 6W41; -.
DR   PDBsum; 6YLA; -.
DR   PDBsum; 6YM0; -.
DR   PDBsum; 6YOR; -.
DR   PDBsum; 7BZ5; -.
DR   SMR; P0DTC2; -.
DR   BioGRID; 4383848; 7.
DR   ComplexPortal; CPX-5682; SARS-CoV-2 Spike protein complex.
DR   IntAct; P0DTC2; 20.
DR   GlyConnect; 2838; 256 N-Linked glycans (24 sites), 5 O-Linked glycans (3 sites).
DR   GlyConnect; 2839; 38 N-Linked glycans (20 sites).
DR   GlyConnect; 2840; 109 N-Linked glycans (22 sites).
DR   GlyGen; P0DTC2; 24 sites, 172 N-linked glycans (22 sites), 4 O-linked glycans (2 sites).
DR   ABCD; P0DTC2; 65 sequenced antibodies.
DR   GeneID; 43740568; -.
DR   SIGNOR; P0DTC2; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044173; C:host cell endoplasmic reticulum-Golgi intermediate compartment membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046789; F:host cell surface receptor binding; IDA:UniProtKB.
DR   GO; GO:0039654; P:fusion of virus membrane with host endosome membrane; IEA:UniProtKB-KW.
DR   GO; GO:0009405; P:pathogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0046813; P:receptor-mediated virion attachment to host cell; IEA:InterPro.
DR   GO; GO:0046718; P:viral entry into host cell; IDA:UniProtKB.
DR   Gene3D; 1.20.5.790; -; 1.
DR   HAMAP; MF_04099; BETA_CORONA_SPIKE; 1.
DR   InterPro; IPR043473; S2_sf_CoV.
DR   InterPro; IPR027400; S_HR2_CoV.
DR   InterPro; IPR018548; Spike_rcpt-bd_bCoV.
DR   InterPro; IPR036326; Spike_rcpt-bd_sf_CoV.
DR   InterPro; IPR002552; Spike_S2_CoV.
DR   Pfam; PF01601; Corona_S2; 1.
DR   Pfam; PF09408; Spike_rec_bind; 1.
DR   SUPFAM; SSF111474; SSF111474; 2.
DR   SUPFAM; SSF143587; SSF143587; 1.
DR   PROSITE; PS51921; BCOV_S1_CTD; 1.
DR   PROSITE; PS51922; BCOV_S1_NTD; 1.
DR   PROSITE; PS51923; COV_S2_HR1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Disulfide bond;
KW   Fusion of virus membrane with host endosomal membrane;
KW   Fusion of virus membrane with host membrane; Glycoprotein;
KW   Host cell membrane; Host membrane; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host tetherin by virus; Lipoprotein; Membrane; Palmitate;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Viral attachment to host cell; Viral envelope protein; Viral immunoevasion;
KW   Viral penetration into host cytoplasm; Virion; Virulence;
KW   Virus entry into host cell.
FT   SIGNAL          1..12
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CHAIN           13..1273
FT                   /note="Spike glycoprotein"
FT                   /id="PRO_0000449646"
FT   CHAIN           13..685
FT                   /note="Spike protein S1"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT                   /id="PRO_0000449647"
FT   CHAIN           686..1273
FT                   /note="Spike protein S2"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT                   /id="PRO_0000449648"
FT   CHAIN           816..1273
FT                   /note="Spike protein S2'"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT                   /id="PRO_0000449649"
FT   TOPO_DOM        13..1213
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   TRANSMEM        1214..1234
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   TOPO_DOM        1235..1273
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   DOMAIN          13..303
FT                   /note="BetaCoV S1-NTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01270"
FT   DOMAIN          334..527
FT                   /note="BetaCoV S1-CTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01269,
FT                   ECO:0000269|PubMed:32132184"
FT   REGION          319..541
FT                   /note="Receptor-binding domain (RBD)"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32132184"
FT   REGION          437..508
FT                   /note="Receptor-binding motif; binding to human ACE2"
FT                   /evidence="ECO:0000250|UniProtKB:P59594"
FT   REGION          816..837
FT                   /note="Fusion peptide 1"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   REGION          835..855
FT                   /note="Fusion peptide 2"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   REGION          920..970
FT                   /note="Heptad repeat 1"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   REGION          1163..1202
FT                   /note="Heptad repeat 2"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   COILED          949..993
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   COILED          1176..1203
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   MOTIF           1269..1273
FT                   /note="KxHxx"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   SITE            685..686
FT                   /note="Cleavage; by TMPRSS2 or furin"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32142651, ECO:0000269|PubMed:32362314"
FT   SITE            815..816
FT                   /note="Cleavage; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        17
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        61
FT                   /note="N-linked (GlcNAc...) (hybrid) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        74
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32363391, ECO:0000269|PubMed:32366695"
FT   CARBOHYD        122
FT                   /note="N-linked (GlcNAc...) (hybrid) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        149
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32363391, ECO:0000269|PubMed:32366695"
FT   CARBOHYD        165
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        234
FT                   /note="N-linked (GlcNAc...) (high mannose) asparagine; by
FT                   host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        282
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        323
FT                   /note="O-linked (GalNAc) threonine; by host"
FT                   /evidence="ECO:0000269|PubMed:32363391"
FT   CARBOHYD        325
FT                   /note="O-linked (HexNAc...) serine; by host"
FT                   /evidence="ECO:0000269|PubMed:32363391"
FT   CARBOHYD        331
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        343
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        603
FT                   /note="N-linked (GlcNAc...) (hybrid) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32366695"
FT   CARBOHYD        616
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        657
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        709
FT                   /note="N-linked (GlcNAc...) (high mannose) asparagine; by
FT                   host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        717
FT                   /note="N-linked (GlcNAc...) (hybrid) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        801
FT                   /note="N-linked (GlcNAc...) (hybrid) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        1074
FT                   /note="N-linked (GlcNAc...) (hybrid) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        1098
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32363391,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        1134
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32366695"
FT   CARBOHYD        1158
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        1173
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32366695"
FT   CARBOHYD        1194
FT                   /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:32363391, ECO:0000269|PubMed:32366695"
FT   DISULFID        15..136
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01270"
FT   DISULFID        131..166
FT                   /evidence="ECO:0000244|PDB:6VXX, ECO:0000255|PROSITE-
FT                   ProRule:PRU01270, ECO:0000269|PubMed:32155444"
FT   DISULFID        291..301
FT                   /evidence="ECO:0000244|PDB:6VXX, ECO:0000255|PROSITE-
FT                   ProRule:PRU01270, ECO:0000269|PubMed:32155444"
FT   DISULFID        336..361
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01269,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784"
FT   DISULFID        379..432
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01269,
FT                   ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784"
FT   DISULFID        391..525
FT                   /evidence="ECO:0000244|PDB:6VXX, ECO:0000255|PROSITE-
FT                   ProRule:PRU01269, ECO:0000269|PubMed:32155444,
FT                   ECO:0000269|PubMed:32225175, ECO:0000269|PubMed:32225176,
FT                   ECO:0000269|PubMed:32245784"
FT   DISULFID        480..488
FT                   /evidence="ECO:0000269|PubMed:32245784"
FT   DISULFID        538..590
FT                   /evidence="ECO:0000244|PDB:6VXX,
FT                   ECO:0000269|PubMed:32155444"
FT   DISULFID        617..649
FT                   /evidence="ECO:0000244|PDB:6VXX,
FT                   ECO:0000269|PubMed:32155444"
FT   DISULFID        662..671
FT                   /evidence="ECO:0000244|PDB:6VXX,
FT                   ECO:0000269|PubMed:32155444"
FT   DISULFID        738..760
FT                   /evidence="ECO:0000244|PDB:6VXX,
FT                   ECO:0000269|PubMed:32155444"
FT   DISULFID        743..749
FT                   /evidence="ECO:0000244|PDB:6VXX,
FT                   ECO:0000269|PubMed:32155444"
FT   DISULFID        840..851
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   DISULFID        1032..1043
FT                   /evidence="ECO:0000244|PDB:6VXX,
FT                   ECO:0000269|PubMed:32155444"
FT   DISULFID        1082..1126
FT                   /evidence="ECO:0000244|PDB:6VXX,
FT                   ECO:0000269|PubMed:32155444"
FT   MUTAGEN         493
FT                   /note="Q->N: Reduced host ACE2-binding affinity in vitro."
FT                   /evidence="ECO:0000269|PubMed:32225175"
FT   MUTAGEN         493
FT                   /note="Q->Y: Reduced host ACE2-binding affinity in vitro."
FT                   /evidence="ECO:0000269|PubMed:32225175"
FT   MUTAGEN         501
FT                   /note="N->T: Reduced host ACE2-binding affinity in vitro."
FT                   /evidence="ECO:0000269|PubMed:32225175"
FT   MUTAGEN         679..684
FT                   /note="NSPRRA->IL: About 50% stronger entry efficiency in
FT                   Vero E6 cells while 30% weaker entry efficiency in
FT                   hACE2-expressing BHK cells."
FT                   /evidence="ECO:0000269|PubMed:32155444"
FT   MUTAGEN         681..684
FT                   /note="PRRA->RRRK: Optimized cleavage by host furin."
FT                   /evidence="ECO:0000269|PubMed:32362314"
FT   MUTAGEN         682..684
FT                   /note="Missing: Complete loss of cleavage by host furin."
FT                   /evidence="ECO:0000269|PubMed:32362314"
FT   STRAND          28..30
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          39..43
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          46..55
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          61..65
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          83..85
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          90..98
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          101..109
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          111..114
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          117..122
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          125..129
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          169..171
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          188..197
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          200..209
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          213..215
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          223..229
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          237..244
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          265..269
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          271..279
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          285..290
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           295..302
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          310..319
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          324..328
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          333..335
FT                   /evidence="ECO:0000244|PDB:6YLA"
FT   HELIX           338..342
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   HELIX           350..352
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   STRAND          354..358
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   STRAND          360..362
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   HELIX           366..369
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   STRAND          375..382
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   HELIX           384..386
FT                   /evidence="ECO:0000244|PDB:6YLA"
FT   TURN            387..389
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          391..403
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   HELIX           404..409
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   STRAND          411..413
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   HELIX           417..421
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   STRAND          431..437
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   HELIX           439..442
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   TURN            445..447
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   STRAND          452..454
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   STRAND          476..478
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   STRAND          491..494
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   HELIX           503..505
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   STRAND          506..516
FT                   /evidence="ECO:0000244|PDB:7BZ5"
FT   STRAND          518..520
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          536..543
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          546..554
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          565..567
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          573..577
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          579..581
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          584..588
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          592..599
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   TURN            602..604
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          609..613
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   TURN            617..619
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          642..645
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          648..652
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          663..667
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          670..675
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          691..696
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          700..702
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          711..728
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          733..736
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           738..742
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           747..753
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           754..759
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           761..782
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          786..788
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   TURN            803..805
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          811..813
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           817..823
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          856..861
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           867..884
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           887..890
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           898..907
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   TURN            908..910
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           914..918
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           920..940
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           942..945
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           946..964
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           965..967
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           977..981
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           986..1032
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   TURN            1040..1043
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          1044..1056
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          1059..1079
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          1081..1100
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          1102..1105
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   TURN            1117..1119
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   STRAND          1120..1125
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   TURN            1126..1128
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           1142..1146
FT                   /evidence="ECO:0000244|PDB:6VXX"
FT   HELIX           1170..1201
FT                   /evidence="ECO:0000244|PDB:6LVN"
SQ   SEQUENCE   1273 AA;  141178 MW;  B17BE6D9F1C4EA34 CRC64;
     MFVFLVLLPL VSSQCVNLTT RTQLPPAYTN SFTRGVYYPD KVFRSSVLHS TQDLFLPFFS
     NVTWFHAIHV SGTNGTKRFD NPVLPFNDGV YFASTEKSNI IRGWIFGTTL DSKTQSLLIV
     NNATNVVIKV CEFQFCNDPF LGVYYHKNNK SWMESEFRVY SSANNCTFEY VSQPFLMDLE
     GKQGNFKNLR EFVFKNIDGY FKIYSKHTPI NLVRDLPQGF SALEPLVDLP IGINITRFQT
     LLALHRSYLT PGDSSSGWTA GAAAYYVGYL QPRTFLLKYN ENGTITDAVD CALDPLSETK
     CTLKSFTVEK GIYQTSNFRV QPTESIVRFP NITNLCPFGE VFNATRFASV YAWNRKRISN
     CVADYSVLYN SASFSTFKCY GVSPTKLNDL CFTNVYADSF VIRGDEVRQI APGQTGKIAD
     YNYKLPDDFT GCVIAWNSNN LDSKVGGNYN YLYRLFRKSN LKPFERDIST EIYQAGSTPC
     NGVEGFNCYF PLQSYGFQPT NGVGYQPYRV VVLSFELLHA PATVCGPKKS TNLVKNKCVN
     FNFNGLTGTG VLTESNKKFL PFQQFGRDIA DTTDAVRDPQ TLEILDITPC SFGGVSVITP
     GTNTSNQVAV LYQDVNCTEV PVAIHADQLT PTWRVYSTGS NVFQTRAGCL IGAEHVNNSY
     ECDIPIGAGI CASYQTQTNS PRRARSVASQ SIIAYTMSLG AENSVAYSNN SIAIPTNFTI
     SVTTEILPVS MTKTSVDCTM YICGDSTECS NLLLQYGSFC TQLNRALTGI AVEQDKNTQE
     VFAQVKQIYK TPPIKDFGGF NFSQILPDPS KPSKRSFIED LLFNKVTLAD AGFIKQYGDC
     LGDIAARDLI CAQKFNGLTV LPPLLTDEMI AQYTSALLAG TITSGWTFGA GAALQIPFAM
     QMAYRFNGIG VTQNVLYENQ KLIANQFNSA IGKIQDSLSS TASALGKLQD VVNQNAQALN
     TLVKQLSSNF GAISSVLNDI LSRLDKVEAE VQIDRLITGR LQSLQTYVTQ QLIRAAEIRA
     SANLAATKMS ECVLGQSKRV DFCGKGYHLM SFPQSAPHGV VFLHVTYVPA QEKNFTTAPA
     ICHDGKAHFP REGVFVSNGT HWFVTQRNFY EPQIITTDNT FVSGNCDVVI GIVNNTVYDP
     LQPELDSFKE ELDKYFKNHT SPDVDLGDIS GINASVVNIQ KEIDRLNEVA KNLNESLIDL
     QELGKYEQYI KWPWYIWLGF IAGLIAIVMV TIMLCCMTSC CSCLKGCCSC GSCCKFDEDD
     SEPVLKGVKL HYT
//
ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE              EC=3.4.19.12;
DE              EC=3.4.22.-;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Proofreading exoribonuclease;
DE              Short=ExoN;
DE              EC=3.1.13.-;
DE     AltName: Full=Guanine-N7 methyltransferase;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease;
DE              EC=3.1.-.-;
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase;
DE              EC=2.1.1.-;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
RN   [2]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE AND IN COMPLEX
RP   WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   "The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3.";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE APOENZYME AND
RP   IN COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE
RP   PROTEINASE), FUNCTION (3C-LIKE PROTEINASE), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE), ACTIVE SITE (3C-LIKE PROTEINASE), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   "Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors.";
RL   Science 0:0-0(2020).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE APOENZYME AND
RP   IN COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE
RP   PROTEINASE) (3C-LIKE PROTEINASE), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE),
RP   AND ACTIVITY REGULATION (3C-LIKE PROTEINASE).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   "Structure of Mpro from COVID-19 virus and discovery of its inhibitors.";
RL   Nature 0:0-0(2020).
RN   [5]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   "Structure of the RNA-dependent RNA polymerase from COVID-19 virus.";
RL   Science 0:0-0(2020).
RN   [6]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE), AND ACTIVITY
RP   REGULATION (RNA-DIRECTED RNA POLYMERASE).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   "Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir.";
RL   Science 0:0-0(2020).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE APOENZYME IN
RP   COMPLEX WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE), AND ACTIVITY REGULATION (3C-LIKE
RP   PROTEINASE).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   "Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease.";
RL   Science 0:0-0(2020).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2. Indeed, these two proteins play a role in maintaining the
CC       functional integrity of the mitochondria and protecting cells from
CC       various stresses. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates. Participates together with nsp4 in the assembly of virally-
CC       induced cytoplasmic double-membrane vesicles necessary for viral
CC       replication. Antagonizes innate immune induction of type I interferon
CC       by blocking the phosphorylation, dimerization and subsequent nuclear
CC       translocation of host IRF3. Prevents also host NF-kappa-B signaling.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 4]: Participates in the assembly of
CC       virally-induced cytoplasmic double-membrane vesicles necessary for
CC       viral replication. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [3C-like proteinase]: Cleaves the C-terminus of replicase
CC       polyprotein at 11 sites (PubMed:32321856). Recognizes substrates
CC       containing the core sequence [ILMVF]-Q-|-[SGACN] (PubMed:32198291,
CC       PubMed:32272481). Also able to bind an ADP-ribose-1''-phosphate (ADRP)
CC       (By similarity) (PubMed:32198291, PubMed:32272481).
CC       {ECO:0000250|UniProtKB:P0C6X7, ECO:0000269|PubMed:32198291,
CC       ECO:0000269|PubMed:32272481, ECO:0000269|PubMed:32321856}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in the initial
CC       induction of autophagosomes from host reticulum endoplasmic. Later,
CC       limits the expansion of these phagosomes that are no longer able to
CC       deliver viral components to lysosomes. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 7]: Plays a role in viral RNA
CC       synthesis (PubMed:32358203, PubMed:32277040). Forms a hexadecamer with
CC       nsp8 (8 subunits of each) that may participate in viral replication by
CC       acting as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers (By similarity).
CC       {ECO:0000250|UniProtKB:P0C6X7, ECO:0000269|PubMed:32277040,
CC       ECO:0000269|PubMed:32358203}.
CC   -!- FUNCTION: [Non-structural protein 8]: Plays a role in viral RNA
CC       synthesis (PubMed:32358203, PubMed:32277040). Forms a hexadecamer with
CC       nsp8 (8 subunits of each) that may participate in viral replication by
CC       acting as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers (By similarity).
CC       {ECO:0000250|UniProtKB:P0C6X7, ECO:0000269|PubMed:32277040,
CC       ECO:0000269|PubMed:32358203}.
CC   -!- FUNCTION: [Non-structural protein 9]: May participate in viral
CC       replication by acting as a ssRNA-binding protein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [RNA-directed RNA polymerase]: Responsible for replication
CC       and transcription of the viral RNA genome.
CC       {ECO:0000305|PubMed:32277040, ECO:0000305|PubMed:32358203}.
CC   -!- FUNCTION: [Helicase]: Multi-functional protein with a zinc-binding
CC       domain in N-terminus displaying RNA and DNA duplex-unwinding activities
CC       with 5' to 3' polarity. Activity of helicase is dependent on magnesium.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Proofreading exoribonuclease]: Enzyme possessing two
CC       different activities: an exoribonuclease activity acting on both ssRNA
CC       and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase
CC       activity. Acts as a proofreading exoribonuclease for RNA replication,
CC       thereby lowering The sensitivity of the virus to RNA mutagens.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Uridylate-specific endoribonuclease]: Mn(2+)-dependent,
CC       uridylate-specific enzyme, which leaves 2'-3'-cyclic phosphates 5' to
CC       the cleaved bond. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [2'-O-methyltransferase]: Methyltransferase that mediates
CC       mRNA cap 2'-O-ribose methylation to the 5'-cap structure of viral
CC       mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16.
CC       Therefore plays an essential role in viral mRNAs cap methylation which
CC       is essential to evade immune system. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a ribonucleoside 5'-triphosphate + RNA(n) = diphosphate +
CC         RNA(n+1); Xref=Rhea:RHEA:21248, Rhea:RHEA-COMP:11128, Rhea:RHEA-
CC         COMP:11129, ChEBI:CHEBI:33019, ChEBI:CHEBI:61557, ChEBI:CHEBI:83400;
CC         EC=2.7.7.48; Evidence={ECO:0000269|PubMed:32358203};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.12;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=TSAVLQ-|-SGFRK-NH(2) and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481,
CC         ECO:0000269|PubMed:32321856};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- ACTIVITY REGULATION: [Proofreading exoribonuclease]: Inhibited by
CC       Remdesivir antiviral drug (GS-5734). {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- ACTIVITY REGULATION: [RNA-directed RNA polymerase]: Inhibited by
CC       Remdesivir antiviral drug (GS-5734) through non-obligate RNA chain
CC       termination. {ECO:0000269|PubMed:32358203}.
CC   -!- ACTIVITY REGULATION: [3C-like proteinase]: Inhibited by pyridone-
CC       containing alpha-ketoamides compounds 13a and 13b. In turn, alpha-
CC       ketoamide 13b (tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-
CC       ((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-
CC       2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate) inhibits SARS-CoV-2
CC       replication in human lung cells (PubMed:32198291). Inhibited ex vivo by
CC       michael acceptor inhibitor N3 (PubMed:32272481). Inhibited ex vivo by
CC       compound 11a and 11b (PubMed:32321856). {ECO:0000269|PubMed:32198291,
CC       ECO:0000269|PubMed:32272481, ECO:0000269|PubMed:32321856}.
CC   -!- SUBUNIT: [Non-structural protein 2]: Interacts with host PHB and PHB2.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [3C-like proteinase]: 3CL-PRO exists as monomer and homodimer.
CC       Only the homodimer shows catalytic activity.
CC       {ECO:0000269|PubMed:32198291}.
CC   -!- SUBUNIT: [Non-structural protein 4]: Interacts with PL-PRO and nsp6.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 7]: Eight copies of nsp7 and eight
CC       copies of nsp8 assemble to form a heterohexadecamer dsRNA-encircling
CC       ring structure (By similarity). Interacts with RNA-directed RNA
CC       polymerase (PubMed:32277040, PubMed:32358203).
CC       {ECO:0000250|UniProtKB:P0C6X7, ECO:0000269|PubMed:32277040,
CC       ECO:0000269|PubMed:32358203}.
CC   -!- SUBUNIT: [Non-structural protein 8]: Eight copies of nsp7 and eight
CC       copies of nsp8 assemble to form a heterohexadecamer dsRNA-encircling
CC       ring structure (By similarity). Interacts with RNA-directed RNA
CC       polymerase (PubMed:32277040, PubMed:32358203).
CC       {ECO:0000250|UniProtKB:P0C6X7, ECO:0000269|PubMed:32277040,
CC       ECO:0000269|PubMed:32358203}.
CC   -!- SUBUNIT: [Non-structural protein 9]: Is a dimer.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 10]: Forms a dodecamer and interacts
CC       with nsp14 and nsp16; these interactions enhance nsp14 and nsp16
CC       enzymatic activities. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [RNA-directed RNA polymerase]: Interacts with nsp7 and nsp8.
CC       {ECO:0000269|PubMed:32277040, ECO:0000269|PubMed:32358203}.
CC   -!- SUBUNIT: [Proofreading exoribonuclease]: Interacts (via N-terminus)
CC       with DDX1. Interacts with nsp10. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [2'-O-methyltransferase]: Interacts with nsp10.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- INTERACTION:
CC       PRO_0000449625; PRO_0000449626 [P0DTD1]: rep; NbExp=3; IntAct=EBI-25475871, EBI-25475874;
CC       PRO_0000449629; PRO_0000449626 [P0DTD1]: rep; NbExp=2; IntAct=EBI-25475885, EBI-25475874;
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 3]: Host membrane
CC       {ECO:0000250|UniProtKB:P0C6X7}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P0C6X7}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 4]: Host membrane
CC       {ECO:0000250|UniProtKB:P0C6X7}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P0C6X7}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P0C6X7}. Note=Localizes in virally-induced
CC       cytoplasmic double-membrane vesicles. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 6]: Host membrane
CC       {ECO:0000250|UniProtKB:P0C6X7}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 7]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250|UniProtKB:P0C6X9}. Note=nsp7, nsp8,
CC       nsp9 and nsp10 are localized in cytoplasmic foci, largely perinuclear.
CC       Late in infection, they merge into confluent complexes.
CC       {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 8]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250|UniProtKB:P0C6X9}. Note=nsp7, nsp8,
CC       nsp9 and nsp10 are localized in cytoplasmic foci, largely perinuclear.
CC       Late in infection, they merge into confluent complexes.
CC       {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 9]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250|UniProtKB:P0C6X9}. Note=nsp7, nsp8,
CC       nsp9 and nsp10 are localized in cytoplasmic foci, largely perinuclear.
CC       Late in infection, they merge into confluent complexes.
CC       {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 10]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250|UniProtKB:P0C6X9}. Note=nsp7, nsp8,
CC       nsp9 and nsp10 are localized in cytoplasmic foci, largely perinuclear.
CC       Late in infection, they merge into confluent complexes.
CC       {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- SUBCELLULAR LOCATION: [Helicase]: Host endoplasmic reticulum-Golgi
CC       intermediate compartment {ECO:0000250|UniProtKB:P0C6X7}. Note=The
CC       helicase interacts with the N protein in membranous complexes and
CC       colocalizes with sites of synthesis of new viral RNA.
CC       {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- SUBCELLULAR LOCATION: [Uridylate-specific endoribonuclease]: Host
CC       cytoplasm, host perinuclear region {ECO:0000250|UniProtKB:P0C6X9}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC         Comment=Normal translation results in Replicase polyprotein 1a.
CC         Ribosomal frameshifting at the end of this protein occurs at low
CC         frequency and produces Replicase polyprotein 1ab.;
CC       Name=Replicase polyprotein 1ab;
CC         IsoId=P0DTD1-1; Sequence=Displayed;
CC       Name=Replicase polyprotein 1a;
CC         IsoId=P0DTC1-1; Sequence=External;
CC   -!- DOMAIN: The hydrophobic domains (HD) could mediate the membrane
CC       association of the replication complex and thereby alter the
CC       architecture of the host cell membrane. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- PTM: Specific enzymatic cleavages in vivo by its own proteases yield
CC       mature proteins. 3CL-PRO and PL-PRO proteinases are autocatalytically
CC       processed. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- MISCELLANEOUS: [Replicase polyprotein 1ab]: Produced by -1 ribosomal
CC       frameshifting at the 1a-1b genes boundary.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SIMILARITY: Belongs to the coronaviruses polyprotein 1ab family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43415.1; -; Genomic_RNA.
DR   RefSeq; YP_009724389.1; NC_045512.2.
DR   PDB; 5R7Y; X-ray; 1.65 A; A=3264-3569.
DR   PDB; 5R7Z; X-ray; 1.59 A; A=3264-3569.
DR   PDB; 5R80; X-ray; 1.93 A; A=3264-3569.
DR   PDB; 5R81; X-ray; 1.95 A; A=3264-3569.
DR   PDB; 5R82; X-ray; 1.31 A; A=3264-3569.
DR   PDB; 5R83; X-ray; 1.58 A; A=3264-3569.
DR   PDB; 5R84; X-ray; 1.83 A; A=3264-3569.
DR   PDB; 5R8T; X-ray; 1.27 A; A=3264-3569.
DR   PDB; 5RE4; X-ray; 1.88 A; A=3264-3569.
DR   PDB; 5RE5; X-ray; 2.07 A; A=3264-3569.
DR   PDB; 5RE6; X-ray; 1.87 A; A=3264-3569.
DR   PDB; 5RE7; X-ray; 1.79 A; A=3264-3569.
DR   PDB; 5RE8; X-ray; 1.81 A; A=3264-3569.
DR   PDB; 5RE9; X-ray; 1.72 A; A=3264-3569.
DR   PDB; 5REA; X-ray; 1.63 A; A=3264-3569.
DR   PDB; 5REB; X-ray; 1.68 A; A=3264-3569.
DR   PDB; 5REC; X-ray; 1.73 A; A=3264-3569.
DR   PDB; 5RED; X-ray; 1.47 A; A=3264-3569.
DR   PDB; 5REE; X-ray; 1.77 A; A=3264-3569.
DR   PDB; 5REF; X-ray; 1.61 A; A=3264-3569.
DR   PDB; 5REG; X-ray; 1.67 A; A=3264-3569.
DR   PDB; 5REH; X-ray; 1.80 A; A=3264-3569.
DR   PDB; 5REI; X-ray; 1.82 A; A=3264-3569.
DR   PDB; 5REJ; X-ray; 1.72 A; A=3264-3569.
DR   PDB; 5REK; X-ray; 1.74 A; A=3264-3569.
DR   PDB; 5REL; X-ray; 1.62 A; A=3264-3569.
DR   PDB; 5REM; X-ray; 1.96 A; A=3264-3569.
DR   PDB; 5REN; X-ray; 2.15 A; A=3264-3569.
DR   PDB; 5REO; X-ray; 1.88 A; A=3264-3569.
DR   PDB; 5REP; X-ray; 1.81 A; A=3264-3569.
DR   PDB; 5RER; X-ray; 1.88 A; A=3264-3569.
DR   PDB; 5RES; X-ray; 1.65 A; A=3264-3569.
DR   PDB; 5RET; X-ray; 1.68 A; A=3264-3569.
DR   PDB; 5REU; X-ray; 1.69 A; A=3264-3569.
DR   PDB; 5REV; X-ray; 1.60 A; A=3264-3569.
DR   PDB; 5REW; X-ray; 1.55 A; A=3264-3569.
DR   PDB; 5REX; X-ray; 2.07 A; A=3264-3569.
DR   PDB; 5REY; X-ray; 1.96 A; A=3264-3569.
DR   PDB; 5REZ; X-ray; 1.79 A; A=3264-3569.
DR   PDB; 5RF0; X-ray; 1.65 A; A=3264-3569.
DR   PDB; 5RF1; X-ray; 1.73 A; A=3264-3569.
DR   PDB; 5RF2; X-ray; 1.53 A; A=3264-3569.
DR   PDB; 5RF3; X-ray; 1.50 A; A=3264-3569.
DR   PDB; 5RF4; X-ray; 1.61 A; A=3264-3569.
DR   PDB; 5RF5; X-ray; 1.74 A; A=3264-3569.
DR   PDB; 5RF6; X-ray; 1.45 A; A=3264-3569.
DR   PDB; 5RF7; X-ray; 1.54 A; A=3264-3569.
DR   PDB; 5RF8; X-ray; 1.44 A; A=3264-3569.
DR   PDB; 5RF9; X-ray; 1.43 A; A=3264-3569.
DR   PDB; 5RFA; X-ray; 1.52 A; A=3264-3569.
DR   PDB; 5RFB; X-ray; 1.48 A; A=3264-3569.
DR   PDB; 5RFC; X-ray; 1.40 A; A=3264-3569.
DR   PDB; 5RFD; X-ray; 1.41 A; A=3264-3569.
DR   PDB; 5RFE; X-ray; 1.46 A; A=3264-3569.
DR   PDB; 5RFF; X-ray; 1.78 A; A=3264-3569.
DR   PDB; 5RFG; X-ray; 2.32 A; A=3264-3569.
DR   PDB; 5RFH; X-ray; 1.58 A; A=3264-3569.
DR   PDB; 5RFI; X-ray; 1.69 A; A=3264-3569.
DR   PDB; 5RFJ; X-ray; 1.80 A; A=3264-3569.
DR   PDB; 5RFK; X-ray; 1.75 A; A=3264-3569.
DR   PDB; 5RFL; X-ray; 1.64 A; A=3264-3569.
DR   PDB; 5RFM; X-ray; 2.06 A; A=3264-3569.
DR   PDB; 5RFN; X-ray; 1.80 A; A=3264-3569.
DR   PDB; 5RFO; X-ray; 1.83 A; A=3264-3569.
DR   PDB; 5RFP; X-ray; 2.03 A; A=3264-3569.
DR   PDB; 5RFQ; X-ray; 1.76 A; A=3264-3569.
DR   PDB; 5RFR; X-ray; 1.71 A; A=3264-3569.
DR   PDB; 5RFS; X-ray; 1.70 A; A=3264-3569.
DR   PDB; 5RFT; X-ray; 1.58 A; A=3264-3569.
DR   PDB; 5RFU; X-ray; 1.53 A; A=3264-3569.
DR   PDB; 5RFV; X-ray; 1.48 A; A=3264-3569.
DR   PDB; 5RFW; X-ray; 1.43 A; A=3264-3569.
DR   PDB; 5RFX; X-ray; 1.55 A; A=3264-3569.
DR   PDB; 5RFY; X-ray; 1.90 A; A=3264-3569.
DR   PDB; 5RFZ; X-ray; 1.68 A; A=3264-3569.
DR   PDB; 5RG0; X-ray; 1.72 A; A=3264-3569.
DR   PDB; 5RG1; X-ray; 1.65 A; A=3264-3569.
DR   PDB; 5RG2; X-ray; 1.63 A; A=3264-3569.
DR   PDB; 5RG3; X-ray; 1.58 A; A=3264-3569.
DR   PDB; 5RGG; X-ray; 2.26 A; A=3264-3569.
DR   PDB; 5RGH; X-ray; 1.70 A; A=3264-3569.
DR   PDB; 5RGI; X-ray; 1.57 A; A=3264-3569.
DR   PDB; 5RGJ; X-ray; 1.34 A; A=3264-3569.
DR   PDB; 5RGK; X-ray; 1.43 A; A=3264-3569.
DR   PDB; 5RGL; X-ray; 1.76 A; A=3264-3569.
DR   PDB; 5RGM; X-ray; 2.04 A; A=3264-3569.
DR   PDB; 5RGN; X-ray; 1.86 A; A=3264-3569.
DR   PDB; 5RGO; X-ray; 1.74 A; A=3264-3569.
DR   PDB; 5RGP; X-ray; 2.07 A; A=3264-3569.
DR   PDB; 5RGQ; X-ray; 2.15 A; A=3264-3569.
DR   PDB; 5RGR; X-ray; 1.41 A; A=3264-3569.
DR   PDB; 5RGS; X-ray; 1.72 A; A=3264-3569.
DR   PDB; 6LU7; X-ray; 2.16 A; A=3264-3569.
DR   PDB; 6LZE; X-ray; 1.50 A; A=3264-3566.
DR   PDB; 6M03; X-ray; 2.00 A; A=3264-3569.
DR   PDB; 6M0K; X-ray; 1.50 A; A=3264-3567.
DR   PDB; 6M2N; X-ray; 2.20 A; A/B/C/D=3264-3569.
DR   PDB; 6M2Q; X-ray; 1.70 A; A=3264-3569.
DR   PDB; 6M71; EM; 2.90 A; C=3860-3942, D=3943-4090, A=4393-5324.
DR   PDB; 6VWW; X-ray; 2.20 A; A/B=6453-6798.
DR   PDB; 6VXS; X-ray; 2.03 A; A/B=1024-1192.
DR   PDB; 6W01; X-ray; 1.90 A; A/B=6453-6798.
DR   PDB; 6W02; X-ray; 1.50 A; A/B=1024-1192.
DR   PDB; 6W4B; X-ray; 2.95 A; A/B=4141-4253.
DR   PDB; 6W4H; X-ray; 1.80 A; A=6799-7096, B=4254-4392.
DR   PDB; 6W61; X-ray; 2.00 A; B=4254-4392, A=6799-7096.
DR   PDB; 6W63; X-ray; 2.10 A; A=3264-3569.
DR   PDB; 6W6Y; X-ray; 1.45 A; A/B=1024-1192.
DR   PDB; 6W75; X-ray; 1.95 A; B/D=4254-4392, A/C=6799-7096.
DR   PDB; 6W9C; X-ray; 2.70 A; A/B/C=1564-1878.
DR   PDB; 6W9Q; X-ray; 2.05 A; A=4141-4253.
DR   PDB; 6WCF; X-ray; 1.06 A; A=1024-1192.
DR   PDB; 6WEN; X-ray; 1.35 A; A=1024-1192.
DR   PDB; 6WEY; X-ray; 0.95 A; A=1025-1195.
DR   PDB; 6WIQ; X-ray; 2.85 A; A=3860-3942, B=4019-4140.
DR   PDB; 6WJT; X-ray; 2.00 A; A/C=6799-7096, B/D=4254-4392.
DR   PDB; 6WKQ; X-ray; 1.98 A; A/C=6799-7096, B/D=4254-4392.
DR   PDB; 6WKS; X-ray; 1.80 A; AAA=6799-7096, BBB=4254-4392.
DR   PDB; 6WLC; X-ray; 1.82 A; A/B=6453-6798.
DR   PDB; 6WNP; X-ray; 1.44 A; A=3264-3569.
DR   PDB; 6WOJ; X-ray; 2.20 A; A/B/C/D=1023-1197.
DR   PDB; 6WQ3; X-ray; 2.10 A; A=6799-7096, B=4254-4392.
DR   PDB; 6WQD; X-ray; 1.95 A; A/C=3860-3942, B/D=4019-4140.
DR   PDB; 6WQF; X-ray; 2.30 A; A=3264-3569.
DR   PDB; 6WRH; X-ray; 1.60 A; A=1564-1878.
DR   PDB; 6WRZ; X-ray; 2.25 A; A=6799-7096, B=4254-4392.
DR   PDB; 6WTC; X-ray; 1.85 A; A/C=3860-3942, B/D=4019-4140.
DR   PDB; 6WTJ; X-ray; 1.90 A; A=3264-3569.
DR   PDB; 6WTK; X-ray; 2.00 A; A=3264-3569.
DR   PDB; 6WTM; X-ray; 1.85 A; A/B=3264-3569.
DR   PDB; 6WTT; X-ray; 2.15 A; A/B/C=3264-3567.
DR   PDB; 6WUU; X-ray; 2.79 A; A/B/C/D=1562-1879.
DR   PDB; 6WVN; X-ray; 2.00 A; A=6799-7096, B=4254-4392.
DR   PDB; 6WX4; X-ray; 1.66 A; D=1562-1879.
DR   PDB; 6WXC; X-ray; 1.85 A; A/B=6453-6798.
DR   PDB; 6WXD; X-ray; 2.00 A; A/B=4141-4253.
DR   PDB; 6Y2E; X-ray; 1.75 A; A=3264-3569.
DR   PDB; 6Y2F; X-ray; 2.16 A; A=3264-3569.
DR   PDB; 6Y2G; X-ray; 2.16 A; A=3264-3569.
DR   PDB; 6Y84; X-ray; 1.39 A; A=3264-3569.
DR   PDB; 6YB7; X-ray; 1.25 A; A=3264-3569.
DR   PDB; 6YNQ; X-ray; 1.80 A; A=3264-3569.
DR   PDB; 6YT8; X-ray; 2.05 A; A=3264-3569.
DR   PDB; 6YVA; X-ray; 3.18 A; A=1564-1878.
DR   PDB; 6YVF; X-ray; 1.60 A; A=3264-3569.
DR   PDB; 6YWK; X-ray; 2.20 A; A/B/C/D/E=1025-1194.
DR   PDB; 6YWL; X-ray; 2.50 A; A/B/C/D/E=1025-1194.
DR   PDB; 6YWM; X-ray; 2.16 A; A/B/C=1025-1194.
DR   PDB; 6YZ1; X-ray; 2.40 A; A=6798-7096, B=4263-4384.
DR   PDB; 6YZ6; X-ray; 1.70 A; A=3264-3569.
DR   PDB; 7BQY; X-ray; 1.70 A; A=3264-3569.
DR   PDB; 7BRO; X-ray; 2.00 A; A=3264-3569.
DR   PDB; 7BRP; X-ray; 1.80 A; A/B=3264-3569.
DR   PDB; 7BRR; X-ray; 1.40 A; A/B=3264-3569.
DR   PDB; 7BTF; EM; 2.95 A; A=4393-5324, B=3943-4090, C=3860-3942.
DR   PDB; 7BUY; X-ray; 1.60 A; A=3264-3569.
DR   PDB; 7BV1; EM; 2.80 A; C=3860-3942, B=3943-4140, A=4393-5324.
DR   PDB; 7BV2; EM; 2.50 A; C=3860-3942, B=3943-4140, A=4393-5324.
DR   PDBsum; 5R7Y; -.
DR   PDBsum; 5R7Z; -.
DR   PDBsum; 5R80; -.
DR   PDBsum; 5R81; -.
DR   PDBsum; 5R82; -.
DR   PDBsum; 5R83; -.
DR   PDBsum; 5R84; -.
DR   PDBsum; 5R8T; -.
DR   PDBsum; 5RE4; -.
DR   PDBsum; 5RE5; -.
DR   PDBsum; 5RE6; -.
DR   PDBsum; 5RE7; -.
DR   PDBsum; 5RE8; -.
DR   PDBsum; 5RE9; -.
DR   PDBsum; 5REA; -.
DR   PDBsum; 5REB; -.
DR   PDBsum; 5REC; -.
DR   PDBsum; 5RED; -.
DR   PDBsum; 5REE; -.
DR   PDBsum; 5REF; -.
DR   PDBsum; 5REG; -.
DR   PDBsum; 5REH; -.
DR   PDBsum; 5REI; -.
DR   PDBsum; 5REJ; -.
DR   PDBsum; 5REK; -.
DR   PDBsum; 5REL; -.
DR   PDBsum; 5REM; -.
DR   PDBsum; 5REN; -.
DR   PDBsum; 5REO; -.
DR   PDBsum; 5REP; -.
DR   PDBsum; 5RER; -.
DR   PDBsum; 5RES; -.
DR   PDBsum; 5RET; -.
DR   PDBsum; 5REU; -.
DR   PDBsum; 5REV; -.
DR   PDBsum; 5REW; -.
DR   PDBsum; 5REX; -.
DR   PDBsum; 5REY; -.
DR   PDBsum; 5REZ; -.
DR   PDBsum; 5RF0; -.
DR   PDBsum; 5RF1; -.
DR   PDBsum; 5RF2; -.
DR   PDBsum; 5RF3; -.
DR   PDBsum; 5RF4; -.
DR   PDBsum; 5RF5; -.
DR   PDBsum; 5RF6; -.
DR   PDBsum; 5RF7; -.
DR   PDBsum; 5RF8; -.
DR   PDBsum; 5RF9; -.
DR   PDBsum; 5RFA; -.
DR   PDBsum; 5RFB; -.
DR   PDBsum; 5RFC; -.
DR   PDBsum; 5RFD; -.
DR   PDBsum; 5RFE; -.
DR   PDBsum; 5RFF; -.
DR   PDBsum; 5RFG; -.
DR   PDBsum; 5RFH; -.
DR   PDBsum; 5RFI; -.
DR   PDBsum; 5RFJ; -.
DR   PDBsum; 5RFK; -.
DR   PDBsum; 5RFL; -.
DR   PDBsum; 5RFM; -.
DR   PDBsum; 5RFN; -.
DR   PDBsum; 5RFO; -.
DR   PDBsum; 5RFP; -.
DR   PDBsum; 5RFQ; -.
DR   PDBsum; 5RFR; -.
DR   PDBsum; 5RFS; -.
DR   PDBsum; 5RFT; -.
DR   PDBsum; 5RFU; -.
DR   PDBsum; 5RFV; -.
DR   PDBsum; 5RFW; -.
DR   PDBsum; 5RFX; -.
DR   PDBsum; 5RFY; -.
DR   PDBsum; 5RFZ; -.
DR   PDBsum; 5RG0; -.
DR   PDBsum; 5RG1; -.
DR   PDBsum; 5RG2; -.
DR   PDBsum; 5RG3; -.
DR   PDBsum; 5RGG; -.
DR   PDBsum; 5RGH; -.
DR   PDBsum; 5RGI; -.
DR   PDBsum; 5RGJ; -.
DR   PDBsum; 5RGK; -.
DR   PDBsum; 5RGL; -.
DR   PDBsum; 5RGM; -.
DR   PDBsum; 5RGN; -.
DR   PDBsum; 5RGO; -.
DR   PDBsum; 5RGP; -.
DR   PDBsum; 5RGQ; -.
DR   PDBsum; 5RGR; -.
DR   PDBsum; 5RGS; -.
DR   PDBsum; 6LU7; -.
DR   PDBsum; 6LZE; -.
DR   PDBsum; 6M03; -.
DR   PDBsum; 6M0K; -.
DR   PDBsum; 6M2N; -.
DR   PDBsum; 6M2Q; -.
DR   PDBsum; 6M71; -.
DR   PDBsum; 6VWW; -.
DR   PDBsum; 6VXS; -.
DR   PDBsum; 6W01; -.
DR   PDBsum; 6W02; -.
DR   PDBsum; 6W4B; -.
DR   PDBsum; 6W4H; -.
DR   PDBsum; 6W61; -.
DR   PDBsum; 6W63; -.
DR   PDBsum; 6W6Y; -.
DR   PDBsum; 6W75; -.
DR   PDBsum; 6W9C; -.
DR   PDBsum; 6W9Q; -.
DR   PDBsum; 6WCF; -.
DR   PDBsum; 6WEN; -.
DR   PDBsum; 6WEY; -.
DR   PDBsum; 6WIQ; -.
DR   PDBsum; 6WJT; -.
DR   PDBsum; 6WKQ; -.
DR   PDBsum; 6WKS; -.
DR   PDBsum; 6WLC; -.
DR   PDBsum; 6WNP; -.
DR   PDBsum; 6WOJ; -.
DR   PDBsum; 6WQ3; -.
DR   PDBsum; 6WQD; -.
DR   PDBsum; 6WQF; -.
DR   PDBsum; 6WRH; -.
DR   PDBsum; 6WRZ; -.
DR   PDBsum; 6WTC; -.
DR   PDBsum; 6WTJ; -.
DR   PDBsum; 6WTK; -.
DR   PDBsum; 6WTM; -.
DR   PDBsum; 6WTT; -.
DR   PDBsum; 6WUU; -.
DR   PDBsum; 6WVN; -.
DR   PDBsum; 6WX4; -.
DR   PDBsum; 6WXC; -.
DR   PDBsum; 6WXD; -.
DR   PDBsum; 6Y2E; -.
DR   PDBsum; 6Y2F; -.
DR   PDBsum; 6Y2G; -.
DR   PDBsum; 6Y84; -.
DR   PDBsum; 6YB7; -.
DR   PDBsum; 6YNQ; -.
DR   PDBsum; 6YT8; -.
DR   PDBsum; 6YVA; -.
DR   PDBsum; 6YVF; -.
DR   PDBsum; 6YWK; -.
DR   PDBsum; 6YWL; -.
DR   PDBsum; 6YWM; -.
DR   PDBsum; 6YZ1; -.
DR   PDBsum; 6YZ6; -.
DR   PDBsum; 7BQY; -.
DR   PDBsum; 7BRO; -.
DR   PDBsum; 7BRP; -.
DR   PDBsum; 7BRR; -.
DR   PDBsum; 7BTF; -.
DR   PDBsum; 7BUY; -.
DR   PDBsum; 7BV1; -.
DR   PDBsum; 7BV2; -.
DR   SMR; P0DTD1; -.
DR   BioGRID; 4383850; 6.
DR   BioGRID; 4383851; 7.
DR   BioGRID; 4383853; 8.
DR   BioGRID; 4383854; 4.
DR   BioGRID; 4383855; 4.
DR   BioGRID; 4383856; 33.
DR   BioGRID; 4383857; 25.
DR   BioGRID; 4383858; 16.
DR   BioGRID; 4383859; 5.
DR   BioGRID; 4383860; 22.
DR   BioGRID; 4383861; 40.
DR   BioGRID; 4383862; 3.
DR   BioGRID; 4383863; 3.
DR   ComplexPortal; CPX-5685; SARS-CoV-2 main protease complex.
DR   ComplexPortal; CPX-5687; SARS-CoV-2 NSP9 complex.
DR   ComplexPortal; CPX-5688; SARS-CoV-2 NSP10-NSP16 2'-O-methyltransferase complex.
DR   ComplexPortal; CPX-5689; SARS-CoV-2 NSP15 complex.
DR   ComplexPortal; CPX-5690; SARS-CoV-2 primase complex.
DR   ComplexPortal; CPX-5691; SARS-CoV-2 NSP3-NSP4-NSP6 complex.
DR   ComplexPortal; CPX-5692; SARS-CoV-2 3'-5' exoribonuclease proof-reading complex.
DR   ComplexPortal; CPX-5742; SARS-CoV-2 polymerase complex.
DR   IntAct; P0DTD1; 327.
DR   GeneID; 43740578; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0003678; F:DNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0004527; F:exonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0008168; F:methyltransferase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008242; F:omega peptidase activity; IEA:InterPro.
DR   GO; GO:0003724; F:RNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003968; F:RNA-directed 5'-3' RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003727; F:single-stranded RNA binding; IEA:InterPro.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0039595; P:induction by virus of catabolism of host mRNA; IEA:UniProtKB-KW.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0032259; P:methylation; IEA:UniProtKB-KW.
DR   GO; GO:0039648; P:modulation by virus of host protein ubiquitination; IEA:UniProtKB-KW.
DR   GO; GO:0039579; P:suppression by virus of host ISG15 activity; IEA:UniProtKB-KW.
DR   GO; GO:0039644; P:suppression by virus of host NF-kappaB transcription factor activity; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:suppression by virus of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   GO; GO:0019082; P:viral protein processing; IEA:InterPro.
DR   CDD; cd15239; 7tm_YRO2_fungal-like; 1.
DR   CDD; cd18808; SF1_C_Upf1; 1.
DR   Gene3D; 1.10.150.420; -; 1.
DR   Gene3D; 1.10.1840.10; -; 1.
DR   Gene3D; 1.10.8.1190; -; 1.
DR   Gene3D; 1.10.8.370; -; 1.
DR   Gene3D; 2.20.25.360; -; 1.
DR   Gene3D; 2.30.30.590; -; 1.
DR   Gene3D; 2.40.10.10; -; 2.
DR   Gene3D; 2.40.10.250; -; 1.
DR   Gene3D; 2.40.10.290; -; 1.
DR   Gene3D; 3.10.20.350; -; 1.
DR   Gene3D; 3.10.20.540; -; 1.
DR   Gene3D; 3.40.220.10; -; 1.
DR   Gene3D; 3.40.220.20; -; 1.
DR   Gene3D; 3.40.220.30; -; 1.
DR   Gene3D; 3.40.50.11020; -; 1.
DR   Gene3D; 3.40.50.11580; -; 1.
DR   Gene3D; 3.90.70.90; -; 1.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR041679; DNA2/NAM7-like_AAA.
DR   InterPro; IPR022733; DPUP_SUD_C_bCoV.
DR   InterPro; IPR037227; EndoU-like.
DR   InterPro; IPR002589; Macro_dom.
DR   InterPro; IPR043472; Macro_dom-like.
DR   InterPro; IPR042570; NAR_sf.
DR   InterPro; IPR036333; NSP10_sf_CoV.
DR   InterPro; IPR009466; NSP11_CoV.
DR   InterPro; IPR043174; NSP15_middle_sf.
DR   InterPro; IPR042515; NSP15_N_CoV.
DR   InterPro; IPR009461; NSP16_CoV-like.
DR   InterPro; IPR021590; NSP1_bCoV.
DR   InterPro; IPR038030; NSP1_sf_bCoV.
DR   InterPro; IPR024375; NSP3_bCoV.
DR   InterPro; IPR024358; NSP3_N_bCoV.
DR   InterPro; IPR032592; NSP3_NAR_bCoV.
DR   InterPro; IPR038166; NSP3_PL2pro_sf_CoV.
DR   InterPro; IPR038400; NSP3_SUD-M_sf_bCoV.
DR   InterPro; IPR043478; NSP3_SUD-N_bCoV.
DR   InterPro; IPR038083; NSP3A-like.
DR   InterPro; IPR032505; NSP4_C_CoV.
DR   InterPro; IPR038123; NSP4_C_sf_CoV.
DR   InterPro; IPR014828; NSP7_CoV.
DR   InterPro; IPR037204; NSP7_sf_CoV.
DR   InterPro; IPR014829; NSP8_CoV-like.
DR   InterPro; IPR037230; NSP8_sf_CoV.
DR   InterPro; IPR014822; NSP9_CoV.
DR   InterPro; IPR036499; NSP9_sf_CoV.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR013016; Peptidase_C16_CoV.
DR   InterPro; IPR008740; Peptidase_C30_CoV.
DR   InterPro; IPR043477; Peptidase_C30_dom3_CoV.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR043177; PLpro_N_sf_CoV.
DR   InterPro; IPR043503; PLpro_palm_finger_dom_CoV.
DR   InterPro; IPR043178; PLpro_thumb_sf_CoV.
DR   InterPro; IPR009469; RNA_pol_N_coronovir.
DR   InterPro; IPR018995; RNA_synth_NSP10_CoV.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   InterPro; IPR043476; Yro2-like_7TM.
DR   Pfam; PF16348; Corona_NSP4_C; 1.
DR   Pfam; PF06478; Corona_RPol_N; 1.
DR   Pfam; PF12379; DUF3655; 1.
DR   Pfam; PF01661; Macro; 1.
DR   Pfam; PF16251; NAR; 1.
DR   Pfam; PF11501; Nsp1; 1.
DR   Pfam; PF09401; NSP10; 1.
DR   Pfam; PF06471; NSP11; 1.
DR   Pfam; PF06460; NSP16; 1.
DR   Pfam; PF12124; Nsp3_PL2pro; 1.
DR   Pfam; PF08716; nsp7; 1.
DR   Pfam; PF08717; nsp8; 1.
DR   Pfam; PF08710; nsp9; 1.
DR   Pfam; PF05409; Peptidase_C30; 1.
DR   Pfam; PF11633; SUD-M; 1.
DR   Pfam; PF08715; Viral_protease; 1.
DR   SMART; SM00506; A1pp; 1.
DR   SUPFAM; SSF101816; SSF101816; 1.
DR   SUPFAM; SSF140367; SSF140367; 1.
DR   SUPFAM; SSF142877; SSF142877; 1.
DR   SUPFAM; SSF143076; SSF143076; 1.
DR   SUPFAM; SSF144246; SSF144246; 1.
DR   SUPFAM; SSF159936; SSF159936; 1.
DR   SUPFAM; SSF160099; SSF160099; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF52949; SSF52949; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   SUPFAM; SSF56672; SSF56672; 1.
DR   PROSITE; PS00867; CPSASE_2; 1.
DR   PROSITE; PS51653; CV_ZBD; 1.
DR   PROSITE; PS00213; LIPOCALIN; 1.
DR   PROSITE; PS51442; M_PRO; 1.
DR   PROSITE; PS51154; MACRO; 1.
DR   PROSITE; PS51124; PEPTIDASE_C16; 1.
DR   PROSITE; PS51657; PSRV_HELICASE; 1.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host autophagy by virus; ATP-binding;
KW   Decay of host mRNAs by virus; Endonuclease;
KW   Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Exonuclease; Helicase;
KW   Host cytoplasm; Host gene expression shutoff by virus; Host membrane;
KW   Host mRNA suppression by virus; Host-virus interaction; Hydrolase;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host ISG15 by virus; Inhibition of host NF-kappa-B by virus;
KW   Leucine-rich repeat; Membrane; Metal-binding; Methyltransferase;
KW   Modulation of host ubiquitin pathway by viral deubiquitinase;
KW   Modulation of host ubiquitin pathway by virus; Nuclease;
KW   Nucleotide-binding; Nucleotidyltransferase; Protease; Reference proteome;
KW   Repeat; Ribosomal frameshifting; RNA-binding; RNA-directed RNA polymerase;
KW   Thiol protease; Transferase; Transmembrane; Transmembrane helix;
KW   Ubl conjugation pathway; Viral immunoevasion; Viral RNA replication; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..7096
FT                   /note="Replicase polyprotein 1ab"
FT                   /id="PRO_0000449618"
FT   CHAIN           1..180
FT                   /note="Host translation inhibitor nsp1"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449619"
FT   CHAIN           181..818
FT                   /note="Non-structural protein 2"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449620"
FT   CHAIN           819..2763
FT                   /note="Non-structural protein 3"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449621"
FT   CHAIN           2764..3263
FT                   /note="Non-structural protein 4"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449622"
FT   CHAIN           3264..3569
FT                   /note="3C-like proteinase"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449623"
FT   CHAIN           3570..3859
FT                   /note="Non-structural protein 6"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449624"
FT   CHAIN           3860..3942
FT                   /note="Non-structural protein 7"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449625"
FT   CHAIN           3943..4140
FT                   /note="Non-structural protein 8"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449626"
FT   CHAIN           4141..4253
FT                   /note="Non-structural protein 9"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449627"
FT   CHAIN           4254..4392
FT                   /note="Non-structural protein 10"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449628"
FT   CHAIN           4393..5324
FT                   /note="RNA-directed RNA polymerase"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449629"
FT   CHAIN           5325..5925
FT                   /note="Helicase"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449630"
FT   CHAIN           5926..6452
FT                   /note="Proofreading exoribonuclease"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449631"
FT   CHAIN           6453..6798
FT                   /note="Uridylate-specific endoribonuclease"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449632"
FT   CHAIN           6799..7096
FT                   /note="2'-O-methyltransferase"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT                   /id="PRO_0000449633"
FT   TOPO_DOM        1..2225
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2226..2246
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2247..2317
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2318..2338
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2339..2775
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        2776..2796
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2797..3044
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3045..3065
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3066..3099
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3100..3120
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3121..3127
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3128..3148
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3149..3586
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3587..3607
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3608
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3609..3629
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3630..3634
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3635..3655
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3656..3673
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3674..3694
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3695..3729
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3730..3750
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3751..3778
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        3779..3799
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        3800..7096
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   REPEAT          545..569
FT                   /note="LRR 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          697..719
FT                   /note="LRR 2"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          1025..1194
FT                   /note="Macro"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00490"
FT   DOMAIN          1634..1898
FT                   /note="Peptidase C16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   REPEAT          1680..1702
FT                   /note="LRR 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          3185..3206
FT                   /note="LRR 4"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          3264..3569
FT                   /note="Peptidase C30"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772"
FT   REPEAT          3935..3959
FT                   /note="LRR 5"
FT                   /evidence="ECO:0000255"
FT   REPEAT          3977..4004
FT                   /note="LRR 6"
FT                   /evidence="ECO:0000255"
FT   REPEAT          4591..4616
FT                   /note="LRR 7"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          5004..5166
FT                   /note="RdRp catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00539"
FT   DOMAIN          5325..5408
FT                   /note="CV ZBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   REPEAT          5552..5572
FT                   /note="LRR 8"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          5581..5762
FT                   /note="(+)RNA virus helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00990"
FT   DOMAIN          5763..5932
FT                   /note="(+)RNA virus helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00990"
FT   REPEAT          6817..6841
FT                   /note="LRR 9"
FT                   /evidence="ECO:0000255"
FT   ZN_FING         1752..1789
FT                   /note="C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   NP_BIND         5606..5613
FT                   /note="NTP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00990"
FT   REGION          4937..4947
FT                   /note="Interaction with RMP Remdesivir"
FT                   /evidence="ECO:0000269|PubMed:32358203"
FT   ACT_SITE        1674
FT                   /note="For PL1-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ACT_SITE        1835
FT                   /note="For PL2-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00444"
FT   ACT_SITE        3304
FT                   /note="For 3CL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772,
FT                   ECO:0000305|PubMed:32198291"
FT   ACT_SITE        3408
FT                   /note="Nucleophile; for 3CL-PRO activity"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00772,
FT                   ECO:0000269|PubMed:32198291"
FT   METAL           4687
FT                   /note="Zinc 1; structural"
FT                   /evidence="ECO:0000269|PubMed:32358203"
FT   METAL           4693
FT                   /note="Zinc 1; structural"
FT                   /evidence="ECO:0000269|PubMed:32358203"
FT   METAL           4698
FT                   /note="Zinc 1; structural"
FT                   /evidence="ECO:0000269|PubMed:32358203"
FT   METAL           4702
FT                   /note="Zinc 1; structural"
FT                   /evidence="ECO:0000269|PubMed:32358203"
FT   METAL           4879
FT                   /note="Zinc 2; structural"
FT                   /evidence="ECO:0000269|PubMed:32358203"
FT   METAL           5034
FT                   /note="Zinc 2; structural"
FT                   /evidence="ECO:0000269|PubMed:32358203"
FT   METAL           5037
FT                   /note="Zinc 2; structural"
FT                   /evidence="ECO:0000269|PubMed:32358203"
FT   METAL           5038
FT                   /note="Zinc 2; structural"
FT                   /evidence="ECO:0000269|PubMed:32358203"
FT   METAL           5329
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5332
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5340
FT                   /note="Zinc 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5343
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5350
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5353
FT                   /note="Zinc 4; via tele nitrogen"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5357
FT                   /note="Zinc 4; via pros nitrogen"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5363
FT                   /note="Zinc 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5374
FT                   /note="Zinc 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5379
FT                   /note="Zinc 5; via pros nitrogen"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5396
FT                   /note="Zinc 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   METAL           5399
FT                   /note="Zinc 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00986"
FT   SITE            180..181
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            818..819
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            2763..2764
FT                   /note="Cleavage; by PL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            3263..3264
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            3569..3570
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            3859..3860
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            3942..3943
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            4140..4141
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            4253..4254
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            4392..4393
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            5324..5325
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            5925..5926
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            6452..6453
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   SITE            6798..6799
FT                   /note="Cleavage; by 3CL-PRO"
FT                   /evidence="ECO:0000250|UniProtKB:P0C6V3"
FT   STRAND          1032..1042
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   HELIX           1045..1052
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   STRAND          1055..1060
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   HELIX           1070..1078
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   TURN            1079..1081
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   HELIX           1082..1094
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   STRAND          1102..1106
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   TURN            1108..1110
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   STRAND          1112..1117
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   HELIX           1122..1124
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   HELIX           1128..1130
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   HELIX           1131..1136
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   HELIX           1137..1140
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   STRAND          1141..1146
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   HELIX           1152..1154
FT                   /evidence="ECO:0000244|PDB:6WEN"
FT   HELIX           1158..1168
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   STRAND          1171..1177
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   HELIX           1180..1191
FT                   /evidence="ECO:0000244|PDB:6WEY"
FT   STRAND          1567..1578
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1580..1585
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   HELIX           1590..1594
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1595..1599
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1605..1607
FT                   /evidence="ECO:0000244|PDB:6W9C"
FT   HELIX           1611..1613
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1617..1620
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   HELIX           1625..1635
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   HELIX           1642..1653
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1660..1665
FT                   /evidence="ECO:0000244|PDB:6W9C"
FT   TURN            1671..1673
FT                   /evidence="ECO:0000244|PDB:6WX4"
FT   HELIX           1674..1683
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1690..1692
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   HELIX           1693..1703
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   HELIX           1708..1718
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   HELIX           1728..1737
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1745..1752
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   TURN            1753..1755
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1756..1763
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   HELIX           1765..1768
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1769..1772
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   HELIX           1776..1781
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1783..1786
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1790..1816
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   TURN            1818..1820
FT                   /evidence="ECO:0000244|PDB:6YVA"
FT   STRAND          1822..1830
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1833..1849
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1852..1869
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   STRAND          1871..1874
FT                   /evidence="ECO:0000244|PDB:6WRH"
FT   HELIX           3274..3277
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3280..3285
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3288..3295
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3298..3302
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3303..3306
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3311..3313
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3317..3322
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3326..3328
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3329..3333
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3336..3338
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3340..3346
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3349..3356
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3363..3366
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3374..3381
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3384..3392
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3411..3416
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3419..3429
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   TURN            3431..3433
FT                   /evidence="ECO:0000244|PDB:7BRP"
FT   STRAND          3435..3438
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3444..3447
FT                   /evidence="ECO:0000244|PDB:7BRR"
FT   STRAND          3450..3453
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3464..3476
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3490..3499
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3507..3512
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3514..3520
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3524..3537
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   STRAND          3547..3549
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3556..3564
FT                   /evidence="ECO:0000244|PDB:6YB7"
FT   HELIX           3861..3878
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   HELIX           3881..3883
FT                   /evidence="ECO:0000244|PDB:6WQD"
FT   HELIX           3886..3900
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   HELIX           3904..3920
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   TURN            3922..3924
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   HELIX           3927..3930
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   TURN            4011..4013
FT                   /evidence="ECO:0000244|PDB:7BTF"
FT   TURN            4019..4021
FT                   /evidence="ECO:0000244|PDB:7BTF"
FT   HELIX           4022..4040
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   HELIX           4043..4053
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   STRAND          4058..4060
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   HELIX           4061..4066
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4069..4074
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   HELIX           4077..4083
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   STRAND          4088..4091
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   STRAND          4094..4102
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   HELIX           4111..4113
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   TURN            4116..4118
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   HELIX           4119..4121
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   STRAND          4124..4134
FT                   /evidence="ECO:0000244|PDB:6WTC"
FT   STRAND          4144..4148
FT                   /evidence="ECO:0000244|PDB:6W9Q"
FT   STRAND          4150..4160
FT                   /evidence="ECO:0000244|PDB:6WXD"
FT   STRAND          4165..4175
FT                   /evidence="ECO:0000244|PDB:6WXD"
FT   STRAND          4178..4187
FT                   /evidence="ECO:0000244|PDB:6WXD"
FT   STRAND          4193..4197
FT                   /evidence="ECO:0000244|PDB:6WXD"
FT   STRAND          4199..4202
FT                   /evidence="ECO:0000244|PDB:6W9Q"
FT   STRAND          4204..4209
FT                   /evidence="ECO:0000244|PDB:6WXD"
FT   STRAND          4213..4219
FT                   /evidence="ECO:0000244|PDB:6WXD"
FT   STRAND          4222..4231
FT                   /evidence="ECO:0000244|PDB:6WXD"
FT   HELIX           4236..4249
FT                   /evidence="ECO:0000244|PDB:6WXD"
FT   HELIX           4264..4273
FT                   /evidence="ECO:0000244|PDB:6WVN"
FT   HELIX           4276..4285
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          4307..4311
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          4318..4323
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           4324..4326
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           4328..4332
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           4339..4341
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          4348..4353
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           4354..4356
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           4360..4366
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   TURN            4371..4373
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          4375..4377
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           4397..4404
FT                   /evidence="ECO:0000244|PDB:7BTF"
FT   STRAND          4416..4418
FT                   /evidence="ECO:0000244|PDB:7BTF"
FT   STRAND          4424..4430
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4435..4441
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4447..4451
FT                   /evidence="ECO:0000244|PDB:7BTF"
FT   STRAND          4457..4466
FT                   /evidence="ECO:0000244|PDB:7BTF"
FT   HELIX           4477..4481
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            4482..4484
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4491..4511
FT                   /evidence="ECO:0000244|PDB:7BTF"
FT   STRAND          4513..4515
FT                   /evidence="ECO:0000244|PDB:6M71"
FT   HELIX           4516..4524
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4528..4530
FT                   /evidence="ECO:0000244|PDB:7BV1"
FT   HELIX           4532..4540
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4546..4550
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            4552..4555
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            4557..4559
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4563..4567
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4568..4570
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4571..4591
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4593..4596
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4599..4601
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4623..4625
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4627..4639
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4642..4647
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4649..4651
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4668..4678
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4690..4692
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4696..4709
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            4710..4712
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4715..4717
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4718..4727
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4730..4740
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            4741..4743
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4744..4747
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4753..4756
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4760..4768
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4770..4776
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4777..4784
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4789..4796
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4809..4817
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            4818..4821
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4840..4845
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4846..4850
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4858..4868
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4869..4872
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4882..4884
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4890..4893
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4898..4900
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4904..4910
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4913..4922
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            4923..4925
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4931..4936
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4941..4943
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4948..4951
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4954..4973
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          4976..4979
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            4986..4988
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           4989..4997
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            4998..5000
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5002..5008
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5014..5017
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5020..5030
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5031..5033
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   TURN            5035..5037
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5040..5054
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5058..5060
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5062..5067
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5079..5100
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5104..5106
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5110..5124
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5131..5144
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5145..5150
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5153..5159
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5160..5164
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5166..5168
FT                   /evidence="ECO:0000244|PDB:6M71"
FT   HELIX           5171..5181
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5188..5190
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5192..5194
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5197..5199
FT                   /evidence="ECO:0000244|PDB:6M71"
FT   STRAND          5204..5206
FT                   /evidence="ECO:0000244|PDB:6M71"
FT   STRAND          5207..5214
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5217..5223
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5226..5234
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   STRAND          5235..5237
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5239..5242
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5244..5258
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5259..5263
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5267..5286
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5310..5314
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           5315..5317
FT                   /evidence="ECO:0000244|PDB:7BV2"
FT   HELIX           6454..6464
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6476..6479
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6482..6487
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6490..6496
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6499..6501
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   HELIX           6503..6511
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   HELIX           6521..6526
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6531..6536
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   TURN            6540..6543
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6544..6548
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6550..6553
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   TURN            6555..6557
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6558..6562
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   HELIX           6566..6568
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6573..6576
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   HELIX           6582..6588
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6590..6598
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6612..6614
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6617..6619
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6622..6624
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6629..6634
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6637..6639
FT                   /evidence="ECO:0000244|PDB:6VWW"
FT   HELIX           6660..6667
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   HELIX           6670..6676
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   HELIX           6684..6687
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6693..6696
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   HELIX           6703..6712
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6715..6718
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6726..6734
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   TURN            6735..6737
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6740..6747
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   HELIX           6751..6758
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6765..6774
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6777..6786
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   STRAND          6789..6795
FT                   /evidence="ECO:0000244|PDB:6WLC"
FT   HELIX           6800..6803
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          6804..6808
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           6811..6814
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   TURN            6826..6829
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           6840..6852
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          6864..6869
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           6878..6886
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          6892..6899
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          6905..6911
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           6913..6915
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          6916..6920
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          6922..6927
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           6932..6934
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           6947..6958
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          6959..6969
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          6971..6973
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           6976..6982
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          6985..6994
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   TURN            6995..6998
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          7002..7009
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           7019..7032
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           7040..7043
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          7056..7058
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           7062..7064
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   HELIX           7067..7074
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          7078..7081
FT                   /evidence="ECO:0000244|PDB:6W4H"
FT   STRAND          7088..7090
FT                   /evidence="ECO:0000244|PDB:6W4H"
SQ   SEQUENCE   7096 AA;  794058 MW;  A4E62D97150BB8CC CRC64;
     MESLVPGFNE KTHVQLSLPV LQVRDVLVRG FGDSVEEVLS EARQHLKDGT CGLVEVEKGV
     LPQLEQPYVF IKRSDARTAP HGHVMVELVA ELEGIQYGRS GETLGVLVPH VGEIPVAYRK
     VLLRKNGNKG AGGHSYGADL KSFDLGDELG TDPYEDFQEN WNTKHSSGVT RELMRELNGG
     AYTRYVDNNF CGPDGYPLEC IKDLLARAGK ASCTLSEQLD FIDTKRGVYC CREHEHEIAW
     YTERSEKSYE LQTPFEIKLA KKFDTFNGEC PNFVFPLNSI IKTIQPRVEK KKLDGFMGRI
     RSVYPVASPN ECNQMCLSTL MKCDHCGETS WQTGDFVKAT CEFCGTENLT KEGATTCGYL
     PQNAVVKIYC PACHNSEVGP EHSLAEYHNE SGLKTILRKG GRTIAFGGCV FSYVGCHNKC
     AYWVPRASAN IGCNHTGVVG EGSEGLNDNL LEILQKEKVN INIVGDFKLN EEIAIILASF
     SASTSAFVET VKGLDYKAFK QIVESCGNFK VTKGKAKKGA WNIGEQKSIL SPLYAFASEA
     ARVVRSIFSR TLETAQNSVR VLQKAAITIL DGISQYSLRL IDAMMFTSDL ATNNLVVMAY
     ITGGVVQLTS QWLTNIFGTV YEKLKPVLDW LEEKFKEGVE FLRDGWEIVK FISTCACEIV
     GGQIVTCAKE IKESVQTFFK LVNKFLALCA DSIIIGGAKL KALNLGETFV THSKGLYRKC
     VKSREETGLL MPLKAPKEII FLEGETLPTE VLTEEVVLKT GDLQPLEQPT SEAVEAPLVG
     TPVCINGLML LEIKDTEKYC ALAPNMMVTN NTFTLKGGAP TKVTFGDDTV IEVQGYKSVN
     ITFELDERID KVLNEKCSAY TVELGTEVNE FACVVADAVI KTLQPVSELL TPLGIDLDEW
     SMATYYLFDE SGEFKLASHM YCSFYPPDED EEEGDCEEEE FEPSTQYEYG TEDDYQGKPL
     EFGATSAALQ PEEEQEEDWL DDDSQQTVGQ QDGSEDNQTT TIQTIVEVQP QLEMELTPVV
     QTIEVNSFSG YLKLTDNVYI KNADIVEEAK KVKPTVVVNA ANVYLKHGGG VAGALNKATN
     NAMQVESDDY IATNGPLKVG GSCVLSGHNL AKHCLHVVGP NVNKGEDIQL LKSAYENFNQ
     HEVLLAPLLS AGIFGADPIH SLRVCVDTVR TNVYLAVFDK NLYDKLVSSF LEMKSEKQVE
     QKIAEIPKEE VKPFITESKP SVEQRKQDDK KIKACVEEVT TTLEETKFLT ENLLLYIDIN
     GNLHPDSATL VSDIDITFLK KDAPYIVGDV VQEGVLTAVV IPTKKAGGTT EMLAKALRKV
     PTDNYITTYP GQGLNGYTVE EAKTVLKKCK SAFYILPSII SNEKQEILGT VSWNLREMLA
     HAEETRKLMP VCVETKAIVS TIQRKYKGIK IQEGVVDYGA RFYFYTSKTT VASLINTLND
     LNETLVTMPL GYVTHGLNLE EAARYMRSLK VPATVSVSSP DAVTAYNGYL TSSSKTPEEH
     FIETISLAGS YKDWSYSGQS TQLGIEFLKR GDKSVYYTSN PTTFHLDGEV ITFDNLKTLL
     SLREVRTIKV FTTVDNINLH TQVVDMSMTY GQQFGPTYLD GADVTKIKPH NSHEGKTFYV
     LPNDDTLRVE AFEYYHTTDP SFLGRYMSAL NHTKKWKYPQ VNGLTSIKWA DNNCYLATAL
     LTLQQIELKF NPPALQDAYY RARAGEAANF CALILAYCNK TVGELGDVRE TMSYLFQHAN
     LDSCKRVLNV VCKTCGQQQT TLKGVEAVMY MGTLSYEQFK KGVQIPCTCG KQATKYLVQQ
     ESPFVMMSAP PAQYELKHGT FTCASEYTGN YQCGHYKHIT SKETLYCIDG ALLTKSSEYK
     GPITDVFYKE NSYTTTIKPV TYKLDGVVCT EIDPKLDNYY KKDNSYFTEQ PIDLVPNQPY
     PNASFDNFKF VCDNIKFADD LNQLTGYKKP ASRELKVTFF PDLNGDVVAI DYKHYTPSFK
     KGAKLLHKPI VWHVNNATNK ATYKPNTWCI RCLWSTKPVE TSNSFDVLKS EDAQGMDNLA
     CEDLKPVSEE VVENPTIQKD VLECNVKTTE VVGDIILKPA NNSLKITEEV GHTDLMAAYV
     DNSSLTIKKP NELSRVLGLK TLATHGLAAV NSVPWDTIAN YAKPFLNKVV STTTNIVTRC
     LNRVCTNYMP YFFTLLLQLC TFTRSTNSRI KASMPTTIAK NTVKSVGKFC LEASFNYLKS
     PNFSKLINII IWFLLLSVCL GSLIYSTAAL GVLMSNLGMP SYCTGYREGY LNSTNVTIAT
     YCTGSIPCSV CLSGLDSLDT YPSLETIQIT ISSFKWDLTA FGLVAEWFLA YILFTRFFYV
     LGLAAIMQLF FSYFAVHFIS NSWLMWLIIN LVQMAPISAM VRMYIFFASF YYVWKSYVHV
     VDGCNSSTCM MCYKRNRATR VECTTIVNGV RRSFYVYANG GKGFCKLHNW NCVNCDTFCA
     GSTFISDEVA RDLSLQFKRP INPTDQSSYI VDSVTVKNGS IHLYFDKAGQ KTYERHSLSH
     FVNLDNLRAN NTKGSLPINV IVFDGKSKCE ESSAKSASVY YSQLMCQPIL LLDQALVSDV
     GDSAEVAVKM FDAYVNTFSS TFNVPMEKLK TLVATAEAEL AKNVSLDNVL STFISAARQG
     FVDSDVETKD VVECLKLSHQ SDIEVTGDSC NNYMLTYNKV ENMTPRDLGA CIDCSARHIN
     AQVAKSHNIA LIWNVKDFMS LSEQLRKQIR SAAKKNNLPF KLTCATTRQV VNVVTTKIAL
     KGGKIVNNWL KQLIKVTLVF LFVAAIFYLI TPVHVMSKHT DFSSEIIGYK AIDGGVTRDI
     ASTDTCFANK HADFDTWFSQ RGGSYTNDKA CPLIAAVITR EVGFVVPGLP GTILRTTNGD
     FLHFLPRVFS AVGNICYTPS KLIEYTDFAT SACVLAAECT IFKDASGKPV PYCYDTNVLE
     GSVAYESLRP DTRYVLMDGS IIQFPNTYLE GSVRVVTTFD SEYCRHGTCE RSEAGVCVST
     SGRWVLNNDY YRSLPGVFCG VDAVNLLTNM FTPLIQPIGA LDISASIVAG GIVAIVVTCL
     AYYFMRFRRA FGEYSHVVAF NTLLFLMSFT VLCLTPVYSF LPGVYSVIYL YLTFYLTNDV
     SFLAHIQWMV MFTPLVPFWI TIAYIICIST KHFYWFFSNY LKRRVVFNGV SFSTFEEAAL
     CTFLLNKEMY LKLRSDVLLP LTQYNRYLAL YNKYKYFSGA MDTTSYREAA CCHLAKALND
     FSNSGSDVLY QPPQTSITSA VLQSGFRKMA FPSGKVEGCM VQVTCGTTTL NGLWLDDVVY
     CPRHVICTSE DMLNPNYEDL LIRKSNHNFL VQAGNVQLRV IGHSMQNCVL KLKVDTANPK
     TPKYKFVRIQ PGQTFSVLAC YNGSPSGVYQ CAMRPNFTIK GSFLNGSCGS VGFNIDYDCV
     SFCYMHHMEL PTGVHAGTDL EGNFYGPFVD RQTAQAAGTD TTITVNVLAW LYAAVINGDR
     WFLNRFTTTL NDFNLVAMKY NYEPLTQDHV DILGPLSAQT GIAVLDMCAS LKELLQNGMN
     GRTILGSALL EDEFTPFDVV RQCSGVTFQS AVKRTIKGTH HWLLLTILTS LLVLVQSTQW
     SLFFFLYENA FLPFAMGIIA MSAFAMMFVK HKHAFLCLFL LPSLATVAYF NMVYMPASWV
     MRIMTWLDMV DTSLSGFKLK DCVMYASAVV LLILMTARTV YDDGARRVWT LMNVLTLVYK
     VYYGNALDQA ISMWALIISV TSNYSGVVTT VMFLARGIVF MCVEYCPIFF ITGNTLQCIM
     LVYCFLGYFC TCYFGLFCLL NRYFRLTLGV YDYLVSTQEF RYMNSQGLLP PKNSIDAFKL
     NIKLLGVGGK PCIKVATVQS KMSDVKCTSV VLLSVLQQLR VESSSKLWAQ CVQLHNDILL
     AKDTTEAFEK MVSLLSVLLS MQGAVDINKL CEEMLDNRAT LQAIASEFSS LPSYAAFATA
     QEAYEQAVAN GDSEVVLKKL KKSLNVAKSE FDRDAAMQRK LEKMADQAMT QMYKQARSED
     KRAKVTSAMQ TMLFTMLRKL DNDALNNIIN NARDGCVPLN IIPLTTAAKL MVVIPDYNTY
     KNTCDGTTFT YASALWEIQQ VVDADSKIVQ LSEISMDNSP NLAWPLIVTA LRANSAVKLQ
     NNELSPVALR QMSCAAGTTQ TACTDDNALA YYNTTKGGRF VLALLSDLQD LKWARFPKSD
     GTGTIYTELE PPCRFVTDTP KGPKVKYLYF IKGLNNLNRG MVLGSLAATV RLQAGNATEV
     PANSTVLSFC AFAVDAAKAY KDYLASGGQP ITNCVKMLCT HTGTGQAITV TPEANMDQES
     FGGASCCLYC RCHIDHPNPK GFCDLKGKYV QIPTTCANDP VGFTLKNTVC TVCGMWKGYG
     CSCDQLREPM LQSADAQSFL NRVCGVSAAR LTPCGTGTST DVVYRAFDIY NDKVAGFAKF
     LKTNCCRFQE KDEDDNLIDS YFVVKRHTFS NYQHEETIYN LLKDCPAVAK HDFFKFRIDG
     DMVPHISRQR LTKYTMADLV YALRHFDEGN CDTLKEILVT YNCCDDDYFN KKDWYDFVEN
     PDILRVYANL GERVRQALLK TVQFCDAMRN AGIVGVLTLD NQDLNGNWYD FGDFIQTTPG
     SGVPVVDSYY SLLMPILTLT RALTAESHVD TDLTKPYIKW DLLKYDFTEE RLKLFDRYFK
     YWDQTYHPNC VNCLDDRCIL HCANFNVLFS TVFPPTSFGP LVRKIFVDGV PFVVSTGYHF
     RELGVVHNQD VNLHSSRLSF KELLVYAADP AMHAASGNLL LDKRTTCFSV AALTNNVAFQ
     TVKPGNFNKD FYDFAVSKGF FKEGSSVELK HFFFAQDGNA AISDYDYYRY NLPTMCDIRQ
     LLFVVEVVDK YFDCYDGGCI NANQVIVNNL DKSAGFPFNK WGKARLYYDS MSYEDQDALF
     AYTKRNVIPT ITQMNLKYAI SAKNRARTVA GVSICSTMTN RQFHQKLLKS IAATRGATVV
     IGTSKFYGGW HNMLKTVYSD VENPHLMGWD YPKCDRAMPN MLRIMASLVL ARKHTTCCSL
     SHRFYRLANE CAQVLSEMVM CGGSLYVKPG GTSSGDATTA YANSVFNICQ AVTANVNALL
     STDGNKIADK YVRNLQHRLY ECLYRNRDVD TDFVNEFYAY LRKHFSMMIL SDDAVVCFNS
     TYASQGLVAS IKNFKSVLYY QNNVFMSEAK CWTETDLTKG PHEFCSQHTM LVKQGDDYVY
     LPYPDPSRIL GAGCFVDDIV KTDGTLMIER FVSLAIDAYP LTKHPNQEYA DVFHLYLQYI
     RKLHDELTGH MLDMYSVMLT NDNTSRYWEP EFYEAMYTPH TVLQAVGACV LCNSQTSLRC
     GACIRRPFLC CKCCYDHVIS TSHKLVLSVN PYVCNAPGCD VTDVTQLYLG GMSYYCKSHK
     PPISFPLCAN GQVFGLYKNT CVGSDNVTDF NAIATCDWTN AGDYILANTC TERLKLFAAE
     TLKATEETFK LSYGIATVRE VLSDRELHLS WEVGKPRPPL NRNYVFTGYR VTKNSKVQIG
     EYTFEKGDYG DAVVYRGTTT YKLNVGDYFV LTSHTVMPLS APTLVPQEHY VRITGLYPTL
     NISDEFSSNV ANYQKVGMQK YSTLQGPPGT GKSHFAIGLA LYYPSARIVY TACSHAAVDA
     LCEKALKYLP IDKCSRIIPA RARVECFDKF KVNSTLEQYV FCTVNALPET TADIVVFDEI
     SMATNYDLSV VNARLRAKHY VYIGDPAQLP APRTLLTKGT LEPEYFNSVC RLMKTIGPDM
     FLGTCRRCPA EIVDTVSALV YDNKLKAHKD KSAQCFKMFY KGVITHDVSS AINRPQIGVV
     REFLTRNPAW RKAVFISPYN SQNAVASKIL GLPTQTVDSS QGSEYDYVIF TQTTETAHSC
     NVNRFNVAIT RAKVGILCIM SDRDLYDKLQ FTSLEIPRRN VATLQAENVT GLFKDCSKVI
     TGLHPTQAPT HLSVDTKFKT EGLCVDIPGI PKDMTYRRLI SMMGFKMNYQ VNGYPNMFIT
     REEAIRHVRA WIGFDVEGCH ATREAVGTNL PLQLGFSTGV NLVAVPTGYV DTPNNTDFSR
     VSAKPPPGDQ FKHLIPLMYK GLPWNVVRIK IVQMLSDTLK NLSDRVVFVL WAHGFELTSM
     KYFVKIGPER TCCLCDRRAT CFSTASDTYA CWHHSIGFDY VYNPFMIDVQ QWGFTGNLQS
     NHDLYCQVHG NAHVASCDAI MTRCLAVHEC FVKRVDWTIE YPIIGDELKI NAACRKVQHM
     VVKAALLADK FPVLHDIGNP KAIKCVPQAD VEWKFYDAQP CSDKAYKIEE LFYSYATHSD
     KFTDGVCLFW NCNVDRYPAN SIVCRFDTRV LSNLNLPGCD GGSLYVNKHA FHTPAFDKSA
     FVNLKQLPFF YYSDSPCESH GKQVVSDIDY VPLKSATCIT RCNLGGAVCR HHANEYRLYL
     DAYNMMISAG FSLWVYKQFD TYNLWNTFTR LQSLENVAFN VVNKGHFDGQ QGEVPVSIIN
     NTVYTKVDGV DVELFENKTT LPVNVAFELW AKRNIKPVPE VKILNNLGVD IAANTVIWDY
     KRDAPAHIST IGVCSMTDIA KKPTETICAP LTVFFDGRVD GQVDLFRNAR NGVLITEGSV
     KGLQPSVGPK QASLNGVTLI GEAVKTQFNY YKKVDGVVQQ LPETYFTQSR NLQEFKPRSQ
     MEIDFLELAM DEFIERYKLE GYAFEHIVYG DFSHSQLGGL HLLIGLAKRF KESPFELEDF
     IPMDSTVKNY FITDAQTGSS KCVCSVIDLL LDDFVEIIKS QDLSVVSKVV KVTIDYTEIS
     FMLWCKDGHV ETFYPKLQSS QAWQPGVAMP NLYKMQRMLL EKCDLQNYGD SATLPKGIMM
     NVAKYTQLCQ YLNTLTLAVP YNMRVIHFGA GSDKGVAPGT AVLRQWLPTG TLLVDSDLND
     FVSDADSTLI GDCATVHTAN KWDLIISDMY DPKTKNVTKE NDSKEGFFTY ICGFIQQKLA
     LGGSVAIKIT EHSWNADLYK LMGHFAWWTA FVTNVNASSS EAFLIGCNYL GKPREQIDGY
     VMHANYIFWR NTNPIQLSSY SLFDMSKFPL KLRGTAVMSL KEGQINDMIL SLLSKGRLII
     RENNRVVISS DVLVNN
//
ID   ITAL_HUMAN              Reviewed;        1170 AA.
AC   P20701; O43746; Q45H73; Q96HB1; Q9UBC8;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   07-FEB-2006, sequence version 3.
DT   12-AUG-2020, entry version 217.
DE   RecName: Full=Integrin alpha-L;
DE   AltName: Full=CD11 antigen-like family member A;
DE   AltName: Full=Leukocyte adhesion glycoprotein LFA-1 alpha chain;
DE            Short=LFA-1A;
DE   AltName: Full=Leukocyte function-associated molecule 1 alpha chain;
DE   AltName: CD_antigen=CD11a;
DE   Flags: Precursor;
GN   Name=ITGAL; Synonyms=CD11A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 120-132;
RP   226-237; 282-288; 433-441; 522-531; 569-582; 591-604; 831-844 AND 957-974,
RP   DOMAIN, AND VARIANT TRP-214.
RX   PubMed=2537322; DOI=10.1083/jcb.108.2.703;
RA   Larson R.S., Corbi A.L., Berman L., Springer T.;
RT   "Primary structure of the leukocyte function-associated molecule-1 alpha
RT   subunit: an integrin with an embedded domain defining a protein
RT   superfamily.";
RL   J. Cell Biol. 108:703-712(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-144; TRP-214; LYS-746
RP   AND THR-791.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM 2), AND VARIANT
RP   TRP-214.
RX   PubMed=10493829; DOI=10.1006/geno.1999.5927;
RA   Loftus B.J., Kim U.-J., Sneddon V.P., Kalush F., Brandon R., Fuhrmann J.,
RA   Mason T., Crosby M.L., Barnstead M., Cronin L., Mays A.D., Cao Y., Xu R.X.,
RA   Kang H.-L., Mitchell S., Eichler E.E., Harris P.C., Venter J.C.,
RA   Adams M.D.;
RT   "Genome duplications and other features in 12 Mb of DNA sequence from human
RT   chromosome 16p and 16q.";
RL   Genomics 60:295-308(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-20.
RX   PubMed=8099450; DOI=10.1073/pnas.90.11.5364;
RA   Shelley C.S., Farokhzad O.C., Arnaout M.A.;
RT   "Identification of cell-specific and developmentally regulated nuclear
RT   factors that direct myeloid and lymphoid expression of the CD11a gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5364-5368(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-20.
RX   PubMed=8103515;
RA   Nueda A., Lopez-Cabrera M., Vara A., Corbi A.L.;
RT   "Characterization of the CD11a (alpha L, LFA-1 alpha) integrin gene
RT   promoter.";
RL   J. Biol. Chem. 268:19305-19311(1993).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-20.
RX   PubMed=8097887; DOI=10.1073/pnas.90.9.4221;
RA   Cornwell R.D., Gollahon K.A., Hickstein D.D.;
RT   "Description of the leukocyte function-associated antigen 1 (LFA-1 or
RT   CD11a) promoter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:4221-4225(1993).
RN   [10]
RP   FUNCTION.
RX   PubMed=11812992; DOI=10.1038/ni755;
RA   Ostermann G., Weber K.S., Zernecke A., Schroeder A., Weber C.;
RT   "JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in
RT   transendothelial migration of leukocytes.";
RL   Nat. Immunol. 3:151-158(2002).
RN   [11]
RP   FUNCTION.
RX   PubMed=15356110; DOI=10.4049/jimmunol.173.6.3653;
RA   Barber D.F., Faure M., Long E.O.;
RT   "LFA-1 contributes an early signal for NK cell cytotoxicity.";
RL   J. Immunol. 173:3653-3659(2004).
RN   [12]
RP   DOMAIN, AND FUNCTION.
RX   PubMed=15528364; DOI=10.4049/jimmunol.173.10.6259;
RA   Fraemohs L., Koenen R.R., Ostermann G., Heinemann B., Weber C.;
RT   "The functional interaction of the beta 2 integrin lymphocyte function-
RT   associated antigen-1 with junctional adhesion molecule-A is mediated by the
RT   I domain.";
RL   J. Immunol. 173:6259-6264(2004).
RN   [13]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, PHOSPHORYLATION AT SER-1165, AND
RP   MUTAGENESIS OF SER-1165.
RX   PubMed=16301335; DOI=10.1083/jcb.200504016;
RA   Fagerholm S.C., Hilden T.J., Nurmi S.M., Gahmberg C.G.;
RT   "Specific integrin alpha and beta chain phosphorylations regulate LFA-1
RT   activation through affinity-dependent and -independent mechanisms.";
RL   J. Cell Biol. 171:705-715(2005).
RN   [14]
RP   INTERACTION WITH SARS-COV ORF7A PROTEIN (MICROBIAL INFECTION).
RX   PubMed=18020948; DOI=10.1515/bc.2007.157;
RA   Haenel K., Willbold D.;
RT   "SARS-CoV accessory protein 7a directly interacts with human LFA-1.";
RL   Biol. Chem. 388:1325-1332(2007).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-188.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [16]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=23775590; DOI=10.1007/s10495-013-0873-z;
RA   Kristof E., Zahuczky G., Katona K., Doro Z., Nagy E., Fesues L.;
RT   "Novel role of ICAM3 and LFA-1 in the clearance of apoptotic neutrophils by
RT   human macrophages.";
RL   Apoptosis 18:1235-1251(2013).
RN   [17]
RP   INTERACTION WITH THBD.
RX   PubMed=27055590; DOI=10.1016/j.bbrc.2016.04.007;
RA   Kawamoto E., Okamoto T., Takagi Y., Honda G., Suzuki K., Imai H.,
RA   Shimaoka M.;
RT   "LFA-1 and Mac-1 integrins bind to the serine/threonine-rich domain of
RT   thrombomodulin.";
RL   Biochem. Biophys. Res. Commun. 473:1005-1012(2016).
RN   [18]
RP   FUNCTION.
RX   PubMed=29100055; DOI=10.1016/j.molcel.2017.10.003;
RA   Swaim C.D., Scott A.F., Canadeo L.A., Huibregtse J.M.;
RT   "Extracellular ISG15 signals cytokine secretion through the LFA-1 integrin
RT   receptor.";
RL   Mol. Cell 68:581-590(2017).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 153-335, AND SEQUENCE REVISION TO
RP   214.
RX   PubMed=7479767; DOI=10.1073/pnas.92.22.10277;
RA   Qu A., Leahy D.J.;
RT   "Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alpha L beta
RT   2) integrin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:10277-10281(1995).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 153-335.
RX   PubMed=8805579; DOI=10.1016/s0969-2126(96)00100-1;
RA   Qu A., Leahy D.J.;
RT   "The role of the divalent cation in the structure of the I domain from the
RT   CD11a/CD18 integrin.";
RL   Structure 4:931-942(1996).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 153-334.
RX   PubMed=10493852; DOI=10.1006/jmbi.1999.3047;
RA   Kallen J., Welzenbach K., Ramage P., Geyl D., Kriwacki R., Legge G.,
RA   Cottens S., Weitz-Schmidt G., Hommel U.;
RT   "Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a
RT   I-domain.";
RL   J. Mol. Biol. 292:1-9(1999).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 155-331 IN COMPLEX WITH ICAM1.
RX   PubMed=12526797; DOI=10.1016/s0092-8674(02)01257-6;
RA   Shimaoka M., Xiao T., Liu J.H., Yang Y., Dong Y., Jun C.D., McCormack A.,
RA   Zhang R., Joachimiak A., Takagi J., Wang J.H., Springer T.A.;
RT   "Structures of the alpha L I domain and its complex with ICAM-1 reveal a
RT   shape-shifting pathway for integrin regulation.";
RL   Cell 112:99-111(2003).
CC   -!- FUNCTION: Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3
CC       and ICAM4. Integrin ITGAL/ITGB2 is a receptor for F11R
CC       (PubMed:11812992, PubMed:15528364). Integin ITGAL/ITGB2 is a receptor
CC       for the secreted form of ubiquitin-like protein ISG15; the interaction
CC       is mediated by ITGAL (PubMed:29100055). Involved in a variety of immune
CC       phenomena including leukocyte-endothelial cell interaction, cytotoxic
CC       T-cell mediated killing, and antibody dependent killing by granulocytes
CC       and monocytes. Contributes to natural killer cell cytotoxicity
CC       (PubMed:15356110). Involved in leukocyte adhesion and transmigration of
CC       leukocytes including T-cells and neutrophils (PubMed:11812992).
CC       Required for generation of common lymphoid progenitor cells in bone
CC       marrow, indicating a role in lymphopoiesis (By similarity). Integrin
CC       ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic
CC       neutrophil phagocytosis by macrophages (PubMed:23775590).
CC       {ECO:0000250|UniProtKB:P24063, ECO:0000269|PubMed:11812992,
CC       ECO:0000269|PubMed:15356110, ECO:0000269|PubMed:15528364,
CC       ECO:0000269|PubMed:23775590, ECO:0000269|PubMed:29100055}.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit (PubMed:12526797).
CC       The ITGAL alpha subunit associates with the ITGB2 beta subunit
CC       (PubMed:12526797). Interacts with THBD (PubMed:27055590).
CC       {ECO:0000269|PubMed:12526797, ECO:0000269|PubMed:27055590}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV Orf7a protein.
CC       {ECO:0000269|PubMed:18020948}.
CC   -!- INTERACTION:
CC       P20701; P05362: ICAM1; NbExp=2; IntAct=EBI-961214, EBI-1035358;
CC       P20701; P08575: PTPRC; NbExp=2; IntAct=EBI-961214, EBI-1341;
CC       P20701; PRO_0000037551 [Q9WMX2]; Xeno; NbExp=2; IntAct=EBI-961214, EBI-6863748;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16301335};
CC       Single-pass type I membrane protein {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P20701-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P20701-2; Sequence=VSP_002738;
CC       Name=3;
CC         IsoId=P20701-3; Sequence=VSP_042842, VSP_042843;
CC   -!- TISSUE SPECIFICITY: Leukocytes. {ECO:0000269|PubMed:16301335,
CC       ECO:0000269|PubMed:23775590}.
CC   -!- DOMAIN: The integrin I-domain (insert) is a VWFA domain
CC       (PubMed:2537322). Integrins with I-domains do not undergo protease
CC       cleavage. The I-domain is necessary and sufficient for interaction with
CC       ICAM1 and F11R (PubMed:15528364). {ECO:0000269|PubMed:15528364,
CC       ECO:0000269|PubMed:2537322}.
CC   -!- PTM: In resting T-cells, up to 40% of surface ITGAL is constitutively
CC       phosphorylated. Phosphorylation causes conformational changes needed
CC       for ligand binding and is necessary for activation by some
CC       physiological agents. {ECO:0000269|PubMed:16301335}.
CC   -!- SIMILARITY: Belongs to the integrin alpha chain family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/itgal/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y00796; CAA68747.1; -; mRNA.
DR   EMBL; DQ131904; AAZ38713.1; -; Genomic_DNA.
DR   EMBL; AC002310; AAC31672.1; -; Genomic_DNA.
DR   EMBL; AC116348; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471192; EAW52243.1; -; Genomic_DNA.
DR   EMBL; BC008777; AAH08777.1; -; mRNA.
DR   EMBL; M95609; AAA16474.2; -; Genomic_DNA.
DR   EMBL; Z22804; CAA80461.1; -; Genomic_DNA.
DR   EMBL; M87662; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS32433.1; -. [P20701-1]
DR   CCDS; CCDS45461.1; -. [P20701-3]
DR   PIR; S03308; S03308.
DR   RefSeq; NP_001107852.1; NM_001114380.1. [P20701-3]
DR   RefSeq; NP_002200.2; NM_002209.2. [P20701-1]
DR   PDB; 1CQP; X-ray; 2.60 A; A/B=153-334.
DR   PDB; 1DGQ; NMR; -; A=152-336.
DR   PDB; 1IJ4; Model; -; L=153-333.
DR   PDB; 1LFA; X-ray; 1.80 A; A/B=150-336.
DR   PDB; 1MJN; X-ray; 1.30 A; A=153-331.
DR   PDB; 1MQ8; X-ray; 3.30 A; B/D=155-331.
DR   PDB; 1MQ9; X-ray; 2.00 A; A=153-331.
DR   PDB; 1MQA; X-ray; 2.50 A; A=153-331.
DR   PDB; 1RD4; X-ray; 2.40 A; A/B/C/D=150-336.
DR   PDB; 1T0P; X-ray; 1.66 A; A=153-326.
DR   PDB; 1XDD; X-ray; 2.20 A; A/B=152-336.
DR   PDB; 1XDG; X-ray; 2.10 A; A/B=152-336.
DR   PDB; 1XUO; X-ray; 1.80 A; A/B=152-336.
DR   PDB; 1ZON; X-ray; 2.00 A; A=150-336.
DR   PDB; 1ZOO; X-ray; 3.00 A; A/B=150-336.
DR   PDB; 1ZOP; X-ray; 2.00 A; A/B=150-336.
DR   PDB; 2ICA; X-ray; 1.56 A; A=154-332.
DR   PDB; 2K8O; NMR; -; A=1113-1170.
DR   PDB; 2M3E; NMR; -; A=1082-1128.
DR   PDB; 2O7N; X-ray; 1.75 A; A=154-332.
DR   PDB; 3BN3; X-ray; 2.10 A; A=154-332.
DR   PDB; 3BQM; X-ray; 1.95 A; B/C=153-334.
DR   PDB; 3BQN; X-ray; 1.80 A; B/C=153-334.
DR   PDB; 3E2M; X-ray; 2.00 A; A/B=152-334.
DR   PDB; 3EOA; X-ray; 2.80 A; I/J=153-333.
DR   PDB; 3EOB; X-ray; 3.60 A; I/J=153-333.
DR   PDB; 3F74; X-ray; 1.70 A; A/B/C=153-332.
DR   PDB; 3F78; X-ray; 1.60 A; A/B/C=153-332.
DR   PDB; 3HI6; X-ray; 2.30 A; A/B=153-332.
DR   PDB; 3M6F; X-ray; 1.85 A; A=154-332.
DR   PDB; 3TCX; X-ray; 3.60 A; B/D/F/H/J/L/N/P/R/T/V/X/Z/b=154-332.
DR   PDB; 4IXD; X-ray; 1.80 A; A=152-336.
DR   PDB; 5E6R; X-ray; 2.90 A; A=26-770.
DR   PDB; 5E6S; X-ray; 2.15 A; A/C/E=26-770.
DR   PDB; 5E6U; X-ray; 2.50 A; A=26-770.
DR   PDB; 6BXB; X-ray; 2.39 A; A/B=153-331.
DR   PDB; 6BXF; X-ray; 3.20 A; A/B=153-331.
DR   PDB; 6BXJ; X-ray; 2.09 A; A=153-331.
DR   PDB; 6CKB; X-ray; 2.80 A; A/B=153-331.
DR   PDBsum; 1CQP; -.
DR   PDBsum; 1DGQ; -.
DR   PDBsum; 1IJ4; -.
DR   PDBsum; 1LFA; -.
DR   PDBsum; 1MJN; -.
DR   PDBsum; 1MQ8; -.
DR   PDBsum; 1MQ9; -.
DR   PDBsum; 1MQA; -.
DR   PDBsum; 1RD4; -.
DR   PDBsum; 1T0P; -.
DR   PDBsum; 1XDD; -.
DR   PDBsum; 1XDG; -.
DR   PDBsum; 1XUO; -.
DR   PDBsum; 1ZON; -.
DR   PDBsum; 1ZOO; -.
DR   PDBsum; 1ZOP; -.
DR   PDBsum; 2ICA; -.
DR   PDBsum; 2K8O; -.
DR   PDBsum; 2M3E; -.
DR   PDBsum; 2O7N; -.
DR   PDBsum; 3BN3; -.
DR   PDBsum; 3BQM; -.
DR   PDBsum; 3BQN; -.
DR   PDBsum; 3E2M; -.
DR   PDBsum; 3EOA; -.
DR   PDBsum; 3EOB; -.
DR   PDBsum; 3F74; -.
DR   PDBsum; 3F78; -.
DR   PDBsum; 3HI6; -.
DR   PDBsum; 3M6F; -.
DR   PDBsum; 3TCX; -.
DR   PDBsum; 4IXD; -.
DR   PDBsum; 5E6R; -.
DR   PDBsum; 5E6S; -.
DR   PDBsum; 5E6U; -.
DR   PDBsum; 6BXB; -.
DR   PDBsum; 6BXF; -.
DR   PDBsum; 6BXJ; -.
DR   PDBsum; 6CKB; -.
DR   SMR; P20701; -.
DR   BioGRID; 109889; 7.
DR   ComplexPortal; CPX-1825; Integrin alphaL-beta2 complex.
DR   DIP; DIP-623N; -.
DR   IntAct; P20701; 9.
DR   MINT; P20701; -.
DR   STRING; 9606.ENSP00000349252; -.
DR   BindingDB; P20701; -.
DR   ChEMBL; CHEMBL1803; -.
DR   DrugBank; DB04724; (S)-2-((S)-3-isobutyl-2,5-dioxo-4-quinolin-3-ylmethyl-[1,4]diazepan-1yl)-N-methyl-3-naphtalen-2-yl-propionamide.
DR   DrugBank; DB02177; 1-Acetyl-4-(4-{4-[(2-Ethoxyphenyl)Thio]-3-Nitrophenyl}Pyridin-2-Yl)Piperazine.
DR   DrugBank; DB07486; 3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline.
DR   DrugBank; DB06972; 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile.
DR   DrugBank; DB00098; Antithymocyte immunoglobulin (rabbit).
DR   DrugBank; DB00095; Efalizumab.
DR   DrugBank; DB03932; LFA703.
DR   DrugBank; DB11611; Lifitegrast.
DR   DrugBank; DB00227; Lovastatin.
DR   DrugBank; DB08860; Pitavastatin.
DR   DrugBank; DB01098; Rosuvastatin.
DR   DrugBank; DB00641; Simvastatin.
DR   DrugCentral; P20701; -.
DR   GuidetoPHARMACOLOGY; 2451; -.
DR   GlyConnect; 1410; 9 N-Linked glycans (1 site).
DR   GlyGen; P20701; 12 sites.
DR   iPTMnet; P20701; -.
DR   PhosphoSitePlus; P20701; -.
DR   BioMuta; ITGAL; -.
DR   DMDM; 88911345; -.
DR   jPOST; P20701; -.
DR   MassIVE; P20701; -.
DR   MaxQB; P20701; -.
DR   PaxDb; P20701; -.
DR   PeptideAtlas; P20701; -.
DR   PRIDE; P20701; -.
DR   ProteomicsDB; 53774; -. [P20701-1]
DR   ProteomicsDB; 53775; -. [P20701-2]
DR   ProteomicsDB; 53776; -. [P20701-3]
DR   ABCD; P20701; 36 sequenced antibodies.
DR   Antibodypedia; 13698; 2051 antibodies.
DR   DNASU; 3683; -.
DR   Ensembl; ENST00000356798; ENSP00000349252; ENSG00000005844. [P20701-1]
DR   Ensembl; ENST00000358164; ENSP00000350886; ENSG00000005844. [P20701-3]
DR   GeneID; 3683; -.
DR   KEGG; hsa:3683; -.
DR   UCSC; uc002dyi.5; human. [P20701-1]
DR   CTD; 3683; -.
DR   DisGeNET; 3683; -.
DR   EuPathDB; HostDB:ENSG00000005844.17; -.
DR   GeneCards; ITGAL; -.
DR   HGNC; HGNC:6148; ITGAL.
DR   HPA; ENSG00000005844; Tissue enhanced (blood, lymphoid tissue).
DR   MIM; 153370; gene.
DR   neXtProt; NX_P20701; -.
DR   OpenTargets; ENSG00000005844; -.
DR   PharmGKB; PA29948; -.
DR   eggNOG; KOG3637; Eukaryota.
DR   GeneTree; ENSGT00940000161495; -.
DR   HOGENOM; CLU_004111_3_0_1; -.
DR   InParanoid; P20701; -.
DR   KO; K05718; -.
DR   OMA; TVCFQLK; -.
DR   PhylomeDB; P20701; -.
DR   TreeFam; TF105391; -.
DR   PathwayCommons; P20701; -.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-8949275; RUNX3 Regulates Immune Response and Cell Migration.
DR   SignaLink; P20701; -.
DR   SIGNOR; P20701; -.
DR   BioGRID-ORCS; 3683; 9 hits in 871 CRISPR screens.
DR   ChiTaRS; ITGAL; human.
DR   EvolutionaryTrace; P20701; -.
DR   GeneWiki; CD11a; -.
DR   GenomeRNAi; 3683; -.
DR   Pharos; P20701; Tclin.
DR   PRO; PR:P20701; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; P20701; protein.
DR   Bgee; ENSG00000005844; Expressed in granulocyte and 223 other tissues.
DR   ExpressionAtlas; P20701; baseline and differential.
DR   Genevisible; P20701; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0034687; C:integrin alphaL-beta2 complex; IDA:UniProtKB.
DR   GO; GO:0008305; C:integrin complex; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IMP:UniProtKB.
DR   GO; GO:0030369; F:ICAM-3 receptor activity; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; NAS:UniProtKB.
DR   GO; GO:0098609; P:cell-cell adhesion; ISS:BHF-UCL.
DR   GO; GO:0007160; P:cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; IMP:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; NAS:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IMP:ARUK-UCL.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0035683; P:memory T cell extravasation; IDA:ARUK-UCL.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0006909; P:phagocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0043113; P:receptor clustering; IMP:UniProtKB.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0002291; P:T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell; IMP:BHF-UCL.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.130.10.130; -; 1.
DR   Gene3D; 3.40.50.410; -; 1.
DR   InterPro; IPR013517; FG-GAP.
DR   InterPro; IPR013519; Int_alpha_beta-p.
DR   InterPro; IPR000413; Integrin_alpha.
DR   InterPro; IPR013649; Integrin_alpha-2.
DR   InterPro; IPR018184; Integrin_alpha_C_CS.
DR   InterPro; IPR028994; Integrin_alpha_N.
DR   InterPro; IPR032695; Integrin_dom_sf.
DR   InterPro; IPR002035; VWF_A.
DR   InterPro; IPR036465; vWFA_dom_sf.
DR   Pfam; PF01839; FG-GAP; 1.
DR   Pfam; PF00357; Integrin_alpha; 1.
DR   Pfam; PF08441; Integrin_alpha2; 1.
DR   Pfam; PF00092; VWA; 1.
DR   PRINTS; PR01185; INTEGRINA.
DR   SMART; SM00191; Int_alpha; 5.
DR   SMART; SM00327; VWA; 1.
DR   SUPFAM; SSF53300; SSF53300; 1.
DR   SUPFAM; SSF69179; SSF69179; 2.
DR   PROSITE; PS51470; FG_GAP; 7.
DR   PROSITE; PS00242; INTEGRIN_ALPHA; 1.
DR   PROSITE; PS50234; VWFA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell membrane;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Integrin; Magnesium; Membrane; Metal-binding;
KW   Phagocytosis; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..1170
FT                   /note="Integrin alpha-L"
FT                   /id="PRO_0000016292"
FT   TOPO_DOM        26..1090
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1091..1111
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1112..1170
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          31..82
FT                   /note="FG-GAP 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          83..141
FT                   /note="FG-GAP 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   DOMAIN          156..327
FT                   /note="VWFA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00219"
FT   REPEAT          338..389
FT                   /note="FG-GAP 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          390..445
FT                   /note="FG-GAP 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          446..506
FT                   /note="FG-GAP 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          507..563
FT                   /note="FG-GAP 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          567..627
FT                   /note="FG-GAP 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   CA_BIND         468..476
FT                   /evidence="ECO:0000255"
FT   CA_BIND         530..538
FT                   /evidence="ECO:0000255"
FT   CA_BIND         590..598
FT                   /evidence="ECO:0000255"
FT   MOTIF           1115..1119
FT                   /note="GFFKR motif"
FT   MOD_RES         1165
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16301335"
FT   CARBOHYD        65
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        89
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        188
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19349973"
FT   CARBOHYD        649
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        670
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        726
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        730
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        862
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        885
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        897
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1060
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1071
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        73..80
FT                   /evidence="ECO:0000250"
FT   DISULFID        111..129
FT                   /evidence="ECO:0000250"
FT   DISULFID        653..707
FT                   /evidence="ECO:0000250"
FT   DISULFID        771..777
FT                   /evidence="ECO:0000250"
FT   DISULFID        845..861
FT                   /evidence="ECO:0000250"
FT   DISULFID        998..1013
FT                   /evidence="ECO:0000250"
FT   DISULFID        1021..1052
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         110..192
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042842"
FT   VAR_SEQ         746
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042843"
FT   VAR_SEQ         954
FT                   /note="Q -> QGVHGLVEMQTSKQILCRPAGDAEHTVGAQEGELPCPWGVSEAFRDN
FT                   IRAGPCR (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002738"
FT   VARIANT         144
FT                   /note="R -> H (in dbSNP:rs34166708)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_025235"
FT   VARIANT         214
FT                   /note="R -> W (in dbSNP:rs1064524)"
FT                   /evidence="ECO:0000269|PubMed:10493829,
FT                   ECO:0000269|PubMed:2537322, ECO:0000269|Ref.2"
FT                   /id="VAR_025236"
FT   VARIANT         746
FT                   /note="Q -> K (in dbSNP:rs34838942)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_025237"
FT   VARIANT         791
FT                   /note="R -> T (in dbSNP:rs2230433)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_025238"
FT   MUTAGEN         1165
FT                   /note="S->A: Abolishes phosphorylation and MEM-83-activated
FT                   T-cell adhesion to ICAM1. Abolishes integrin alpha-L/beta-2
FT                   activation by CXCL12 and TERF2IP/RAP1. Does not affect
FT                   heterodimerization of cell surface expression. Does not
FT                   affect TCR- or phorbol ester-activated T-cell adhesion to
FT                   ICAM1."
FT                   /evidence="ECO:0000269|PubMed:16301335"
FT   CONFLICT        660
FT                   /note="I -> Y (in Ref. 1; CAA68747)"
FT                   /evidence="ECO:0000305"
FT   HELIX           30..32
FT                   /evidence="ECO:0000244|PDB:5E6U"
FT   STRAND          34..36
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   TURN            43..46
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          47..52
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          55..60
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          69..73
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   TURN            75..77
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          80..82
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   TURN            93..96
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          97..101
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   TURN            103..105
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          108..119
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          122..134
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          140..143
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          155..162
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           169..185
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   TURN            186..188
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   STRAND          189..206
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           208..214
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           217..221
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           233..243
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           247..249
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   STRAND          255..265
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           274..276
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   STRAND          279..287
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           288..290
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           293..297
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           298..302
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           307..310
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   STRAND          311..316
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           317..319
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   HELIX           323..330
FT                   /evidence="ECO:0000244|PDB:1MJN"
FT   STRAND          331..333
FT                   /evidence="ECO:0000244|PDB:3BQN"
FT   STRAND          352..359
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          362..367
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   HELIX           370..373
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          375..380
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          387..391
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   TURN            398..401
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          406..411
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          413..416
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          419..424
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   HELIX           427..429
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          432..437
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          446..452
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          462..467
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          472..474
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          477..482
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          493..499
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          501..510
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          514..516
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          523..527
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          531..535
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          539..543
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          549..554
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          558..561
FT                   /evidence="ECO:0000244|PDB:5E6R"
FT   STRAND          566..570
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   HELIX           571..574
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          583..589
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          593..595
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          598..603
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   STRAND          606..612
FT                   /evidence="ECO:0000244|PDB:5E6S"
FT   TURN            1082..1086
FT                   /evidence="ECO:0000244|PDB:2M3E"
FT   HELIX           1090..1114
FT                   /evidence="ECO:0000244|PDB:2M3E"
FT   HELIX           1118..1123
FT                   /evidence="ECO:0000244|PDB:2K8O"
FT   TURN            1124..1127
FT                   /evidence="ECO:0000244|PDB:2K8O"
FT   HELIX           1137..1147
FT                   /evidence="ECO:0000244|PDB:2K8O"
FT   HELIX           1153..1155
FT                   /evidence="ECO:0000244|PDB:2K8O"
FT   HELIX           1156..1165
FT                   /evidence="ECO:0000244|PDB:2K8O"
FT   HELIX           1167..1170
FT                   /evidence="ECO:0000244|PDB:2K8O"
SQ   SEQUENCE   1170 AA;  128770 MW;  22A7AF92EF286876 CRC64;
     MKDSCITVMA MALLSGFFFF APASSYNLDV RGARSFSPPR AGRHFGYRVL QVGNGVIVGA
     PGEGNSTGSL YQCQSGTGHC LPVTLRGSNY TSKYLGMTLA TDPTDGSILA CDPGLSRTCD
     QNTYLSGLCY LFRQNLQGPM LQGRPGFQEC IKGNVDLVFL FDGSMSLQPD EFQKILDFMK
     DVMKKLSNTS YQFAAVQFST SYKTEFDFSD YVKRKDPDAL LKHVKHMLLL TNTFGAINYV
     ATEVFREELG ARPDATKVLI IITDGEATDS GNIDAAKDII RYIIGIGKHF QTKESQETLH
     KFASKPASEF VKILDTFEKL KDLFTELQKK IYVIEGTSKQ DLTSFNMELS SSGISADLSR
     GHAVVGAVGA KDWAGGFLDL KADLQDDTFI GNEPLTPEVR AGYLGYTVTW LPSRQKTSLL
     ASGAPRYQHM GRVLLFQEPQ GGGHWSQVQT IHGTQIGSYF GGELCGVDVD QDGETELLLI
     GAPLFYGEQR GGRVFIYQRR QLGFEEVSEL QGDPGYPLGR FGEAITALTD INGDGLVDVA
     VGAPLEEQGA VYIFNGRHGG LSPQPSQRIE GTQVLSGIQW FGRSIHGVKD LEGDGLADVA
     VGAESQMIVL SSRPVVDMVT LMSFSPAEIP VHEVECSYST SNKMKEGVNI TICFQIKSLI
     PQFQGRLVAN LTYTLQLDGH RTRRRGLFPG GRHELRRNIA VTTSMSCTDF SFHFPVCVQD
     LISPINVSLN FSLWEEEGTP RDQRAQGKDI PPILRPSLHS ETWEIPFEKN CGEDKKCEAN
     LRVSFSPARS RALRLTAFAS LSVELSLSNL EEDAYWVQLD LHFPPGLSFR KVEMLKPHSQ
     IPVSCEELPE ESRLLSRALS CNVSSPIFKA GHSVALQMMF NTLVNSSWGD SVELHANVTC
     NNEDSDLLED NSATTIIPIL YPINILIQDQ EDSTLYVSFT PKGPKIHQVK HMYQVRIQPS
     IHDHNIPTLE AVVGVPQPPS EGPITHQWSV QMEPPVPCHY EDLERLPDAA EPCLPGALFR
     CPVVFRQEIL VQVIGTLELV GEIEASSMFS LCSSLSISFN SSKHFHLYGS NASLAQVVMK
     VDVVYEKQML YLYVLSGIGG LLLLLLIFIV LYKVGFFKRN LKEKMEAGRG VPNGIPAEDS
     EQLASGQEAG DPGCLKPLHE KDSESGGGKD
//
ID   PHB_HUMAN               Reviewed;         272 AA.
AC   P35232; B4DY47; Q4VBQ0;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   12-AUG-2020, entry version 200.
DE   RecName: Full=Prohibitin {ECO:0000305};
GN   Name=PHB {ECO:0000312|HGNC:HGNC:8912};
GN   Synonyms=PHB1 {ECO:0000303|PubMed:28017329};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-88 AND HIS-105.
RC   TISSUE=Mammary gland;
RX   PubMed=1540973;
RA   Sato T., Saito H., Swensen J., Olifant A., Wood C., Danner D., Sakamoto T.,
RA   Takita K., Kasumi F., Miki Y., Skolnick M., Nakamura Y.;
RT   "The human prohibitin gene located on chromosome 17q21 is mutated in
RT   sporadic breast cancer.";
RL   Cancer Res. 52:1643-1646(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8244394; DOI=10.1006/geno.1993.1402;
RA   Sato T., Sakamoto T., Takita K., Saito H., Okui K., Nakamura Y.;
RT   "The human prohibitin (PHB) gene family and its somatic mutations in human
RT   tumors.";
RL   Genomics 17:762-764(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 5-11; 84-93; 106-128; 134-143; 178-186 AND 209-219, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (MAR-2005) to UniProtKB.
RN   [8]
RP   PROTEIN SEQUENCE OF 75-83; 94-117; 134-143; 158-177; 220-253 AND 256-272,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [9]
RP   FUNCTION, INTERACTION WITH PHB2, DEVELOPMENTAL STAGE, AND INDUCTION.
RX   PubMed=11302691; DOI=10.1006/excr.2001.5166;
RA   Coates P.J., Nenutil R., McGregor A., Picksley S.M., Crouch D.H.,
RA   Hall P.A., Wright E.G.;
RT   "Mammalian prohibitin proteins respond to mitochondrial stress and decrease
RT   during cellular senescence.";
RL   Exp. Cell Res. 265:262-273(2001).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=14500729; DOI=10.1074/jbc.m305171200;
RA   Fusaro G., Dasgupta P., Rastogi S., Joshi B., Chellappan S.;
RT   "Prohibitin induces the transcriptional activity of p53 and is exported
RT   from the nucleus upon apoptotic signaling.";
RL   J. Biol. Chem. 278:47853-47861(2003).
RN   [11]
RP   INTERACTION WITH SARS-COV NSP2 (MICROBIAL INFECTION).
RX   PubMed=19640993; DOI=10.1128/jvi.00842-09;
RA   Cornillez-Ty C.T., Liao L., Yates J.R., Kuhn P., Buchmeier M.J.;
RT   "Severe acute respiratory syndrome coronavirus nonstructural protein 2
RT   interacts with a host protein complex involved in mitochondrial biogenesis
RT   and intracellular signaling.";
RL   J. Virol. 83:10314-10318(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-202, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   INTERACTION WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENVELOPE GLYCOPROTEIN
RP   GP160.
RX   PubMed=19906925; DOI=10.1128/jvi.01641-09;
RA   Emerson V., Holtkotte D., Pfeiffer T., Wang I.H., Schnoelzer M., Kempf T.,
RA   Bosch V.;
RT   "Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an
RT   interaction partner of the C-terminal cytoplasmic domain of the HIV-1
RT   glycoprotein.";
RL   J. Virol. 84:1355-1365(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PHB2.
RX   PubMed=20959514; DOI=10.1096/fj.10-167502;
RA   Strub G.M., Paillard M., Liang J., Gomez L., Allegood J.C., Hait N.C.,
RA   Maceyka M., Price M.M., Chen Q., Simpson D.C., Kordula T., Milstien S.,
RA   Lesnefsky E.J., Spiegel S.;
RT   "Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria
RT   interacts with prohibitin 2 to regulate complex IV assembly and
RT   respiration.";
RL   FASEB J. 25:600-612(2011).
RN   [16]
RP   INTERACTION WITH STOML2.
RX   PubMed=21746876; DOI=10.1128/mcb.05393-11;
RA   Christie D.A., Lemke C.D., Elias I.M., Chau L.A., Kirchhof M.G., Li B.,
RA   Ball E.H., Dunn S.D., Hatch G.M., Madrenas J.;
RT   "Stomatin-like protein 2 binds cardiolipin and regulates mitochondrial
RT   biogenesis and function.";
RL   Mol. Cell. Biol. 31:3845-3856(2011).
RN   [17]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CHIKUNGUNYA VIRUS SPIKE
RP   GLYCOPROTEIN E2.
RX   PubMed=22997079; DOI=10.1002/jmv.23403;
RA   Wintachai P., Wikan N., Kuadkitkan A., Jaimipuk T., Ubol S.,
RA   Pulmanausahakul R., Auewarakul P., Kasinrerk W., Weng W.Y.,
RA   Panyasrivanit M., Paemanee A., Kittisenachai S., Roytrakul S., Smith D.R.;
RT   "Identification of prohibitin as a Chikungunya virus receptor protein.";
RL   J. Med. Virol. 84:1757-1770(2012).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=24003225; DOI=10.1074/jbc.m113.510826;
RA   Fu P., Yang Z., Bach L.A.;
RT   "Prohibitin-2 binding modulates insulin-like growth factor-binding protein-
RT   6 (IGFBP-6)-induced rhabdomyosarcoma cell migration.";
RL   J. Biol. Chem. 288:29890-29900(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-91 AND TYR-249, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [21]
RP   INTERACTION WITH PHB2 AND MAP1LC3B.
RX   PubMed=28017329; DOI=10.1016/j.cell.2016.11.042;
RA   Wei Y., Chiang W.C., Sumpter R. Jr., Mishra P., Levine B.;
RT   "Prohibitin 2 Is an Inner Mitochondrial Membrane Mitophagy Receptor.";
RL   Cell 168:224.e10-238.e10(2017).
RN   [22]
RP   INTERACTION WITH PHB2 AND CLPB, AND FUNCTION.
RX   PubMed=31522117; DOI=10.1016/j.isci.2019.08.056;
RA   Yoshinaka T., Kosako H., Yoshizumi T., Furukawa R., Hirano Y., Kuge O.,
RA   Tamada T., Koshiba T.;
RT   "Structural Basis of Mitochondrial Scaffolds by Prohibitin Complexes:
RT   Insight into a Role of the Coiled-Coil Region.";
RL   IScience 19:1065-1078(2019).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STAT3, AND DEVELOPMENTAL
RP   STAGE.
RX   PubMed=31899195; DOI=10.1016/j.imlet.2019.12.008;
RA   Zhang J., Sun Z., Wu Q., Shen J.;
RT   "Prohibitin 1 interacts with signal transducer and activator of
RT   transcription 3 in T-helper 17 cells.";
RL   Immunol. Lett. 219:8-14(2020).
CC   -!- FUNCTION: Protein with pleiotropic attributes mediated in a cell-
CC       compartment- and tissue-specific manner, which include the plasma
CC       membrane-associated cell signaling functions, mitochondrial chaperone,
CC       and transcriptional co-regulator of transcription factors in the
CC       nucleus (PubMed:11302691, PubMed:20959514, PubMed:28017329,
CC       PubMed:31522117). Plays a role in adipose tissue and glucose
CC       Homeostasis in a sex-specific manner (By similarity). Contributes to
CC       pulmonary vascular remodeling by accelerating proliferation of
CC       pulmonary arterial smooth muscle cells (By similarity).
CC       {ECO:0000250|UniProtKB:P67778, ECO:0000250|UniProtKB:P67779,
CC       ECO:0000269|PubMed:11302691, ECO:0000269|PubMed:20959514,
CC       ECO:0000269|PubMed:28017329, ECO:0000269|PubMed:31522117}.
CC   -!- FUNCTION: In the mitochondria, together with PHB2, forms large ring
CC       complexes (prohibitin complexes) in the inner mitochondrial membrane
CC       (IMM) and functions as chaperone protein that stabilizes mitochondrial
CC       respiratory enzymes and maintains mitochondrial integrity in the IMM,
CC       which is required for mitochondrial morphogenesis, neuronal survival,
CC       and normal lifespan (Probable). The prohibitin complex, with DNAJC19,
CC       regulates cardiolipin remodeling and the protein turnover of OMA1 in a
CC       cardiolipin-binding manner (By similarity). Regulates mitochondrial
CC       respiration activity playing a role in cellular aging
CC       (PubMed:11302691). The prohibitin complex plays a role of mitophagy
CC       receptor involved in targeting mitochondria for autophagic degradation
CC       (PubMed:28017329). Involved in mitochondrial-mediated antiviral innate
CC       immunity, activates DDX58/RIG-I-mediated signal transduction and
CC       production of IFNB1 and proinflammatory cytokine IL6 (PubMed:31522117).
CC       {ECO:0000250|UniProtKB:P67778, ECO:0000269|PubMed:11302691,
CC       ECO:0000269|PubMed:28017329, ECO:0000269|PubMed:31522117, ECO:0000305}.
CC   -!- FUNCTION: In the nucleus, acts as a transcription coregulator, enhances
CC       promoter binding by TP53, a transcription factor it activates, but
CC       reduces the promoter binding by E2F1, a transcription factor it
CC       represses (PubMed:14500729). Interacts with STAT3 to affect IL17
CC       secretion in T-helper Th17 cells (PubMed:31899195).
CC       {ECO:0000269|PubMed:14500729, ECO:0000269|PubMed:31899195}.
CC   -!- FUNCTION: In the plasma membrane, cooperates with CD86 to mediate CD86-
CC       signaling in B lymphocytes that regulates the level of IgG1 produced
CC       through the activation of distal signaling intermediates (By
CC       similarity). Upon CD40 engagement, required to activate NF-kappa-B
CC       signaling pathway via phospholipase C and protein kinase C activation
CC       (By similarity). {ECO:0000250|UniProtKB:P67778}.
CC   -!- SUBUNIT: The mitochondrial prohibitin complex consists of two subunits
CC       (PHB and PHB2), assembled into a membrane-associated ring-shaped
CC       supercomplex of approximately 1 mDa (PubMed:11302691, PubMed:20959514,
CC       PubMed:28017329, PubMed:31522117). Interacts with STOML2
CC       (PubMed:21746876). Interacts with MAP1LC3B (membrane-bound form LC3-
CC       II); the interaction requires PHB2 and takes place upon Parkin-mediated
CC       mitochondrial damage (PubMed:28017329). Interacts with STAT3
CC       (unphosphorylated or phosphorylated at 'Ser-727') (PubMed:31899195).
CC       Interacts with CLPB (PubMed:31522117). Interacts with CD86 (via
CC       cytoplasmic domain); the interactions increases after priming with CD40
CC       (By similarity). {ECO:0000250|UniProtKB:P67778,
CC       ECO:0000269|PubMed:11302691, ECO:0000269|PubMed:20959514,
CC       ECO:0000269|PubMed:21746876, ECO:0000269|PubMed:28017329,
CC       ECO:0000269|PubMed:31522117, ECO:0000269|PubMed:31899195}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS coronavirus/SARS-CoV
CC       nsp2 protein. {ECO:0000269|PubMed:19640993}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with chikungunya virus spike
CC       glycoprotein E2. {ECO:0000269|PubMed:22997079}.
CC   -!- SUBUNIT: (Microbial infection) Interaction with human immunodeficiency
CC       virus type 1/HIV-1 envelope glycoprotein GP160.
CC       {ECO:0000269|PubMed:19906925}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human enterovirus 71/EV-
CC       71 capsid protein VP0, protein 3CD and protease 3C.
CC       {ECO:0000250|UniProtKB:P67778}.
CC   -!- INTERACTION:
CC       P35232; Q496Y0: LONRF3; NbExp=2; IntAct=EBI-354213, EBI-2690768;
CC       P35232; Q99623: PHB2; NbExp=3; IntAct=EBI-354213, EBI-358348;
CC       P35232; Q96IW7: SEC22A; NbExp=3; IntAct=EBI-354213, EBI-8652744;
CC       P35232; Q13309-2: SKP2; NbExp=2; IntAct=EBI-354213, EBI-7791408;
CC       P35232; Q9NS68: TNFRSF19; NbExp=3; IntAct=EBI-354213, EBI-530381;
CC       P35232; P04637: TP53; NbExp=6; IntAct=EBI-354213, EBI-366083;
CC       P35232; O14980: XPO1; NbExp=2; IntAct=EBI-354213, EBI-355867;
CC       P35232; Q9JLL3: Tnfrsf19; Xeno; NbExp=3; IntAct=EBI-354213, EBI-20800437;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane
CC       {ECO:0000269|PubMed:14500729, ECO:0000269|PubMed:20959514}. Nucleus
CC       {ECO:0000269|PubMed:14500729, ECO:0000269|PubMed:20959514,
CC       ECO:0000269|PubMed:31899195}. Cytoplasm {ECO:0000269|PubMed:14500729,
CC       ECO:0000269|PubMed:31899195}. Cell membrane
CC       {ECO:0000269|PubMed:22997079, ECO:0000269|PubMed:24003225}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P35232-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35232-2; Sequence=VSP_054922;
CC   -!- TISSUE SPECIFICITY: Widely expressed in different tissues.
CC   -!- DEVELOPMENTAL STAGE: Levels of expression in fibroblasts decrease
CC       heterogeneously during cellular aging (PubMed:11302691). In CD4(+) T
CC       cells, expression increases during polarization towards T-helper Th17,
CC       Th1 and Th2 (PubMed:31899195). {ECO:0000269|PubMed:11302691,
CC       ECO:0000269|PubMed:31899195}.
CC   -!- INDUCTION: Expression increases approximately 3-fold upon entry into G1
CC       phase compared with other phases of the cell cycle. Also induced
CC       following inhibition of mitochondrial protein synthesis by
CC       thiamphenicol. {ECO:0000269|PubMed:11302691}.
CC   -!- SIMILARITY: Belongs to the prohibitin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S85655; AAB21614.1; -; mRNA.
DR   EMBL; L14272; AAO18340.1; -; Genomic_DNA.
DR   EMBL; BT007411; AAP36079.1; -; mRNA.
DR   EMBL; AK302258; BAG63609.1; -; mRNA.
DR   EMBL; AC091180; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC013401; AAH13401.1; -; mRNA.
DR   EMBL; BC095460; AAH95460.1; -; mRNA.
DR   CCDS; CCDS11548.1; -. [P35232-1]
DR   CCDS; CCDS62244.1; -. [P35232-2]
DR   PIR; I52690; I52690.
DR   RefSeq; NP_001268425.1; NM_001281496.1. [P35232-1]
DR   RefSeq; NP_001268426.1; NM_001281497.1. [P35232-2]
DR   RefSeq; NP_001268644.1; NM_001281715.1. [P35232-1]
DR   RefSeq; NP_002625.1; NM_002634.3. [P35232-1]
DR   RefSeq; XP_016880252.1; XM_017024763.1. [P35232-1]
DR   PDB; 1LU7; Model; -; A=1-272.
DR   PDBsum; 1LU7; -.
DR   SMR; P35232; -.
DR   BioGRID; 111264; 947.
DR   ComplexPortal; CPX-5741; Prohibitin complex.
DR   CORUM; P35232; -.
DR   DIP; DIP-24248N; -.
DR   IntAct; P35232; 141.
DR   MINT; P35232; -.
DR   STRING; 9606.ENSP00000479488; -.
DR   ChEMBL; CHEMBL4295750; -.
DR   DrugBank; DB15496; Didesmethylrocaglamide.
DR   DrugBank; DB15495; Rocaglamide.
DR   iPTMnet; P35232; -.
DR   PhosphoSitePlus; P35232; -.
DR   SwissPalm; P35232; -.
DR   BioMuta; PHB; -.
DR   DMDM; 464371; -.
DR   DOSAC-COBS-2DPAGE; P35232; -.
DR   OGP; P35232; -.
DR   REPRODUCTION-2DPAGE; IPI00017334; -.
DR   REPRODUCTION-2DPAGE; P35232; -.
DR   SWISS-2DPAGE; P35232; -.
DR   UCD-2DPAGE; P35232; -.
DR   EPD; P35232; -.
DR   jPOST; P35232; -.
DR   MassIVE; P35232; -.
DR   MaxQB; P35232; -.
DR   PaxDb; P35232; -.
DR   PeptideAtlas; P35232; -.
DR   PRIDE; P35232; -.
DR   ProteomicsDB; 5497; -.
DR   ProteomicsDB; 54995; -. [P35232-1]
DR   TopDownProteomics; P35232-1; -. [P35232-1]
DR   Antibodypedia; 1078; 696 antibodies.
DR   DNASU; 5245; -.
DR   Ensembl; ENST00000300408; ENSP00000300408; ENSG00000167085. [P35232-1]
DR   Ensembl; ENST00000511832; ENSP00000425035; ENSG00000167085. [P35232-2]
DR   Ensembl; ENST00000614445; ENSP00000479488; ENSG00000167085. [P35232-1]
DR   Ensembl; ENST00000617874; ENSP00000484113; ENSG00000167085. [P35232-1]
DR   GeneID; 5245; -.
DR   KEGG; hsa:5245; -.
DR   UCSC; uc002iox.3; human. [P35232-1]
DR   CTD; 5245; -.
DR   DisGeNET; 5245; -.
DR   EuPathDB; HostDB:ENSG00000167085.11; -.
DR   GeneCards; PHB; -.
DR   HGNC; HGNC:8912; PHB.
DR   HPA; ENSG00000167085; Low tissue specificity.
DR   MalaCards; PHB; -.
DR   MIM; 176705; gene.
DR   neXtProt; NX_P35232; -.
DR   OpenTargets; ENSG00000167085; -.
DR   PharmGKB; PA33251; -.
DR   eggNOG; KOG3083; Eukaryota.
DR   GeneTree; ENSGT00950000183070; -.
DR   HOGENOM; CLU_047969_0_0_1; -.
DR   InParanoid; P35232; -.
DR   KO; K17080; -.
DR   OMA; RTRIRDN; -.
DR   PhylomeDB; P35232; -.
DR   TreeFam; TF300095; -.
DR   PathwayCommons; P35232; -.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-8949664; Processing of SMDT1.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   BioGRID-ORCS; 5245; 763 hits in 883 CRISPR screens.
DR   ChiTaRS; PHB; human.
DR   GeneWiki; Prohibitin; -.
DR   GenomeRNAi; 5245; -.
DR   Pharos; P35232; Tbio.
DR   PRO; PR:P35232; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P35232; protein.
DR   Bgee; ENSG00000167085; Expressed in adult mammalian kidney and 245 other tissues.
DR   ExpressionAtlas; P35232; baseline and differential.
DR   Genevisible; P35232; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:HGNC-UCL.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0035632; C:mitochondrial prohibitin complex; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001850; F:complement component C3a binding; IDA:UniProtKB.
DR   GO; GO:0001851; F:complement component C3b binding; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0031871; F:proteinase activated receptor binding; IPI:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0007202; P:activation of phospholipase C activity; ISS:UniProtKB.
DR   GO; GO:1990051; P:activation of protein kinase C activity; ISS:UniProtKB.
DR   GO; GO:0140374; P:antiviral innate immune response; IDA:UniProtKB.
DR   GO; GO:0042113; P:B cell activation; ISS:UniProtKB.
DR   GO; GO:0023035; P:CD40 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0071354; P:cellular response to interleukin-6; IDA:BHF-UCL.
DR   GO; GO:0071897; P:DNA biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0016575; P:histone deacetylation; IDA:UniProtKB.
DR   GO; GO:0002377; P:immunoglobulin production; ISS:UniProtKB.
DR   GO; GO:0072615; P:interleukin-17 secretion; IMP:UniProtKB.
DR   GO; GO:0006851; P:mitochondrial calcium ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0007005; P:mitochondrion organization; IMP:UniProtKB.
DR   GO; GO:0044830; P:modulation by host of viral RNA genome replication; ISS:UniProtKB.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:2000323; P:negative regulation of glucocorticoid receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0010944; P:negative regulation of transcription by competitive promoter binding; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0001649; P:osteoblast differentiation; HDA:UniProtKB.
DR   GO; GO:0010942; P:positive regulation of cell death; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0045917; P:positive regulation of complement activation; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0045745; P:positive regulation of G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IGI:ParkinsonsUK-UCL.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0050847; P:progesterone receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050821; P:protein stabilization; IMP:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0039529; P:RIG-I signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   GO; GO:0072538; P:T-helper 17 type immune response; IDA:UniProtKB.
DR   GO; GO:0046718; P:viral entry into host cell; ISS:UniProtKB.
DR   CDD; cd03401; SPFH_prohibitin; 1.
DR   InterPro; IPR001107; Band_7.
DR   InterPro; IPR036013; Band_7/SPFH_dom_sf.
DR   InterPro; IPR000163; Prohibitin.
DR   PANTHER; PTHR23222; PTHR23222; 1.
DR   Pfam; PF01145; Band_7; 1.
DR   PRINTS; PR00679; PROHIBITIN.
DR   SMART; SM00244; PHB; 1.
DR   SUPFAM; SSF117892; SSF117892; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell membrane;
KW   Coiled coil; Cytoplasm; Direct protein sequencing; DNA synthesis; Membrane;
KW   Mitochondrion; Mitochondrion inner membrane; Nucleus; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:25944712"
FT   CHAIN           2..272
FT                   /note="Prohibitin"
FT                   /id="PRO_0000213878"
FT   COILED          177..211
FT                   /evidence="ECO:0000255"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:25944712"
FT   MOD_RES         91
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         128
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P67778"
FT   MOD_RES         186
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P67778"
FT   MOD_RES         202
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         202
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P67778"
FT   MOD_RES         249
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   VAR_SEQ         140..256
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054922"
FT   VARIANT         88
FT                   /note="V -> A (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs121918373)"
FT                   /evidence="ECO:0000269|PubMed:1540973"
FT                   /id="VAR_006479"
FT   VARIANT         105
FT                   /note="R -> H (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs121918372)"
FT                   /evidence="ECO:0000269|PubMed:1540973"
FT                   /id="VAR_006480"
SQ   SEQUENCE   272 AA;  29804 MW;  915494273E342C76 CRC64;
     MAAKVFESIG KFGLALAVAG GVVNSALYNV DAGHRAVIFD RFRGVQDIVV GEGTHFLIPW
     VQKPIIFDCR SRPRNVPVIT GSKDLQNVNI TLRILFRPVA SQLPRIFTSI GEDYDERVLP
     SITTEILKSV VARFDAGELI TQRELVSRQV SDDLTERAAT FGLILDDVSL THLTFGKEFT
     EAVEAKQVAQ QEAERARFVV EKAEQQKKAA IISAEGDSKA AELIANSLAT AGDGLIELRK
     LEAAEDIAYQ LSRSRNITYL PAGQSVLLQL PQ
//
ID   BASI_HUMAN              Reviewed;         385 AA.
AC   P35613; A6NJW1; D3YLG5; Q7Z796; Q8IZL7;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   31-AUG-2004, sequence version 2.
DT   12-AUG-2020, entry version 217.
DE   RecName: Full=Basigin;
DE   AltName: Full=5F7;
DE   AltName: Full=Collagenase stimulatory factor;
DE   AltName: Full=Extracellular matrix metalloproteinase inducer;
DE            Short=EMMPRIN;
DE   AltName: Full=Hepatoma-associated antigen {ECO:0000303|PubMed:15688292};
DE            Short=HAb18G {ECO:0000303|PubMed:15688292};
DE   AltName: Full=Leukocyte activation antigen M6;
DE   AltName: Full=OK blood group antigen;
DE   AltName: Full=Tumor cell-derived collagenase stimulatory factor;
DE            Short=TCSF;
DE   AltName: CD_antigen=CD147;
DE   Flags: Precursor;
GN   Name=BSG; ORFNames=UNQ6505/PRO21383;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1634773;
RA   Kasinrerk W., Fiebiger E., Stefanova I., Baumruker T., Knapp W.,
RA   Stockinger H.;
RT   "Human leukocyte activation antigen M6, a member of the Ig superfamily, is
RT   the species homologue of rat OX-47, mouse basigin, and chicken HT7
RT   molecule.";
RL   J. Immunol. 149:847-854(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2).
RX   PubMed=1783610; DOI=10.1093/oxfordjournals.jbchem.a123657;
RA   Miyauchi T., Masuzawa Y., Muramatsu T.;
RT   "The basigin group of the immunoglobulin superfamily: complete conservation
RT   of a segment in and around transmembrane domains of human and mouse basigin
RT   and chicken HT7 antigen.";
RL   J. Biochem. 110:770-774(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=7812975;
RA   Biswas C., Zhang Y., Decastro R., Guo H., Nakamura T., Kataoka H.,
RA   Nabeshima K.;
RT   "The human tumor cell-derived collagenase stimulatory factor (renamed
RT   EMMPRIN) is a member of the immunoglobulin superfamily.";
RL   Cancer Res. 55:434-439(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 2).
RA   Wakasugi H., Scamps C., Yang G., Vancong N., Bernheim A., Tursz T.,
RA   Harada N.;
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 2).
RA   Decastro R., Zhang Y., Kataoka H., Coon J., Biswas C.;
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2).
RX   PubMed=9767135; DOI=10.1016/s0378-1119(98)00400-4;
RA   Guo H., Majmudar G., Jensen T.C., Biswas C., Toole B.P., Gordon M.K.;
RT   "Characterization of the gene for human EMMPRIN, a tumor cell surface
RT   inducer of matrix metalloproteinases.";
RL   Gene 220:99-108(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 2).
RA   Sato T., Takita M., Noguchi Y., Hirata M., Sakai T., Ito A.;
RT   "Regulation of EMMPRIN/CD147 expression and its function of controlling
RT   matrix metalloproteinases production and cell-surface localization in co-
RT   culture of human uterine cervical carcinoma SKG-II cells and human uterine
RT   cervical fibroblasts.";
RL   Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 2).
RA   Kim D., Kanai Y., Choi H., Shin H., Kim J., Teraoka H., Shigeta Y.,
RA   Chairoungdua A., Babu E., Anzai N., Iribe Y., Endou H.;
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1).
RC   TISSUE=Retina;
RX   PubMed=12939332; DOI=10.1167/iovs.02-0995;
RA   Ochrietor J.D., Moroz T.P., van Ekeris L., Clamp M.F., Jefferson S.C.,
RA   deCarvalho A.C., Fadool J.M., Wistow G., Muramatsu T., Linser P.J.;
RT   "Retina-specific expression of 5A11/Basigin-2, a member of the
RT   immunoglobulin gene superfamily.";
RL   Invest. Ophthalmol. Vis. Sci. 44:4086-4096(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), SUBUNIT (ISOFORMS 2 AND 3),
RP   SUBCELLULAR LOCATION (ISOFORMS 2; 3 AND 4), ALTERNATIVE PROMOTER USAGE,
RP   TISSUE SPECIFICITY (ISOFORMS 2; 3 AND 4), AND GLYCOSYLATION (ISOFORMS 2; 3
RP   AND 4).
RX   PubMed=21536654; DOI=10.1128/mcb.05160-11;
RA   Liao C.G., Kong L.M., Song F., Xing J.L., Wang L.X., Sun Z.J., Tang H.,
RA   Yao H., Zhang Y., Wang L., Wang Y., Yang X.M., Li Y., Chen Z.N.;
RT   "Characterization of basigin isoforms and the inhibitory function of
RT   basigin-3 in human hepatocellular carcinoma proliferation and invasion.";
RL   Mol. Cell. Biol. 31:2591-2604(2011).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   PROTEIN SEQUENCE OF 22-36 (ISOFORM 1).
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [17]
RP   PARTIAL PROTEIN SEQUENCE, AND CHARACTERIZATION.
RX   PubMed=1846736; DOI=10.1016/0003-9861(91)90332-d;
RA   Nabeshima K., Lane W.S., Biswas C.;
RT   "Partial sequencing and characterization of the tumor cell-derived
RT   collagenase stimulatory factor.";
RL   Arch. Biochem. Biophys. 285:90-96(1991).
RN   [18]
RP   FUNCTION (ISOFORM 2).
RX   PubMed=11688976; DOI=10.1006/bbrc.2001.5847;
RA   Yurchenko V., O'Connor M., Dai W.W., Guo H., Toole B., Sherry B.,
RA   Bukrinsky M.;
RT   "CD147 is a signaling receptor for cyclophilin B.";
RL   Biochem. Biophys. Res. Commun. 288:786-788(2001).
RN   [19]
RP   FUNCTION (ISOFORM 2) (MICROBIAL INFECTION), AND INTERACTION WITH PPIA
RP   (ISOFORM 2).
RX   PubMed=11353871; DOI=10.1073/pnas.111583198;
RA   Pushkarsky T., Zybarth G., Dubrovsky L., Yurchenko V., Tang H., Guo H.,
RA   Toole B., Sherry B., Bukrinsky M.;
RT   "CD147 facilitates HIV-1 infection by interacting with virus-associated
RT   cyclophilin A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6360-6365(2001).
RN   [20]
RP   FUNCTION (ISOFORM 2).
RX   PubMed=12553375; DOI=10.1023/a:1021350718226;
RA   Caudroy S., Polette M., Nawrocki-Raby B., Cao J., Toole B.P., Zucker S.,
RA   Birembaut P.;
RT   "EMMPRIN-mediated MMP regulation in tumor and endothelial cells.";
RL   Clin. Exp. Metastasis 19:697-702(2002).
RN   [21]
RP   FUNCTION (ISOFORM 2), SUBCELLULAR LOCATION (ISOFORM 2), AND TISSUE
RP   SPECIFICITY (ISOFORM 2).
RX   PubMed=11992541; DOI=10.1002/ijc.10390;
RA   Kanekura T., Chen X., Kanzaki T.;
RT   "Basigin (CD147) is expressed on melanoma cells and induces tumor cell
RT   invasion by stimulating production of matrix metalloproteinases by
RT   fibroblasts.";
RL   Int. J. Cancer 99:520-528(2002).
RN   [22]
RP   FUNCTION (ISOFORM 2), MUTAGENESIS (ISOFORM 2), AND INTERACTION WITH PPIA
RP   (ISOFORM 2).
RX   PubMed=11943775; DOI=10.1074/jbc.m201593200;
RA   Yurchenko V., Zybarth G., O'Connor M., Dai W.W., Franchin G., Hao T.,
RA   Guo H., Hung H.C., Toole B., Gallay P., Sherry B., Bukrinsky M.;
RT   "Active site residues of cyclophilin A are crucial for its signaling
RT   activity via CD147.";
RL   J. Biol. Chem. 277:22959-22965(2002).
RN   [23]
RP   REVIEW.
RX   PubMed=12792908; DOI=10.14670/hh-18.981;
RA   Muramatsu T., Miyauchi T.;
RT   "Basigin (CD147): a multifunctional transmembrane protein involved in
RT   reproduction, neural function, inflammation and tumor invasion.";
RL   Histol. Histopathol. 18:981-987(2003).
RN   [24]
RP   GLYCOSYLATION AT ASN-160 AND ASN-268.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [25]
RP   FUNCTION (ISOFORM 2).
RX   PubMed=15833850; DOI=10.1158/0008-5472.can-04-3605;
RA   Tang Y., Nakada M.T., Kesavan P., McCabe F., Millar H., Rafferty P.,
RA   Bugelski P., Yan L.;
RT   "Extracellular matrix metalloproteinase inducer stimulates tumor
RT   angiogenesis by elevating vascular endothelial cell growth factor and
RT   matrix metalloproteinases.";
RL   Cancer Res. 65:3193-3199(2005).
RN   [26]
RP   FUNCTION (ISOFORM 2) (MICROBIAL INFECTION), INTERACTION WITH PPIA (ISOFORM
RP   2), AND SUBCELLULAR LOCATION (ISOFORM 2).
RX   PubMed=15688292; DOI=10.1086/427811;
RA   Chen Z., Mi L., Xu J., Yu J., Wang X., Jiang J., Xing J., Shang P.,
RA   Qian A., Li Y., Shaw P.X., Wang J., Duan S., Ding J., Fan C., Zhang Y.,
RA   Yang Y., Yu X., Feng Q., Li B., Yao X., Zhang Z., Li L., Xue X., Zhu P.;
RT   "Function of HAb18G/CD147 in invasion of host cells by severe acute
RT   respiratory syndrome coronavirus.";
RL   J. Infect. Dis. 191:755-760(2005).
RN   [27]
RP   INTERACTION WITH PPIL2 (ISOFORM 2), SUBCELLULAR LOCATION (ISOFORM 2), AND
RP   MUTAGENESIS (ISOFORM 2).
RX   PubMed=15946952; DOI=10.1074/jbc.m503770200;
RA   Pushkarsky T., Yurchenko V., Vanpouille C., Brichacek B., Vaisman I.,
RA   Hatakeyama S., Nakayama K.I., Sherry B., Bukrinsky M.I.;
RT   "Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60.";
RL   J. Biol. Chem. 280:27866-27871(2005).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-362, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [29]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J.,
RA   Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S.,
RA   Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [30]
RP   FUNCTION (ISOFORM 2), SUBCELLULAR LOCATION (ISOFORM 2), AND INTERACTION
RP   WITH SLC16A1 (ISOFORM 2).
RX   PubMed=17127621; DOI=10.1080/09687860600841967;
RA   Manoharan C., Wilson M.C., Sessions R.B., Halestrap A.P.;
RT   "The role of charged residues in the transmembrane helices of
RT   monocarboxylate transporter 1 and its ancillary protein basigin in
RT   determining plasma membrane expression and catalytic activity.";
RL   Mol. Membr. Biol. 23:486-498(2006).
RN   [31]
RP   INTERACTION WITH AJAP1 (ISOFORM 2), AND SUBCELLULAR LOCATION (ISOFORM 2).
RX   PubMed=17267690; DOI=10.1091/mbc.e06-07-0637;
RA   Schreiner A., Ruonala M., Jakob V., Suthaus J., Boles E., Wouters F.,
RA   Starzinski-Powitz A.;
RT   "junction protein shrew-1 influences cell invasion and interacts with
RT   invasion-promoting protein CD147.";
RL   Mol. Biol. Cell 18:1272-1281(2007).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [33]
RP   FUNCTION (ISOFORM 2).
RX   PubMed=19837976; DOI=10.1182/blood-2009-04-217380;
RA   Bougatef F., Quemener C., Kellouche S., Naimi B., Podgorniak M.P.,
RA   Millot G., Gabison E.E., Calvo F., Dosquet C., Lebbe C., Menashi S.,
RA   Mourah S.;
RT   "EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-
RT   mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2.";
RL   Blood 114:5547-5556(2009).
RN   [34]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-160 AND ASN-268.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [35]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-160 AND ASN-268.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [36]
RP   FUNCTION (ISOFORM 2) (MICROBIAL INFECTION).
RX   PubMed=20147391; DOI=10.1128/jvi.02168-09;
RA   Watanabe A., Yoneda M., Ikeda F., Terao-Muto Y., Sato H., Kai C.;
RT   "CD147/EMMPRIN acts as a functional entry receptor for measles virus on
RT   epithelial cells.";
RL   J. Virol. 84:4183-4193(2010).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-362, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   FUNCTION (ISOFORM 2), AND INTERACTION WITH SLC16A12 (ISOFORM 2).
RX   PubMed=21778275; DOI=10.1167/iovs.10-6579;
RA   Castorino J.J., Gallagher-Colombo S.M., Levin A.V., Fitzgerald P.G.,
RA   Polishook J., Kloeckener-Gruissem B., Ostertag E., Philp N.J.;
RT   "Juvenile cataract-associated mutation of solute carrier SLC16A12 impairs
RT   trafficking of the protein to the plasma membrane.";
RL   Invest. Ophthalmol. Vis. Sci. 52:6774-6784(2011).
RN   [40]
RP   FUNCTION (ISOFORMS 1 AND 2) (MICROBIAL INFECTION), INTERACTION WITH
RP   P.FALCIPARUM RH5 (ISOFORMS 1 AND 2) (MICROBIAL INFECTION), GLYCOSYLATION,
RP   VARIANTS ASN-152; LEU-176; PRO-206; LYS-208 AND VAL-269, AND MUTAGENESIS OF
RP   ASN-160; ASN-268 AND ASN-302.
RX   PubMed=22080952; DOI=10.1038/nature10606;
RA   Crosnier C., Bustamante L.Y., Bartholdson S.J., Bei A.K., Theron M.,
RA   Uchikawa M., Mboup S., Ndir O., Kwiatkowski D.P., Duraisingh M.T.,
RA   Rayner J.C., Wright G.J.;
RT   "Basigin is a receptor essential for erythrocyte invasion by Plasmodium
RT   falciparum.";
RL   Nature 480:534-537(2011).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-362, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-362, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [43]
RP   INTERACTION WITH P.FALCIPARUM RH5 (ISOFORM 2) (MICROBIAL INFECTION), AND
RP   MUTAGENESIS OF (ISOFORM 2).
RX   PubMed=24297912; DOI=10.1073/pnas.1320771110;
RA   Wanaguru M., Liu W., Hahn B.H., Rayner J.C., Wright G.J.;
RT   "RH5-Basigin interaction plays a major role in the host tropism of
RT   Plasmodium falciparum.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:20735-20740(2013).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-362 AND SER-368, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [45]
RP   FUNCTION (ISOFORM 1), SUBCELLULAR LOCATION (ISOFORM 1), TISSUE SPECIFICITY
RP   (ISOFORM 1), AND INTERACTION WITH NXNL1 (ISOFORM 1).
RX   PubMed=25957687; DOI=10.1016/j.cell.2015.03.023;
RA   Ait-Ali N., Fridlich R., Millet-Puel G., Clerin E., Delalande F.,
RA   Jaillard C., Blond F., Perrocheau L., Reichman S., Byrne L.C.,
RA   Olivier-Bandini A., Bellalou J., Moyse E., Bouillaud F., Nicol X.,
RA   Dalkara D., van Dorsselaer A., Sahel J.A., Leveillard T.;
RT   "Rod-derived cone viability factor promotes cone survival by stimulating
RT   aerobic glycolysis.";
RL   Cell 161:817-832(2015).
RN   [46]
RP   FUNCTION (ISOFORM 2) (MICROBIAL INFECTION), INTERACTION WITH P.FACILPARUM
RP   RH5 (ISOFORM 2)(MICROBIAL INFECTION), SUBCELLULAR LOCATION (ISOFORM 2),
RP   TISSUE SPECIFICITY (ISOFORM 2), AND BIOTECHNOLOGY (ISOFORM 2).
RX   PubMed=26195724; DOI=10.1084/jem.20150032;
RA   Zenonos Z.A., Dummler S.K., Mueller-Sienerth N., Chen J., Preiser P.R.,
RA   Rayner J.C., Wright G.J.;
RT   "Basigin is a druggable target for host-oriented antimalarial
RT   interventions.";
RL   J. Exp. Med. 212:1145-1151(2015).
RN   [47]
RP   FUNCTION (ISOFORM 2), SUBCELLULAR LOCATION (ISOFORM 2), INTERACTION WITH
RP   VEGFA AND VEGFR2 (ISOFORM 2), MUTAGENESIS (ISOFORM 2), AND REGION (ISOFORM
RP   2).
RX   PubMed=25825981; DOI=10.18632/oncotarget.2870;
RA   Khayati F., Perez-Cano L., Maouche K., Sadoux A., Boutalbi Z.,
RA   Podgorniak M.P., Maskos U., Setterblad N., Janin A., Calvo F., Lebbe C.,
RA   Menashi S., Fernandez-Recio J., Mourah S.;
RT   "EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by
RT   VEGF.";
RL   Oncotarget 6:9766-9780(2015).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [49]
RP   FUNCTION (ISOFORM 2), AND INTERACTION WITH SLC16A11 (ISOFORM 2).
RX   PubMed=28666119; DOI=10.1016/j.cell.2017.06.011;
RG   MEDIA Consortium;
RG   SIGMA T2D Consortium;
RA   Rusu V., Hoch E., Mercader J.M., Tenen D.E., Gymrek M., Hartigan C.R.,
RA   DeRan M., von Grotthuss M., Fontanillas P., Spooner A., Guzman G.,
RA   Deik A.A., Pierce K.A., Dennis C., Clish C.B., Carr S.A., Wagner B.K.,
RA   Schenone M., Ng M.C.Y., Chen B.H., Centeno-Cruz F., Zerrweck C., Orozco L.,
RA   Altshuler D.M., Schreiber S.L., Florez J.C., Jacobs S.B.R., Lander E.S.;
RT   "Type 2 diabetes variants disrupt function of SLC16A11 through two distinct
RT   mechanisms.";
RL   Cell 170:199-212(2017).
RN   [50]
RP   FUNCTION (ISOFORM 2) (MICROBIAL INFECTION), SUBCELLULAR LOCATION (ISOFORM
RP   2), AND TISSUE SPECIFICITY (ISOFORM 2).
RX   PubMed=28409866; DOI=10.1111/cmi.12747;
RA   Aniweh Y., Gao X., Hao P., Meng W., Lai S.K., Gunalan K., Chu T.T.,
RA   Sinha A., Lescar J., Chandramohanadas R., Li H.Y., Sze S.K., Preiser P.R.;
RT   "P. falciparum RH5-Basigin interaction induces changes in the cytoskeleton
RT   of the host RBC.";
RL   Cell. Microbiol. 19:0-0(2017).
RN   [51]
RP   FUNCTION (MICROBIAL INFECTION) (ISOFORM 2), AND SUBCELLULAR LOCATION
RP   (ISOFORM 2).
RX   PubMed=29739904; DOI=10.1128/mbio.00781-18;
RA   Vanarsdall A.L., Pritchard S.R., Wisner T.W., Liu J., Jardetzky T.S.,
RA   Johnson D.C.;
RT   "CD147 Promotes Entry of Pentamer-Expressing Human Cytomegalovirus into
RT   Epithelial and Endothelial Cells.";
RL   MBio 9:0-0(2018).
RN   [52]
RP   REVIEW ON FUNCTION (MICROBIAL FUNCTION), AND REVIEW ON INTERACTION WITH
RP   SARS-COV-2 SPIKE GLYCOPROTEIN (MICROBIAL FUNCTION).
RX   PubMed=32307653; DOI=10.1007/s12015-020-09976-7;
RA   Ulrich H., Pillat M.M.;
RT   "CD147 as a Target for COVID-19 Treatment: Suggested Effects of
RT   Azithromycin and Stem Cell Engagement.";
RL   Stem. Cell. Rev. Rep. 0:0-0(2020).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 140-321, SUBUNIT (ISOFORM 2), AND
RP   DISULFIDE BONDS.
RX   PubMed=18430721; DOI=10.1074/jbc.m802694200;
RA   Yu X.-L., Hu T., Du J.-M., Ding J.-P., Yang X.-M., Zhang J., Yang B.,
RA   Shen X., Zhang Z., Zhong W.-D., Wen N., Jiang H., Zhu P., Chen Z.-N.;
RT   "Crystal structure of HAb18G/CD147: implications for immunoglobulin
RT   superfamily homophilic adhesion.";
RL   J. Biol. Chem. 283:18056-18065(2008).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 13-219, IDENTIFICATION BY MASS
RP   SPECTROMETRY, SUBUNIT (ISOFORM 1), AND DISULFIDE BONDS.
RX   PubMed=19768682; DOI=10.1002/prot.22577;
RA   Luo J., Teplyakov A., Obmolova G., Malia T., Wu S.-J., Beil E., Baker A.,
RA   Swencki-Underwood B., Zhao Y., Sprenkle J., Dixon K., Sweet R.,
RA   Gilliland G.L.;
RT   "Structure of the EMMPRIN N-terminal domain 1: dimerization via beta-strand
RT   swapping.";
RL   Proteins 77:1009-1014(2009).
RN   [55] {ECO:0000244|PDB:3QQN, ECO:0000244|PDB:3QR2}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 23-138, FUNCTION (ISOFORM 1),
RP   DISULFIDE BOND, AND MUTAGENESIS OF CYS-67.
RX   PubMed=21620857; DOI=10.1016/j.jmb.2011.04.060;
RA   Redzic J.S., Armstrong G.S., Isern N.G., Jones D.N., Kieft J.S.,
RA   Eisenmesser E.Z.;
RT   "The retinal specific CD147 Ig0 domain: from molecular structure to
RT   biological activity.";
RL   J. Mol. Biol. 411:68-82(2011).
RN   [56] {ECO:0000244|PDB:4U0Q}
RP   X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 140-385, INTERACTION WITH
RP   P.FACILPARUM RH5 (ISOFORM 2) (MICROBIAL INFECTION), AND DISULFIDE BONDS.
RX   PubMed=25132548; DOI=10.1038/nature13715;
RA   Wright K.E., Hjerrild K.A., Bartlett J., Douglas A.D., Jin J., Brown R.E.,
RA   Illingworth J.J., Ashfield R., Clemmensen S.B., de Jongh W.A., Draper S.J.,
RA   Higgins M.K.;
RT   "Structure of malaria invasion protein RH5 with erythrocyte basigin and
RT   blocking antibodies.";
RL   Nature 515:427-430(2014).
RN   [57] {ECO:0000244|PDB:5X0T}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 138-217, AND DISULFIDE BONDS.
RA   Zhang M.-Y., Lin P., Zhu P., Chen Z.-N.;
RT   "Crystal structure of CD147 C2 domain in complex with Fab of its monoclonal
RT   antibody.";
RL   Submitted (JAN-2017) to the PDB data bank.
RN   [58]
RP   VARIANT LYS-208.
RX   PubMed=9130641; DOI=10.1002/eji.1830270414;
RA   Spring F.A., Holmes C.H., Simpson K.L., Mawby W.J., Mattes M.J., Okubo Y.,
RA   Parsons S.F.;
RT   "The Ok(a) blood group antigen is a marker for the M6 leukocyte activation
RT   antigen, the human homolog of OX-47 antigen, basigin and neurothelin, an
RT   immunoglobulin superfamily molecule that is widely expressed in human cells
RT   and tissues.";
RL   Eur. J. Immunol. 27:891-897(1997).
CC   -!- FUNCTION: [Isoform 1]: Essential for normal retinal maturation and
CC       development (By similarity). Acts as a retinal cell surface receptor
CC       for NXNL1 and plays an important role in NXNL1-mediated survival of
CC       retinal cone photoreceptors (PubMed:25957687). In association with
CC       glucose transporter SLC16A1/GLUT1 and NXNL1, promotes retinal cone
CC       survival by enhancing aerobic glycolysis and accelerating the entry of
CC       glucose into photoreceptors (PubMed:25957687). May act as a potent
CC       stimulator of IL6 secretion in multiple cell lines that include
CC       monocytes (PubMed:21620857). {ECO:0000250|UniProtKB:P18572,
CC       ECO:0000269|PubMed:21620857, ECO:0000269|PubMed:25957687}.
CC   -!- FUNCTION: [Isoform 2]: Signaling receptor for cyclophilins, essential
CC       for PPIA/CYPA and PPIB/CYPB-dependent signaling related to chemotaxis
CC       and adhesion of immune cells (PubMed:11943775, PubMed:11688976). Plays
CC       an important role in targeting monocarboxylate transporters
CC       SLC16A1/GLUT1, SLC16A11 and SLC16A12 to the plasma membrane
CC       (PubMed:17127621, PubMed:21778275, PubMed:28666119). Acts as a
CC       coreceptor for vascular endothelial growth factor receptor 2
CC       (KDR/VEGFR2) in endothelial cells enhancing its VEGFA-mediated
CC       activation and downstream signaling (PubMed:25825981). Promotes
CC       angiogenesis through EPAS1/HIF2A-mediated up-regulation of VEGFA
CC       (isoform VEGF-165 and VEGF-121) and KDR/VEGFR2 in endothelial cells
CC       (PubMed:19837976). Plays a key role in regulating tumor growth,
CC       invasion, metastasis and neoangiogenesis by stimulating the production
CC       and release of extracellular matrix metalloproteinases and KDR/VEGFR2
CC       by both tumor cells and stromal cells (fibroblasts and endothelial
CC       cells) (PubMed:12553375, PubMed:11992541, PubMed:15833850).
CC       {ECO:0000269|PubMed:11688976, ECO:0000269|PubMed:11943775,
CC       ECO:0000269|PubMed:11992541, ECO:0000269|PubMed:12553375,
CC       ECO:0000269|PubMed:15833850, ECO:0000269|PubMed:17127621,
CC       ECO:0000269|PubMed:19837976, ECO:0000269|PubMed:21778275,
CC       ECO:0000269|PubMed:25825981, ECO:0000269|PubMed:28666119}.
CC   -!- FUNCTION: [Isoform 1]: (Microbial infection) Erythrocyte receptor for
CC       P.falciparum RH5 which is essential for erythrocyte invasion by the
CC       merozoite stage of P.falciparum isolates 3D7 and Dd2.
CC       {ECO:0000269|PubMed:22080952}.
CC   -!- FUNCTION: [Isoform 2]: (Microbial infection) Erythrocyte receptor for
CC       P.falciparum RH5 which is essential for erythrocyte invasion by the
CC       merozoite stage of P.falciparum isolates 3D7, Dd2, 7G8 and HB3
CC       (PubMed:22080952, PubMed:26195724). Binding of P.falciparum RH5 results
CC       in BSG dimerization which triggers an increase in intracellular Ca(2+)
CC       in the erythrocyte (PubMed:28409866). This essential step leads to a
CC       rearrangement of the erythrocyte cytoskeleton required for the
CC       merozoite invasion (PubMed:28409866). {ECO:0000269|PubMed:22080952,
CC       ECO:0000269|PubMed:26195724, ECO:0000269|PubMed:28409866}.
CC   -!- FUNCTION: [Isoform 2]: (Microbial infection) Can facilitate human SARS
CC       coronavirus (SARS-CoV-1) infection via its interaction with virus-
CC       associated PPIA/CYPA. {ECO:0000269|PubMed:15688292}.
CC   -!- FUNCTION: [Isoform 2]: (Microbial infection) Can facilitate HIV-1
CC       infection via its interaction with virus-associated PPIA/CYPA.
CC       {ECO:0000269|PubMed:11353871}.
CC   -!- FUNCTION: [Isoform 2]: (Microbial infection) Acts as a receptor for
CC       severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
CC       {ECO:0000303|PubMed:32307653}.
CC   -!- FUNCTION: [Isoform 2]: (Microbial infection) Acts as a receptor for
CC       measles virus. {ECO:0000269|PubMed:20147391}.
CC   -!- FUNCTION: [Isoform 2]: (Microbial infection) Promotes entry of
CC       pentamer-expressing human cytomegalovirus (HCMV) into epithelial and
CC       endothelial cells. {ECO:0000269|PubMed:29739904}.
CC   -!- SUBUNIT: [Isoform 1]: Homooligomer (PubMed:19768682). Interacts with
CC       NXNL1 (PubMed:25957687). Interacts with SLC2A1 and SLC16A1/GLUT1 (By
CC       similarity). {ECO:0000250|UniProtKB:P17790,
CC       ECO:0000269|PubMed:19768682, ECO:0000269|PubMed:25957687}.
CC   -!- SUBUNIT: [Isoform 2]: Homooligomer (PubMed:18430721). Forms
CC       heterooligomers with isoform 3 (PubMed:21536654). Interacts with VEGFA
CC       and KDR/VEGFR2 (PubMed:25825981). Interacts with PPIA/CYPA
CC       (PubMed:11353871, PubMed:11943775, PubMed:15688292). Interacts with
CC       PPIL2; regulates BSG transport to the cell membrane (PubMed:15946952).
CC       Interacts with SLC16A1/GLUT1 (PubMed:17127621). Interacts with SLC16A12
CC       (PubMed:21778275). Interacts with SLC16A11 (PubMed:28666119). Interacts
CC       with AJAP1 (PubMed:17267690). Interacts with SLC1A3, ATP1B2, MAG and
CC       L1CAM (By similarity). {ECO:0000250|UniProtKB:P18572,
CC       ECO:0000250|UniProtKB:P26453, ECO:0000269|PubMed:11353871,
CC       ECO:0000269|PubMed:11943775, ECO:0000269|PubMed:15688292,
CC       ECO:0000269|PubMed:15946952, ECO:0000269|PubMed:17127621,
CC       ECO:0000269|PubMed:17267690, ECO:0000269|PubMed:18430721,
CC       ECO:0000269|PubMed:21536654, ECO:0000269|PubMed:21778275,
CC       ECO:0000269|PubMed:25825981, ECO:0000269|PubMed:28666119}.
CC   -!- SUBUNIT: [Isoform 3]: Forms heterooligomers with isoform 2.
CC       {ECO:0000269|PubMed:21536654}.
CC   -!- SUBUNIT: [Isoform 1]: (Microbial infection) Interacts with P.falciparum
CC       (isolate 3D7) RH5/PfRH5; the interaction is required for the invasion
CC       of the host erythrocytes by the parasite at the merozoite stage.
CC       {ECO:0000269|PubMed:22080952}.
CC   -!- SUBUNIT: [Isoform 2]: (Microbial infection) Interacts with P.falciparum
CC       (isolates 3D7 or 7G8) RH5/PfRH5; the interaction is required for the
CC       invasion of the host erythrocytes by the parasite at the merozoite
CC       stage. {ECO:0000269|PubMed:22080952, ECO:0000269|PubMed:24297912,
CC       ECO:0000269|PubMed:25132548, ECO:0000269|PubMed:26195724}.
CC   -!- SUBUNIT: [Isoform 2]: (Microbial infection) Interacts with severe acute
CC       respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein.
CC       {ECO:0000303|PubMed:32307653}.
CC   -!- INTERACTION:
CC       P35613; P05067: APP; NbExp=2; IntAct=EBI-750709, EBI-77613;
CC       P35613; Q9UJC3: HOOK1; NbExp=3; IntAct=EBI-750709, EBI-746704;
CC       P35613; Q92542: NCSTN; NbExp=6; IntAct=EBI-750709, EBI-998440;
CC       P35613; PRO_0000025592 [P49768]: PSEN1; NbExp=6; IntAct=EBI-750709, EBI-2606356;
CC       P35613; P0DTC2: S; Xeno; NbExp=5; IntAct=EBI-750709, EBI-25474821;
CC       P35613; P53987: Slc16a1; Xeno; NbExp=4; IntAct=EBI-750709, EBI-15348773;
CC       P35613-2; Q13520: AQP6; NbExp=3; IntAct=EBI-11037868, EBI-13059134;
CC       P35613-2; Q7RTY0: SLC16A13; NbExp=3; IntAct=EBI-11037868, EBI-12243266;
CC       P35613-2; B2L3N7; Xeno; NbExp=5; IntAct=EBI-11037868, EBI-16118096;
CC   -!- SUBCELLULAR LOCATION: Melanosome {ECO:0000269|PubMed:17081065}.
CC       Note=Identified by mass spectrometry in melanosome fractions from stage
CC       I to stage IV. {ECO:0000269|PubMed:17081065}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:25957687}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P26453}. Photoreceptor inner segment
CC       {ECO:0000250|UniProtKB:P18572}. Cell projection, cilium, photoreceptor
CC       outer segment {ECO:0000250|UniProtKB:P18572}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
CC       {ECO:0000269|PubMed:11992541, ECO:0000269|PubMed:15688292,
CC       ECO:0000269|PubMed:15946952, ECO:0000269|PubMed:17127621,
CC       ECO:0000269|PubMed:21536654, ECO:0000269|PubMed:25825981,
CC       ECO:0000269|PubMed:26195724, ECO:0000269|PubMed:28409866,
CC       ECO:0000269|PubMed:29739904}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P26453}. Endosome {ECO:0000269|PubMed:29739904}.
CC       Endoplasmic reticulum membrane {ECO:0000269|PubMed:15688292}; Single-
CC       pass type I membrane protein {ECO:0000250|UniProtKB:P26453}.
CC       Basolateral cell membrane {ECO:0000269|PubMed:17267690}; Single-pass
CC       type I membrane protein {ECO:0000250|UniProtKB:P26453}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane
CC       {ECO:0000269|PubMed:21536654}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P26453}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Cell membrane
CC       {ECO:0000269|PubMed:21536654}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P26453}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long, Basigin-1 {ECO:0000303|PubMed:25957687};
CC         IsoId=P35613-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short, Basigin-2 {ECO:0000303|PubMed:25957687};
CC         IsoId=P35613-2; Sequence=VSP_011501;
CC       Name=3; Synonyms=Basigin-3;
CC         IsoId=P35613-3; Sequence=VSP_043225;
CC       Name=4; Synonyms=Basigin-4;
CC         IsoId=P35613-4; Sequence=VSP_043226, VSP_043227;
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Retina-specific (PubMed:25957687).
CC       Expressed in retinal cone photoreceptors (at protein level)
CC       (PubMed:25957687). {ECO:0000269|PubMed:25957687}.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in erythrocytes (at protein
CC       level) (PubMed:26195724, PubMed:28409866). Highly expressed in melanoma
CC       cell lines (at protein level) (PubMed:11992541). Highly expressed in
CC       the heart, kidney, skeletal muscle and testis (PubMed:21536654).
CC       {ECO:0000269|PubMed:11992541, ECO:0000269|PubMed:21536654,
CC       ECO:0000269|PubMed:26195724, ECO:0000269|PubMed:28409866}.
CC   -!- TISSUE SPECIFICITY: [Isoform 3]: Highly expressed in the bone marrow,
CC       fetal liver, lung, testis and thymus. {ECO:0000269|PubMed:21536654}.
CC   -!- TISSUE SPECIFICITY: [Isoform 4]: Highly expressed in the bone marrow,
CC       fetal liver, lung, testis and thymus. {ECO:0000269|PubMed:21536654}.
CC   -!- PTM: [Isoform 2]: N-glycosylated. {ECO:0000269|PubMed:21536654}.
CC   -!- PTM: [Isoform 3]: N-glycosylated. {ECO:0000269|PubMed:21536654}.
CC   -!- PTM: [Isoform 4]: N-glycosylated. {ECO:0000269|PubMed:21536654}.
CC   -!- BIOTECHNOLOGY: [Isoform 2]: Potential candidate for the development of
CC       parasite blood stage vaccines. In vitro and in vivo, neutralizing
CC       antibodies are capable of inhibiting merozoite invasion of host
CC       erythrocytes. {ECO:0000269|PubMed:26195724}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage.
CC       {ECO:0000269|PubMed:21536654}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative promoter usage.
CC       {ECO:0000269|PubMed:21536654}.
CC   -!- WEB RESOURCE: Name=dbRBC/BGMUT; Note=Blood group antigen gene mutation
CC       database;
CC       URL="https://www.ncbi.nlm.nih.gov/gv/mhc/xslcgi.cgi?cmd=bgmut/systems_info&system=ok";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/bsg/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X64364; CAA45716.1; -; mRNA.
DR   EMBL; D45131; BAA08109.1; -; mRNA.
DR   EMBL; L10240; AAA68936.1; -; mRNA.
DR   EMBL; M87879; AAA91084.1; -; mRNA.
DR   EMBL; L20471; AAB41120.1; -; mRNA.
DR   EMBL; AF042854; AAD10704.1; -; Genomic_DNA.
DR   EMBL; AF042848; AAD10704.1; JOINED; Genomic_DNA.
DR   EMBL; AF042849; AAD10704.1; JOINED; Genomic_DNA.
DR   EMBL; AF042850; AAD10704.1; JOINED; Genomic_DNA.
DR   EMBL; AF042851; AAD10704.1; JOINED; Genomic_DNA.
DR   EMBL; AF042852; AAD10704.1; JOINED; Genomic_DNA.
DR   EMBL; AF042853; AAD10704.1; JOINED; Genomic_DNA.
DR   EMBL; AB072923; BAB88938.1; -; mRNA.
DR   EMBL; AB085790; BAC76828.1; -; mRNA.
DR   EMBL; AF548371; AAN40694.1; -; mRNA.
DR   EMBL; GU557064; ADD31881.1; -; mRNA.
DR   EMBL; GU557065; ADD31882.1; -; mRNA.
DR   EMBL; AY358113; AAQ88480.1; -; mRNA.
DR   EMBL; AY942196; AAX20110.1; -; Genomic_DNA.
DR   EMBL; AC005559; AAC33279.1; -; Genomic_DNA.
DR   EMBL; CH471242; EAW61181.1; -; Genomic_DNA.
DR   EMBL; CH471242; EAW61185.1; -; Genomic_DNA.
DR   EMBL; BC009040; AAH09040.1; -; mRNA.
DR   CCDS; CCDS12032.1; -. [P35613-4]
DR   CCDS; CCDS12033.1; -. [P35613-1]
DR   CCDS; CCDS12034.1; -. [P35613-2]
DR   CCDS; CCDS58635.1; -. [P35613-3]
DR   PIR; A46506; A46506.
DR   RefSeq; NP_001309172.1; NM_001322243.1. [P35613-2]
DR   RefSeq; NP_001719.2; NM_001728.3. [P35613-1]
DR   RefSeq; NP_940991.1; NM_198589.2. [P35613-2]
DR   RefSeq; NP_940992.1; NM_198590.2. [P35613-3]
DR   RefSeq; NP_940993.1; NM_198591.2. [P35613-4]
DR   RefSeq; XP_016882662.1; XM_017027173.1. [P35613-1]
DR   PDB; 3B5H; X-ray; 2.80 A; A/B/C/D=140-321.
DR   PDB; 3I84; X-ray; 2.00 A; A/B=13-219.
DR   PDB; 3I85; X-ray; 2.50 A; A/B=13-219.
DR   PDB; 3QQN; X-ray; 2.31 A; A/B=23-138.
DR   PDB; 3QR2; X-ray; 2.30 A; A/B=23-138.
DR   PDB; 4U0Q; X-ray; 3.10 A; B/D=1-385.
DR   PDB; 5X0T; X-ray; 2.50 A; E/F=138-217.
DR   PDB; 5XF0; NMR; -; A=215-321.
DR   PDBsum; 3B5H; -.
DR   PDBsum; 3I84; -.
DR   PDBsum; 3I85; -.
DR   PDBsum; 3QQN; -.
DR   PDBsum; 3QR2; -.
DR   PDBsum; 4U0Q; -.
DR   PDBsum; 5X0T; -.
DR   PDBsum; 5XF0; -.
DR   SMR; P35613; -.
DR   BioGRID; 107147; 221.
DR   CORUM; P35613; -.
DR   DIP; DIP-50310N; -.
DR   IntAct; P35613; 137.
DR   MINT; P35613; -.
DR   STRING; 9606.ENSP00000333769; -.
DR   ChEMBL; CHEMBL3580492; -.
DR   TCDB; 8.A.23.1.1; the basigin (basigin) family.
DR   GlyConnect; 1027; 9 N-Linked glycans (2 sites).
DR   GlyGen; P35613; 4 sites, 2 O-linked glycans (1 site).
DR   iPTMnet; P35613; -.
DR   MetOSite; P35613; -.
DR   PhosphoSitePlus; P35613; -.
DR   SwissPalm; P35613; -.
DR   BioMuta; BSG; -.
DR   DMDM; 51704273; -.
DR   CPTAC; CPTAC-319; -.
DR   CPTAC; CPTAC-320; -.
DR   EPD; P35613; -.
DR   jPOST; P35613; -.
DR   MassIVE; P35613; -.
DR   MaxQB; P35613; -.
DR   PaxDb; P35613; -.
DR   PeptideAtlas; P35613; -.
DR   PRIDE; P35613; -.
DR   ProteomicsDB; 55113; -. [P35613-1]
DR   ProteomicsDB; 55114; -. [P35613-2]
DR   ProteomicsDB; 55115; -. [P35613-3]
DR   ProteomicsDB; 55116; -. [P35613-4]
DR   TopDownProteomics; P35613-1; -. [P35613-1]
DR   TopDownProteomics; P35613-2; -. [P35613-2]
DR   TopDownProteomics; P35613-3; -. [P35613-3]
DR   ABCD; P35613; 84 sequenced antibodies.
DR   Antibodypedia; 3719; 1918 antibodies.
DR   DNASU; 682; -.
DR   Ensembl; ENST00000333511; ENSP00000333769; ENSG00000172270. [P35613-1]
DR   Ensembl; ENST00000346916; ENSP00000344707; ENSG00000172270. [P35613-4]
DR   Ensembl; ENST00000353555; ENSP00000343809; ENSG00000172270. [P35613-2]
DR   Ensembl; ENST00000545507; ENSP00000473664; ENSG00000172270. [P35613-3]
DR   GeneID; 682; -.
DR   KEGG; hsa:682; -.
DR   UCSC; uc002loy.5; human. [P35613-1]
DR   CTD; 682; -.
DR   DisGeNET; 682; -.
DR   EuPathDB; HostDB:ENSG00000172270.18; -.
DR   GeneCards; BSG; -.
DR   HGNC; HGNC:1116; BSG.
DR   HPA; ENSG00000172270; Low tissue specificity.
DR   MIM; 109480; gene.
DR   MIM; 111380; phenotype.
DR   neXtProt; NX_P35613; -.
DR   OpenTargets; ENSG00000172270; -.
DR   PharmGKB; PA25433; -.
DR   eggNOG; ENOG502QPKN; Eukaryota.
DR   GeneTree; ENSGT00940000159142; -.
DR   HOGENOM; CLU_058449_0_0_1; -.
DR   InParanoid; P35613; -.
DR   KO; K06535; -.
DR   OMA; NATNHKD; -.
DR   OrthoDB; 1021787at2759; -.
DR   PhylomeDB; P35613; -.
DR   TreeFam; TF326759; -.
DR   PathwayCommons; P35613; -.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-433692; Proton-coupled monocarboxylate transport.
DR   Reactome; R-HSA-5619070; Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT).
DR   Reactome; R-HSA-70268; Pyruvate metabolism.
DR   BioGRID-ORCS; 682; 50 hits in 877 CRISPR screens.
DR   ChiTaRS; BSG; human.
DR   EvolutionaryTrace; P35613; -.
DR   GeneWiki; Basigin; -.
DR   GenomeRNAi; 682; -.
DR   Pharos; P35613; Tbio.
DR   PRO; PR:P35613; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P35613; protein.
DR   Bgee; ENSG00000172270; Expressed in apex of heart and 242 other tissues.
DR   ExpressionAtlas; P35613; baseline and differential.
DR   Genevisible; P35613; HS.
DR   GO; GO:0002080; C:acrosomal membrane; IEA:Ensembl.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; IEA:Ensembl.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0098632; F:cell-cell adhesion mediator activity; IBA:GO_Central.
DR   GO; GO:0005537; F:mannose binding; IEA:UniProtKB-KW.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0046697; P:decidualization; IEA:Ensembl.
DR   GO; GO:0070593; P:dendrite self-avoidance; IBA:GO_Central.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IBA:GO_Central.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:UniProtKB.
DR   GO; GO:0072659; P:protein localization to plasma membrane; ISS:UniProtKB.
DR   GO; GO:0006090; P:pyruvate metabolic process; TAS:Reactome.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0046689; P:response to mercury ion; IEA:Ensembl.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR043204; Basigin-like.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR027112; Neuroplastin/Basigin.
DR   PANTHER; PTHR10075; PTHR10075; 1.
DR   PANTHER; PTHR10075:SF5; PTHR10075:SF5; 1.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00408; IGc2; 2.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   PROSITE; PS50835; IG_LIKE; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   Angiogenesis; Blood group antigen; Cell membrane; Cell projection;
KW   Direct protein sequencing; Disulfide bond; Endoplasmic reticulum; Endosome;
KW   Glycoprotein; Host cell receptor for virus entry; Host-virus interaction;
KW   Immunoglobulin domain; Lectin; Mannose-binding; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..21
FT   CHAIN           22..385
FT                   /note="Basigin"
FT                   /id="PRO_0000014518"
FT   TOPO_DOM        138..323
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P26453"
FT   TRANSMEM        324..344
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        345..385
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P26453"
FT   DOMAIN          37..120
FT                   /note="Ig-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          138..219
FT                   /note="Ig-like C2-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          221..315
FT                   /note="Ig-like V-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   COMPBIAS        356..359
FT                   /note="Poly-Asp"
FT   MOD_RES         362
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   MOD_RES         368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   CARBOHYD        160
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973"
FT   CARBOHYD        268
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973"
FT   CARBOHYD        302
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        44..108
FT                   /evidence="ECO:0000244|PDB:3QQN, ECO:0000244|PDB:3QR2,
FT                   ECO:0000269|PubMed:21620857"
FT   DISULFID        157..203
FT                   /evidence="ECO:0000244|PDB:3B5H, ECO:0000244|PDB:3I84,
FT                   ECO:0000244|PDB:4U0Q, ECO:0000244|PDB:5X0T,
FT                   ECO:0000269|PubMed:18430721, ECO:0000269|PubMed:19768682,
FT                   ECO:0000269|PubMed:25132548, ECO:0000269|Ref.57"
FT   DISULFID        242..301
FT                   /evidence="ECO:0000244|PDB:3B5H, ECO:0000244|PDB:4U0Q,
FT                   ECO:0000269|PubMed:18430721, ECO:0000269|PubMed:25132548"
FT   VAR_SEQ         1..209
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:21536654"
FT                   /id="VSP_043225"
FT   VAR_SEQ         1..11
FT                   /note="MAAALFVLLGF -> MKQSDASPQER (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:21536654"
FT                   /id="VSP_043226"
FT   VAR_SEQ         12..191
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:21536654"
FT                   /id="VSP_043227"
FT   VAR_SEQ         24..139
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:1634773, ECO:0000303|PubMed:7812975"
FT                   /id="VSP_011501"
FT   VARIANT         152
FT                   /note="K -> N (no effect on the interaction with
FT                   P.falciparum RH5; dbSNP:rs14704)"
FT                   /evidence="ECO:0000269|PubMed:22080952"
FT                   /id="VAR_082637"
FT   VARIANT         176
FT                   /note="V -> L (no effect on the interaction with
FT                   P.falciparum RH5; dbSNP:rs2229662)"
FT                   /evidence="ECO:0000269|PubMed:22080952"
FT                   /id="VAR_082638"
FT   VARIANT         206
FT                   /note="L -> P (loss of interaction with P.falciparum RH5;
FT                   dbSNP:rs55911144)"
FT                   /evidence="ECO:0000269|PubMed:22080952"
FT                   /id="VAR_082639"
FT   VARIANT         208
FT                   /note="E -> K (in Ok(A-); 2-fold reduction in the binding
FT                   affinity for P.falciparum RH5 with reduced erythrocyte
FT                   invasion by P.falciparum isolates 3D7 and Dd2;
FT                   dbSNP:rs104894669)"
FT                   /evidence="ECO:0000269|PubMed:22080952,
FT                   ECO:0000269|PubMed:9130641"
FT                   /id="VAR_013574"
FT   VARIANT         269
FT                   /note="G -> V (loss of interaction with P.falciparum RH5;
FT                   dbSNP:rs1803203)"
FT                   /evidence="ECO:0000269|PubMed:22080952"
FT                   /id="VAR_011720"
FT   MUTAGEN         67
FT                   /note="C->M: Loss of ability to stimulate interleukin-6
FT                   secretion"
FT                   /evidence="ECO:0000269|PubMed:21620857"
FT   MUTAGEN         160
FT                   /note="N->D: No effect on the interaction with P.falciparum
FT                   RH5; when associated with D-268 and D-302."
FT                   /evidence="ECO:0000269|PubMed:22080952"
FT   MUTAGEN         268
FT                   /note="N->D: No effect on the interaction with P.falciparum
FT                   RH5; when associated with D-160 and D-302."
FT                   /evidence="ECO:0000269|PubMed:22080952"
FT   MUTAGEN         302
FT                   /note="N->D: No effect on the interaction with P.falciparum
FT                   RH5; when associated with D-160 and D-268."
FT                   /evidence="ECO:0000269|PubMed:22080952"
FT   CONFLICT        328
FT                   /note="F -> L (in Ref. 2; BAC76828)"
FT                   /evidence="ECO:0000305"
FT   STRAND          24..27
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   STRAND          32..35
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   STRAND          40..47
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   STRAND          53..62
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   HELIX           74..77
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   STRAND          79..95
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   HELIX           100..102
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   STRAND          104..111
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   STRAND          116..118
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   STRAND          128..137
FT                   /evidence="ECO:0000244|PDB:3QR2"
FT   STRAND          142..149
FT                   /evidence="ECO:0000244|PDB:3I84"
FT   STRAND          152..159
FT                   /evidence="ECO:0000244|PDB:3I84"
FT   STRAND          166..173
FT                   /evidence="ECO:0000244|PDB:3I84"
FT   STRAND          176..181
FT                   /evidence="ECO:0000244|PDB:3I84"
FT   STRAND          186..192
FT                   /evidence="ECO:0000244|PDB:3I84"
FT   HELIX           194..196
FT                   /evidence="ECO:0000244|PDB:3I84"
FT   STRAND          199..207
FT                   /evidence="ECO:0000244|PDB:3I84"
FT   STRAND          210..217
FT                   /evidence="ECO:0000244|PDB:3I84"
FT   STRAND          224..226
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   STRAND          228..233
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   STRAND          238..243
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   STRAND          252..257
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   STRAND          260..262
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   STRAND          264..266
FT                   /evidence="ECO:0000244|PDB:4U0Q"
FT   HELIX           270..272
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   STRAND          274..279
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   STRAND          282..287
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   TURN            292..294
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   STRAND          295..305
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   STRAND          308..319
FT                   /evidence="ECO:0000244|PDB:3B5H"
FT   MUTAGEN         P35613-2:27
FT                   /note="F->L: Severe reduction in the interaction with
FT                   P.falciparum RH5"
FT                   /evidence="ECO:0000269|PubMed:24297912"
FT   MUTAGEN         P35613-2:32
FT                   /note="D->E: No effect on the interaction with P.falciparum
FT                   RH5"
FT                   /evidence="ECO:0000269|PubMed:24297912"
FT   MUTAGEN         P35613-2:75
FT                   /note="K->E: No effect on the interaction with P.falciparum
FT                   RH5"
FT                   /evidence="ECO:0000269|PubMed:24297912"
FT   MUTAGEN         P35613-2:100
FT                   /note="Q->K: Severe reduction in the interaction with
FT                   P.falciparum RH5"
FT                   /evidence="ECO:0000269|PubMed:24297912"
FT   MUTAGEN         P35613-2:102
FT                   /note="H->HH: Severe reduction in the interaction with
FT                   P.falciparum RH5"
FT                   /evidence="ECO:0000269|PubMed:24297912"
FT   MUTAGEN         P35613-2:144
FT                   /note="D->A: Reduced interaction with KDR/VEGFR2"
FT                   /evidence="ECO:0000269|PubMed:25825981"
FT   MUTAGEN         P35613-2:180..181
FT                   /note="PG->AA: Loss of its ability to mediate chemotactic
FT                   activity of PPIA/CYPA"
FT                   /evidence="ECO:0000269|PubMed:11943775"
FT   MUTAGEN         P35613-2:182
FT                   /note="Q->A: Reduced interaction with KDR/VEGFR2.
FT                   Significant loss of interaction with KDR/VEGFR2; when
FT                   associated with A-184."
FT                   /evidence="ECO:0000269|PubMed:25825981"
FT   MUTAGEN         P35613-2:184
FT                   /note="R->A: Reduced interaction with KDR/VEGFR2.
FT                   Significant loss of interaction with KDR/VEGFR2; when
FT                   associated with A-182."
FT                   /evidence="ECO:0000269|PubMed:25825981"
FT   MUTAGEN         P35613-2:195
FT                   /note="Q->A: Reduced interaction with KDR/VEGFR2. Complete
FT                   loss of interaction with KDR/VEGFR2 when associated with
FT                   A-199."
FT                   /evidence="ECO:0000269|PubMed:25825981"
FT   MUTAGEN         P35613-2:199
FT                   /note="T->A: Reduced interaction with KDR/VEGFR2. Complete
FT                   loss of interaction with KDR/VEGFR2; when associated with
FT                   A-195."
FT                   /evidence="ECO:0000269|PubMed:25825981"
FT   MUTAGEN         P35613-2:211
FT                   /note="P->A: Loss of interaction with PPIL2."
FT                   /evidence="ECO:0000269|PubMed:15946952"
FT   REGION          P35613-2:195..199
FT                   /note="Essential for interaction with KDR/VEGFR2"
FT                   /evidence="ECO:0000269|PubMed:25825981"
SQ   SEQUENCE   385 AA;  42200 MW;  D74C37455BF26685 CRC64;
     MAAALFVLLG FALLGTHGAS GAAGFVQAPL SQQRWVGGSV ELHCEAVGSP VPEIQWWFEG
     QGPNDTCSQL WDGARLDRVH IHATYHQHAA STISIDTLVE EDTGTYECRA SNDPDRNHLT
     RAPRVKWVRA QAVVLVLEPG TVFTTVEDLG SKILLTCSLN DSATEVTGHR WLKGGVVLKE
     DALPGQKTEF KVDSDDQWGE YSCVFLPEPM GTANIQLHGP PRVKAVKSSE HINEGETAML
     VCKSESVPPV TDWAWYKITD SEDKALMNGS ESRFFVSSSQ GRSELHIENL NMEADPGQYR
     CNGTSSKGSD QAIITLRVRS HLAALWPFLG IVAEVLVLVT IIFIYEKRRK PEDVLDDDDA
     GSAPLKSSGQ HQNDKGKNVR QRNSS
//
ID   IL6RB_HUMAN             Reviewed;         918 AA.
AC   P40189; A0N0L4; Q5FC04; Q9UQ41;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   12-AUG-2020, entry version 227.
DE   RecName: Full=Interleukin-6 receptor subunit beta {ECO:0000305};
DE            Short=IL-6 receptor subunit beta;
DE            Short=IL-6R subunit beta;
DE            Short=IL-6R-beta;
DE            Short=IL-6RB;
DE   AltName: Full=CDw130;
DE   AltName: Full=Interleukin-6 signal transducer;
DE   AltName: Full=Membrane glycoprotein 130;
DE            Short=gp130 {ECO:0000303|PubMed:12829785};
DE   AltName: Full=Oncostatin-M receptor subunit alpha;
DE   AltName: CD_antigen=CD130;
DE   Flags: Precursor;
GN   Name=IL6ST {ECO:0000312|HGNC:HGNC:6021};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   VARIANT VAL-8, AND SUBUNIT.
RC   TISSUE=Myeloma, and Placenta;
RX   PubMed=2261637; DOI=10.1016/0092-8674(90)90411-7;
RA   Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T.;
RT   "Molecular cloning and expression of an IL-6 signal transducer, gp130.";
RL   Cell 63:1149-1157(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT VAL-8, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Synovium;
RX   PubMed=10880057; DOI=10.1172/jci7479;
RA   Tanaka M., Kishimura M., Ozaki S., Osakada F., Hashimoto H., Okubo M.,
RA   Murakami M., Nakao K.;
RT   "Cloning of novel soluble gp130 and detection of its neutralizing
RT   autoantibodies in rheumatoid arthritis.";
RL   J. Clin. Invest. 106:137-144(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Hayashi A., Sameshima E., Tabata Y., Iida K., Mitsuyama M., Kanai S.,
RA   Furuya T., Saito T.;
RT   "IL6ST mRNA, nirs splice variant 4.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Livingston R.J., Shaffer T., McFarland I., Nguyen C.P., Stanaway I.B.,
RA   Rajkumar N., Johnson E.J., da Ponte S.H., Willa H., Ahearn M.O.,
RA   Bertucci C., Acklestad J., Carroll A., Swanson J., Gildersleeve H.I.,
RA   Nickerson D.A.;
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-43;
RP   ASN-83; ASN-131; ASN-157; ASN-227; ASN-379; ASN-383; ASN-553 AND ASN-564.
RX   PubMed=11098061; DOI=10.1074/jbc.m009979200;
RA   Moritz R.L., Hall N.E., Connolly L.M., Simpson R.J.;
RT   "Determination of the disulfide structure and N-glycosylation sites of the
RT   extracellular domain of the human signal transducer gp130.";
RL   J. Biol. Chem. 276:8244-8253(2001).
RN   [8]
RP   SUBUNIT, AND INDUCTION.
RX   PubMed=8999038; DOI=10.1074/jbc.271.51.32635;
RA   Mosley B., De Imus C., Friend D., Boiani N., Thoma B., Park L.S.,
RA   Cosman D.;
RT   "Dual oncostatin M (OSM) receptors. Cloning and characterization of an
RT   alternative signaling subunit conferring OSM-specific receptor
RT   activation.";
RL   J. Biol. Chem. 271:32635-32643(1996).
RN   [9]
RP   INTERACTION WITH HCK.
RX   PubMed=9406996;
RA   Hallek M., Neumann C., Schaffer M., Danhauser-Riedl S., von Bubnoff N.,
RA   de Vos G., Druker B.J., Yasukawa K., Griffin J.D., Emmerich B.;
RT   "Signal transduction of interleukin-6 involves tyrosine phosphorylation of
RT   multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck,
RT   and Lyn in multiple myeloma cell lines.";
RL   Exp. Hematol. 25:1367-1377(1997).
RN   [10]
RP   PHOSPHORYLATION AT SER-782, MUTAGENESIS OF SER-782, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=10811661; DOI=10.1074/jbc.m907658199;
RA   Gibson R.M., Schiemann W.P., Prichard L.B., Reno J.M., Ericsson L.H.,
RA   Nathanson N.M.;
RT   "Phosphorylation of human gp130 at Ser-782 adjacent to the di-leucine
RT   internalization motif. Effects on expression and signaling.";
RL   J. Biol. Chem. 275:22574-22582(2000).
RN   [11]
RP   FUNCTION (ISOFORM 2), AND BIOTECHNOLOGY.
RX   PubMed=11121117; DOI=10.1046/j.1432-1327.2001.01867.x;
RA   Jostock T., Muellberg J., Ozbek S., Atreya R., Blinn G., Voltz N.,
RA   Fischer M., Neurath M.F., Rose-John S.;
RT   "Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor
RT   transsignaling responses.";
RL   Eur. J. Biochem. 268:160-167(2001).
RN   [12]
RP   INTERACTION WITH HERPES VIRUS-8/HHV-8 PROTEIN VIL6 (MICROBIAL INFECTION).
RX   PubMed=11238858; DOI=10.1128/jvi.75.7.3325-3334.2001;
RA   Li H., Wang H., Nicholas J.;
RT   "Detection of direct binding of human herpesvirus 8-encoded interleukin-6
RT   (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino
RT   acid residues of vIL-6 important for IL-6R-dependent and -independent
RT   signaling.";
RL   J. Virol. 75:3325-3334(2001).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-379 AND ASN-383.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-829, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-227 AND ASN-390.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [18]
RP   GLYCOSYLATION AT ASN-390.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=19915009; DOI=10.1074/jbc.m109.075952;
RA   Waetzig G.H., Chalaris A., Rosenstiel P., Suthaus J., Holland C., Karl N.,
RA   Valles Uriarte L., Till A., Scheller J., Grotzinger J., Schreiber S.,
RA   Rose-John S., Seegert D.;
RT   "N-linked glycosylation is essential for the stability but not the
RT   signaling function of the interleukin-6 signal transducer glycoprotein
RT   130.";
RL   J. Biol. Chem. 285:1781-1789(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   FUNCTION (ISOFORM 2), AND BIOTECHNOLOGY.
RX   PubMed=21990364; DOI=10.1074/jbc.m111.295758;
RA   Garbers C., Thaiss W., Jones G.W., Waetzig G.H., Lorenzen I., Guilhot F.,
RA   Lissilaa R., Ferlin W.G., Groetzinger J., Jones S.A., Rose-John S.,
RA   Scheller J.;
RT   "Inhibition of classic signaling is a novel function of soluble
RT   glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin
RT   6 and soluble interleukin 6 receptor.";
RL   J. Biol. Chem. 286:42959-42970(2011).
RN   [22]
RP   FUNCTION, AND MUTAGENESIS OF CYS-172; 186-TYR--TYR-190; VAL-189; TYR-190;
RP   ASP-215 AND VAL-252.
RX   PubMed=23294003; DOI=10.1042/bj20121660;
RA   Schutt A., Zacharias M., Schneider N., Horn S., Grotzinger J.,
RA   Rose-John S., Schmidt-Arras D.;
RT   "gp130 activation is regulated by D2-D3 interdomain connectivity.";
RL   Biochem. J. 450:487-496(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667 AND SER-839, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-661 AND SER-667, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   FUNCTION, MUTAGENESIS OF TYR-759, AND INTERACTION WITH SRC AND YES.
RX   PubMed=25731159; DOI=10.1038/nature14228;
RA   Taniguchi K., Wu L.W., Grivennikov S.I., de Jong P.R., Lian I., Yu F.X.,
RA   Wang K., Ho S.B., Boland B.S., Chang J.T., Sandborn W.J., Hardiman G.,
RA   Raz E., Maehara Y., Yoshimura A., Zucman-Rossi J., Guan K.L., Karin M.;
RT   "A gp130-Src-YAP module links inflammation to epithelial regeneration.";
RL   Nature 519:57-62(2015).
RN   [26]
RP   BIOTECHNOLOGY.
RX   PubMed=26876177; DOI=10.1016/j.celrep.2016.01.053;
RA   Lokau J., Nitz R., Agthe M., Monhasery N., Aparicio-Siegmund S.,
RA   Schumacher N., Wolf J., Moeller-Hackbarth K., Waetzig G.H., Groetzinger J.,
RA   Mueller-Newen G., Rose-John S., Scheller J., Garbers C.;
RT   "Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.";
RL   Cell Rep. 14:1761-1773(2016).
RN   [27]
RP   FUNCTION (ISOFORM 2), AND BIOTECHNOLOGY.
RX   PubMed=30279168; DOI=10.1126/scisignal.aar7388;
RA   Lamertz L., Rummel F., Polz R., Baran P., Hansen S., Waetzig G.H.,
RA   Moll J.M., Floss D.M., Scheller J.;
RT   "Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling
RT   but not intracellular autocrine responses.";
RL   Sci. Signal. 11:0-0(2018).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 122-325.
RX   PubMed=9501088; DOI=10.1093/emboj/17.6.1665;
RA   Bravo J., Staunton D., Heath J.K., Jones E.Y.;
RT   "Crystal structure of a cytokine-binding region of gp130.";
RL   EMBO J. 17:1665-1674(1998).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 23-325 IN COMPLEX WITH HERPES
RP   VIRUS-8/HHV-8 PROTEIN VIL6 (MICROBIAL INFECTION), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=11251120; DOI=10.1126/science.1058308;
RA   Chow D.-C., He X.-L., Snow A.L., Rose-John S., Garcia K.C.;
RT   "Structure of an extracellular gp130 cytokine receptor signaling complex.";
RL   Science 291:2150-2155(2001).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 123-323 IN COMPLEX WITH LIF.
RX   PubMed=14527405; DOI=10.1016/s1097-2765(03)00365-4;
RA   Boulanger M.J., Bankovich A.J., Kortemme T., Baker D., Garcia K.C.;
RT   "Convergent mechanisms for recognition of divergent cytokines by the shared
RT   signaling receptor gp130.";
RL   Mol. Cell 12:577-589(2003).
RN   [31] {ECO:0000244|PDB:1P9M}
RP   X-RAY CRYSTALLOGRAPHY (3.65 ANGSTROMS) OF 23-321 IN COMPLEX WITH IL6 AND
RP   IL6R, AND SUBUNIT.
RX   PubMed=12829785; DOI=10.1126/science.1083901;
RA   Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C.;
RT   "Hexameric structure and assembly of the interleukin-6/IL-6 alpha-
RT   receptor/gp130 complex.";
RL   Science 300:2101-2104(2003).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 24-612, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-43; ASN-83; ASN-227; ASN-383 AND ASN-553.
RX   PubMed=20489211; DOI=10.1074/jbc.c110.129502;
RA   Xu Y., Kershaw N.J., Luo C.S., Soo P., Pocock M.J., Czabotar P.E.,
RA   Hilton D.J., Nicola N.A., Garrett T.P., Zhang J.G.;
RT   "Crystal structure of the entire ectodomain of gp130: insights into the
RT   molecular assembly of the tall cytokine receptor complexes.";
RL   J. Biol. Chem. 285:21214-21218(2010).
RN   [33]
RP   VARIANT [LARGE SCALE ANALYSIS] ILE-415.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [34]
RP   VARIANT GLY-200.
RX   PubMed=25242236; DOI=10.1016/j.cancergen.2014.07.003;
RA   Sun L., Sui L., Cong X., Ma K., Ma X., Huang Y., Fan C., Fu X., Ma K.;
RT   "Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a
RT   Chinese cohort.";
RL   Cancer Genet. 207:291-298(2014).
RN   [35]
RP   VARIANT ARG-148, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=24629561; DOI=10.1016/j.metabol.2014.02.005;
RA   Wonnerth A., Katsaros K.M., Krychtiuk K.A., Speidl W.S., Kaun C.,
RA   Thaler K., Huber K., Wojta J., Maurer G., Seljeflot I., Arnesen H.,
RA   Weiss T.W.;
RT   "Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels.";
RL   Metabolism 63:647-653(2014).
RN   [36]
RP   VARIANT HIES4 TYR-404, INVOLVEMENT IN HIES4, FUNCTION, AND CHARACTERIZATION
RP   OF VARIANT HIES4 TYR-404.
RX   PubMed=28747427; DOI=10.1084/jem.20161810;
RA   Schwerd T., Twigg S.R.F., Aschenbrenner D., Manrique S., Miller K.A.,
RA   Taylor I.B., Capitani M., McGowan S.J., Sweeney E., Weber A., Chen L.,
RA   Bowness P., Riordan A., Cant A., Freeman A.F., Milner J.D., Holland S.M.,
RA   Frede N., Mueller M., Schmidt-Arras D., Grimbacher B., Wall S.A.,
RA   Jones E.Y., Wilkie A.O.M., Uhlig H.H.;
RT   "A biallelic mutation in IL6ST encoding the GP130 co-receptor causes
RT   immunodeficiency and craniosynostosis.";
RL   J. Exp. Med. 214:2547-2562(2017).
RN   [37]
RP   VARIANT HIES4 LEU-498, INVOLVEMENT IN HIES4, FUNCTION, AND CHARACTERIZATION
RP   OF VARIANT HIES4 LEU-498.
RX   PubMed=30309848; DOI=10.3324/haematol.2018.194233;
RA   Shahin T., Aschenbrenner D., Cagdas D., Bal S.K., Conde C.D., Garncarz W.,
RA   Medgyesi D., Schwerd T., Karaatmaca B., Cetinkaya P.G., Esenboga S.,
RA   Twigg S.R.F., Cant A., Wilkie A.O.M., Tezcan I., Uhlig H.H., Boztug K.;
RT   "Selective loss of function variants in IL6ST cause Hyper-IgE syndrome with
RT   distinct impairments of T-cell phenotype and function.";
RL   Haematologica 104:609-621(2019).
CC   -!- FUNCTION: Signal-transducing molecule (PubMed:2261637). The receptor
CC       systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize IL6ST
CC       for initiating signal transmission. Binding of IL6 to IL6R induces
CC       IL6ST homodimerization and formation of a high-affinity receptor
CC       complex, which activate the intracellular JAK-MAPK and JAK-STAT3
CC       signaling pathways (PubMed:2261637, PubMed:19915009, PubMed:23294003).
CC       That causes phosphorylation of IL6ST tyrosine residues which in turn
CC       activates STAT3 (PubMed:19915009, PubMed:23294003, PubMed:25731159). In
CC       parallel, the IL6 signaling pathway induces the expression of two
CC       cytokine receptor signaling inhibitors, SOCS1 and SOCS3, which inhibit
CC       JAK and terminate the activity of the IL6 signaling pathway as a
CC       negative feedback loop (By similarity). Also activates the yes-
CC       associated protein 1 (YAP) and NOTCH pathways to control inflammation-
CC       induced epithelial regeneration, independently of STAT3 (By
CC       similarity). Mediates signals which regulate immune response,
CC       hematopoiesis, pain control and bone metabolism (By similarity). Has a
CC       role in embryonic development (By similarity). Essential for survival
CC       of motor and sensory neurons and for differentiation of astrocytes (By
CC       similarity). Required for expression of TRPA1 in nociceptive neurons
CC       (By similarity). Required for the maintenance of PTH1R expression in
CC       the osteoblast lineage and for the stimulation of PTH-induced
CC       osteoblast differentiation (By similarity). Required for normal
CC       trabecular bone mass and cortical bone composition (By similarity).
CC       {ECO:0000250|UniProtKB:Q00560, ECO:0000269|PubMed:19915009,
CC       ECO:0000269|PubMed:2261637, ECO:0000269|PubMed:23294003,
CC       ECO:0000269|PubMed:25731159, ECO:0000269|PubMed:28747427,
CC       ECO:0000269|PubMed:30309848}.
CC   -!- FUNCTION: [Isoform 2]: Binds to the soluble IL6:sIL6R complex (hyper-
CC       IL6), thereby blocking IL6 trans-signaling. Inhibits sIL6R-dependent
CC       acute phase response (PubMed:11121117, PubMed:21990364,
CC       PubMed:30279168). Also blocks IL11 cluster signaling through IL11R
CC       (PubMed:30279168). {ECO:0000269|PubMed:11121117,
CC       ECO:0000269|PubMed:21990364, ECO:0000269|PubMed:30279168}.
CC   -!- SUBUNIT: Component of a hexamer of two molecules each of IL6, IL6R and
CC       IL6ST; associates with the complex IL6:IL6R but does not interact with
CC       IL6 (PubMed:12829785, PubMed:2261637). Forms heterodimers composed of
CC       LIFR and IL6ST (type I OSM receptor) which are activated by LIF and OSM
CC       (PubMed:8999038). Also forms heterodimers composed of OSMR and IL6ST
CC       (type II receptor) which are activated by OSM but not by LIF
CC       (PubMed:8999038). Interacts with HCK (PubMed:9406996). Interacts with
CC       INPP5D/SHIP1 (By similarity). Interacts with SRC and YES
CC       (PubMed:25731159). {ECO:0000250|UniProtKB:Q00560,
CC       ECO:0000269|PubMed:12829785, ECO:0000269|PubMed:14527405,
CC       ECO:0000269|PubMed:2261637, ECO:0000269|PubMed:25731159,
CC       ECO:0000269|PubMed:8999038, ECO:0000269|PubMed:9406996}.
CC   -!- SUBUNIT: (Microbial infection) The homodimer binds two molecules of
CC       herpes virus 8/HHV-8 protein vIL-6. {ECO:0000269|PubMed:11238858,
CC       ECO:0000269|PubMed:11251120}.
CC   -!- INTERACTION:
CC       P40189; P26441: CNTF; NbExp=10; IntAct=EBI-1030834, EBI-1050897;
CC       P40189; P40189: IL6ST; NbExp=2; IntAct=EBI-1030834, EBI-1030834;
CC       P40189; Q9NZI2-2: KCNIP1; NbExp=3; IntAct=EBI-1030834, EBI-22452746;
CC       P40189; Q9Y2W7: KCNIP3; NbExp=7; IntAct=EBI-1030834, EBI-751501;
CC       P40189; P15018: LIF; NbExp=2; IntAct=EBI-1030834, EBI-1037189;
CC       P40189; P43364: MAGEA11; NbExp=3; IntAct=EBI-1030834, EBI-739552;
CC       P40189; P13725: OSM; NbExp=2; IntAct=EBI-1030834, EBI-6595724;
CC       P40189; Q99650: OSMR; NbExp=2; IntAct=EBI-1030834, EBI-2804080;
CC       P40189; O43765: SGTA; NbExp=3; IntAct=EBI-1030834, EBI-347996;
CC       P40189; Q96EQ0: SGTB; NbExp=4; IntAct=EBI-1030834, EBI-744081;
CC       P40189; Q2HRC7: K2; Xeno; NbExp=2; IntAct=EBI-1030834, EBI-9007403;
CC       P40189; P42227: Stat3; Xeno; NbExp=4; IntAct=EBI-1030834, EBI-602878;
CC       P40189-1; P23458: JAK1; NbExp=3; IntAct=EBI-15742214, EBI-1383438;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:19915009}; Single-pass type I membrane protein
CC       {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted
CC       {ECO:0000269|PubMed:24629561}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P40189-1; Sequence=Displayed;
CC       Name=2; Synonyms=GP130-RAPS {ECO:0000303|PubMed:10880057};
CC         IsoId=P40189-2; Sequence=VSP_001684, VSP_001685;
CC       Name=3;
CC         IsoId=P40189-3; Sequence=VSP_043716;
CC   -!- TISSUE SPECIFICITY: Found in all the tissues and cell lines examined
CC       (PubMed:2261637). Expression not restricted to IL6 responsive cells
CC       (PubMed:2261637). {ECO:0000269|PubMed:2261637}.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in blood serum (at protein
CC       level) (PubMed:24629561). {ECO:0000269|PubMed:24629561}.
CC   -!- INDUCTION: LIF and OSM activate the type I OSM receptor while only OSM
CC       can activate the type II OSM receptor. {ECO:0000269|PubMed:8999038}.
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-surface
CC       receptor binding.
CC   -!- DOMAIN: The box 1 motif is required for JAK interaction and/or
CC       activation.
CC   -!- PTM: Phosphorylation of Ser-782 down-regulates cell surface expression.
CC       {ECO:0000269|PubMed:10811661}.
CC   -!- PTM: Heavily N-glycosylated (PubMed:11098061, PubMed:16335952,
CC       PubMed:19159218, PubMed:19139490, PubMed:11251120). Glycosylation is
CC       required for protein stability and localization in plasma membrane but
CC       not for ligand binding (PubMed:19915009). {ECO:0000269|PubMed:11098061,
CC       ECO:0000269|PubMed:11251120, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19915009}.
CC   -!- DISEASE: Hyper-IgE recurrent infection syndrome 4, autosomal recessive
CC       (HIES4) [MIM:618523]: An immunologic disorder characterized by
CC       recurrent infections, mainly affecting the respiratory tract, skin and
CC       eye, and skeletal abnormalities including craniosynostosis and
CC       scoliosis. Immunologic workup shows increased serum IgE, intermittent
CC       eosinophilia, impaired development of certain B- and T-cell
CC       populations, as well as impaired acute-phase response. Disease onset is
CC       in early childhood. {ECO:0000269|PubMed:28747427,
CC       ECO:0000269|PubMed:30309848}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- BIOTECHNOLOGY: Two extracellular parts of IL6ST/gp130 linked to the Fc-
CC       portions of a human IgG1 antibody (sgp130Fc) inhibit IL6 trans-
CC       signaling by the IL6:IL6R complex and has no affinity of IL6 or IL6R
CC       alone (PubMed:11121117, PubMed:21990364, PubMed:30279168). Also blocks
CC       IL11 cluster signaling through IL11R (PubMed:30279168,
CC       PubMed:26876177). {ECO:0000269|PubMed:11121117,
CC       ECO:0000269|PubMed:21990364, ECO:0000269|PubMed:26876177,
CC       ECO:0000269|PubMed:30279168}.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 2
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M57230; AAA59155.1; -; mRNA.
DR   EMBL; AB015706; BAA78112.1; -; mRNA.
DR   EMBL; AB102802; BAD89393.1; -; mRNA.
DR   EMBL; EF064722; ABK41905.1; -; Genomic_DNA.
DR   EMBL; AC008914; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016596; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471123; EAW54936.1; -; Genomic_DNA.
DR   CCDS; CCDS3971.1; -. [P40189-1]
DR   CCDS; CCDS47209.1; -. [P40189-2]
DR   CCDS; CCDS54856.1; -. [P40189-3]
DR   PIR; A36337; A36337.
DR   RefSeq; NP_001177910.1; NM_001190981.1. [P40189-3]
DR   RefSeq; NP_002175.2; NM_002184.3. [P40189-1]
DR   RefSeq; NP_786943.1; NM_175767.2. [P40189-2]
DR   PDB; 1BJ8; NMR; -; A=219-325.
DR   PDB; 1BQU; X-ray; 2.00 A; A/B=122-333.
DR   PDB; 1I1R; X-ray; 2.40 A; A=23-325.
DR   PDB; 1N2Q; Model; -; A/B=23-324.
DR   PDB; 1P9M; X-ray; 3.65 A; A=23-321.
DR   PDB; 1PVH; X-ray; 2.50 A; A/C=123-323.
DR   PDB; 3L5H; X-ray; 3.60 A; A=24-612.
DR   PDB; 3L5I; X-ray; 1.90 A; A=323-612.
DR   PDB; 3L5J; X-ray; 3.04 A; A/B=323-610.
DR   PDBsum; 1BJ8; -.
DR   PDBsum; 1BQU; -.
DR   PDBsum; 1I1R; -.
DR   PDBsum; 1N2Q; -.
DR   PDBsum; 1P9M; -.
DR   PDBsum; 1PVH; -.
DR   PDBsum; 3L5H; -.
DR   PDBsum; 3L5I; -.
DR   PDBsum; 3L5J; -.
DR   SMR; P40189; -.
DR   BioGRID; 109786; 36.
DR   CORUM; P40189; -.
DR   DIP; DIP-95N; -.
DR   IntAct; P40189; 23.
DR   MINT; P40189; -.
DR   STRING; 9606.ENSP00000370698; -.
DR   BindingDB; P40189; -.
DR   ChEMBL; CHEMBL3124734; -.
DR   DrugCentral; P40189; -.
DR   GuidetoPHARMACOLOGY; 2317; -.
DR   GlyConnect; 649; 16 N-Linked glycans (9 sites).
DR   GlyGen; P40189; 13 sites, 3 N-linked glycans (3 sites).
DR   iPTMnet; P40189; -.
DR   PhosphoSitePlus; P40189; -.
DR   SwissPalm; P40189; -.
DR   UniCarbKB; P40189; -.
DR   BioMuta; IL6ST; -.
DR   DMDM; 215273999; -.
DR   EPD; P40189; -.
DR   jPOST; P40189; -.
DR   MassIVE; P40189; -.
DR   MaxQB; P40189; -.
DR   PaxDb; P40189; -.
DR   PeptideAtlas; P40189; -.
DR   PRIDE; P40189; -.
DR   ProteomicsDB; 55338; -. [P40189-1]
DR   ProteomicsDB; 55339; -. [P40189-2]
DR   ProteomicsDB; 55340; -. [P40189-3]
DR   Antibodypedia; 2448; 751 antibodies.
DR   DNASU; 3572; -.
DR   Ensembl; ENST00000336909; ENSP00000338799; ENSG00000134352. [P40189-1]
DR   Ensembl; ENST00000381287; ENSP00000370687; ENSG00000134352. [P40189-2]
DR   Ensembl; ENST00000381294; ENSP00000370694; ENSG00000134352. [P40189-3]
DR   Ensembl; ENST00000381298; ENSP00000370698; ENSG00000134352. [P40189-1]
DR   Ensembl; ENST00000502326; ENSP00000462158; ENSG00000134352. [P40189-1]
DR   Ensembl; ENST00000522633; ENSP00000435399; ENSG00000134352. [P40189-2]
DR   GeneID; 3572; -.
DR   KEGG; hsa:3572; -.
DR   UCSC; uc003jqq.4; human. [P40189-1]
DR   CTD; 3572; -.
DR   DisGeNET; 3572; -.
DR   EuPathDB; HostDB:ENSG00000134352.19; -.
DR   GeneCards; IL6ST; -.
DR   HGNC; HGNC:6021; IL6ST.
DR   HPA; ENSG00000134352; Low tissue specificity.
DR   MalaCards; IL6ST; -.
DR   MIM; 600694; gene.
DR   MIM; 618523; phenotype.
DR   neXtProt; NX_P40189; -.
DR   OpenTargets; ENSG00000134352; -.
DR   PharmGKB; PA29837; -.
DR   eggNOG; ENOG502QXEG; Eukaryota.
DR   GeneTree; ENSGT00940000159608; -.
DR   HOGENOM; CLU_017990_0_0_1; -.
DR   InParanoid; P40189; -.
DR   KO; K05060; -.
DR   OMA; YLITVYP; -.
DR   PhylomeDB; P40189; -.
DR   TreeFam; TF338122; -.
DR   PathwayCommons; P40189; -.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation. [P40189-1]
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation. [P40189-1]
DR   Reactome; R-HSA-6788467; IL-6-type cytokine receptor ligand interactions.
DR   Reactome; R-HSA-8984722; Interleukin-35 Signalling.
DR   Reactome; R-HSA-9020956; Interleukin-27 signaling.
DR   SignaLink; P40189; -.
DR   SIGNOR; P40189; -.
DR   BioGRID-ORCS; 3572; 26 hits in 888 CRISPR screens.
DR   ChiTaRS; IL6ST; human.
DR   EvolutionaryTrace; P40189; -.
DR   GeneWiki; Glycoprotein_130; -.
DR   GenomeRNAi; 3572; -.
DR   Pharos; P40189; Tclin.
DR   PRO; PR:P40189; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P40189; protein.
DR   Bgee; ENSG00000134352; Expressed in female gonad and 259 other tissues.
DR   ExpressionAtlas; P40189; baseline and differential.
DR   Genevisible; P40189; HS.
DR   GO; GO:0070110; C:ciliary neurotrophic factor receptor complex; IDA:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005896; C:interleukin-6 receptor complex; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005900; C:oncostatin-M receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0004897; F:ciliary neurotrophic factor receptor activity; IDA:BHF-UCL.
DR   GO; GO:0005127; F:ciliary neurotrophic factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0019955; F:cytokine binding; IBA:GO_Central.
DR   GO; GO:0004896; F:cytokine receptor activity; IBA:GO_Central.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019970; F:interleukin-11 binding; IEA:Ensembl.
DR   GO; GO:0004921; F:interleukin-11 receptor activity; IEA:Ensembl.
DR   GO; GO:0045509; F:interleukin-27 receptor activity; IC:BHF-UCL.
DR   GO; GO:0070120; P:ciliary neurotrophic factor-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0005977; P:glycogen metabolic process; IEA:Ensembl.
DR   GO; GO:0070106; P:interleukin-27-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0070757; P:interleukin-35-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0048861; P:leukemia inhibitory factor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:BHF-UCL.
DR   GO; GO:0070104; P:negative regulation of interleukin-6-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0038165; P:oncostatin-M-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002675; P:positive regulation of acute inflammatory response; IC:BHF-UCL.
DR   GO; GO:0002821; P:positive regulation of adaptive immune response; IC:BHF-UCL.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; TAS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; TAS:BHF-UCL.
DR   GO; GO:0008593; P:regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0034097; P:response to cytokine; IDA:BHF-UCL.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 6.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR003529; Hematopoietin_rcpt_Gp130_CS.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR010457; IgC2-like_lig-bd.
DR   InterPro; IPR015321; TypeI_recpt_CBD.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF09240; IL6Ra-bind; 1.
DR   Pfam; PF06328; Lep_receptor_Ig; 1.
DR   SMART; SM00060; FN3; 5.
DR   SUPFAM; SSF49265; SSF49265; 5.
DR   PROSITE; PS50853; FN3; 4.
DR   PROSITE; PS01353; HEMATOPO_REC_L_F2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Direct protein sequencing; Disease mutation; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunoglobulin domain; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Secreted; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..22
FT   CHAIN           23..918
FT                   /note="Interleukin-6 receptor subunit beta"
FT                   /id="PRO_0000010899"
FT   TOPO_DOM        23..619
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        620..641
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        642..918
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          26..120
FT                   /note="Ig-like C2-type"
FT   DOMAIN          125..216
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          224..324
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          329..424
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          426..517
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          518..613
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   MOTIF           310..314
FT                   /note="WSXWS motif"
FT   MOTIF           651..659
FT                   /note="Box 1 motif"
FT   COMPBIAS        725..755
FT                   /note="Ser-rich"
FT   MOD_RES         661
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         667
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18088087,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         782
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10811661"
FT   MOD_RES         789
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q00560"
FT   MOD_RES         829
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983"
FT   MOD_RES         839
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   CARBOHYD        43
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   CARBOHYD        83
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   CARBOHYD        131
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061"
FT   CARBOHYD        157
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061"
FT   CARBOHYD        227
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:20489211"
FT   CARBOHYD        379
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:16335952"
FT   CARBOHYD        383
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:20489211"
FT   CARBOHYD        390
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19139490,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        553
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   CARBOHYD        564
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061"
FT   DISULFID        28..54
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   DISULFID        48..103
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   DISULFID        134..144
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   DISULFID        172..182
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   DISULFID        458..466
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   VAR_SEQ         325..329
FT                   /note="RPSKA -> NIASF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10880057"
FT                   /id="VSP_001684"
FT   VAR_SEQ         330..918
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10880057"
FT                   /id="VSP_001685"
FT   VAR_SEQ         423..483
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_043716"
FT   VARIANT         8
FT                   /note="L -> V (in dbSNP:rs1063560)"
FT                   /evidence="ECO:0000269|PubMed:10880057,
FT                   ECO:0000269|PubMed:2261637"
FT                   /id="VAR_047782"
FT   VARIANT         148
FT                   /note="G -> R (polymorphism; associated with increased
FT                   levels of soluble IL6RB in blood serum; dbSNP:rs2228044)"
FT                   /evidence="ECO:0000269|PubMed:24629561"
FT                   /id="VAR_047783"
FT   VARIANT         200
FT                   /note="A -> G (found in patient with lung cancer; unknown
FT                   pathological significance; dbSNP:rs199905033)"
FT                   /evidence="ECO:0000269|PubMed:25242236"
FT                   /id="VAR_074654"
FT   VARIANT         397
FT                   /note="L -> V (in dbSNP:rs2228043)"
FT                   /id="VAR_047784"
FT   VARIANT         404
FT                   /note="N -> Y (in HIES4; results in defective
FT                   cytokine-mediated signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:28747427"
FT                   /id="VAR_083197"
FT   VARIANT         415
FT                   /note="T -> I (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036165"
FT   VARIANT         454
FT                   /note="I -> T (in dbSNP:rs2228046)"
FT                   /id="VAR_047785"
FT   VARIANT         498
FT                   /note="P -> L (in HIES4; results in defective
FT                   cytokine-mediated signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:30309848"
FT                   /id="VAR_083198"
FT   VARIANT         499
FT                   /note="V -> I (in dbSNP:rs34417936)"
FT                   /id="VAR_047786"
FT   MUTAGEN         172
FT                   /note="C->S: Induces ligand-independent activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         186..190
FT                   /note="Missing: Induces ligand-independent activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         189
FT                   /note="V->G: Does not induce ligand-independent
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         190
FT                   /note="Y->G: Does not induce ligand-independent
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         215
FT                   /note="D->G: Induces ligand-independent activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         252
FT                   /note="V->G: Induces ligand-independent activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         759
FT                   /note="Y->F: Refractory to inhibition by SOCS3."
FT                   /evidence="ECO:0000269|PubMed:25731159"
FT   MUTAGEN         782
FT                   /note="S->A: Increases cell surface expression."
FT                   /evidence="ECO:0000269|PubMed:10811661"
FT   STRAND          28..35
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   STRAND          37..39
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   STRAND          44..50
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   HELIX           52..58
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   HELIX           62..64
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   STRAND          65..69
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   HELIX           76..78
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   STRAND          80..83
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   STRAND          86..91
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   STRAND          97..107
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   TURN            108..110
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   STRAND          111..123
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   STRAND          130..137
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          143..147
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          157..164
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          176..178
FT                   /evidence="ECO:0000244|PDB:1PVH"
FT   STRAND          181..183
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          194..202
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          205..208
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          212..214
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   HELIX           216..218
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          219..221
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          226..231
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          234..238
FT                   /evidence="ECO:0000244|PDB:1I1R"
FT   STRAND          240..245
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   HELIX           248..251
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          255..263
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   HELIX           274..277
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          282..286
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          291..303
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          317..321
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   HELIX           325..331
FT                   /evidence="ECO:0000244|PDB:1BQU"
FT   STRAND          332..338
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          345..351
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   HELIX           356..359
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          363..372
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          378..391
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          396..406
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          412..416
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          428..435
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          438..444
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          452..460
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          462..464
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          469..474
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          478..481
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          491..500
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          508..515
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          525..530
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          535..539
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   HELIX           544..547
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          553..560
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          566..571
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          575..579
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          587..596
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          599..602
FT                   /evidence="ECO:0000244|PDB:3L5I"
FT   STRAND          606..609
FT                   /evidence="ECO:0000244|PDB:3L5I"
SQ   SEQUENCE   918 AA;  103537 MW;  6510A4409FFCF08C CRC64;
     MLTLQTWLVQ ALFIFLTTES TGELLDPCGY ISPESPVVQL HSNFTAVCVL KEKCMDYFHV
     NANYIVWKTN HFTIPKEQYT IINRTASSVT FTDIASLNIQ LTCNILTFGQ LEQNVYGITI
     ISGLPPEKPK NLSCIVNEGK KMRCEWDGGR ETHLETNFTL KSEWATHKFA DCKAKRDTPT
     SCTVDYSTVY FVNIEVWVEA ENALGKVTSD HINFDPVYKV KPNPPHNLSV INSEELSSIL
     KLTWTNPSIK SVIILKYNIQ YRTKDASTWS QIPPEDTAST RSSFTVQDLK PFTEYVFRIR
     CMKEDGKGYW SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN
     GKILDYEVTL TRWKSHLQNY TVNATKLTVN LTNDRYLATL TVRNLVGKSD AAVLTIPACD
     FQATHPVMDL KAFPKDNMLW VEWTTPRESV KKYILEWCVL SDKAPCITDW QQEDGTVHRT
     YLRGNLAESK CYLITVTPVY ADGPGSPESI KAYLKQAPPS KGPTVRTKKV GKNEAVLEWD
     QLPVDVQNGF IRNYTIFYRT IIGNETAVNV DSSHTEYTLS SLTSDTLYMV RMAAYTDEGG
     KDGPEFTFTT PKFAQGEIEA IVVPVCLAFL LTTLLGVLFC FNKRDLIKKH IWPNVPDPSK
     SHIAQWSPHT PPRHNFNSKD QMYSDGNFTD VSVVEIEAND KKPFPEDLKS LDLFKKEKIN
     TEGHSSGIGG SSCMSSSRPS ISSSDENESS QNTSSTVQYS TVVHSGYRHQ VPSVQVFSRS
     ESTQPLLDSE ERPEDLQLVD HVDGGDGILP RQQYFKQNCS QHESSPDISH FERSKQVSSV
     NEEDFVRLKQ QISDHISQSC GSGQMKMFQE VSAADAFGPG TEGQVERFET VGMEAATDEG
     MPKSYLPQTV RQGGYMPQ
//
ID   IMA1_HUMAN              Reviewed;         529 AA.
AC   P52292; B9EJD6; Q53YE3; Q6NVW7; Q9BRU5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-AUG-2020, entry version 233.
DE   RecName: Full=Importin subunit alpha-1 {ECO:0000305};
DE   AltName: Full=Karyopherin subunit alpha-2;
DE   AltName: Full=RAG cohort protein 1;
DE   AltName: Full=SRP1-alpha;
GN   Name=KPNA2 {ECO:0000312|HGNC:HGNC:6395}; Synonyms=RCH1, SRP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7754385; DOI=10.1126/science.7754385;
RA   Weis K., Mattaj I.W., Lamond A.I.;
RT   "Identification of hSRP1 alpha as a functional receptor for nuclear
RT   localization sequences.";
RL   Science 268:1049-1053(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-165.
RX   PubMed=11735022; DOI=10.1007/s004390100605;
RA   Doerr S., Schlicker M., Hansmann I.;
RT   "Genomic structure of karyopherin alpha2 (KPNA2) within a low-copy repeat
RT   on chromosome 17q23-q24 and mutation analysis in patients with Russell-
RT   Silver syndrome.";
RL   Hum. Genet. 109:479-486(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS VAL-157 AND ASN-453.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS VAL-157; ARG-165 AND
RP   ASN-453.
RC   TISSUE=Bone marrow, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-13; 69-101; 107-117; 239-258; 292-315; 354-388 AND
RP   487-494, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Kolch W.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-529.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=8016130; DOI=10.1073/pnas.91.13.6156;
RA   Cuomo C.A., Kirch S.A., Gyuris J., Brent R., Oettinger M.A.;
RT   "Rch1, a protein that specifically interacts with the RAG-1 recombination-
RT   activating protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:6156-6160(1994).
RN   [8]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=7604027; DOI=10.1073/pnas.92.14.6532;
RA   Moroianu J., Hijikata M., Blobel G., Radu A.;
RT   "Mammalian karyopherin alpha 1 beta and alpha 2 beta heterodimers: alpha 1
RT   or alpha 2 subunit binds nuclear localization signal and beta subunit
RT   interacts with peptide repeat-containing nucleoporins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:6532-6536(1995).
RN   [9]
RP   DOMAIN IBB.
RX   PubMed=8617227; DOI=10.1002/j.1460-2075.1996.tb00531.x;
RA   Weis K., Ryder U., Lamond A.I.;
RT   "The conserved amino-terminal domain of hSRP1 alpha is essential for
RT   nuclear protein import.";
RL   EMBO J. 15:1818-1825(1996).
RN   [10]
RP   IDENTIFICATION IN A COMPLEX WITH RAN AND CSE1L.
RX   PubMed=9323134; DOI=10.1016/s0092-8674(00)80372-4;
RA   Kutay U., Bischoff F.R., Kostka S., Kraft R., Goerlich D.;
RT   "Export of importin-alpha from the nucleus is mediated by a specific
RT   nuclear transport factor.";
RL   Cell 90:1061-1071(1997).
RN   [11]
RP   INTERACTION WITH HIV-1 VPR (MICROBIAL INFECTION).
RX   PubMed=9463369; DOI=10.1093/emboj/17.4.909;
RA   Popov S., Rexach M., Zybarth G., Reiling N., Lee M.A., Ratner L.,
RA   Lane C.M., Moore M.S., Blobel G., Bukrinsky M.;
RT   "Viral protein R regulates nuclear import of the HIV-1 pre-integration
RT   complex.";
RL   EMBO J. 17:909-917(1998).
RN   [12]
RP   INTERACTION WITH XPO2/CSE1L.
RX   PubMed=9786944; DOI=10.1083/jcb.143.2.309;
RA   Herold A., Truant R., Wiegand H., Cullen B.R.;
RT   "Determination of the functional domain organization of the importin alpha
RT   nuclear import factor.";
RL   J. Cell Biol. 143:309-318(1998).
RN   [13]
RP   INTERACTION WITH ARL4A.
RX   PubMed=10980193; DOI=10.1074/jbc.m002470200;
RA   Lin C.Y., Huang P.H., Liao W.L., Cheng H.J., Huang C.F., Kuo J.C.,
RA   Patton W.A., Massenburg D., Moss J., Lee F.J.;
RT   "ARL4, an ARF-like protein that is developmentally regulated and localized
RT   to nuclei and nucleoli.";
RL   J. Biol. Chem. 275:37815-37823(2000).
RN   [14]
RP   INTERACTION WITH PLAG1.
RX   PubMed=11882654; DOI=10.1074/jbc.m112112200;
RA   Braem C.V., Kas K., Meyen E., Debiec-Rychter M., Van De Ven W.J.M.,
RA   Voz M.L.;
RT   "Identification of a karyopherin alpha 2 recognition site in PLAG1, which
RT   functions as a nuclear localization signal.";
RL   J. Biol. Chem. 277:19673-19678(2002).
RN   [15]
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   PubMed=11840567;
RX   DOI=10.1002/1615-9861(200202)2:2<212::aid-prot212>3.0.co;2-h;
RA   Harris R.A., Yang A., Stein R.C., Lucy K., Brusten L., Herath A.,
RA   Parekh R., Waterfield M.D., O'Hare M.J., Neville M.A., Page M.J.,
RA   Zvelebil M.J.;
RT   "Cluster analysis of an extensive human breast cancer cell line protein
RT   expression map database.";
RL   Proteomics 2:212-223(2002).
RN   [16]
RP   INTERACTION WITH NBN.
RX   PubMed=16188882; DOI=10.1074/jbc.m508425200;
RA   Tseng S.-F., Chang C.-Y., Wu K.-J., Teng S.-C.;
RT   "Importin KPNA2 is required for proper nuclear localization and multiple
RT   functions of NBS1.";
RL   J. Biol. Chem. 280:39594-39600(2005).
RN   [17]
RP   INTERACTION WITH APEX1.
RX   PubMed=15942031; DOI=10.1093/nar/gki641;
RA   Jackson E.B., Theriot C.A., Chattopadhyay R., Mitra S., Izumi T.;
RT   "Analysis of nuclear transport signals in the human apurinic/apyrimidinic
RT   endonuclease (APE1/Ref1).";
RL   Nucleic Acids Res. 33:3303-3312(2005).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-62, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [20]
RP   INTERACTION WITH SARS VIRUS ORF6 PROTEIN (MICROBIAL INFECTION), SUBCELLULAR
RP   LOCATION (MICROBIAL INFECTION), MUTAGENESIS OF 2-SER--ASP-80, AND
RP   INTERACTION WITH KPNB1.
RX   PubMed=17596301; DOI=10.1128/jvi.01012-07;
RA   Frieman M., Yount B., Heise M., Kopecky-Bromberg S.A., Palese P.,
RA   Baric R.S.;
RT   "Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1
RT   function by sequestering nuclear import factors on the rough endoplasmic
RT   reticulum/Golgi membrane.";
RL   J. Virol. 81:9812-9824(2007).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-62 AND SER-490, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   INTERACTION WITH SNAI1 AND SNAI2.
RX   PubMed=19386897; DOI=10.1242/jcs.041749;
RA   Mingot J.M., Vega S., Maestro B., Sanz J.M., Nieto M.A.;
RT   "Characterization of Snail nuclear import pathways as representatives of
RT   C2H2 zinc finger transcription factors.";
RL   J. Cell Sci. 122:1452-1460(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-62, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-62 AND SER-490, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION IN COMPLEX WITH CRM1 AND VENEZUELAN EQUINE ENCEPHALITIS
RP   VIRUS CAPSID PROTEIN (MICROBIAL INFECTION).
RX   PubMed=20147401; DOI=10.1128/jvi.02554-09;
RA   Atasheva S., Fish A., Fornerod M., Frolova E.I.;
RT   "Venezuelan equine encephalitis virus capsid protein forms a tetrameric
RT   complex with CRM1 and importin alpha/beta that obstructs nuclear pore
RT   complex function.";
RL   J. Virol. 84:4158-4171(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   INTERACTION WITH SNAI1.
RX   PubMed=21454664; DOI=10.1074/jbc.m110.213579;
RA   Sekimoto T., Miyamoto Y., Arai S., Yoneda Y.;
RT   "Importin alpha protein acts as a negative regulator for Snail protein
RT   nuclear import.";
RL   J. Biol. Chem. 286:15126-15131(2011).
RN   [31]
RP   INTERACTION WITH CTNNBL1.
RX   PubMed=21385873; DOI=10.1074/jbc.m110.208769;
RA   Ganesh K., Adam S., Taylor B., Simpson P., Rada C., Neuberger M.;
RT   "CTNNBL1 is a novel nuclear localization sequence-binding protein that
RT   recognizes RNA-splicing factors CDC5L and Prp31.";
RL   J. Biol. Chem. 286:17091-17102(2011).
RN   [32]
RP   INTERACTION WITH FRG1.
RX   PubMed=21699900; DOI=10.1016/j.jmb.2011.06.014;
RA   Sun C.Y., van Koningsbruggen S., Long S.W., Straasheijm K., Klooster R.,
RA   Jones T.I., Bellini M., Levesque L., Brieher W.M., van der Maarel S.M.,
RA   Jones P.L.;
RT   "Facioscapulohumeral muscular dystrophy region gene 1 is a dynamic RNA-
RT   associated and actin-bundling protein.";
RL   J. Mol. Biol. 411:397-416(2011).
RN   [33]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-62, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE
RP   ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-62 AND SER-490, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   INTERACTION WITH BAG6.
RX   PubMed=29042515; DOI=10.1073/pnas.1702940114;
RA   Mock J.Y., Xu Y., Ye Y., Clemons W.M. Jr.;
RT   "Structural basis for regulation of the nucleo-cytoplasmic distribution of
RT   Bag6 by TRC35.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:11679-11684(2017).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 11-54.
RX   PubMed=10353244; DOI=10.1038/20367;
RA   Cingolani G., Petosa C., Weis K., Muller C.W.;
RT   "Structure of importin-beta bound to the IBB domain of importin-alpha.";
RL   Nature 399:221-229(1999).
CC   -!- FUNCTION: Functions in nuclear protein import as an adapter protein for
CC       nuclear receptor KPNB1. Binds specifically and directly to substrates
CC       containing either a simple or bipartite NLS motif. Docking of the
CC       importin/substrate complex to the nuclear pore complex (NPC) is
CC       mediated by KPNB1 through binding to nucleoporin FxFG repeats and the
CC       complex is subsequently translocated through the pore by an energy
CC       requiring, Ran-dependent mechanism. At the nucleoplasmic side of the
CC       NPC, Ran binds to importin-beta and the three components separate and
CC       importin-alpha and -beta are re-exported from the nucleus to the
CC       cytoplasm where GTP hydrolysis releases Ran from importin. The
CC       directionality of nuclear import is thought to be conferred by an
CC       asymmetric distribution of the GTP- and GDP-bound forms of Ran between
CC       the cytoplasm and nucleus.
CC   -!- SUBUNIT: Heterodimer; with KPNB1 (PubMed:17596301). Interacts with
CC       ANP32E (By similarity). Component of a complex containing CSE1L, RAN
CC       and KPNA2. Interacts directly with CSE1L. Interacts with PLAG1.
CC       Interacts with APEX1 (via N-terminus). Interacts with FRG1 (via N-
CC       terminus). Interacts with ARL4A, CTNNBL1 and NBN. Interacts with SNAI1
CC       (via zinc fingers) and SNAI2 (via zinc fingers). Interacts with BAG6
CC       (PubMed:29042515). Interacts with AIFM2; this interaction likely
CC       mediates the translocation of AIFM2 into the nucleus upon oxidative
CC       stress. {ECO:0000250, ECO:0000250|UniProtKB:P52293,
CC       ECO:0000269|PubMed:10980193, ECO:0000269|PubMed:11882654,
CC       ECO:0000269|PubMed:15942031, ECO:0000269|PubMed:16188882,
CC       ECO:0000269|PubMed:17596301, ECO:0000269|PubMed:19386897,
CC       ECO:0000269|PubMed:21385873, ECO:0000269|PubMed:21454664,
CC       ECO:0000269|PubMed:21699900, ECO:0000269|PubMed:29042515,
CC       ECO:0000269|PubMed:7604027, ECO:0000269|PubMed:9323134,
CC       ECO:0000269|PubMed:9786944}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Vpr.
CC       {ECO:0000269|PubMed:9463369}.
CC   -!- SUBUNIT: (Microbial infection) Part of a tetrameric complex composed of
CC       CRM1, importin alpha/beta dimer and the Venezuelan equine encephalitis
CC       virus (VEEV) capsid; this complex blocks the receptor-mediated
CC       transport through the nuclear pore. {ECO:0000269|PubMed:20147401}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS-COV virus ORF6
CC       protein; this interaction blocks the receptor-mediated transport
CC       through the nuclear pore. {ECO:0000269|PubMed:17596301}.
CC   -!- INTERACTION:
CC       P52292; P63010: AP2B1; NbExp=3; IntAct=EBI-349938, EBI-432924;
CC       P52292; P38398: BRCA1; NbExp=3; IntAct=EBI-349938, EBI-349905;
CC       P52292; Q96C86: DCPS; NbExp=3; IntAct=EBI-349938, EBI-3917181;
CC       P52292; Q53SE7: FLJ13057; NbExp=3; IntAct=EBI-349938, EBI-10172181;
CC       P52292; Q9NP66: HMG20A; NbExp=3; IntAct=EBI-349938, EBI-740641;
CC       P52292; P07910: HNRNPC; NbExp=4; IntAct=EBI-349938, EBI-357966;
CC       P52292; Q8IX15-3: HOMEZ; NbExp=3; IntAct=EBI-349938, EBI-10172004;
CC       P52292; Q8NBZ0: INO80E; NbExp=3; IntAct=EBI-349938, EBI-769401;
CC       P52292; P05412: JUN; NbExp=4; IntAct=EBI-349938, EBI-852823;
CC       P52292; Q14974: KPNB1; NbExp=10; IntAct=EBI-349938, EBI-286758;
CC       P52292; Q14974-1: KPNB1; NbExp=4; IntAct=EBI-349938, EBI-15488647;
CC       P52292; Q6A162: KRT40; NbExp=3; IntAct=EBI-349938, EBI-10171697;
CC       P52292; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-349938, EBI-741037;
CC       P52292; Q9Y5V3: MAGED1; NbExp=4; IntAct=EBI-349938, EBI-716006;
CC       P52292; Q99750: MDFI; NbExp=3; IntAct=EBI-349938, EBI-724076;
CC       P52292; P40692: MLH1; NbExp=9; IntAct=EBI-349938, EBI-744248;
CC       P52292; Q9UBU8-2: MORF4L1; NbExp=3; IntAct=EBI-349938, EBI-10288852;
CC       P52292; Q7Z6G3-2: NECAB2; NbExp=3; IntAct=EBI-349938, EBI-10172876;
CC       P52292; Q9HAN9: NMNAT1; NbExp=8; IntAct=EBI-349938, EBI-3917542;
CC       P52292; Q9UKX7: NUP50; NbExp=9; IntAct=EBI-349938, EBI-2371082;
CC       P52292; P37198: NUP62; NbExp=3; IntAct=EBI-349938, EBI-347978;
CC       P52292; Q86Y26: NUTM1; NbExp=3; IntAct=EBI-349938, EBI-10178410;
CC       P52292; Q96PV4: PNMA5; NbExp=3; IntAct=EBI-349938, EBI-10171633;
CC       P52292; Q93062: RBPMS; NbExp=3; IntAct=EBI-349938, EBI-740322;
CC       P52292; P46063: RECQL; NbExp=2; IntAct=EBI-349938, EBI-2823728;
CC       P52292; O43148: RNMT; NbExp=3; IntAct=EBI-349938, EBI-877832;
CC       P52292; P29034: S100A2; NbExp=5; IntAct=EBI-349938, EBI-752230;
CC       P52292; P06703: S100A6; NbExp=3; IntAct=EBI-349938, EBI-352877;
CC       P52292; Q9UJW9: SERTAD3; NbExp=4; IntAct=EBI-349938, EBI-748621;
CC       P52292; Q15637: SF1; NbExp=5; IntAct=EBI-349938, EBI-744603;
CC       P52292; Q9UH99: SUN2; NbExp=3; IntAct=EBI-349938, EBI-1044964;
CC       P52292; O75478: TADA2A; NbExp=3; IntAct=EBI-349938, EBI-742268;
CC       P52292; Q9BYV2: TRIM54; NbExp=3; IntAct=EBI-349938, EBI-2130429;
CC       P52292; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-349938, EBI-739895;
CC       P52292; P03101: L1; Xeno; NbExp=3; IntAct=EBI-349938, EBI-7362698;
CC       P52292; P03107: L2; Xeno; NbExp=3; IntAct=EBI-349938, EBI-7362531;
CC       P52292; Q6GQG6: npm2; Xeno; NbExp=2; IntAct=EBI-349938, EBI-8469111;
CC       P52292; P04620: rev; Xeno; NbExp=2; IntAct=EBI-349938, EBI-10687101;
CC       P52292; A0A3G5BIZ0; Xeno; NbExp=6; IntAct=EBI-349938, EBI-25564606;
CC       P52292; P03070; Xeno; NbExp=2; IntAct=EBI-349938, EBI-617698;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:7604027}. Nucleus
CC       {ECO:0000269|PubMed:7604027}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane. Golgi apparatus
CC       membrane {ECO:0000269|PubMed:17596301}. Note=(Microbial infection)
CC       Retained in ER/Golgi membranes upon interaction with SARS-COV virus
CC       ORF6 protein. {ECO:0000269|PubMed:17596301}.
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously.
CC   -!- DOMAIN: Consists of an N-terminal hydrophilic region, a hydrophobic
CC       central region composed of 10 repeats, and a short hydrophilic C-
CC       terminus. The N-terminal hydrophilic region contains the importin beta
CC       binding domain (IBB domain), which is sufficient for binding importin
CC       beta and essential for nuclear protein import.
CC       {ECO:0000269|PubMed:8617227}.
CC   -!- DOMAIN: The IBB domain is thought to act as an intrasteric
CC       autoregulatory sequence by interacting with the internal autoinhibitory
CC       NLS. Binding of KPNB1 probably overlaps the internal NLS and
CC       contributes to a high affinity for cytoplasmic NLS-containing cargo
CC       substrates. After dissociation of the importin/substrate complex in the
CC       nucleus the internal autohibitory NLS contributes to a low affinity for
CC       nuclear NLS-containing proteins (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The major and minor NLS binding sites are mainly involved in
CC       recognition of simple or bipartite NLS motifs. Structurally located
CC       within in a helical surface groove they contain several conserved Trp
CC       and Asn residues of the corresponding third helices (H3) of ARM repeats
CC       which mainly contribute to binding (By similarity). {ECO:0000250}.
CC   -!- MASS SPECTROMETRY: Mass=57861.92; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:11840567};
CC   -!- SIMILARITY: Belongs to the importin alpha family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U28386; AAA69957.1; -; mRNA.
DR   EMBL; AJ303086; CAC83080.1; -; Genomic_DNA.
DR   EMBL; BT006665; AAP35311.1; -; mRNA.
DR   EMBL; CH471099; EAW89041.1; -; Genomic_DNA.
DR   EMBL; BC005978; AAH05978.1; -; mRNA.
DR   EMBL; BC067848; AAH67848.1; -; mRNA.
DR   EMBL; BC146905; AAI46906.1; -; mRNA.
DR   EMBL; U09559; AAA65700.1; -; mRNA.
DR   CCDS; CCDS32713.1; -.
DR   PIR; A56516; A56516.
DR   RefSeq; NP_001307540.1; NM_001320611.1.
DR   RefSeq; NP_002257.1; NM_002266.3.
DR   PDB; 1EFX; X-ray; 3.00 A; C=204-212.
DR   PDB; 1QGK; X-ray; 2.50 A; B=11-54.
DR   PDB; 1QGR; X-ray; 2.30 A; B=28-54.
DR   PDB; 3FEX; X-ray; 3.55 A; C=70-529.
DR   PDB; 3FEY; X-ray; 2.20 A; C=70-529.
DR   PDB; 3WPT; X-ray; 2.63 A; A/B=75-497.
DR   PDB; 4E4V; X-ray; 2.53 A; A/B=70-529.
DR   PDB; 4WV6; X-ray; 1.75 A; A=60-529.
DR   PDB; 5H43; X-ray; 2.30 A; A=70-497.
DR   PDBsum; 1EFX; -.
DR   PDBsum; 1QGK; -.
DR   PDBsum; 1QGR; -.
DR   PDBsum; 3FEX; -.
DR   PDBsum; 3FEY; -.
DR   PDBsum; 3WPT; -.
DR   PDBsum; 4E4V; -.
DR   PDBsum; 4WV6; -.
DR   PDBsum; 5H43; -.
DR   SMR; P52292; -.
DR   BioGRID; 110036; 252.
DR   ComplexPortal; CPX-1027; Importin complex, KPNA2 variant.
DR   CORUM; P52292; -.
DR   DIP; DIP-6205N; -.
DR   IntAct; P52292; 160.
DR   MINT; P52292; -.
DR   STRING; 9606.ENSP00000438483; -.
DR   BindingDB; P52292; -.
DR   ChEMBL; CHEMBL1741187; -.
DR   TCDB; 1.I.1.1.3; the nuclear pore complex (npc) family.
DR   iPTMnet; P52292; -.
DR   PhosphoSitePlus; P52292; -.
DR   SwissPalm; P52292; -.
DR   BioMuta; KPNA2; -.
DR   DMDM; 1708480; -.
DR   SWISS-2DPAGE; P52292; -.
DR   CPTAC; CPTAC-232; -.
DR   CPTAC; CPTAC-233; -.
DR   EPD; P52292; -.
DR   jPOST; P52292; -.
DR   MassIVE; P52292; -.
DR   MaxQB; P52292; -.
DR   PaxDb; P52292; -.
DR   PeptideAtlas; P52292; -.
DR   PRIDE; P52292; -.
DR   ProteomicsDB; 56475; -.
DR   Antibodypedia; 4226; 415 antibodies.
DR   DNASU; 3838; -.
DR   Ensembl; ENST00000330459; ENSP00000332455; ENSG00000182481.
DR   Ensembl; ENST00000537025; ENSP00000438483; ENSG00000182481.
DR   GeneID; 3838; -.
DR   KEGG; hsa:3838; -.
DR   UCSC; uc002jgk.4; human.
DR   CTD; 3838; -.
DR   DisGeNET; 3838; -.
DR   EuPathDB; HostDB:ENSG00000182481.8; -.
DR   GeneCards; KPNA2; -.
DR   HGNC; HGNC:6395; KPNA2.
DR   HPA; ENSG00000182481; Tissue enhanced (testis).
DR   MIM; 600685; gene.
DR   neXtProt; NX_P52292; -.
DR   OpenTargets; ENSG00000182481; -.
DR   PharmGKB; PA30186; -.
DR   eggNOG; KOG0166; Eukaryota.
DR   GeneTree; ENSGT01000000214531; -.
DR   HOGENOM; CLU_018084_6_1_1; -.
DR   InParanoid; P52292; -.
DR   KO; K15043; -.
DR   OMA; IVPICIR; -.
DR   OrthoDB; 1111872at2759; -.
DR   PhylomeDB; P52292; -.
DR   TreeFam; TF101178; -.
DR   PathwayCommons; P52292; -.
DR   Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-168276; NS1 Mediated Effects on Host Pathways.
DR   Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde.
DR   Reactome; R-HSA-5693548; Sensing of DNA Double Strand Breaks.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   SignaLink; P52292; -.
DR   SIGNOR; P52292; -.
DR   BioGRID-ORCS; 3838; 73 hits in 880 CRISPR screens.
DR   ChiTaRS; KPNA2; human.
DR   EvolutionaryTrace; P52292; -.
DR   GeneWiki; Karyopherin_alpha_2; -.
DR   GenomeRNAi; 3838; -.
DR   Pharos; P52292; Tbio.
DR   PRO; PR:P52292; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P52292; protein.
DR   Bgee; ENSG00000182481; Expressed in testis and 114 other tissues.
DR   ExpressionAtlas; P52292; baseline and differential.
DR   Genevisible; P52292; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0098892; C:extrinsic component of postsynaptic specialization membrane; IDA:SynGO.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0042025; C:host cell nucleus; IEA:InterPro.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0061608; F:nuclear import signal receptor activity; IBA:GO_Central.
DR   GO; GO:0008139; F:nuclear localization sequence binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0006259; P:DNA metabolic process; TAS:ProtInc.
DR   GO; GO:0075506; P:entry of viral genome into host nucleus through nuclear pore complex via importin; IMP:MGI.
DR   GO; GO:0019054; P:modulation by virus of host cellular process; TAS:Reactome.
DR   GO; GO:0006607; P:NLS-bearing protein import into nucleus; IDA:UniProtKB.
DR   GO; GO:1903902; P:positive regulation of viral life cycle; IMP:MGI.
DR   GO; GO:0099527; P:postsynapse to nucleus signaling pathway; IDA:SynGO.
DR   GO; GO:0000018; P:regulation of DNA recombination; TAS:ProtInc.
DR   Gene3D; 1.20.5.690; -; 1.
DR   Gene3D; 1.25.10.10; -; 1.
DR   IDEAL; IID00153; -.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR032413; Arm_3.
DR   InterPro; IPR000225; Armadillo.
DR   InterPro; IPR002652; Importin-a_IBB.
DR   InterPro; IPR036975; Importin-a_IBB_sf.
DR   InterPro; IPR024931; Importing_su_alpha.
DR   Pfam; PF00514; Arm; 8.
DR   Pfam; PF16186; Arm_3; 1.
DR   Pfam; PF01749; IBB; 1.
DR   PIRSF; PIRSF005673; Importin_alpha; 1.
DR   SMART; SM00185; ARM; 8.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   PROSITE; PS50176; ARM_REPEAT; 5.
DR   PROSITE; PS51214; IBB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; Direct protein sequencing;
KW   Endoplasmic reticulum; Golgi apparatus; Host-virus interaction; Membrane;
KW   Nucleus; Phosphoprotein; Polymorphism; Protein transport;
KW   Reference proteome; Repeat; Transport.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:22814378,
FT                   ECO:0000269|Ref.6"
FT   CHAIN           2..529
FT                   /note="Importin subunit alpha-1"
FT                   /id="PRO_0000120722"
FT   DOMAIN          2..60
FT                   /note="IBB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00561"
FT   REPEAT          71..111
FT                   /note="ARM 1; truncated"
FT   REPEAT          112..151
FT                   /note="ARM 2"
FT   REPEAT          152..193
FT                   /note="ARM 3"
FT   REPEAT          200..244
FT                   /note="ARM 4"
FT   REPEAT          246..282
FT                   /note="ARM 5"
FT   REPEAT          283..322
FT                   /note="ARM 6"
FT   REPEAT          325..364
FT                   /note="ARM 7"
FT   REPEAT          367..409
FT                   /note="ARM 8"
FT   REPEAT          410..456
FT                   /note="ARM 9"
FT   REPEAT          457..496
FT                   /note="ARM 10; atypical"
FT   REGION          142..238
FT                   /note="NLS binding site (major)"
FT                   /evidence="ECO:0000250"
FT   REGION          315..403
FT                   /note="NLS binding site (minor)"
FT                   /evidence="ECO:0000250"
FT   MOTIF           45..54
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        28..31
FT                   /note="Poly-Arg"
FT   COMPBIAS        499..502
FT                   /note="Poly-Glu"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:22814378,
FT                   ECO:0000269|Ref.6"
FT   MOD_RES         62
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:16964243,
FT                   ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         490
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163"
FT   VARIANT         157
FT                   /note="A -> V (in dbSNP:rs17850032)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3"
FT                   /id="VAR_067625"
FT   VARIANT         165
FT                   /note="P -> R (in dbSNP:rs11545989)"
FT                   /evidence="ECO:0000269|PubMed:11735022,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_013137"
FT   VARIANT         365
FT                   /note="G -> S (in dbSNP:rs1059558)"
FT                   /id="VAR_067626"
FT   VARIANT         453
FT                   /note="K -> N (in dbSNP:rs17850031)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3"
FT                   /id="VAR_067627"
FT   MUTAGEN         2..80
FT                   /note="Missing: Complete loss of binding to KPNB1."
FT                   /evidence="ECO:0000269|PubMed:17596301"
FT   CONFLICT        182
FT                   /note="A -> D (in Ref. 5; AAH67848)"
FT                   /evidence="ECO:0000305"
FT   HELIX           14..16
FT                   /evidence="ECO:0000244|PDB:1QGK"
FT   TURN            18..21
FT                   /evidence="ECO:0000244|PDB:1QGK"
FT   HELIX           30..48
FT                   /evidence="ECO:0000244|PDB:1QGR"
FT   HELIX           74..85
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           90..104
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   STRAND          106..108
FT                   /evidence="ECO:0000244|PDB:3FEY"
FT   HELIX           112..117
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           121..128
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           134..148
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           152..160
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           163..170
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           176..190
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           194..202
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           206..213
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   STRAND          214..216
FT                   /evidence="ECO:0000244|PDB:5H43"
FT   HELIX           218..220
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           223..236
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           246..259
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           265..278
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           283..290
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   TURN            291..293
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           295..302
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           307..320
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           325..333
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           336..339
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           340..344
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           349..362
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           367..375
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           379..388
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           391..407
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           410..418
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           422..427
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           428..430
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           434..454
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           457..466
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           469..475
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           476..478
FT                   /evidence="ECO:0000244|PDB:4WV6"
FT   HELIX           479..481
FT                   /evidence="ECO:0000244|PDB:3WPT"
FT   HELIX           482..495
FT                   /evidence="ECO:0000244|PDB:4WV6"
SQ   SEQUENCE   529 AA;  57862 MW;  B0F94A0475B80EED CRC64;
     MSTNENANTP AARLHRFKNK GKDSTEMRRR RIEVNVELRK AKKDDQMLKR RNVSSFPDDA
     TSPLQENRNN QGTVNWSVDD IVKGINSSNV ENQLQATQAA RKLLSREKQP PIDNIIRAGL
     IPKFVSFLGR TDCSPIQFES AWALTNIASG TSEQTKAVVD GGAIPAFISL LASPHAHISE
     QAVWALGNIA GDGSVFRDLV IKYGAVDPLL ALLAVPDMSS LACGYLRNLT WTLSNLCRNK
     NPAPPIDAVE QILPTLVRLL HHDDPEVLAD TCWAISYLTD GPNERIGMVV KTGVVPQLVK
     LLGASELPIV TPALRAIGNI VTGTDEQTQV VIDAGALAVF PSLLTNPKTN IQKEATWTMS
     NITAGRQDQI QQVVNHGLVP FLVSVLSKAD FKTQKEAVWA VTNYTSGGTV EQIVYLVHCG
     IIEPLMNLLT AKDTKIILVI LDAISNIFQA AEKLGETEKL SIMIEECGGL DKIEALQNHE
     NESVYKASLS LIEKYFSVEE EEDQNVVPET TSEGYTFQVQ DGAPGTFNF
//
ID   SPIKE_SARS              Reviewed;        1255 AA.
AC   P59594; Q6QU82; Q7T696; Q7TA19; Q7TFA2; Q7TFB1; Q80BV6;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 1.
DT   12-AUG-2020, entry version 137.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, and Isolate HKU-36871;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   "Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China.";
RL   Science 302:276-278(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   "Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection.";
RL   Lancet 361:1779-1785(2003).
RN   [8]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   "Mechanisms and enzymes involved in SARS coronavirus genome expression.";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   "Genomic sequence of SARS isolate from the first fatal case in Taiwan.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Isolate ZJ01;
RA   Cong L.-M., Ding G.-Q., Lu Y.-Y., Weng J.-Q., Yan J.-Y., Hu N.-P.,
RA   Wo J.-E., Chen S.-Y., Zhang Y.-J., Mei L.-L., Wang Z.-G., Yao J.,
RA   Zhu H.-P., Lu Q.-Y., Li M.-H., Gong L.-M., Shi W., Li L.-J.;
RT   "SARS coronavirus ZJ01 isolate spike glycoprotein.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC2, and Isolate TWC3;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee H.-C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chen P.-J., Su I.-J.;
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   "Analysis of SARS coronavirus genome in Shanghai isolates.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GD03;
RX   PubMed=15695582; DOI=10.1073/pnas.0409608102;
RA   Song H.D., Tu C.C., Zhang G.W., Wang S.Y., Zheng K., Lei L.C., Chen Q.X.,
RA   Gao Y.W., Zhou H.Q., Xiang H., Zheng H.J., Chern S.W., Cheng F., Pan C.M.,
RA   Xuan H., Chen S.J., Luo H.M., Zhou D.H., Liu Y.F., He J.F., Qin P.Z.,
RA   Li L.H., Ren Y.Q., Liang W.J., Yu Y.D., Anderson L., Wang M., Xu R.H.,
RA   Wu X.W., Zheng H.Y., Chen J.D., Liang G., Gao Y., Liao M., Fang L.,
RA   Jiang L.Y., Li H., Chen F., Di B., He L.J., Lin J.Y., Tong S., Kong X.,
RA   Du L., Hao P., Tang H., Bernini A., Yu X.J., Spiga O., Guo Z.M., Pan H.Y.,
RA   He W.Z., Manuguerra J.C., Fontanet A., Danchin A., Niccolai N., Li Y.X.,
RA   Wu C.I., Zhao G.P.;
RT   "Cross-host evolution of severe acute respiratory syndrome coronavirus in
RT   palm civet and human.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:2430-2435(2005).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2, AND CHARACTERIZATION OF CELLULAR RECEPTOR.
RX   PubMed=14647384; DOI=10.1038/nature02145;
RA   Li W., Moore M.J., Vasilieva N., Sui J., Wong S.-K., Berne M.A.,
RA   Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H.,
RA   Farzan M.;
RT   "Angiotensin-converting enzyme 2 is a functional receptor for the SARS
RT   coronavirus.";
RL   Nature 426:450-454(2003).
RN   [23]
RP   FUNCTION, INTERACTION WITH HUMAN ACE2, AND MUTAGENESIS OF CYS-323; CYS-348;
RP   GLU-452; ASP-454; ASP-463; CYS-467; CYS-474 AND ASP-480.
RX   PubMed=14670965; DOI=10.1074/jbc.c300520200;
RA   Wong S.K., Li W., Moore M.J., Choe H., Farzan M.;
RT   "A 193-amino acid fragment of the SARS coronavirus S protein efficiently
RT   binds angiotensin-converting enzyme 2.";
RL   J. Biol. Chem. 279:3197-3201(2004).
RN   [24]
RP   CHARACTERIZATION OF HEPTAD REPEAT REGIONS.
RX   PubMed=15518555; DOI=10.1021/bi049101q;
RA   Xu Y., Zhu J., Liu Y., Lou Z., Yuan F., Liu Y., Cole D.K., Ni L., Su N.,
RA   Qin L., Li X., Bai Z., Bell J.I., Pang H., Tien P., Gao G.F., Rao Z.;
RT   "Characterization of the heptad repeat regions, HR1 and HR2, and design of
RT   a fusion core structure model of the spike protein from severe acute
RT   respiratory syndrome (SARS) coronavirus.";
RL   Biochemistry 43:14064-14071(2004).
RN   [25]
RP   CLEAVAGE.
RX   PubMed=15450134; DOI=10.1038/sj.cr.7290240;
RA   Wu X.D., Shang B., Yang R.F., Yu H., Ma Z.H., Shen X., Ji Y.Y., Lin Y.,
RA   Wu Y.D., Lin G.M., Tian L., Gan X.Q., Yang S., Jiang W.H., Dai E.H.,
RA   Wang X.Y., Jiang H.L., Xie Y.H., Zhu X.L., Pei G., Li L., Wu J.R., Sun B.;
RT   "The spike protein of severe acute respiratory syndrome (SARS) is cleaved
RT   in virus infected Vero-E6 cells.";
RL   Cell Res. 14:400-406(2004).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH HUMAN CLEC4M/DC-SIGNR.
RX   PubMed=15496474; DOI=10.1073/pnas.0403812101;
RA   Jeffers S.A., Tusell S.M., Gillim-Ross L., Hemmila E.M., Achenbach J.E.,
RA   Babcock G.J., Thomas W.D. Jr., Thackray L.B., Young M.D., Mason R.J.,
RA   Ambrosino D.M., Wentworth D.E., Demartini J.C., Holmes K.V.;
RT   "CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome
RT   coronavirus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15748-15753(2004).
RN   [27]
RP   HOMOTRIMERIZATION.
RX   PubMed=15313178; DOI=10.1016/j.bbrc.2004.07.084;
RA   Xiao X., Feng Y., Chakraborti S., Dimitrov D.S.;
RT   "Oligomerization of the SARS-CoV S glycoprotein: dimerization of the N-
RT   terminus and trimerization of the ectodomain.";
RL   Biochem. Biophys. Res. Commun. 322:93-99(2004).
RN   [28]
RP   CHARACTERIZATION OF FUSION PEPTIDE.
RX   PubMed=15890958; DOI=10.1128/jvi.79.11.7195-7206.2005;
RA   Sainz B. Jr., Rausch J.M., Gallaher W.R., Garry R.F., Wimley W.C.;
RT   "Identification and characterization of the putative fusion peptide of the
RT   severe acute respiratory syndrome-associated coronavirus spike protein.";
RL   J. Virol. 79:7195-7206(2005).
RN   [29]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15831954; DOI=10.1099/vir.0.80671-0;
RA   Nal B., Chan C., Kien F., Siu L., Tse J., Chu K., Kam J., Staropoli I.,
RA   Crescenzo-Chaigne B., Escriou N., van der Werf S., Yuen K.Y., Altmeyer R.;
RT   "Differential maturation and subcellular localization of severe acute
RT   respiratory syndrome coronavirus surface proteins S, M and E.";
RL   J. Gen. Virol. 86:1423-1434(2005).
RN   [30]
RP   CHARACTERIZATION OF VARIANTS ARG-344; SER-360; LYS-479 AND SER-487.
RX   PubMed=15791205; DOI=10.1038/sj.emboj.7600640;
RA   Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., Wong S.-K.,
RA   Huang I.-C., Xu K., Vasilieva N., Murakami A., He Y., Marasco W.A.,
RA   Guan Y., Choe H., Farzan M.;
RT   "Receptor and viral determinants of SARS-coronavirus adaptation to human
RT   ACE2.";
RL   EMBO J. 24:1634-1643(2005).
RN   [31]
RP   PROTEOLYSIS BY HUMAN CTSL.
RX   PubMed=16081529; DOI=10.1073/pnas.0505577102;
RA   Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L.,
RA   Bates P.;
RT   "Inhibitors of cathepsin L prevent severe acute respiratory syndrome
RT   coronavirus entry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:11876-11881(2005).
RN   [32]
RP   INTERACTION WITH ACCESSORY PROTEIN 3A.
RX   PubMed=15194747; DOI=10.1128/jvi.78.13.6723-6734.2004;
RA   Tan Y.-J., Teng E., Shen S., Tan T.H.P., Goh P.-Y., Fielding B.C.,
RA   Ooi E.-E., Tan H.-C., Lim S.G., Hong W.;
RT   "A novel severe acute respiratory syndrome coronavirus protein, U274, is
RT   transported to the cell surface and undergoes endocytosis.";
RL   J. Virol. 78:6723-6734(2004).
RN   [33]
RP   INTERACTION WITH ACCESSORY PROTEIN 7A.
RX   PubMed=16840309; DOI=10.1128/jvi.00414-06;
RA   Huang C., Ito N., Tseng C.-T.K., Makino S.;
RT   "Severe acute respiratory syndrome coronavirus 7a accessory protein is a
RT   viral structural protein.";
RL   J. Virol. 80:7287-7294(2006).
RN   [34]
RP   MUTAGENESIS OF ARG-667 AND LYS-672.
RX   PubMed=16519916; DOI=10.1016/j.virol.2006.02.003;
RA   Follis K.E., York J., Nunberg J.H.;
RT   "Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-
RT   cell fusion but does not affect virion entry.";
RL   Virology 350:358-369(2006).
RN   [35]
RP   PALMITOYLATION.
RX   PubMed=17134730; DOI=10.1016/j.virol.2006.10.034;
RA   Petit C.M., Chouljenko V.N., Iyer A., Colgrove R., Farzan M., Knipe D.M.,
RA   Kousoulas K.G.;
RT   "Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus
RT   spike glycoprotein is important for spike-mediated cell fusion.";
RL   Virology 360:264-274(2007).
RN   [36]
RP   ENDOPLASMIC RETICULUM RETENTION MOTIF, AND MUTAGENESIS OF LYS-1251 AND
RP   HIS-1253.
RX   PubMed=17166901; DOI=10.1128/jvi.02146-06;
RA   McBride C.E., Li J., Machamer C.E.;
RT   "The cytoplasmic tail of the severe acute respiratory syndrome coronavirus
RT   spike protein contains a novel endoplasmic reticulum retrieval signal that
RT   binds COPI and promotes interaction with membrane protein.";
RL   J. Virol. 81:2418-2428(2007).
RN   [37]
RP   CLEAVAGE, AND FUNCTION.
RX   PubMed=19321428; DOI=10.1073/pnas.0809524106;
RA   Belouzard S., Chu V.C., Whittaker G.R.;
RT   "Activation of the SARS coronavirus spike protein via sequential
RT   proteolytic cleavage at two distinct sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:5871-5876(2009).
RN   [38]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20861307; DOI=10.1091/mbc.e10-04-0338;
RA   Teoh K.T., Siu Y.L., Chan W.L., Schlueter M.A., Liu C.J., Peiris J.S.,
RA   Bruzzone R., Margolis B., Nal B.;
RT   "The SARS coronavirus E protein interacts with PALS1 and alters tight
RT   junction formation and epithelial morphogenesis.";
RL   Mol. Biol. Cell 21:3838-3852(2010).
RN   [39]
RP   CHARACTERIZATION OF FUSION PEPTIDE.
RX   PubMed=29056462; DOI=10.1016/j.jmb.2017.10.017;
RA   Lai A.L., Millet J.K., Daniel S., Freed J.H., Whittaker G.R.;
RT   "The SARS-CoV fusion peptide forms an extended bipartite fusion platform
RT   that perturbs membrane order in a calcium-dependent manner.";
RL   J. Mol. Biol. 429:3875-3892(2017).
RN   [40]
RP   FUNCTION.
RX   PubMed=31199522; DOI=10.1002/jmv.25518;
RA   Wang S.M., Huang K.J., Wang C.T.;
RT   "Severe acute respiratory syndrome coronavirus spike protein counteracts
RT   BST2-mediated restriction of virus-like particle release.";
RL   J. Med. Virol. 91:1743-1750(2019).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 900-948.
RX   PubMed=15345712; DOI=10.1074/jbc.m408782200;
RA   Xu Y., Lou Z., Liu Y., Pang H., Tien P., Gao G.F., Rao Z.;
RT   "Crystal structure of severe acute respiratory syndrome coronavirus spike
RT   protein fusion core.";
RL   J. Biol. Chem. 279:49414-49419(2004).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 895-972 AND 1142-1180.
RX   PubMed=15604146; DOI=10.1073/pnas.0406128102;
RA   Supekar V.M., Bruckmann C., Ingallinella P., Bianchi E., Pessi A.,
RA   Carfi A.;
RT   "Structure of a proteolytically resistant core from the severe acute
RT   respiratory syndrome coronavirus S2 fusion protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:17958-17963(2004).
RN   [43]
RP   3D-STRUCTURE MODELING OF 17-680.
RX   PubMed=14511651; DOI=10.1016/j.bbrc.2003.08.122;
RA   Spiga O., Bernini A., Ciutti A., Chiellini S., Menciassi N., Finetti F.,
RA   Causarono V., Anselmi F., Prischi F., Niccolai N.;
RT   "Molecular modelling of S1 and S2 subunits of SARS coronavirus spike
RT   glycoprotein.";
RL   Biochem. Biophys. Res. Commun. 310:78-83(2003).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 323-502 IN COMPLEX WITH HUMAN
RP   ACE2.
RX   PubMed=16166518; DOI=10.1126/science.1116480;
RA   Li F., Li W., Farzan M., Harrison S.C.;
RT   "Structure of SARS coronavirus spike receptor-binding domain complexed with
RT   receptor.";
RL   Science 309:1864-1868(2005).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1150-1193.
RX   PubMed=16698550; DOI=10.1016/j.str.2006.03.007;
RA   Deng Y., Liu J., Zheng Q., Yong W., Lu M.;
RT   "Structures and polymorphic interactions of two heptad-repeat regions of
RT   the SARS virus S2 protein.";
RL   Structure 14:889-899(2006).
CC   -!- FUNCTION: [Spike glycoprotein]: May down-regulate host tetherin (BST2)
CC       by lysosomal degradation, thereby counteracting its antiviral activity.
CC       {ECO:0000269|PubMed:31199522}.
CC   -!- FUNCTION: [Spike protein S1]: attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection (By
CC       similarity). Binding to human ACE2 and CLEC4M/DC-SIGNR receptors and
CC       internalization of the virus into the endosomes of the host cell
CC       induces conformational changes in the S glycoprotein. Proteolysis by
CC       cathepsin CTSL may unmask the fusion peptide of S2 and activate
CC       membranes fusion within endosomes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:14670965, ECO:0000269|PubMed:15496474}.
CC   -!- FUNCTION: [Spike protein S2]: mediates fusion of the virion and
CC       cellular membranes by acting as a class I viral fusion protein. Under
CC       the current model, the protein has at least three conformational
CC       states: pre-fusion native state, pre-hairpin intermediate state, and
CC       post-fusion hairpin state. During viral and target cell membrane
CC       fusion, the coiled coil regions (heptad repeats) assume a trimer-of-
CC       hairpins structure, positioning the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. The formation of this
CC       structure appears to drive apposition and subsequent fusion of viral
CC       and target cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099}.
CC   -!- FUNCTION: [Spike protein S2']: Acts as a viral fusion peptide which is
CC       unmasked following S2 cleavage occurring upon virus endocytosis.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:19321428}.
CC   -!- SUBUNIT: Homotrimer; each monomer consists of a S1 and a S2 subunit.
CC       The resulting peplomers protrude from the virus surface as spikes (By
CC       similarity). Binds to human and palm civet ACE2 and human CLEC4M/DC-
CC       SIGNR. Interacts with the accessory proteins 3a and 7a.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:14670965, ECO:0000269|PubMed:15194747,
CC       ECO:0000269|PubMed:15496474, ECO:0000269|PubMed:16166518,
CC       ECO:0000269|PubMed:16840309}.
CC   -!- INTERACTION:
CC       P59594; P59594: S; NbExp=10; IntAct=EBI-15582614, EBI-15582614;
CC       P59594; Q56NL1: ACE2; Xeno; NbExp=4; IntAct=EBI-15582614, EBI-25498790;
CC       P59594; Q5EGZ1: Ace2; Xeno; NbExp=2; IntAct=EBI-15582614, EBI-25503774;
CC       P59594; Q9BYF1: ACE2; Xeno; NbExp=29; IntAct=EBI-15582614, EBI-7730807;
CC       P59594; Q9BYF1-1: ACE2; Xeno; NbExp=2; IntAct=EBI-15582614, EBI-15814450;
CC       P59594; O00303: EIF3F; Xeno; NbExp=5; IntAct=EBI-15582614, EBI-711990;
CC       PRO_0000037209; Q9BYF1: ACE2; Xeno; NbExp=3; IntAct=EBI-25475261, EBI-7730807;
CC   -!- SUBCELLULAR LOCATION: Virion membrane {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:15831954}; Single-pass type I membrane protein
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:15831954}. Host
CC       endoplasmic reticulum-Golgi intermediate compartment membrane
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:20861307}; Single-
CC       pass type I membrane protein {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:15831954}. Host cell membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:15831954}; Single-pass type I
CC       membrane protein {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:15831954}. Note=Accumulates in the endoplasmic
CC       reticulum-Golgi intermediate compartment, where it participates in
CC       virus particle assembly. Colocalizes with S in the host endoplasmic
CC       reticulum-Golgi intermediate compartment (PubMed:20861307). Some S
CC       oligomers are transported to the host plasma membrane, where they may
CC       mediate cell-cell fusion. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:20861307}.
CC   -!- DOMAIN: The KxHxx motif seems to function as an ER retrieval and binds
CC       COPI in vitro.
CC   -!- DOMAIN: Fusion peptide 1 (FP1) and fusion peptide 2 (FP2) function
CC       cooperatively and have a membrane-ordering effect on lipid headgroups
CC       and shallow hydrophobic regions of target bilayers. They are considered
CC       as two domains of an extended, bipartite FP. The membrane-ordering
CC       activity is calcium-dependent and also dependent on correct folding,
CC       which is maintained by an internal disulfide bond in FP2.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:29056462}.
CC   -!- PTM: The cytoplasmic Cys-rich domain is palmitoylated. Spike
CC       glycoprotein is digested by cathepsin CTSL within endosomes.
CC       {ECO:0000269|PubMed:17134730}.
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins. The
CC       precursor is processed into S1 and S2 by host cell furin or another
CC       cellular protease to yield the mature S1 and S2 proteins. Additionally,
CC       a second cleavage leads to the release of a fusion peptide after viral
CC       attachment to host cell receptor. {ECO:0000255|HAMAP-Rule:MF_04099}.
CC   -!- PTM: The cytoplasmic Cys-rich domain is palmitoylated. Spike
CC       glycoprotein is digested within host endosomes. {ECO:0000255|HAMAP-
CC       Rule:MF_04099}.
CC   -!- MISCELLANEOUS: Tor2 is the prototype of the virus isolated during the
CC       severe SARS outbreak in 2002-2003. GD03 has been isolated from the
CC       second mild SARS outbreak in winter 2003-2004. SZ3 has been isolated
CC       from palm civet, the presumed animal reservoir. The spike proteins from
CC       those three isolates display a strong affinity for palm civet ACE2
CC       receptor, whereas only the Tor2 spike protein efficiently binds human
CC       ACE2. This may explain the high pathogenicity of Tor2 virus, whose
CC       spike is highly adapted to the human host. Therefore, the lack of
CC       severity of disease during the 2003-2004 outbreak could be due to the
CC       incomplete adaptation of GD03 virus to bind human ACE2. Mutation Asn-
CC       479 and Thr-487 in palm civet coronavirus seems necessary and
CC       sufficient for the virus to acquire the ability to efficiently infect
CC       humans.
CC   -!- SIMILARITY: Belongs to the betacoronaviruses spike protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04099}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13441.1; -; Genomic_RNA.
DR   EMBL; AY274119; AAP41037.1; -; Genomic_RNA.
DR   EMBL; AY282752; AAP30713.1; -; Genomic_RNA.
DR   EMBL; AY278554; AAP13567.1; -; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY304495; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY304492; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; AAP30030.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278489; AAP51227.1; -; Genomic_RNA.
DR   EMBL; AY283794; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283795; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283796; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283797; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283798; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37017.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50485.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33697.1; -; Genomic_RNA.
DR   EMBL; AY304486; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY321118; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY323976; AAP73417.1; -; mRNA.
DR   EMBL; AY322207; AAP82968.1; -; Genomic_RNA.
DR   EMBL; AY338174; AAQ01597.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01609.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97882.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81348.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81362.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81376.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81390.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81404.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72986.1; -; Genomic_RNA.
DR   EMBL; AY362698; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY362699; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY427439; AAQ94060.1; -; Genomic_RNA.
DR   EMBL; AY463059; AAR86788.1; -; Genomic_RNA.
DR   EMBL; AY525636; AAS10463.1; -; Genomic_RNA.
DR   RefSeq; NP_828851.1; NC_004718.3.
DR   PDB; 1Q4Z; Model; -; A=17-680.
DR   PDB; 1T7G; Model; -; A/C/E=17-680, B/D/F=737-1026.
DR   PDB; 1U4K; Model; -; D=764-1089.
DR   PDB; 1WNC; X-ray; 2.80 A; A/B/C/D/E/F=900-948, A/B/C/D/E/F=1144-1185.
DR   PDB; 1WYY; X-ray; 2.20 A; A/B=885-981, A/B=1145-1189.
DR   PDB; 1XJP; Model; -; A=17-680.
DR   PDB; 1ZV7; X-ray; 1.70 A; A/B=1150-1193.
DR   PDB; 1ZV8; X-ray; 1.94 A; A/C/E/G/I/K=901-950, B/D/F/H/J/L=1150-1185.
DR   PDB; 1ZVB; X-ray; 1.70 A; A/B/C=940-973.
DR   PDB; 2AJF; X-ray; 2.90 A; E/F=323-502.
DR   PDB; 2BEQ; X-ray; 1.60 A; A/B/C=914-949, D/E/F=1148-1193.
DR   PDB; 2BEZ; X-ray; 1.60 A; C=896-972, F=1142-1183.
DR   PDB; 2DD8; X-ray; 2.30 A; S=317-518.
DR   PDB; 2FXP; NMR; -; A/B/C=1141-1193.
DR   PDB; 2GHV; X-ray; 2.20 A; C/E=317-510.
DR   PDB; 2GHW; X-ray; 2.30 A; A/C=317-510.
DR   PDB; 2RUM; NMR; -; A=770-788.
DR   PDB; 2RUN; NMR; -; A=1185-1202.
DR   PDB; 2RUO; NMR; -; A=873-888.
DR   PDB; 3BGF; X-ray; 3.00 A; A/S=318-510.
DR   PDB; 3D0G; X-ray; 2.80 A; E/F=324-502.
DR   PDB; 3D0H; X-ray; 3.10 A; E/F=324-502.
DR   PDB; 3D0I; X-ray; 2.90 A; E/F=324-502.
DR   PDB; 3SCI; X-ray; 2.90 A; E/F=306-527.
DR   PDB; 3SCJ; X-ray; 3.00 A; E/F=323-502.
DR   PDB; 3SCK; X-ray; 3.00 A; E/F=324-502.
DR   PDB; 3SCL; X-ray; 3.00 A; E/F=324-502.
DR   PDB; 5WRG; EM; 4.30 A; A/B/C=1-1196.
DR   PDB; 5X4S; X-ray; 2.20 A; A=14-292.
DR   PDB; 5X58; EM; 3.20 A; A/B/C=14-1193.
DR   PDB; 5X5B; EM; 3.70 A; A/B/C=14-1193.
DR   PDB; 5XJK; NMR; -; A=758-821.
DR   PDB; 5XLR; EM; 3.80 A; A/B/C=1-1196.
DR   PDB; 5ZVM; X-ray; 3.30 A; A/B/C=892-970.
DR   PDB; 6ACC; EM; 3.60 A; A/B/C=1-1196.
DR   PDB; 6ACD; EM; 3.90 A; A/B/C=1-1196.
DR   PDB; 6ACG; EM; 5.40 A; A/B/C=1-1196.
DR   PDB; 6ACJ; EM; 4.20 A; A/B/C=1-1196.
DR   PDB; 6ACK; EM; 4.50 A; A/B/C=1-1196.
DR   PDB; 6CRV; EM; 3.20 A; A/B/C=14-1190.
DR   PDB; 6CRW; EM; 3.90 A; A/B/C=14-1190.
DR   PDB; 6CRX; EM; 3.90 A; A/B/C=14-1190.
DR   PDB; 6CRZ; EM; 3.30 A; A/B/C=14-1190.
DR   PDB; 6CS0; EM; 3.80 A; A/B/C=14-1190.
DR   PDB; 6CS1; EM; 4.60 A; A/B/C=14-1190.
DR   PDB; 6CS2; EM; 4.40 A; A/B/C=14-1190.
DR   PDB; 6NB6; EM; 4.20 A; A/B/C=14-1193.
DR   PDB; 6NB7; EM; 4.50 A; A/B/C=14-1193.
DR   PDB; 6VW1; X-ray; 2.68 A; E/F=306-441, E/F=505-521.
DR   PDB; 6WAQ; X-ray; 2.20 A; B/D=320-502.
DR   PDBsum; 1Q4Z; -.
DR   PDBsum; 1T7G; -.
DR   PDBsum; 1U4K; -.
DR   PDBsum; 1WNC; -.
DR   PDBsum; 1WYY; -.
DR   PDBsum; 1XJP; -.
DR   PDBsum; 1ZV7; -.
DR   PDBsum; 1ZV8; -.
DR   PDBsum; 1ZVB; -.
DR   PDBsum; 2AJF; -.
DR   PDBsum; 2BEQ; -.
DR   PDBsum; 2BEZ; -.
DR   PDBsum; 2DD8; -.
DR   PDBsum; 2FXP; -.
DR   PDBsum; 2GHV; -.
DR   PDBsum; 2GHW; -.
DR   PDBsum; 2RUM; -.
DR   PDBsum; 2RUN; -.
DR   PDBsum; 2RUO; -.
DR   PDBsum; 3BGF; -.
DR   PDBsum; 3D0G; -.
DR   PDBsum; 3D0H; -.
DR   PDBsum; 3D0I; -.
DR   PDBsum; 3SCI; -.
DR   PDBsum; 3SCJ; -.
DR   PDBsum; 3SCK; -.
DR   PDBsum; 3SCL; -.
DR   PDBsum; 5WRG; -.
DR   PDBsum; 5X4S; -.
DR   PDBsum; 5X58; -.
DR   PDBsum; 5X5B; -.
DR   PDBsum; 5XJK; -.
DR   PDBsum; 5XLR; -.
DR   PDBsum; 5ZVM; -.
DR   PDBsum; 6ACC; -.
DR   PDBsum; 6ACD; -.
DR   PDBsum; 6ACG; -.
DR   PDBsum; 6ACJ; -.
DR   PDBsum; 6ACK; -.
DR   PDBsum; 6CRV; -.
DR   PDBsum; 6CRW; -.
DR   PDBsum; 6CRX; -.
DR   PDBsum; 6CRZ; -.
DR   PDBsum; 6CS0; -.
DR   PDBsum; 6CS1; -.
DR   PDBsum; 6CS2; -.
DR   PDBsum; 6NB6; -.
DR   PDBsum; 6NB7; -.
DR   PDBsum; 6VW1; -.
DR   PDBsum; 6WAQ; -.
DR   SMR; P59594; -.
DR   BioGRID; 4383915; 8.
DR   ComplexPortal; CPX-5694; SARS-CoV Spike protein complex.
DR   DIP; DIP-29105N; -.
DR   IntAct; P59594; 14.
DR   GlyGen; P59594; 23 sites.
DR   PRIDE; P59594; -.
DR   ABCD; P59594; 66 sequenced antibodies.
DR   GeneID; 1489668; -.
DR   KEGG; vg:1489668; -.
DR   KO; K24152; -.
DR   SIGNOR; P59594; -.
DR   EvolutionaryTrace; P59594; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000164441; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0044173; C:host cell endoplasmic reticulum-Golgi intermediate compartment membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-UniRule.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-UniRule.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046789; F:host cell surface receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0075509; P:endocytosis involved in viral entry into host cell; IEA:UniProtKB-UniRule.
DR   GO; GO:0039654; P:fusion of virus membrane with host endosome membrane; IEA:UniProtKB-UniRule.
DR   GO; GO:0019064; P:fusion of virus membrane with host plasma membrane; IEA:UniProtKB-UniRule.
DR   GO; GO:0009405; P:pathogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0046813; P:receptor-mediated virion attachment to host cell; IDA:BHF-UCL.
DR   Gene3D; 1.20.5.790; -; 1.
DR   HAMAP; MF_04099; BETA_CORONA_SPIKE; 1.
DR   InterPro; IPR042578; BETA_CORONA_SPIKE.
DR   InterPro; IPR043473; S2_sf_CoV.
DR   InterPro; IPR027400; S_HR2_CoV.
DR   InterPro; IPR032500; Spike_N.
DR   InterPro; IPR018548; Spike_rcpt-bd_bCoV.
DR   InterPro; IPR036326; Spike_rcpt-bd_sf_CoV.
DR   InterPro; IPR002552; Spike_S2_CoV.
DR   Pfam; PF01601; Corona_S2; 1.
DR   Pfam; PF16451; Spike_NTD; 1.
DR   Pfam; PF09408; Spike_rec_bind; 1.
DR   SUPFAM; SSF111474; SSF111474; 2.
DR   SUPFAM; SSF143587; SSF143587; 1.
DR   PROSITE; PS51921; BCOV_S1_CTD; 1.
DR   PROSITE; PS51922; BCOV_S1_NTD; 1.
DR   PROSITE; PS51923; COV_S2_HR1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Disulfide bond;
KW   Fusion of virus membrane with host endosomal membrane;
KW   Fusion of virus membrane with host membrane; Glycoprotein;
KW   Host cell membrane; Host membrane; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host tetherin by virus; Lipoprotein; Membrane; Palmitate;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Viral attachment to host cell; Viral envelope protein; Viral immunoevasion;
KW   Viral penetration into host cytoplasm; Virion; Virulence;
KW   Virus entry into host cell.
FT   SIGNAL          1..13
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CHAIN           14..1255
FT                   /note="Spike glycoprotein"
FT                   /id="PRO_0000037208"
FT   CHAIN           14..667
FT                   /note="Spike protein S1"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT                   /id="PRO_0000037209"
FT   CHAIN           668..1255
FT                   /note="Spike protein S2"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT                   /id="PRO_0000037210"
FT   CHAIN           798..1255
FT                   /note="Spike protein S2'"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT                   /id="PRO_0000444082"
FT   TOPO_DOM        14..1195
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   TRANSMEM        1196..1216
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   TOPO_DOM        1217..1255
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   DOMAIN          14..290
FT                   /note="BetaCoV S1-NTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01270"
FT   DOMAIN          321..513
FT                   /note="BetaCoV S1-CTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01269"
FT   REGION          306..527
FT                   /note="Receptor-binding domain"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   REGION          424..494
FT                   /note="Receptor-binding motif; binding to human ACE2"
FT   REGION          798..819
FT                   /note="Fusion peptide 1"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000305|PubMed:29056462"
FT   REGION          817..837
FT                   /note="Fusion peptide 2"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000305|PubMed:29056462"
FT   REGION          902..952
FT                   /note="Heptad repeat 1"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   REGION          1145..1184
FT                   /note="Heptad repeat 2"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   COILED          931..975
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   COILED          1157..1185
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   MOTIF           1251..1255
FT                   /note="KxHxx"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   COMPBIAS        1217..1236
FT                   /note="Cys-rich"
FT   SITE            667..668
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:19321428"
FT   SITE            797..798
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000269|PubMed:19321428"
FT   CARBOHYD        29
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        65
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        73
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        109
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        118
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        119
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        158
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        227
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        269
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        318
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        330
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        357
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        589
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        602
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        691
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        699
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        783
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        1056
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        1080
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        1116
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        1140
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        1155
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   CARBOHYD        1176
FT                   /note="N-linked (GlcNAc...) asparagine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099"
FT   DISULFID        19..133
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01270"
FT   DISULFID        128..159
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01270"
FT   DISULFID        278..288
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01270"
FT   DISULFID        323..348
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01269"
FT   DISULFID        366..419
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01269"
FT   DISULFID        378..511
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01269"
FT   DISULFID        467..474
FT   DISULFID        822..833
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04099,
FT                   ECO:0000305|PubMed:29056462"
FT   VARIANT         49
FT                   /note="S -> L (in strain: Isolate GZ50)"
FT   VARIANT         77
FT                   /note="G -> D (in strain: Isolate BJ01, Isolate BJ02,
FT                   Isolate BJ03, Isolate GZ50, Isolate CUHK-W1, Isolate
FT                   HKU-36871, Isolate GD01, Isolate GD03 and Isolate SZ3)"
FT   VARIANT         78
FT                   /note="N -> D (in strain: Isolate GD03)"
FT   VARIANT         118
FT                   /note="N -> S (in strain: Isolate Shanghai LY)"
FT   VARIANT         139
FT                   /note="A -> V (in strain: Isolate GD03)"
FT   VARIANT         144
FT                   /note="M -> L (in strain: Isolate BJ03)"
FT   VARIANT         147
FT                   /note="Q -> R (in strain: Isolate GD03)"
FT   VARIANT         193
FT                   /note="F -> S (in strain: Isolate Shanghai LY)"
FT   VARIANT         227
FT                   /note="N -> K (in strain: Isolate SZ3)"
FT   VARIANT         239
FT                   /note="S -> L (in strain: Isolate GD01 and Isolate SZ3)"
FT   VARIANT         244
FT                   /note="I -> T (in strain: Isolate BJ01, Isolate BJ02,
FT                   Isolate BJ03, Isolate BJ04, Isolate GZ50, Isolate CUHK-W1,
FT                   Isolate HKU-36871, Isolate GD01, Isolate GD03 and Isolate
FT                   SZ3)"
FT   VARIANT         261
FT                   /note="T -> K (in strain: Isolate SZ3)"
FT   VARIANT         311
FT                   /note="G -> R (in strain: Isolate GD01 and Isolate BJ02)"
FT   VARIANT         344
FT                   /note="K -> R (in strain: Isolate GD01, Isolate GD03 and
FT                   Isolate SZ3; no effect on affinity with either human or
FT                   palm civet ACE2)"
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   VARIANT         360
FT                   /note="F -> S (in strain: Isolate GD03 and Isolate SZ3; no
FT                   effect on affinity with either human or palm civet ACE2)"
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   VARIANT         426
FT                   /note="R -> G (in strain: Isolate Shanghai LY)"
FT   VARIANT         437
FT                   /note="N -> D (in strain: Isolate Shanghai LY)"
FT   VARIANT         472
FT                   /note="L -> P (in strain: Isolate GD03)"
FT   VARIANT         479
FT                   /note="N -> K (in strain: Isolate SZ3; 20fold decrease of
FT                   affinity with human ACE2; no effect on affinity with palm
FT                   civet ACE2)"
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   VARIANT         480
FT                   /note="D -> G (in strain: Isolate GD03)"
FT   VARIANT         487
FT                   /note="T -> S (in strain: Isolate GD03 and Isolate SZ3;
FT                   20fold decrease of affinity with human ACE2; decrease of
FT                   affinity with palm civet ACE2)"
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   VARIANT         501
FT                   /note="F -> Y (in strain: Isolate GD01)"
FT   VARIANT         577
FT                   /note="S -> A (in strain: Isolate Tor2 and Isolate Shanghai
FT                   QXC1)"
FT   VARIANT         605
FT                   /note="D -> N (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         607
FT                   /note="S -> P (in strain: Isolate SZ3)"
FT   VARIANT         608
FT                   /note="T -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         609
FT                   /note="A -> L (in strain: Isolate GD03)"
FT   VARIANT         613
FT                   /note="D -> E (in strain: Isolate GD03)"
FT   VARIANT         665
FT                   /note="L -> S (in strain: Isolate GD03 and Isolate SZ3)"
FT   VARIANT         701
FT                   /note="S -> L (in strain: Isolate SZ3)"
FT   VARIANT         743
FT                   /note="T -> A (in strain: Isolate SZ3)"
FT   VARIANT         743
FT                   /note="T -> R (in strain: Isolate GD03)"
FT   VARIANT         754
FT                   /note="A -> V (in strain: Isolate SZ3)"
FT   VARIANT         765
FT                   /note="A -> V (in strain: Isolate GD03)"
FT   VARIANT         778
FT                   /note="Y -> D (in strain: Isolate GD01, Isolate GZ50,
FT                   Isolate GD03 and Isolate SZ3)"
FT   VARIANT         794
FT                   /note="P -> S (in strain: Isolate GD01)"
FT   VARIANT         804
FT                   /note="L -> P (in strain: Isolate Shanghai LY)"
FT   VARIANT         860..861
FT                   /note="VS -> LR (in strain: Isolate BJ03)"
FT   VARIANT         894
FT                   /note="T -> A (in strain: Isolate SZ3)"
FT   VARIANT         999
FT                   /note="E -> G (in strain: Isolate Shanghai LY)"
FT   VARIANT         1001
FT                   /note="R -> M (in strain: Isolate BJ04)"
FT   VARIANT         1132
FT                   /note="E -> G (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         1148
FT                   /note="L -> F (in strain: Isolate Frankfurt 1 and Isolate
FT                   FRA)"
FT   VARIANT         1163
FT                   /note="K -> E (in strain: Isolate GD03 and Isolate SZ3)"
FT   MUTAGEN         323
FT                   /note="C->A: No effect on human ACE2 binding in vitro."
FT                   /evidence="ECO:0000269|PubMed:14670965"
FT   MUTAGEN         348
FT                   /note="C->A: Complete loss of human ACE2 binding in vitro."
FT                   /evidence="ECO:0000269|PubMed:14670965"
FT   MUTAGEN         452
FT                   /note="E->A: 90% loss of human ACE2 binding in vitro."
FT                   /evidence="ECO:0000269|PubMed:14670965"
FT   MUTAGEN         454
FT                   /note="D->A: Complete loss of human ACE2 binding in vitro."
FT                   /evidence="ECO:0000269|PubMed:14670965"
FT   MUTAGEN         463
FT                   /note="D->A: Partial loss of human ACE2 binding in vitro."
FT                   /evidence="ECO:0000269|PubMed:14670965"
FT   MUTAGEN         467
FT                   /note="C->A: Complete loss of human ACE2 binding in vitro."
FT                   /evidence="ECO:0000269|PubMed:14670965"
FT   MUTAGEN         474
FT                   /note="C->A: Complete loss of human ACE2 binding in vitro."
FT                   /evidence="ECO:0000269|PubMed:14670965"
FT   MUTAGEN         480
FT                   /note="D->A: No effect on human ACE2 binding in vitro."
FT                   /evidence="ECO:0000269|PubMed:14670965"
FT   MUTAGEN         667
FT                   /note="R->S: 40% loss of cell-cell fusion."
FT                   /evidence="ECO:0000269|PubMed:16519916"
FT   MUTAGEN         672
FT                   /note="K->S: No effect on cell-cell fusion."
FT                   /evidence="ECO:0000269|PubMed:16519916"
FT   MUTAGEN         797
FT                   /note="R->N: Complete loss of trypsin-induced membrane
FT                   fusion."
FT                   /evidence="ECO:0000269|PubMed:19321428"
FT   MUTAGEN         1251
FT                   /note="K->A: Decrease in Golgi localization, and complete
FT                   loss of COPI binding; when associated with A-1253."
FT                   /evidence="ECO:0000269|PubMed:17166901"
FT   MUTAGEN         1253
FT                   /note="H->A: Decrease in Golgi localization, and complete
FT                   loss of COPI binding; when associated with A-1251."
FT                   /evidence="ECO:0000269|PubMed:17166901"
FT   STRAND          31..34
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          37..41
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          44..48
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          50..59
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          65..72
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          73..75
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          87..95
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          100..111
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          113..118
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          123..141
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   TURN            142..144
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          146..164
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          177..190
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          193..208
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          216..222
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          229..239
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          250..256
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          258..266
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          268..270
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          272..277
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   TURN            282..288
FT                   /evidence="ECO:0000244|PDB:5X4S"
FT   STRAND          297..299
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          310..312
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           326..329
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   HELIX           337..339
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          341..345
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          347..349
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   HELIX           352..354
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          362..368
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   HELIX           371..378
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          380..390
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   HELIX           391..396
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          397..400
FT                   /evidence="ECO:0000244|PDB:3D0G"
FT   HELIX           404..408
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          414..416
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          418..424
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   HELIX           426..429
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          431..433
FT                   /evidence="ECO:0000244|PDB:2DD8"
FT   STRAND          439..441
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          462..464
FT                   /evidence="ECO:0000244|PDB:3D0I"
FT   STRAND          471..473
FT                   /evidence="ECO:0000244|PDB:6WAQ"
FT   STRAND          478..480
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          483..487
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   HELIX           489..491
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          492..501
FT                   /evidence="ECO:0000244|PDB:2GHV"
FT   STRAND          509..511
FT                   /evidence="ECO:0000244|PDB:2DD8"
FT   STRAND          523..527
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          536..540
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          551..563
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   TURN            565..567
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          570..574
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          583..585
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   TURN            588..590
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          596..599
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           604..610
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   TURN            611..613
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          615..617
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   STRAND          628..631
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   STRAND          635..638
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          640..646
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   STRAND          649..653
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          656..659
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          675..678
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          682..685
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          691..698
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          704..710
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          716..718
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   HELIX           720..725
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           730..735
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           736..738
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          740..744
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           745..764
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          768..771
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           773..777
FT                   /evidence="ECO:0000244|PDB:2RUM"
FT   STRAND          778..781
FT                   /evidence="ECO:0000244|PDB:6CRZ"
FT   TURN            785..787
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   STRAND          790..792
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          794..797
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           799..806
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           813..817
FT                   /evidence="ECO:0000244|PDB:5XJK"
FT   STRAND          820..823
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   STRAND          832..834
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   STRAND          837..842
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   HELIX           849..865
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           869..872
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           880..891
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          898..900
FT                   /evidence="ECO:0000244|PDB:2BEZ"
FT   HELIX           915..948
FT                   /evidence="ECO:0000244|PDB:2BEQ"
FT   HELIX           959..963
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   TURN            964..969
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   HELIX           971..1013
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   TURN            1014..1016
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1027..1032
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1035..1038
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1041..1048
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1054..1059
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1061..1063
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1066..1068
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1070..1074
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1078..1080
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1083..1086
FT                   /evidence="ECO:0000244|PDB:5X58"
FT   STRAND          1089..1091
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   STRAND          1101..1111
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   STRAND          1114..1116
FT                   /evidence="ECO:0000244|PDB:6CRV"
FT   HELIX           1148..1151
FT                   /evidence="ECO:0000244|PDB:2FXP"
FT   HELIX           1162..1172
FT                   /evidence="ECO:0000244|PDB:2BEQ"
FT   HELIX           1173..1178
FT                   /evidence="ECO:0000244|PDB:2BEQ"
FT   HELIX           1182..1192
FT                   /evidence="ECO:0000244|PDB:2BEQ"
SQ   SEQUENCE   1255 AA;  139125 MW;  1C49ACA2CFD38FC0 CRC64;
     MFIFLLFLTL TSGSDLDRCT TFDDVQAPNY TQHTSSMRGV YYPDEIFRSD TLYLTQDLFL
     PFYSNVTGFH TINHTFGNPV IPFKDGIYFA ATEKSNVVRG WVFGSTMNNK SQSVIIINNS
     TNVVIRACNF ELCDNPFFAV SKPMGTQTHT MIFDNAFNCT FEYISDAFSL DVSEKSGNFK
     HLREFVFKNK DGFLYVYKGY QPIDVVRDLP SGFNTLKPIF KLPLGINITN FRAILTAFSP
     AQDIWGTSAA AYFVGYLKPT TFMLKYDENG TITDAVDCSQ NPLAELKCSV KSFEIDKGIY
     QTSNFRVVPS GDVVRFPNIT NLCPFGEVFN ATKFPSVYAW ERKKISNCVA DYSVLYNSTF
     FSTFKCYGVS ATKLNDLCFS NVYADSFVVK GDDVRQIAPG QTGVIADYNY KLPDDFMGCV
     LAWNTRNIDA TSTGNYNYKY RYLRHGKLRP FERDISNVPF SPDGKPCTPP ALNCYWPLND
     YGFYTTTGIG YQPYRVVVLS FELLNAPATV CGPKLSTDLI KNQCVNFNFN GLTGTGVLTP
     SSKRFQPFQQ FGRDVSDFTD SVRDPKTSEI LDISPCSFGG VSVITPGTNA SSEVAVLYQD
     VNCTDVSTAI HADQLTPAWR IYSTGNNVFQ TQAGCLIGAE HVDTSYECDI PIGAGICASY
     HTVSLLRSTS QKSIVAYTMS LGADSSIAYS NNTIAIPTNF SISITTEVMP VSMAKTSVDC
     NMYICGDSTE CANLLLQYGS FCTQLNRALS GIAAEQDRNT REVFAQVKQM YKTPTLKYFG
     GFNFSQILPD PLKPTKRSFI EDLLFNKVTL ADAGFMKQYG ECLGDINARD LICAQKFNGL
     TVLPPLLTDD MIAAYTAALV SGTATAGWTF GAGAALQIPF AMQMAYRFNG IGVTQNVLYE
     NQKQIANQFN KAISQIQESL TTTSTALGKL QDVVNQNAQA LNTLVKQLSS NFGAISSVLN
     DILSRLDKVE AEVQIDRLIT GRLQSLQTYV TQQLIRAAEI RASANLAATK MSECVLGQSK
     RVDFCGKGYH LMSFPQAAPH GVVFLHVTYV PSQERNFTTA PAICHEGKAY FPREGVFVFN
     GTSWFITQRN FFSPQIITTD NTFVSGNCDV VIGIINNTVY DPLQPELDSF KEELDKYFKN
     HTSPDVDLGD ISGINASVVN IQKEIDRLNE VAKNLNESLI DLQELGKYEQ YIKWPWYVWL
     GFIAGLIAIV MVTILLCCMT SCCSCLKGAC SCGSCCKFDE DDSEPVLKGV KLHYT
//
ID   NCAP_SARS               Reviewed;         422 AA.
AC   P59595; Q7T3Z4; Q7TA14; Q7TF99; Q80E50;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 1.
DT   12-AUG-2020, entry version 124.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096}; ORFNames=9a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, and Isolate HKU-36871;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   "Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China.";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   "Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection.";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   "Mechanisms and enzymes involved in SARS coronavirus genome expression.";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RA   Sun K., Anwar A., Gupta V., Tabiin M.T., Atkinson R., Chandrasekarn A.,
RA   August T.J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   "Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization.";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   "Genomic sequence of SARS isolate from the first fatal case in Taiwan.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RT   "The complete genome of SARS coronavirus TWH.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC2, and Isolate TWC3;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee H.-C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chen P.-J., Su I.-J.;
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   INTERACTION WITH MEMBRANE PROTEIN M.
RX   PubMed=15351485; DOI=10.1016/j.virusres.2004.05.002;
RA   He R., Leeson A., Ballantine M., Andonov A., Baker L., Dobie F., Li Y.,
RA   Bastien N., Feldmann H., Strocher U., Theriault S., Cutts T., Cao J.,
RA   Booth T.F., Plummer F.A., Tyler S., Li X.;
RT   "Characterization of protein-protein interactions between the nucleocapsid
RT   protein and membrane protein of the SARS coronavirus.";
RL   Virus Res. 105:121-125(2004).
RN   [22]
RP   INTERACTION WITH HOST HNRNPA1.
RX   PubMed=15862300; DOI=10.1016/j.febslet.2005.03.080;
RA   Luo H., Chen Q., Chen J., Chen K., Shen X., Jiang H.;
RT   "The nucleocapsid protein of SARS coronavirus has a high binding affinity
RT   to the human cellular heterogeneous nuclear ribonucleoprotein A1.";
RL   FEBS Lett. 579:2623-2628(2005).
RN   [23]
RP   INTERACTION WITH HOST PPIA.
RX   PubMed=15688292; DOI=10.1086/427811;
RA   Chen Z., Mi L., Xu J., Yu J., Wang X., Jiang J., Xing J., Shang P.,
RA   Qian A., Li Y., Shaw P.X., Wang J., Duan S., Ding J., Fan C., Zhang Y.,
RA   Yang Y., Yu X., Feng Q., Li B., Yao X., Zhang Z., Li L., Xue X., Zhu P.;
RT   "Function of HAb18G/CD147 in invasion of host cells by severe acute
RT   respiratory syndrome coronavirus.";
RL   J. Infect. Dis. 191:755-760(2005).
RN   [24]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=17210170; DOI=10.1016/j.virol.2006.11.027;
RA   Stertz S., Reichelt M., Spiegel M., Kuri T., Martinez-Sobrido L.,
RA   Garcia-Sastre A., Weber F., Kochs G.;
RT   "The intracellular sites of early replication and budding of SARS-
RT   coronavirus.";
RL   Virology 361:304-315(2007).
RN   [25]
RP   INTERACTION WITH HOST SMAD3, AND FUNCTION.
RX   PubMed=18055455; DOI=10.1074/jbc.m708033200;
RA   Zhao X., Nicholls J.M., Chen Y.G.;
RT   "Severe acute respiratory syndrome-associated coronavirus nucleocapsid
RT   protein interacts with Smad3 and modulates transforming growth factor-beta
RT   signaling.";
RL   J. Biol. Chem. 283:3272-3280(2008).
RN   [26]
RP   PHOSPHORYLATION AT SER-177 BY HOST GSK3A AND GSK3B, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19106108; DOI=10.1074/jbc.m805747200;
RA   Wu C.H., Yeh S.H., Tsay Y.G., Shieh Y.H., Kao C.L., Chen Y.S., Wang S.H.,
RA   Kuo T.J., Chen D.S., Chen P.J.;
RT   "Glycogen synthase kinase-3 regulates the phosphorylation of severe acute
RT   respiratory syndrome coronavirus nucleocapsid protein and viral
RT   replication.";
RL   J. Biol. Chem. 284:5229-5239(2009).
RN   [27]
RP   INTERACTION WITH ENVELOPE SMALL MEMBRANE PROTEIN E.
RX   PubMed=24766657; DOI=10.1186/1423-0127-21-34;
RA   Tseng Y.T., Wang S.M., Huang K.J., Wang C.T.;
RT   "SARS-CoV envelope protein palmitoylation or nucleocapid association is not
RT   required for promoting virus-like particle production.";
RL   J. Biomed. Sci. 21:34-34(2014).
RN   [28]
RP   STRUCTURE BY NMR OF 45-181.
RX   PubMed=15147189; DOI=10.1021/bi036155b;
RA   Huang Q., Yu L., Petros A.M., Gunasekera A., Liu Z., Xu N., Hajduk P.,
RA   Mack J., Fesik S.W., Olejniczak E.T.;
RT   "Structure of the N-terminal RNA-binding domain of the SARS CoV
RT   nucleocapsid protein.";
RL   Biochemistry 43:6059-6063(2004).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 362-370.
RX   PubMed=16041067; DOI=10.1107/s0907444905013090;
RA   Blicher T., Kastrup J.S., Buus S., Gajhede M.;
RT   "High-resolution structure of HLA-A*1101 in complex with SARS nucleocapsid
RT   peptide.";
RL   Acta Crystallogr. D 61:1031-1040(2005).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 270-370.
RX   PubMed=16627473; DOI=10.1074/jbc.m602107200;
RA   Yu I.M., Oldham M.L., Zhang J., Chen J.;
RT   "Crystal structure of the severe acute respiratory syndrome (SARS)
RT   coronavirus nucleocapsid protein dimerization domain reveals evolutionary
RT   linkage between corona- and arteriviridae.";
RL   J. Biol. Chem. 281:17134-17139(2006).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 248-365.
RX   PubMed=17379242; DOI=10.1016/j.jmb.2007.02.069;
RA   Chen C.Y., Chang C.K., Chang Y.W., Sue S.C., Bai H.I., Riang L.,
RA   Hsiao C.D., Huang T.H.;
RT   "Structure of the SARS coronavirus nucleocapsid protein RNA-binding
RT   dimerization domain suggests a mechanism for helical packaging of viral
RT   RNA.";
RL   J. Mol. Biol. 368:1075-1086(2007).
RN   [32]
RP   RNA-BINDING, AND X-RAY CRYSTALLOGRAPHY (1.17 ANGSTROMS) OF 49-129.
RC   STRAIN=Isolate Tor2;
RX   PubMed=17229691; DOI=10.1128/jvi.02236-06;
RA   Saikatendu K.S., Joseph J.S., Subramanian V., Neuman B.W., Buchmeier M.J.,
RA   Stevens R.C., Kuhn P.;
RT   "Ribonucleocapsid formation of severe acute respiratory syndrome
RT   coronavirus through molecular action of the N-terminal domain of N
RT   protein.";
RL   J. Virol. 81:3913-3921(2007).
RN   [33]
RP   STRUCTURE BY NMR OF 248-365.
RX   PubMed=18561946; DOI=10.1016/j.jmb.2007.11.093;
RA   Takeda M., Chang C.K., Ikeya T., Guentert P., Chang Y.H., Hsu Y.L.,
RA   Huang T.H., Kainosho M.;
RT   "Solution structure of the c-terminal dimerization domain of SARS
RT   coronavirus nucleocapsid protein solved by the SAIL-NMR method.";
RL   J. Mol. Biol. 380:608-622(2008).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 346-354.
RX   PubMed=20844028; DOI=10.1128/jvi.01464-10;
RA   Liu J., Wu P., Gao F., Qi J., Kawana-Tachikawa A., Xie J., Vavricka C.J.,
RA   Iwamoto A., Li T., Gao G.F.;
RT   "Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-
RT   restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen
RT   bonds from severe acute respiratory syndrome coronavirus nucleocapsid
RT   protein.";
RL   J. Virol. 84:11849-11857(2010).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M. Plays an important role in enhancing the efficiency of
CC       subgenomic viral RNA transcription as well as viral replication
CC       (PubMed:17210170). May modulate transforming growth factor-beta
CC       signaling by binding host SMAD3 (PubMed:18055455). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:17210170,
CC       ECO:0000269|PubMed:18055455}.
CC   -!- SUBUNIT: Homooligomer. Both monomeric and oligomeric forms interact
CC       with RNA. Interacts with protein M (PubMed:15351485). Interacts with
CC       protein E (PubMed:24766657). May bind to host HNRNPA1 (Probable).
CC       Interacts with NSP3; this interaction serves to tether the genome to
CC       the newly translated replicase-transcriptase complex at a very early
CC       stage of infection (By similarity). May interact with host SMAD3
CC       (Probable). Interacts with host PPIA/CYPA (PubMed:15688292).
CC       {ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:15351485,
CC       ECO:0000269|PubMed:15688292, ECO:0000269|PubMed:24766657,
CC       ECO:0000305|PubMed:15862300, ECO:0000305|PubMed:18055455}.
CC   -!- INTERACTION:
CC       P59595; P59596: M; NbExp=2; IntAct=EBI-7602718, EBI-25487824;
CC       P59595; P59595: N; NbExp=17; IntAct=EBI-7602718, EBI-7602718;
CC       P59595; Q05639: EEF1A2; Xeno; NbExp=10; IntAct=EBI-7602718, EBI-354943;
CC       P59595; P62937: PPIA; Xeno; NbExp=2; IntAct=EBI-7602718, EBI-437708;
CC       P59595; P63279: UBE2I; Xeno; NbExp=12; IntAct=EBI-7602718, EBI-80168;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096,
CC       ECO:0000269|PubMed:17210170, ECO:0000269|PubMed:19106108}. Host
CC       endoplasmic reticulum-Golgi intermediate compartment
CC       {ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:17210170}. Host
CC       Golgi apparatus {ECO:0000255|HAMAP-Rule:MF_04096,
CC       ECO:0000269|PubMed:17210170}. Host cytoplasm, host perinuclear region
CC       {ECO:0000269|PubMed:17210170}. Note=Located inside the virion,
CC       complexed with the viral RNA. Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine and threonine residues (By similarity).
CC       Phosphorylated by host GSK3A and GSK3B. Phosphorylation allows
CC       recruitment of host RNA helicase DDX1 which facilitates template
CC       readthrough and enables longer subgenomic mRNA synthesis.
CC       {ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:19106108,
CC       ECO:0000269|PubMed:24766657}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13445.1; -; Genomic_RNA.
DR   EMBL; AY274119; AAP41047.1; -; Genomic_RNA.
DR   EMBL; AY278554; AAP13814.1; -; Genomic_RNA.
DR   EMBL; AY282752; AAP30714.1; -; Genomic_RNA.
DR   EMBL; AY304492; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY304495; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283794; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283795; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283796; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283797; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; AAP30037.1; -; Genomic_RNA.
DR   EMBL; AY278489; AAP51234.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37024.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50495.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33707.1; -; Genomic_RNA.
DR   EMBL; AY307165; AAP49024.1; -; Genomic_RNA.
DR   EMBL; AY290752; AAP44772.1; -; Genomic_RNA.
DR   EMBL; AY321118; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY322208; AAP82974.1; -; Genomic_RNA.
DR   EMBL; AY338174; AAQ01605.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01617.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97890.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81358.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81372.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81386.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81400.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81414.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72984.1; -; Genomic_RNA.
DR   EMBL; AY362698; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY362699; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY427439; AAQ94070.1; -; Genomic_RNA.
DR   RefSeq; NP_828858.1; NC_004718.3.
DR   PDB; 1SSK; NMR; -; A=45-181.
DR   PDB; 1X7Q; X-ray; 1.45 A; C=362-370.
DR   PDB; 2CJR; X-ray; 2.50 A; A/B/C/D/E/F/G/H=248-365.
DR   PDB; 2GIB; X-ray; 1.75 A; A/B=270-370.
DR   PDB; 2JW8; NMR; -; A/B=248-365.
DR   PDB; 2OFZ; X-ray; 1.17 A; A=49-174.
DR   PDB; 2OG3; X-ray; 1.85 A; A=49-174.
DR   PDB; 3I6L; X-ray; 2.40 A; F=346-354.
DR   PDB; 6IEX; X-ray; 2.31 A; C=216-225.
DR   PDBsum; 1SSK; -.
DR   PDBsum; 1X7Q; -.
DR   PDBsum; 2CJR; -.
DR   PDBsum; 2GIB; -.
DR   PDBsum; 2JW8; -.
DR   PDBsum; 2OFZ; -.
DR   PDBsum; 2OG3; -.
DR   PDBsum; 3I6L; -.
DR   PDBsum; 6IEX; -.
DR   SMR; P59595; -.
DR   BioGRID; 4383916; 14.
DR   ComplexPortal; CPX-5720; SARS-CoV nucleocapsid complex.
DR   IntAct; P59595; 5.
DR   MINT; P59595; -.
DR   iPTMnet; P59595; -.
DR   PRIDE; P59595; -.
DR   ABCD; P59595; 11 sequenced antibodies.
DR   GeneID; 1489678; -.
DR   KEGG; vg:1489678; -.
DR   KO; K24106; -.
DR   SIGNOR; P59595; -.
DR   EvolutionaryTrace; P59595; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0044177; C:host cell Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0019013; C:viral nucleocapsid; IEA:UniProtKB-UniRule.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   DisProt; DP00948; -.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; Corona_nucleoca; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF103068; SSF103068; 1.
DR   SUPFAM; SSF110304; SSF110304; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Host Golgi apparatus;
KW   Host-virus interaction; Phosphoprotein; Reference proteome;
KW   Ribonucleoprotein; RNA-binding; Transcription; Transcription regulation;
KW   Viral nucleoprotein; Virion.
FT   CHAIN           1..422
FT                   /note="Nucleoprotein"
FT                   /id="PRO_0000106003"
FT   DOMAIN          49..176
FT                   /note="CoV N NTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01276"
FT   DOMAIN          248..365
FT                   /note="CoV N CTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01277"
FT   REGION          42..187
FT                   /note="RNA-binding"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04096"
FT   REGION          45..181
FT                   /note="RNA-binding"
FT   REGION          259..362
FT                   /note="Dimerization"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04096"
FT   COMPBIAS        181..213
FT                   /note="Ser-rich"
FT   COMPBIAS        220..225
FT                   /note="Poly-Leu"
FT   COMPBIAS        240..245
FT                   /note="Poly-Gln"
FT   COMPBIAS        370..376
FT                   /note="Poly-Lys"
FT   MOD_RES         177
FT                   /note="Phosphoserine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04096,
FT                   ECO:0000269|PubMed:19106108"
FT   VARIANT         50
FT                   /note="T -> I (in strain: Isolate Frankfurt 1 and Isolate
FT                   FRA)"
FT   VARIANT         154
FT                   /note="N -> Y (in strain: Isolate BJ03)"
FT   VARIANT         193
FT                   /note="G -> C (in strain: Isolate CUHK-Su10)"
FT   VARIANT         325..326
FT                   /note="VT -> AA (in strain: Isolate Shanghai LY)"
FT   STRAND          56..59
FT                   /evidence="ECO:0000244|PDB:1SSK"
FT   STRAND          61..63
FT                   /evidence="ECO:0000244|PDB:2OG3"
FT   STRAND          77..79
FT                   /evidence="ECO:0000244|PDB:1SSK"
FT   HELIX           81..83
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   STRAND          85..91
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   STRAND          94..96
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   TURN            98..100
FT                   /evidence="ECO:0000244|PDB:1SSK"
FT   STRAND          102..104
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   STRAND          108..113
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   TURN            118..121
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   STRAND          131..135
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   STRAND          140..142
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   TURN            145..147
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   TURN            152..154
FT                   /evidence="ECO:0000244|PDB:2OFZ"
FT   STRAND          254..258
FT                   /evidence="ECO:0000244|PDB:2CJR"
FT   HELIX           260..262
FT                   /evidence="ECO:0000244|PDB:2CJR"
FT   HELIX           271..275
FT                   /evidence="ECO:0000244|PDB:2GIB"
FT   TURN            282..284
FT                   /evidence="ECO:0000244|PDB:2JW8"
FT   HELIX           290..295
FT                   /evidence="ECO:0000244|PDB:2GIB"
FT   HELIX           296..298
FT                   /evidence="ECO:0000244|PDB:2GIB"
FT   HELIX           302..306
FT                   /evidence="ECO:0000244|PDB:2GIB"
FT   HELIX           312..318
FT                   /evidence="ECO:0000244|PDB:2GIB"
FT   STRAND          319..325
FT                   /evidence="ECO:0000244|PDB:2GIB"
FT   STRAND          330..340
FT                   /evidence="ECO:0000244|PDB:2GIB"
FT   HELIX           347..357
FT                   /evidence="ECO:0000244|PDB:2GIB"
FT   HELIX           360..363
FT                   /evidence="ECO:0000244|PDB:2GIB"
SQ   SEQUENCE   422 AA;  46025 MW;  43FC8750F1253034 CRC64;
     MSDNGPQSNQ RSAPRITFGG PTDSTDNNQN GGRNGARPKQ RRPQGLPNNT ASWFTALTQH
     GKEELRFPRG QGVPINTNSG PDDQIGYYRR ATRRVRGGDG KMKELSPRWY FYYLGTGPEA
     SLPYGANKEG IVWVATEGAL NTPKDHIGTR NPNNNAATVL QLPQGTTLPK GFYAEGSRGG
     SQASSRSSSR SRGNSRNSTP GSSRGNSPAR MASGGGETAL ALLLLDRLNQ LESKVSGKGQ
     QQQGQTVTKK SAAEASKKPR QKRTATKQYN VTQAFGRRGP EQTQGNFGDQ DLIRQGTDYK
     HWPQIAQFAP SASAFFGMSR IGMEVTPSGT WLTYHGAIKL DDKDPQFKDN VILLNKHIDA
     YKTFPPTEPK KDKKKKTDEA QPLPQRQKKQ PTVTLLPAAD MDDFSRQLQN SMSGASADST
     QA
//
ID   AP3A_SARS               Reviewed;         274 AA.
AC   P59632; Q7T6R6; Q7TA10; Q7TA18; Q7TFB0; Q7TLD0; Q80BV5;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 1.
DT   12-AUG-2020, entry version 97.
DE   RecName: Full=ORF3a protein;
DE   AltName: Full=Accessory protein 3a;
DE   AltName: Full=Protein 3a;
DE   AltName: Full=Protein U274;
DE   AltName: Full=Protein X1;
GN   ORFNames=3a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RT   "The complete genome of SARS coronavirus TWH.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   "Analysis of SARS coronavirus genome in Shanghai isolates.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-125.
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   IDENTIFICATION.
RX   PubMed=15135062; DOI=10.1016/j.febslet.2004.03.086;
RA   Yu C.-J., Chen Y.-C., Hsiao C.-H., Kuo T.-C., Chang S.C., Lu C.-Y.,
RA   Wei W.-C., Lee C.-H., Huang L.-M., Chang M.-F., Ho H.-N., Lee F.-J.S.;
RT   "Identification of a novel protein 3a from severe acute respiratory
RT   syndrome coronavirus.";
RL   FEBS Lett. 565:111-116(2004).
RN   [16]
RP   SUBCELLULAR LOCATION, TOPOLOGY, AND INTERACTION WITH M PROTEIN; E PROTEIN;
RP   SPIKE GLYCOPROTEIN AND ACCESSORY PROTEIN 7A.
RX   PubMed=15194747; DOI=10.1128/jvi.78.13.6723-6734.2004;
RA   Tan Y.-J., Teng E., Shen S., Tan T.H.P., Goh P.-Y., Fielding B.C.,
RA   Ooi E.-E., Tan H.-C., Lim S.G., Hong W.;
RT   "A novel severe acute respiratory syndrome coronavirus protein, U274, is
RT   transported to the cell surface and undergoes endocytosis.";
RL   J. Virol. 78:6723-6734(2004).
RN   [17]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH M AND E PROTEINS.
RX   PubMed=15763150; DOI=10.1016/j.virusres.2005.01.001;
RA   Yuan X., Li J., Shan Y., Yang Z., Zhao Z., Chen B., Yao Z., Dong B.,
RA   Wang S., Chen J., Cong Y.;
RT   "Subcellular localization and membrane association of SARS-CoV 3a
RT   protein.";
RL   Virus Res. 109:191-202(2005).
RN   [18]
RP   CHARACTERIZATION.
RX   PubMed=15781262; DOI=10.1016/j.bbrc.2005.02.153;
RA   Shen S., Lin P.S., Chao Y.C., Zhang A., Yang X., Lim S.G., Hong W.,
RA   Tan Y.J.;
RT   "The severe acute respiratory syndrome coronavirus 3a is a novel structural
RT   protein.";
RL   Biochem. Biophys. Res. Commun. 330:286-292(2005).
RN   [19]
RP   CHARACTERIZATION, AND SUBCELLULAR LOCATION.
RX   PubMed=15709039; DOI=10.1128/jvi.79.5.3182-3186.2005;
RA   Ito N., Mossel E.C., Narayanan K., Popov V.L., Huang C., Inoue T.,
RA   Peters C.J., Makino S.;
RT   "Severe acute respiratory syndrome coronavirus 3a protein is a viral
RT   structural protein.";
RL   J. Virol. 79:3182-3186(2005).
RN   [20]
RP   FUNCTION.
RX   PubMed=16014971; DOI=10.1128/jvi.79.15.10083-10087.2005;
RA   Tan Y.J., Tham P.Y., Chan D.Z., Chou C.-F., Shen S., Fielding B.C.,
RA   Tan T.H., Lim S.G., Hong W.;
RT   "The severe acute respiratory syndrome coronavirus 3a protein up-regulates
RT   expression of fibrinogen in lung epithelial cells.";
RL   J. Virol. 79:10083-10087(2005).
RN   [21]
RP   FUNCTION.
RX   PubMed=15958670; DOI=10.1099/vir.0.80813-0;
RA   Law P.T., Wong C.H., Au T.C., Chuck C.P., Kong S.K., Chan P.K., To K.F.,
RA   Lo A.W., Chan J.Y., Suen Y.K., Chan H.Y., Fung K.P., Waye M.M., Sung J.J.,
RA   Lo Y.M.D., Tsui S.K.W.;
RT   "The 3a protein of severe acute respiratory syndrome-associated coronavirus
RT   induces apoptosis in Vero E6 cells.";
RL   J. Gen. Virol. 86:1921-1930(2005).
RN   [22]
RP   GLYCOSYLATION, AND MUTAGENESIS OF SER-27; THR-28; THR-32 AND THR-34.
RX   PubMed=16474139; DOI=10.1128/jvi.80.5.2326-2336.2006;
RA   Oostra M., de Haan C.A., de Groot R.J., Rottier P.J.M.;
RT   "Glycosylation of the severe acute respiratory syndrome coronavirus triple-
RT   spanning membrane proteins 3a and M.";
RL   J. Virol. 80:2326-2336(2006).
RN   [23]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16352545; DOI=10.1128/jvi.80.1.210-217.2006;
RA   Huang C., Narayanan K., Ito N., Peters C.J., Makino S.;
RT   "Severe acute respiratory syndrome coronavirus 3a protein is released in
RT   membranous structures from 3a protein-expressing cells and infected
RT   cells.";
RL   J. Virol. 80:210-217(2006).
RN   [24]
RP   FUNCTION, SUBUNIT, AND MUTAGENESIS OF CYS-81; CYS-117; CYS-121; CYS-127;
RP   CYS-130; CYS-133; CYS-148 AND CYS-157.
RX   PubMed=16894145; DOI=10.1073/pnas.0605402103;
RA   Lu W., Zheng B.-J., Xu K., Schwarz W., Du L., Wong C.K.L., Chen J.,
RA   Duan S., Deubel V., Sun B.;
RT   "Severe acute respiratory syndrome-associated coronavirus 3a protein forms
RT   an ion channel and modulates virus release.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:12540-12545(2006).
RN   [25]
RP   FUNCTION.
RX   PubMed=20020050; DOI=10.1371/journal.pone.0008342;
RA   Minakshi R., Padhan K., Rani M., Khan N., Ahmad F., Jameel S.;
RT   "The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and
RT   induces ligand-independent downregulation of the type 1 interferon
RT   receptor.";
RL   PLoS ONE 4:E8342-E8342(2009).
CC   -!- FUNCTION: Forms homotetrameric potassium sensitive ion channels
CC       (viroporin) and may modulate virus release. Up-regulates expression of
CC       fibrinogen subunits FGA, FGB and FGG in host lung epithelial cells.
CC       Induces apoptosis in cell culture. Downregulates the type 1 interferon
CC       receptor by inducing serine phosphorylation within the IFN alpha-
CC       receptor subunit 1 (IFNAR1) degradation motif and increasing IFNAR1
CC       ubiquitination. {ECO:0000269|PubMed:15958670,
CC       ECO:0000269|PubMed:16014971, ECO:0000269|PubMed:16894145,
CC       ECO:0000269|PubMed:20020050}.
CC   -!- SUBUNIT: Homotetramer composed of two homodimers linked non covalently.
CC       Interacts with M, S and E proteins. Also interacts with the accessory
CC       protein 7a. {ECO:0000269|PubMed:15194747, ECO:0000269|PubMed:15763150,
CC       ECO:0000269|PubMed:16894145}.
CC   -!- INTERACTION:
CC       P59632; PRO_0000037310 [P0C6X7]: rep; NbExp=2; IntAct=EBI-15595051, EBI-25474098;
CC       P59632; P33724: CAV1; Xeno; NbExp=5; IntAct=EBI-15595051, EBI-79998;
CC   -!- SUBCELLULAR LOCATION: Virion. Host Golgi apparatus membrane; Multi-pass
CC       membrane protein. Host cell membrane; Multi-pass membrane protein.
CC       Secreted. Host cytoplasm. Note=The cell surface expressed protein can
CC       undergo endocytosis. The protein is secreted in association with
CC       membranous structures.
CC   -!- DOMAIN: The second or the third transmembrane region are responsible
CC       for Golgi localization.
CC   -!- PTM: Exists in both O-glycosylated and non-glycosylated forms. The
CC       glycosylated form is associated with the virion.
CC       {ECO:0000269|PubMed:16474139}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13446.1; -; Genomic_RNA.
DR   EMBL; AY274119; AAP41038.1; -; Genomic_RNA.
DR   EMBL; AY282752; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278554; AAP13568.1; -; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; AAP30031.1; -; Genomic_RNA.
DR   EMBL; AY278489; AAP51228.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37018.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50486.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33698.1; -; Genomic_RNA.
DR   EMBL; AY338174; AAQ01598.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01610.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97883.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81349.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81363.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81377.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81391.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81405.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72975.1; -; Genomic_RNA.
DR   EMBL; AY427439; AAQ94061.1; -; Genomic_RNA.
DR   EMBL; AY463059; AAP82984.2; -; Genomic_RNA.
DR   EMBL; AY322207; AAP82969.1; -; Genomic_RNA.
DR   RefSeq; NP_828852.2; NC_004718.3.
DR   SMR; P59632; -.
DR   BioGRID; 4383917; 11.
DR   DIP; DIP-61251N; -.
DR   IntAct; P59632; 3.
DR   TCDB; 1.A.57.1.1; the human sars caronavirus viroporin (sars-vp).
DR   GlyGen; P59632; 4 sites.
DR   iPTMnet; P59632; -.
DR   PRIDE; P59632; -.
DR   GeneID; 1489669; -.
DR   KEGG; vg:1489669; -.
DR   SIGNOR; P59632; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000164441; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0044385; C:integral to membrane of host cell; IEA:UniProtKB-KW.
DR   GO; GO:0019012; C:virion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:UniProtKB-KW.
DR   GO; GO:0039707; P:pore formation by virus in membrane of host cell; IEA:UniProtKB-KW.
DR   GO; GO:0051259; P:protein complex oligomerization; IEA:UniProtKB-KW.
DR   GO; GO:0039511; P:suppression by virus of host interferon receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:suppression by virus of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR024407; Protein_3a_bCoV.
DR   Pfam; PF11289; APA3_viroporin; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; Glycoprotein; Host cell membrane; Host cytoplasm;
KW   Host Golgi apparatus; Host membrane; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon receptors by virus;
KW   Inhibition of host interferon signaling pathway by virus; Ion channel;
KW   Ion transport; Membrane; Reference proteome; Secreted; Transmembrane;
KW   Transmembrane helix; Transport; Viral immunoevasion; Viral ion channel;
KW   Virion.
FT   CHAIN           1..274
FT                   /note="ORF3a protein"
FT                   /id="PRO_0000106131"
FT   TOPO_DOM        1..34
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:15194747"
FT   TRANSMEM        35..55
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        56..78
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        79..99
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        100..104
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        105..125
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        126..274
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:15194747"
FT   COMPBIAS        83..86
FT                   /note="Poly-Leu"
FT   COMPBIAS        267..270
FT                   /note="Poly-Thr"
FT   SITE            133
FT                   /note="Involved in polymerization"
FT   CARBOHYD        27
FT                   /note="O-linked (GalNAc...) serine; by host"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        28
FT                   /note="O-linked (GalNAc...) threonine; by host"
FT                   /evidence="ECO:0000305|PubMed:16474139"
FT   CARBOHYD        32
FT                   /note="O-linked (GalNAc...) threonine; by host"
FT                   /evidence="ECO:0000305|PubMed:16474139"
FT   CARBOHYD        34
FT                   /note="O-linked (GalNAc...) threonine; by host"
FT                   /evidence="ECO:0000255"
FT   VARIANT         11
FT                   /note="G -> R (in strain: Isolate Tor2, Isolate BJ02 and
FT                   Isolate BJ03)"
FT   VARIANT         20
FT                   /note="I -> T (in strain: Isolate Shanghai LY)"
FT   VARIANT         29
FT                   /note="V -> A (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         101
FT                   /note="M -> K (in strain: Isolate HKU-39849)"
FT   VARIANT         129
FT                   /note="L -> F (in strain: Isolate TWK)"
FT   VARIANT         136
FT                   /note="K -> Q (in strain: Isolate BJ01)"
FT   VARIANT         171
FT                   /note="E -> A (in strain: Isolate GD01)"
FT   VARIANT         193
FT                   /note="R -> W (in strain: Isolate GD01)"
FT   VARIANT         222
FT                   /note="D -> N (in strain: Isolate Shanghai QXC1)"
FT   MUTAGEN         27
FT                   /note="S->G: Complete loss of O-glycosylation; when
FT                   associated with A-28; A-32 and A-34."
FT                   /evidence="ECO:0000269|PubMed:16474139"
FT   MUTAGEN         28
FT                   /note="T->A: Complete loss of O-glycosylation; when
FT                   associated with A-27; A-32 and A-34."
FT                   /evidence="ECO:0000269|PubMed:16474139"
FT   MUTAGEN         32
FT                   /note="T->A: Complete loss of O-glycosylation; when
FT                   associated with A-27; A-28 and A-34."
FT                   /evidence="ECO:0000269|PubMed:16474139"
FT   MUTAGEN         34
FT                   /note="T->A: Complete loss of O-glycosylation; when
FT                   associated with A-27; A-28 and A-32."
FT                   /evidence="ECO:0000269|PubMed:16474139"
FT   MUTAGEN         81
FT                   /note="C->A: No effect on polymerization."
FT                   /evidence="ECO:0000269|PubMed:16894145"
FT   MUTAGEN         117
FT                   /note="C->A: No effect on polymerization."
FT                   /evidence="ECO:0000269|PubMed:16894145"
FT   MUTAGEN         121
FT                   /note="C->A: No effect on polymerization."
FT                   /evidence="ECO:0000269|PubMed:16894145"
FT   MUTAGEN         127
FT                   /note="C->A: No effect on polymerization."
FT                   /evidence="ECO:0000269|PubMed:16894145"
FT   MUTAGEN         130
FT                   /note="C->A: No effect on polymerization."
FT                   /evidence="ECO:0000269|PubMed:16894145"
FT   MUTAGEN         133
FT                   /note="C->A: Almost complete loss of polimerization
FT                   ability."
FT                   /evidence="ECO:0000269|PubMed:16894145"
FT   MUTAGEN         148
FT                   /note="C->A: No effect on polymerization."
FT                   /evidence="ECO:0000269|PubMed:16894145"
FT   MUTAGEN         157
FT                   /note="C->A: No effect on polymerization."
FT                   /evidence="ECO:0000269|PubMed:16894145"
SQ   SEQUENCE   274 AA;  30903 MW;  E48C7D44A4DE34FE CRC64;
     MDLFMRFFTL GSITAQPVKI DNASPASTVH ATATIPLQAS LPFGWLVIGV AFLAVFQSAT
     KIIALNKRWQ LALYKGFQFI CNLLLLFVTI YSHLLLVAAG MEAQFLYLYA LIYFLQCINA
     CRIIMRCWLC WKCKSKNPLL YDANYFVCWH THNYDYCIPY NSVTDTIVVT EGDGISTPKL
     KEDYQIGGYS EDRHSGVKDY VVVHGYFTEV YYQLESTQIT TDTGIENATF FIFNKLVKDP
     PNVQIHTIDG SSGVANPAMD PIYDEPTTTT SVPL
//
ID   NS7A_SARS               Reviewed;         122 AA.
AC   P59635; Q7TA11; Q7TA17;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 1.
DT   12-AUG-2020, entry version 103.
DE   RecName: Full=ORF7a protein;
DE   AltName: Full=Accessory protein 7a;
DE   AltName: Full=Protein U122;
DE   AltName: Full=Protein X4;
DE   Flags: Precursor;
GN   ORFNames=7a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RT   "The complete genome of SARS coronavirus TWH.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   "Analysis of SARS coronavirus genome in Shanghai isolates.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 32-122.
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   PEPTIDE SEQUENCE OF 16-29, SUBCELLULAR LOCATION, AND X-RAY CRYSTALLOGRAPHY
RP   (1.8 ANGSTROMS) OF 16-96.
RX   PubMed=15642263; DOI=10.1016/j.str.2004.10.010;
RA   Nelson C.A., Pekosz A., Lee C.A., Diamond M.S., Fremont D.H.;
RT   "Structure and intracellular targeting of the SARS-coronavirus Orf7a
RT   accessory protein.";
RL   Structure 13:75-85(2005).
RN   [16]
RP   INTERACTION WITH ACCESSORY PROTEIN 3A.
RX   PubMed=15194747; DOI=10.1128/jvi.78.13.6723-6734.2004;
RA   Tan Y.-J., Teng E., Shen S., Tan T.H.P., Goh P.-Y., Fielding B.C.,
RA   Ooi E.-E., Tan H.-C., Lim S.G., Hong W.;
RT   "A novel severe acute respiratory syndrome coronavirus protein, U274, is
RT   transported to the cell surface and undergoes endocytosis.";
RL   J. Virol. 78:6723-6734(2004).
RN   [17]
RP   SUBCELLULAR LOCATION, DI-LYSINE MOTIF, AND MUTAGENESIS OF 14-SER--TYR-18
RP   AND 118-LYS--LYS-120.
RX   PubMed=15220404; DOI=10.1128/jvi.78.14.7311-7318.2004;
RA   Fielding B.C., Tan Y.-J., Shuo S., Tan T.H.P., Ooi E.-E., Lim S.G.,
RA   Hong W., Goh P.-Y.;
RT   "Characterization of a unique group-specific protein (U122) of the severe
RT   acute respiratory syndrome coronavirus.";
RL   J. Virol. 78:7311-7318(2004).
RN   [18]
RP   FUNCTION.
RX   PubMed=15564512; DOI=10.1128/jvi.78.24.14043-14047.2004;
RA   Tan Y.-J., Fielding B.C., Goh P.-Y., Shen S., Tan T.H.P., Lim S.G.,
RA   Hong W.;
RT   "Overexpression of 7a, a protein specifically encoded by the severe acute
RT   respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent
RT   pathway.";
RL   J. Virol. 78:14043-14047(2004).
RN   [19]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH SPIKE GLYCOPROTEIN.
RX   PubMed=16840309; DOI=10.1128/jvi.00414-06;
RA   Huang C., Ito N., Tseng C.-T.K., Makino S.;
RT   "Severe acute respiratory syndrome coronavirus 7a accessory protein is a
RT   viral structural protein.";
RL   J. Virol. 80:7287-7294(2006).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17037516; DOI=10.1007/978-0-387-33012-9_20;
RA   Pekosz A., Schaecher S.R., Diamond M.S., Fremont D.H., Sims A.C.,
RA   Baric R.S.;
RT   "Structure, expression, and intracellular localization of the SARS-CoV
RT   accessory proteins 7a and 7b.";
RL   Adv. Exp. Med. Biol. 581:115-120(2006).
RN   [21]
RP   INTERACTION WITH M PROTEIN; E PROTEIN AND HUMAN SGT.
RX   PubMed=16580632; DOI=10.1016/j.bbrc.2006.03.091;
RA   Fielding B.C., Gunalan V., Tan T.H.P., Chou C.-F., Shen S., Khan S.,
RA   Lim S.G., Hong W., Tan Y.-J.;
RT   "Severe acute respiratory syndrome coronavirus protein 7a interacts with
RT   hSGT.";
RL   Biochem. Biophys. Res. Commun. 343:1201-1208(2006).
RN   [22]
RP   STRUCTURE BY NMR OF 16-99.
RX   PubMed=16328780; DOI=10.1007/s11373-005-9043-9;
RA   Haenel K., Stangler T., Stoldt M., Willbold D.;
RT   "Solution structure of the X4 protein coded by the SARS related coronavirus
RT   reveals an immunoglobulin like fold and suggests a binding activity to
RT   integrin I domains.";
RL   J. Biomed. Sci. 13:281-293(2006).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH HOST ITGAL.
RX   PubMed=18020948; DOI=10.1515/bc.2007.157;
RA   Haenel K., Willbold D.;
RT   "SARS-CoV accessory protein 7a directly interacts with human LFA-1.";
RL   Biol. Chem. 388:1325-1332(2007).
RN   [24]
RP   FUNCTION.
RX   PubMed=20631126; DOI=10.1128/jvi.00748-10;
RA   Karjee S., Minhas A., Sood V., Ponia S.S., Banerjea A.C., Chow V.T.,
RA   Mukherjee S.K., Lal S.K.;
RT   "The 7a accessory protein of severe acute respiratory syndrome coronavirus
RT   acts as an RNA silencing suppressor.";
RL   J. Virol. 84:10395-10401(2010).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH HOST BST2.
RX   PubMed=26378163; DOI=10.1128/jvi.02274-15;
RA   Taylor J.K., Coleman C.M., Postel S., Sisk J.M., Bernbaum J.G.,
RA   Venkataraman T., Sundberg E.J., Frieman M.B.;
RT   "Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow
RT   Stromal Antigen 2 Virion Tethering through a Novel Mechanism of
RT   Glycosylation Interference.";
RL   J. Virol. 89:11820-11833(2015).
CC   -!- FUNCTION: Plays a role as antagonist of host tetherin (BST2),
CC       disrupting its antiviral effect. Acts by binding to BST2 thereby
CC       interfering with its glycosylation. May suppress small interfering RNA
CC       (siRNA). May bind to host ITGAL, thereby playing a role in attachment
CC       or modulation of leukocytes. {ECO:0000269|PubMed:15564512,
CC       ECO:0000269|PubMed:18020948, ECO:0000269|PubMed:20631126,
CC       ECO:0000269|PubMed:26378163}.
CC   -!- SUBUNIT: Interacts with the spike glycoprotein (PubMed:16840309).
CC       Interacts with M protein (PubMed:16580632). Interacts with E protein
CC       (PubMed:16580632). Interacts with the ORF3a protein (PubMed:15194747).
CC       Interacts with human SGT (PubMed:16580632). Interacts with host ITGAL
CC       (PubMed:18020948). Interacts with host BST2 (PubMed:26378163).
CC       {ECO:0000269|PubMed:15194747, ECO:0000269|PubMed:16580632,
CC       ECO:0000269|PubMed:16840309, ECO:0000269|PubMed:18020948,
CC       ECO:0000269|PubMed:26378163}.
CC   -!- INTERACTION:
CC       P59635; O43765: SGTA; Xeno; NbExp=3; IntAct=EBI-25492879, EBI-347996;
CC   -!- SUBCELLULAR LOCATION: Virion. Host endoplasmic reticulum membrane;
CC       Single-pass membrane protein. Host endoplasmic reticulum-Golgi
CC       intermediate compartment membrane; Single-pass type I membrane protein.
CC       Host Golgi apparatus membrane; Single-pass membrane protein.
CC   -!- DOMAIN: The di-lysine motif confers endoplasmic reticulum localization
CC       for type I membrane proteins. {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13449.1; -; Genomic_RNA.
DR   EMBL; AY274119; AAP41043.1; -; Genomic_RNA.
DR   EMBL; AY282752; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278554; AAP13573.1; -; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; AAP30036.1; -; Genomic_RNA.
DR   EMBL; AY278489; AAP51233.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37023.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50491.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33703.1; -; Genomic_RNA.
DR   EMBL; AY338174; AAQ01603.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01615.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97888.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81354.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81368.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81382.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81396.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81410.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72980.1; -; Genomic_RNA.
DR   EMBL; AY427439; AAQ94066.1; -; Genomic_RNA.
DR   EMBL; AY463059; AAP82982.2; -; Genomic_RNA.
DR   EMBL; AY322208; AAP82970.1; -; Genomic_RNA.
DR   RefSeq; NP_828857.1; NC_004718.3.
DR   PDB; 1XAK; X-ray; 1.80 A; A=14-96.
DR   PDB; 1YO4; NMR; -; A=16-99.
DR   PDBsum; 1XAK; -.
DR   PDBsum; 1YO4; -.
DR   SMR; P59635; -.
DR   BioGRID; 4383920; 7.
DR   ELM; P59635; -.
DR   IntAct; P59635; 12.
DR   PRIDE; P59635; -.
DR   GeneID; 1489674; -.
DR   KEGG; vg:1489674; -.
DR   SIGNOR; P59635; -.
DR   EvolutionaryTrace; P59635; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000164441; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0044165; C:host cell endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044173; C:host cell endoplasmic reticulum-Golgi intermediate compartment membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044177; C:host cell Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019012; C:virion; IEA:UniProtKB-SubCell.
DR   GO; GO:0019051; P:induction by virus of host apoptotic process; IDA:DIBU.
DR   GO; GO:0039646; P:modulation by virus of host G0/G1 transition checkpoint; IEA:UniProtKB-KW.
DR   GO; GO:0039587; P:suppression by virus of host tetherin activity; IDA:UniProtKB.
DR   Gene3D; 2.60.40.1550; -; 1.
DR   InterPro; IPR014888; NS7A_CoV.
DR   InterPro; IPR036495; NS7A_sf_CoV.
DR   Pfam; PF08779; SARS_X4; 1.
DR   SUPFAM; SSF117066; SSF117066; 1.
DR   PROSITE; PS51919; X4E; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disulfide bond;
KW   G0/G1 host cell cycle checkpoint dysregulation by virus;
KW   Host endoplasmic reticulum; Host Golgi apparatus; Host membrane;
KW   Host-virus interaction; Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host tetherin by virus; Membrane;
KW   Modulation of host cell cycle by virus; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Viral immunoevasion; Virion.
FT   SIGNAL          1..15
FT   CHAIN           16..122
FT                   /note="ORF7a protein"
FT                   /id="PRO_0000037435"
FT   TOPO_DOM        16..96
FT                   /note="Virion surface"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        97..117
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        118..122
FT                   /note="Intravirion"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          16..81
FT                   /note="X4e"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01267"
FT   MOTIF           118..122
FT                   /note="Di-lysine motif"
FT   DISULFID        23..58
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01267"
FT   DISULFID        35..67
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01267"
FT   VARIANT         38
FT                   /note="G -> A (in strain: Isolate Shanghai LY)"
FT   MUTAGEN         14..18
FT                   /note="SCELY->LLLLL: Complete loss of signal sequence
FT                   cleavage."
FT                   /evidence="ECO:0000269|PubMed:15220404"
FT   MUTAGEN         118..120
FT                   /note="KRK->ERE: Induces rapid exit from the endoplasmic
FT                   reticulum."
FT                   /evidence="ECO:0000269|PubMed:15220404"
FT   STRAND          16..24
FT                   /evidence="ECO:0000244|PDB:1XAK"
FT   STRAND          27..32
FT                   /evidence="ECO:0000244|PDB:1XAK"
FT   STRAND          34..37
FT                   /evidence="ECO:0000244|PDB:1YO4"
FT   STRAND          39..44
FT                   /evidence="ECO:0000244|PDB:1XAK"
FT   TURN            50..52
FT                   /evidence="ECO:0000244|PDB:1XAK"
FT   STRAND          53..57
FT                   /evidence="ECO:0000244|PDB:1XAK"
FT   STRAND          60..66
FT                   /evidence="ECO:0000244|PDB:1XAK"
FT   STRAND          72..80
FT                   /evidence="ECO:0000244|PDB:1XAK"
FT   STRAND          82..84
FT                   /evidence="ECO:0000244|PDB:1YO4"
FT   STRAND          89..93
FT                   /evidence="ECO:0000244|PDB:1YO4"
FT   STRAND          95..97
FT                   /evidence="ECO:0000244|PDB:1YO4"
SQ   SEQUENCE   122 AA;  13941 MW;  6D8D8D949B0DB4B5 CRC64;
     MKIILFLTLI VFTSCELYHY QECVRGTTVL LKEPCPSGTY EGNSPFHPLA DNKFALTCTS
     THFAFACADG TRHTYQLRAR SVSPKLFIRQ EEVQQELYSP LFLIVAALVF LILCFTIKRK
     TE
//
ID   ORF9B_SARS              Reviewed;          98 AA.
AC   P59636; Q7T6R2;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 1.
DT   12-AUG-2020, entry version 93.
DE   RecName: Full=ORF9b protein;
DE   AltName: Full=Accessory protein 9b;
DE   AltName: Full=ORF-9b;
DE   AltName: Full=Protein 9b;
GN   ORFNames=9b;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   "Mechanisms and enzymes involved in SARS coronavirus genome expression.";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   "Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization.";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RT   "The complete genome of SARS coronavirus TWH.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   SUBCELLULAR LOCATION, AND REGION.
RX   PubMed=17448558; DOI=10.1016/j.virusres.2007.03.011;
RA   Moshynskyy I., Viswanathan S., Vasilenko N., Lobanov V., Petric M.,
RA   Babiuk L.A., Zakhartchouk A.N.;
RT   "Intracellular localization of the SARS coronavirus protein 9b: evidence of
RT   active export from the nucleus.";
RL   Virus Res. 127:116-121(2007).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19394665; DOI=10.1016/j.virol.2009.03.032;
RA   Xu K., Zheng B.J., Zeng R., Lu W., Lin Y.P., Xue L., Li L., Yang L.L.,
RA   Xu C., Dai J., Wang F., Li Q., Dong Q.X., Yang R.F., Wu J.R., Sun B.;
RT   "Severe acute respiratory syndrome coronavirus accessory protein 9b is a
RT   virion-associated protein.";
RL   Virology 388:279-285(2009).
RN   [15]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH HOST XPO1.
RX   PubMed=21637748; DOI=10.1371/journal.pone.0019436;
RA   Sharma K., Aakerstroem S., Sharma A.K., Chow V.T., Teow S., Abrenica B.,
RA   Booth S.A., Booth T.F., Mirazimi A., Lal S.K.;
RT   "SARS-CoV 9b protein diffuses into nucleus, undergoes active Crm1 mediated
RT   nucleocytoplasmic export and triggers apoptosis when retained in the
RT   nucleus.";
RL   PLoS ONE 6:e19436-e19436(2011).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH HOST MAVS.
RX   PubMed=25135833; DOI=10.4049/jimmunol.1303196;
RA   Shi C.S., Qi H.Y., Boularan C., Huang N.N., Abu-Asab M., Shelhamer J.H.,
RA   Kehrl J.H.;
RT   "SARS-coronavirus open reading frame-9b suppresses innate immunity by
RT   targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome.";
RL   J. Immunol. 193:3080-3089(2014).
RN   [17]
RP   INTERACTION WITH PROTEIN ORF6, AND SUBCELLULAR LOCATION.
RX   PubMed=22820404; DOI=10.1016/j.virusres.2012.07.012;
RA   Calvo E., DeDiego M.L., Garcia P., Lopez J.A., Perez-Brena P., Falcon A.;
RT   "Severe acute respiratory syndrome coronavirus accessory proteins 6 and 9b
RT   interact in vivo.";
RL   Virus Res. 169:282-288(2012).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 9-98, AND SUBCELLULAR LOCATION.
RX   PubMed=16843897; DOI=10.1016/j.str.2006.05.012;
RA   Meier C., Aricescu A.R., Assenberg R., Aplin R.T., Gilbert R.J.C.,
RA   Grimes J.M., Stuart D.I.;
RT   "The crystal structure of ORF-9b, a lipid binding protein from the SARS
RT   coronavirus.";
RL   Structure 14:1157-1165(2006).
CC   -!- FUNCTION: Plays a role in the inhibition of host innate immune response
CC       by targeting the mitochondrial-associated adapter MAVS.
CC       Mechanistically, usurps the E3 ligase ITCH to trigger the degradation
CC       of MAVS, TRAF3, and TRAF6. In addition, causes mitochondrial elongation
CC       by triggering ubiquitination and proteasomal degradation of dynamin-
CC       like protein 1/DNM1L. {ECO:0000269|PubMed:25135833}.
CC   -!- SUBUNIT: Homodimer. Interacts with host XPO1; this interaction mediates
CC       protein ORF9b export out of the nucleus (PubMed:21637748). Interacts
CC       with host MAVS (PubMed:25135833). Interacts with protein ORF6
CC       (PubMed:22820404). {ECO:0000269|PubMed:21637748,
CC       ECO:0000269|PubMed:22820404, ECO:0000269|PubMed:25135833}.
CC   -!- INTERACTION:
CC       P59636; P59636: 9b; NbExp=3; IntAct=EBI-9021274, EBI-9021274;
CC       P59636; Q7TLC7: ORF14; NbExp=3; IntAct=EBI-9021274, EBI-25488942;
CC       P59636; PRO_0000037320 [P0C6X7]: rep; NbExp=3; IntAct=EBI-9021274, EBI-25487328;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000269|PubMed:19394665}. Host
CC       cytoplasmic vesicle membrane {ECO:0000269|PubMed:16843897}; Peripheral
CC       membrane protein {ECO:0000269|PubMed:16843897}. Host cytoplasm
CC       {ECO:0000269|PubMed:16843897, ECO:0000269|PubMed:21637748,
CC       ECO:0000269|PubMed:22820404}. Host endoplasmic reticulum
CC       {ECO:0000269|PubMed:17448558}. Host nucleus
CC       {ECO:0000269|PubMed:21637748}. Host mitochondrion
CC       {ECO:0000269|PubMed:25135833}. Note=Binds non-covalently to
CC       intracellular lipid bilayers.
CC   -!- MISCELLANEOUS: The gene encoding this protein is included within the N
CC       gene (alternative ORF).
CC   -!- SIMILARITY: Belongs to the coronavirus group 2 protein 9b family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY274119; AAP41048.1; -; Genomic_RNA.
DR   EMBL; AY282752; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278554; AAP13574.1; -; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; AAP30038.1; -; Genomic_RNA.
DR   EMBL; AY278489; AAP51235.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37025.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50496.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33708.1; -; Genomic_RNA.
DR   EMBL; AY290752; AAP69659.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81359.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81373.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81387.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81401.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81415.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72985.1; -; Genomic_RNA.
DR   EMBL; AY427439; AAQ94071.1; -; Genomic_RNA.
DR   RefSeq; NP_828859.1; NC_004718.3.
DR   PDB; 2CME; X-ray; 2.80 A; A/B=9-98, E/G=9-98, C/D/F/H=10-98.
DR   PDBsum; 2CME; -.
DR   SMR; P59636; -.
DR   BioGRID; 4383924; 19.
DR   IntAct; P59636; 6.
DR   GeneID; 1489679; -.
DR   KEGG; vg:1489679; -.
DR   SIGNOR; P59636; -.
DR   EvolutionaryTrace; P59636; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0044162; C:host cell cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   InterPro; IPR037223; Protein_9b_SARS.
DR   InterPro; IPR018542; Protein_9b_SARS-like.
DR   Pfam; PF09399; SARS_lipid_bind; 1.
DR   SUPFAM; SSF141666; SSF141666; 1.
DR   PROSITE; PS51920; SARS_9B; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Host cytoplasm; Host cytoplasmic vesicle;
KW   Host endoplasmic reticulum; Host membrane; Host mitochondrion;
KW   Host nucleus; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host MAVS by virus; Inhibition of host RLR pathway by virus;
KW   Membrane; Reference proteome; Viral immunoevasion; Virion.
FT   CHAIN           1..98
FT                   /note="ORF9b protein"
FT                   /id="PRO_0000106137"
FT   DOMAIN          9..98
FT                   /note="9b"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01268"
FT   MOTIF           46..54
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000269|PubMed:17448558"
FT   VARIANT         58
FT                   /note="A -> V (in strain: Isolate TWK)"
FT   STRAND          14..23
FT                   /evidence="ECO:0000244|PDB:2CME"
FT   STRAND          42..47
FT                   /evidence="ECO:0000244|PDB:2CME"
FT   STRAND          54..60
FT                   /evidence="ECO:0000244|PDB:2CME"
FT   STRAND          65..67
FT                   /evidence="ECO:0000244|PDB:2CME"
FT   STRAND          69..74
FT                   /evidence="ECO:0000244|PDB:2CME"
FT   HELIX           85..87
FT                   /evidence="ECO:0000244|PDB:2CME"
FT   STRAND          90..97
FT                   /evidence="ECO:0000244|PDB:2CME"
SQ   SEQUENCE   98 AA;  10802 MW;  5166F22872915FCB CRC64;
     MDPNQTNVVP PALHLVDPQI QLTITRMEDA MGQGQNSADP KVYPIILRLG SQLSLSMARR
     NLDSLEARAF QSTPIVVQMT KLATTEELPD EFVVVTAK
//
ID   VEMP_SARS               Reviewed;          76 AA.
AC   P59637; Q7TA13; Q7TFA8;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 1.
DT   12-AUG-2020, entry version 95.
DE   RecName: Full=Envelope small membrane protein {ECO:0000255|HAMAP-Rule:MF_04204};
DE            Short=E protein {ECO:0000255|HAMAP-Rule:MF_04204};
DE            Short=sM protein {ECO:0000255|HAMAP-Rule:MF_04204};
GN   Name=E {ECO:0000255|HAMAP-Rule:MF_04204}; Synonyms=sM; ORFNames=4;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, and Isolate HKU-36871;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   "Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China.";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   "Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection.";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   "Mechanisms and enzymes involved in SARS coronavirus genome expression.";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   "Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization.";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Isolate ZJ01;
RA   Cong L.-M., Ding G.-Q., Lu Y.-Y., Weng J.-Q., Yan J.-Y., Hu N.-P.,
RA   Wo J.-E., Chen S.-Y., Zhang Y.-J., Mei L.-L., Wang Z.-G., Yao J.,
RA   Zhu H.-P., Lu Q.-Y., Li M.-H., Gong L.-M., Shi W., Li L.-J.;
RT   "SARS coronavirus ZJ01 isolate small envelope E protein.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   "Genomic sequence of SARS isolate from the first fatal case in Taiwan.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   "Analysis of SARS coronavirus genome in Shanghai isolates.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RT   "The complete genome of SARS coronavirus TWH.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC2, and Isolate TWC3;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee H.-C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chen P.-J., Su I.-J.;
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   INTERACTION WITH ACCESSORY PROTEIN 3A.
RX   PubMed=15194747; DOI=10.1128/jvi.78.13.6723-6734.2004;
RA   Tan Y.-J., Teng E., Shen S., Tan T.H.P., Goh P.-Y., Fielding B.C.,
RA   Ooi E.-E., Tan H.-C., Lim S.G., Hong W.;
RT   "A novel severe acute respiratory syndrome coronavirus protein, U274, is
RT   transported to the cell surface and undergoes endocytosis.";
RL   J. Virol. 78:6723-6734(2004).
RN   [22]
RP   INTERACTION WITH ACCESSORY PROTEIN 3A.
RX   PubMed=15763150; DOI=10.1016/j.virusres.2005.01.001;
RA   Yuan X., Li J., Shan Y., Yang Z., Zhao Z., Chen B., Yao Z., Dong B.,
RA   Wang S., Chen J., Cong Y.;
RT   "Subcellular localization and membrane association of SARS-CoV 3a
RT   protein.";
RL   Virus Res. 109:191-202(2005).
RN   [23]
RP   INTERACTION WITH ACCESSORY PROTEIN 7A.
RX   PubMed=16580632; DOI=10.1016/j.bbrc.2006.03.091;
RA   Fielding B.C., Gunalan V., Tan T.H.P., Chou C.-F., Shen S., Khan S.,
RA   Lim S.G., Hong W., Tan Y.-J.;
RT   "Severe acute respiratory syndrome coronavirus protein 7a interacts with
RT   hSGT.";
RL   Biochem. Biophys. Res. Commun. 343:1201-1208(2006).
RN   [24]
RP   INTERACTION WITH PROTEIN M.
RX   PubMed=19322648; DOI=10.1007/s11262-009-0341-6;
RA   Chen S.C., Lo S.Y., Ma H.C., Li H.C.;
RT   "Expression and membrane integration of SARS-CoV E protein and its
RT   interaction with M protein.";
RL   Virus Genes 38:365-371(2009).
RN   [25]
RP   INTERACTION WITH HUMAN MPP5, SUBCELLULAR LOCATION, MOTIF, AND MUTAGENESIS
RP   OF 73-ASP--VAL-76.
RX   PubMed=20861307; DOI=10.1091/mbc.e10-04-0338;
RA   Teoh K.T., Siu Y.L., Chan W.L., Schlueter M.A., Liu C.J., Peiris J.S.,
RA   Bruzzone R., Margolis B., Nal B.;
RT   "The SARS coronavirus E protein interacts with PALS1 and alters tight
RT   junction formation and epithelial morphogenesis.";
RL   Mol. Biol. Cell 21:3838-3852(2010).
RN   [26]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21450821; DOI=10.1128/jvi.00060-11;
RA   Cohen J.R., Lin L.D., Machamer C.E.;
RT   "Identification of a Golgi complex-targeting signal in the cytoplasmic tail
RT   of the severe acute respiratory syndrome coronavirus envelope protein.";
RL   J. Virol. 85:5794-5803(2011).
RN   [27]
RP   SUBUNIT.
RX   PubMed=22819936; DOI=10.1016/j.pep.2012.07.005;
RA   Parthasarathy K., Lu H., Surya W., Vararattanavech A., Pervushin K.,
RA   Torres J.;
RT   "Expression and purification of coronavirus envelope proteins using a
RT   modified beta-barrel construct.";
RL   Protein Expr. Purif. 85:133-141(2012).
RN   [28]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24788150; DOI=10.1371/journal.ppat.1004077;
RA   Nieto-Torres J.L., DeDiego M.L., Verdia-Baguena C., Jimenez-Guardeno J.M.,
RA   Regla-Nava J.A., Fernandez-Delgado R., Castano-Rodriguez C., Alcaraz A.,
RA   Torres J., Aguilella V.M., Enjuanes L.;
RT   "Severe acute respiratory syndrome coronavirus envelope protein ion channel
RT   activity promotes virus fitness and pathogenesis.";
RL   PLoS Pathog. 10:E1004077-E1004077(2014).
RN   [29]
RP   INTERACTION WITH NUCLEOPROTEIN.
RX   PubMed=24766657; DOI=10.1186/1423-0127-21-34;
RA   Tseng Y.T., Wang S.M., Huang K.J., Wang C.T.;
RT   "SARS-CoV envelope protein palmitoylation or nucleocapid association is not
RT   required for promoting virus-like particle production.";
RL   J. Biomed. Sci. 21:34-34(2014).
RN   [30]
RP   FUNCTION.
RX   PubMed=26331680; DOI=10.1016/j.virol.2015.08.010;
RA   Nieto-Torres J.L., Verdia-Baguena C., Jimenez-Guardeno J.M.,
RA   Regla-Nava J.A., Castano-Rodriguez C., Fernandez-Delgado R., Torres J.,
RA   Aguilella V.M., Enjuanes L.;
RT   "Severe acute respiratory syndrome coronavirus E protein transports calcium
RT   ions and activates the NLRP3 inflammasome.";
RL   Virology 485:330-339(2015).
CC   -!- FUNCTION: Plays a central role in virus morphogenesis and assembly.
CC       Acts as a viroporin and self-assembles in host membranes forming
CC       pentameric protein-lipid pores that allow ion transport. Also plays a
CC       role in the induction of apoptosis (By similarity). Activates the host
CC       NLRP3 inflammasome, leading to IL-1beta overproduction.
CC       {ECO:0000255|HAMAP-Rule:MF_04204, ECO:0000269|PubMed:24788150,
CC       ECO:0000269|PubMed:26331680}.
CC   -!- SUBUNIT: Homopentamer (PubMed:22819936). Interacts with membrane
CC       protein M in the budding compartment of the host cell, which is located
CC       between endoplasmic reticulum and the Golgi complex (PubMed:19322648).
CC       Interacts with Nucleoprotein (PubMed:24766657). Interacts with the
CC       accessory proteins 3a and 7a. Interacts (via C-terminus) with human
CC       MPP5 (via PDZ domain); this inhibits the interaction between human MPP5
CC       and human CRB3, and causes delayed tight junction formation and
CC       defective cell polarity (PubMed:20861307). {ECO:0000255|HAMAP-
CC       Rule:MF_04204, ECO:0000269|PubMed:15194747,
CC       ECO:0000269|PubMed:15763150, ECO:0000269|PubMed:16580632,
CC       ECO:0000269|PubMed:20861307, ECO:0000269|PubMed:22819936}.
CC   -!- INTERACTION:
CC       P59637; Q7TFA1: 7b; NbExp=2; IntAct=EBI-25487741, EBI-25492846;
CC       P59637; P59637: E; NbExp=2; IntAct=EBI-25487741, EBI-25487741;
CC       P59637; PRO_0000037309 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25487741, EBI-25475797;
CC       P59637; PRO_0000037315 [P0C6X7]: rep; NbExp=2; IntAct=EBI-25487741, EBI-25487941;
CC       P59637; O35843: Bcl2l1; Xeno; NbExp=2; IntAct=EBI-25487741, EBI-25487771;
CC       P59637; Q64373: Bcl2l1; Xeno; NbExp=2; IntAct=EBI-25487741, EBI-526361;
CC   -!- SUBCELLULAR LOCATION: Host endoplasmic reticulum-Golgi intermediate
CC       compartment {ECO:0000269|PubMed:20861307}. Host Golgi apparatus
CC       membrane {ECO:0000255|HAMAP-Rule:MF_04204, ECO:0000269|PubMed:21450821,
CC       ECO:0000269|PubMed:24788150}; Single-pass type III membrane protein
CC       {ECO:0000255|HAMAP-Rule:MF_04204}. Note=Colocalizes with S in the host
CC       endoplasmic reticulum-Golgi intermediate compartment (PubMed:20861307).
CC       The cytoplasmic tail functions as a Golgi complex-targeting signal.
CC       {ECO:0000255|HAMAP-Rule:MF_04204, ECO:0000269|PubMed:20861307,
CC       ECO:0000269|PubMed:21450821}.
CC   -!- SIMILARITY: Belongs to the betacoronaviruses E protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04204}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13443.1; -; Genomic_RNA.
DR   EMBL; AY274119; AAP41040.1; -; Genomic_RNA.
DR   EMBL; AY304492; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY282752; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278554; AAP13570.1; -; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283794; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283795; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283796; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283797; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283798; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; AAP30033.1; -; Genomic_RNA.
DR   EMBL; AY278489; AAP51230.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37020.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50488.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33700.1; -; Genomic_RNA.
DR   EMBL; AY297028; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY323975; AAP73416.1; -; mRNA.
DR   EMBL; AY321118; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY463059; AAP82979.2; -; Genomic_RNA.
DR   EMBL; AY338174; AAQ01600.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01612.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97885.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81351.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81365.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81379.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81393.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81407.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72977.1; -; Genomic_RNA.
DR   EMBL; AY362698; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY362699; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY427439; AAQ94063.1; -; Genomic_RNA.
DR   RefSeq; NP_828854.1; NC_004718.3.
DR   PDB; 2MM4; NMR; -; A=8-65.
DR   PDB; 5X29; NMR; -; A/B/C/D/E=8-65.
DR   PDB; 5XER; NMR; -; A=55-63.
DR   PDB; 5XES; NMR; -; A=55-63.
DR   PDBsum; 2MM4; -.
DR   PDBsum; 5X29; -.
DR   PDBsum; 5XER; -.
DR   PDBsum; 5XES; -.
DR   SMR; P59637; -.
DR   BioGRID; 4383914; 10.
DR   IntAct; P59637; 10.
DR   PRIDE; P59637; -.
DR   GeneID; 1489671; -.
DR   KEGG; vg:1489671; -.
DR   KO; K24151; -.
DR   SIGNOR; P59637; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000164441; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0044177; C:host cell Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-UniRule.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0044662; P:disruption by virus of host cell membrane; IDA:CACAO.
DR   GO; GO:0039707; P:pore formation by virus in membrane of host cell; IEA:InterPro.
DR   GO; GO:0046760; P:viral budding from Golgi membrane; IDA:UniProtKB.
DR   HAMAP; MF_04204; BETA_CORONA_E; 1.
DR   InterPro; IPR043506; E_protein_bCoV.
DR   InterPro; IPR003873; E_protein_CoV.
DR   Pfam; PF02723; NS3_envE; 1.
DR   PROSITE; PS51926; COV_E; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Host Golgi apparatus; Host membrane; Membrane;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..76
FT                   /note="Envelope small membrane protein"
FT                   /id="PRO_0000106074"
FT   TOPO_DOM        1..16
FT                   /note="Virion surface"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04204"
FT   TRANSMEM        17..37
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04204"
FT   TOPO_DOM        38..76
FT                   /note="Intravirion"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04204"
FT   MOTIF           73..76
FT                   /note="PDZ-binding; required for interaction with human
FT                   MPP5"
FT                   /evidence="ECO:0000269|PubMed:20861307"
FT   VARIANT         24
FT                   /note="V -> M (in strain: Isolate GD01)"
FT   MUTAGEN         73..76
FT                   /note="Missing: Abolishes interaction with PDZ domain of
FT                   human MPP5; loss of accumulation in host perinuclear
FT                   compartment."
FT                   /evidence="ECO:0000269|PubMed:20861307"
FT   HELIX           14..42
FT                   /evidence="ECO:0000244|PDB:2MM4"
FT   TURN            43..45
FT                   /evidence="ECO:0000244|PDB:2MM4"
FT   HELIX           56..64
FT                   /evidence="ECO:0000244|PDB:2MM4"
SQ   SEQUENCE   76 AA;  8361 MW;  A6D9A31652DDA194 CRC64;
     MYSFVSEETG TLIVNSVLLF LAFVVFLLVT LAILTALRLC AYCCNIVNVS LVKPTVYVYS
     RVKNLNSSEG VPDLLV
//
ID   PPIA_HUMAN              Reviewed;         165 AA.
AC   P62937; A8K220; P05092; Q3KQW3; Q567Q0; Q6IBU5; Q96IX3; Q9BRU4; Q9BTY9;
AC   Q9UC61;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   12-AUG-2020, entry version 185.
DE   RecName: Full=Peptidyl-prolyl cis-trans isomerase A;
DE            Short=PPIase A;
DE            EC=5.2.1.8 {ECO:0000269|PubMed:2001362, ECO:0000269|PubMed:20676357, ECO:0000269|PubMed:21245143, ECO:0000269|PubMed:21593166, ECO:0000269|PubMed:25678563, ECO:0000305|PubMed:19207730, ECO:0000305|PubMed:26095851};
DE   AltName: Full=Cyclophilin A;
DE   AltName: Full=Cyclosporin A-binding protein;
DE   AltName: Full=Rotamase A;
DE   Contains:
DE     RecName: Full=Peptidyl-prolyl cis-trans isomerase A, N-terminally processed;
GN   Name=PPIA; Synonyms=CYPA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Leukemic T-cell;
RX   PubMed=3297675; DOI=10.1002/j.1460-2075.1987.tb04843.x;
RA   Haendler B., Hofer-Warbinek R., Hofer E.;
RT   "Complementary DNA for human T-cell cyclophilin.";
RL   EMBO J. 6:947-950(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2197089; DOI=10.1111/j.1432-1033.1990.tb15598.x;
RA   Haendler B., Hofer E.;
RT   "Characterization of the human cyclophilin gene and of related processed
RT   pseudogenes.";
RL   Eur. J. Biochem. 190:477-482(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Subthalamic nucleus, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Blood, Bone marrow, Brain, Cervix, Colon, Lung, Skeletal
RC   muscle, Skin, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 2-30.
RX   PubMed=7657784; DOI=10.1093/oxfordjournals.humrep.a136138;
RA   Meier U., Beier-Hellwig K., Klug J., Linder D., Beier H.M.;
RT   "Identification of cyclophilin A from human decidual and placental tissue
RT   in the first trimester of pregnancy.";
RL   Hum. Reprod. 10:1305-1310(1995).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-19.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-31; 56-69; 77-118; 132-144 AND 155-165, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 2-28, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT
RP   VAL-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   TRP-121.
RX   PubMed=2001362; DOI=10.1021/bi00223a003;
RA   Liu J., Chen C.-M., Walsh C.T.;
RT   "Human and Escherichia coli cyclophilins: sensitivity to inhibition by the
RT   immunosuppressant cyclosporin A correlates with a specific tryptophan
RT   residue.";
RL   Biochemistry 30:2306-2310(1991).
RN   [14]
RP   INTERACTION WITH HIV-1 CAPSID PROTEIN (MICROBIAL INFECTION).
RX   PubMed=8513493; DOI=10.1016/0092-8674(93)90637-6;
RA   Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., Goff S.P.;
RT   "Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A
RT   and B.";
RL   Cell 73:1067-1078(1993).
RN   [15]
RP   INTERACTION WITH BSG.
RX   PubMed=11353871; DOI=10.1073/pnas.111583198;
RA   Pushkarsky T., Zybarth G., Dubrovsky L., Yurchenko V., Tang H., Guo H.,
RA   Toole B., Sherry B., Bukrinsky M.;
RT   "CD147 facilitates HIV-1 infection by interacting with virus-associated
RT   cyclophilin A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6360-6365(2001).
RN   [16]
RP   FUNCTION, INTERACTION WITH BSG, AND MUTAGENESIS OF PHE-60; PHE-113; TRP-121
RP   AND HIS-126.
RX   PubMed=11943775; DOI=10.1074/jbc.m201593200;
RA   Yurchenko V., Zybarth G., O'Connor M., Dai W.W., Franchin G., Hao T.,
RA   Guo H., Hung H.C., Toole B., Gallay P., Sherry B., Bukrinsky M.;
RT   "Active site residues of cyclophilin A are crucial for its signaling
RT   activity via CD147.";
RL   J. Biol. Chem. 277:22959-22965(2002).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [18]
RP   FUNCTION.
RX   PubMed=15130913; DOI=10.1161/01.atv.0000130664.51010.28;
RA   Jin Z.G., Lungu A.O., Xie L., Wang M., Wong C., Berk B.C.;
RT   "Cyclophilin A is a proinflammatory cytokine that activates endothelial
RT   cells.";
RL   Arterioscler. Thromb. Vasc. Biol. 24:1186-1191(2004).
RN   [19]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH BSG, AND INTERACTION WITH
RP   SARS-COV NUCLEOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=15688292; DOI=10.1086/427811;
RA   Chen Z., Mi L., Xu J., Yu J., Wang X., Jiang J., Xing J., Shang P.,
RA   Qian A., Li Y., Shaw P.X., Wang J., Duan S., Ding J., Fan C., Zhang Y.,
RA   Yang Y., Yu X., Feng Q., Li B., Yao X., Zhang Z., Li L., Xue X., Zhu P.;
RT   "Function of HAb18G/CD147 in invasion of host cells by severe acute
RT   respiratory syndrome coronavirus.";
RL   J. Infect. Dis. 191:755-760(2005).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16527992; DOI=10.1161/01.res.0000216405.85080.a6;
RA   Suzuki J., Jin Z.G., Meoli D.F., Matoba T., Berk B.C.;
RT   "Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle
RT   cells.";
RL   Circ. Res. 98:811-817(2006).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 AND VAL-2, CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [22]
RP   FUNCTION, INTERACTION WITH INFLUENZA A VIRUS MATRIX PROTEIN 1 (MICROBIAL
RP   INFECTION), CATALYTIC ACTIVITY, AND MUTAGENESIS OF ARG-55.
RX   PubMed=19207730; DOI=10.1111/j.1462-5822.2009.01286.x;
RA   Liu X., Sun L., Yu M., Wang Z., Xu C., Xue Q., Zhang K., Ye X.,
RA   Kitamura Y., Liu W.;
RT   "Cyclophilin A interacts with influenza A virus M1 protein and impairs the
RT   early stage of the viral replication.";
RL   Cell. Microbiol. 11:730-741(2009).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-28; LYS-44; LYS-76; LYS-82;
RP   LYS-125 AND LYS-131, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [24]
RP   INTERACTION WITH MEASLES VIRUS NUCLEOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=20147391; DOI=10.1128/jvi.02168-09;
RA   Watanabe A., Yoneda M., Ikeda F., Terao-Muto Y., Sato H., Kai C.;
RT   "CD147/EMMPRIN acts as a functional entry receptor for measles virus on
RT   epithelial cells.";
RL   J. Virol. 84:4183-4193(2010).
RN   [25]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF TRP-121.
RX   PubMed=20676357; DOI=10.1371/journal.pbio.1000439;
RA   Davis T.L., Walker J.R., Campagna-Slater V., Finerty P.J., Paramanathan R.,
RA   Bernstein G., MacKenzie F., Tempel W., Ouyang H., Lee W.H.,
RA   Eisenmesser E.Z., Dhe-Paganon S.;
RT   "Structural and biochemical characterization of the human cyclophilin
RT   family of peptidyl-prolyl isomerases.";
RL   PLoS Biol. 8:E1000439-E1000439(2010).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-93, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH BSG, AND MUTAGENESIS OF
RP   ARG-55; ARG-69; HIS-70 AND THR-107.
RX   PubMed=21245143; DOI=10.1074/jbc.c110.181347;
RA   Song F., Zhang X., Ren X.B., Zhu P., Xu J., Wang L., Li Y.F., Zhong N.,
RA   Ru Q., Zhang D.W., Jiang J.L., Xia B., Chen Z.N.;
RT   "Cyclophilin A (CyPA) induces chemotaxis independent of its peptidylprolyl
RT   cis-trans isomerase activity: direct binding between CyPA and the
RT   ectodomain of CD147.";
RL   J. Biol. Chem. 286:8197-8203(2011).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH HCV NS5A (MICROBIAL
RP   INFECTION), CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-126.
RX   PubMed=21593166; DOI=10.1128/jvi.00393-11;
RA   Foster T.L., Gallay P., Stonehouse N.J., Harris M.;
RT   "Cyclophilin A interacts with domain II of hepatitis C virus NS5A and
RT   stimulates RNA binding in an isomerase-dependent manner.";
RL   J. Virol. 85:7460-7464(2011).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [31]
RP   FUNCTION.
RX   PubMed=22347431; DOI=10.1371/journal.pone.0031063;
RA   Liu X., Zhao Z., Xu C., Sun L., Chen J., Zhang L., Liu W.;
RT   "Cyclophilin A restricts influenza A virus replication through degradation
RT   of the M1 protein.";
RL   PLoS ONE 7:e31063-e31063(2012).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [33]
RP   FUNCTION.
RX   PubMed=23180369; DOI=10.1007/s10753-012-9578-7;
RA   Wei Y., Jinchuan Y., Yi L., Jun W., Zhongqun W., Cuiping W.;
RT   "Antiapoptotic and proapoptotic signaling of cyclophilin A in endothelial
RT   cells.";
RL   Inflammation 36:567-572(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH
RP   MAP3K5, AND MUTAGENESIS OF ARG-55.
RX   PubMed=26095851; DOI=10.1016/j.bbrc.2015.06.078;
RA   Kim H., Oh Y., Kim K., Jeong S., Chon S., Kim D., Jung M.H., Pak Y.K.,
RA   Ha J., Kang I., Choe W.;
RT   "Cyclophilin A regulates JNK/p38-MAPK signaling through its physical
RT   interaction with ASK1.";
RL   Biochem. Biophys. Res. Commun. 464:112-117(2015).
RN   [37]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH TARDBP; HNRNPA1; HNRNPA2B1;
RP   HNRNPC; RBMX; HNRNPK AND HNRNPM, SUBCELLULAR LOCATION, ACETYLATION AT
RP   LYS-125, AND MUTAGENESIS OF ARG-55 AND LYS-125.
RX   PubMed=25678563; DOI=10.1093/brain/awv005;
RA   Lauranzano E., Pozzi S., Pasetto L., Stucchi R., Massignan T., Paolella K.,
RA   Mombrini M., Nardo G., Lunetta C., Corbo M., Mora G., Bendotti C.,
RA   Bonetto V.;
RT   "Peptidylprolyl isomerase A governs TARDBP function and assembly in
RT   heterogeneous nuclear ribonucleoprotein complexes.";
RL   Brain 138:974-991(2015).
RN   [38]
RP   ACETYLATION AT VAL-2, AND CLEAVAGE OF INITIATOR METHIONINE.
RX   PubMed=25489052; DOI=10.1093/hmg/ddu611;
RA   Myklebust L.M., Van Damme P., Stoeve S.I., Doerfel M.J., Abboud A.,
RA   Kalvik T.V., Grauffel C., Jonckheere V., Wu Y., Swensen J., Kaasa H.,
RA   Liszczak G., Marmorstein R., Reuter N., Lyon G.J., Gevaert K., Arnesen T.;
RT   "Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-
RT   acetylation defects.";
RL   Hum. Mol. Genet. 24:1956-1976(2015).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 AND VAL-2, CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [40]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-28 AND LYS-82, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [41]
RP   FUNCTION.
RX   PubMed=30328013; DOI=10.1007/s12250-018-0058-6;
RA   Mahesutihan M., Zheng W., Cui L., Li Y., Jiao P., Yang W., Liu W., Li J.,
RA   Fan W., Yang L., Liu W., Sun L.;
RT   "CypA Regulates AIP4-Mediated M1 Ubiquitination of Influenza A Virus.";
RL   Virol. Sin. 33:440-448(2018).
RN   [42]
RP   FUNCTION, AND INTERACTION WITH FOXO1.
RX   PubMed=31063815; DOI=10.1016/j.cellsig.2019.04.014;
RA   Xie Y., Li X., Ge J.;
RT   "Cyclophilin A-FoxO1 signaling pathway in endothelial cell apoptosis.";
RL   Cell. Signal. 61:57-65(2019).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS), AND STRUCTURE BY NMR.
RX   PubMed=1896075; DOI=10.1038/353276a0;
RA   Kallen J., Spitzfaden C., Zurini M.G.M., Wider G., Widmer H., Wuethrich K.,
RA   Walkinshaw M.D.;
RT   "Structure of human cyclophilin and its binding site for cyclosporin A
RT   determined by X-ray crystallography and NMR spectroscopy.";
RL   Nature 353:276-279(1991).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=1946361; DOI=10.1073/pnas.88.21.9483;
RA   Ke H., Zydowsky L.D., Liu J., Walsh C.T.;
RT   "Crystal structure of recombinant human T-cell cyclophilin A at 2.5-A
RT   resolution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9483-9487(1991).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF COMPLEX WITH CYCLOPHILIN.
RX   PubMed=8421501; DOI=10.1038/361091a0;
RA   Pfuegl G., Kallen J., Schirmer T., Jansonius J.N., Zurini M.G.M.,
RA   Walkinshaw M.D.;
RT   "X-ray structure of a decameric cyclophilin-cyclosporin crystal complex.";
RL   Nature 361:91-94(1993).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   PubMed=8263916; DOI=10.1006/jmbi.1993.1664;
RA   Mikol V., Kallen J., Pfluegl G., Walkinshaw M.D.;
RT   "X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex
RT   at 2.1-A resolution.";
RL   J. Mol. Biol. 234:1119-1130(1993).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=8652511; DOI=10.1021/bi9602775;
RA   Zhao Y., Ke H.;
RT   "Crystal structure implies that cyclophilin predominantly catalyzes the
RT   trans to cis isomerization.";
RL   Biochemistry 35:7356-7361(1996).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS).
RX   PubMed=9385632; DOI=10.1002/pro.5560061103;
RA   Vajdos F.F., Yoo S., Houseweart M., Sundquist W.I., Hill C.P.;
RT   "Crystal structure of cyclophilin A complexed with a binding site peptide
RT   from the HIV-1 capsid protein.";
RL   Protein Sci. 6:2297-2307(1997).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   PubMed=9769216; DOI=10.1006/jmbi.1998.2108;
RA   Kallen J., Mikol V., Taylor P., Walkinshaw M.D.;
RT   "X-ray structures and analysis of 11 cyclosporin derivatives complexed with
RT   cyclophilin A.";
RL   J. Mol. Biol. 283:435-449(1998).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH PPP3CA.
RX   PubMed=12218175; DOI=10.1073/pnas.192206699;
RA   Huai Q., Kim H.Y., Liu Y., Zhao Y., Mondragon A., Liu J.O., Ke H.;
RT   "Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but
RT   distinct recognition of immunophilin-drug complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:12037-12042(2002).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) IN COMPLEX WITH PPP3CA.
RX   PubMed=12357034; DOI=10.1073/pnas.212504399;
RA   Jin L., Harrison S.C.;
RT   "Crystal structure of human calcineurin complexed with cyclosporin A and
RT   human cyclophilin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:13522-13526(2002).
RN   [52]
RP   STRUCTURE BY NMR OF COMPLEX WITH CYCLOPHILIN.
RX   PubMed=8421500; DOI=10.1038/361088a0;
RA   Theriault Y., Logan T.M., Meadows R., Yu L., Olejniczak E.T., Holzman T.F.,
RA   Simmer R.L., Fesik S.W.;
RT   "Solution structure of the cyclosporin A/cyclophilin complex by NMR.";
RL   Nature 361:88-91(1993).
RN   [53]
RP   STRUCTURE BY NMR.
RX   PubMed=9299338; DOI=10.1006/jmbi.1997.1220;
RA   Ottiger M., Zerbe O., Guentert P., Wuethrich K.;
RT   "The NMR solution conformation of unligated human cyclophilin A.";
RL   J. Mol. Biol. 272:64-81(1997).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) ALONE AND IN COMPLEX WITH
RP   CYCLOSPORINE AND HIV-1 CAPSID, AND ACETYLATION AT LYS-125.
RX   PubMed=20364129; DOI=10.1038/nchembio.342;
RA   Lammers M., Neumann H., Chin J.W., James L.C.;
RT   "Acetylation regulates cyclophilin A catalysis, immunosuppression and HIV
RT   isomerization.";
RL   Nat. Chem. Biol. 6:331-337(2010).
CC   -!- FUNCTION: Catalyzes the cis-trans isomerization of proline imidic
CC       peptide bonds in oligopeptides (PubMed:2001362, PubMed:20676357,
CC       PubMed:21245143, PubMed:25678563, PubMed:21593166). Exerts a strong
CC       chemotactic effect on leukocytes partly through activation of one of
CC       its membrane receptors BSG/CD147, initiating a signaling cascade that
CC       culminates in MAPK/ERK activation (PubMed:11943775, PubMed:21245143).
CC       Activates endothelial cells (ECs) in a proinflammatory manner by
CC       stimulating activation of NF-kappa-B and ERK, JNK and p38 MAP-kinases
CC       and by inducing expression of adhesion molecules including SELE and
CC       VCAM1 (PubMed:15130913). Induces apoptosis in ECs by promoting the
CC       FOXO1-dependent expression of CCL2 and BCL2L11 which are involved in
CC       EC chemotaxis and apoptosis (PubMed:31063815). In response to oxidative
CC       stress, initiates proapoptotic and antiapoptotic signaling in ECs via
CC       activation of NF-kappa-B and AKT1 and up-regulation of antiapoptotic
CC       protein BCL2 (PubMed:23180369). Negatively regulates MAP3K5/ASK1 kinase
CC       activity, autophosphorylation and oxidative stress-induced apoptosis
CC       mediated by MAP3K5/ASK1 (PubMed:26095851). Necessary for the assembly
CC       of TARDBP in heterogeneous nuclear ribonucleoprotein (hnRNP) complexes
CC       and regulates TARDBP binding to RNA UG repeats and TARDBP-dependent
CC       expression of HDAC6, ATG7 and VCP which are involved in clearance of
CC       protein aggregates (PubMed:25678563). Plays an important role in
CC       platelet activation and aggregation (By similarity). Regulates calcium
CC       mobilization and integrin ITGA2B:ITGB3 bidirectional signaling via
CC       increased ROS production as well as by facilitating the interaction
CC       between integrin and the cell cytoskeleton (By similarity). Binds
CC       heparan sulfate glycosaminoglycans (PubMed:11943775). Inhibits
CC       replication of influenza A virus (IAV) (PubMed:19207730). Inhibits
CC       ITCH/AIP4-mediated ubiquitination of matrix protein 1 (M1) of IAV by
CC       impairing the interaction of ITCH/AIP4 with M1, followed by the
CC       suppression of the nuclear export of M1, and finally reduction of the
CC       replication of IAV (PubMed:30328013, PubMed:22347431).
CC       {ECO:0000250|UniProtKB:P17742, ECO:0000269|PubMed:11943775,
CC       ECO:0000269|PubMed:15130913, ECO:0000269|PubMed:19207730,
CC       ECO:0000269|PubMed:2001362, ECO:0000269|PubMed:20676357,
CC       ECO:0000269|PubMed:21245143, ECO:0000269|PubMed:21593166,
CC       ECO:0000269|PubMed:22347431, ECO:0000269|PubMed:23180369,
CC       ECO:0000269|PubMed:25678563, ECO:0000269|PubMed:26095851,
CC       ECO:0000269|PubMed:30328013, ECO:0000269|PubMed:31063815}.
CC   -!- FUNCTION: (Microbial infection) May act as a mediator between human
CC       SARS coronavirus nucleoprotein and BSG/CD147 in the process of invasion
CC       of host cells by the virus (PubMed:15688292).
CC       {ECO:0000269|PubMed:15688292}.
CC   -!- FUNCTION: (Microbial infection) Stimulates RNA-binding ability of HCV
CC       NS5A in a peptidyl-prolyl cis-trans isomerase activity-dependent
CC       manner. {ECO:0000269|PubMed:21593166}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[protein]-peptidylproline (omega=180) = [protein]-
CC         peptidylproline (omega=0); Xref=Rhea:RHEA:16237, Rhea:RHEA-
CC         COMP:10747, Rhea:RHEA-COMP:10748, ChEBI:CHEBI:83833,
CC         ChEBI:CHEBI:83834; EC=5.2.1.8; Evidence={ECO:0000269|PubMed:2001362,
CC         ECO:0000269|PubMed:20676357, ECO:0000269|PubMed:21245143,
CC         ECO:0000269|PubMed:21593166, ECO:0000269|PubMed:25678563,
CC         ECO:0000305|PubMed:19207730, ECO:0000305|PubMed:26095851};
CC   -!- ACTIVITY REGULATION: Binds cyclosporin A (CsA). CsA mediates some of
CC       its effects via an inhibitory action on PPIase.
CC       {ECO:0000269|PubMed:2001362}.
CC   -!- SUBUNIT: Interacts with protein phosphatase PPP3CA/calcineurin A
CC       (PubMed:12218175, PubMed:12357034). Interacts with PRPF19 isoform 2
CC       (via N-terminus) (By similarity). Interacts with isoform 2 of BSG/CD147
CC       (PubMed:15688292, PubMed:11353871, PubMed:11943775, PubMed:21245143).
CC       Interacts with FOXO1; the interaction promotes FOXO1 dephosphorylation,
CC       nuclear accumulation and transcriptional activity (PubMed:31063815).
CC       Interacts with integrin ITGA2B:ITGB3; the interaction is ROS and
CC       peptidyl-prolyl cis-trans isomerase (PPIase) activity-dependent and is
CC       increased in the presence of thrombin (By similarity). Interacts with
CC       MAP3K5 (PubMed:26095851). Interacts with TARDBP; the interaction is
CC       dependent on the RNA-binding activity of TARDBP and the PPIase activity
CC       of PPIA/CYPA and the acetylation of PPIA/CYPA at Lys-125 favors the
CC       interaction (PubMed:25678563). Interacts with HNRNPA1, HNRNPA2B1,
CC       HNRNPC, RBMX, HNRNPK and HNRNPM (PubMed:25678563).
CC       {ECO:0000250|UniProtKB:P17742, ECO:0000269|PubMed:11353871,
CC       ECO:0000269|PubMed:11943775, ECO:0000269|PubMed:12218175,
CC       ECO:0000269|PubMed:12357034, ECO:0000269|PubMed:15688292,
CC       ECO:0000269|PubMed:21245143, ECO:0000269|PubMed:25678563,
CC       ECO:0000269|PubMed:26095851, ECO:0000269|PubMed:31063815}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 capsid protein
CC       (PubMed:20364129, PubMed:8513493). {ECO:0000269|PubMed:20364129,
CC       ECO:0000269|PubMed:8513493}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human SARS coronavirus
CC       nucleoprotein. {ECO:0000269|PubMed:15688292}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with measles virus
CC       nucleoprotein. {ECO:0000269|PubMed:20147391}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with influenza A virus matrix
CC       protein 1. {ECO:0000269|PubMed:19207730}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HCV NS5A; the interaction
CC       stimulates RNA-binding ability of NS5A and is dependent on the
CC       peptidyl-prolyl cis-trans isomerase activity of PPIA/CYPA.
CC       {ECO:0000269|PubMed:21593166}.
CC   -!- INTERACTION:
CC       P62937; P46108-1: CRK; NbExp=4; IntAct=EBI-437708, EBI-287556;
CC       P62937; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-437708, EBI-739832;
CC       P62937; Q16849: PTPRN; NbExp=3; IntAct=EBI-437708, EBI-728153;
CC       P62937; O00267: SUPT5H; NbExp=2; IntAct=EBI-437708, EBI-710464;
CC       P62937; Q72497: gag; Xeno; NbExp=7; IntAct=EBI-437708, EBI-1036263;
CC       P62937; P59595: N; Xeno; NbExp=2; IntAct=EBI-437708, EBI-7602718;
CC       P62937; PRO_0000037309 [P0C6X7]: rep; Xeno; NbExp=4; IntAct=EBI-437708, EBI-25475797;
CC       P62937; PRO_0000045602 [Q99IB8]; Xeno; NbExp=2; IntAct=EBI-437708, EBI-6927873;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:26095851}. Secreted
CC       {ECO:0000269|PubMed:16527992}. Nucleus {ECO:0000269|PubMed:25678563}.
CC       Note=Secretion occurs in response to oxidative stress in vascular
CC       smooth muscle through a vesicular secretory pathway that includes Rho
CC       GTPase signaling, actin remodeling, and myosin II activation.
CC       {ECO:0000269|PubMed:16527992}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P62937-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P62937-2; Sequence=VSP_056050;
CC   -!- PTM: Acetylation at Lys-125 markedly inhibits catalysis of cis to trans
CC       isomerization and stabilizes cis rather than trans forms of the HIV-1
CC       capsid. PPIA acetylation also antagonizes the immunosuppressive effects
CC       of cyclosporine by inhibiting the sequential steps of cyclosporine
CC       binding and calcineurin inhibition (PubMed:20364129, Ref.12).
CC       Acetylation at Lys-125 favors its interaction with TARDBP
CC       (PubMed:25678563). {ECO:0000269|PubMed:20364129,
CC       ECO:0000269|PubMed:25678563, ECO:0000269|Ref.12}.
CC   -!- SIMILARITY: Belongs to the cyclophilin-type PPIase family. PPIase A
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ppia/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Cyclophilin entry;
CC       URL="https://en.wikipedia.org/wiki/Cyclophilin";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y00052; CAA68264.1; -; mRNA.
DR   EMBL; X52851; CAA37039.1; -; Genomic_DNA.
DR   EMBL; AK290085; BAF82774.1; -; mRNA.
DR   EMBL; AK293003; BAF85692.1; -; mRNA.
DR   EMBL; CR456707; CAG32988.1; -; mRNA.
DR   EMBL; AB451307; BAG70121.1; -; mRNA.
DR   EMBL; AB451438; BAG70252.1; -; mRNA.
DR   EMBL; AY739283; AAU13906.1; -; Genomic_DNA.
DR   EMBL; AC004854; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC013436; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000689; AAH00689.1; -; mRNA.
DR   EMBL; BC003026; AAH03026.2; -; mRNA.
DR   EMBL; BC005320; AAH05320.1; -; mRNA.
DR   EMBL; BC005982; AAH05982.1; -; mRNA.
DR   EMBL; BC007104; AAH07104.1; -; mRNA.
DR   EMBL; BC013915; AAH13915.1; -; mRNA.
DR   EMBL; BC073992; AAH73992.1; -; mRNA.
DR   EMBL; BC093076; AAH93076.1; -; mRNA.
DR   EMBL; BC106030; AAI06031.1; -; mRNA.
DR   EMBL; BC137057; AAI37058.1; -; mRNA.
DR   EMBL; BC137058; AAI37059.1; -; mRNA.
DR   CCDS; CCDS5494.1; -. [P62937-1]
DR   CCDS; CCDS75592.1; -. [P62937-2]
DR   PIR; A94496; CSHUA.
DR   RefSeq; NP_001287910.1; NM_001300981.1. [P62937-2]
DR   RefSeq; NP_066953.1; NM_021130.4. [P62937-1]
DR   PDB; 1AK4; X-ray; 2.36 A; A/B=1-165.
DR   PDB; 1AWQ; X-ray; 1.58 A; A=2-165.
DR   PDB; 1AWR; X-ray; 1.58 A; A/B/C/D/E/F=2-165.
DR   PDB; 1AWS; X-ray; 2.55 A; A=2-165.
DR   PDB; 1AWT; X-ray; 2.55 A; A/B/C/D/E/F=2-165.
DR   PDB; 1AWU; X-ray; 2.34 A; A=2-165.
DR   PDB; 1AWV; X-ray; 2.34 A; A/B/C/D/E/F=2-165.
DR   PDB; 1BCK; X-ray; 1.80 A; A=1-165.
DR   PDB; 1CWA; X-ray; 2.10 A; A=1-165.
DR   PDB; 1CWB; X-ray; 2.20 A; A=1-165.
DR   PDB; 1CWC; X-ray; 1.86 A; A=1-165.
DR   PDB; 1CWF; X-ray; 1.86 A; A=1-165.
DR   PDB; 1CWH; X-ray; 1.86 A; A=1-165.
DR   PDB; 1CWI; X-ray; 1.90 A; A=1-165.
DR   PDB; 1CWJ; X-ray; 1.80 A; A=1-165.
DR   PDB; 1CWK; X-ray; 1.80 A; A=1-165.
DR   PDB; 1CWL; X-ray; 1.80 A; A=1-165.
DR   PDB; 1CWM; X-ray; 2.00 A; A=1-165.
DR   PDB; 1CWO; X-ray; 1.86 A; A=1-165.
DR   PDB; 1FGL; X-ray; 1.80 A; A=1-165.
DR   PDB; 1M63; X-ray; 2.80 A; C/G=1-165.
DR   PDB; 1M9C; X-ray; 2.00 A; A/B=1-165.
DR   PDB; 1M9D; X-ray; 1.90 A; A/B=1-165.
DR   PDB; 1M9E; X-ray; 1.72 A; A/B=1-164.
DR   PDB; 1M9F; X-ray; 1.73 A; A/B=1-165.
DR   PDB; 1M9X; X-ray; 1.70 A; A/B/E/F=1-165.
DR   PDB; 1M9Y; X-ray; 1.90 A; A/B/E/F=1-165.
DR   PDB; 1MF8; X-ray; 3.10 A; C=1-165.
DR   PDB; 1MIK; X-ray; 1.76 A; A=1-165.
DR   PDB; 1NMK; X-ray; 2.10 A; A/B=1-165.
DR   PDB; 1OCA; NMR; -; A=1-165.
DR   PDB; 1RMH; X-ray; 2.40 A; A/B=2-165.
DR   PDB; 1VBS; X-ray; 2.00 A; A=1-165.
DR   PDB; 1VBT; X-ray; 2.30 A; A/B=1-165.
DR   PDB; 1W8L; X-ray; 1.80 A; A=2-165.
DR   PDB; 1W8M; X-ray; 1.65 A; A=2-165.
DR   PDB; 1W8V; X-ray; 1.70 A; A=2-165.
DR   PDB; 1YND; X-ray; 1.60 A; A/B=1-165.
DR   PDB; 1ZKF; X-ray; 2.55 A; A/B=1-165.
DR   PDB; 2ALF; X-ray; 1.90 A; A=2-165.
DR   PDB; 2CPL; X-ray; 1.63 A; A=1-165.
DR   PDB; 2CYH; X-ray; 1.64 A; A=2-165.
DR   PDB; 2MS4; NMR; -; A=1-165.
DR   PDB; 2MZU; NMR; -; A=1-165.
DR   PDB; 2N0T; NMR; -; A=1-165.
DR   PDB; 2RMA; X-ray; 2.10 A; A/C/E/G/I/K/M/O/Q/S=1-165.
DR   PDB; 2RMB; X-ray; 2.10 A; A/C/E/G/I/K/M/O/Q/S=1-165.
DR   PDB; 2X25; X-ray; 1.20 A; B=2-165.
DR   PDB; 2X2A; X-ray; 1.40 A; A/B=1-165.
DR   PDB; 2X2C; X-ray; 2.41 A; K/M/O/Q/S=1-165.
DR   PDB; 2X2D; X-ray; 1.95 A; B/C=1-165.
DR   PDB; 2XGY; X-ray; 1.80 A; B=1-165.
DR   PDB; 3CYH; X-ray; 1.90 A; A=2-165.
DR   PDB; 3CYS; NMR; -; A=1-165.
DR   PDB; 3K0M; X-ray; 1.25 A; A=1-165.
DR   PDB; 3K0N; X-ray; 1.39 A; A=1-165.
DR   PDB; 3K0O; X-ray; 1.55 A; A=1-165.
DR   PDB; 3K0P; X-ray; 1.65 A; A=1-165.
DR   PDB; 3K0Q; X-ray; 2.32 A; A=1-165.
DR   PDB; 3K0R; X-ray; 2.42 A; A=1-165.
DR   PDB; 3ODI; X-ray; 2.20 A; A/C/E/G/I/K/M/O/Q/S=1-165.
DR   PDB; 3ODL; X-ray; 2.31 A; A/C/E/G/I/K/M/O/Q/S=1-165.
DR   PDB; 3RDD; X-ray; 2.14 A; A=1-165.
DR   PDB; 4CYH; X-ray; 2.10 A; A=2-165.
DR   PDB; 4IPZ; X-ray; 1.67 A; A=1-165.
DR   PDB; 4N1M; X-ray; 1.15 A; A=1-165.
DR   PDB; 4N1N; X-ray; 1.50 A; A=1-165.
DR   PDB; 4N1O; X-ray; 1.75 A; A=1-165.
DR   PDB; 4N1P; X-ray; 1.90 A; A=1-165.
DR   PDB; 4N1Q; X-ray; 1.65 A; A=1-165.
DR   PDB; 4N1R; X-ray; 1.80 A; A=1-165.
DR   PDB; 4N1S; X-ray; 1.47 A; A=1-165.
DR   PDB; 4YUG; X-ray; 1.48 A; A=1-165.
DR   PDB; 4YUH; X-ray; 1.34 A; A=1-165.
DR   PDB; 4YUI; X-ray; 1.38 A; A=1-165.
DR   PDB; 4YUJ; X-ray; 1.42 A; A=1-165.
DR   PDB; 4YUK; X-ray; 1.48 A; A=1-165.
DR   PDB; 4YUL; X-ray; 1.42 A; A=1-165.
DR   PDB; 4YUM; X-ray; 1.50 A; A=1-165.
DR   PDB; 4YUN; X-ray; 1.58 A; A=1-165.
DR   PDB; 4YUO; X-ray; 1.20 A; A=1-165.
DR   PDB; 4YUP; X-ray; 1.75 A; A=1-165.
DR   PDB; 5CYH; X-ray; 2.10 A; A=2-165.
DR   PDB; 5F66; X-ray; 1.15 A; A=1-165.
DR   PDB; 5FJB; EM; 9.00 A; C=2-165.
DR   PDB; 5KUL; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUN; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUO; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUQ; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUR; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUS; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUU; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUV; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUW; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUZ; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV0; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV1; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV2; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV3; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV4; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV5; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV6; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV7; X-ray; 1.70 A; A=2-165.
DR   PDB; 5LUD; X-ray; 1.25 A; A=1-165.
DR   PDB; 5NOQ; X-ray; 1.60 A; A=1-165.
DR   PDB; 5NOR; X-ray; 1.80 A; A=1-165.
DR   PDB; 5NOS; X-ray; 1.35 A; A=1-165.
DR   PDB; 5NOT; X-ray; 1.45 A; A=1-165.
DR   PDB; 5NOU; X-ray; 1.30 A; A=1-165.
DR   PDB; 5NOV; X-ray; 2.00 A; A=1-165.
DR   PDB; 5NOW; X-ray; 1.48 A; A=1-165.
DR   PDB; 5NOX; X-ray; 1.49 A; A=1-165.
DR   PDB; 5NOY; X-ray; 1.43 A; A=1-165.
DR   PDB; 5NOZ; X-ray; 1.61 A; A=1-165.
DR   PDB; 5T9U; X-ray; 2.30 A; A/B/C/D=1-164.
DR   PDB; 5T9W; X-ray; 2.00 A; A=2-165.
DR   PDB; 5T9Z; X-ray; 1.40 A; A=2-164.
DR   PDB; 5TA2; X-ray; 1.48 A; A=2-164.
DR   PDB; 5TA4; X-ray; 1.50 A; A=2-165.
DR   PDB; 5WC7; X-ray; 1.43 A; A=1-165.
DR   PDB; 6BTA; X-ray; 1.50 A; A=1-165.
DR   PDB; 6GJI; X-ray; 1.60 A; A=1-165.
DR   PDB; 6GJJ; X-ray; 1.38 A; A=1-165.
DR   PDB; 6GJL; X-ray; 1.16 A; A=1-165.
DR   PDB; 6GJM; X-ray; 1.35 A; A=1-165.
DR   PDB; 6GJN; X-ray; 1.70 A; A=1-165.
DR   PDB; 6GJP; X-ray; 1.94 A; A=1-165.
DR   PDB; 6GJR; X-ray; 1.69 A; A=1-165.
DR   PDB; 6GJY; X-ray; 1.29 A; A=1-165.
DR   PDB; 6GS6; X-ray; 1.16 A; A=1-165.
DR   PDB; 6I42; X-ray; 1.38 A; A=2-165.
DR   PDB; 6U5C; X-ray; 1.62 A; A=1-165.
DR   PDB; 6U5D; X-ray; 1.65 A; A=1-165.
DR   PDB; 6U5E; X-ray; 1.56 A; A=1-165.
DR   PDB; 6U5G; EM; 2.50 A; A=1-165.
DR   PDBsum; 1AK4; -.
DR   PDBsum; 1AWQ; -.
DR   PDBsum; 1AWR; -.
DR   PDBsum; 1AWS; -.
DR   PDBsum; 1AWT; -.
DR   PDBsum; 1AWU; -.
DR   PDBsum; 1AWV; -.
DR   PDBsum; 1BCK; -.
DR   PDBsum; 1CWA; -.
DR   PDBsum; 1CWB; -.
DR   PDBsum; 1CWC; -.
DR   PDBsum; 1CWF; -.
DR   PDBsum; 1CWH; -.
DR   PDBsum; 1CWI; -.
DR   PDBsum; 1CWJ; -.
DR   PDBsum; 1CWK; -.
DR   PDBsum; 1CWL; -.
DR   PDBsum; 1CWM; -.
DR   PDBsum; 1CWO; -.
DR   PDBsum; 1FGL; -.
DR   PDBsum; 1M63; -.
DR   PDBsum; 1M9C; -.
DR   PDBsum; 1M9D; -.
DR   PDBsum; 1M9E; -.
DR   PDBsum; 1M9F; -.
DR   PDBsum; 1M9X; -.
DR   PDBsum; 1M9Y; -.
DR   PDBsum; 1MF8; -.
DR   PDBsum; 1MIK; -.
DR   PDBsum; 1NMK; -.
DR   PDBsum; 1OCA; -.
DR   PDBsum; 1RMH; -.
DR   PDBsum; 1VBS; -.
DR   PDBsum; 1VBT; -.
DR   PDBsum; 1W8L; -.
DR   PDBsum; 1W8M; -.
DR   PDBsum; 1W8V; -.
DR   PDBsum; 1YND; -.
DR   PDBsum; 1ZKF; -.
DR   PDBsum; 2ALF; -.
DR   PDBsum; 2CPL; -.
DR   PDBsum; 2CYH; -.
DR   PDBsum; 2MS4; -.
DR   PDBsum; 2MZU; -.
DR   PDBsum; 2N0T; -.
DR   PDBsum; 2RMA; -.
DR   PDBsum; 2RMB; -.
DR   PDBsum; 2X25; -.
DR   PDBsum; 2X2A; -.
DR   PDBsum; 2X2C; -.
DR   PDBsum; 2X2D; -.
DR   PDBsum; 2XGY; -.
DR   PDBsum; 3CYH; -.
DR   PDBsum; 3CYS; -.
DR   PDBsum; 3K0M; -.
DR   PDBsum; 3K0N; -.
DR   PDBsum; 3K0O; -.
DR   PDBsum; 3K0P; -.
DR   PDBsum; 3K0Q; -.
DR   PDBsum; 3K0R; -.
DR   PDBsum; 3ODI; -.
DR   PDBsum; 3ODL; -.
DR   PDBsum; 3RDD; -.
DR   PDBsum; 4CYH; -.
DR   PDBsum; 4IPZ; -.
DR   PDBsum; 4N1M; -.
DR   PDBsum; 4N1N; -.
DR   PDBsum; 4N1O; -.
DR   PDBsum; 4N1P; -.
DR   PDBsum; 4N1Q; -.
DR   PDBsum; 4N1R; -.
DR   PDBsum; 4N1S; -.
DR   PDBsum; 4YUG; -.
DR   PDBsum; 4YUH; -.
DR   PDBsum; 4YUI; -.
DR   PDBsum; 4YUJ; -.
DR   PDBsum; 4YUK; -.
DR   PDBsum; 4YUL; -.
DR   PDBsum; 4YUM; -.
DR   PDBsum; 4YUN; -.
DR   PDBsum; 4YUO; -.
DR   PDBsum; 4YUP; -.
DR   PDBsum; 5CYH; -.
DR   PDBsum; 5F66; -.
DR   PDBsum; 5FJB; -.
DR   PDBsum; 5KUL; -.
DR   PDBsum; 5KUN; -.
DR   PDBsum; 5KUO; -.
DR   PDBsum; 5KUQ; -.
DR   PDBsum; 5KUR; -.
DR   PDBsum; 5KUS; -.
DR   PDBsum; 5KUU; -.
DR   PDBsum; 5KUV; -.
DR   PDBsum; 5KUW; -.
DR   PDBsum; 5KUZ; -.
DR   PDBsum; 5KV0; -.
DR   PDBsum; 5KV1; -.
DR   PDBsum; 5KV2; -.
DR   PDBsum; 5KV3; -.
DR   PDBsum; 5KV4; -.
DR   PDBsum; 5KV5; -.
DR   PDBsum; 5KV6; -.
DR   PDBsum; 5KV7; -.
DR   PDBsum; 5LUD; -.
DR   PDBsum; 5NOQ; -.
DR   PDBsum; 5NOR; -.
DR   PDBsum; 5NOS; -.
DR   PDBsum; 5NOT; -.
DR   PDBsum; 5NOU; -.
DR   PDBsum; 5NOV; -.
DR   PDBsum; 5NOW; -.
DR   PDBsum; 5NOX; -.
DR   PDBsum; 5NOY; -.
DR   PDBsum; 5NOZ; -.
DR   PDBsum; 5T9U; -.
DR   PDBsum; 5T9W; -.
DR   PDBsum; 5T9Z; -.
DR   PDBsum; 5TA2; -.
DR   PDBsum; 5TA4; -.
DR   PDBsum; 5WC7; -.
DR   PDBsum; 6BTA; -.
DR   PDBsum; 6GJI; -.
DR   PDBsum; 6GJJ; -.
DR   PDBsum; 6GJL; -.
DR   PDBsum; 6GJM; -.
DR   PDBsum; 6GJN; -.
DR   PDBsum; 6GJP; -.
DR   PDBsum; 6GJR; -.
DR   PDBsum; 6GJY; -.
DR   PDBsum; 6GS6; -.
DR   PDBsum; 6I42; -.
DR   PDBsum; 6U5C; -.
DR   PDBsum; 6U5D; -.
DR   PDBsum; 6U5E; -.
DR   PDBsum; 6U5G; -.
DR   SMR; P62937; -.
DR   BioGRID; 111474; 176.
DR   CORUM; P62937; -.
DR   DIP; DIP-6080N; -.
DR   IntAct; P62937; 98.
DR   MINT; P62937; -.
DR   STRING; 9606.ENSP00000419425; -.
DR   BindingDB; P62937; -.
DR   ChEMBL; CHEMBL1949; -.
DR   DrugBank; DB01742; (3r)-1-Acetyl-3-Methylpiperidine.
DR   DrugBank; DB11638; Artenimol.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB00091; Cyclosporine.
DR   DrugBank; DB02419; Ethyl Oxo(Piperidin-1-Yl)Acetate.
DR   DrugBank; DB00172; Proline.
DR   DrugBank; DB03393; Sanglifehrin A.
DR   DrugCentral; P62937; -.
DR   GuidetoPHARMACOLOGY; 2751; -.
DR   GlyGen; P62937; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P62937; -.
DR   MetOSite; P62937; -.
DR   PhosphoSitePlus; P62937; -.
DR   SwissPalm; P62937; -.
DR   BioMuta; PPIA; -.
DR   DMDM; 51702775; -.
DR   DOSAC-COBS-2DPAGE; P62937; -.
DR   OGP; P62937; -.
DR   REPRODUCTION-2DPAGE; IPI00419585; -.
DR   REPRODUCTION-2DPAGE; P62937; -.
DR   SWISS-2DPAGE; P62937; -.
DR   UCD-2DPAGE; P62937; -.
DR   EPD; P62937; -.
DR   jPOST; P62937; -.
DR   MassIVE; P62937; -.
DR   PaxDb; P62937; -.
DR   PeptideAtlas; P62937; -.
DR   PRIDE; P62937; -.
DR   ProteomicsDB; 12696; -. [P62937-1]
DR   ProteomicsDB; 57455; -. [P62937-1]
DR   ProteomicsDB; 62564; -.
DR   TopDownProteomics; P62937-1; -. [P62937-1]
DR   Antibodypedia; 13466; 622 antibodies.
DR   DNASU; 5478; -.
DR   Ensembl; ENST00000355968; ENSP00000430817; ENSG00000196262. [P62937-2]
DR   Ensembl; ENST00000468812; ENSP00000419425; ENSG00000196262. [P62937-1]
DR   Ensembl; ENST00000489459; ENSP00000427976; ENSG00000196262. [P62937-2]
DR   Ensembl; ENST00000620047; ENSP00000479961; ENSG00000196262. [P62937-2]
DR   GeneID; 5478; -.
DR   KEGG; hsa:5478; -.
DR   UCSC; uc064djo.1; human. [P62937-1]
DR   CTD; 5478; -.
DR   DisGeNET; 5478; -.
DR   EuPathDB; HostDB:ENSG00000196262.13; -.
DR   GeneCards; PPIA; -.
DR   HGNC; HGNC:9253; PPIA.
DR   HPA; ENSG00000196262; Low tissue specificity.
DR   MIM; 123840; gene.
DR   neXtProt; NX_P62937; -.
DR   OpenTargets; ENSG00000196262; -.
DR   PharmGKB; PA33574; -.
DR   eggNOG; KOG0865; Eukaryota.
DR   GeneTree; ENSGT00950000183087; -.
DR   HOGENOM; CLU_012062_38_0_1; -.
DR   InParanoid; P62937; -.
DR   KO; K03767; -.
DR   OMA; CVSIYGH; -.
DR   PhylomeDB; P62937; -.
DR   TreeFam; TF316719; -.
DR   BRENDA; 5.2.1.8; 2681.
DR   PathwayCommons; P62937; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-162585; Uncoating of the HIV Virion.
DR   Reactome; R-HSA-162588; Budding and maturation of HIV virion.
DR   Reactome; R-HSA-162592; Integration of provirus.
DR   Reactome; R-HSA-162594; Early Phase of HIV Life Cycle.
DR   Reactome; R-HSA-164516; Minus-strand DNA synthesis.
DR   Reactome; R-HSA-164525; Plus-strand DNA synthesis.
DR   Reactome; R-HSA-173107; Binding and entry of HIV virion.
DR   Reactome; R-HSA-175474; Assembly Of The HIV Virion.
DR   Reactome; R-HSA-180689; APOBEC3G mediated resistance to HIV-1 infection.
DR   Reactome; R-HSA-2025928; Calcineurin activates NFAT.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation.
DR   BioGRID-ORCS; 5478; 535 hits in 879 CRISPR screens.
DR   ChiTaRS; PPIA; human.
DR   EvolutionaryTrace; P62937; -.
DR   GeneWiki; Peptidylprolyl_isomerase_A; -.
DR   GenomeRNAi; 5478; -.
DR   Pharos; P62937; Tclin.
DR   PRO; PR:P62937; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P62937; protein.
DR   Bgee; ENSG00000196262; Expressed in Brodmann (1909) area 9 and 220 other tissues.
DR   ExpressionAtlas; P62937; baseline and differential.
DR   Genevisible; P62937; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; HDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0031982; C:vesicle; HDA:UniProtKB.
DR   GO; GO:0016018; F:cyclosporin A binding; IDA:UniProtKB.
DR   GO; GO:0003755; F:peptidyl-prolyl cis-trans isomerase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:UniProtKB.
DR   GO; GO:0046790; F:virion binding; NAS:UniProtKB.
DR   GO; GO:0075713; P:establishment of integrated proviral latency; TAS:Reactome.
DR   GO; GO:0019064; P:fusion of virus membrane with host plasma membrane; TAS:Reactome.
DR   GO; GO:0035722; P:interleukin-12-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0034389; P:lipid droplet organization; IMP:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IMP:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IMP:UniProtKB.
DR   GO; GO:0006457; P:protein folding; IBA:GO_Central.
DR   GO; GO:0000413; P:protein peptidyl-prolyl isomerization; IDA:UniProtKB.
DR   GO; GO:0045069; P:regulation of viral genome replication; IMP:UniProtKB.
DR   GO; GO:0006278; P:RNA-dependent DNA biosynthetic process; TAS:Reactome.
DR   GO; GO:0019061; P:uncoating of virus; TAS:Reactome.
DR   GO; GO:0019058; P:viral life cycle; TAS:Reactome.
DR   GO; GO:0019076; P:viral release from host cell; TAS:UniProtKB.
DR   GO; GO:0019068; P:virion assembly; TAS:Reactome.
DR   Gene3D; 2.40.100.10; -; 1.
DR   InterPro; IPR029000; Cyclophilin-like_dom_sf.
DR   InterPro; IPR024936; Cyclophilin-type_PPIase.
DR   InterPro; IPR020892; Cyclophilin-type_PPIase_CS.
DR   InterPro; IPR002130; Cyclophilin-type_PPIase_dom.
DR   Pfam; PF00160; Pro_isomerase; 1.
DR   PIRSF; PIRSF001467; Peptidylpro_ismrse; 1.
DR   PRINTS; PR00153; CSAPPISMRASE.
DR   SUPFAM; SSF50891; SSF50891; 1.
DR   PROSITE; PS00170; CSA_PPIASE_1; 1.
DR   PROSITE; PS50072; CSA_PPIASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; Cytoplasm;
KW   Direct protein sequencing; Glycoprotein; Host-virus interaction; Isomerase;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome; Rotamase;
KW   Secreted; Ubl conjugation.
FT   CHAIN           1..165
FT                   /note="Peptidyl-prolyl cis-trans isomerase A"
FT                   /id="PRO_0000423240"
FT   INIT_MET        1
FT                   /note="Removed; alternate"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:22223895, ECO:0000244|PubMed:25944712,
FT                   ECO:0000269|PubMed:12665801, ECO:0000269|PubMed:25489052,
FT                   ECO:0000269|PubMed:7657784, ECO:0000269|Ref.11,
FT                   ECO:0000269|Ref.12"
FT   CHAIN           2..165
FT                   /note="Peptidyl-prolyl cis-trans isomerase A, N-terminally
FT                   processed"
FT                   /id="PRO_0000064115"
FT   DOMAIN          7..163
FT                   /note="PPIase cyclophilin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00156"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:22223895, ECO:0000244|PubMed:22814378,
FT                   ECO:0000244|PubMed:25944712"
FT   MOD_RES         2
FT                   /note="N-acetylvaline; partial; in Peptidyl-prolyl cis-
FT                   trans isomerase A, N-terminally processed"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:25944712, ECO:0000269|PubMed:25489052,
FT                   ECO:0000269|Ref.12"
FT   MOD_RES         28
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         44
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         76
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         77
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         82
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         93
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         125
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861,
FT                   ECO:0000269|PubMed:20364129, ECO:0000269|PubMed:25678563"
FT   MOD_RES         131
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         133
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17742"
FT   CARBOHYD        108
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CROSSLNK        28
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        28
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT   CROSSLNK        82
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1..60
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056050"
FT   MUTAGEN         55
FT                   /note="R->A: Loss of peptidyl-prolyl cis-trans isomerase
FT                   activity. No loss of its interaction with BSG/CD147 or its
FT                   ability to induce leukocyte chemotaxis. No effect on its
FT                   interaction with MAP3K5/ASK1. Loss of its ability to
FT                   negatively regulate oxidative stress-induced apoptosis
FT                   mediated by MAP3K5/ASK1. Reduced interaction with TARDBP.
FT                   No loss of interaction with influenza A virus matrix
FT                   protein 1 or its ability to inhibit viral replication."
FT                   /evidence="ECO:0000269|PubMed:19207730,
FT                   ECO:0000269|PubMed:21245143, ECO:0000269|PubMed:25678563,
FT                   ECO:0000269|PubMed:26095851"
FT   MUTAGEN         60
FT                   /note="F->A: Loss of ability to stimulate MAPK/ERK
FT                   phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11943775"
FT   MUTAGEN         69
FT                   /note="R->A: No effect on peptidyl-prolyl cis-trans
FT                   isomerase activity. Reduced interaction with BSG/CD147 and
FT                   ability to induce leukocyte chemotaxis."
FT                   /evidence="ECO:0000269|PubMed:21245143"
FT   MUTAGEN         70
FT                   /note="H->A: No effect on peptidyl-prolyl cis-trans
FT                   isomerase activity. Reduced interaction with BSG/CD147 and
FT                   ability to induce leukocyte chemotaxis."
FT                   /evidence="ECO:0000269|PubMed:21245143"
FT   MUTAGEN         107
FT                   /note="T->A: No effect on peptidyl-prolyl cis-trans
FT                   isomerase activity. Reduced interaction with BSG/CD147 and
FT                   ability to induce leukocyte chemotaxis."
FT                   /evidence="ECO:0000269|PubMed:21245143"
FT   MUTAGEN         113
FT                   /note="F->A: Reduced ability to stimulate MAPK/ERK
FT                   phosphorylation"
FT                   /evidence="ECO:0000269|PubMed:11943775"
FT   MUTAGEN         121
FT                   /note="W->A: 200-fold decrease of sensitivity to CsA.
FT                   Reduced ability to stimulate MAPK/ERK phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11943775,
FT                   ECO:0000269|PubMed:2001362"
FT   MUTAGEN         121
FT                   /note="W->E: Loss of peptidyl-prolyl cis-trans isomerase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:20676357"
FT   MUTAGEN         121
FT                   /note="W->F: 75-fold decrease of sensitivity to CsA."
FT                   /evidence="ECO:0000269|PubMed:2001362"
FT   MUTAGEN         121
FT                   /note="W->H: No effect on peptidyl-prolyl cis-trans
FT                   isomerase activity."
FT                   /evidence="ECO:0000269|PubMed:20676357"
FT   MUTAGEN         125
FT                   /note="K->Q: Acetylation-mimetic mutant; no effect on its
FT                   interaction with TARDBP"
FT                   /evidence="ECO:0000269|PubMed:25678563"
FT   MUTAGEN         125
FT                   /note="K->R: Loss of acetylation and interaction with
FT                   TARDBP"
FT                   /evidence="ECO:0000269|PubMed:25678563"
FT   MUTAGEN         126
FT                   /note="H->A: Loss of peptidyl-prolyl cis-trans isomerase
FT                   activity and interaction with HCVNS5A. Loss of ability to
FT                   stimulate MAPK/ERK phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11943775,
FT                   ECO:0000269|PubMed:21593166"
FT   CONFLICT        89
FT                   /note="I -> T (in Ref. 8; AAH05982)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        106
FT                   /note="N -> I (in Ref. 8; AAH07104)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        165
FT                   /note="E -> D (in Ref. 4; CAG32988)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..12
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   STRAND          15..24
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   TURN            26..28
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   HELIX           30..41
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   TURN            42..44
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   STRAND          55..57
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   TURN            58..60
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   STRAND          61..64
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   TURN            67..69
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   STRAND          70..73
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   STRAND          74..77
FT                   /evidence="ECO:0000244|PDB:2MS4"
FT   STRAND          78..81
FT                   /evidence="ECO:0000244|PDB:4YUI"
FT   STRAND          97..100
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   STRAND          102..104
FT                   /evidence="ECO:0000244|PDB:6I42"
FT   STRAND          108..110
FT                   /evidence="ECO:0000244|PDB:1FGL"
FT   STRAND          112..117
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   HELIX           120..122
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   TURN            123..125
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   STRAND          128..134
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   HELIX           136..143
FT                   /evidence="ECO:0000244|PDB:4N1M"
FT   HELIX           148..150
FT                   /evidence="ECO:0000244|PDB:3K0O"
FT   STRAND          152..154
FT                   /evidence="ECO:0000244|PDB:2MS4"
FT   STRAND          156..164
FT                   /evidence="ECO:0000244|PDB:4N1M"
SQ   SEQUENCE   165 AA;  18012 MW;  9B2E637A555E4434 CRC64;
     MVNPTVFFDI AVDGEPLGRV SFELFADKVP KTAENFRALS TGEKGFGYKG SCFHRIIPGF
     MCQGGDFTRH NGTGGKSIYG EKFEDENFIL KHTGPGILSM ANAGPNTNGS QFFICTAKTE
     WLDGKHVVFG KVKEGMNIVE AMERFGSRNG KTSKKITIAD CGQLE
//
ID   SMAD3_HUMAN             Reviewed;         425 AA.
AC   P84022; A8K4B6; B7Z4Z5; B7Z6M9; B7Z9Q2; F5H383; O09064; O09144; O14510;
AC   O35273; Q92940; Q93002; Q9GKR4;
DT   05-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   12-AUG-2020, entry version 190.
DE   RecName: Full=Mothers against decapentaplegic homolog 3;
DE            Short=MAD homolog 3;
DE            Short=Mad3;
DE            Short=Mothers against DPP homolog 3;
DE            Short=hMAD-3;
DE   AltName: Full=JV15-2;
DE   AltName: Full=SMAD family member 3;
DE            Short=SMAD 3;
DE            Short=Smad3;
DE            Short=hSMAD3;
GN   Name=SMAD3; Synonyms=MADH3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PHOSPHORYLATION.
RC   TISSUE=Placenta;
RX   PubMed=8774881; DOI=10.1038/383168a0;
RA   Zhang Y., Feng X.-H., Wu R.-Y., Derynck R.;
RT   "Receptor-associated Mad homologues synergize as effectors of the TGF-beta
RT   response.";
RL   Nature 383:168-172(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8673135; DOI=10.1038/ng0796-347;
RA   Riggins G.J., Thiagalingam S., Rosenblum E., Weinstein C.L., Kern S.E.,
RA   Hamilton S.R., Willson J.K.V., Markowitz S.D., Kinzler K.W.,
RA   Vogelstein B.V.;
RT   "Mad-related genes in the human.";
RL   Nat. Genet. 13:347-349(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Colon carcinoma;
RX   PubMed=9464505; DOI=10.1016/s0304-3835(97)00384-4;
RA   Arai T., Akiyama Y., Okabe S., Ando M., Endo M., Yuasa Y.;
RT   "Genomic structure of the human Smad3 gene and its infrequent alterations
RT   in colorectal cancers.";
RL   Cancer Lett. 122:157-163(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Hagiwara K., Yang K., McMenamin M.G., Freeman A.H., Bennett W.P.,
RA   Nagashima M., Minter A.R., Miyazono K., Takenoshita S., Harris C.C.;
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH TGFBR1.
RX   PubMed=9311995; DOI=10.1093/emboj/16.17.5353;
RA   Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A., Oeda E.,
RA   Tamaki K., Hanai J., Heldin C.H., Miyazono K., ten Dijke P.;
RT   "TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.";
RL   EMBO J. 16:5353-5362(1997).
RN   [10]
RP   INTERACTION WITH ZFYVE9.
RX   PubMed=9865696; DOI=10.1016/s0092-8674(00)81701-8;
RA   Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.;
RT   "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor.";
RL   Cell 95:779-791(1998).
RN   [11]
RP   SUBUNIT.
RX   PubMed=9670020; DOI=10.1093/emboj/17.14.4056;
RA   Kawabata M., Inoue H., Hanyu A., Imamura T., Miyazono K.;
RT   "Smad proteins exist as monomers in vivo and undergo homo- and hetero-
RT   oligomerization upon activation by serine/threonine kinase receptors.";
RL   EMBO J. 17:4056-4065(1998).
RN   [12]
RP   PHOSPHORYLATION, AND INTERACTION WITH EP300.
RX   PubMed=9843571; DOI=10.1091/mbc.9.12.3309;
RA   Shen X., Hu P.P., Liberati N.T., Datto M.B., Frederick J.P., Wang X.F.;
RT   "TGF-beta-induced phosphorylation of Smad3 regulates its interaction with
RT   coactivator p300/CREB-binding protein.";
RL   Mol. Biol. Cell 9:3309-3319(1998).
RN   [13]
RP   INTERACTION WITH MECOM.
RX   PubMed=9665135; DOI=10.1038/27945;
RA   Kurokawa M., Mitani K., Irie K., Matsuyama T., Takahashi T., Chiba S.,
RA   Yazaki Y., Matsumoto K., Hirai H.;
RT   "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.";
RL   Nature 394:92-96(1998).
RN   [14]
RP   IDENTIFICATION AS A COMPONENT OF THE SMAD3/SMAD4/JUN/FOS COMPLEX,
RP   INTERACTION WITH JUN AND FOS, DNA-BINDING, AND FUNCTION.
RX   PubMed=9732876; DOI=10.1038/29814;
RA   Zhang Y., Feng X.H., Derynck R.;
RT   "Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced
RT   transcription.";
RL   Nature 394:909-913(1998).
RN   [15]
RP   INTERACTION WITH ACVR1B, AND FUNCTION.
RX   PubMed=9892009; DOI=10.1210/mend.13.1.0218;
RA   Lebrun J.J., Takabe K., Chen Y., Vale W.;
RT   "Roles of pathway-specific and inhibitory Smads in activin receptor
RT   signaling.";
RL   Mol. Endocrinol. 13:15-23(1999).
RN   [16]
RP   INTERACTION WITH JUN IN THE SMAD3/SMAD4/JUN/FOS COMPLEX, DNA-BINDING,
RP   FUNCTION, AND MUTAGENESIS OF LYS-40; LYS-41; LYS-43; LYS-44 AND ARG-74.
RX   PubMed=10995748; DOI=10.1074/jbc.m004731200;
RA   Qing J., Zhang Y., Derynck R.;
RT   "Structural and functional characterization of the transforming growth
RT   factor-beta -induced Smad3/c-Jun transcriptional cooperativity.";
RL   J. Biol. Chem. 275:38802-38812(2000).
RN   [17]
RP   INTERACTION WITH DAB2.
RX   PubMed=11387212; DOI=10.1093/emboj/20.11.2789;
RA   Hocevar B.A., Smine A., Xu X.X., Howe P.H.;
RT   "The adaptor molecule Disabled-2 links the transforming growth factor beta
RT   receptors to the Smad pathway.";
RL   EMBO J. 20:2789-2801(2001).
RN   [18]
RP   INTERACTION WITH SNW1.
RX   PubMed=11278756; DOI=10.1074/jbc.m010815200;
RA   Leong G.M., Subramaniam N., Figueroa J., Flanagan J.L., Hayman M.J.,
RA   Eisman J.A., Kouzmenko A.P.;
RT   "Ski-interacting protein interacts with Smad proteins to augment
RT   transforming growth factor-beta-dependent transcription.";
RL   J. Biol. Chem. 276:18243-18248(2001).
RN   [19]
RP   INTERACTION WITH TGIF2.
RX   PubMed=11427533; DOI=10.1074/jbc.m103377200;
RA   Melhuish T.A., Gallo C.M., Wotton D.;
RT   "TGIF2 interacts with histone deacetylase 1 and represses transcription.";
RL   J. Biol. Chem. 276:32109-32114(2001).
RN   [20]
RP   SUBUNIT, PHOSPHORYLATION, AND MUTAGENESIS OF 422-SER--SER-425.
RX   PubMed=11224571; DOI=10.1038/84995;
RA   Chacko B.M., Qin B., Correia J.J., Lam S.S., de Caestecker M.P., Lin K.;
RT   "The L3 loop and C-terminal phosphorylation jointly define Smad protein
RT   trimerization.";
RL   Nat. Struct. Biol. 8:248-253(2001).
RN   [21]
RP   INTERACTION WITH MEN1.
RX   PubMed=11274402; DOI=10.1073/pnas.061358098;
RA   Kaji H., Canaff L., Lebrun J.J., Goltzman D., Hendy G.N.;
RT   "Inactivation of menin, a Smad3-interacting protein, blocks transforming
RT   growth factor type beta signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:3837-3842(2001).
RN   [22]
RP   INTERACTION WITH ZNF8.
RX   PubMed=12370310; DOI=10.1128/mcb.22.21.7633-7644.2002;
RA   Jiao K., Zhou Y., Hogan B.L.M.;
RT   "Identification of mZnf8, a mouse Kruppel-like transcriptional repressor,
RT   as a novel nuclear interaction partner of Smad1.";
RL   Mol. Cell. Biol. 22:7633-7644(2002).
RN   [23]
RP   INTERACTION WITH DACH1.
RX   PubMed=14525983; DOI=10.1074/jbc.m310021200;
RA   Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K.,
RA   Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.;
RT   "DACH1 inhibits transforming growth factor-beta signaling through binding
RT   Smad4.";
RL   J. Biol. Chem. 278:51673-51684(2003).
RN   [24]
RP   PHOSPHORYLATION AT THR-8; THR-179; SER-204; SER-208 AND SER-213, FUNCTION,
RP   AND MUTAGENESIS OF THR-8; THR-179; SER-204; SER-208 AND SER-213.
RX   PubMed=15241418; DOI=10.1038/nature02650;
RA   Matsuura I., Denissova N.G., Wang G., He D., Long J., Liu F.;
RT   "Cyclin-dependent kinases regulate the antiproliferative function of
RT   Smads.";
RL   Nature 430:226-231(2004).
RN   [25]
RP   TRANSCRIPTIONAL ACTIVATION DOMAIN, FUNCTION, PHOSPHORYLATION, SUBUNIT, AND
RP   INTERACTION WITH EP300.
RX   PubMed=15588252; DOI=10.1042/bj20041820;
RA   Wang G., Long J., Matsuura I., He D., Liu F.;
RT   "The Smad3 linker region contains a transcriptional activation domain.";
RL   Biochem. J. 386:29-34(2005).
RN   [26]
RP   PHOSPHORYLATION AT THR-179; SER-204 AND SER-208, SUBCELLULAR LOCATION,
RP   FUNCTION, AND MUTAGENESIS OF THR-179; SER-204 AND SER-208.
RX   PubMed=16156666; DOI=10.1021/bi050560g;
RA   Matsuura I., Wang G., He D., Liu F.;
RT   "Identification and characterization of ERK MAP kinase phosphorylation
RT   sites in Smad3.";
RL   Biochemistry 44:12546-12553(2005).
RN   [27]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH LEMD3.
RX   PubMed=15601644; DOI=10.1093/hmg/ddi040;
RA   Lin F., Morrison J.M., Wu W., Worman H.J.;
RT   "MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and
RT   Smad3 and antagonizes transforming growth factor-beta signaling.";
RL   Hum. Mol. Genet. 14:437-445(2005).
RN   [28]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=15561701; DOI=10.1074/jbc.m411575200;
RA   Wang H., Song K., Sponseller T.L., Danielpour D.;
RT   "Novel function of androgen receptor-associated protein 55/Hic-5 as a
RT   negative regulator of Smad3 signaling.";
RL   J. Biol. Chem. 280:5154-5162(2005).
RN   [29]
RP   INTERACTION WITH LEMD3.
RX   PubMed=15647271; DOI=10.1074/jbc.m411234200;
RA   Pan D., Estevez-Salmeron L.D., Stroschein S.L., Zhu X., He J., Zhou S.,
RA   Luo K.;
RT   "The integral inner nuclear membrane protein MAN1 physically interacts with
RT   the R-Smad proteins to repress signaling by the transforming growth
RT   factor-{beta} superfamily of cytokines.";
RL   J. Biol. Chem. 280:15992-16001(2005).
RN   [30]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=15799969; DOI=10.1074/jbc.m500362200;
RA   Chen H.B., Rud J.G., Lin K., Xu L.;
RT   "Nuclear targeting of transforming growth factor-beta-activated Smad
RT   complexes.";
RL   J. Biol. Chem. 280:21329-21336(2005).
RN   [31]
RP   INTERACTION WITH SKOR2.
RX   PubMed=16200078; DOI=10.1038/labinvest.3700344;
RA   Arndt S., Poser I., Schubert T., Moser M., Bosserhoff A.-K.;
RT   "Cloning and functional characterization of a new Ski homolog, Fussel-18,
RT   specifically expressed in neuronal tissues.";
RL   Lab. Invest. 85:1330-1341(2005).
RN   [32]
RP   INTERACTION WITH MECOM.
RX   PubMed=15897867; DOI=10.1038/sj.onc.1208754;
RA   Nitta E., Izutsu K., Yamaguchi Y., Imai Y., Ogawa S., Chiba S.,
RA   Kurokawa M., Hirai H.;
RT   "Oligomerization of Evi-1 regulated by the PR domain contributes to
RT   recruitment of corepressor CtBP.";
RL   Oncogene 24:6165-6173(2005).
RN   [33]
RP   INTERACTION WITH PPM1A, DEPHOSPHORYLATION, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16751101; DOI=10.1016/j.cell.2006.03.044;
RA   Lin X., Duan X., Liang Y.Y., Su Y., Wrighton K.H., Long J., Hu M.,
RA   Davis C.M., Wang J., Brunicardi F.C., Shi Y., Chen Y.G., Meng A.,
RA   Feng X.H.;
RT   "PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling.";
RL   Cell 125:915-928(2006).
RN   [34]
RP   IDENTIFICATION IN A COMPLEX WITH SMAD2 AND TRIM33, AND INTERACTION WITH
RP   SMAD2 AND TRIM33.
RX   PubMed=16751102; DOI=10.1016/j.cell.2006.03.045;
RA   He W., Dorn D.C., Erdjument-Bromage H., Tempst P., Moore M.A., Massague J.;
RT   "Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the
RT   TGFbeta pathway.";
RL   Cell 125:929-941(2006).
RN   [35]
RP   INTERACTION WITH ZMIZ1.
RX   PubMed=16777850; DOI=10.1074/jbc.m508365200;
RA   Li X., Thyssen G., Beliakoff J., Sun Z.;
RT   "The novel PIAS-like protein hZimp10 enhances Smad transcriptional
RT   activity.";
RL   J. Biol. Chem. 281:23748-23756(2006).
RN   [36]
RP   IDENTIFICATION IN A COMPLEX WITH RAN AND XPO4, INTERACTION WITH XPO4, AND
RP   MUTAGENESIS OF 422-SER--SER-425.
RX   PubMed=16449645; DOI=10.1128/mcb.26.4.1318-1332.2006;
RA   Kurisaki A., Kurisaki K., Kowanetz M., Sugino H., Yoneda Y., Heldin C.-H.,
RA   Moustakas A.;
RT   "The mechanism of nuclear export of Smad3 involves exportin 4 and Ran.";
RL   Mol. Cell. Biol. 26:1318-1332(2006).
RN   [37]
RP   INTERACTION WITH RBPMS.
RX   PubMed=17099224; DOI=10.1093/nar/gkl914;
RA   Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J., Song H.,
RA   Ye Q.;
RT   "Potentiation of Smad-mediated transcriptional activation by the RNA-
RT   binding protein RBPMS.";
RL   Nucleic Acids Res. 34:6314-6326(2006).
RN   [38]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION BY PDPK1, AND INTERACTION
RP   WITH PDPK1.
RX   PubMed=17327236; DOI=10.1074/jbc.m609279200;
RA   Seong H.A., Jung H., Kim K.T., Ha H.;
RT   "3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth
RT   factor-beta-induced signaling in a kinase-dependent manner through physical
RT   interaction with Smad proteins.";
RL   J. Biol. Chem. 282:12272-12289(2007).
RN   [39]
RP   INTERACTION WITH SKOR1.
RX   PubMed=17292623; DOI=10.1016/j.mcn.2007.01.002;
RA   Arndt S., Poser I., Moser M., Bosserhoff A.-K.;
RT   "Fussel-15, a novel Ski/Sno homolog protein, antagonizes BMP signaling.";
RL   Mol. Cell. Neurosci. 34:603-611(2007).
RN   [40]
RP   ACETYLATION AT LYS-378, FUNCTION, AND MUTAGENESIS OF LYS-333; LYS-341;
RP   LYS-378; LYS-409 AND 422-SER--SER-425.
RX   PubMed=16862174; DOI=10.1038/sj.onc.1209826;
RA   Inoue Y., Itoh Y., Abe K., Okamoto T., Daitoku H., Fukamizu A., Onozaki K.,
RA   Hayashi H.;
RT   "Smad3 is acetylated by p300/CBP to regulate its transactivation
RT   activity.";
RL   Oncogene 26:500-508(2007).
RN   [41]
RP   INTERACTION WITH WWTR1.
RX   PubMed=18568018; DOI=10.1038/ncb1748;
RA   Varelas X., Sakuma R., Samavarchi-Tehrani P., Peerani R., Rao B.M.,
RA   Dembowy J., Yaffe M.B., Zandstra P.W., Wrana J.L.;
RT   "TAZ controls Smad nucleocytoplasmic shuttling and regulates human
RT   embryonic stem-cell self-renewal.";
RL   Nat. Cell Biol. 10:837-848(2008).
RN   [42]
RP   INTERACTION WITH SARS-COV NUCLEOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=18055455; DOI=10.1074/jbc.m708033200;
RA   Zhao X., Nicholls J.M., Chen Y.G.;
RT   "Severe acute respiratory syndrome-associated coronavirus nucleocapsid
RT   protein interacts with Smad3 and modulates transforming growth factor-beta
RT   signaling.";
RL   J. Biol. Chem. 283:3272-3280(2008).
RN   [43]
RP   INTERACTION WITH CSNK1G2, UBIQUITINATION, PHOSPHORYLATION AT SER-418 BY
RP   CSNK1G2/CK1, AND MUTAGENESIS OF SER-418.
RX   PubMed=18794808; DOI=10.1038/onc.2008.337;
RA   Guo X., Waddell D.S., Wang W., Wang Z., Liberati N.T., Yong S., Liu X.,
RA   Wang X.-F.;
RT   "Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1
RT   gamma 2, an inhibitor of TGF-beta signaling.";
RL   Oncogene 27:7235-7247(2008).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-416, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [45]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [46]
RP   INTERACTION WITH RANBP3, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=19289081; DOI=10.1016/j.devcel.2009.01.022;
RA   Dai F., Lin X., Chang C., Feng X.H.;
RT   "Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of
RT   TGF-beta signaling.";
RL   Dev. Cell 16:345-357(2009).
RN   [47]
RP   INTERACTION WITH PRDM16; SKI AND HDAC1.
RX   PubMed=19049980; DOI=10.1074/jbc.m808989200;
RA   Takahata M., Inoue Y., Tsuda H., Imoto I., Koinuma D., Hayashi M.,
RA   Ichikura T., Yamori T., Nagasaki K., Yoshida M., Matsuoka M., Morishita K.,
RA   Yuki K., Hanyu A., Miyazawa K., Inazawa J., Miyazono K., Imamura T.;
RT   "SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal
RT   in gastric cancer cells.";
RL   J. Biol. Chem. 284:3334-3344(2009).
RN   [48]
RP   PHOSPHORYLATION AT THR-179; SER-204 AND SER-208, SUBCELLULAR LOCATION,
RP   FUNCTION, AND MUTAGENESIS OF THR-179; SER-204 AND SER-208.
RX   PubMed=19218245; DOI=10.1074/jbc.m809281200;
RA   Wang G., Matsuura I., He D., Liu F.;
RT   "Transforming growth factor-{beta}-inducible phosphorylation of Smad3.";
RL   J. Biol. Chem. 284:9663-9673(2009).
RN   [49]
RP   INTERACTION WITH PMEPA1.
RX   PubMed=20129061; DOI=10.1016/j.molcel.2009.10.028;
RA   Watanabe Y., Itoh S., Goto T., Ohnishi E., Inamitsu M., Itoh F., Satoh K.,
RA   Wiercinska E., Yang W., Shi L., Tanaka A., Nakano N., Mommaas A.M.,
RA   Shibuya H., Ten Dijke P., Kato M.;
RT   "TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad
RT   proteins from active participation in TGF-beta signaling.";
RL   Mol. Cell 37:123-134(2010).
RN   [50]
RP   INTERACTION WITH IL1F7.
RX   PubMed=20935647; DOI=10.1038/ni.1944;
RA   Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P.,
RA   Dinarello C.A.;
RT   "IL-37 is a fundamental inhibitor of innate immunity.";
RL   Nat. Immunol. 11:1014-1022(2010).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [52]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP15, DNA-BINDING, INTERACTION WITH
RP   USP15, UBIQUITINATION AT LYS-33 AND LYS-81, AND MUTAGENESIS OF LYS-33;
RP   LYS-53 AND LYS-81.
RX   PubMed=21947082; DOI=10.1038/ncb2346;
RA   Inui M., Manfrin A., Mamidi A., Martello G., Morsut L., Soligo S., Enzo E.,
RA   Moro S., Polo S., Dupont S., Cordenonsi M., Piccolo S.;
RT   "USP15 is a deubiquitylating enzyme for receptor-activated SMADs.";
RL   Nat. Cell Biol. 13:1368-1375(2011).
RN   [53]
RP   INTERACTION WITH PPP5C, AND SUBCELLULAR LOCATION.
RX   PubMed=22781750; DOI=10.1016/j.cellsig.2012.07.003;
RA   Bruce D.L., Macartney T., Yong W., Shou W., Sapkota G.P.;
RT   "Protein phosphatase 5 modulates SMAD3 function in the transforming growth
RT   factor-beta pathway.";
RL   Cell. Signal. 24:1999-2006(2012).
RN   [54]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [55]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-416, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [56]
RP   INTERACTION WITH STUB1; HSPA1A; HSPA1B; HSP90AA1 AND HSP90AB1,
RP   UBIQUITINATION, AND PROTEASOMAL DEGRADATION.
RX   PubMed=24613385; DOI=10.1016/j.bbrc.2014.02.124;
RA   Shang Y., Xu X., Duan X., Guo J., Wang Y., Ren F., He D., Chang Z.;
RT   "Hsp70 and Hsp90 oppositely regulate TGF-beta signaling through
RT   CHIP/Stub1.";
RL   Biochem. Biophys. Res. Commun. 446:387-392(2014).
RN   [57]
RP   INTERACTION WITH ZNF451, AND IDENTIFICATION IN A COMPLEX WITH ZNF451; SMAD2
RP   AND SMAD4.
RX   PubMed=24324267; DOI=10.1074/jbc.m113.526905;
RA   Feng Y., Wu H., Xu Y., Zhang Z., Liu T., Lin X., Feng X.H.;
RT   "Zinc finger protein 451 is a novel Smad corepressor in transforming growth
RT   factor-beta signaling.";
RL   J. Biol. Chem. 289:2072-2083(2014).
RN   [58]
RP   INTERACTION WITH LDLRAD4.
RX   PubMed=24627487; DOI=10.1074/jbc.m114.558981;
RA   Nakano N., Maeyama K., Sakata N., Itoh F., Akatsu R., Nakata M., Katsu Y.,
RA   Ikeno S., Togawa Y., Vo Nguyen T.T., Watanabe Y., Kato M., Itoh S.;
RT   "C18 ORF1, a novel negative regulator of transforming growth factor-beta
RT   signaling.";
RL   J. Biol. Chem. 289:12680-12692(2014).
RN   [59]
RP   INTERACTION WITH ZFHX3.
RX   PubMed=25105025; DOI=10.1155/2014/970346;
RA   Sakata N., Kaneko S., Ikeno S., Miura Y., Nakabayashi H., Dong X.Y.,
RA   Dong J.T., Tamaoki T., Nakano N., Itoh S.;
RT   "TGF-beta signaling cooperates with AT motif-binding factor-1 for
RT   repression of the alpha -fetoprotein promoter.";
RL   J. Signal Transduct. 2014:970346-970346(2014).
RN   [60]
RP   ADP-RIBOSYLATION.
RX   PubMed=25133494; DOI=10.1371/journal.pone.0103651;
RA   Dahl M., Maturi V., Lonn P., Papoutsoglou P., Zieba A., Vanlandewijck M.,
RA   van der Heide L.P., Watanabe Y., Soderberg O., Hottiger M.O., Heldin C.H.,
RA   Moustakas A.;
RT   "Fine-tuning of Smad protein function by poly(ADP-ribose) polymerases and
RT   poly(ADP-ribose) glycohydrolase during transforming growth factor beta
RT   Signaling.";
RL   PLoS ONE 9:E103651-E103651(2014).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-144.
RX   PubMed=9741623; DOI=10.1016/s0092-8674(00)81600-1;
RA   Shi Y., Wang Y.-F., Jayaraman L., Yang H., Massague J., Pavletich N.P.;
RT   "Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA
RT   binding in TGF-beta signaling.";
RL   Cell 94:585-594(1998).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.74 ANGSTROMS) OF 220-425 IN COMPLEX WITH ZFYVE9.
RX   PubMed=12154125; DOI=10.1101/gad.1002002;
RA   Qin B.Y., Lam S.S., Correia J.J., Lin K.;
RT   "Smad3 allostery links TGF-beta receptor kinase activation to
RT   transcriptional control.";
RL   Genes Dev. 16:1950-1963(2002).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-144 IN COMPLEX WITH DNA, AND
RP   ZINC.
RX   PubMed=12686552; DOI=10.1074/jbc.c300134200;
RA   Chai J., Wu J.W., Yan N., Massague J., Pavletich N.P., Shi Y.;
RT   "Features of a Smad3 MH1-DNA complex. Roles of water and zinc in DNA
RT   binding.";
RL   J. Biol. Chem. 278:20327-20331(2003).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 228-424 IN COMPLEX WITH SMAD4, AND
RP   SUBUNIT.
RX   PubMed=15350224; DOI=10.1016/j.molcel.2004.07.016;
RA   Chacko B.M., Qin B.Y., Tiwari A., Shi G., Lam S., Hayward L.J.,
RA   De Caestecker M., Lin K.;
RT   "Structural basis of heteromeric smad protein assembly in TGF-beta
RT   signaling.";
RL   Mol. Cell 15:813-823(2004).
RN   [65]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-393, AND INVOLVEMENT IN COLORECTAL
RP   CANCER.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [66]
RP   VARIANTS LDS3 VAL-112; LYS-239 AND LYS-279.
RX   PubMed=21778426; DOI=10.1161/circresaha.111.248161;
RA   Regalado E.S., Guo D.C., Villamizar C., Avidan N., Gilchrist D.,
RA   McGillivray B., Clarke L., Bernier F., Santos-Cortez R.L., Leal S.M.,
RA   Bertoli-Avella A.M., Shendure J., Rieder M.J., Nickerson D.A.,
RA   Milewicz D.M.;
RT   "Exome sequencing identifies SMAD3 mutations as a cause of familial
RT   thoracic aortic aneurysm and dissection with intracranial and other
RT   arterial aneurysms.";
RL   Circ. Res. 109:680-686(2011).
RN   [67]
RP   VARIANTS LDS3 ILE-261 AND TRP-287.
RX   PubMed=21217753; DOI=10.1038/ng.744;
RA   van de Laar I.M., Oldenburg R.A., Pals G., Roos-Hesselink J.W.,
RA   de Graaf B.M., Verhagen J.M., Hoedemaekers Y.M., Willemsen R.,
RA   Severijnen L.A., Venselaar H., Vriend G., Pattynama P.M., Collee M.,
RA   Majoor-Krakauer D., Poldermans D., Frohn-Mulder I.M., Micha D.,
RA   Timmermans J., Hilhorst-Hofstee Y., Bierma-Zeinstra S.M., Willems P.J.,
RA   Kros J.M., Oei E.H., Oostra B.A., Wessels M.W., Bertoli-Avella A.M.;
RT   "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and
RT   dissections with early-onset osteoarthritis.";
RL   Nat. Genet. 43:121-126(2011).
CC   -!- FUNCTION: Receptor-regulated SMAD (R-SMAD) that is an intracellular
CC       signal transducer and transcriptional modulator activated by TGF-beta
CC       (transforming growth factor) and activin type 1 receptor kinases. Binds
CC       the TRE element in the promoter region of many genes that are regulated
CC       by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates
CC       transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-
CC       1/SMAD site to regulate TGF-beta-mediated transcription. Has an
CC       inhibitory effect on wound healing probably by modulating both growth
CC       and migration of primary keratinocytes and by altering the TGF-mediated
CC       chemotaxis of monocytes. This effect on wound healing appears to be
CC       hormone-sensitive. Regulator of chondrogenesis and osteogenesis and
CC       inhibits early healing of bone fractures. Positively regulates PDPK1
CC       kinase activity by stimulating its dissociation from the 14-3-3 protein
CC       YWHAQ which acts as a negative regulator. {ECO:0000269|PubMed:10995748,
CC       ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252,
CC       ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101,
CC       ECO:0000269|PubMed:16862174, ECO:0000269|PubMed:17327236,
CC       ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:19289081,
CC       ECO:0000269|PubMed:9732876, ECO:0000269|PubMed:9892009}.
CC   -!- SUBUNIT: Monomer; in the absence of TGF-beta. Homooligomer; in the
CC       presence of TGF-beta. Heterotrimer; forms a heterotrimer in the
CC       presence of TGF-beta consisting of two molecules of C-terminally
CC       phosphorylated SMAD2 or SMAD3 and one of SMAD4 to form the
CC       transcriptionally active SMAD2/SMAD3-SMAD4 complex. Interacts with
CC       TGFBR1. Part of a complex consisting of AIP1, ACVR2A, ACVR1B and SMAD3.
CC       Interacts with AIP1, TGFB1I1, TTRAP, FOXL2, PML, PRDM16, HGS, WWP1 and
CC       SNW1. Interacts (via MH2 domain) with CITED2 (via C-terminus).
CC       Interacts with NEDD4L; the interaction requires TGF-beta stimulation.
CC       Interacts (via MH2 domain) with ZFYVE9. Interacts with HDAC1, TGIF and
CC       TGIF2, RUNX3, CREBBP, SKOR1, SKOR2, SNON, ATF2, SMURF2 and TGFB1I1.
CC       Interacts with DACH1; the interaction inhibits the TGF-beta signaling.
CC       Forms a complex with SMAD2 and TRIM33 upon addition of TGF-beta. Found
CC       in a complex with SMAD3, RAN and XPO4. Interacts in the complex
CC       directly with XPO4. Interacts (via MH2 domain) with LEMD3; the
CC       interaction represses SMAD3 transcriptional activity through preventing
CC       the formation of the heteromeric complex with SMAD4 and translocation
CC       to the nucleus. Interacts with RBPMS. Interacts (via MH2 domain) with
CC       MECOM. Interacts with WWTR1 (via its coiled-coil domain). Interacts
CC       (via the linker region) with EP300 (C-terminal); the interaction
CC       promotes SMAD3 acetylation and is enhanced by TGF-beta phosphorylation
CC       in the C-terminal of SMAD3. This interaction can be blocked by
CC       competitive binding of adenovirus oncoprotein E1A to the same C-
CC       terminal site on EP300, which then results in partially inhibited
CC       SMAD3/SMAD4 transcriptional activity. Interacts with SKI; the
CC       interaction represses SMAD3 transcriptional activity. Component of the
CC       multimeric complex SMAD3/SMAD4/JUN/FOS which forms at the AP1 promoter
CC       site; required for synergistic transcriptional activity in response to
CC       TGF-beta. Interacts (via an N-terminal domain) with JUN (via its basic
CC       DNA binding and leucine zipper domains); this interaction is essential
CC       for DNA binding and cooperative transcriptional activity in response to
CC       TGF-beta. Interacts with PPM1A; the interaction dephosphorylates SMAD3
CC       in the C-terminal SXS motif leading to disruption of the SMAD2/3-SMAD4
CC       complex, nuclear export and termination of TGF-beta signaling.
CC       Interacts (dephosphorylated form via the MH1 and MH2 domains) with
CC       RANBP3 (via its C-terminal R domain); the interaction results in the
CC       export of dephosphorylated SMAD3 out of the nucleus and termination of
CC       the TGF-beta signaling. Interacts with MEN1. Interacts with IL1F7.
CC       Interaction with CSNK1G2. Interacts with PDPK1 (via PH domain).
CC       Interacts with DAB2; the interactions are enhanced upon TGF-beta
CC       stimulation. Interacts with USP15. Interacts with PPP5C; the
CC       interaction decreases SMAD3 phosphorylation and protein levels.
CC       Interacts with LDLRAD4 (via the SMAD interaction motif). Interacts with
CC       PMEPA1. Interacts with ZC3H3 (By similarity). Interacts with ZNF451
CC       (PubMed:24324267). Identified in a complex that contains at least
CC       ZNF451, SMAD2, SMAD3 and SMAD4 (PubMed:24324267). Interacts with ZFHX3.
CC       Interacts weakly with ZNF8 (PubMed:12370310). Interacts (when
CC       phosphorylated) with RNF111; RNF111 acts as an enhancer of the
CC       transcriptional responses by mediating ubiquitination and degradation
CC       of SMAD3 inhibitors (By similarity). Interacts with STUB1, HSPA1A,
CC       HSPA1B, HSP90AA1 and HSP90AB1 (PubMed:24613385). Interacts (via MH2
CC       domain) with ZMIZ1 (via SP-RING-type domain); in the TGF-beta signaling
CC       pathway increases the activity of the SMAD3/SMAD4 transcriptional
CC       complex (PubMed:16777850). {ECO:0000250|UniProtKB:Q8BUN5,
CC       ECO:0000269|PubMed:10995748, ECO:0000269|PubMed:11224571,
CC       ECO:0000269|PubMed:11274402, ECO:0000269|PubMed:11278756,
CC       ECO:0000269|PubMed:11387212, ECO:0000269|PubMed:11427533,
CC       ECO:0000269|PubMed:12154125, ECO:0000269|PubMed:12370310,
CC       ECO:0000269|PubMed:12686552, ECO:0000269|PubMed:14525983,
CC       ECO:0000269|PubMed:15350224, ECO:0000269|PubMed:15561701,
CC       ECO:0000269|PubMed:15588252, ECO:0000269|PubMed:15601644,
CC       ECO:0000269|PubMed:15647271, ECO:0000269|PubMed:15799969,
CC       ECO:0000269|PubMed:15897867, ECO:0000269|PubMed:16200078,
CC       ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16751101,
CC       ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:16777850,
CC       ECO:0000269|PubMed:17099224, ECO:0000269|PubMed:17292623,
CC       ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:18568018,
CC       ECO:0000269|PubMed:18794808, ECO:0000269|PubMed:19049980,
CC       ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:20129061,
CC       ECO:0000269|PubMed:20935647, ECO:0000269|PubMed:21947082,
CC       ECO:0000269|PubMed:22781750, ECO:0000269|PubMed:24324267,
CC       ECO:0000269|PubMed:24613385, ECO:0000269|PubMed:24627487,
CC       ECO:0000269|PubMed:25105025, ECO:0000269|PubMed:9311995,
CC       ECO:0000269|PubMed:9665135, ECO:0000269|PubMed:9670020,
CC       ECO:0000269|PubMed:9732876, ECO:0000269|PubMed:9843571,
CC       ECO:0000269|PubMed:9865696, ECO:0000269|PubMed:9892009}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV nucleoprotein.
CC       {ECO:0000269|PubMed:18055455}.
CC   -!- INTERACTION:
CC       P84022; Q9H2G9: BLZF1; NbExp=9; IntAct=EBI-347161, EBI-2548012;
CC       P84022; E9PSE9: CCDC198; NbExp=3; IntAct=EBI-347161, EBI-11748295;
CC       P84022; Q9H2X0: CHRD; NbExp=2; IntAct=EBI-347161, EBI-947551;
CC       P84022; Q8N684: CPSF7; NbExp=3; IntAct=EBI-347161, EBI-746909;
CC       P84022; Q8N684-3: CPSF7; NbExp=3; IntAct=EBI-347161, EBI-11523759;
CC       P84022; O43186: CRX; NbExp=3; IntAct=EBI-347161, EBI-748171;
CC       P84022; P98082: DAB2; NbExp=3; IntAct=EBI-347161, EBI-1171238;
CC       P84022; P17844: DDX5; NbExp=2; IntAct=EBI-347161, EBI-351962;
CC       P84022; Q9BZ29: DOCK9; NbExp=3; IntAct=EBI-347161, EBI-2695893;
CC       P84022; Q99814: EPAS1; NbExp=2; IntAct=EBI-347161, EBI-447470;
CC       P84022; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-347161, EBI-6658203;
CC       P84022; O75593: FOXH1; NbExp=4; IntAct=EBI-347161, EBI-1759806;
CC       P84022; O43524: FOXO3; NbExp=5; IntAct=EBI-347161, EBI-1644164;
CC       P84022; P10070: GLI2; NbExp=4; IntAct=EBI-347161, EBI-10821567;
CC       P84022; Q16665: HIF1A; NbExp=6; IntAct=EBI-347161, EBI-447269;
CC       P84022; O15397: IPO8; NbExp=2; IntAct=EBI-347161, EBI-358808;
CC       P84022; P50222: MEOX2; NbExp=6; IntAct=EBI-347161, EBI-748397;
CC       P84022; Q9NYA4: MTMR4; NbExp=2; IntAct=EBI-347161, EBI-1052346;
CC       P84022; Q99836: MYD88; NbExp=3; IntAct=EBI-347161, EBI-447677;
CC       P84022; P46934-3: NEDD4; NbExp=3; IntAct=EBI-347161, EBI-11980721;
CC       P84022; Q16822: PCK2; NbExp=2; IntAct=EBI-347161, EBI-2825219;
CC       P84022; Q8IXK0: PHC2; NbExp=3; IntAct=EBI-347161, EBI-713786;
CC       P84022; Q8IXK0-5: PHC2; NbExp=3; IntAct=EBI-347161, EBI-11527347;
CC       P84022; Q9BZL4: PPP1R12C; NbExp=2; IntAct=EBI-347161, EBI-721802;
CC       P84022; P20618: PSMB1; NbExp=3; IntAct=EBI-347161, EBI-372273;
CC       P84022; Q96EP0: RNF31; NbExp=2; IntAct=EBI-347161, EBI-948111;
CC       P84022; P0C264: SBK3; NbExp=3; IntAct=EBI-347161, EBI-17181801;
CC       P84022; Q9BYW2: SETD2; NbExp=2; IntAct=EBI-347161, EBI-945869;
CC       P84022; P12755: SKI; NbExp=8; IntAct=EBI-347161, EBI-347281;
CC       P84022; Q15796: SMAD2; NbExp=2; IntAct=EBI-347161, EBI-1040141;
CC       P84022; P84022: SMAD3; NbExp=3; IntAct=EBI-347161, EBI-347161;
CC       P84022; Q13485: SMAD4; NbExp=33; IntAct=EBI-347161, EBI-347263;
CC       P84022; Q9HAU4: SMURF2; NbExp=8; IntAct=EBI-347161, EBI-396727;
CC       P84022; Q13573: SNW1; NbExp=5; IntAct=EBI-347161, EBI-632715;
CC       P84022; Q13501: SQSTM1; NbExp=3; IntAct=EBI-347161, EBI-307104;
CC       P84022; Q8WW24: TEKT4; NbExp=3; IntAct=EBI-347161, EBI-750487;
CC       P84022; Q08117: TLE5; NbExp=4; IntAct=EBI-347161, EBI-717810;
CC       P84022; Q08117-2: TLE5; NbExp=3; IntAct=EBI-347161, EBI-11741437;
CC       P84022; Q9Y3Q8: TSC22D4; NbExp=2; IntAct=EBI-347161, EBI-739485;
CC       P84022; Q93009: USP7; NbExp=2; IntAct=EBI-347161, EBI-302474;
CC       P84022; Q9H0M0: WWP1; NbExp=9; IntAct=EBI-347161, EBI-742157;
CC       P84022; O00308: WWP2; NbExp=7; IntAct=EBI-347161, EBI-743923;
CC       P84022; Q5D1E8: ZC3H12A; NbExp=2; IntAct=EBI-347161, EBI-747793;
CC       P84022; O95405: ZFYVE9; NbExp=5; IntAct=EBI-347161, EBI-296817;
CC       P84022; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-347161, EBI-10251462;
CC       P84022; Q64729: Tgfbr1; Xeno; NbExp=6; IntAct=EBI-347161, EBI-2899393;
CC       P84022; PRO_0000278742 [O92972]; Xeno; NbExp=6; IntAct=EBI-347161, EBI-9213553;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15799969,
CC       ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101,
CC       ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19218245,
CC       ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:22781750}. Nucleus
CC       {ECO:0000269|PubMed:15601644, ECO:0000269|PubMed:15799969,
CC       ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101,
CC       ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:19289081,
CC       ECO:0000269|PubMed:22781750}. Note=Cytoplasmic and nuclear in the
CC       absence of TGF-beta. On TGF-beta stimulation, migrates to the nucleus
CC       when complexed with SMAD4 (PubMed:15799969). Through the action of the
CC       phosphatase PPM1A, released from the SMAD2/SMAD4 complex, and exported
CC       out of the nucleus by interaction with RANBP1 (PubMed:16751101,
CC       PubMed:19289081). Co-localizes with LEMD3 at the nucleus inner membrane
CC       (PubMed:15601644). MAPK-mediated phosphorylation appears to have no
CC       effect on nuclear import (PubMed:19218245). PDPK1 prevents its nuclear
CC       translocation in response to TGF-beta (PubMed:17327236).
CC       {ECO:0000269|PubMed:15601644, ECO:0000269|PubMed:15799969,
CC       ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:17327236,
CC       ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:19289081}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P84022-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P84022-2; Sequence=VSP_042900;
CC       Name=3;
CC         IsoId=P84022-3; Sequence=VSP_043793;
CC       Name=4;
CC         IsoId=P84022-4; Sequence=VSP_045348;
CC   -!- DOMAIN: The MH1 domain is required for DNA binding. Also binds zinc
CC       ions which are necessary for the DNA binding.
CC   -!- DOMAIN: The MH2 domain is required for both homomeric and heteromeric
CC       interactions and for transcriptional regulation. Sufficient for nuclear
CC       import.
CC   -!- DOMAIN: The linker region is required for the TGFbeta-mediated
CC       transcriptional activity and acts synergistically with the MH2 domain.
CC   -!- PTM: Phosphorylated on serine and threonine residues. Enhanced
CC       phosphorylation in the linker region on Thr-179, Ser-204 and Ser-208 on
CC       EGF and TGF-beta treatment. Ser-208 is the main site of MAPK-mediated
CC       phosphorylation. CDK-mediated phosphorylation occurs in a cell-cycle
CC       dependent manner and inhibits both the transcriptional activity and
CC       antiproliferative functions of SMAD3. This phosphorylation is inhibited
CC       by flavopiridol. Maximum phosphorylation at the G(1)/S junction. Also
CC       phosphorylated on serine residues in the C-terminal SXS motif by TGFBR1
CC       and ACVR1. TGFBR1-mediated phosphorylation at these C-terminal sites is
CC       required for interaction with SMAD4, nuclear location and
CC       transactivational activity, and appears to be a prerequisite for the
CC       TGF-beta mediated phosphorylation in the linker region.
CC       Dephosphorylated in the C-terminal SXS motif by PPM1A. This
CC       dephosphorylation disrupts the interaction with SMAD4, promotes nuclear
CC       export and terminates TGF-beta-mediated signaling. Phosphorylation at
CC       Ser-418 by CSNK1G2/CK1 promotes ligand-dependent ubiquitination and
CC       subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF-
CC       beta responses. Phosphorylated by PDPK1. {ECO:0000269|PubMed:11224571,
CC       ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252,
CC       ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:17327236,
CC       ECO:0000269|PubMed:18794808, ECO:0000269|PubMed:19218245,
CC       ECO:0000269|PubMed:21947082, ECO:0000269|PubMed:8774881,
CC       ECO:0000269|PubMed:9843571}.
CC   -!- PTM: Acetylation in the nucleus by EP300 in the MH2 domain regulates
CC       positively its transcriptional activity and is enhanced by TGF-beta.
CC       {ECO:0000269|PubMed:16862174}.
CC   -!- PTM: Poly-ADP-ribosylated by PARP1 and PARP2. ADP-ribosylation
CC       negatively regulates SMAD3 transcriptional responses during the course
CC       of TGF-beta signaling. {ECO:0000269|PubMed:25133494}.
CC   -!- PTM: Ubiquitinated. Monoubiquitinated, leading to prevent DNA-binding
CC       (PubMed:21947082). Deubiquitination by USP15 alleviates inhibition and
CC       promotes activation of TGF-beta target genes (PubMed:21947082).
CC       Ubiquitinated by RNF111, leading to its degradation: only SMAD3
CC       proteins that are 'in use' are targeted by RNF111, RNF111 playing a key
CC       role in activating SMAD3 and regulating its turnover (By similarity).
CC       Undergoes STUB1-mediated ubiquitination and degradation
CC       (PubMed:24613385). {ECO:0000250|UniProtKB:Q8BUN5,
CC       ECO:0000269|PubMed:21947082, ECO:0000269|PubMed:24613385}.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of the
CC       large intestine (the colon) and the rectum. Genetic alterations are
CC       often associated with progression from premalignant lesion (adenoma) to
CC       invasive adenocarcinoma. Risk factors for cancer of the colon and
CC       rectum include colon polyps, long-standing ulcerative colitis, and
CC       genetic family history. {ECO:0000269|PubMed:16959974}. Note=The disease
CC       may be caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Loeys-Dietz syndrome 3 (LDS3) [MIM:613795]: An aortic aneurysm
CC       syndrome with widespread systemic involvement. The disorder is
CC       characterized by the triad of arterial tortuosity and aneurysms,
CC       hypertelorism, and bifid uvula or cleft palate. Patients with LDS3 also
CC       manifest early-onset osteoarthritis. They lack craniosynostosis and
CC       mental retardation. {ECO:0000269|PubMed:21217753,
CC       ECO:0000269|PubMed:21778426}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry. SMAD3 mutations have been
CC       reported to be also associated with thoracic aortic aneurysms and
CC       dissection (TAAD) (PubMed:21778426). This phenotype is distinguised
CC       from LDS3 by having aneurysms restricted to thoracic aorta. As
CC       individuals carrying these mutations also exhibit aneurysms of other
CC       arteries, including abdominal aorta, iliac, and/or intracranial
CC       arteries (PubMed:21778426), they have been classified as LDS3 by the
CC       OMIM resource. {ECO:0000269|PubMed:21778426}.
CC   -!- SIMILARITY: Belongs to the dwarfin/SMAD family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U68019; AAB80960.1; -; mRNA.
DR   EMBL; U76622; AAB18967.1; -; mRNA.
DR   EMBL; AB004930; BAA22032.1; -; Genomic_DNA.
DR   EMBL; AF025300; AAL68976.1; -; Genomic_DNA.
DR   EMBL; AF025293; AAL68976.1; JOINED; Genomic_DNA.
DR   EMBL; AF025294; AAL68976.1; JOINED; Genomic_DNA.
DR   EMBL; AF025295; AAL68976.1; JOINED; Genomic_DNA.
DR   EMBL; AF025296; AAL68976.1; JOINED; Genomic_DNA.
DR   EMBL; AF025297; AAL68976.1; JOINED; Genomic_DNA.
DR   EMBL; AF025298; AAL68976.1; JOINED; Genomic_DNA.
DR   EMBL; AF025299; AAL68976.1; JOINED; Genomic_DNA.
DR   EMBL; AK290881; BAF83570.1; -; mRNA.
DR   EMBL; AK298139; BAH12731.1; -; mRNA.
DR   EMBL; AK300614; BAH13315.1; -; mRNA.
DR   EMBL; AK316017; BAH14388.1; -; mRNA.
DR   EMBL; AC012568; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087482; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471082; EAW77788.1; -; Genomic_DNA.
DR   EMBL; BC050743; AAH50743.1; -; mRNA.
DR   CCDS; CCDS10222.1; -. [P84022-1]
DR   CCDS; CCDS45288.1; -. [P84022-2]
DR   CCDS; CCDS53950.1; -. [P84022-3]
DR   CCDS; CCDS53951.1; -. [P84022-4]
DR   PIR; S71798; S71798.
DR   RefSeq; NP_001138574.1; NM_001145102.1. [P84022-3]
DR   RefSeq; NP_001138575.1; NM_001145103.1. [P84022-2]
DR   RefSeq; NP_001138576.1; NM_001145104.1. [P84022-4]
DR   RefSeq; NP_005893.1; NM_005902.3. [P84022-1]
DR   PDB; 1MHD; X-ray; 2.80 A; A/B=1-132.
DR   PDB; 1MJS; X-ray; 1.91 A; A=229-425.
DR   PDB; 1MK2; X-ray; 2.74 A; A=220-425.
DR   PDB; 1OZJ; X-ray; 2.40 A; A/B=1-144.
DR   PDB; 1U7F; X-ray; 2.60 A; A/C=228-425.
DR   PDB; 2LAJ; NMR; -; B=202-211.
DR   PDB; 2LB2; NMR; -; B=178-189.
DR   PDB; 5OD6; X-ray; 2.00 A; A/B=11-135.
DR   PDB; 5ODG; X-ray; 2.12 A; A/B=11-135.
DR   PDB; 5XOC; X-ray; 2.40 A; A=220-416.
DR   PDBsum; 1MHD; -.
DR   PDBsum; 1MJS; -.
DR   PDBsum; 1MK2; -.
DR   PDBsum; 1OZJ; -.
DR   PDBsum; 1U7F; -.
DR   PDBsum; 2LAJ; -.
DR   PDBsum; 2LB2; -.
DR   PDBsum; 5OD6; -.
DR   PDBsum; 5ODG; -.
DR   PDBsum; 5XOC; -.
DR   SMR; P84022; -.
DR   BioGRID; 110263; 363.
DR   ComplexPortal; CPX-1; SMAD2-SMAD3-SMAD4 complex.
DR   ComplexPortal; CPX-12; SMAD3 homotrimer.
DR   ComplexPortal; CPX-3252; SMAD3-SMAD4 complex.
DR   CORUM; P84022; -.
DR   DIP; DIP-29720N; -.
DR   IntAct; P84022; 195.
DR   MINT; P84022; -.
DR   STRING; 9606.ENSP00000332973; -.
DR   BindingDB; P84022; -.
DR   ChEMBL; CHEMBL1293258; -.
DR   MoonDB; P84022; Predicted.
DR   iPTMnet; P84022; -.
DR   PhosphoSitePlus; P84022; -.
DR   SwissPalm; P84022; -.
DR   BioMuta; SMAD3; -.
DR   DMDM; 51338669; -.
DR   EPD; P84022; -.
DR   jPOST; P84022; -.
DR   MassIVE; P84022; -.
DR   MaxQB; P84022; -.
DR   PaxDb; P84022; -.
DR   PeptideAtlas; P84022; -.
DR   PRIDE; P84022; -.
DR   ProteomicsDB; 26192; -.
DR   ProteomicsDB; 57743; -. [P84022-1]
DR   ProteomicsDB; 57744; -. [P84022-2]
DR   ProteomicsDB; 57745; -. [P84022-3]
DR   Antibodypedia; 26224; 2235 antibodies.
DR   DNASU; 4088; -.
DR   Ensembl; ENST00000327367; ENSP00000332973; ENSG00000166949. [P84022-1]
DR   Ensembl; ENST00000439724; ENSP00000401133; ENSG00000166949. [P84022-2]
DR   Ensembl; ENST00000537194; ENSP00000445348; ENSG00000166949. [P84022-4]
DR   Ensembl; ENST00000540846; ENSP00000437757; ENSG00000166949. [P84022-3]
DR   GeneID; 4088; -.
DR   KEGG; hsa:4088; -.
DR   UCSC; uc002aqj.4; human. [P84022-1]
DR   CTD; 4088; -.
DR   DisGeNET; 4088; -.
DR   EuPathDB; HostDB:ENSG00000166949.15; -.
DR   GeneCards; SMAD3; -.
DR   GeneReviews; SMAD3; -.
DR   HGNC; HGNC:6769; SMAD3.
DR   HPA; ENSG00000166949; Low tissue specificity.
DR   MalaCards; SMAD3; -.
DR   MIM; 114500; phenotype.
DR   MIM; 603109; gene.
DR   MIM; 613795; phenotype.
DR   neXtProt; NX_P84022; -.
DR   OpenTargets; ENSG00000166949; -.
DR   Orphanet; 284984; Aneurysm-osteoarthritis syndrome.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   PharmGKB; PA30526; -.
DR   eggNOG; KOG3701; Eukaryota.
DR   GeneTree; ENSGT00940000153499; -.
DR   HOGENOM; CLU_026736_0_0_1; -.
DR   InParanoid; P84022; -.
DR   KO; K23605; -.
DR   OMA; NPVSPAH; -.
DR   PhylomeDB; P84022; -.
DR   TreeFam; TF314923; -.
DR   PathwayCommons; P84022; -.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-1502540; Signaling by Activin.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer.
DR   Reactome; R-HSA-3311021; SMAD4 MH2 Domain Mutants in Cancer.
DR   Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer.
DR   Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription.
DR   Reactome; R-HSA-8952158; RUNX3 regulates BCL2L11 (BIM) transcription.
DR   Reactome; R-HSA-9008059; Interleukin-37 signaling.
DR   Reactome; R-HSA-9013695; NOTCH4 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes.
DR   Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes.
DR   SignaLink; P84022; -.
DR   SIGNOR; P84022; -.
DR   BioGRID-ORCS; 4088; 7 hits in 894 CRISPR screens.
DR   ChiTaRS; SMAD3; human.
DR   EvolutionaryTrace; P84022; -.
DR   GeneWiki; Mothers_against_decapentaplegic_homolog_3; -.
DR   GenomeRNAi; 4088; -.
DR   Pharos; P84022; Tbio.
DR   PRO; PR:P84022; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P84022; protein.
DR   Bgee; ENSG00000166949; Expressed in amniotic fluid and 241 other tissues.
DR   ExpressionAtlas; P84022; baseline and differential.
DR   Genevisible; P84022; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0071144; C:heteromeric SMAD protein complex; IDA:BHF-UCL.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005637; C:nuclear inner membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0043235; C:receptor complex; IMP:BHF-UCL.
DR   GO; GO:0071141; C:SMAD protein complex; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription regulator complex; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:Ensembl.
DR   GO; GO:0043425; F:bHLH transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0070410; F:co-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0005518; F:collagen binding; IEA:Ensembl.
DR   GO; GO:0017151; F:DEAD/H-box RNA helicase binding; IPI:BHF-UCL.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IMP:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0035259; F:glucocorticoid receptor binding; IPI:CAFA.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0031962; F:mineralocorticoid receptor binding; IPI:CAFA.
DR   GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0070878; F:primary miRNA binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0070412; F:R-SMAD binding; IPI:UniProtKB.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB.
DR   GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IPI:BHF-UCL.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0097296; P:activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0032924; P:activin receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IMP:BHF-UCL.
DR   GO; GO:0045216; P:cell-cell junction organization; IMP:BHF-UCL.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; TAS:Reactome.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:CAFA.
DR   GO; GO:0048589; P:developmental growth; IEA:Ensembl.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IEA:Ensembl.
DR   GO; GO:0048617; P:embryonic foregut morphogenesis; IEA:Ensembl.
DR   GO; GO:0009880; P:embryonic pattern specification; IEA:Ensembl.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0001947; P:heart looping; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IMP:BHF-UCL.
DR   GO; GO:0002520; P:immune system development; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0070306; P:lens fiber cell differentiation; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:1903243; P:negative regulation of cardiac muscle hypertrophy in response to stress; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IDA:BHF-UCL.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0061767; P:negative regulation of lung blood pressure; IEA:Ensembl.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; IMP:BHF-UCL.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0033689; P:negative regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0061045; P:negative regulation of wound healing; IEA:Ensembl.
DR   GO; GO:0038092; P:nodal signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002076; P:osteoblast development; IEA:Ensembl.
DR   GO; GO:0048340; P:paraxial mesoderm morphogenesis; IEA:Ensembl.
DR   GO; GO:0060039; P:pericardium development; IEA:Ensembl.
DR   GO; GO:0010694; P:positive regulation of alkaline phosphatase activity; IEA:Ensembl.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; NAS:BHF-UCL.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:1901203; P:positive regulation of extracellular matrix assembly; IDA:BHF-UCL.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IEA:Ensembl.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; NAS:BHF-UCL.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0032916; P:positive regulation of transforming growth factor beta3 production; IEA:Ensembl.
DR   GO; GO:0031053; P:primary miRNA processing; TAS:BHF-UCL.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0050821; P:protein stabilization; IEA:Ensembl.
DR   GO; GO:0051098; P:regulation of binding; IEA:Ensembl.
DR   GO; GO:0050678; P:regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0050776; P:regulation of immune response; IEA:Ensembl.
DR   GO; GO:0016202; P:regulation of striated muscle tissue development; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0032909; P:regulation of transforming growth factor beta2 production; IMP:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0007183; P:SMAD protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0060395; P:SMAD protein signal transduction; NAS:BHF-UCL.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0042110; P:T cell activation; IEA:Ensembl.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0060290; P:transdifferentiation; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   GO; GO:0042060; P:wound healing; TAS:BHF-UCL.
DR   DisProt; DP01648; -.
DR   Gene3D; 2.60.200.10; -; 1.
DR   Gene3D; 3.90.520.10; -; 1.
DR   IDEAL; IID00113; -.
DR   InterPro; IPR013790; Dwarfin.
DR   InterPro; IPR003619; MAD_homology1_Dwarfin-type.
DR   InterPro; IPR013019; MAD_homology_MH1.
DR   InterPro; IPR017855; SMAD-like_dom_sf.
DR   InterPro; IPR001132; SMAD_dom_Dwarfin-type.
DR   InterPro; IPR008984; SMAD_FHA_dom_sf.
DR   InterPro; IPR036578; SMAD_MH1_sf.
DR   PANTHER; PTHR13703; PTHR13703; 1.
DR   Pfam; PF03165; MH1; 1.
DR   Pfam; PF03166; MH2; 1.
DR   SMART; SM00523; DWA; 1.
DR   SMART; SM00524; DWB; 1.
DR   SUPFAM; SSF49879; SSF49879; 1.
DR   SUPFAM; SSF56366; SSF56366; 1.
DR   PROSITE; PS51075; MH1; 1.
DR   PROSITE; PS51076; MH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ADP-ribosylation; Alternative splicing;
KW   Aortic aneurysm; Cytoplasm; Disease mutation; DNA-binding;
KW   Host-virus interaction; Isopeptide bond; Metal-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:22814378"
FT   CHAIN           2..425
FT                   /note="Mothers against decapentaplegic homolog 3"
FT                   /id="PRO_0000090856"
FT   DOMAIN          10..136
FT                   /note="MH1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00438"
FT   DOMAIN          232..425
FT                   /note="MH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00439"
FT   REGION          137..231
FT                   /note="Linker"
FT   REGION          271..324
FT                   /note="Sufficient for interaction with XPO4"
FT                   /evidence="ECO:0000269|PubMed:16449645"
FT   METAL           64
FT                   /note="Zinc"
FT   METAL           109
FT                   /note="Zinc"
FT   METAL           121
FT                   /note="Zinc"
FT   METAL           126
FT                   /note="Zinc"
FT   SITE            40
FT                   /note="Required for trimerization"
FT   SITE            41
FT                   /note="Required for interaction with DNA and JUN and for
FT                   functional cooperation with JUN"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:22814378"
FT   MOD_RES         8
FT                   /note="Phosphothreonine; by CDK2 and CDK4"
FT                   /evidence="ECO:0000269|PubMed:15241418"
FT   MOD_RES         179
FT                   /note="Phosphothreonine; by CDK2, CDK4 and MAPK"
FT                   /evidence="ECO:0000269|PubMed:15241418,
FT                   ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245"
FT   MOD_RES         204
FT                   /note="Phosphoserine; by GSK3 and MAPK"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00439,
FT                   ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:16156666,
FT                   ECO:0000269|PubMed:19218245"
FT   MOD_RES         208
FT                   /note="Phosphoserine; by MAPK"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00439,
FT                   ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:16156666,
FT                   ECO:0000269|PubMed:19218245"
FT   MOD_RES         213
FT                   /note="Phosphoserine; by CDK2 and CDK4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00439,
FT                   ECO:0000269|PubMed:15241418"
FT   MOD_RES         378
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:16862174"
FT   MOD_RES         416
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         418
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00439,
FT                   ECO:0000269|PubMed:18794808"
FT   MOD_RES         422
FT                   /note="Phosphoserine; by TGFBR1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUN5,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   MOD_RES         423
FT                   /note="Phosphoserine; by TGFBR1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUN5,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   MOD_RES         425
FT                   /note="Phosphoserine; by TGFBR1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUN5,
FT                   ECO:0000255|PROSITE-ProRule:PRU00439"
FT   CROSSLNK        33
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000305|PubMed:21947082"
FT   CROSSLNK        81
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000305|PubMed:21947082"
FT   VAR_SEQ         1..195
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045348"
FT   VAR_SEQ         1..105
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043793"
FT   VAR_SEQ         1..68
FT                   /note="MSSILPFTPPIVKRLLGWKKGEQNGQEEKWCEKAVKSLVKKLKKTGQLDELE
FT                   KAITTQNVNTKCITIP -> MSCLHPRQTWKGAALVHRKAWWMG (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042900"
FT   VARIANT         112
FT                   /note="A -> V (in LDS3; dbSNP:rs387906854)"
FT                   /evidence="ECO:0000269|PubMed:21778426"
FT                   /id="VAR_067051"
FT   VARIANT         170
FT                   /note="I -> V (in dbSNP:rs35874463)"
FT                   /id="VAR_052021"
FT   VARIANT         239
FT                   /note="E -> K (in LDS3; dbSNP:rs387906853)"
FT                   /evidence="ECO:0000269|PubMed:21778426"
FT                   /id="VAR_067047"
FT   VARIANT         261
FT                   /note="T -> I (in LDS3; dbSNP:rs387906851)"
FT                   /evidence="ECO:0000269|PubMed:21217753"
FT                   /id="VAR_065578"
FT   VARIANT         279
FT                   /note="R -> K (in LDS3; dbSNP:rs387906852)"
FT                   /evidence="ECO:0000269|PubMed:21778426"
FT                   /id="VAR_067048"
FT   VARIANT         287
FT                   /note="R -> W (in LDS3; dbSNP:rs387906850)"
FT                   /evidence="ECO:0000269|PubMed:21217753"
FT                   /id="VAR_065579"
FT   VARIANT         393
FT                   /note="P -> L (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036474"
FT   MUTAGEN         8
FT                   /note="T->V: Reduced phosphorylation, increased
FT                   transcriptional and antiproliferative activities. Further
FT                   increase in transcriptional and antiproliferative
FT                   activities; when associated with V-179 and A-213."
FT                   /evidence="ECO:0000269|PubMed:15241418"
FT   MUTAGEN         33
FT                   /note="K->R: Slightly decreased monoubiquitination."
FT                   /evidence="ECO:0000269|PubMed:21947082"
FT   MUTAGEN         40
FT                   /note="K->A: Little effect on interaction with DNA or JUN.
FT                   Abolishes interaction with DNA and JUN; when associated
FT                   with A-41; A-43 and A-44."
FT                   /evidence="ECO:0000269|PubMed:10995748"
FT   MUTAGEN         41
FT                   /note="K->A: Greatly reduced interaction with DNA and JUN.
FT                   Abolishes interaction with DNA and JUN; when associated
FT                   with A-40; A-44 and A-43."
FT                   /evidence="ECO:0000269|PubMed:10995748"
FT   MUTAGEN         43
FT                   /note="K->A: Little effect on interaction with DNA or JUN.
FT                   Abolishes interaction with DNA and JUN; when associated
FT                   with A-40; A-41 and A-44."
FT                   /evidence="ECO:0000269|PubMed:10995748"
FT   MUTAGEN         44
FT                   /note="K->A: Little effect on interaction with DNA or JUN.
FT                   Abolishes interaction with JUN; when associated with A-40;
FT                   A-41 and A-43."
FT                   /evidence="ECO:0000269|PubMed:10995748"
FT   MUTAGEN         53
FT                   /note="K->R: Slightly decreased monoubiquitination."
FT                   /evidence="ECO:0000269|PubMed:21947082"
FT   MUTAGEN         74
FT                   /note="R->D: Reduced interaction with JUN. Loss of
FT                   transcriptional activity and cooperation with JUN."
FT                   /evidence="ECO:0000269|PubMed:10995748"
FT   MUTAGEN         81
FT                   /note="K->R: Decreased monoubiquitination."
FT                   /evidence="ECO:0000269|PubMed:21947082"
FT   MUTAGEN         179
FT                   /note="T->V: Reduced phosphorylation, increased
FT                   transcriptional and increased antiproliferative activities.
FT                   Further increase in transcriptional and antiproliferative
FT                   activities; when associated with V-8 and A-213."
FT                   /evidence="ECO:0000269|PubMed:15241418,
FT                   ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245"
FT   MUTAGEN         204
FT                   /note="S->A: Increased transcriptional activity. Further
FT                   increased transcriptional activity; when associated with
FT                   S-208."
FT                   /evidence="ECO:0000269|PubMed:15241418,
FT                   ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245"
FT   MUTAGEN         208
FT                   /note="S->A: Increased transcriptional activity. Further
FT                   increased transcriptional activity; when associated with
FT                   S-208."
FT                   /evidence="ECO:0000269|PubMed:15241418,
FT                   ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245"
FT   MUTAGEN         213
FT                   /note="S->A: Reduced phosphorylation. Increased
FT                   transcriptional and antiproliferative activities. Further
FT                   increase in transcriptional and antiproliferative
FT                   activities; when associated with V-8 and V-179."
FT                   /evidence="ECO:0000269|PubMed:15241418"
FT   MUTAGEN         333
FT                   /note="K->R: No effect on acetylation. Completely abolishes
FT                   acetylation and 97% reduction in transcriptional activity;
FT                   when associated with R-341; R-378 and R-409."
FT                   /evidence="ECO:0000269|PubMed:16862174"
FT   MUTAGEN         341
FT                   /note="K->R: No effect on acetylation. Completely abolishes
FT                   acetylation and 97% reduction in transcriptional activity;
FT                   when associated with R-333; R-378 and R-409."
FT                   /evidence="ECO:0000269|PubMed:16862174"
FT   MUTAGEN         378
FT                   /note="K->Q: Increased transcriptional activity. No further
FT                   increase in transcriptional activity with EP300."
FT                   /evidence="ECO:0000269|PubMed:16862174"
FT   MUTAGEN         378
FT                   /note="K->R: Greatly reduced acetylation and 85% reduction
FT                   in transcriptional activity. Completely abolishes
FT                   acetylation and 97% reduction in transcriptional activity;
FT                   when associated with R-333; R-341 and R-409."
FT                   /evidence="ECO:0000269|PubMed:16862174"
FT   MUTAGEN         409
FT                   /note="K->R: No effect on acetylation. Completely abolishes
FT                   acetylation and 97% reduction in transcriptional activity;
FT                   when associated with R-333; R-341 and R-378."
FT                   /evidence="ECO:0000269|PubMed:16862174"
FT   MUTAGEN         418
FT                   /note="S->A: Increased constitutive activity."
FT                   /evidence="ECO:0000269|PubMed:18794808"
FT   MUTAGEN         418
FT                   /note="S->D: Decreased activity."
FT                   /evidence="ECO:0000269|PubMed:18794808"
FT   MUTAGEN         422..425
FT                   /note="SSVS->AAVA: Does not abolish protein nuclear export.
FT                   Abolishes almost completely acetylation."
FT                   /evidence="ECO:0000269|PubMed:11224571,
FT                   ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16862174"
FT   MUTAGEN         422..425
FT                   /note="SSVS->EEVE: Forms heterotrimers."
FT                   /evidence="ECO:0000269|PubMed:11224571,
FT                   ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16862174"
FT   MUTAGEN         422..425
FT                   /note="SSVS->RRVR: Diminishes cargo protein export."
FT                   /evidence="ECO:0000269|PubMed:11224571,
FT                   ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16862174"
FT   CONFLICT        178
FT                   /note="E -> EVGTWAAQAGL (in Ref. 3; BAA22032)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        360
FT                   /note="F -> L (in Ref. 5; BAH13315)"
FT                   /evidence="ECO:0000305"
FT   HELIX           11..17
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   HELIX           25..44
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   HELIX           48..57
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   STRAND          60..62
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   STRAND          66..68
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   STRAND          75..77
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   STRAND          80..82
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   HELIX           84..92
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   HELIX           100..102
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   STRAND          103..105
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   HELIX           113..115
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   STRAND          118..121
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   HELIX           124..126
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   STRAND          127..129
FT                   /evidence="ECO:0000244|PDB:5OD6"
FT   STRAND          221..225
FT                   /evidence="ECO:0000244|PDB:1MK2"
FT   STRAND          231..239
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          242..250
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          252..258
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          268..270
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   HELIX           271..273
FT                   /evidence="ECO:0000244|PDB:1U7F"
FT   HELIX           281..290
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          294..299
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          302..307
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          309..311
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          313..316
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   HELIX           318..321
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   HELIX           323..325
FT                   /evidence="ECO:0000244|PDB:1MK2"
FT   STRAND          332..334
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          339..343
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   HELIX           345..358
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   HELIX           360..364
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   HELIX           365..370
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          371..377
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   STRAND          384..386
FT                   /evidence="ECO:0000244|PDB:1MK2"
FT   HELIX           389..391
FT                   /evidence="ECO:0000244|PDB:5XOC"
FT   STRAND          392..400
FT                   /evidence="ECO:0000244|PDB:1MJS"
FT   HELIX           401..413
FT                   /evidence="ECO:0000244|PDB:1MJS"
SQ   SEQUENCE   425 AA;  48081 MW;  46DF5E8B371321AC CRC64;
     MSSILPFTPP IVKRLLGWKK GEQNGQEEKW CEKAVKSLVK KLKKTGQLDE LEKAITTQNV
     NTKCITIPRS LDGRLQVSHR KGLPHVIYCR LWRWPDLHSH HELRAMELCE FAFNMKKDEV
     CVNPYHYQRV ETPVLPPVLV PRHTEIPAEF PPLDDYSHSI PENTNFPAGI EPQSNIPETP
     PPGYLSEDGE TSDHQMNHSM DAGSPNLSPN PMSPAHNNLD LQPVTYCEPA FWCSISYYEL
     NQRVGETFHA SQPSMTVDGF TDPSNSERFC LGLLSNVNRN AAVELTRRHI GRGVRLYYIG
     GEVFAECLSD SAIFVQSPNC NQRYGWHPAT VCKIPPGCNL KIFNNQEFAA LLAQSVNQGF
     EAVYQLTRMC TIRMSFVKGW GAEYRRQTVT STPCWIELHL NGPLQWLDKV LTQMGSPSIR
     CSSVS
//
ID   BST2_HUMAN              Reviewed;         180 AA.
AC   Q10589; A8K4Y4; Q53G07;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-AUG-2020, entry version 172.
DE   RecName: Full=Bone marrow stromal antigen 2;
DE            Short=BST-2;
DE   AltName: Full=HM1.24 antigen;
DE   AltName: Full=Tetherin;
DE   AltName: CD_antigen=CD317;
DE   Flags: Precursor;
GN   Name=BST2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7607676; DOI=10.1016/0888-7543(95)80171-h;
RA   Ishikawa J., Kaisho T., Tomizawa H., Lee B.O., Kobune Y., Inazawa J.,
RA   Oritani K., Itoh M., Ochi T., Ishihara K., Hirano T.;
RT   "Molecular cloning and chromosomal mapping of a bone marrow stromal cell
RT   surface gene, BST2, that may be involved in pre-B-cell growth.";
RL   Genomics 26:527-534(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND SUBUNIT.
RX   PubMed=10329429; DOI=10.1006/bbrc.1999.0683;
RA   Ohtomo T., Sugamata Y., Ozaki Y., Ono K., Yoshimura Y., Kawai S.,
RA   Koishihara Y., Ozaki S., Kosaka M., Hirano T., Tsuchiya M.;
RT   "Molecular cloning and characterization of a surface antigen preferentially
RT   overexpressed on multiple myeloma cells.";
RL   Biochem. Biophys. Res. Commun. 258:583-591(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   TISSUE SPECIFICITY, INDUCTION BY B-CELL ACTIVATION, AND NOMENCLATURE.
RX   PubMed=16157322; DOI=10.1016/j.cellimm.2005.08.002;
RA   Vidal-Laliena M., Romero X., March S., Requena V., Petriz J., Engel P.;
RT   "Characterization of antibodies submitted to the B cell section of the 8th
RT   Human Leukocyte Differentiation Antigens Workshop by flow cytometry and
RT   immunohistochemistry.";
RL   Cell. Immunol. 236:6-16(2005).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND GPI-ANCHOR [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16602701; DOI=10.1021/pr050419u;
RA   Elortza F., Mohammed S., Bunkenborg J., Foster L.J., Nuehse T.S.,
RA   Brodbeck U., Peck S.C., Jensen O.N.;
RT   "Modification-specific proteomics of plasma membrane proteins:
RT   identification and characterization of glycosylphosphatidylinositol-
RT   anchored proteins released upon phospholipase D treatment.";
RL   J. Proteome Res. 5:935-943(2006).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17566972; DOI=10.1002/pmic.200700068;
RA   Omaetxebarria M.J., Elortza F., Rodriguez-Suarez E., Aloria K.,
RA   Arizmendi J.M., Jensen O.N., Matthiesen R.;
RT   "Computational approach for identification and characterization of GPI-
RT   anchored peptides in proteomics experiments.";
RL   Proteomics 7:1951-1960(2007).
RN   [11]
RP   FUNCTION IN HIV-1 INFECTION, AND INDUCTION BY HIV-1 VPU (MICROBIAL
RP   INFECTION).
RX   PubMed=18342597; DOI=10.1016/j.chom.2008.03.001;
RA   Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R.,
RA   Johnson M.C., Stephens E.B., Guatelli J.;
RT   "The interferon-induced protein BST-2 restricts HIV-1 release and is
RT   downregulated from the cell surface by the viral Vpu protein.";
RL   Cell Host Microbe 3:245-252(2008).
RN   [12]
RP   FUNCTION, AND INDUCTION NY HIV-1 VPU (MICROBIAL INFECTION).
RX   PubMed=18200009; DOI=10.1038/nature06553;
RA   Neil S.J., Zang T., Bieniasz P.D.;
RT   "Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.";
RL   Nature 451:425-430(2008).
RN   [13]
RP   FUNCTION IN HIV-1 INFECTION, GLYCOSYLATION AT ASN-65 AND ASN-92,
RP   SUBCELLULAR LOCATION, DISULFIDE BONDS, SUBUNIT, TOPOLOGY, GPI-ANCHOR, AND
RP   MUTAGENESIS OF ASN-65 AND ASN-92.
RX   PubMed=19879838; DOI=10.1016/j.cell.2009.08.039;
RA   Perez-Caballero D., Zang T., Ebrahimi A., McNatt M.W., Gregory D.A.,
RA   Johnson M.C., Bieniasz P.D.;
RT   "Tetherin inhibits HIV-1 release by directly tethering virions to cells.";
RL   Cell 139:499-511(2009).
RN   [14]
RP   REVIEW.
RX   PubMed=19917491; DOI=10.1016/j.chom.2009.11.002;
RA   Gupta R.K., Towers G.J.;
RT   "A tail of Tetherin: how pandemic HIV-1 conquered the world.";
RL   Cell Host Microbe 6:393-395(2009).
RN   [15]
RP   INTERACTION WITH HIV-1 VPU (MICROBIAL INFECTION), AND INDUCTION BY HIV-1
RP   VPU (MICROBIAL INFECTION).
RX   PubMed=19837671; DOI=10.1074/jbc.m109.058305;
RA   Iwabu Y., Fujita H., Kinomoto M., Kaneko K., Ishizaka Y., Tanaka Y.,
RA   Sata T., Tokunaga K.;
RT   "HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin
RT   through transmembrane interactions leading to lysosomes.";
RL   J. Biol. Chem. 284:35060-35072(2009).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH LILRA4/ILT7.
RX   PubMed=19564354; DOI=10.1084/jem.20090547;
RA   Cao W., Bover L., Cho M., Wen X., Hanabuchi S., Bao M., Rosen D.B.,
RA   Wang Y.H., Shaw J.L., Du Q., Li C., Arai N., Yao Z., Lanier L.L., Liu Y.J.;
RT   "Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and
RT   ILT7 receptor interaction.";
RL   J. Exp. Med. 206:1603-1614(2009).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-65.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [18]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19036818; DOI=10.1128/jvi.02211-08;
RA   Jouvenet N., Neil S.J., Zhadina M., Zang T., Kratovac Z., Lee Y.,
RA   McNatt M., Hatziioannou T., Bieniasz P.D.;
RT   "Broad-spectrum inhibition of retroviral and filoviral particle release by
RT   tetherin.";
RL   J. Virol. 83:1837-1844(2009).
RN   [19]
RP   INTERACTION WITH HIV-2 ENV (MICROBIAL INFECTION), SUBCELLULAR LOCATION, AND
RP   INDUCTION BY HIV-2 ENV (MICROBIAL INFECTION).
RX   PubMed=19740980; DOI=10.1128/jvi.01515-09;
RA   Le Tortorec A., Neil S.J.;
RT   "Antagonism to and intracellular sequestration of human tetherin by the
RT   human immunodeficiency virus type 2 envelope glycoprotein.";
RL   J. Virol. 83:11966-11978(2009).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-65.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [21]
RP   FUNCTION, INTERACTION WITH EBOLA GP PROTEIN (MICROBIAL INFECTION), AND
RP   INDUCTION BY EBOLA GP PROTEIN (MICROBIAL INFECTION).
RX   PubMed=19179289; DOI=10.1073/pnas.0811014106;
RA   Kaletsky R.L., Francica J.R., Agrawal-Gamse C., Bates P.;
RT   "Tetherin-mediated restriction of filovirus budding is antagonized by the
RT   Ebola glycoprotein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:2886-2891(2009).
RN   [22]
RP   GLYCOSYLATION AT ASN-65 AND ASN-92, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=19737401; DOI=10.1186/1742-4690-6-80;
RA   Andrew A.J., Miyagi E., Kao S., Strebel K.;
RT   "The formation of cysteine-linked dimers of BST-2/tetherin is important for
RT   inhibition of HIV-1 virus release but not for sensitivity to Vpu.";
RL   Retrovirology 6:80-80(2009).
RN   [23]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20686043; DOI=10.1128/jvi.00103-10;
RA   Radoshitzky S.R., Dong L., Chi X., Clester J.C., Retterer C., Spurgers K.,
RA   Kuhn J.H., Sandwick S., Ruthel G., Kota K., Boltz D., Warren T.,
RA   Kranzusch P.J., Whelan S.P., Bavari S.;
RT   "Infectious Lassa virus, but not filoviruses, is restricted by BST-
RT   2/tetherin.";
RL   J. Virol. 84:10569-10580(2010).
RN   [24]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20943977; DOI=10.1128/jvi.01328-10;
RA   Weidner J.M., Jiang D., Pan X.B., Chang J., Block T.M., Guo J.T.;
RT   "Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit
RT   vesicular stomatitis virus infection via distinct mechanisms.";
RL   J. Virol. 84:12646-12657(2010).
RN   [25]
RP   FUNCTION IN KSHV AND HIV-1 INFECTION, SUBCELLULAR LOCATION (MICROBIAL
RP   INFECTION), MUTAGENESIS OF LYS-18 AND LYS-21, UBIQUITINATION AT LYS-18 BY
RP   KSH VIRUS E3 UBIQUITIN-PROTEIN LIGASE K5 (MICROBIAL INFECTION), AND
RP   INDUCTION BY KSHV K5 (MICROBIAL INFECTION).
RX   PubMed=20419159; DOI=10.1371/journal.ppat.1000843;
RA   Pardieu C., Vigan R., Wilson S.J., Calvi A., Zang T., Bieniasz P.,
RA   Kellam P., Towers G.J., Neil S.J.;
RT   "The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle
RT   release by mediating ubiquitin-dependent endosomal degradation of
RT   tetherin.";
RL   PLoS Pathog. 6:E1000843-E1000843(2010).
RN   [26]
RP   REVIEW.
RX   PubMed=20688520; DOI=10.1016/j.tim.2010.06.010;
RA   Evans D.T., Serra-Moreno R., Singh R.K., Guatelli J.C.;
RT   "BST-2/tetherin: a new component of the innate immune response to enveloped
RT   viruses.";
RL   Trends Microbiol. 18:388-396(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   REVIEW.
RX   PubMed=22180752; DOI=10.3389/fmicb.2011.00250;
RA   Arias J.F., Iwabu Y., Tokunaga K.;
RT   "structural basis for the antiviral activity of Bst-2/tetherin and its
RT   viral antagonism.";
RL   Front. Microbiol. 2:250-250(2011).
RN   [29]
RP   REVIEW.
RX   PubMed=21166593; DOI=10.1089/jir.2010.0108;
RA   Andrew A., Strebel K.;
RT   "The interferon-inducible host factor bone marrow stromal antigen
RT   2/tetherin restricts virion release, but is it actually a viral restriction
RT   factor?";
RL   J. Interferon Cytokine Res. 31:137-144(2011).
RN   [30]
RP   REVIEW.
RX   PubMed=21222046; DOI=10.1007/s11481-010-9256-1;
RA   Kuhl B.D., Cheng V., Wainberg M.A., Liang C.;
RT   "Tetherin and its viral antagonists.";
RL   J. Neuroimmun. Pharmacol. 6:188-201(2011).
RN   [31]
RP   FUNCTION.
RX   PubMed=21529378; DOI=10.1186/1743-422x-8-198;
RA   Xu F., Tan J., Liu R., Xu D., Li Y., Geng Y., Liang C., Qiao W.;
RT   "Tetherin inhibits prototypic foamy virus release.";
RL   Virol. J. 8:198-198(2011).
RN   [32]
RP   FUNCTION.
RX   PubMed=21621240; DOI=10.1016/j.virol.2011.05.006;
RA   Watanabe R., Leser G.P., Lamb R.A.;
RT   "Influenza virus is not restricted by tetherin whereas influenza VLP
RT   production is restricted by tetherin.";
RL   Virology 417:50-56(2011).
RN   [33]
RP   REVIEW.
RX   PubMed=21994744; DOI=10.3390/v3050520;
RA   Le Tortorec A., Willey S., Neil S.J.;
RT   "Antiviral inhibition of enveloped virus release by tetherin/BST-2: action
RT   and counteraction.";
RL   Viruses 3:520-540(2011).
RN   [34]
RP   REVIEW.
RX   PubMed=22509177; DOI=10.3389/fmicb.2012.00131;
RA   Sato K., Gee P., Koyanagi Y.;
RT   "Vpu and BST2: still not there yet?";
RL   Front. Microbiol. 3:131-131(2012).
RN   [35]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MMP14.
RX   PubMed=22065321; DOI=10.1002/jcb.23433;
RA   Gu G., Zhao D., Yin Z., Liu P.;
RT   "BST-2 binding with cellular MT1-MMP blocks cell growth and migration via
RT   decreasing MMP2 activity.";
RL   J. Cell. Biochem. 113:1013-1021(2012).
RN   [36]
RP   REVIEW.
RX   PubMed=22811908; DOI=10.1155/2012/424768;
RA   Hammonds J., Wang J.J., Spearman P.;
RT   "Restriction of retroviral replication by tetherin/BST-2.";
RL   Mol. Biol. Int. 2012:424768-424768(2012).
RN   [37]
RP   FUNCTION, SUBUNIT, ALTERNATIVE INITIATION (ISOFORMS 1 AND 2), INDUCTION,
RP   AND MUTAGENESIS OF 3-SER--SER-5; TYR-6 AND TYR-8.
RX   PubMed=23028328; DOI=10.1371/journal.ppat.1002931;
RA   Cocka L.J., Bates P.;
RT   "Identification of alternatively translated Tetherin isoforms with
RT   differing antiviral and signaling activities.";
RL   PLoS Pathog. 8:E1002931-E1002931(2012).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [39]
RP   FUNCTION.
RX   PubMed=22520941; DOI=10.1016/j.virol.2012.03.011;
RA   Dafa-Berger A., Kuzmina A., Fassler M., Yitzhak-Asraf H., Shemer-Avni Y.,
RA   Taube R.;
RT   "Modulation of hepatitis C virus release by the interferon-induced protein
RT   BST-2/tetherin.";
RL   Virology 428:98-111(2012).
RN   [40]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBCELLULAR LOCATION (MICROBIAL INFECTION),
RP   INTERACTION WITH LILRA4, AND GPI-ANCHOR.
RX   PubMed=26172439; DOI=10.1371/journal.ppat.1005024;
RA   Bego M.G., Cote E., Aschman N., Mercier J., Weissenhorn W., Cohen E.A.;
RT   "Vpu exploits the cross-talk between BST2 and the ILT7 receptor to suppress
RT   anti-HIV-1 responses by plasmacytoid dendritic Cells.";
RL   PLoS Pathog. 11:E1005024-E1005024(2015).
RN   [41]
RP   FUNCTION, INDUCTION (MICROBIAL INFECTION), INTERACTION WITH SARS-COV ORF7A
RP   PROTEIN (MICROBIAL INFECTION), AND SUBUNIT.
RX   PubMed=26378163; DOI=10.1128/jvi.02274-15;
RA   Taylor J.K., Coleman C.M., Postel S., Sisk J.M., Bernbaum J.G.,
RA   Venkataraman T., Sundberg E.J., Frieman M.B.;
RT   "Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow
RT   Stromal Antigen 2 Virion Tethering through a Novel Mechanism of
RT   Glycosylation Interference.";
RL   J. Virol. 89:11820-11833(2015).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [43]
RP   FUNCTION, INDUCTION (MICROBIAL INFECTION), SUBUNIT, AND MUTAGENESIS OF
RP   CYS-53; CYS-63 AND CYS-91.
RX   PubMed=31199522; DOI=10.1002/jmv.25518;
RA   Wang S.M., Huang K.J., Wang C.T.;
RT   "Severe acute respiratory syndrome coronavirus spike protein counteracts
RT   BST2-mediated restriction of virus-like particle release.";
RL   J. Med. Virol. 91:1743-1750(2019).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.77 ANGSTROMS) OF 87-147, FUNCTION, DOMAIN,
RP   DISULFIDE BONDS, SUBUNIT, SUBCELLULAR LOCATION, AND CIRCULAR DICHROISM.
RX   PubMed=20399176; DOI=10.1016/j.chom.2010.03.005;
RA   Hinz A., Miguet N., Natrajan G., Usami Y., Yamanaka H., Renesto P.,
RA   Hartlieb B., McCarthy A.A., Simorre J.P., Gottlinger H., Weissenhorn W.;
RT   "Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin
RT   ectodomain.";
RL   Cell Host Microbe 7:314-323(2010).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 47-152, SUBUNIT, AND DISULFIDE
RP   BONDS.
RX   PubMed=20880831; DOI=10.1073/pnas.1008206107;
RA   Schubert H.L., Zhai Q., Sandrin V., Eckert D.M., Garcia-Maya M., Saul L.,
RA   Sundquist W.I., Steiner R.A., Hill C.P.;
RT   "Structural and functional studies on the extracellular domain of
RT   BST2/tetherin in reduced and oxidized conformations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:17951-17956(2010).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 47-161, SUBUNIT, FUNCTION, AND
RP   DISULFIDE BONDS.
RX   PubMed=20940320; DOI=10.1073/pnas.1011485107;
RA   Yang H., Wang J., Jia X., McNatt M.W., Zang T., Pan B., Meng W., Wang H.W.,
RA   Bieniasz P.D., Xiong Y.;
RT   "Structural insight into the mechanisms of enveloped virus tethering by
RT   tetherin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:18428-18432(2010).
CC   -!- FUNCTION: IFN-induced antiviral host restriction factor which
CC       efficiently blocks the release of diverse mammalian enveloped viruses
CC       by directly tethering nascent virions to the membranes of infected
CC       cells. Acts as a direct physical tether, holding virions to the cell
CC       membrane and linking virions to each other. The tethered virions can be
CC       internalized by endocytosis and subsequently degraded or they can
CC       remain on the cell surface. In either case, their spread as cell-free
CC       virions is restricted (PubMed:22520941, PubMed:21529378,
CC       PubMed:20940320, PubMed:20419159, PubMed:20399176, PubMed:19879838,
CC       PubMed:19036818, PubMed:18342597, PubMed:18200009). Its target viruses
CC       belong to diverse families, including retroviridae: human
CC       immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus
CC       type 2 (HIV-2), simian immunodeficiency viruses (SIVs), equine
CC       infectious anemia virus (EIAV), feline immunodeficiency virus (FIV),
CC       prototype foamy virus (PFV), Mason-Pfizer monkey virus (MPMV), human T-
CC       cell leukemia virus type 1 (HTLV-1), Rous sarcoma virus (RSV) and
CC       murine leukemia virus (MLV), flavivirideae: hepatitis C virus (HCV),
CC       filoviridae: ebola virus (EBOV) and marburg virus (MARV), arenaviridae:
CC       lassa virus (LASV) and machupo virus (MACV), herpesviridae: kaposis
CC       sarcoma-associated herpesvirus (KSHV), rhabdoviridae: vesicular
CC       stomatitis virus (VSV), orthomyxoviridae: influenza A virus,
CC       paramyxoviridae: nipah virus, and coronaviridae: SARS-CoV
CC       (PubMed:22520941, PubMed:21621240, PubMed:21529378, PubMed:20943977,
CC       PubMed:20686043, PubMed:20419159, PubMed:20399176, PubMed:19879838,
CC       PubMed:19179289, PubMed:18342597, PubMed:18200009, PubMed:26378163,
CC       PubMed:31199522). Can inhibit cell surface proteolytic activity of
CC       MMP14 causing decreased activation of MMP15 which results in inhibition
CC       of cell growth and migration (PubMed:22065321). Can stimulate signaling
CC       by LILRA4/ILT7 and consequently provide negative feedback to the
CC       production of IFN by plasmacytoid dendritic cells in response to viral
CC       infection (PubMed:19564354, PubMed:26172439). Plays a role in the
CC       organization of the subapical actin cytoskeleton in polarized
CC       epithelial cells. Isoform 1 and isoform 2 are both effective viral
CC       restriction factors but have differing antiviral and signaling
CC       activities (PubMed:23028328, PubMed:26172439). Isoform 2 is resistant
CC       to HIV-1 Vpu-mediated degradation and restricts HIV-1 viral budding in
CC       the presence of Vpu (PubMed:23028328, PubMed:26172439). Isoform 1 acts
CC       as an activator of NF-kappa-B and this activity is inhibited by isoform
CC       2 (PubMed:23028328). {ECO:0000269|PubMed:18200009,
CC       ECO:0000269|PubMed:18342597, ECO:0000269|PubMed:19036818,
CC       ECO:0000269|PubMed:19179289, ECO:0000269|PubMed:19564354,
CC       ECO:0000269|PubMed:19879838, ECO:0000269|PubMed:20399176,
CC       ECO:0000269|PubMed:20419159, ECO:0000269|PubMed:20686043,
CC       ECO:0000269|PubMed:20940320, ECO:0000269|PubMed:20943977,
CC       ECO:0000269|PubMed:21529378, ECO:0000269|PubMed:21621240,
CC       ECO:0000269|PubMed:22065321, ECO:0000269|PubMed:22520941,
CC       ECO:0000269|PubMed:23028328, ECO:0000269|PubMed:26172439,
CC       ECO:0000269|PubMed:26378163, ECO:0000269|PubMed:31199522}.
CC   -!- SUBUNIT: Parallel homodimer; disulfide-linked. May form homotetramers
CC       under reducing conditions. Isoform 1 and isoform 2 form homodimers and
CC       also heterodimers with each other. Dimerization is essential for its
CC       antiviral activity (PubMed:26378163, PubMed:10329429, PubMed:19737401,
CC       PubMed:19879838, PubMed:23028328, PubMed:20399176, PubMed:20880831,
CC       PubMed:20940320, PubMed:31199522). Interacts (via cytoplasmic domain)
CC       with ARHGAP44 (By similarity). Interacts with MMP14 (via C-terminal
CC       cytoplasmic tail) (PubMed:22065321). Interacts with LILRA4/ILT7
CC       (PubMed:19564354). {ECO:0000250|UniProtKB:Q811A2,
CC       ECO:0000269|PubMed:10329429, ECO:0000269|PubMed:19564354,
CC       ECO:0000269|PubMed:19737401, ECO:0000269|PubMed:19879838,
CC       ECO:0000269|PubMed:20399176, ECO:0000269|PubMed:20880831,
CC       ECO:0000269|PubMed:20940320, ECO:0000269|PubMed:22065321,
CC       ECO:0000269|PubMed:23028328, ECO:0000269|PubMed:26378163,
CC       ECO:0000269|PubMed:31199522}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with ebola GP protein.
CC       {ECO:0000269|PubMed:19179289}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via transmembrane domain)
CC       with HIV-1 VPU (via transmembrane domain).
CC       {ECO:0000269|PubMed:19837671}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-2 ENV.
CC       {ECO:0000269|PubMed:19740980}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV ORF7a protein.
CC       {ECO:0000269|PubMed:26378163}.
CC   -!- INTERACTION:
CC       Q10589; Q10589: BST2; NbExp=10; IntAct=EBI-2476339, EBI-2476339;
CC       Q10589; P60033: CD81; NbExp=3; IntAct=EBI-2476339, EBI-712921;
CC       Q10589; P59901: LILRA4; NbExp=2; IntAct=EBI-2476339, EBI-2841591;
CC       Q10589; P35585: Ap1m1; Xeno; NbExp=2; IntAct=EBI-2476339, EBI-1040251;
CC       Q10589; A9QPL9: GP; Xeno; NbExp=2; IntAct=EBI-2476339, EBI-15754841;
CC       Q10589; P69699: vpu; Xeno; NbExp=7; IntAct=EBI-2476339, EBI-10757638;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi network. Cell
CC       membrane {ECO:0000269|PubMed:26172439}; Single-pass type II membrane
CC       protein. Cell membrane {ECO:0000269|PubMed:19879838,
CC       ECO:0000269|PubMed:26172439}; Lipid-anchor, GPI-anchor
CC       {ECO:0000269|PubMed:19879838, ECO:0000305|PubMed:26172439}. Membrane
CC       raft. Cytoplasm. Apical cell membrane {ECO:0000250}. Note=Shuttles
CC       between the cell membrane, where it is present predominantly in
CC       membrane/lipid rafts, and the trans-Golgi network. Forms a complex with
CC       MMP14 and localizes to the cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi network
CC       {ECO:0000269|PubMed:26172439}. Late endosome
CC       {ECO:0000269|PubMed:20419159}. Note=(Microbial infection) HIV-1 VPU and
CC       HIV-2 ENV can target it to the trans-Golgi network thus sequestering it
CC       away from virus assembly sites on the cell membrane. Targeted to late
CC       endosomes upon KSHV infection and subsequent ubiquitination.
CC       {ECO:0000269|PubMed:20419159, ECO:0000269|PubMed:26172439}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1; Synonyms=l-Tetherin;
CC         IsoId=Q10589-1; Sequence=Displayed;
CC       Name=2; Synonyms=s-Tetherin;
CC         IsoId=Q10589-2; Sequence=VSP_053250;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in liver, lung, heart and
CC       placenta. Lower levels in pancreas, kidney, skeletal muscle and brain.
CC       Overexpressed in multiple myeloma cells. Highly expressed during B-cell
CC       development, from pro-B precursors to plasma cells. Highly expressed on
CC       T-cells, monocytes, NK cells and dendritic cells (at protein level).
CC       {ECO:0000269|PubMed:10329429, ECO:0000269|PubMed:16157322}.
CC   -!- INDUCTION: By type I interferons. {ECO:0000269|PubMed:16157322,
CC       ECO:0000269|PubMed:23028328}.
CC   -!- INDUCTION: (Microbial infection) Down-regulated by HIV-1 VPU protein.
CC       Antagonizes its function by targeting it to the trans-Golgi network,
CC       sequestering it away from virus assembly sites on the cell membrane.
CC       VPU also acts as an adapter molecule linking it to BTRC, a substrate
CC       recognition subunit of the Skp1/Cullin/F-box protein E3 ubiquitin
CC       ligase, inducing its ubiquitination and subsequent proteasomal
CC       degradation. {ECO:0000269|PubMed:18200009, ECO:0000269|PubMed:18342597,
CC       ECO:0000269|PubMed:19837671}.
CC   -!- INDUCTION: (Microbial infection) Down-regulated by HIV-2 ENV protein.
CC       Antagonizes its function by targeting it to the trans-Golgi network,
CC       sequestering it away from virus assembly sites on the cell membrane.
CC       {ECO:0000269|PubMed:19740980}.
CC   -!- INDUCTION: (Microbial infection) Down-regulated by KSHV K5 protein. K5
CC       ubiquitinates it leading to its targeting to late endosomes and
CC       degradation. {ECO:0000269|PubMed:20419159}.
CC   -!- INDUCTION: (Microbial infection) Down-regulated by ebola virus GP
CC       protein. {ECO:0000269|PubMed:19179289}.
CC   -!- INDUCTION: (Microbial infection) Made inactive by SARS-CoV ORF7a
CC       protein through impairing proper glycosylation (PubMed:26378163). May
CC       be down-regulated by SARS-CoV Spike protein through lysosomal
CC       degradation pathway (PubMed:31199522). {ECO:0000269|PubMed:26378163,
CC       ECO:0000269|PubMed:31199522}.
CC   -!- DOMAIN: The extracellular coiled coil domain forms an extended 170 A
CC       long semi-flexible rod-like structure important for virion retention at
CC       the cell surface and prevention of virus spreading.
CC       {ECO:0000269|PubMed:20399176}.
CC   -!- PTM: Monoubiquitinated by KSHV E3 ubiquitin-protein ligase K5, leading
CC       to its targeting to late endosomes and degradation.
CC       {ECO:0000269|PubMed:20419159}.
CC   -!- PTM: The GPI anchor is essential for its antiviral activity.
CC   -!- MISCELLANEOUS: Tetherin shows evidence of positive (adaptive)
CC       selection, presumably as a result of evolutionary pressure applied by
CC       antagonistic viral proteins that counteract its inhibitiory activity
CC       and this has led to the species-specific tetherin sensitivity to viral
CC       countermeasures. For example, Tantalus monkey tetherin cannot be
CC       abrogated by HIV-1 VPU due to variation in the tetherin transmembrane
CC       region. Similarly, SIV Nefs are able to overcome simian tetherins, but
CC       not human tetherin, due to a unique 5-amino-acid deletion in the
CC       cytoplasmic tail domain of human tetherin (PubMed:19917491).
CC       {ECO:0000305|PubMed:19917491}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative initiation at Met-
CC       13 of isoform 1. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the tetherin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D28137; BAA05679.1; -; mRNA.
DR   EMBL; AK223124; BAD96844.1; -; mRNA.
DR   EMBL; AK291099; BAF83788.1; -; mRNA.
DR   EMBL; AC010319; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471106; EAW84602.1; -; Genomic_DNA.
DR   EMBL; BC033873; AAH33873.1; -; mRNA.
DR   CCDS; CCDS12358.1; -. [Q10589-1]
DR   PIR; A56836; A56836.
DR   RefSeq; NP_004326.1; NM_004335.3. [Q10589-1]
DR   PDB; 2LK9; NMR; -; A=18-47.
DR   PDB; 2X7A; X-ray; 2.77 A; A/B/C/D/E/F/G/H/I/J/K=87-147.
DR   PDB; 2XG7; X-ray; 3.45 A; A/C=51-151.
DR   PDB; 3MQ7; X-ray; 2.28 A; A/B/C/D/E/F/G/H/I/J/K/L=47-161.
DR   PDB; 3MQ9; X-ray; 2.80 A; A/B/C/D/E/F/G/H=66-139.
DR   PDB; 3MQB; X-ray; 3.20 A; A/B/E/F=47-161.
DR   PDB; 3MQC; X-ray; 2.80 A; A/B/C/D=47-161.
DR   PDB; 3NWH; X-ray; 2.60 A; A/B/C/D=47-152.
DR   PDB; 4P6Z; X-ray; 3.00 A; T=1-21.
DR   PDB; 6CM9; EM; 3.73 A; L/N/T=2-21.
DR   PDB; 6CRI; EM; 6.80 A; N/T/Y/Z/c/d=2-21.
DR   PDB; 6D83; EM; 4.27 A; L/T=2-21.
DR   PDB; 6D84; EM; 6.72 A; L/O/R/T=2-21.
DR   PDB; 6DFF; EM; 3.90 A; L/T=2-21.
DR   PDBsum; 2LK9; -.
DR   PDBsum; 2X7A; -.
DR   PDBsum; 2XG7; -.
DR   PDBsum; 3MQ7; -.
DR   PDBsum; 3MQ9; -.
DR   PDBsum; 3MQB; -.
DR   PDBsum; 3MQC; -.
DR   PDBsum; 3NWH; -.
DR   PDBsum; 4P6Z; -.
DR   PDBsum; 6CM9; -.
DR   PDBsum; 6CRI; -.
DR   PDBsum; 6D83; -.
DR   PDBsum; 6D84; -.
DR   PDBsum; 6DFF; -.
DR   SMR; Q10589; -.
DR   BioGRID; 107149; 30.
DR   DIP; DIP-53216N; -.
DR   IntAct; Q10589; 27.
DR   MINT; Q10589; -.
DR   STRING; 9606.ENSP00000252593; -.
DR   TCDB; 1.D.118.1.1; the pore-forming b18 peptide derived from the b49mod1 protein (b49-b18) family.
DR   GlyConnect; 1044; 11 N-Linked glycans (2 sites).
DR   GlyGen; Q10589; 2 sites.
DR   iPTMnet; Q10589; -.
DR   PhosphoSitePlus; Q10589; -.
DR   SwissPalm; Q10589; -.
DR   BioMuta; BST2; -.
DR   DMDM; 1705508; -.
DR   EPD; Q10589; -.
DR   jPOST; Q10589; -.
DR   MassIVE; Q10589; -.
DR   MaxQB; Q10589; -.
DR   PaxDb; Q10589; -.
DR   PeptideAtlas; Q10589; -.
DR   PRIDE; Q10589; -.
DR   ProteomicsDB; 58866; -. [Q10589-1]
DR   ABCD; Q10589; 23 sequenced antibodies.
DR   Antibodypedia; 1532; 672 antibodies.
DR   DNASU; 684; -.
DR   Ensembl; ENST00000252593; ENSP00000252593; ENSG00000130303. [Q10589-1]
DR   GeneID; 684; -.
DR   KEGG; hsa:684; -.
DR   UCSC; uc060vid.1; human. [Q10589-1]
DR   CTD; 684; -.
DR   DisGeNET; 684; -.
DR   EuPathDB; HostDB:ENSG00000130303.12; -.
DR   GeneCards; BST2; -.
DR   HGNC; HGNC:1119; BST2.
DR   HPA; ENSG00000130303; Tissue enhanced (ovary).
DR   MIM; 600534; gene.
DR   neXtProt; NX_Q10589; -.
DR   OpenTargets; ENSG00000130303; -.
DR   PharmGKB; PA25436; -.
DR   eggNOG; ENOG502TB0V; Eukaryota.
DR   GeneTree; ENSGT00390000013782; -.
DR   HOGENOM; CLU_104678_0_0_1; -.
DR   InParanoid; Q10589; -.
DR   KO; K06731; -.
DR   OMA; KNNASSC; -.
DR   PhylomeDB; Q10589; -.
DR   TreeFam; TF338345; -.
DR   PathwayCommons; Q10589; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   BioGRID-ORCS; 684; 6 hits in 876 CRISPR screens.
DR   ChiTaRS; BST2; human.
DR   EvolutionaryTrace; Q10589; -.
DR   GeneWiki; Tetherin; -.
DR   GenomeRNAi; 684; -.
DR   Pharos; Q10589; Tbio.
DR   PRO; PR:Q10589; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q10589; protein.
DR   Bgee; ENSG00000130303; Expressed in left ovary and 223 other tissues.
DR   ExpressionAtlas; Q10589; baseline and differential.
DR   Genevisible; Q10589; HS.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome.
DR   GO; GO:0009986; C:cell surface; IMP:CACAO.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005771; C:multivesicular body; IMP:CACAO.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008191; F:metalloendopeptidase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0042113; P:B cell activation; IEA:UniProtKB-KW.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:1901253; P:negative regulation of intracellular transport of viral material; IDA:UniProtKB.
DR   GO; GO:0002737; P:negative regulation of plasmacytoid dendritic cell cytokine production; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; HMP:UniProtKB.
DR   GO; GO:0070665; P:positive regulation of leukocyte proliferation; TAS:GO_Central.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0035455; P:response to interferon-alpha; ISS:UniProtKB.
DR   GO; GO:0035456; P:response to interferon-beta; ISS:UniProtKB.
DR   GO; GO:0034341; P:response to interferon-gamma; ISS:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IDA:UniProtKB.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   InterPro; IPR024886; BST2.
DR   PANTHER; PTHR15190; PTHR15190; 1.
DR   Pfam; PF16716; BST2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Antiviral defense; B-cell activation;
KW   Cell membrane; Coiled coil; Cytoplasm; Disulfide bond; Endosome;
KW   Glycoprotein; Golgi apparatus; GPI-anchor; Immunity; Innate immunity;
KW   Isopeptide bond; Lipoprotein; Membrane; Polymorphism; Reference proteome;
KW   Signal-anchor; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..161
FT                   /note="Bone marrow stromal antigen 2"
FT                   /id="PRO_0000065005"
FT   PROPEP          162..180
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000253552"
FT   TOPO_DOM        1..20
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        21..48
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        49..161
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   COILED          68..152
FT   LIPID           161
FT                   /note="GPI-anchor amidated serine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        65
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:19737401,
FT                   ECO:0000269|PubMed:19879838"
FT   CARBOHYD        92
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19737401,
FT                   ECO:0000269|PubMed:19879838"
FT   DISULFID        53
FT                   /note="Interchain"
FT   DISULFID        63
FT                   /note="Interchain"
FT   DISULFID        91
FT                   /note="Interchain"
FT   CROSSLNK        18
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:20419159"
FT   VAR_SEQ         1..12
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053250"
FT   VARIANT         143
FT                   /note="V -> F (in dbSNP:rs1804402)"
FT                   /id="VAR_012067"
FT   MUTAGEN         3..5
FT                   /note="STS->AAA: Partial resistance to Vpu."
FT                   /evidence="ECO:0000269|PubMed:23028328"
FT   MUTAGEN         6
FT                   /note="Y->A: Partial resistance to Vpu and significantly
FT                   reduced activation of NF-kB; when associated with A-8."
FT                   /evidence="ECO:0000269|PubMed:23028328"
FT   MUTAGEN         8
FT                   /note="Y->A: Partial resistance to Vpu and significantly
FT                   reduced activation of NF-kB; when associated with A-6."
FT                   /evidence="ECO:0000269|PubMed:23028328"
FT   MUTAGEN         18
FT                   /note="K->R: Abolishes redistribution to late endosomes in
FT                   cells expressing KSH virus E3 ubiquitin-protein ligase K5."
FT                   /evidence="ECO:0000269|PubMed:20419159"
FT   MUTAGEN         21
FT                   /note="K->R: No effect on redistribution to late endosomes
FT                   in cells expressing KSH virus E3 ubiquitin-protein ligase
FT                   K5."
FT                   /evidence="ECO:0000269|PubMed:20419159"
FT   MUTAGEN         53
FT                   /note="C->A: Prevents homodimerization and inhibition of
FT                   SARS-CoV, HCoV-229E, and HIV-1 viral particles production
FT                   ex vivo; when associated with A-63 and A-91."
FT                   /evidence="ECO:0000269|PubMed:31199522"
FT   MUTAGEN         63
FT                   /note="C->A: Prevents homodimerization and inhibition of
FT                   SARS-CoV, HCoV-229E, and HIV-1 viral particles production
FT                   ex vivo; when associated with A-53 and A-91."
FT                   /evidence="ECO:0000269|PubMed:31199522"
FT   MUTAGEN         65
FT                   /note="N->A: Loss of glycosylation site."
FT                   /evidence="ECO:0000269|PubMed:19879838"
FT   MUTAGEN         91
FT                   /note="C->A: Prevents homodimerization and inhibition of
FT                   SARS-CoV, HCoV-229E, and HIV-1 viral particles production
FT                   ex vivo; when associated with A-53 and A-63."
FT                   /evidence="ECO:0000269|PubMed:31199522"
FT   MUTAGEN         92
FT                   /note="N->A: Loss of glycosylation site. Impairs anti-viral
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:19879838"
FT   CONFLICT        141
FT                   /note="N -> D (in Ref. 4; BAD96844)"
FT                   /evidence="ECO:0000305"
FT   HELIX           23..44
FT                   /evidence="ECO:0000244|PDB:2LK9"
FT   HELIX           52..148
FT                   /evidence="ECO:0000244|PDB:3MQ7"
FT   STRAND          152..154
FT                   /evidence="ECO:0000244|PDB:3MQB"
SQ   SEQUENCE   180 AA;  19769 MW;  CAF52340D69061EE CRC64;
     MASTSYDYCR VPMEDGDKRC KLLLGIGILV LLIIVILGVP LIIFTIKANS EACRDGLRAV
     MECRNVTHLL QQELTEAQKG FQDVEAQAAT CNHTVMALMA SLDAEKAQGQ KKVEELEGEI
     TTLNHKLQDA SAEVERLRRE NQVLSVRIAD KKYYPSSQDS SSAAAPQLLI VLLGLSALLQ
//
ID   IL17_HUMAN              Reviewed;         155 AA.
AC   Q16552; Q5T2P0;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-AUG-2020, entry version 181.
DE   RecName: Full=Interleukin-17A;
DE            Short=IL-17;
DE            Short=IL-17A;
DE   AltName: Full=Cytotoxic T-lymphocyte-associated antigen 8;
DE            Short=CTLA-8;
DE   Flags: Precursor;
GN   Name=IL17A; Synonyms=CTLA8, IL17;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND PTM.
RX   PubMed=8676080; DOI=10.1084/jem.183.6.2593;
RA   Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C.,
RA   Pin J.-J., Garrone P., Garcia E., Saeland S., Blanchard D., Gaillard C.,
RA   Das Mahapatra B., Rouvier E., Golstein P., Banchereau J., Lebecque S.;
RT   "T cell interleukin-17 induces stromal cells to produce proinflammatory and
RT   hematopoietic cytokines.";
RL   J. Exp. Med. 183:2593-2603(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=T-cell;
RX   PubMed=7499828;
RA   Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K.,
RA   Armitage R.J.;
RT   "Human IL-17: a novel cytokine derived from T cells.";
RL   J. Immunol. 155:5483-5486(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 24-38.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [8]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION BY IL23A-IL12B.
RX   PubMed=17763419; DOI=10.1002/art.22866;
RA   Chen Z., Tato C.M., Muul L., Laurence A., O'Shea J.J.;
RT   "Distinct regulation of interleukin-17 in human T helper lymphocytes.";
RL   Arthritis Rheum. 56:2936-2946(2007).
RN   [9]
RP   SUBUNIT.
RX   PubMed=17355969; DOI=10.1074/jbc.m700499200;
RA   Wright J.F., Guo Y., Quazi A., Luxenberg D.P., Bennett F., Ross J.F.,
RA   Qiu Y., Whitters M.J., Tomkinson K.N., Dunussi-Joannopoulos K.,
RA   Carreno B.M., Collins M., Wolfman N.M.;
RT   "Identification of an interleukin 17F/17A heterodimer in activated human
RT   CD4+ T cells.";
RL   J. Biol. Chem. 282:13447-13455(2007).
RN   [10]
RP   FUNCTION.
RX   PubMed=17911633; DOI=10.4049/jimmunol.179.8.5462;
RA   Kuestner R.E., Taft D.W., Haran A., Brandt C.S., Brender T., Lum K.,
RA   Harder B., Okada S., Ostrander C.D., Kreindler J.L., Aujla S.J.,
RA   Reardon B., Moore M., Shea P., Schreckhise R., Bukowski T.R., Presnell S.,
RA   Guerra-Lewis P., Parrish-Novak J., Ellsworth J.L., Jaspers S., Lewis K.E.,
RA   Appleby M., Kolls J.K., Rixon M., West J.W., Gao Z., Levin S.D.;
RT   "Identification of the IL-17 receptor related molecule IL-17RC as the
RT   receptor for IL-17F.";
RL   J. Immunol. 179:5462-5473(2007).
RN   [11]
RP   FUNCTION.
RX   PubMed=18684971; DOI=10.4049/jimmunol.181.4.2799;
RA   Wright J.F., Bennett F., Li B., Brooks J., Luxenberg D.P., Whitters M.J.,
RA   Tomkinson K.N., Fitz L.J., Wolfman N.M., Collins M.,
RA   Dunussi-Joannopoulos K., Chatterjee-Kishore M., Carreno B.M.;
RT   "The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-
RT   17RA/IL-17RC receptor complex.";
RL   J. Immunol. 181:2799-2805(2008).
RN   [12]
RP   FUNCTION.
RX   PubMed=19825828; DOI=10.1126/scisignal.2000382;
RA   Liu C., Qian W., Qian Y., Giltiay N.V., Lu Y., Swaidani S., Misra S.,
RA   Deng L., Chen Z.J., Li X.;
RT   "Act1, a U-box E3 ubiquitin ligase for IL-17 signaling.";
RL   Sci. Signal. 2:ra63-ra63(2009).
RN   [13]
RP   FUNCTION.
RX   PubMed=21350122; DOI=10.1126/science.1200439;
RA   Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K.,
RA   Migaud M., Israel L., Chrabieh M., Audry M., Gumbleton M., Toulon A.,
RA   Bodemer C., El-Baghdadi J., Whitters M., Paradis T., Brooks J., Collins M.,
RA   Wolfman N.M., Al-Muhsen S., Galicchio M., Abel L., Picard C.,
RA   Casanova J.L.;
RT   "Chronic mucocutaneous candidiasis in humans with inborn errors of
RT   interleukin-17 immunity.";
RL   Science 332:65-68(2011).
RN   [14]
RP   FUNCTION.
RX   PubMed=24120361; DOI=10.1016/j.immuni.2013.09.002;
RA   Boisson B., Wang C., Pedergnana V., Wu L., Cypowyj S., Rybojad M.,
RA   Belkadi A., Picard C., Abel L., Fieschi C., Puel A., Li X., Casanova J.L.;
RT   "An ACT1 mutation selectively abolishes interleukin-17 responses in humans
RT   with chronic mucocutaneous candidiasis.";
RL   Immunity 39:676-686(2013).
RN   [15]
RP   INDUCTION.
RX   PubMed=27795421; DOI=10.1128/jvi.01529-16;
RA   Acharya D., Wang P., Paul A.M., Dai J., Gate D., Lowery J.E., Stokic D.S.,
RA   Leis A.A., Flavell R.A., Town T., Fikrig E., Bai F.;
RT   "Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate West Nile
RT   Virus Clearance.";
RL   J. Virol. 91:0-0(2017).
RN   [16]
RP   INTERACTION WITH IL17F; IL17RA AND IL17RC.
RX   PubMed=32187518; DOI=10.1016/j.immuni.2020.02.004;
RA   Goepfert A., Lehmann S., Blank J., Kolbinger F., Rondeau J.M.;
RT   "Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric
RT   Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling.";
RL   Immunity 52:499-512.e5(2020).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.63 ANGSTROMS) OF 20-155 IN COMPLEX WITH ANTIBODY,
RP   DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=19835883; DOI=10.1016/j.jmb.2009.10.008;
RA   Gerhardt S., Abbott W.M., Hargreaves D., Pauptit R.A., Davies R.A.,
RA   Needham M.R., Langham C., Barker W., Aziz A., Snow M.J., Dawson S.,
RA   Welsh F., Wilkinson T., Vaugan T., Beste G., Bishop S., Popovic B.,
RA   Rees G., Sleeman M., Tuske S.J., Coales S.J., Hamuro Y., Russell C.;
RT   "Structure of IL-17A in complex with a potent, fully human neutralizing
RT   antibody.";
RL   J. Mol. Biol. 394:905-921(2009).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 34-155 IN COMPLEX WITH IL17RA,
RP   DISULFIDE BONDS, SUBUNIT, AND MUTAGENESIS OF ARG-78; TRP-90; TYR-108 AND
RP   HIS-109.
RX   PubMed=23695682; DOI=10.1038/ncomms2880;
RA   Liu S., Song X., Chrunyk B.A., Shanker S., Hoth L.R., Marr E.S.,
RA   Griffor M.C.;
RT   "Crystal structures of interleukin 17A and its complex with IL-17 receptor
RT   A.";
RL   Nat. Commun. 4:1888-1888(2013).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 24-155 IN COMPLEX WITH IL17F;
RP   IL17RA AND IL17RC, SUBUNIT, AND MUTAGENESIS OF ARG-69.
RX   PubMed=28827714; DOI=10.1038/s41598-017-08360-9;
RA   Goepfert A., Lehmann S., Wirth E., Rondeau J.M.;
RT   "The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor
RT   recognition properties.";
RL   Sci. Rep. 7:8906-8906(2017).
CC   -!- FUNCTION: Effector cytokine of innate and adaptive immune system
CC       involved in antimicrobial host defense and maintenance of tissue
CC       integrity (PubMed:24120361). Signals via IL17RA-IL17RC heterodimeric
CC       receptor complex, triggering homotypic interaction of IL17RA and IL17RC
CC       chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated
CC       activation of NF-kappa-B and MAPkinase pathways ultimately resulting in
CC       transcriptional activation of cytokines, chemokines, antimicrobial
CC       peptides and matrix metalloproteinases, with potential strong immune
CC       inflammation (PubMed:19825828, PubMed:21350122, PubMed:17911633,
CC       PubMed:18684971, PubMed:8676080, PubMed:24120361). Plays an important
CC       role in connecting T cell-mediated adaptive immunity and acute
CC       inflammatory response to destroy extracellular bacteria and fungi. As a
CC       signature effector cytokine of T-helper 17 cells (Th17), primarily
CC       induces neutrophil activation and recruitment at infection and
CC       inflammatory sites (By similarity). In airway epithelium, mediates
CC       neutrophil chemotaxis via induction of CXCL1 and CXCL5 chemokines (By
CC       similarity). In secondary lymphoid organs, contributes to germinal
CC       center formation by regulating the chemotactic response of B cells to
CC       CXCL12 and CXCL13, enhancing retention of B cells within the germinal
CC       centers, B cell somatic hypermutation rate and selection toward plasma
CC       cells (By similarity). Effector cytokine of a subset of gamma-delta T
CC       cells that functions as part of an inflammatory circuit downstream
CC       IL1B, TLR2 and IL23A-IL12B to promote neutrophil recruitment for
CC       efficient bacterial clearance (By similarity). Effector cytokine of
CC       innate immune cells including invariant natural killer cell (iNKT) and
CC       group 3 innate lymphoid cells that mediate initial neutrophilic
CC       inflammation (By similarity). Involved in the maintenance of the
CC       integrity of epithelial barriers during homeostasis and pathogen
CC       infection (PubMed:21350122). Upon acute injury, has a direct role in
CC       epithelial barrier formation by regulating OCLN localization and tight
CC       junction biogenesis (By similarity). As part of the mucosal immune
CC       response induced by commensal bacteria, enhances host's ability to
CC       resist pathogenic bacterial and fungal infections by promoting
CC       neutrophil recruitment and antimicrobial peptides release (By
CC       similarity). In synergy with IL17F, mediates the production of
CC       antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal
CC       epithelial cells, limiting the entry of microbes through the epithelial
CC       barriers (By similarity). Involved in antiviral host defense through
CC       various mechanisms (By similarity). Enhances immunity against West Nile
CC       virus by promoting T cell cytotoxicity (By similarity). May play a
CC       beneficial role in influenza A virus (H5N1) infection by enhancing B
CC       cell recruitment and immune response in the lung (By similarity).
CC       Contributes to influenza A virus (H1N1) clearance by driving the
CC       differentiation of B-1a B cells, providing for production of virus-
CC       specific IgM antibodies at first line of host defense (By similarity).
CC       {ECO:0000250|UniProtKB:Q62386, ECO:0000269|PubMed:17911633,
CC       ECO:0000269|PubMed:18684971, ECO:0000269|PubMed:19825828,
CC       ECO:0000269|PubMed:21350122, ECO:0000269|PubMed:24120361,
CC       ECO:0000269|PubMed:8676080}.
CC   -!- SUBUNIT: Homodimer (PubMed:19835883). Forms complexes with IL17RA and
CC       IL17RC receptors with 2:1 binding stoichiometry: two receptor chains
CC       for one interleukin molecule (PubMed:32187518). IL17A homodimer
CC       preferentially drives the formation of IL17RA-IL17RC heterodimeric
CC       receptor complex (PubMed:32187518). IL17A homodimer adopts an
CC       asymmetrical ternary structure with one IL17RA molecule, allowing for
CC       high affinity interactions of one IL17A monomer with one IL17RA
CC       molecule (via D1 and D2 domains), while disfavoring binding of a second
CC       IL17RA molecule on the other IL17A monomer (PubMed:23695682).
CC       Heterodimer with IL17F (PubMed:17355969). IL17A-IL17F forms complexes
CC       with IL17RA-IL17RC, but with lower affinity when compared to IL17A
CC       homodimer (PubMed:32187518). IL17RA and IL17RC chains can not
CC       distinguish between IL17A and IL17F molecules, potentially enabling the
CC       formation of topologically distinct complexes (PubMed:17355969,
CC       PubMed:28827714). {ECO:0000269|PubMed:17355969,
CC       ECO:0000269|PubMed:19835883, ECO:0000269|PubMed:23695682,
CC       ECO:0000269|PubMed:28827714, ECO:0000269|PubMed:32187518}.
CC   -!- INTERACTION:
CC       Q16552; Q9BQC3: DPH2; NbExp=3; IntAct=EBI-10237926, EBI-10237931;
CC       Q16552; Q6PIL6: KCNIP4; NbExp=3; IntAct=EBI-10237926, EBI-1051469;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:17763419,
CC       ECO:0000269|PubMed:8676080}.
CC   -!- TISSUE SPECIFICITY: Expressed in memory Th17 cells (at protein level).
CC       {ECO:0000269|PubMed:17763419}.
CC   -!- INDUCTION: Induced upon differentiation of CD4-positive T cells. Up-
CC       regulated by IL23A-IL12B (PubMed:17763419). Up-regulated in peripheral
CC       blood mononuclear cells upon West Nile virus infection
CC       (PubMed:27795421). {ECO:0000269|PubMed:17763419,
CC       ECO:0000269|PubMed:27795421}.
CC   -!- PTM: N-glycosylated. Found both in glycosylated and nonglycosylated
CC       forms. {ECO:0000269|PubMed:8676080}.
CC   -!- SIMILARITY: Belongs to the IL-17 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Interleukin-17 entry;
CC       URL="https://en.wikipedia.org/wiki/Interleukin_17";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/il17/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IL17AID40945ch6p12.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z58820; CAA91233.1; -; mRNA.
DR   EMBL; U32659; AAC50341.1; -; mRNA.
DR   EMBL; AY460616; AAR23263.1; -; Genomic_DNA.
DR   EMBL; AL391221; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX04362.1; -; Genomic_DNA.
DR   EMBL; BC066251; AAH66251.1; -; mRNA.
DR   EMBL; BC066252; AAH66252.1; -; mRNA.
DR   EMBL; BC067503; AAH67503.1; -; mRNA.
DR   EMBL; BC067504; AAH67504.1; -; mRNA.
DR   EMBL; BC067505; AAH67505.1; -; mRNA.
DR   CCDS; CCDS4937.1; -.
DR   RefSeq; NP_002181.1; NM_002190.2.
DR   PDB; 2VXS; X-ray; 2.63 A; A/B/C/D=20-155.
DR   PDB; 4HR9; X-ray; 2.48 A; A/B=34-155.
DR   PDB; 4HSA; X-ray; 3.15 A; A/B/D/E=34-155.
DR   PDB; 4QHU; X-ray; 2.20 A; C/D=24-154.
DR   PDB; 5HHV; X-ray; 2.20 A; A/B=34-155.
DR   PDB; 5HHX; X-ray; 3.00 A; A/B=20-155.
DR   PDB; 5HI3; X-ray; 2.15 A; A/B=24-155.
DR   PDB; 5HI4; X-ray; 1.80 A; A/B=24-155.
DR   PDB; 5HI5; X-ray; 1.80 A; A/B=24-155.
DR   PDB; 5N7W; X-ray; 1.96 A; X/Y=1-155.
DR   PDB; 5N92; X-ray; 2.30 A; A=24-155.
DR   PDB; 5NAN; X-ray; 3.30 A; A/D=24-155.
DR   PDB; 5VB9; X-ray; 1.70 A; A/B=38-155.
DR   PDBsum; 2VXS; -.
DR   PDBsum; 4HR9; -.
DR   PDBsum; 4HSA; -.
DR   PDBsum; 4QHU; -.
DR   PDBsum; 5HHV; -.
DR   PDBsum; 5HHX; -.
DR   PDBsum; 5HI3; -.
DR   PDBsum; 5HI4; -.
DR   PDBsum; 5HI5; -.
DR   PDBsum; 5N7W; -.
DR   PDBsum; 5N92; -.
DR   PDBsum; 5NAN; -.
DR   PDBsum; 5VB9; -.
DR   SMR; Q16552; -.
DR   BioGRID; 109818; 10.
DR   DIP; DIP-6014N; -.
DR   IntAct; Q16552; 7.
DR   STRING; 9606.ENSP00000344192; -.
DR   BindingDB; Q16552; -.
DR   ChEMBL; CHEMBL3390822; -.
DR   DrugBank; DB11569; Ixekizumab.
DR   DrugBank; DB09029; Secukinumab.
DR   DrugCentral; Q16552; -.
DR   GlyGen; Q16552; 1 site.
DR   iPTMnet; Q16552; -.
DR   PhosphoSitePlus; Q16552; -.
DR   BioMuta; IL17A; -.
DR   DMDM; 2498481; -.
DR   PaxDb; Q16552; -.
DR   PeptideAtlas; Q16552; -.
DR   PRIDE; Q16552; -.
DR   ProteomicsDB; 60910; -.
DR   ABCD; Q16552; 76 sequenced antibodies.
DR   Antibodypedia; 17132; 1813 antibodies.
DR   DNASU; 3605; -.
DR   Ensembl; ENST00000648244; ENSP00000497968; ENSG00000112115.
DR   GeneID; 3605; -.
DR   KEGG; hsa:3605; -.
DR   UCSC; uc003pak.1; human.
DR   CTD; 3605; -.
DR   DisGeNET; 3605; -.
DR   EuPathDB; HostDB:ENSG00000112115.5; -.
DR   GeneCards; IL17A; -.
DR   HGNC; HGNC:5981; IL17A.
DR   HPA; ENSG00000112115; Group enriched (lymphoid tissue, tongue, urinary bladder).
DR   MIM; 603149; gene.
DR   neXtProt; NX_Q16552; -.
DR   OpenTargets; ENSG00000112115; -.
DR   PharmGKB; PA29794; -.
DR   eggNOG; ENOG502S5A0; Eukaryota.
DR   GeneTree; ENSGT00940000161882; -.
DR   HOGENOM; CLU_118641_0_0_1; -.
DR   InParanoid; Q16552; -.
DR   KO; K05489; -.
DR   OMA; CPHSFRL; -.
DR   OrthoDB; 1469254at2759; -.
DR   PhylomeDB; Q16552; -.
DR   TreeFam; TF314701; -.
DR   PathwayCommons; Q16552; -.
DR   Reactome; R-HSA-448424; Interleukin-17 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   SIGNOR; Q16552; -.
DR   BioGRID-ORCS; 3605; 4 hits in 869 CRISPR screens.
DR   EvolutionaryTrace; Q16552; -.
DR   GeneWiki; IL17A; -.
DR   GenomeRNAi; 3605; -.
DR   Pharos; Q16552; Tclin.
DR   PRO; PR:Q16552; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q16552; protein.
DR   Bgee; ENSG00000112115; Expressed in tonsil and 32 other tissues.
DR   Genevisible; Q16552; HS.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0005125; F:cytokine activity; TAS:ProtInc.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0008219; P:cell death; TAS:ProtInc.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0050832; P:defense response to fungus; IEA:Ensembl.
DR   GO; GO:0072537; P:fibroblast activation; IDA:BHF-UCL.
DR   GO; GO:0097530; P:granulocyte migration; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; IEA:InterPro.
DR   GO; GO:0097400; P:interleukin-17-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IDA:ARUK-UCL.
DR   GO; GO:0050725; P:positive regulation of interleukin-1 beta biosynthetic process; IDA:ARUK-UCL.
DR   GO; GO:0045084; P:positive regulation of interleukin-12 biosynthetic process; IDA:ARUK-UCL.
DR   GO; GO:0045377; P:positive regulation of interleukin-16 biosynthetic process; IDA:ARUK-UCL.
DR   GO; GO:0032747; P:positive regulation of interleukin-23 production; IDA:BHF-UCL.
DR   GO; GO:2000778; P:positive regulation of interleukin-6 secretion; IEA:Ensembl.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; IDA:ARUK-UCL.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR020440; IL-17_chr.
DR   InterPro; IPR010345; IL-17_fam.
DR   Pfam; PF06083; IL17; 1.
DR   PRINTS; PR01932; INTRLEUKIN17.
DR   SUPFAM; SSF57501; SSF57501; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Cytokine; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Immunity; Inflammatory response;
KW   Innate immunity; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           24..155
FT                   /note="Interleukin-17A"
FT                   /id="PRO_0000015423"
FT   CARBOHYD        68
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        94..144
FT                   /evidence="ECO:0000269|PubMed:19835883,
FT                   ECO:0000269|PubMed:23695682"
FT   DISULFID        99..146
FT                   /evidence="ECO:0000269|PubMed:19835883,
FT                   ECO:0000269|PubMed:23695682"
FT   MUTAGEN         69
FT                   /note="R->A: Impairs binding to IL17RA and IL17RC."
FT                   /evidence="ECO:0000269|PubMed:28827714"
FT   MUTAGEN         78
FT                   /note="R->V: Decreases the affinity for IL17RA by 5-fold."
FT                   /evidence="ECO:0000269|PubMed:23695682"
FT   MUTAGEN         90
FT                   /note="W->V: Has no effect on the affinity for IL17RA."
FT                   /evidence="ECO:0000269|PubMed:23695682"
FT   MUTAGEN         108
FT                   /note="Y->I: Decreases the affinity for IL17RA."
FT                   /evidence="ECO:0000269|PubMed:23695682"
FT   MUTAGEN         109
FT                   /note="H->S: Decreases the affinity for IL17RA."
FT                   /evidence="ECO:0000269|PubMed:23695682"
FT   HELIX           35..39
FT                   /evidence="ECO:0000244|PDB:4QHU"
FT   STRAND          44..48
FT                   /evidence="ECO:0000244|PDB:5N7W"
FT   STRAND          50..52
FT                   /evidence="ECO:0000244|PDB:5HI5"
FT   HELIX           60..62
FT                   /evidence="ECO:0000244|PDB:5HI5"
FT   HELIX           66..69
FT                   /evidence="ECO:0000244|PDB:5VB9"
FT   STRAND          70..72
FT                   /evidence="ECO:0000244|PDB:5VB9"
FT   STRAND          74..80
FT                   /evidence="ECO:0000244|PDB:5VB9"
FT   STRAND          84..86
FT                   /evidence="ECO:0000244|PDB:5VB9"
FT   STRAND          88..95
FT                   /evidence="ECO:0000244|PDB:5VB9"
FT   STRAND          97..100
FT                   /evidence="ECO:0000244|PDB:5VB9"
FT   STRAND          104..107
FT                   /evidence="ECO:0000244|PDB:5VB9"
FT   STRAND          110..126
FT                   /evidence="ECO:0000244|PDB:5VB9"
FT   STRAND          133..147
FT                   /evidence="ECO:0000244|PDB:5VB9"
FT   STRAND          151..153
FT                   /evidence="ECO:0000244|PDB:4HSA"
SQ   SEQUENCE   155 AA;  17504 MW;  2BCAE9CB2F4886D1 CRC64;
     MTPGKTSLVS LLLLLSLEAI VKAGITIPRN PGCPNSEDKN FPRTVMVNLN IHNRNTNTNP
     KRSSDYYNRS TSPWNLHRNE DPERYPSVIW EAKCRHLGCI NADGNVDYHM NSVPIQQEIL
     VLRREPPHCP NSFRLEKILV SVGCTCVTPI VHHVA
//
ID   MPP5_HUMAN              Reviewed;         675 AA.
AC   Q8N3R9; A1L380; Q7Z631; Q86T98; Q8N7I5; Q9H9Q0;
DT   10-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   12-AUG-2020, entry version 189.
DE   RecName: Full=MAGUK p55 subfamily member 5;
GN   Name=MPP5 {ECO:0000303|PubMed:15914641};
GN   Synonyms=PALS1 {ECO:0000303|PubMed:21479189};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Skeletal muscle, and Spinal cord;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-441 (ISOFORM 1), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 155-675.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   COMPLEX FORMATION WITH CRB1 AND MPP4, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=15914641; DOI=10.1167/iovs.04-1417;
RA   Kantardzhieva A., Gosens I., Alexeeva S., Punte I.M., Versteeg I.,
RA   Krieger E., Neefjes-Mol C.A., den Hollander A.I., Letteboer S.J.F.,
RA   Klooster J., Cremers F.P.M., Roepman R., Wijnholds J.;
RT   "MPP5 recruits MPP4 to the CRB1 complex in photoreceptors.";
RL   Invest. Ophthalmol. Vis. Sci. 46:2192-2201(2005).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=15558731; DOI=10.1002/cne.20367;
RA   Stoehr H., Molday L.L., Molday R.S., Weber B.H.F., Biedermann B.,
RA   Reichenbach A., Kraemer F.;
RT   "Membrane-associated guanylate kinase proteins MPP4 and MPP5 associate with
RT   Veli3 at distinct intercellular junctions of the neurosensory retina.";
RL   J. Comp. Neurol. 481:31-41(2005).
RN   [7]
RP   INTERACTION WITH MPP1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17584769; DOI=10.1093/hmg/ddm147;
RA   Gosens I., van Wijk E., Kersten F.F., Krieger E., van der Zwaag B.,
RA   Maerker T., Letteboer S.J., Dusseljee S., Peters T., Spierenburg H.A.,
RA   Punte I.M., Wolfrum U., Cremers F.P.M., Kremer H., Roepman R.;
RT   "MPP1 links the Usher protein network and the Crumbs protein complex in the
RT   retina.";
RL   Hum. Mol. Genet. 16:1993-2003(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, IDENTIFICATION IN A COMPLEX
RP   WITH ARHGAP17; AMOT; PATJ AND PARD3, AND INTERACTION WITH MPP7.
RX   PubMed=16678097; DOI=10.1016/j.cell.2006.02.045;
RA   Wells C.D., Fawcett J.P., Traweger A., Yamanaka Y., Goudreault M.,
RA   Elder K., Kulkarni S., Gish G., Virag C., Lim C., Colwill K.,
RA   Starostine A., Metalnikov P., Pawson T.;
RT   "A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity
RT   proteins in epithelial cells.";
RL   Cell 125:535-548(2006).
RN   [9]
RP   IDENTIFICATION IN A COMPLEX WITH MPP3 AND CRB1, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=16519681; DOI=10.1111/j.1742-4658.2006.05140.x;
RA   Kantardzhieva A., Alexeeva S., Versteeg I., Wijnholds J.;
RT   "MPP3 is recruited to the MPP5 protein scaffold at the retinal outer
RT   limiting membrane.";
RL   FEBS J. 273:1152-1165(2006).
RN   [10]
RP   INTERACTION WITH MPP7.
RX   PubMed=17332497; DOI=10.1091/mbc.e06-11-0980;
RA   Stucke V.M., Timmerman E., Vandekerckhove J., Gevaert K., Hall A.;
RT   "The MAGUK protein MPP7 binds to the polarity protein hDlg1 and facilitates
RT   epithelial tight junction formation.";
RL   Mol. Biol. Cell 18:1744-1755(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   INTERACTION WITH NPHP1 AND NPHP4.
RX   PubMed=19755384; DOI=10.1093/hmg/ddp434;
RA   Delous M., Hellman N.E., Gaude H.M., Silbermann F., Le Bivic A.,
RA   Salomon R., Antignac C., Saunier S.;
RT   "Nephrocystin-1 and nephrocystin-4 are required for epithelial
RT   morphogenesis and associate with PALS1/PATJ and Par6.";
RL   Hum. Mol. Genet. 18:4711-4723(2009).
RN   [13]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH SARS-COV E (MICROBIAL
RP   INFECTION), SUBCELLULAR LOCATION (MICROBIAL INFECTION), AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20861307; DOI=10.1091/mbc.e10-04-0338;
RA   Teoh K.T., Siu Y.L., Chan W.L., Schlueter M.A., Liu C.J., Peiris J.S.,
RA   Bruzzone R., Margolis B., Nal B.;
RT   "The SARS coronavirus E protein interacts with PALS1 and alters tight
RT   junction formation and epithelial morphogenesis.";
RL   Mol. Biol. Cell 21:3838-3852(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-25, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=21479189; DOI=10.1371/journal.pone.0018159;
RA   Carvalho G., Poalas K., Demian C., Hatchi E., Vazquez A., Bidere N.;
RT   "Participation of the cell polarity protein PALS1 to T-cell receptor-
RT   mediated NF-kappaB activation.";
RL   PLoS ONE 6:E18159-E18159(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-25 AND SER-83, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-84, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   FUNCTION, INTERACTION WITH CADH5, AND TISSUE SPECIFICITY.
RX   PubMed=27466317; DOI=10.1091/mbc.e16-02-0127;
RA   Brinkmann B.F., Steinbacher T., Hartmann C., Kummer D., Pajonczyk D.,
RA   Mirzapourshafiyi F., Nakayama M., Weide T., Gerke V., Ebnet K.;
RT   "VE-cadherin interacts with cell polarity protein Pals1 to regulate
RT   vascular lumen formation.";
RL   Mol. Biol. Cell 27:2811-2821(2016).
RN   [19]
RP   STRUCTURE BY NMR OF 118-177, AND INTERACTION WITH MPDZ.
RX   PubMed=15863617; DOI=10.1073/pnas.0409346102;
RA   Feng W., Long J.-F., Zhang M.;
RT   "A unified assembly mode revealed by the structures of tetrameric L27
RT   domain complexes formed by mLin-2/mLin-7 and Patj/Pals1 scaffold
RT   proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:6861-6866(2005).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 119-232 IN COMPLEX WITH MOUSE
RP   LIN7B AND RAT PATJ.
RX   PubMed=22337881; DOI=10.1074/jbc.m111.321216;
RA   Zhang J., Yang X., Wang Z., Zhou H., Xie X., Shen Y., Long J.;
RT   "Structure of an L27 domain heterotrimer from cell polarity complex
RT   Patj/Pals1/Mals2 reveals mutually independent L27 domain assembly mode.";
RL   J. Biol. Chem. 287:11132-11140(2012).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 236-675 IN COMPLEX WITH
RP   DROSOPHILA CRB, FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-386.
RX   PubMed=25385611; DOI=10.1073/pnas.1416515111;
RA   Li Y., Wei Z., Yan Y., Wan Q., Du Q., Zhang M.;
RT   "Structure of Crumbs tail in complex with the PALS1 PDZ-SH3-GK tandem
RT   reveals a highly specific assembly mechanism for the apical Crumbs
RT   complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:17444-17449(2014).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.23 ANGSTROMS) OF 251-335 IN COMPLEX WITH CRB1, AND
RP   MUTAGENESIS OF PHE-318.
RX   PubMed=25760605; DOI=10.1107/s139900471402776x;
RA   Ivanova M.E., Fletcher G.C., O'Reilly N., Purkiss A.G., Thompson B.J.,
RA   McDonald N.Q.;
RT   "Structures of the human Pals1 PDZ domain with and without ligand suggest
RT   gated access of Crb to the PDZ peptide-binding groove.";
RL   Acta Crystallogr. D 71:555-564(2015).
CC   -!- FUNCTION: Plays a role in tight junction biogenesis and in the
CC       establishment of cell polarity in epithelial cells (PubMed:16678097,
CC       PubMed:25385611). Also involved in adherens junction biogenesis by
CC       ensuring correct localization of the exocyst complex protein EXOC4/SEC8
CC       which allows trafficking of adherens junction structural component CDH1
CC       to the cell surface (By similarity). Plays a role through its
CC       interaction with CDH5 in vascular lumen formation and endothelial
CC       membrane polarity (PubMed:27466317). Required during embryonic and
CC       postnatal retinal development (By similarity). Required for the
CC       maintenance of cerebellar progenitor cells in an undifferentiated
CC       proliferative state, preventing premature differentiation, and is
CC       required for cerebellar histogenesis, fissure formation and cerebellar
CC       layer organization (By similarity). Plays a role in the radial and
CC       longitudinal extension of the myelin sheath in Schwann cells (By
CC       similarity). May modulate SC6A1/GAT1-mediated GABA uptake by
CC       stabilizing the transporter (By similarity). Plays a role in the T-cell
CC       receptor-mediated activation of NF-kappa-B (PubMed:21479189). Required
CC       for localization of EZR to the apical membrane of parietal cells and
CC       may play a role in the dynamic remodeling of the apical cytoskeleton
CC       (By similarity). Required for the normal polarized localization of the
CC       vesicular marker STX4 (By similarity). Required for the correct
CC       trafficking of the myelin proteins PMP22 and MAG (By similarity).
CC       {ECO:0000250|UniProtKB:B4F7E7, ECO:0000250|UniProtKB:Q9JLB2,
CC       ECO:0000269|PubMed:16678097, ECO:0000269|PubMed:21479189,
CC       ECO:0000269|PubMed:25385611, ECO:0000269|PubMed:27466317}.
CC   -!- FUNCTION: (Microbial infection) Acts as an interaction partner for
CC       SARS-CoV envelope protein E which results in delayed formation of tight
CC       junctions and disregulation of cell polarity.
CC       {ECO:0000269|PubMed:20861307}.
CC   -!- SUBUNIT: Heterodimer with MPP1 (PubMed:17584769). Component of a
CC       complex composed of MPP5, CRB1 and MPP4 (PubMed:15914641). Component of
CC       a complex composed of MPP5, MPP3 and CRB1; MPP5 acts as a bridging
CC       protein between MPP3 (via guanylate kinase-like domain) and CRB1
CC       (PubMed:16519681). Interacts (via PDZ domain) with CRB1 (via C-terminal
CC       ERLI motif) (PubMed:25385611, PubMed:25760605). While the PDZ domain is
CC       sufficient for interaction with CRB1, the adjacent SH3 and guanylate
CC       kinase-like domains are likely to contribute to a high affinity
CC       interaction (PubMed:25385611). Component of a complex whose core is
CC       composed of ARHGAP17, AMOT, MPP5/PALS1, PATJ and PARD3/PAR3
CC       (PubMed:16678097). Forms a heterotrimeric complex composed of MMP5,
CC       LIN7B and PATJ; the N-terminal L27 domain of MPP5 interacts with the
CC       L27 domain of PATJ and the C-terminal L27 domain of MPP5 interacts with
CC       the L27 domain of LIN7B (PubMed:22337881). Interacts with MPP7
CC       (PubMed:16678097, PubMed:17332497). Interacts with CRB3 (By
CC       similarity). Interacts with EZR (By similarity). Interacts with PATJ
CC       (By similarity). Interacts with LIN7C (By similarity). Interacts with
CC       MPDZ (By similarity). Interacts with PARD6B (By similarity). Interacts
CC       with SC6A1 (By similarity). Interacts with CDH; the interaction
CC       promotes MPP5 localization to cell junctions and is required for CDH5-
CC       mediated vascular lumen formation and endothelial cell
CC       (PubMed:27466317). Interacts with NPHP1 (via coiled coil and SH3
CC       domains) (PubMed:19755384). Interacts with NPHP4 (PubMed:19755384).
CC       {ECO:0000250|UniProtKB:Q9JLB2, ECO:0000269|PubMed:15914641,
CC       ECO:0000269|PubMed:16519681, ECO:0000269|PubMed:16678097,
CC       ECO:0000269|PubMed:17332497, ECO:0000269|PubMed:17584769,
CC       ECO:0000269|PubMed:19755384, ECO:0000269|PubMed:22337881,
CC       ECO:0000269|PubMed:25385611, ECO:0000269|PubMed:25760605,
CC       ECO:0000269|PubMed:27466317}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via PDZ domain) with human
CC       SARS-CoV envelope small membrane protein E (via C-terminus); this
CC       inhibits the interaction between MPP5 and CRB3.
CC       {ECO:0000269|PubMed:20861307}.
CC   -!- INTERACTION:
CC       Q8N3R9; Q6PI77: BHLHB9; NbExp=3; IntAct=EBI-2513978, EBI-11519926;
CC       Q8N3R9; Q9Y2H0-1: DLGAP4; NbExp=3; IntAct=EBI-2513978, EBI-12000556;
CC       Q8N3R9; O95954: FTCD; NbExp=3; IntAct=EBI-2513978, EBI-10192648;
CC       Q8N3R9; O14910: LIN7A; NbExp=9; IntAct=EBI-2513978, EBI-2513988;
CC       Q8N3R9; Q9HAP6: LIN7B; NbExp=3; IntAct=EBI-2513978, EBI-821335;
CC       Q8N3R9; Q9NUP9: LIN7C; NbExp=4; IntAct=EBI-2513978, EBI-1171517;
CC       Q8N3R9; Q8NI35: PATJ; NbExp=4; IntAct=EBI-2513978, EBI-724390;
CC       Q8N3R9; Q9NY99-2: SNTG2; NbExp=3; IntAct=EBI-2513978, EBI-18173613;
CC       Q8N3R9; A0A286YEY3: SRGAP2B; NbExp=3; IntAct=EBI-2513978, EBI-17766455;
CC       Q8N3R9; Q12933: TRAF2; NbExp=3; IntAct=EBI-2513978, EBI-355744;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus {ECO:0000269|PubMed:21479189}.
CC       Cell membrane; Peripheral membrane protein. Endomembrane system;
CC       Peripheral membrane protein. Cell junction, tight junction
CC       {ECO:0000269|PubMed:20861307}. Cell junction, adherens junction
CC       {ECO:0000269|PubMed:16519681}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q9JLB2}. Perikaryon
CC       {ECO:0000250|UniProtKB:Q9JLB2}. Apical cell membrane
CC       {ECO:0000269|PubMed:15914641, ECO:0000269|PubMed:16519681,
CC       ECO:0000269|PubMed:25385611}. Note=Localized to the tight junctions of
CC       epithelial cells (By similarity). Localized to the Golgi apparatus in T
CC       lymphocytes (PubMed:21479189). Localized to a subset of intracellular
CC       vesicles (By similarity). Localized to the Purkinje cell body and axon
CC       (By similarity). Localized to intercellular junctions in vascular
CC       endothelial cells (PubMed:27466317). Localized to Schmidt-Lanterman
CC       incisures, the adaxonal domain, and the inner part of paranodal loops
CC       in myelinating Schwann cells of the sciatic nerve (By similarity).
CC       Localized to apical membrane domains of the outer limiting membrane
CC       (OLM) junctions in the retina (By similarity). Colocalizes with CRB1 at
CC       the OLM, apical to the adherens junction (PubMed:15914641). Colocalizes
CC       with MPP1 in the retina at the OLM (PubMed:17584769). Colocalizes with
CC       MPP3 to the subapical region of adherens junctions in the retina OLM
CC       (PubMed:16519681). {ECO:0000250|UniProtKB:Q9JLB2,
CC       ECO:0000269|PubMed:15914641, ECO:0000269|PubMed:16519681,
CC       ECO:0000269|PubMed:17584769, ECO:0000269|PubMed:21479189,
CC       ECO:0000269|PubMed:27466317}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum-Golgi intermediate
CC       compartment {ECO:0000269|PubMed:20861307}. Golgi apparatus
CC       {ECO:0000269|PubMed:20861307}. Note=(Microbial infection) Following
CC       infection by SARS-CoV, partially localized at the site of viral
CC       replication; the endoplasmic reticulum-Golgi intermediate compartment,
CC       reducing its levels at cell-cell contacts which results in delayed
CC       formation of tight junctions and affects establishment of cell
CC       polarity. {ECO:0000269|PubMed:20861307}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8N3R9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8N3R9-2; Sequence=VSP_014002;
CC   -!- TISSUE SPECIFICITY: Expressed at the outer limiting membrane in the
CC       retina (at protein level) (PubMed:15914641, PubMed:15558731,
CC       PubMed:16519681, PubMed:17584769). Expressed in T lymphocytes (at
CC       protein level) (PubMed:21479189). Expressed in the kidney (at protein
CC       level) (PubMed:17584769). {ECO:0000269|PubMed:15558731,
CC       ECO:0000269|PubMed:15914641, ECO:0000269|PubMed:16519681,
CC       ECO:0000269|PubMed:17584769, ECO:0000269|PubMed:21479189}.
CC   -!- DOMAIN: The L27 domain 1 functions in targeting to the tight junctions
CC       by binding to and stabilizing PATJ. {ECO:0000250|UniProtKB:Q9JLB2}.
CC   -!- DOMAIN: The PDZ domain binds to the C-terminus of SC6A1.
CC       {ECO:0000250|UniProtKB:Q9JLB2}.
CC   -!- SIMILARITY: Belongs to the MAGUK family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH53366.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAB14172.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL832326; CAD38620.1; -; mRNA.
DR   EMBL; AL832578; CAD89937.1; -; mRNA.
DR   EMBL; CH471061; EAW80930.1; -; Genomic_DNA.
DR   EMBL; BC053366; AAH53366.1; ALT_SEQ; mRNA.
DR   EMBL; BC129933; AAI29934.1; -; mRNA.
DR   EMBL; AK022677; BAB14172.1; ALT_INIT; mRNA.
DR   EMBL; AK098373; BAC05295.1; -; mRNA.
DR   CCDS; CCDS58325.1; -. [Q8N3R9-2]
DR   CCDS; CCDS9779.1; -. [Q8N3R9-1]
DR   RefSeq; NP_001243479.1; NM_001256550.1. [Q8N3R9-2]
DR   RefSeq; NP_071919.2; NM_022474.3. [Q8N3R9-1]
DR   RefSeq; XP_005268060.1; XM_005268003.1. [Q8N3R9-2]
DR   RefSeq; XP_011535388.1; XM_011537086.2. [Q8N3R9-1]
DR   RefSeq; XP_011535389.1; XM_011537087.2. [Q8N3R9-1]
DR   PDB; 1Y76; NMR; -; B/D=118-177.
DR   PDB; 3UIT; X-ray; 2.05 A; A/B/C/D=119-232.
DR   PDB; 4UU5; X-ray; 1.23 A; A=251-335.
DR   PDB; 4UU6; X-ray; 1.80 A; A=251-335.
DR   PDB; 4WSI; X-ray; 2.95 A; A/B=236-675.
DR   PDBsum; 1Y76; -.
DR   PDBsum; 3UIT; -.
DR   PDBsum; 4UU5; -.
DR   PDBsum; 4UU6; -.
DR   PDBsum; 4WSI; -.
DR   SMR; Q8N3R9; -.
DR   BioGRID; 122155; 40.
DR   CORUM; Q8N3R9; -.
DR   IntAct; Q8N3R9; 60.
DR   MINT; Q8N3R9; -.
DR   STRING; 9606.ENSP00000261681; -.
DR   iPTMnet; Q8N3R9; -.
DR   PhosphoSitePlus; Q8N3R9; -.
DR   SwissPalm; Q8N3R9; -.
DR   BioMuta; MPP5; -.
DR   DMDM; 116242632; -.
DR   EPD; Q8N3R9; -.
DR   jPOST; Q8N3R9; -.
DR   MassIVE; Q8N3R9; -.
DR   MaxQB; Q8N3R9; -.
DR   PaxDb; Q8N3R9; -.
DR   PeptideAtlas; Q8N3R9; -.
DR   PRIDE; Q8N3R9; -.
DR   ProteomicsDB; 71827; -. [Q8N3R9-1]
DR   ProteomicsDB; 71828; -. [Q8N3R9-2]
DR   Antibodypedia; 20; 328 antibodies.
DR   DNASU; 64398; -.
DR   Ensembl; ENST00000261681; ENSP00000261681; ENSG00000072415. [Q8N3R9-1]
DR   Ensembl; ENST00000555925; ENSP00000451488; ENSG00000072415. [Q8N3R9-2]
DR   GeneID; 64398; -.
DR   KEGG; hsa:64398; -.
DR   UCSC; uc001xjc.5; human. [Q8N3R9-1]
DR   CTD; 64398; -.
DR   DisGeNET; 64398; -.
DR   EuPathDB; HostDB:ENSG00000072415.8; -.
DR   GeneCards; MPP5; -.
DR   HGNC; HGNC:18669; MPP5.
DR   HPA; ENSG00000072415; Low tissue specificity.
DR   MIM; 606958; gene.
DR   neXtProt; NX_Q8N3R9; -.
DR   OpenTargets; ENSG00000072415; -.
DR   PharmGKB; PA38631; -.
DR   eggNOG; KOG0609; Eukaryota.
DR   GeneTree; ENSGT00940000156087; -.
DR   HOGENOM; CLU_001715_5_4_1; -.
DR   InParanoid; Q8N3R9; -.
DR   KO; K06091; -.
DR   OMA; MMPMRRS; -.
DR   PhylomeDB; Q8N3R9; -.
DR   TreeFam; TF314263; -.
DR   PathwayCommons; Q8N3R9; -.
DR   Reactome; R-HSA-420029; Tight junction interactions.
DR   SIGNOR; Q8N3R9; -.
DR   BioGRID-ORCS; 64398; 6 hits in 873 CRISPR screens.
DR   ChiTaRS; MPP5; human.
DR   EvolutionaryTrace; Q8N3R9; -.
DR   GeneWiki; MPP5; -.
DR   GenomeRNAi; 64398; -.
DR   Pharos; Q8N3R9; Tbio.
DR   PRO; PR:Q8N3R9; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q8N3R9; protein.
DR   Bgee; ENSG00000072415; Expressed in metanephros and 220 other tissues.
DR   ExpressionAtlas; Q8N3R9; baseline and differential.
DR   Genevisible; Q8N3R9; HS.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005923; C:bicellular tight junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0043219; C:lateral loop; IEA:Ensembl.
DR   GO; GO:0035749; C:myelin sheath adaxonal region; IEA:Ensembl.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:BHF-UCL.
DR   GO; GO:0070830; P:bicellular tight junction assembly; TAS:Reactome.
DR   GO; GO:0090162; P:establishment of epithelial cell polarity; IEA:InterPro.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0002011; P:morphogenesis of an epithelial sheet; IMP:UniProtKB.
DR   GO; GO:0032288; P:myelin assembly; IEA:Ensembl.
DR   GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl.
DR   GO; GO:0035750; P:protein localization to myelin sheath abaxonal region; IEA:Ensembl.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IEA:Ensembl.
DR   CDD; cd12036; SH3_MPP5; 1.
DR   Gene3D; 2.30.42.10; -; 1.
DR   InterPro; IPR008145; GK/Ca_channel_bsu.
DR   InterPro; IPR008144; Guanylate_kin-like_dom.
DR   InterPro; IPR020590; Guanylate_kinase_CS.
DR   InterPro; IPR014775; L27_C.
DR   InterPro; IPR004172; L27_dom.
DR   InterPro; IPR036892; L27_dom_sf.
DR   InterPro; IPR015145; L27_N.
DR   InterPro; IPR031185; MPP5.
DR   InterPro; IPR035601; MPP5_SH3.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR036034; PDZ_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR23122:SF14; PTHR23122:SF14; 1.
DR   Pfam; PF00625; Guanylate_kin; 1.
DR   Pfam; PF02828; L27; 1.
DR   Pfam; PF09060; L27_N; 1.
DR   Pfam; PF00595; PDZ; 1.
DR   Pfam; PF07653; SH3_2; 1.
DR   SMART; SM00072; GuKc; 1.
DR   SMART; SM00569; L27; 2.
DR   SMART; SM00228; PDZ; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF101288; SSF101288; 2.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF50156; SSF50156; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS00856; GUANYLATE_KINASE_1; 1.
DR   PROSITE; PS50052; GUANYLATE_KINASE_2; 1.
DR   PROSITE; PS51022; L27; 2.
DR   PROSITE; PS50106; PDZ; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell junction;
KW   Cell membrane; Cell projection; Golgi apparatus; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat; SH3 domain;
KW   Tight junction.
FT   CHAIN           1..675
FT                   /note="MAGUK p55 subfamily member 5"
FT                   /id="PRO_0000094580"
FT   DOMAIN          120..177
FT                   /note="L27 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00365"
FT   DOMAIN          179..235
FT                   /note="L27 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00365"
FT   DOMAIN          256..336
FT                   /note="PDZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          345..417
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          479..660
FT                   /note="Guanylate kinase-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00100"
FT   NP_BIND         486..493
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00100"
FT   REGION          1..345
FT                   /note="Required for the correct localization of MPP5 and
FT                   PATJ at cell-cell contacts and the normal formation of
FT                   tight junctions and adherens junctions"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JLB2"
FT   REGION          21..140
FT                   /note="Interaction with PARD6B"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JLB2"
FT   REGION          181..243
FT                   /note="Interaction with LIN7C"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JLB2"
FT   MOD_RES         14
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         83
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         84
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   VAR_SEQ         1..34
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_014002"
FT   MUTAGEN         318
FT                   /note="F->A,C: Increases interaction with CRB1."
FT                   /evidence="ECO:0000269|PubMed:25760605"
FT   MUTAGEN         386
FT                   /note="D->K: Reduces binding to Drosophila crb and causes
FT                   incorrect MPP5 localization and cell polarity."
FT                   /evidence="ECO:0000269|PubMed:25385611"
FT   CONFLICT        100
FT                   /note="D -> G (in Ref. 1; CAD38620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        141
FT                   /note="S -> Y (in Ref. 1; CAD89937)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        161
FT                   /note="N -> S (in Ref. 4; BAC05295)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        324
FT                   /note="M -> L (in Ref. 4; BAC05295)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        401
FT                   /note="Q -> H (in Ref. 1; CAD89937)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        460
FT                   /note="N -> H (in Ref. 1; CAD89937)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        490
FT                   /note="C -> F (in Ref. 4; BAB14172)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        613
FT                   /note="G -> V (in Ref. 1; CAD38620)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        634
FT                   /note="N -> S (in Ref. 1; CAD38620)"
FT                   /evidence="ECO:0000305"
FT   HELIX           124..137
FT                   /evidence="ECO:0000244|PDB:3UIT"
FT   HELIX           141..155
FT                   /evidence="ECO:0000244|PDB:3UIT"
FT   HELIX           157..173
FT                   /evidence="ECO:0000244|PDB:3UIT"
FT   HELIX           186..197
FT                   /evidence="ECO:0000244|PDB:3UIT"
FT   TURN            198..200
FT                   /evidence="ECO:0000244|PDB:3UIT"
FT   HELIX           203..213
FT                   /evidence="ECO:0000244|PDB:3UIT"
FT   HELIX           215..229
FT                   /evidence="ECO:0000244|PDB:3UIT"
FT   STRAND          230..232
FT                   /evidence="ECO:0000244|PDB:3UIT"
FT   STRAND          249..251
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          255..261
FT                   /evidence="ECO:0000244|PDB:4UU5"
FT   STRAND          268..274
FT                   /evidence="ECO:0000244|PDB:4UU5"
FT   STRAND          277..283
FT                   /evidence="ECO:0000244|PDB:4UU5"
FT   HELIX           288..292
FT                   /evidence="ECO:0000244|PDB:4UU5"
FT   STRAND          300..304
FT                   /evidence="ECO:0000244|PDB:4UU5"
FT   HELIX           314..322
FT                   /evidence="ECO:0000244|PDB:4UU5"
FT   STRAND          326..333
FT                   /evidence="ECO:0000244|PDB:4UU5"
FT   STRAND          348..352
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           358..360
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           367..369
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          378..383
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          389..394
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          405..408
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          464..472
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          482..486
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   TURN            488..491
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           492..502
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   TURN            503..506
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   TURN            524..527
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           533..541
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          545..551
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          554..559
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           560..567
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   TURN            568..570
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          571..576
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           579..581
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           582..586
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          593..598
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           602..608
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           621..631
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           634..636
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          639..644
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           648..660
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   TURN            661..664
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   STRAND          667..670
FT                   /evidence="ECO:0000244|PDB:4WSI"
FT   HELIX           671..673
FT                   /evidence="ECO:0000244|PDB:4WSI"
SQ   SEQUENCE   675 AA;  77294 MW;  A3B2CB594E0908CA CRC64;
     MTTSHMNGHV TEESDSEVKN VDLASPEEHQ KHREMAVDCP GDLGTRMMPI RRSAQLERIR
     QQQEDMRRRR EEEGKKQELD LNSSMRLKKL AQIPPKTGID NPMFDTEEGI VLESPHYAVK
     ILEIEDLFSS LKHIQHTLVD SQSQEDISLL LQLVQNKDFQ NAFKIHNAIT VHMNKASPPF
     PLISNAQDLA QEVQTVLKPV HHKEGQELTA LLNTPHIQAL LLAHDKVAEQ EMQLEPITDE
     RVYESIGQYG GETVKIVRIE KARDIPLGAT VRNEMDSVII SRIVKGGAAE KSGLLHEGDE
     VLEINGIEIR GKDVNEVFDL LSDMHGTLTF VLIPSQQIKP PPAKETVIHV KAHFDYDPSD
     DPYVPCRELG LSFQKGDILH VISQEDPNWW QAYREGDEDN QPLAGLVPGK SFQQQREAMK
     QTIEEDKEPE KSGKLWCAKK NKKKRKKVLY NANKNDDYDN EEILTYEEMS LYHQPANRKR
     PIILIGPQNC GQNELRQRLM NKEKDRFASA VPHTTRSRRD QEVAGRDYHF VSRQAFEADI
     AAGKFIEHGE FEKNLYGTSI DSVRQVINSG KICLLSLRTQ SLKTLRNSDL KPYIIFIAPP
     SQERLRALLA KEGKNPKPEE LREIIEKTRE MEQNNGHYFD TAIVNSDLDK AYQELLRLIN
     KLDTEPQWVP STWLR
//
ID   I17RC_HUMAN             Reviewed;         791 AA.
AC   Q8NAC3; A8BWC1; A8BWC9; A8BWD5; E9PHG1; E9PHJ6; Q6UVY3; Q6UWD4; Q8NFS1;
AC   Q9BR97;
DT   21-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   12-AUG-2020, entry version 147.
DE   RecName: Full=Interleukin-17 receptor C;
DE            Short=IL-17 receptor C;
DE            Short=IL-17RC;
DE   AltName: Full=Interleukin-17 receptor homolog;
DE            Short=IL17Rhom;
DE   AltName: Full=Interleukin-17 receptor-like protein;
DE            Short=IL-17RL;
DE   AltName: Full=ZcytoR14;
DE   Flags: Precursor;
GN   Name=IL17RC; ORFNames=UNQ6118/PRO20040/PRO38901;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 6 AND 7), FUNCTION, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, AND ALTERNATIVE SPLICING.
RX   PubMed=17911633; DOI=10.4049/jimmunol.179.8.5462;
RA   Kuestner R.E., Taft D.W., Haran A., Brandt C.S., Brender T., Lum K.,
RA   Harder B., Okada S., Ostrander C.D., Kreindler J.L., Aujla S.J.,
RA   Reardon B., Moore M., Shea P., Schreckhise R., Bukowski T.R., Presnell S.,
RA   Guerra-Lewis P., Parrish-Novak J., Ellsworth J.L., Jaspers S., Lewis K.E.,
RA   Appleby M., Kolls J.K., Rixon M., West J.W., Gao Z., Levin S.D.;
RT   "Identification of the IL-17 receptor related molecule IL-17RC as the
RT   receptor for IL-17F.";
RL   J. Immunol. 179:5462-5473(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8).
RA   Presnell S.R., Burkhead S.K., Pownder S.L.;
RL   Patent number JP2003504058, 04-FEB-2003.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT LEU-182.
RA   Gilbert J.M., Gorman D.M.;
RT   "Identification of novel IL-17 related receptors.";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-182.
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 21-35.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [9]
RP   ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=11706037; DOI=10.1074/jbc.m109372200;
RA   Haudenschild D., Moseley T., Rose L., Reddi A.H.;
RT   "Soluble and transmembrane isoforms of novel interleukin-17 receptor-like
RT   protein by RNA splicing and expression in prostate cancer.";
RL   J. Biol. Chem. 277:4309-4316(2002).
RN   [10]
RP   INDUCTION BY HGF AND VEGF.
RX   PubMed=14504135; DOI=10.1038/sj.bjp.0705494;
RA   Gerritsen M.E., Tomlinson J.E., Zlot C., Ziman M., Hwang S.;
RT   "Using gene expression profiling to identify the molecular basis of the
RT   synergistic actions of hepatocyte growth factor and vascular endothelial
RT   growth factor in human endothelial cells.";
RL   Br. J. Pharmacol. 140:595-610(2003).
RN   [11]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=16785495; DOI=10.4049/jimmunol.177.1.36;
RA   Toy D., Kugler D., Wolfson M., Vanden Bos T., Gurgel J., Derry J.,
RA   Tocker J., Peschon J.;
RT   "Interleukin 17 signals through a heteromeric receptor complex.";
RL   J. Immunol. 177:36-39(2006).
RN   [12]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=18684971; DOI=10.4049/jimmunol.181.4.2799;
RA   Wright J.F., Bennett F., Li B., Brooks J., Luxenberg D.P., Whitters M.J.,
RA   Tomkinson K.N., Fitz L.J., Wolfman N.M., Collins M.,
RA   Dunussi-Joannopoulos K., Chatterjee-Kishore M., Carreno B.M.;
RT   "The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-
RT   17RA/IL-17RC receptor complex.";
RL   J. Immunol. 181:2799-2805(2008).
RN   [13]
RP   INTERACTION WITH TRAF3IP2.
RX   PubMed=24120361; DOI=10.1016/j.immuni.2013.09.002;
RA   Boisson B., Wang C., Pedergnana V., Wu L., Cypowyj S., Rybojad M.,
RA   Belkadi A., Picard C., Abel L., Fieschi C., Puel A., Li X., Casanova J.L.;
RT   "An ACT1 mutation selectively abolishes interleukin-17 responses in humans
RT   with chronic mucocutaneous candidiasis.";
RL   Immunity 39:676-686(2013).
RN   [14]
RP   INTERACTION WITH IL17A AND IL17F.
RX   PubMed=28827714; DOI=10.1038/s41598-017-08360-9;
RA   Goepfert A., Lehmann S., Wirth E., Rondeau J.M.;
RT   "The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor
RT   recognition properties.";
RL   Sci. Rep. 7:8906-8906(2017).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 279-538 IN COMPLEX WITH IL17F,
RP   DISULFIDE BOND, INTERACTION WITH IL17RA; IL17F AND IL17A, AND FUNCTION.
RX   PubMed=32187518; DOI=10.1016/j.immuni.2020.02.004;
RA   Goepfert A., Lehmann S., Blank J., Kolbinger F., Rondeau J.M.;
RT   "Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric
RT   Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling.";
RL   Immunity 52:499-512.e5(2020).
RN   [16]
RP   INVOLVEMENT IN CANDF9.
RX   PubMed=25918342; DOI=10.1084/jem.20141065;
RA   Ling Y., Cypowyj S., Aytekin C., Galicchio M., Camcioglu Y., Nepesov S.,
RA   Ikinciogullari A., Dogu F., Belkadi A., Levy R., Migaud M., Boisson B.,
RA   Bolze A., Itan Y., Goudin N., Cottineau J., Picard C., Abel L.,
RA   Bustamante J., Casanova J.L., Puel A.;
RT   "Inherited IL-17RC deficiency in patients with chronic mucocutaneous
RT   candidiasis.";
RL   J. Exp. Med. 212:619-631(2015).
CC   -!- FUNCTION: Receptor for IL17A and IL17F, major effector cytokines of
CC       innate and adaptive immune system involved in antimicrobial host
CC       defense and maintenance of tissue integrity (By similarity). Receptor
CC       for IL17A and IL17F, major effector cytokines of innate and adaptive
CC       immune system involved in antimicrobial host defense and maintenance of
CC       tissue integrity. Receptor for IL17A and IL17F homodimers as part of a
CC       heterodimeric complex with IL17RA (PubMed:16785495). Receptor for the
CC       heterodimer formed by IL17A and IL17B as part of a heterodimeric
CC       complex with IL17RA (PubMed:18684971). Has also been shown to be the
CC       cognate receptor for IL17F and to bind IL17A with high affinity without
CC       the need for IL17RA (PubMed:17911633). Upon binding of IL17F homodimer
CC       triggers downstream activation of TRAF6 and NF-kappa-B signaling
CC       pathway (PubMed:16785495, PubMed:32187518). Induces transcriptional
CC       activation of IL33, a potent cytokine that stimulates group 2 innate
CC       lymphoid cells and adaptive T-helper 2 cells involved in pulmonary
CC       allergic response to fungi (By similarity). Promotes sympathetic
CC       innervation of peripheral organs by coordinating the communication
CC       between gamma-delta T cells and parenchymal cells. Stimulates
CC       sympathetic innervation of thermogenic adipose tissue by driving TGFB1
CC       expression (By similarity). Binding of IL17A-IL17F to IL17RA-IL17RC
CC       heterodimeric receptor complex triggers homotypic interaction of IL17RA
CC       and IL17RC chains with TRAF3IP2 adapter through SEFIR domains. This
CC       leads to downstream TRAF6-mediated activation of NF-kappa-B and
CC       MAPkinase pathways ultimately resulting in transcriptional activation
CC       of cytokines, chemokines, antimicrobial peptides and matrix
CC       metalloproteinases, with potential strong immune inflammation
CC       (PubMed:18684971, PubMed:17911633). Primarily induces neutrophil
CC       activation and recruitment at infection and inflammatory sites (By
CC       similarity). Stimulates the production of antimicrobial beta-defensins
CC       DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the
CC       entry of microbes through the epithelial barriers (By similarity).
CC       {ECO:0000250|UniProtKB:Q8K4C2, ECO:0000269|PubMed:16785495,
CC       ECO:0000269|PubMed:17911633, ECO:0000269|PubMed:18684971,
CC       ECO:0000269|PubMed:32187518}.
CC   -!- FUNCTION: [Isoform 5]: Receptor for both IL17A and IL17F.
CC       {ECO:0000269|PubMed:16785495}.
CC   -!- FUNCTION: [Isoform 6]: Does not bind IL17A or IL17F.
CC       {ECO:0000269|PubMed:16785495}.
CC   -!- FUNCTION: [Isoform 7]: Does not bind IL17A or IL17F.
CC       {ECO:0000269|PubMed:16785495}.
CC   -!- FUNCTION: [Isoform 8]: Receptor for both IL17A and IL17F.
CC       {ECO:0000269|PubMed:16785495}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:32187518). Heterodimer
CC       with IL17RA (PubMed:16785495, PubMed:18684971). Heterodimerization with
CC       IL17RA is independent of the cytoplasmic tail (By similarity).
CC       Associates with non-glycosylated IL17RA constitutively (By similarity).
CC       Binding of IL17A and IL17F induces association with glycosylated IL17RA
CC       (By similarity). Forms complexes with 2:1 binding stoichiometry: two
CC       receptor chains for one interleukin molecule (PubMed:32187518,
CC       PubMed:28827714). IL17A homodimer preferentially drives the formation
CC       of IL17RA-IL17RC heterodimeric receptor complex, whereas IL17F
CC       homodimer forms predominantly complexes with IL17RC homodimer
CC       (PubMed:32187518). IL17A-IL17F forms complexes with IL17RA-IL17RC, but
CC       with lower affinity when compared to IL17A homodimer (PubMed:32187518).
CC       IL17RC chain can not distinguish between IL17A and IL17F molecules,
CC       potentially enabling the formation of topologically distinct complexes
CC       (PubMed:28827714). Interacts (through SEFIR domain and extended
CC       downstream region) with TRAF3IP2/ACT1 (phosphorylated)
CC       (PubMed:24120361). {ECO:0000250|UniProtKB:Q8K4C2,
CC       ECO:0000269|PubMed:16785495, ECO:0000269|PubMed:18684971,
CC       ECO:0000269|PubMed:24120361, ECO:0000269|PubMed:28827714,
CC       ECO:0000269|PubMed:32187518}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17911633};
CC       Single-pass type I membrane protein {ECO:0000255}. Note=Soluble
CC       isoforms may be produced.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=Q8NAC3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NAC3-2; Sequence=VSP_014138;
CC       Name=3;
CC         IsoId=Q8NAC3-3; Sequence=VSP_014138, VSP_014139;
CC       Name=4;
CC         IsoId=Q8NAC3-4; Sequence=VSP_014138, VSP_014139, VSP_014140,
CC                                  VSP_014141;
CC       Name=5; Synonyms=IL17RC {ECO:0000303|PubMed:17911633};
CC         IsoId=Q8NAC3-5; Sequence=VSP_014138, VSP_047292;
CC       Name=6; Synonyms=IL17RC-delta7,12 {ECO:0000303|PubMed:17911633};
CC         IsoId=Q8NAC3-6; Sequence=VSP_014138, VSP_014139, VSP_047291;
CC       Name=7; Synonyms=IL17RC-delta12 {ECO:0000303|PubMed:17911633};
CC         IsoId=Q8NAC3-7; Sequence=VSP_014138, VSP_047291, VSP_047292;
CC       Name=8; Synonyms=IL17RC-delta7 {ECO:0000303|PubMed:17911633};
CC         IsoId=Q8NAC3-8; Sequence=VSP_014138, VSP_014139, VSP_047292;
CC   -!- TISSUE SPECIFICITY: Expressed in prostate, skeletal muscle, kidney and
CC       placenta (at protein level) (PubMed:11706037). Expressed in brain,
CC       cartilage, colon, heart, intestine, kidney, liver, lung, muscle,
CC       placenta, and prostate (PubMed:11706037). Also detected in thyroid,
CC       trachea and adrenal gland (PubMed:17911633). Low expression in thymus
CC       and leukocytes (PubMed:11706037). {ECO:0000269|PubMed:11706037,
CC       ECO:0000269|PubMed:17911633}.
CC   -!- INDUCTION: By HGF and VEGF. {ECO:0000269|PubMed:14504135}.
CC   -!- DISEASE: Candidiasis, familial, 9 (CANDF9) [MIM:616445]: A disorder
CC       characterized by altered immune responses and impaired clearance of
CC       fungal infections, selective against Candida. It is characterized by
CC       persistent and/or recurrent infections of the skin, nails and mucous
CC       membranes caused by organisms of the genus Candida, mainly Candida
CC       albicans. {ECO:0000269|PubMed:25918342}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; EF676032; ABV44615.1; -; mRNA.
DR   EMBL; EF676033; ABV44616.1; -; mRNA.
DR   EMBL; EF676034; ABV44617.1; -; mRNA.
DR   EMBL; BD292072; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AF458065; AAM77569.1; -; mRNA.
DR   EMBL; AY358840; AAQ89199.1; -; mRNA.
DR   EMBL; AY359098; AAQ89456.1; -; mRNA.
DR   EMBL; AK092907; BAC04001.1; -; mRNA.
DR   EMBL; AC018809; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006411; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS2590.1; -. [Q8NAC3-1]
DR   CCDS; CCDS2591.2; -. [Q8NAC3-3]
DR   CCDS; CCDS46746.1; -. [Q8NAC3-2]
DR   CCDS; CCDS56240.1; -. [Q8NAC3-5]
DR   CCDS; CCDS56241.1; -. [Q8NAC3-6]
DR   CCDS; CCDS74898.1; -. [Q8NAC3-7]
DR   RefSeq; NP_001190192.1; NM_001203263.1. [Q8NAC3-5]
DR   RefSeq; NP_001190193.1; NM_001203264.1.
DR   RefSeq; NP_001190194.1; NM_001203265.1. [Q8NAC3-6]
DR   RefSeq; NP_116121.2; NM_032732.5. [Q8NAC3-3]
DR   RefSeq; NP_703190.1; NM_153460.3. [Q8NAC3-2]
DR   RefSeq; NP_703191.1; NM_153461.3. [Q8NAC3-1]
DR   RefSeq; XP_016862835.1; XM_017007346.1.
DR   PDB; 6HG4; X-ray; 3.32 A; B=95-538.
DR   PDB; 6HG9; X-ray; 3.62 A; B=95-538.
DR   PDB; 6HGA; X-ray; 2.60 A; B=279-538.
DR   PDBsum; 6HG4; -.
DR   PDBsum; 6HG9; -.
DR   PDBsum; 6HGA; -.
DR   SMR; Q8NAC3; -.
DR   BioGRID; 124278; 53.
DR   IntAct; Q8NAC3; 45.
DR   STRING; 9606.ENSP00000295981; -.
DR   DrugCentral; Q8NAC3; -.
DR   GlyGen; Q8NAC3; 9 sites.
DR   iPTMnet; Q8NAC3; -.
DR   PhosphoSitePlus; Q8NAC3; -.
DR   BioMuta; IL17RC; -.
DR   DMDM; 229462881; -.
DR   jPOST; Q8NAC3; -.
DR   PaxDb; Q8NAC3; -.
DR   PeptideAtlas; Q8NAC3; -.
DR   PRIDE; Q8NAC3; -.
DR   ProteomicsDB; 20526; -.
DR   ProteomicsDB; 20554; -.
DR   ProteomicsDB; 72669; -. [Q8NAC3-1]
DR   ProteomicsDB; 72670; -. [Q8NAC3-2]
DR   ProteomicsDB; 72671; -. [Q8NAC3-3]
DR   ProteomicsDB; 72672; -. [Q8NAC3-4]
DR   Antibodypedia; 10412; 314 antibodies.
DR   Ensembl; ENST00000295981; ENSP00000295981; ENSG00000163702. [Q8NAC3-1]
DR   Ensembl; ENST00000383812; ENSP00000373323; ENSG00000163702. [Q8NAC3-3]
DR   Ensembl; ENST00000403601; ENSP00000384969; ENSG00000163702. [Q8NAC3-2]
DR   Ensembl; ENST00000413608; ENSP00000396064; ENSG00000163702. [Q8NAC3-5]
DR   Ensembl; ENST00000416074; ENSP00000395315; ENSG00000163702. [Q8NAC3-7]
DR   Ensembl; ENST00000455057; ENSP00000407894; ENSG00000163702. [Q8NAC3-6]
DR   GeneID; 84818; -.
DR   KEGG; hsa:84818; -.
DR   UCSC; uc003btz.4; human. [Q8NAC3-1]
DR   CTD; 84818; -.
DR   DisGeNET; 84818; -.
DR   EuPathDB; HostDB:ENSG00000163702.18; -.
DR   GeneCards; IL17RC; -.
DR   HGNC; HGNC:18358; IL17RC.
DR   HPA; ENSG00000163702; Low tissue specificity.
DR   MalaCards; IL17RC; -.
DR   MIM; 610925; gene.
DR   MIM; 616445; phenotype.
DR   neXtProt; NX_Q8NAC3; -.
DR   OpenTargets; ENSG00000163702; -.
DR   Orphanet; 1334; Chronic mucocutaneous candidiasis.
DR   PharmGKB; PA134986616; -.
DR   eggNOG; ENOG502RYE0; Eukaryota.
DR   GeneTree; ENSGT00730000111286; -.
DR   HOGENOM; CLU_026893_1_0_1; -.
DR   InParanoid; Q8NAC3; -.
DR   KO; K05166; -.
DR   OMA; CLWSDSL; -.
DR   OrthoDB; 297610at2759; -.
DR   PhylomeDB; Q8NAC3; -.
DR   TreeFam; TF335852; -.
DR   PathwayCommons; Q8NAC3; -.
DR   Reactome; R-HSA-448424; Interleukin-17 signaling.
DR   BioGRID-ORCS; 84818; 6 hits in 873 CRISPR screens.
DR   ChiTaRS; IL17RC; human.
DR   GeneWiki; IL17RC; -.
DR   GenomeRNAi; 84818; -.
DR   Pharos; Q8NAC3; Tclin.
DR   PRO; PR:Q8NAC3; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q8NAC3; protein.
DR   Bgee; ENSG00000163702; Expressed in adenohypophysis and 207 other tissues.
DR   ExpressionAtlas; Q8NAC3; baseline and differential.
DR   Genevisible; Q8NAC3; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030368; F:interleukin-17 receptor activity; IDA:MGI.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:Ensembl.
DR   GO; GO:0050832; P:defense response to fungus; IEA:Ensembl.
DR   GO; GO:0071621; P:granulocyte chemotaxis; IEA:Ensembl.
DR   GO; GO:0097400; P:interleukin-17-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IEA:Ensembl.
DR   GO; GO:2000778; P:positive regulation of interleukin-6 secretion; IEA:Ensembl.
DR   InterPro; IPR039465; IL-17_rcpt-like.
DR   InterPro; IPR027841; IL-17_rcpt_C/E_N.
DR   InterPro; IPR013568; SEFIR_dom.
DR   PANTHER; PTHR15583; PTHR15583; 1.
DR   Pfam; PF15037; IL17_R_N; 1.
DR   Pfam; PF08357; SEFIR; 1.
DR   PROSITE; PS51534; SEFIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Inflammatory response; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           21..791
FT                   /note="Interleukin-17 receptor C"
FT                   /id="PRO_0000011034"
FT   TOPO_DOM        21..538
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        539..559
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        560..791
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          583..735
FT                   /note="SEFIR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00867"
FT   CARBOHYD        189
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        257
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        284
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        297
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        324
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        334
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        420
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        443
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        477
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        265..277
FT                   /evidence="ECO:0000244|PDB:6HG4,
FT                   ECO:0000269|PubMed:32187518"
FT   DISULFID        341..391
FT                   /evidence="ECO:0000244|PDB:6HG4,
FT                   ECO:0000269|PubMed:32187518"
FT   DISULFID        343..359
FT                   /evidence="ECO:0000244|PDB:6HG4,
FT                   ECO:0000269|PubMed:32187518"
FT   DISULFID        400..409
FT                   /evidence="ECO:0000244|PDB:6HG4,
FT                   ECO:0000269|PubMed:32187518"
FT   DISULFID        439..453
FT                   /evidence="ECO:0000244|PDB:6HG4,
FT                   ECO:0000269|PubMed:32187518"
FT   DISULFID        481..488
FT                   /evidence="ECO:0000244|PDB:6HG4,
FT                   ECO:0000269|PubMed:32187518"
FT   DISULFID        515..529
FT                   /evidence="ECO:0000244|PDB:6HG4,
FT                   ECO:0000269|PubMed:32187518"
FT   VAR_SEQ         36..106
FT                   /note="Missing (in isoform 2, isoform 3, isoform 4, isoform
FT                   5, isoform 6, isoform 7 and isoform 8)"
FT                   /evidence="ECO:0000269|PubMed:17911633,
FT                   ECO:0000303|PubMed:12975309, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:17911633"
FT                   /id="VSP_014138"
FT   VAR_SEQ         264..278
FT                   /note="Missing (in isoform 3, isoform 4, isoform 6 and
FT                   isoform 8)"
FT                   /evidence="ECO:0000269|PubMed:17911633,
FT                   ECO:0000303|PubMed:12975309, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014139"
FT   VAR_SEQ         425..441
FT                   /note="Missing (in isoform 6 and isoform 7)"
FT                   /evidence="ECO:0000269|PubMed:17911633, ECO:0000305"
FT                   /id="VSP_047291"
FT   VAR_SEQ         566..578
FT                   /note="Missing (in isoform 5, isoform 7 and isoform 8)"
FT                   /evidence="ECO:0000269|PubMed:17911633, ECO:0000305"
FT                   /id="VSP_047292"
FT   VAR_SEQ         579..624
FT                   /note="AAARGRAALLLYSADDSGFERLVGALASALCQLPLRVAVDLWSRRE -> GE
FT                   WEQALGGGPPPGSQACASSPLPSPSVFSGSGRQGPRGSAPLLSR (in isoform
FT                   4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014140"
FT   VAR_SEQ         625..791
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014141"
FT   VARIANT         182
FT                   /note="S -> L (in dbSNP:rs708567)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17911633"
FT                   /id="VAR_022680"
FT   CONFLICT        241
FT                   /note="E -> G (in Ref. 4; AAQ89199)"
FT   CONFLICT        378
FT                   /note="Q -> R (in Ref. 1; ABV44615/ABV44616/ABV44617, 2;
FT                   BD292072, 3; AAM77569, 4; AAQ89199/AAQ89456 and 5;
FT                   BAC04001)"
FT                   /evidence="ECO:0000305"
FT   STRAND          101..104
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          109..112
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          115..117
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          128..149
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          151..165
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          192..202
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          205..215
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   HELIX           217..219
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          224..235
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          241..251
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          256..261
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   HELIX           268..272
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   HELIX           275..278
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          283..286
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          289..296
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          303..312
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          313..315
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   STRAND          321..333
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   HELIX           335..337
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          342..350
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          356..358
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   TURN            360..363
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   HELIX           365..373
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          376..381
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          384..388
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          395..401
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          409..411
FT                   /evidence="ECO:0000244|PDB:6HG4"
FT   TURN            413..415
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          419..421
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          425..427
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          438..444
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          447..452
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   TURN            454..458
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          465..473
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   TURN            474..476
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          477..479
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          481..483
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          485..492
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          495..497
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   HELIX           498..501
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   HELIX           503..511
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          515..521
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   STRAND          524..530
FT                   /evidence="ECO:0000244|PDB:6HGA"
FT   HELIX           532..534
FT                   /evidence="ECO:0000244|PDB:6HGA"
SQ   SEQUENCE   791 AA;  86240 MW;  E9A4032C17ECD4AF CRC64;
     MPVPWFLLSL ALGRSPVVLS LERLVGPQDA THCSPVSLEP WGDEERLRVQ FLAQQSLSLA
     PVTAATARTA LSGLSGADGR REERGRGKSW VCLSLGGSGN TEPQKKGLSC RLWDSDILCL
     PGDIVPAPGP VLAPTHLQTE LVLRCQKETD CDLCLRVAVH LAVHGHWEEP EDEEKFGGAA
     DSGVEEPRNA SLQAQVVLSF QAYPTARCVL LEVQVPAALV QFGQSVGSVV YDCFEAALGS
     EVRIWSYTQP RYEKELNHTQ QLPDCRGLEV WNSIPSCWAL PWLNVSADGD NVHLVLNVSE
     EQHFGLSLYW NQVQGPPKPR WHKNLTGPQI ITLNHTDLVP CLCIQVWPLE PDSVRTNICP
     FREDPRAHQN LWQAARLQLL TLQSWLLDAP CSLPAEAALC WRAPGGDPCQ PLVPPLSWEN
     VTVDKVLEFP LLKGHPNLCV QVNSSEKLQL QECLWADSLG PLKDDVLLLE TRGPQDNRSL
     CALEPSGCTS LPSKASTRAA RLGEYLLQDL QSGQCLQLWD DDLGALWACP MDKYIHKRWA
     LVWLACLLFA AALSLILLLK KDHAKGWLRL LKQDVRSGAA ARGRAALLLY SADDSGFERL
     VGALASALCQ LPLRVAVDLW SRRELSAQGP VAWFHAQRRQ TLQEGGVVVL LFSPGAVALC
     SEWLQDGVSG PGAHGPHDAF RASLSCVLPD FLQGRAPGSY VGACFDRLLH PDAVPALFRT
     VPVFTLPSQL PDFLGALQQP RAPRSGRLQE RAEQVSRALQ PALDSYFHPP GTPAPGRGVG
     PGAGPGAGDG T
//
ID   TPC2_HUMAN              Reviewed;         752 AA.
AC   Q8NHX9; Q9NT82;
DT   06-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 2.
DT   12-AUG-2020, entry version 153.
DE   RecName: Full=Two pore calcium channel protein 2 {ECO:0000305};
DE   AltName: Full=Voltage-dependent calcium channel protein TPC2;
GN   Name=TPCN2 {ECO:0000312|HGNC:HGNC:20820}; Synonyms=TPC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND VARIANTS PRO-564 AND GLU-734.
RX   PubMed=19387438; DOI=10.1038/nature08030;
RA   Calcraft P.J., Ruas M., Pan Z., Cheng X., Arredouani A., Hao X., Tang J.,
RA   Rietdorf K., Teboul L., Chuang K.T., Lin P., Xiao R., Wang C., Zhu Y.,
RA   Lin Y., Wyatt C.N., Parrington J., Ma J., Evans A.M., Galione A., Zhu M.X.;
RT   "NAADP mobilizes calcium from acidic organelles through two-pore
RT   channels.";
RL   Nature 459:596-600(2009).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS PRO-564 AND GLU-734.
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 382-752, AND VARIANTS PRO-564 AND
RP   GLU-734.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19620632; DOI=10.1083/jcb.200904073;
RA   Brailoiu E., Churamani D., Cai X., Schrlau M.G., Brailoiu G.C., Gao X.,
RA   Hooper R., Boulware M.J., Dun N.J., Marchant J.S., Patel S.;
RT   "Essential requirement for two-pore channel 1 in NAADP-mediated calcium
RT   signaling.";
RL   J. Cell Biol. 186:201-209(2009).
RN   [6]
RP   INTERACTION WITH LRRK2.
RX   PubMed=22012985; DOI=10.1093/hmg/ddr481;
RA   Gomez-Suaga P., Luzon-Toro B., Churamani D., Zhang L., Bloor-Young D.,
RA   Patel S., Woodman P.G., Churchill G.C., Hilfiker S.;
RT   "Leucine-rich repeat kinase 2 regulates autophagy through a calcium-
RT   dependent pathway involving NAADP.";
RL   Hum. Mol. Genet. 21:511-525(2012).
RN   [7]
RP   INTERACTION WITH HAX1.
RX   PubMed=24188827; DOI=10.1016/j.febslet.2013.10.031;
RA   Lam A.K., Galione A., Lai F.A., Zissimopoulos S.;
RT   "Hax-1 identified as a two-pore channel (TPC)-binding protein.";
RL   FEBS Lett. 587:3782-3786(2013).
RN   [8]
RP   FUNCTION (MICROBIAL INFECTION), AND ACTIVITY REGULATION.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV.";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [9]
RP   VARIANTS LEU-484 AND GLU-734, AND ASSOCIATION WITH SHEP10.
RX   PubMed=18488028; DOI=10.1038/ng.160;
RA   Sulem P., Gudbjartsson D.F., Stacey S.N., Helgason A., Rafnar T.,
RA   Jakobsdottir M., Steinberg S., Gudjonsson S.A., Palsson A.,
RA   Thorleifsson G., Palsson S., Sigurgeirsson B., Thorisdottir K.,
RA   Ragnarsson R., Benediktsdottir K.R., Aben K.K., Vermeulen S.H.,
RA   Goldstein A.M., Tucker M.A., Kiemeney L.A., Olafsson J.H., Gulcher J.,
RA   Kong A., Thorsteinsdottir U., Stefansson K.;
RT   "Two newly identified genetic determinants of pigmentation in Europeans.";
RL   Nat. Genet. 40:835-837(2008).
CC   -!- FUNCTION: Nicotinic acid adenine dinucleotide phosphate (NAADP)
CC       receptor that may function as one of the major voltage-gated Ca(2+)
CC       channels (VDCC) across the lysosomal membrane. May be involved in
CC       smooth muscle contraction. {ECO:0000269|PubMed:19387438,
CC       ECO:0000269|PubMed:19620632}.
CC   -!- FUNCTION: (Microbial infection) Required for cell entry of
CC       coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus EMC
CC       (HCoV-EMC) by endocytosis. {ECO:0000269|PubMed:32221306}.
CC   -!- ACTIVITY REGULATION: Inhibited by tetrandrine.
CC       {ECO:0000269|PubMed:32221306}.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with LRRK2
CC       (PubMed:22012985). Interacts with HAX1 (PubMed:24188827).
CC       {ECO:0000250|UniProtKB:Q8BWC0, ECO:0000269|PubMed:22012985,
CC       ECO:0000269|PubMed:24188827}.
CC   -!- INTERACTION:
CC       Q8NHX9; O00165: HAX1; NbExp=4; IntAct=EBI-5239949, EBI-357001;
CC       Q8NHX9; P42345: MTOR; NbExp=2; IntAct=EBI-5239949, EBI-359260;
CC       Q8NHX9; Q9ULQ1: TPCN1; NbExp=9; IntAct=EBI-5239949, EBI-5239895;
CC       Q8NHX9; Q8NHX9: TPCN2; NbExp=4; IntAct=EBI-5239949, EBI-5239949;
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000250|UniProtKB:Q8BWC0};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:Q8BWC0}. Note=Only
CC       the acidic lysosomal fraction is sensitive to NAADP.
CC       {ECO:0000250|UniProtKB:Q8BWC0}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. Expressed at high level in liver
CC       and kidney. {ECO:0000269|PubMed:19387438}.
CC   -!- DOMAIN: Each of the two internal repeats contains five hydrophobic
CC       transmembrane segments (S1, S2, S3, S5, S6) and one positively charged
CC       transmembrane segment (S4). S4 segments probably represent the voltage-
CC       sensor and are characterized by a series of positively charged amino
CC       acids at every third position (By similarity). {ECO:0000250}.
CC   -!- PTM: N-glycosylated. {ECO:0000250|UniProtKB:Q8BWC0}.
CC   -!- POLYMORPHISM: Genetic variants in TPCN2 define the skin/hair/eye
CC       pigmentation variation locus 10 (SHEP10) [MIM:612267]. Hair, eye and
CC       skin pigmentation are among the most visible examples of human
CC       phenotypic variation, with a broad normal range that is subject to
CC       substantial geographic stratification. In the case of skin, individuals
CC       tend to have lighter pigmentation with increasing distance from the
CC       equator. By contrast, the majority of variation in human eye and hair
CC       color is found among individuals of European ancestry, with most other
CC       human populations fixed for brown eyes and black hair.
CC       {ECO:0000269|PubMed:18488028}.
CC   -!- SIMILARITY: Belongs to the calcium channel alpha-1 subunit
CC       (TC 1.A.1.11) family. Two pore calcium channel subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY029200; AAK31802.1; -; mRNA.
DR   EMBL; AP003071; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC063008; AAH63008.1; -; mRNA.
DR   EMBL; AL137479; CAB70760.1; -; mRNA.
DR   CCDS; CCDS8189.1; -.
DR   PIR; T46421; T46421.
DR   RefSeq; NP_620714.2; NM_139075.3.
DR   PDB; 6NQ0; EM; 3.70 A; A/B=1-752.
DR   PDB; 6NQ1; EM; 3.50 A; A/B=1-752.
DR   PDB; 6NQ2; EM; 3.40 A; A/B=1-752.
DR   PDBsum; 6NQ0; -.
DR   PDBsum; 6NQ1; -.
DR   PDBsum; 6NQ2; -.
DR   SMR; Q8NHX9; -.
DR   BioGRID; 128596; 62.
DR   IntAct; Q8NHX9; 55.
DR   MINT; Q8NHX9; -.
DR   STRING; 9606.ENSP00000294309; -.
DR   DrugCentral; Q8NHX9; -.
DR   GuidetoPHARMACOLOGY; 393; -.
DR   TCDB; 1.A.1.11.19; the voltage-gated ion channel (vic) superfamily.
DR   GlyGen; Q8NHX9; 2 sites.
DR   iPTMnet; Q8NHX9; -.
DR   PhosphoSitePlus; Q8NHX9; -.
DR   BioMuta; TPCN2; -.
DR   DMDM; 125991221; -.
DR   EPD; Q8NHX9; -.
DR   jPOST; Q8NHX9; -.
DR   MassIVE; Q8NHX9; -.
DR   MaxQB; Q8NHX9; -.
DR   PaxDb; Q8NHX9; -.
DR   PeptideAtlas; Q8NHX9; -.
DR   PRIDE; Q8NHX9; -.
DR   ProteomicsDB; 73782; -.
DR   Antibodypedia; 16750; 74 antibodies.
DR   Ensembl; ENST00000294309; ENSP00000294309; ENSG00000162341.
DR   GeneID; 219931; -.
DR   KEGG; hsa:219931; -.
DR   UCSC; uc001oos.3; human.
DR   CTD; 219931; -.
DR   DisGeNET; 219931; -.
DR   EuPathDB; HostDB:ENSG00000162341.15; -.
DR   GeneCards; TPCN2; -.
DR   HGNC; HGNC:20820; TPCN2.
DR   HPA; ENSG00000162341; Low tissue specificity.
DR   MalaCards; TPCN2; -.
DR   MIM; 612163; gene.
DR   MIM; 612267; phenotype.
DR   neXtProt; NX_Q8NHX9; -.
DR   OpenTargets; ENSG00000162341; -.
DR   PharmGKB; PA134937857; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   GeneTree; ENSGT00940000159763; -.
DR   HOGENOM; CLU_019500_1_0_1; -.
DR   InParanoid; Q8NHX9; -.
DR   KO; K14077; -.
DR   OMA; PPCGFTE; -.
DR   OrthoDB; 761764at2759; -.
DR   PhylomeDB; Q8NHX9; -.
DR   TreeFam; TF328550; -.
DR   PathwayCommons; Q8NHX9; -.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   BioGRID-ORCS; 219931; 4 hits in 873 CRISPR screens.
DR   ChiTaRS; TPCN2; human.
DR   GeneWiki; TPCN2; -.
DR   GenomeRNAi; 219931; -.
DR   Pharos; Q8NHX9; Tchem.
DR   PRO; PR:Q8NHX9; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q8NHX9; protein.
DR   Bgee; ENSG00000162341; Expressed in amniotic fluid and 197 other tissues.
DR   ExpressionAtlas; Q8NHX9; baseline and differential.
DR   Genevisible; Q8NHX9; HS.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0072345; F:NAADP-sensitive calcium-release channel activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0007040; P:lysosome organization; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0010506; P:regulation of autophagy; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0034765; P:regulation of ion transmembrane transport; IEA:UniProtKB-KW.
DR   GO; GO:0006939; P:smooth muscle contraction; ISS:UniProtKB.
DR   Gene3D; 1.20.120.350; -; 2.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR028798; TPC2.
DR   InterPro; IPR027359; Volt_channel_dom_sf.
DR   PANTHER; PTHR46768; PTHR46768; 1.
DR   Pfam; PF00520; Ion_trans; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Calcium channel; Calcium transport; Glycoprotein;
KW   Ion channel; Ion transport; Lysosome; Membrane; Polymorphism;
KW   Reference proteome; Repeat; Transmembrane; Transmembrane helix; Transport;
KW   Voltage-gated channel.
FT   CHAIN           1..752
FT                   /note="Two pore calcium channel protein 2"
FT                   /id="PRO_0000276856"
FT   TOPO_DOM        1..84
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        85..105
FT                   /note="Helical; Name=S1 of repeat I"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        106..127
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        128..148
FT                   /note="Helical; Name=S2 of repeat I"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        149..155
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        156..176
FT                   /note="Helical; Name=S3 of repeat I"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        177..183
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        184..204
FT                   /note="Helical; Name=S4 of repeat I"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        205..218
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        219..239
FT                   /note="Helical; Name=S5 of repeat I"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        240..254
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        255..279
FT                   /note="Helical; Pore-forming"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        280..289
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        290..310
FT                   /note="Helical; Name=S6 of repeat I"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        311..436
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        437..459
FT                   /note="Helical; Name=S1 of repeat II"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        460..465
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        466..486
FT                   /note="Helical; Name=S2 of repeat II"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        487..502
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        503..523
FT                   /note="Helical; Name=S3 of repeat II"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        524..554
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        555..575
FT                   /note="Helical; Name=S4 of repeat II"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        576..580
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        581..601
FT                   /note="Helical; Name=S5 of repeat II"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        602..635
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        636..658
FT                   /note="Helical; Pore-forming"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        659..673
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        674..694
FT                   /note="Helical; Name=S6 of repeat II"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        695..752
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        17..20
FT                   /note="Poly-Gly"
FT   CARBOHYD        611
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        618
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         376
FT                   /note="K -> R (in dbSNP:rs3750965)"
FT                   /id="VAR_030492"
FT   VARIANT         484
FT                   /note="M -> L (associated with SHEP10; dbSNP:rs35264875)"
FT                   /evidence="ECO:0000269|PubMed:18488028"
FT                   /id="VAR_047956"
FT   VARIANT         564
FT                   /note="L -> P (in dbSNP:rs2376558)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17974005, ECO:0000269|PubMed:19387438"
FT                   /id="VAR_030493"
FT   VARIANT         734
FT                   /note="G -> E (associated with SHEP10; dbSNP:rs3829241)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17974005, ECO:0000269|PubMed:18488028,
FT                   ECO:0000269|PubMed:19387438"
FT                   /id="VAR_030494"
FT   HELIX           40..57
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           70..77
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           80..95
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           96..98
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   STRAND          99..102
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   STRAND          111..113
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           124..145
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           149..154
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           156..177
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           186..188
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   TURN            189..191
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           192..198
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           201..237
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   STRAND          254..257
FT                   /evidence="ECO:0000244|PDB:6NQ1"
FT   HELIX           258..269
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   TURN            274..278
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           279..284
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           286..288
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           289..298
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   TURN            299..301
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           302..312
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           318..341
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           359..365
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   STRAND          366..369
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           373..385
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           393..399
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           419..427
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   TURN            428..431
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           434..458
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           469..488
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   TURN            489..491
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           493..498
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           500..522
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           540..551
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           552..557
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   TURN            558..560
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           566..576
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           580..600
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   STRAND          601..603
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   TURN            626..630
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           631..633
FT                   /evidence="ECO:0000244|PDB:6NQ1"
FT   HELIX           639..650
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           655..665
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           668..670
FT                   /evidence="ECO:0000244|PDB:6NQ1"
FT   HELIX           671..680
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   TURN            681..683
FT                   /evidence="ECO:0000244|PDB:6NQ2"
FT   HELIX           684..697
FT                   /evidence="ECO:0000244|PDB:6NQ2"
SQ   SEQUENCE   752 AA;  85243 MW;  8A0794952A46C67E CRC64;
     MAEPQAESEP LLGGARGGGG DWPAGLTTYR SIQVGPGAAA RWDLCIDQAV VFIEDAIQYR
     SINHRVDASS MWLYRRYYSN VCQRTLSFTI FLILFLAFIE TPSSLTSTAD VRYRAAPWEP
     PCGLTESVEV LCLLVFAADL SVKGYLFGWA HFQKNLWLLG YLVVLVVSLV DWTVSLSLVC
     HEPLRIRRLL RPFFLLQNSS MMKKTLKCIR WSLPEMASVG LLLAIHLCLF TMFGMLLFAG
     GKQDDGQDRE RLTYFQNLPE SLTSLLVLLT TANNPDVMIP AYSKNRAYAI FFIVFTVIGS
     LFLMNLLTAI IYSQFRGYLM KSLQTSLFRR RLGTRAAFEV LSSMVGEGGA FPQAVGVKPQ
     NLLQVLQKVQ LDSSHKQAMM EKVRSYGSVL LSAEEFQKLF NELDRSVVKE HPPRPEYQSP
     FLQSAQFLFG HYYFDYLGNL IALANLVSIC VFLVLDADVL PAERDDFILG ILNCVFIVYY
     LLEMLLKVFA LGLRGYLSYP SNVFDGLLTV VLLVLEISTL AVYRLPHPGW RPEMVGLLSL
     WDMTRMLNML IVFRFLRIIP SMKLMAVVAS TVLGLVQNMR AFGGILVVVY YVFAIIGINL
     FRGVIVALPG NSSLAPANGS APCGSFEQLE YWANNFDDFA AALVTLWNLM VVNNWQVFLD
     AYRRYSGPWS KIYFVLWWLV SSVIWVNLFL ALILENFLHK WDPRSHLQPL AGTPEATYQM
     TVELLFRDIL EEPGEDELTE RLSQHPHLWL CR
//
ID   DDX1_HUMAN              Reviewed;         740 AA.
AC   Q92499; B4DME8; B4DPN6;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 2.
DT   12-AUG-2020, entry version 195.
DE   RecName: Full=ATP-dependent RNA helicase DDX1;
DE            EC=3.6.4.13 {ECO:0000269|PubMed:21589879};
DE   AltName: Full=DEAD box protein 1;
DE   AltName: Full=DEAD box protein retinoblastoma;
DE            Short=DBP-RB;
GN   Name=DDX1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Retinoblastoma;
RX   PubMed=7689221; DOI=10.1073/pnas.90.16.7578;
RA   Godbout R., Squire J.;
RT   "Amplification of a DEAD box protein gene in retinoblastoma cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7578-7582(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Brain, and Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH CSTF2, AND SUBCELLULAR LOCATION.
RX   PubMed=11598190; DOI=10.1091/mbc.12.10.3046;
RA   Bleoo S., Sun X., Hendzel M.J., Rowe J.M., Packer M., Godbout R.;
RT   "Association of human DEAD box protein DDX1 with a cleavage stimulation
RT   factor involved in 3'-end processing of pre-MRNA.";
RL   Mol. Biol. Cell 12:3046-3059(2001).
RN   [5]
RP   FUNCTION, INTERACTION WITH HNRNPK, AND RNA-BINDING.
RX   PubMed=12183465; DOI=10.1074/jbc.m206981200;
RA   Chen H.C., Lin W.C., Tsay Y.G., Lee S.C., Chang C.J.;
RT   "An RNA helicase, DDX1, interacting with poly(A) RNA and heterogeneous
RT   nuclear ribonucleoprotein K.";
RL   J. Biol. Chem. 277:40403-40409(2002).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [7]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH REV OF HIV-1 (MICROBIAL
RP   INFECTION), RNA-BINDING (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION
RP   (MICROBIAL INFECTION).
RX   PubMed=15567440; DOI=10.1016/j.virol.2004.09.039;
RA   Fang J., Kubota S., Yang B., Zhou N., Zhang H., Godbout R., Pomerantz R.J.;
RT   "A DEAD box protein facilitates HIV-1 replication as a cellular co-factor
RT   of Rev.";
RL   Virology 330:471-480(2004).
RN   [8]
RP   FUNCTION, INTERACTION WITH MBNL1, SUBCELLULAR LOCATION, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=18335541; DOI=10.1002/jnr.21655;
RA   Onishi H., Kino Y., Morita T., Futai E., Sasagawa N., Ishiura S.;
RT   "MBNL1 associates with YB-1 in cytoplasmic stress granules.";
RL   J. Neurosci. Res. 86:1994-2002(2008).
RN   [9]
RP   FUNCTION, INTERACTION WITH ATM, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18710941; DOI=10.1128/mcb.01053-08;
RA   Li L., Monckton E.A., Godbout R.;
RT   "A role for DEAD box 1 at DNA double-strand breaks.";
RL   Mol. Cell. Biol. 28:6413-6425(2008).
RN   [10]
RP   INTERACTION WITH RELA, MUTAGENESIS OF GLU-371, SUBCELLULAR LOCATION, AND
RP   DOMAIN HELICASE ATP-BINDING.
RX   PubMed=19058135; DOI=10.1002/jcb.22004;
RA   Ishaq M., Ma L., Wu X., Mu Y., Pan J., Hu J., Hu T., Fu Q., Guo D.;
RT   "The DEAD-box RNA helicase DDX1 interacts with RelA and enhances nuclear
RT   factor kappaB-mediated transcription.";
RL   J. Cell. Biochem. 106:296-305(2009).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-239; LYS-268 AND LYS-281, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH REPLICASE POLYPROTEIN 1AB
RP   NSP14 OF IBV AND SARS-COV (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION
RP   (MICROBIAL INFECTION).
RX   PubMed=20573827; DOI=10.1128/jvi.00392-10;
RA   Xu L., Khadijah S., Fang S., Wang L., Tay F.P., Liu D.X.;
RT   "The cellular RNA helicase DDX1 interacts with coronavirus nonstructural
RT   protein 14 and enhances viral replication.";
RL   J. Virol. 84:8571-8583(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   INTERACTION WITH PQBP1.
RX   PubMed=21933836; DOI=10.1093/hmg/ddr430;
RA   Kunde S.A., Musante L., Grimme A., Fischer U., Mueller E., Wanker E.E.,
RA   Kalscheuer V.M.;
RT   "The X-chromosome-linked intellectual disability protein PQBP1 is a
RT   component of neuronal RNA granules and regulates the appearance of stress
RT   granules.";
RL   Hum. Mol. Genet. 20:4916-4931(2011).
RN   [16]
RP   CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=21589879; DOI=10.1371/journal.pone.0019810;
RA   Garbelli A., Beermann S., Di Cicco G., Dietrich U., Maga G.;
RT   "A motif unique to the human DEAD-box protein DDX3 is important for nucleic
RT   acid binding, ATP hydrolysis, RNA/DNA unwinding and HIV-1 replication.";
RL   PLoS ONE 6:E19810-E19810(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   IDENTIFICATION IN THE TRNA SPLICING LIGASE COMPLEX.
RX   PubMed=21311021; DOI=10.1126/science.1197847;
RA   Popow J., Englert M., Weitzer S., Schleiffer A., Mierzwa B., Mechtler K.,
RA   Trowitzsch S., Will C.L., Luhrmann R., Soll D., Martinez J.;
RT   "HSPC117 is the essential subunit of a human tRNA splicing ligase
RT   complex.";
RL   Science 331:760-764(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   FUNCTION, IDENTIFICATION IN THE TRNA SPLICING LIGASE COMPLEX, AND
RP   MUTAGENESIS OF LYS-52 AND GLU-371.
RX   PubMed=24870230; DOI=10.1038/nature13284;
RA   Popow J., Jurkin J., Schleiffer A., Martinez J.;
RT   "Analysis of orthologous groups reveals archease and DDX1 as tRNA splicing
RT   factors.";
RL   Nature 511:104-107(2014).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=24608264; DOI=10.1371/journal.pone.0090957;
RA   Perez-Gonzalez A., Pazo A., Navajas R., Ciordia S., Rodriguez-Frandsen A.,
RA   Nieto A.;
RT   "hCLE/C14orf166 associates with DDX1-HSPC117-FAM98B in a novel
RT   transcription-dependent shuttling RNA-transporting complex.";
RL   PLoS ONE 9:E90957-E90957(2014).
RN   [23]
RP   INTERACTION WITH ERCC6.
RX   PubMed=26030138; DOI=10.1371/journal.pone.0128558;
RA   Nicolai S., Filippi S., Caputo M., Cipak L., Gregan J., Ammerer G.,
RA   Frontini M., Willems D., Prantera G., Balajee A.S., Proietti-De-Santis L.;
RT   "Identification of Novel Proteins Co-Purifying with Cockayne Syndrome Group
RT   B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and Chromatin
RT   Dynamics.";
RL   PLoS ONE 10:E0128558-E0128558(2015).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [25]
RP   INTERACTION WITH VENEZUELAN EQUINE ENCEPHALITIS VIRUS NON-STRUCTURAL
RP   PROTEIN 3 (MICROBIAL INFECTION).
RX   PubMed=27105836; DOI=10.1016/j.antiviral.2016.04.008;
RA   Amaya M., Brooks-Faulconer T., Lark T., Keck F., Bailey C., Raman V.,
RA   Narayanan A.;
RT   "Venezuelan equine encephalitis virus non-structural protein 3 (nsP3)
RT   interacts with RNA helicases DDX1 and DDX3 in infected cells.";
RL   Antiviral Res. 131:49-60(2016).
RN   [26]
RP   INTERACTION WITH FAM98A, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=28040436; DOI=10.1016/j.biocel.2016.12.013;
RA   Akter K.A., Mansour M.A., Hyodo T., Senga T.;
RT   "FAM98A associates with DDX1-C14orf166-FAM98B in a novel complex involved
RT   in colorectal cancer progression.";
RL   Int. J. Biochem. Cell Biol. 84:1-13(2017).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-281, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 72-283.
RX   PubMed=26323305; DOI=10.1107/s2053230x15013709;
RA   Kellner J.N., Meinhart A.;
RT   "Structure of the SPRY domain of the human RNA helicase DDX1, a putative
RT   interaction platform within a DEAD-box protein.";
RL   Acta Crystallogr. F 71:1176-1188(2015).
CC   -!- FUNCTION: Acts as an ATP-dependent RNA helicase, able to unwind both
CC       RNA-RNA and RNA-DNA duplexes. Possesses 5' single-stranded RNA overhang
CC       nuclease activity. Possesses ATPase activity on various RNA, but not
CC       DNA polynucleotides. May play a role in RNA clearance at DNA double-
CC       strand breaks (DSBs), thereby facilitating the template-guided repair
CC       of transcriptionally active regions of the genome. Together with RELA,
CC       acts as a coactivator to enhance NF-kappa-B-mediated transcriptional
CC       activation. Acts as a positive transcriptional regulator of cyclin
CC       CCND2 expression. Binds to the cyclin CCND2 promoter region. Associates
CC       with chromatin at the NF-kappa-B promoter region via association with
CC       RELA. Binds to poly(A) RNA. May be involved in 3'-end cleavage and
CC       polyadenylation of pre-mRNAs. Component of the tRNA-splicing ligase
CC       complex required to facilitate the enzymatic turnover of catalytic
CC       subunit RTCB: together with archease (ZBTB8OS), acts by facilitating
CC       the guanylylation of RTCB, a key intermediate step in tRNA ligation
CC       (PubMed:24870230). Component of a multi-helicase-TICAM1 complex that
CC       acts as a cytoplasmic sensor of viral double-stranded RNA (dsRNA) and
CC       plays a role in the activation of a cascade of antiviral responses
CC       including the induction of proinflammatory cytokines via the adapter
CC       molecule TICAM1. Specifically binds (via helicase ATP-binding domain)
CC       on both short and long poly(I:C) dsRNA (By similarity).
CC       {ECO:0000250|UniProtKB:Q91VR5, ECO:0000269|PubMed:12183465,
CC       ECO:0000269|PubMed:15567440, ECO:0000269|PubMed:18335541,
CC       ECO:0000269|PubMed:18710941, ECO:0000269|PubMed:20573827,
CC       ECO:0000269|PubMed:24870230}.
CC   -!- FUNCTION: (Microbial infection) Required for HIV-1 Rev function as well
CC       as for HIV-1 and coronavirus IBV replication. Binds to the RRE sequence
CC       of HIV-1 mRNAs. {ECO:0000269|PubMed:15567440}.
CC   -!- FUNCTION: (Microbial infection) Required for Coronavirus IBV
CC       replication. {ECO:0000269|PubMed:20573827}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC         Evidence={ECO:0000269|PubMed:21589879};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.12 mM for ATP (in the absence of nucleic acid)
CC         {ECO:0000269|PubMed:21589879};
CC         KM=0.09 mM for ATP (in the presence of RNA oligo(rU)20)
CC         {ECO:0000269|PubMed:21589879};
CC         KM=0.095 mM for ATP (in the presence of DNA oligo(dT)20)
CC         {ECO:0000269|PubMed:21589879};
CC         Note=kcat is 1.9 min(-1) for ATP hydrolysis in the absence of nucleic
CC         acid (PubMed:21589879). kcat is 3.8 min(-1) for ATP hydrolysis in the
CC         presence of RNA oligo(rU)20 (PubMed:21589879). kcat is 2.1 min(-1)
CC         for ATP hydrolysis in the presence of DNA oligo(dT)20
CC         (PubMed:21589879). {ECO:0000269|PubMed:21589879};
CC   -!- SUBUNIT: (Microbial infection) Interacts with Venezuelan equine
CC       encephalitis virus non-structural protein 3.
CC       {ECO:0000269|PubMed:27105836}.
CC   -!- SUBUNIT: Found in a multi-helicase-TICAM1 complex at least composed of
CC       DHX36, DDX1, DDX21 and TICAM1; this complex exists in resting cells
CC       with or without poly(I:C) RNA ligand stimulation. Interacts with DHX36.
CC       Interacts (via B30.2/SPRY domain) with DDX21 (via N-terminus); this
CC       interaction serves as bridges to TICAM1 (By similarity). Interacts with
CC       FAM98A (via N- and C-terminus) (PubMed:28040436). Interacts with MBNL1
CC       (PubMed:18335541). Interacts with CSTF2 (PubMed:11598190). Interacts
CC       with HNRNPK (PubMed:12183465). Interacts with ATM (PubMed:18710941).
CC       Interacts with RELA (via C-terminus) (PubMed:19058135). Component of
CC       the tRNA-splicing ligase complex (PubMed:21311021, PubMed:24870230).
CC       Interacts with PQBP1 (PubMed:21933836). Interacts with PHF5A (via C-
CC       terminus) (By similarity). Interacts with ERCC6 (PubMed:26030138).
CC       {ECO:0000250|UniProtKB:Q91VR5, ECO:0000269|PubMed:11598190,
CC       ECO:0000269|PubMed:12183465, ECO:0000269|PubMed:18335541,
CC       ECO:0000269|PubMed:18710941, ECO:0000269|PubMed:19058135,
CC       ECO:0000269|PubMed:21311021, ECO:0000269|PubMed:21933836,
CC       ECO:0000269|PubMed:24870230, ECO:0000269|PubMed:26030138,
CC       ECO:0000269|PubMed:28040436}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Rev of HIV-1.
CC       {ECO:0000269|PubMed:15567440}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Severe acute respiratory
CC       syndrome coronavirus (SARS-CoV) (via N-terminus) (PubMed:20573827).
CC       Interacts (via C-terminus) with the replicase polyprotein 1ab Nsp14 of
CC       the Avian infectious bronchitis virus (IBV).
CC       {ECO:0000269|PubMed:20573827}.
CC   -!- INTERACTION:
CC       Q92499-1; P04618: rev; Xeno; NbExp=6; IntAct=EBI-15532186, EBI-6164309;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cytoplasmic granule.
CC       Cytoplasm, cytosol {ECO:0000250|UniProtKB:Q91VR5}. Mitochondrion
CC       {ECO:0000250|UniProtKB:Q91VR5}. Note=Localized with MBNL1, TIAL1 and
CC       YBX1 in stress granules upon stress. Localized with CSTF2 in cleavage
CC       bodies. Forms large aggregates called DDX1 bodies. Relocalized into
CC       multiple foci (IR-induced foci or IRIF) after IR treatment, a process
CC       that depends on the presence of chromosomal DNA and/or RNA-DNA
CC       duplexes. Relocalized at sites of DNA double-strand breaks (DSBs) in an
CC       ATM-dependent manner after IR treatment. Colocalized with RELA in the
CC       nucleus upon TNF-alpha induction. Enters into the nucleus in case of
CC       active transcription while it accumulates in cytosol when transcription
CC       level is low (PubMed:24608264). Colocalizes in the cytosol with DDX21,
CC       DHX36 and TICAM1. Colocalizes in the mitochondria with TICAM1 and
CC       poly(I:C) RNA ligand. The multi-helicase-TICAM1 complex may translocate
CC       to the mitochondria upon poly(I:C) stimulation (By similarity).
CC       {ECO:0000250|UniProtKB:Q91VR5, ECO:0000269|PubMed:24608264}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20573827}.
CC       Note=(Microbial infection) Relocalized to the cytoplasm with a
CC       perinuclear staining pattern in avian infectious bronchitis virus
CC       (IBV)-infected cells (PubMed:20573827). Required for proper
CC       localization of HIV-1 Rev (PubMed:15567440).
CC       {ECO:0000269|PubMed:15567440, ECO:0000269|PubMed:20573827}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q92499-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92499-2; Sequence=VSP_055454, VSP_055455;
CC       Name=3;
CC         IsoId=Q92499-3; Sequence=VSP_055453;
CC   -!- TISSUE SPECIFICITY: Highest levels of transcription in 2 retinoblastoma
CC       cell lines and in tissues of neuroectodermal origin including the
CC       retina, brain, and spinal cord. {ECO:0000269|PubMed:7689221}.
CC   -!- DOMAIN: The helicase domain is involved in the stimulation of RELA
CC       transcriptional activity. {ECO:0000269|PubMed:19058135}.
CC   -!- PTM: Phosphorylated by ATM kinase; phosphorylation is increased in
CC       response to ionizing radiation (IR). {ECO:0000269|PubMed:18710941}.
CC   -!- SIMILARITY: Belongs to the DEAD box helicase family. DDX1 subfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: According to some authors the unwinding activity is ADP-
CC       dependent and not ATP-dependent. {ECO:0000305|PubMed:18710941}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DDX1ID40283ch2p24.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X70649; CAA49992.1; -; mRNA.
DR   EMBL; AK297432; BAG59860.1; -; mRNA.
DR   EMBL; AK298426; BAG60648.1; -; mRNA.
DR   EMBL; BC012132; AAH12132.1; -; mRNA.
DR   EMBL; BC053673; AAH53673.1; -; mRNA.
DR   CCDS; CCDS1686.1; -. [Q92499-1]
DR   RefSeq; NP_004930.1; NM_004939.2. [Q92499-1]
DR   PDB; 4XW3; X-ray; 2.00 A; A/B=72-283.
DR   PDBsum; 4XW3; -.
DR   SMR; Q92499; -.
DR   BioGRID; 108019; 280.
DR   CORUM; Q92499; -.
DR   DIP; DIP-38163N; -.
DR   IntAct; Q92499; 68.
DR   MINT; Q92499; -.
DR   STRING; 9606.ENSP00000370745; -.
DR   BindingDB; Q92499; -.
DR   ChEMBL; CHEMBL2010634; -.
DR   iPTMnet; Q92499; -.
DR   PhosphoSitePlus; Q92499; -.
DR   SwissPalm; Q92499; -.
DR   BioMuta; DDX1; -.
DR   DMDM; 6919862; -.
DR   REPRODUCTION-2DPAGE; IPI00293655; -.
DR   CPTAC; CPTAC-190; -.
DR   CPTAC; CPTAC-191; -.
DR   EPD; Q92499; -.
DR   jPOST; Q92499; -.
DR   MassIVE; Q92499; -.
DR   MaxQB; Q92499; -.
DR   PaxDb; Q92499; -.
DR   PeptideAtlas; Q92499; -.
DR   PRIDE; Q92499; -.
DR   ProteomicsDB; 4603; -.
DR   ProteomicsDB; 4798; -.
DR   ProteomicsDB; 75269; -. [Q92499-1]
DR   Antibodypedia; 3224; 233 antibodies.
DR   Ensembl; ENST00000233084; ENSP00000233084; ENSG00000079785. [Q92499-1]
DR   Ensembl; ENST00000381341; ENSP00000370745; ENSG00000079785. [Q92499-1]
DR   GeneID; 1653; -.
DR   KEGG; hsa:1653; -.
DR   UCSC; uc002rce.5; human. [Q92499-1]
DR   CTD; 1653; -.
DR   DisGeNET; 1653; -.
DR   EuPathDB; HostDB:ENSG00000079785.14; -.
DR   GeneCards; DDX1; -.
DR   HGNC; HGNC:2734; DDX1.
DR   HPA; ENSG00000079785; Low tissue specificity.
DR   MIM; 601257; gene.
DR   neXtProt; NX_Q92499; -.
DR   OpenTargets; ENSG00000079785; -.
DR   PharmGKB; PA27199; -.
DR   eggNOG; KOG0349; Eukaryota.
DR   GeneTree; ENSGT00940000155678; -.
DR   HOGENOM; CLU_016321_0_0_1; -.
DR   InParanoid; Q92499; -.
DR   KO; K13177; -.
DR   OMA; DGVHDRD; -.
DR   PhylomeDB; Q92499; -.
DR   TreeFam; TF106114; -.
DR   BioCyc; MetaCyc:ENSG00000079785-MONOMER; -.
DR   PathwayCommons; Q92499; -.
DR   Reactome; R-HSA-6784531; tRNA processing in the nucleus.
DR   SIGNOR; Q92499; -.
DR   BioGRID-ORCS; 1653; 316 hits in 884 CRISPR screens.
DR   ChiTaRS; DDX1; human.
DR   GeneWiki; DDX1; -.
DR   GenomeRNAi; 1653; -.
DR   Pharos; Q92499; Tbio.
DR   PRO; PR:Q92499; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q92499; protein.
DR   Bgee; ENSG00000079785; Expressed in tendon and 247 other tissues.
DR   ExpressionAtlas; Q92499; baseline and differential.
DR   Genevisible; Q92499; HS.
DR   GO; GO:0071920; C:cleavage body; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0010494; C:cytoplasmic stress granule; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IDA:MGI.
DR   GO; GO:0072669; C:tRNA-splicing ligase complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0033677; F:DNA/RNA helicase activity; IDA:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; IEA:Ensembl.
DR   GO; GO:0004527; F:exonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0004386; F:helicase activity; IDA:UniProtKB.
DR   GO; GO:0004518; F:nuclease activity; IDA:UniProtKB.
DR   GO; GO:0008143; F:poly(A) binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0003724; F:RNA helicase activity; IBA:GO_Central.
DR   GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0032508; P:DNA duplex unwinding; IDA:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0007275; P:multicellular organism development; IEP:UniProtKB.
DR   GO; GO:0090305; P:nucleic acid phosphodiester bond hydrolysis; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0002735; P:positive regulation of myeloid dendritic cell cytokine production; IEA:Ensembl.
DR   GO; GO:1903608; P:protein localization to cytoplasmic stress granule; IMP:AgBase.
DR   GO; GO:0006446; P:regulation of translational initiation; NAS:UniProtKB.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0000245; P:spliceosomal complex assembly; NAS:UniProtKB.
DR   GO; GO:0006388; P:tRNA splicing, via endonucleolytic cleavage and ligation; IMP:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.120.920; -; 1.
DR   InterPro; IPR001870; B30.2/SPRY.
DR   InterPro; IPR043136; B30.2/SPRY_sf.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR014014; RNA_helicase_DEAD_Q_motif.
DR   InterPro; IPR003877; SPRY_dom.
DR   Pfam; PF00270; DEAD; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   Pfam; PF00622; SPRY; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SMART; SM00449; SPRY; 1.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   PROSITE; PS50188; B302_SPRY; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 2.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS51195; Q_MOTIF; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Antiviral defense; ATP-binding; Cytoplasm; DNA-binding; Exonuclease;
KW   Helicase; Host-virus interaction; Hydrolase; Immunity; Innate immunity;
KW   Isopeptide bond; Mitochondrion; mRNA processing; Nuclease;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   RNA-binding; Transcription; Transcription regulation; tRNA processing;
KW   Ubl conjugation.
FT   CHAIN           1..740
FT                   /note="ATP-dependent RNA helicase DDX1"
FT                   /id="PRO_0000054986"
FT   DOMAIN          2..428
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          70..247
FT                   /note="B30.2/SPRY"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   DOMAIN          493..681
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   NP_BIND         46..53
FT                   /note="ATP"
FT                   /evidence="ECO:0000305"
FT   REGION          1..525
FT                   /note="Necessary for interaction with RELA"
FT                   /evidence="ECO:0000269|PubMed:19058135"
FT   REGION          1..448
FT                   /note="Interaction with dsRNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q91VR5"
FT   REGION          1..295
FT                   /note="Necessary for interaction with HNRNPK"
FT                   /evidence="ECO:0000269|PubMed:12183465"
FT   REGION          525..740
FT                   /note="Necessary for interaction with HNRNPK"
FT                   /evidence="ECO:0000269|PubMed:12183465"
FT   REGION          536..631
FT                   /note="Necessary for interaction with replicase polyprotein
FT                   1ab nsp14 of IBV"
FT                   /evidence="ECO:0000269|PubMed:20573827"
FT   MOTIF           370..373
FT                   /note="DEAD box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   MOD_RES         239
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         268
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         281
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         481
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163"
FT   CROSSLNK        281
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1..128
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055453"
FT   VAR_SEQ         98..113
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055454"
FT   VAR_SEQ         630..740
FT                   /note="VCSSRGKGCYNTRLKEDGGCTIWYNEMQLLSEIEEHLNCTISQVEPDIKVPV
FT                   DEFDGKVTYGQKRAAGGGSYKGHVDILAPTVQELAALEKEAQTSFLHLGYLPNQLFRTF
FT                   -> MVQRDAVTI (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055455"
FT   MUTAGEN         52
FT                   /note="K->N: Abolishes ability to promote guanylylation of
FT                   RTCB."
FT                   /evidence="ECO:0000269|PubMed:24870230"
FT   MUTAGEN         371
FT                   /note="E->G: Inhibits the transcriptional activity of RELA
FT                   and attenuates NF-kappa-B-mediated gene expression."
FT                   /evidence="ECO:0000269|PubMed:19058135,
FT                   ECO:0000269|PubMed:24870230"
FT   MUTAGEN         371
FT                   /note="E->Q: Abolishes ability to promote guanylylation of
FT                   RTCB."
FT                   /evidence="ECO:0000269|PubMed:19058135,
FT                   ECO:0000269|PubMed:24870230"
FT   STRAND          90..98
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          102..104
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          110..113
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          120..139
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          141..150
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          164..168
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   TURN            169..171
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          172..175
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          178..181
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          191..197
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   TURN            198..201
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          202..207
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          210..217
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   HELIX           220..222
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          227..245
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   HELIX           258..260
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   HELIX           263..265
FT                   /evidence="ECO:0000244|PDB:4XW3"
FT   STRAND          266..268
FT                   /evidence="ECO:0000244|PDB:4XW3"
SQ   SEQUENCE   740 AA;  82432 MW;  C6D0179F83BD8C73 CRC64;
     MAAFSEMGVM PEIAQAVEEM DWLLPTDIQA ESIPLILGGG DVLMAAETGS GKTGAFSIPV
     IQIVYETLKD QQEGKKGKTT IKTGASVLNK WQMNPYDRGS AFAIGSDGLC CQSREVKEWH
     GCRATKGLMK GKHYYEVSCH DQGLCRVGWS TMQASLDLGT DKFGFGFGGT GKKSHNKQFD
     NYGEEFTMHD TIGCYLDIDK GHVKFSKNGK DLGLAFEIPP HMKNQALFPA CVLKNAELKF
     NFGEEEFKFP PKDGFVALSK APDGYIVKSQ HSGNAQVTQT KFLPNAPKAL IVEPSRELAE
     QTLNNIKQFK KYIDNPKLRE LLIIGGVAAR DQLSVLENGV DIVVGTPGRL DDLVSTGKLN
     LSQVRFLVLD EADGLLSQGY SDFINRMHNQ IPQVTSDGKR LQVIVCSATL HSFDVKKLSE
     KIMHFPTWVD LKGEDSVPDT VHHVVVPVNP KTDRLWERLG KSHIRTDDVH AKDNTRPGAN
     SPEMWSEAIK ILKGEYAVRA IKEHKMDQAI IFCRTKIDCD NLEQYFIQQG GGPDKKGHQF
     SCVCLHGDRK PHERKQNLER FKKGDVRFLI CTDVAARGID IHGVPYVINV TLPDEKQNYV
     HRIGRVGRAE RMGLAISLVA TEKEKVWYHV CSSRGKGCYN TRLKEDGGCT IWYNEMQLLS
     EIEEHLNCTI SQVEPDIKVP VDEFDGKVTY GQKRAAGGGS YKGHVDILAP TVQELAALEK
     EAQTSFLHLG YLPNQLFRTF
//
ID   I17RA_HUMAN             Reviewed;         866 AA.
AC   Q96F46; O43844; Q20WK1;
DT   02-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   12-AUG-2020, entry version 170.
DE   RecName: Full=Interleukin-17 receptor A;
DE            Short=IL-17 receptor A;
DE            Short=IL-17RA;
DE   AltName: Full=CDw217;
DE   AltName: CD_antigen=CD217;
DE   Flags: Precursor;
GN   Name=IL17RA; Synonyms=IL17R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=T-cell;
RX   PubMed=9367539; DOI=10.1006/cyto.1997.0240;
RA   Yao Z., Spriggs M.K., Derry J.M.J., Strockbine L., Park L.S.,
RA   Vanden Bos T., Zappone J., Painter S.L., Armitage R.J.;
RT   "Molecular characterization of the human interleukin (Il)-17 receptor.";
RL   Cytokine 9:794-800(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS VAL-367
RP   AND HIS-580.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 33-47.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 237-431 (ISOFORM 2).
RC   TISSUE=Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=16785495; DOI=10.4049/jimmunol.177.1.36;
RA   Toy D., Kugler D., Wolfson M., Vanden Bos T., Gurgel J., Derry J.,
RA   Tocker J., Peschon J.;
RT   "Interleukin 17 signals through a heteromeric receptor complex.";
RL   J. Immunol. 177:36-39(2006).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17911633; DOI=10.4049/jimmunol.179.8.5462;
RA   Kuestner R.E., Taft D.W., Haran A., Brandt C.S., Brender T., Lum K.,
RA   Harder B., Okada S., Ostrander C.D., Kreindler J.L., Aujla S.J.,
RA   Reardon B., Moore M., Shea P., Schreckhise R., Bukowski T.R., Presnell S.,
RA   Guerra-Lewis P., Parrish-Novak J., Ellsworth J.L., Jaspers S., Lewis K.E.,
RA   Appleby M., Kolls J.K., Rixon M., West J.W., Gao Z., Levin S.D.;
RT   "Identification of the IL-17 receptor related molecule IL-17RC as the
RT   receptor for IL-17F.";
RL   J. Immunol. 179:5462-5473(2007).
RN   [9]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=18684971; DOI=10.4049/jimmunol.181.4.2799;
RA   Wright J.F., Bennett F., Li B., Brooks J., Luxenberg D.P., Whitters M.J.,
RA   Tomkinson K.N., Fitz L.J., Wolfman N.M., Collins M.,
RA   Dunussi-Joannopoulos K., Chatterjee-Kishore M., Carreno B.M.;
RT   "The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-
RT   17RA/IL-17RC receptor complex.";
RL   J. Immunol. 181:2799-2805(2008).
RN   [10]
RP   FUNCTION, IDENTIFICATION AS IL17C CORECEPTOR, INTERACTION WITH IL17RE, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=21993848; DOI=10.1038/ni.2156;
RA   Ramirez-Carrozzi V., Sambandam A., Luis E., Lin Z., Jeet S., Lesch J.,
RA   Hackney J., Kim J., Zhou M., Lai J., Modrusan Z., Sai T., Lee W., Xu M.,
RA   Caplazi P., Diehl L., de Voss J., Balazs M., Gonzalez L. Jr., Singh H.,
RA   Ouyang W., Pappu R.;
RT   "IL-17C regulates the innate immune function of epithelial cells in an
RT   autocrine manner.";
RL   Nat. Immunol. 12:1159-1166(2011).
RN   [11]
RP   ALTERNATIVE SPLICING, AND SUBCELLULAR LOCATION.
RX   PubMed=24084331; DOI=10.1016/j.cyto.2013.09.012;
RA   Sohda M., Misumi Y., Tashiro K., Yamazaki M., Saku T., Oda K.;
RT   "Identification of a soluble isoform of human IL-17RA generated by
RT   alternative splicing.";
RL   Cytokine 64:642-645(2013).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH TRAF3IP2.
RX   PubMed=24120361; DOI=10.1016/j.immuni.2013.09.002;
RA   Boisson B., Wang C., Pedergnana V., Wu L., Cypowyj S., Rybojad M.,
RA   Belkadi A., Picard C., Abel L., Fieschi C., Puel A., Li X., Casanova J.L.;
RT   "An ACT1 mutation selectively abolishes interleukin-17 responses in humans
RT   with chronic mucocutaneous candidiasis.";
RL   Immunity 39:676-686(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-708, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   INTERACTION WITH IL17RC; IL17A AND IL17F.
RX   PubMed=32187518; DOI=10.1016/j.immuni.2020.02.004;
RA   Goepfert A., Lehmann S., Blank J., Kolbinger F., Rondeau J.M.;
RT   "Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric
RT   Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling.";
RL   Immunity 52:499-512.e5(2020).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 32-317 IN COMPLEX WITH IL17F,
RP   GLYCOSYLATION AT ASN-49; ASN-54; ASN-67; ASN-225 AND ASN-265, FUNCTION, AND
RP   DISULFIDE BONDS.
RX   PubMed=19838198; DOI=10.1038/ni.1813;
RA   Ely L.K., Fischer S., Garcia K.C.;
RT   "Structural basis of receptor sharing by interleukin 17 cytokines.";
RL   Nat. Immunol. 10:1245-1251(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 32-317 IN COMPLEX WITH IL17A,
RP   DISULFIDE BONDS, SUBUNIT, AND GLYCOSYLATION AT ASN-49; ASN-54 AND ASN-225.
RX   PubMed=23695682; DOI=10.1038/ncomms2880;
RA   Liu S., Song X., Chrunyk B.A., Shanker S., Hoth L.R., Marr E.S.,
RA   Griffor M.C.;
RT   "Crystal structures of interleukin 17A and its complex with IL-17 receptor
RT   A.";
RL   Nat. Commun. 4:1888-1888(2013).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (3.30 ANGSTROMS) OF 33-320 IN COMPLEX WITH IL17A AND
RP   IL17F, AND SUBUNIT.
RX   PubMed=28827714; DOI=10.1038/s41598-017-08360-9;
RA   Goepfert A., Lehmann S., Wirth E., Rondeau J.M.;
RT   "The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor
RT   recognition properties.";
RL   Sci. Rep. 7:8906-8906(2017).
RN   [18]
RP   INVOLVEMENT IN IMD51, VARIANT IMD51 284-GLN--ALA-866 DEL, AND FUNCTION.
RX   PubMed=21350122; DOI=10.1126/science.1200439;
RA   Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K.,
RA   Migaud M., Israel L., Chrabieh M., Audry M., Gumbleton M., Toulon A.,
RA   Bodemer C., El-Baghdadi J., Whitters M., Paradis T., Brooks J., Collins M.,
RA   Wolfman N.M., Al-Muhsen S., Galicchio M., Abel L., Picard C.,
RA   Casanova J.L.;
RT   "Chronic mucocutaneous candidiasis in humans with inborn errors of
RT   interleukin-17 immunity.";
RL   Science 332:65-68(2011).
CC   -!- FUNCTION: Receptor for IL17A and IL17F, major effector cytokines of
CC       innate and adaptive immune system involved in antimicrobial host
CC       defense and maintenance of tissue integrity. Receptor for IL17A
CC       (PubMed:17911633, PubMed:9367539). Receptor for IL17F (PubMed:19838198,
CC       PubMed:17911633). Binds to IL17A with higher affinity than to IL17F
CC       (PubMed:17911633). Binds IL17A and IL17F homodimers as part of a
CC       heterodimeric complex with IL17RC (PubMed:16785495). Also binds
CC       heterodimers formed by IL17A and IL17F as part of a heterodimeric
CC       complex with IL17RC (PubMed:18684971). Cytokine binding triggers
CC       homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2
CC       adapter, leading to TRAF6-mediated activation of NF-kappa-B and
CC       MAPkinase pathways, ultimately resulting in transcriptional activation
CC       of cytokines, chemokines, antimicrobial peptides and matrix
CC       metalloproteinases, with potential strong immune inflammation
CC       (PubMed:16785495, PubMed:24120361, PubMed:17911633, PubMed:18684971,
CC       PubMed:21350122). Involved in antimicrobial host defense primarily
CC       promoting neutrophil activation and recruitment at infection sites to
CC       destroy extracellular bacteria and fungi (By similarity). In secondary
CC       lymphoid organs, contributes to germinal center formation by regulating
CC       the chemotactic response of B cells to CXCL12 and CXCL13, enhancing
CC       retention of B cells within the germinal centers, B cell somatic
CC       hypermutation rate and selection toward plasma cells (By similarity).
CC       Plays a role in the maintenance of the integrity of epithelial barriers
CC       during homeostasis and pathogen infection. Stimulates the production of
CC       antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal
CC       epithelial cells, limiting the entry of microbes through the epithelial
CC       barriers (By similarity). Involved in antiviral host defense through
CC       various mechanisms. Enhances immunity against West Nile virus by
CC       promoting T cell cytotoxicity. Contributes to Influenza virus clearance
CC       by driving the differentiation of B-1a B cells, providing for
CC       production of virus-specific IgM antibodies at first line of host
CC       defense (By similarity). Receptor for IL17C as part of a heterodimeric
CC       complex with IL17RE (PubMed:21993848). {ECO:0000250|UniProtKB:Q60943,
CC       ECO:0000269|PubMed:16785495, ECO:0000269|PubMed:17911633,
CC       ECO:0000269|PubMed:18684971, ECO:0000269|PubMed:19838198,
CC       ECO:0000269|PubMed:21350122, ECO:0000269|PubMed:21993848,
CC       ECO:0000269|PubMed:24120361, ECO:0000269|PubMed:9367539}.
CC   -!- SUBUNIT: Forms heterodimers with IL17RC; the heterodimer binds IL17A
CC       and IL17F homodimers as well as the heterodimer formed by IL17A and
CC       IL17F (PubMed:16785495, PubMed:18684971, PubMed:32187518). Forms
CC       complexes with 2:1 binding stoichiometry: two receptor chains for one
CC       interleukin molecule (PubMed:32187518). IL17A homodimer preferentially
CC       drives the formation of IL17RA-IL17RC heterodimeric receptor complex,
CC       whereas IL17F homodimer forms predominantly complexes with IL17RC
CC       homodimer (PubMed:32187518). IL17A homodimer adopts an asymmetrical
CC       ternary structure with one IL17RA molecule, allowing for high affinity
CC       interactions of one IL17A monomer with one IL17RA molecule (via D1 and
CC       D2 domains), while disfavoring binding of a second IL17RA molecule on
CC       the other IL17A monomer (PubMed:23695682). IL17A-IL17F forms complexes
CC       with IL17RA-IL17RC, but with lower affinity when compared to IL17A
CC       homodimer (PubMed:32187518). IL17RA chain can not distinguish between
CC       IL17A and IL17F molecules, potentially enabling the formation of
CC       topologically distinct complexes (PubMed:28827714). Interacts with
CC       TRAF3IP2 (PubMed:24120361). Forms heterodimers with IL17RE; the
CC       heterodimer binds IL17C (PubMed:21993848, PubMed:16785495,
CC       PubMed:18684971). {ECO:0000269|PubMed:16785495,
CC       ECO:0000269|PubMed:18684971, ECO:0000269|PubMed:21993848,
CC       ECO:0000269|PubMed:23695682, ECO:0000269|PubMed:24120361,
CC       ECO:0000269|PubMed:28827714, ECO:0000269|PubMed:32187518}.
CC   -!- INTERACTION:
CC       Q96F46; Q8NFR9: IL17RE; NbExp=2; IntAct=EBI-5591258, EBI-5591275;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:17911633}; Single-pass type I membrane protein
CC       {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted
CC       {ECO:0000269|PubMed:24084331}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96F46-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96F46-2; Sequence=VSP_053496;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:21993848}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:19838198}.
CC   -!- DISEASE: Immunodeficiency 51 (IMD51) [MIM:613953]: A primary
CC       immunodeficiency disorder with altered immune responses and impaired
CC       clearance of fungal infections, selective against Candida. It is
CC       characterized by persistent and/or recurrent infections of the skin,
CC       nails and mucous membranes caused by organisms of the genus Candida,
CC       mainly Candida albicans. {ECO:0000269|PubMed:21350122}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Soluble isoform lacking the transmembrane
CC       segment. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U58917; AAB99730.1; -; mRNA.
DR   EMBL; CT841520; CAJ86450.1; -; mRNA.
DR   EMBL; CH471193; EAW57739.1; -; Genomic_DNA.
DR   EMBL; BC011624; AAH11624.1; -; mRNA.
DR   EMBL; BX368715; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS13739.1; -. [Q96F46-1]
DR   CCDS; CCDS77645.1; -. [Q96F46-2]
DR   RefSeq; NP_001276834.1; NM_001289905.1. [Q96F46-2]
DR   RefSeq; NP_055154.3; NM_014339.6. [Q96F46-1]
DR   PDB; 3JVF; X-ray; 3.30 A; C=32-317.
DR   PDB; 4HSA; X-ray; 3.15 A; C/F=32-317.
DR   PDB; 4NUX; X-ray; 2.30 A; A=376-591.
DR   PDB; 5N9B; X-ray; 1.90 A; A=33-318.
DR   PDB; 5NAN; X-ray; 3.30 A; B/C=33-320.
DR   PDBsum; 3JVF; -.
DR   PDBsum; 4HSA; -.
DR   PDBsum; 4NUX; -.
DR   PDBsum; 5N9B; -.
DR   PDBsum; 5NAN; -.
DR   SMR; Q96F46; -.
DR   BioGRID; 117265; 90.
DR   IntAct; Q96F46; 67.
DR   STRING; 9606.ENSP00000320936; -.
DR   ChEMBL; CHEMBL3580485; -.
DR   DrugCentral; Q96F46; -.
DR   GuidetoPHARMACOLOGY; 1738; -.
DR   GlyGen; Q96F46; 7 sites.
DR   iPTMnet; Q96F46; -.
DR   PhosphoSitePlus; Q96F46; -.
DR   BioMuta; IL17RA; -.
DR   DMDM; 116242517; -.
DR   EPD; Q96F46; -.
DR   jPOST; Q96F46; -.
DR   MassIVE; Q96F46; -.
DR   MaxQB; Q96F46; -.
DR   PaxDb; Q96F46; -.
DR   PeptideAtlas; Q96F46; -.
DR   PRIDE; Q96F46; -.
DR   ProteomicsDB; 76496; -. [Q96F46-1]
DR   ABCD; Q96F46; 16 sequenced antibodies.
DR   Antibodypedia; 22632; 702 antibodies.
DR   DNASU; 23765; -.
DR   Ensembl; ENST00000319363; ENSP00000320936; ENSG00000177663. [Q96F46-1]
DR   Ensembl; ENST00000612619; ENSP00000479970; ENSG00000177663. [Q96F46-2]
DR   GeneID; 23765; -.
DR   KEGG; hsa:23765; -.
DR   UCSC; uc002zly.5; human. [Q96F46-1]
DR   CTD; 23765; -.
DR   DisGeNET; 23765; -.
DR   EuPathDB; HostDB:ENSG00000177663.13; -.
DR   GeneCards; IL17RA; -.
DR   HGNC; HGNC:5985; IL17RA.
DR   HPA; ENSG00000177663; Tissue enhanced (lymphoid).
DR   MalaCards; IL17RA; -.
DR   MIM; 605461; gene.
DR   MIM; 613953; phenotype.
DR   neXtProt; NX_Q96F46; -.
DR   OpenTargets; ENSG00000177663; -.
DR   Orphanet; 1334; Chronic mucocutaneous candidiasis.
DR   PharmGKB; PA29801; -.
DR   eggNOG; ENOG502QV5J; Eukaryota.
DR   GeneTree; ENSGT00940000159018; -.
DR   HOGENOM; CLU_018087_0_0_1; -.
DR   InParanoid; Q96F46; -.
DR   KO; K05164; -.
DR   OMA; KRWHFTF; -.
DR   OrthoDB; 577180at2759; -.
DR   PhylomeDB; Q96F46; -.
DR   TreeFam; TF329644; -.
DR   PathwayCommons; Q96F46; -.
DR   Reactome; R-HSA-448424; Interleukin-17 signaling.
DR   SIGNOR; Q96F46; -.
DR   BioGRID-ORCS; 23765; 2 hits in 872 CRISPR screens.
DR   ChiTaRS; IL17RA; human.
DR   EvolutionaryTrace; Q96F46; -.
DR   GeneWiki; IL17RA; -.
DR   GenomeRNAi; 23765; -.
DR   Pharos; Q96F46; Tclin.
DR   PRO; PR:Q96F46; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; Q96F46; protein.
DR   Bgee; ENSG00000177663; Expressed in blood and 224 other tissues.
DR   Genevisible; Q96F46; HS.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030368; F:interleukin-17 receptor activity; IBA:GO_Central.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0050832; P:defense response to fungus; IEA:Ensembl.
DR   GO; GO:0072537; P:fibroblast activation; IDA:BHF-UCL.
DR   GO; GO:0071621; P:granulocyte chemotaxis; IEA:Ensembl.
DR   GO; GO:0097400; P:interleukin-17-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IEA:Ensembl.
DR   GO; GO:2000667; P:positive regulation of interleukin-13 secretion; IEA:Ensembl.
DR   GO; GO:0032747; P:positive regulation of interleukin-23 production; IDA:BHF-UCL.
DR   GO; GO:2000664; P:positive regulation of interleukin-5 secretion; IEA:Ensembl.
DR   Gene3D; 2.60.40.2150; -; 1.
DR   Gene3D; 2.60.40.2160; -; 1.
DR   InterPro; IPR039465; IL-17_rcpt-like.
DR   InterPro; IPR032356; IL17R_fnIII_D1.
DR   InterPro; IPR038683; IL17RA/B_FnIII-like_1_sf.
DR   InterPro; IPR043046; IL17RA/B_FnIII-like_2_sf.
DR   InterPro; IPR013568; SEFIR_dom.
DR   PANTHER; PTHR15583; PTHR15583; 1.
DR   Pfam; PF16556; IL17R_fnIII_D1; 1.
DR   Pfam; PF08357; SEFIR; 1.
DR   PROSITE; PS51534; SEFIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Cell membrane;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Immunity;
KW   Inflammatory response; Innate immunity; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Secreted; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..32
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           33..866
FT                   /note="Interleukin-17 receptor A"
FT                   /id="PRO_0000011030"
FT   TOPO_DOM        33..320
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        321..341
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        342..866
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          377..534
FT                   /note="SEFIR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00867"
FT   COMPBIAS        810..818
FT                   /note="Poly-Glu"
FT   MOD_RES         708
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         736
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60943"
FT   CARBOHYD        49
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:23695682"
FT   CARBOHYD        54
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:23695682"
FT   CARBOHYD        67
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19838198"
FT   CARBOHYD        206
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        225
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:23695682"
FT   CARBOHYD        242
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        265
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19838198"
FT   DISULFID        43..50
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:23695682"
FT   DISULFID        57..126
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:23695682"
FT   DISULFID        185..196
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:23695682"
FT   DISULFID        245..276
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:23695682"
FT   DISULFID        277..303
FT                   /evidence="ECO:0000269|PubMed:23695682"
FT   DISULFID        290..294
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:23695682"
FT   VAR_SEQ         315..348
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_053496"
FT   VARIANT         284..866
FT                   /note="Missing (in IMD51; results in complete loss of
FT                   expression and loss-of-function)"
FT                   /evidence="ECO:0000269|PubMed:21350122"
FT                   /id="VAR_083722"
FT   VARIANT         367
FT                   /note="A -> V (in dbSNP:rs879577)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_027966"
FT   VARIANT         562
FT                   /note="P -> Q (in dbSNP:rs12484684)"
FT                   /id="VAR_049176"
FT   VARIANT         580
FT                   /note="R -> H (in dbSNP:rs17850765)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_027967"
FT   STRAND          34..36
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          50..55
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   HELIX           60..63
FT                   /evidence="ECO:0000244|PDB:4HSA"
FT   STRAND          74..84
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          86..88
FT                   /evidence="ECO:0000244|PDB:4HSA"
FT   STRAND          90..101
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   HELIX           104..108
FT                   /evidence="ECO:0000244|PDB:4HSA"
FT   STRAND          111..118
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   TURN            119..121
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          124..131
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          141..150
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          156..164
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          176..181
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   HELIX           188..191
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   HELIX           194..198
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   TURN            199..202
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          208..212
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   TURN            213..215
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          216..222
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          225..227
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          230..237
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          245..252
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   HELIX           257..259
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          263..269
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          278..285
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   TURN            288..292
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          297..301
FT                   /evidence="ECO:0000244|PDB:5N9B"
FT   STRAND          379..383
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           389..406
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   STRAND          409..411
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           413..416
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           417..422
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           425..438
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   STRAND          442..446
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           449..458
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           478..486
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           487..491
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           493..498
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   STRAND          499..504
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   TURN            505..507
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           510..512
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   STRAND          522..525
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   TURN            526..528
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           529..537
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           557..560
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           564..580
FT                   /evidence="ECO:0000244|PDB:4NUX"
FT   HELIX           584..588
FT                   /evidence="ECO:0000244|PDB:4NUX"
SQ   SEQUENCE   866 AA;  96122 MW;  88AF626A83F3FF70 CRC64;
     MGAARSPPSA VPGPLLGLLL LLLGVLAPGG ASLRLLDHRA LVCSQPGLNC TVKNSTCLDD
     SWIHPRNLTP SSPKDLQIQL HFAHTQQGDL FPVAHIEWTL QTDASILYLE GAELSVLQLN
     TNERLCVRFE FLSKLRHHHR RWRFTFSHFV VDPDQEYEVT VHHLPKPIPD GDPNHQSKNF
     LVPDCEHARM KVTTPCMSSG SLWDPNITVE TLEAHQLRVS FTLWNESTHY QILLTSFPHM
     ENHSCFEHMH HIPAPRPEEF HQRSNVTLTL RNLKGCCRHQ VQIQPFFSSC LNDCLRHSAT
     VSCPEMPDTP EPIPDYMPLW VYWFITGISI LLVGSVILLI VCMTWRLAGP GSEKYSDDTK
     YTDGLPAADL IPPPLKPRKV WIIYSADHPL YVDVVLKFAQ FLLTACGTEV ALDLLEEQAI
     SEAGVMTWVG RQKQEMVESN SKIIVLCSRG TRAKWQALLG RGAPVRLRCD HGKPVGDLFT
     AAMNMILPDF KRPACFGTYV VCYFSEVSCD GDVPDLFGAA PRYPLMDRFE EVYFRIQDLE
     MFQPGRMHRV GELSGDNYLR SPGGRQLRAA LDRFRDWQVR CPDWFECENL YSADDQDAPS
     LDEEVFEEPL LPPGTGIVKR APLVREPGSQ ACLAIDPLVG EEGGAAVAKL EPHLQPRGQP
     APQPLHTLVL AAEEGALVAA VEPGPLADGA AVRLALAGEG EACPLLGSPG AGRNSVLFLP
     VDPEDSPLGS STPMASPDLL PEDVREHLEG LMLSLFEQSL SCQAQGGCSR PAMVLTDPHT
     PYEEEQRQSV QSDQGYISRS SPQPPEGLTE MEEEEEEEQD PGKPALPLSP EDLESLRSLQ
     RQLLFRQLQK NSGWDTMGSE SEGPSA
//
ID   IL17F_HUMAN             Reviewed;         163 AA.
AC   Q96PD4; Q6NSI0; Q7Z6P4; Q96PI8; Q9NUE6;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   16-JUN-2009, sequence version 3.
DT   12-AUG-2020, entry version 159.
DE   RecName: Full=Interleukin-17F;
DE            Short=IL-17F;
DE   AltName: Full=Cytokine ML-1;
DE   Flags: Precursor;
GN   Name=IL17F;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=11591732; DOI=10.4049/jimmunol.167.8.4137;
RA   Starnes T., Robertson M.J., Sledge G., Kelich S., Nakshatri H.,
RA   Broxmeyer H.E., Hromas R.;
RT   "IL-17F, a novel cytokine selectively expressed in activated T cells and
RT   monocytes, regulates angiogenesis and endothelial cell cytokine
RT   production.";
RL   J. Immunol. 167:4137-4140(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-161.
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 12-163, FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=11591768; DOI=10.4049/jimmunol.167.8.4430;
RA   Kawaguchi M., Onuchic L.F., Li X.-D., Essayan D.M., Schroeder J.,
RA   Xiao H.-Q., Liu M.C., Krishnaswamy G., Germino G., Huang S.-K.;
RT   "Identification of a novel cytokine, ML-1, and its expression in subjects
RT   with asthma.";
RL   J. Immunol. 167:4430-4435(2001).
RN   [5]
RP   PROTEIN SEQUENCE OF 31-45.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [6]
RP   SUBUNIT.
RX   PubMed=17355969; DOI=10.1074/jbc.m700499200;
RA   Wright J.F., Guo Y., Quazi A., Luxenberg D.P., Bennett F., Ross J.F.,
RA   Qiu Y., Whitters M.J., Tomkinson K.N., Dunussi-Joannopoulos K.,
RA   Carreno B.M., Collins M., Wolfman N.M.;
RT   "Identification of an interleukin 17F/17A heterodimer in activated human
RT   CD4+ T cells.";
RL   J. Biol. Chem. 282:13447-13455(2007).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH IL17RC.
RX   PubMed=17911633; DOI=10.4049/jimmunol.179.8.5462;
RA   Kuestner R.E., Taft D.W., Haran A., Brandt C.S., Brender T., Lum K.,
RA   Harder B., Okada S., Ostrander C.D., Kreindler J.L., Aujla S.J.,
RA   Reardon B., Moore M., Shea P., Schreckhise R., Bukowski T.R., Presnell S.,
RA   Guerra-Lewis P., Parrish-Novak J., Ellsworth J.L., Jaspers S., Lewis K.E.,
RA   Appleby M., Kolls J.K., Rixon M., West J.W., Gao Z., Levin S.D.;
RT   "Identification of the IL-17 receptor related molecule IL-17RC as the
RT   receptor for IL-17F.";
RL   J. Immunol. 179:5462-5473(2007).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH IL17RA AND IL17RC.
RX   PubMed=18684971; DOI=10.4049/jimmunol.181.4.2799;
RA   Wright J.F., Bennett F., Li B., Brooks J., Luxenberg D.P., Whitters M.J.,
RA   Tomkinson K.N., Fitz L.J., Wolfman N.M., Collins M.,
RA   Dunussi-Joannopoulos K., Chatterjee-Kishore M., Carreno B.M.;
RT   "The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-
RT   17RA/IL-17RC receptor complex.";
RL   J. Immunol. 181:2799-2805(2008).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS), AND FUNCTION.
RX   PubMed=11574464; DOI=10.1093/emboj/20.19.5332;
RA   Hymowitz S.G., Filvaroff E.H., Yin J.P., Lee J., Cai L., Risser P.,
RA   Maruoka M., Mao W., Foster J., Kelley R.F., Pan G., Gurney A.L.,
RA   de Vos A.M., Starovasnik M.A.;
RT   "IL-17s adopt a cystine knot fold: structure and activity of a novel
RT   cytokine, IL-17F, and implications for receptor binding.";
RL   EMBO J. 20:5332-5341(2001).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 31-163 IN COMPLEX WITH IL17R,
RP   GLYCOSYLATION AT ASN-83, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=19838198; DOI=10.1038/ni.1813;
RA   Ely L.K., Fischer S., Garcia K.C.;
RT   "Structural basis of receptor sharing by interleukin 17 cytokines.";
RL   Nat. Immunol. 10:1245-1251(2009).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 31-163 IN COMPLEX WITH IL17A;
RP   INTERACTION WITH IL17RA AND IL17RC, FUNCTION, AND MUTAGENESIS OF ARG-77.
RX   PubMed=28827714; DOI=10.1038/s41598-017-08360-9;
RA   Goepfert A., Lehmann S., Wirth E., Rondeau J.M.;
RT   "The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor
RT   recognition properties.";
RL   Sci. Rep. 7:8906-8906(2017).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (3.32 ANGSTROMS) OF 31-163 IN COMPLEX WITH IL17RC,
RP   DISULFIDE BOND, INTERACTION WITH IL17A; IL17RC AND IL17RA, AND FUNCTION.
RX   PubMed=32187518; DOI=10.1016/j.immuni.2020.02.004;
RA   Goepfert A., Lehmann S., Blank J., Kolbinger F., Rondeau J.M.;
RT   "Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric
RT   Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling.";
RL   Immunity 52:499-512.e5(2020).
RN   [13]
RP   VARIANT CANDF6 LEU-95, AND FUNCTION.
RX   PubMed=21350122; DOI=10.1126/science.1200439;
RA   Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K.,
RA   Migaud M., Israel L., Chrabieh M., Audry M., Gumbleton M., Toulon A.,
RA   Bodemer C., El-Baghdadi J., Whitters M., Paradis T., Brooks J., Collins M.,
RA   Wolfman N.M., Al-Muhsen S., Galicchio M., Abel L., Picard C.,
RA   Casanova J.L.;
RT   "Chronic mucocutaneous candidiasis in humans with inborn errors of
RT   interleukin-17 immunity.";
RL   Science 332:65-68(2011).
CC   -!- FUNCTION: Effector cytokine of innate and adaptive immune system
CC       involved in antimicrobial host defense and maintenance of tissue
CC       integrity (PubMed:21350122). IL17A-IL17F signals via IL17RA-IL17RC
CC       heterodimeric receptor complex, triggering homotypic interaction of
CC       IL17RA and IL17RC chains with TRAF3IP2 adapter through SEFIR domains.
CC       This leads to downstream TRAF6-mediated activation of NF-kappa-B and
CC       MAPkinase pathways ultimately resulting in transcriptional activation
CC       of cytokines, chemokines, antimicrobial peptides and matrix
CC       metalloproteinases, with potential strong immune inflammation
CC       (PubMed:18684971, PubMed:21350122, PubMed:11591732, PubMed:11591768,
CC       PubMed:17911633, PubMed:11574464, PubMed:28827714). IL17A-IL17F is
CC       primarily involved in host defense against extracellular bacteria and
CC       fungi by inducing neutrophilic inflammation (By similarity). As
CC       signature effector cytokine of T-helper 17 cells (Th17), primarily
CC       induces neutrophil activation and recruitment at infection and
CC       inflammatory sites (By similarity). Stimulates the production of
CC       antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal
CC       epithelial cells, limiting the entry of microbes through the epithelial
CC       barriers (By similarity). IL17F homodimer can signal via IL17RC
CC       homodimeric receptor complex, triggering downstream activation of TRAF6
CC       and NF-kappa-B signaling pathway (PubMed:32187518). Via IL17RC induces
CC       transcriptional activation of IL33, a potent cytokine that stimulates
CC       group 2 innate lymphoid cells and adaptive T-helper 2 cells involved in
CC       pulmonary allergic response to fungi. Likely via IL17RC, promotes
CC       sympathetic innervation of peripheral organs by coordinating the
CC       communication between gamma-delta T cells and parenchymal cells.
CC       Stimulates sympathetic innervation of thermogenic adipose tissue by
CC       driving TGFB1 expression (By similarity). Regulates the composition of
CC       intestinal microbiota and immune tolerance by inducing antimicrobial
CC       proteins that specifically control the growth of commensal Firmicutes
CC       and Bacteroidetes (By similarity). {ECO:0000250|UniProtKB:Q7TNI7,
CC       ECO:0000269|PubMed:11574464, ECO:0000269|PubMed:11591732,
CC       ECO:0000269|PubMed:11591768, ECO:0000269|PubMed:17911633,
CC       ECO:0000269|PubMed:18684971, ECO:0000269|PubMed:21350122,
CC       ECO:0000269|PubMed:28827714, ECO:0000269|PubMed:32187518}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:19838198,
CC       PubMed:32187518). Heterodimer with IL17A (IL17A-IL17F)
CC       (PubMed:17355969). Forms complexes with IL17RA and IL17RC receptors
CC       with 2:1 binding stoichiometry: two receptor chains for one interleukin
CC       molecule. IL17F homodimer forms predominantly complexes with IL17RC
CC       homodimer, whereas IL17A-IL17F favors complexes with IL17RA-IL17RC
CC       (PubMed:32187518, PubMed:28827714, PubMed:17911633, PubMed:18684971).
CC       IL17RA and IL17RC chains can not distinguish between IL17A and IL17F
CC       molecules, potentially enabling the formation of topologically distinct
CC       complexes (PubMed:28827714). {ECO:0000269|PubMed:17355969,
CC       ECO:0000269|PubMed:17911633, ECO:0000269|PubMed:18684971,
CC       ECO:0000269|PubMed:19838198, ECO:0000269|PubMed:28827714,
CC       ECO:0000269|PubMed:32187518}.
CC   -!- INTERACTION:
CC       Q96PD4; Q53SE7: FLJ13057; NbExp=3; IntAct=EBI-10292310, EBI-10172181;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:Q7TNI7}.
CC   -!- TISSUE SPECIFICITY: Expressed in T-helper 1 and T-helper 2 cells,
CC       basophils and mast cells. {ECO:0000269|PubMed:11591768}.
CC   -!- DISEASE: Candidiasis, familial, 6 (CANDF6) [MIM:613956]: A primary
CC       immunodeficiency disorder with altered immune responses and impaired
CC       clearance of fungal infections, selective against Candida. It is
CC       characterized by persistent and/or recurrent infections of the skin,
CC       nails and mucous membranes caused by organisms of the genus Candida,
CC       mainly Candida albicans. {ECO:0000269|PubMed:21350122}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the IL-17 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL14427.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Interleukin-17 entry;
CC       URL="https://en.wikipedia.org/wiki/Interleukin_17";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF384857; AAK83350.1; -; mRNA.
DR   EMBL; AL034343; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC070124; AAH70124.1; -; mRNA.
DR   EMBL; AF332389; AAL14427.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS4938.1; -.
DR   RefSeq; NP_443104.1; NM_052872.3.
DR   RefSeq; XP_011512578.1; XM_011514276.1.
DR   PDB; 1JPY; X-ray; 2.85 A; A/B/X/Y=31-163.
DR   PDB; 3JVF; X-ray; 3.30 A; A/B=31-163.
DR   PDB; 5N92; X-ray; 2.30 A; F=31-163.
DR   PDB; 5NAN; X-ray; 3.30 A; E/F=31-163.
DR   PDB; 6HG4; X-ray; 3.32 A; A=31-163.
DR   PDB; 6HG9; X-ray; 3.62 A; A=31-163.
DR   PDB; 6HGO; X-ray; 2.10 A; A/B/C/D=31-163.
DR   PDB; 6PPG; X-ray; 2.75 A; F/G=31-163.
DR   PDBsum; 1JPY; -.
DR   PDBsum; 3JVF; -.
DR   PDBsum; 5N92; -.
DR   PDBsum; 5NAN; -.
DR   PDBsum; 6HG4; -.
DR   PDBsum; 6HG9; -.
DR   PDBsum; 6HGO; -.
DR   PDBsum; 6PPG; -.
DR   SMR; Q96PD4; -.
DR   BioGRID; 125201; 31.
DR   IntAct; Q96PD4; 1.
DR   STRING; 9606.ENSP00000337432; -.
DR   BindingDB; Q96PD4; -.
DR   GlyGen; Q96PD4; 1 site.
DR   iPTMnet; Q96PD4; -.
DR   PhosphoSitePlus; Q96PD4; -.
DR   BioMuta; IL17F; -.
DR   DMDM; 239938888; -.
DR   MassIVE; Q96PD4; -.
DR   PaxDb; Q96PD4; -.
DR   PeptideAtlas; Q96PD4; -.
DR   PRIDE; Q96PD4; -.
DR   ProteomicsDB; 77668; -.
DR   ABCD; Q96PD4; 54 sequenced antibodies.
DR   Antibodypedia; 30885; 812 antibodies.
DR   Ensembl; ENST00000336123; ENSP00000337432; ENSG00000112116.
DR   GeneID; 112744; -.
DR   KEGG; hsa:112744; -.
DR   UCSC; uc003pam.2; human.
DR   CTD; 112744; -.
DR   DisGeNET; 112744; -.
DR   EuPathDB; HostDB:ENSG00000112116.9; -.
DR   GeneCards; IL17F; -.
DR   HGNC; HGNC:16404; IL17F.
DR   HPA; ENSG00000112116; Group enriched (esophagus, lymphoid tissue, urinary bladder).
DR   MalaCards; IL17F; -.
DR   MIM; 606496; gene.
DR   MIM; 613956; phenotype.
DR   neXtProt; NX_Q96PD4; -.
DR   OpenTargets; ENSG00000112116; -.
DR   Orphanet; 1334; Chronic mucocutaneous candidiasis.
DR   PharmGKB; PA29800; -.
DR   eggNOG; ENOG502S5A0; Eukaryota.
DR   GeneTree; ENSGT00940000156618; -.
DR   HOGENOM; CLU_118641_0_0_1; -.
DR   InParanoid; Q96PD4; -.
DR   KO; K05494; -.
DR   OMA; SPWDYNV; -.
DR   OrthoDB; 1469254at2759; -.
DR   PhylomeDB; Q96PD4; -.
DR   TreeFam; TF314701; -.
DR   PathwayCommons; Q96PD4; -.
DR   Reactome; R-HSA-448424; Interleukin-17 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   BioGRID-ORCS; 112744; 6 hits in 862 CRISPR screens.
DR   EvolutionaryTrace; Q96PD4; -.
DR   GenomeRNAi; 112744; -.
DR   Pharos; Q96PD4; Tbio.
DR   PRO; PR:Q96PD4; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q96PD4; protein.
DR   Bgee; ENSG00000112116; Expressed in tonsil and 30 other tissues.
DR   Genevisible; Q96PD4; HS.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:UniProtKB-KW.
DR   GO; GO:0005125; F:cytokine activity; IDA:UniProtKB.
DR   GO; GO:0019955; F:cytokine binding; IDA:UniProtKB.
DR   GO; GO:0005126; F:cytokine receptor binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0051216; P:cartilage development; IDA:UniProtKB.
DR   GO; GO:0042089; P:cytokine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; IEA:InterPro.
DR   GO; GO:0097400; P:interleukin-17-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0042109; P:lymphotoxin A biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IEA:Ensembl.
DR   GO; GO:2000778; P:positive regulation of interleukin-6 secretion; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0045423; P:regulation of granulocyte macrophage colony-stimulating factor biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045076; P:regulation of interleukin-2 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045408; P:regulation of interleukin-6 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045414; P:regulation of interleukin-8 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR020440; IL-17_chr.
DR   InterPro; IPR010345; IL-17_fam.
DR   Pfam; PF06083; IL17; 1.
DR   PRINTS; PR01932; INTRLEUKIN17.
DR   SUPFAM; SSF57501; SSF57501; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Cytokine; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Immunity;
KW   Inflammatory response; Innate immunity; Polymorphism; Reference proteome;
KW   Secreted; Signal.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           31..163
FT                   /note="Interleukin-17F"
FT                   /id="PRO_0000015432"
FT   CARBOHYD        83
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19838198"
FT   DISULFID        47
FT                   /note="Interchain (with C-137)"
FT                   /evidence="ECO:0000269|PubMed:19838198"
FT   DISULFID        102..152
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:32187518"
FT   DISULFID        107..154
FT                   /evidence="ECO:0000269|PubMed:19838198,
FT                   ECO:0000269|PubMed:32187518"
FT   DISULFID        137
FT                   /note="Interchain (with C-47)"
FT                   /evidence="ECO:0000269|PubMed:19838198"
FT   VARIANT         95
FT                   /note="S -> L (in CANDF6; dbSNP:rs748486078)"
FT                   /evidence="ECO:0000269|PubMed:21350122"
FT                   /id="VAR_065813"
FT   VARIANT         126
FT                   /note="E -> G (in dbSNP:rs2397084)"
FT                   /id="VAR_058287"
FT   VARIANT         155
FT                   /note="V -> I (in dbSNP:rs11465553)"
FT                   /id="VAR_058288"
FT   VARIANT         161
FT                   /note="H -> R (in dbSNP:rs763780)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_058289"
FT   MUTAGEN         77
FT                   /note="R->A: Significantly decreases the affinity for
FT                   IL17RA and IL17RC by nearly 5-fold and 200-fold,
FT                   respectively."
FT                   /evidence="ECO:0000269|PubMed:28827714"
FT   HELIX           39..41
FT                   /evidence="ECO:0000244|PDB:1JPY"
FT   STRAND          55..62
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   TURN            63..65
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   TURN            68..71
FT                   /evidence="ECO:0000244|PDB:5N92"
FT   HELIX           74..77
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   STRAND          78..80
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   STRAND          82..88
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   STRAND          92..103
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   STRAND          105..108
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   STRAND          110..112
FT                   /evidence="ECO:0000244|PDB:5N92"
FT   STRAND          118..134
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   HELIX           136..138
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   STRAND          140..155
FT                   /evidence="ECO:0000244|PDB:6HGO"
FT   STRAND          159..161
FT                   /evidence="ECO:0000244|PDB:3JVF"
SQ   SEQUENCE   163 AA;  18045 MW;  E5287737C9E7BD46 CRC64;
     MTVKTLHGPA MVKYLLLSIL GLAFLSEAAA RKIPKVGHTF FQKPESCPPV PGGSMKLDIG
     IINENQRVSM SRNIESRSTS PWNYTVTWDP NRYPSEVVQA QCRNLGCINA QGKEDISMNS
     VPIQQETLVV RRKHQGCSVS FQLEKVLVTV GCTCVTPVIH HVQ
//
ID   PHB2_HUMAN              Reviewed;         299 AA.
AC   Q99623; B4DP75; Q2YDA4; Q7KYU3; Q92978;
DT   27-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1997, sequence version 2.
DT   12-AUG-2020, entry version 188.
DE   RecName: Full=Prohibitin-2;
DE   AltName: Full=B-cell receptor-associated protein BAP37;
DE   AltName: Full=D-prohibitin;
DE   AltName: Full=Repressor of estrogen receptor activity;
GN   Name=PHB2 {ECO:0000312|EMBL:AAH14766.1, ECO:0000312|HGNC:HGNC:30306};
GN   Synonyms=BAP {ECO:0000312|EMBL:AAB51324.1}, REA
GN   {ECO:0000312|EMBL:AAD38042.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAC51639.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=9074930; DOI=10.1101/gr.7.3.268;
RA   Ansari-Lari M.A., Shen Y., Muzny D.M., Lee W., Gibbs R.A.;
RT   "Large-scale sequencing in human chromosome 12p13: experimental and
RT   computational gene structure determination.";
RL   Genome Res. 7:268-280(1997).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAD38042.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND INTERACTION WITH
RP   ESR1.
RC   TISSUE=Mammary cancer {ECO:0000312|EMBL:AAD38042.1};
RX   PubMed=10359819; DOI=10.1073/pnas.96.12.6947;
RA   Montano M.M., Ekena K., Delage-Mourroux R., Chang W., Martini P.,
RA   Katzenellenbogen B.S.;
RT   "An estrogen receptor-selective coregulator that potentiates the
RT   effectiveness of antiestrogens and represses the activity of estrogens.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6947-6952(1999).
RN   [3] {ECO:0000312|EMBL:AAF44345.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Dendritic cell;
RA   Zhang W., Wan T., Chen T., Cao X.;
RT   "Identification of a novel D-prohibitin from dendritic cells.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000312|EMBL:AAF17231.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hypothalamus {ECO:0000312|EMBL:AAF17231.1};
RX   PubMed=10931946; DOI=10.1073/pnas.160270997;
RA   Hu R.-M., Han Z.-G., Song H.-D., Peng Y.-D., Huang Q.-H., Ren S.-X.,
RA   Gu Y.-J., Huang C.-H., Li Y.-B., Jiang C.-L., Fu G., Zhang Q.-H., Gu B.-W.,
RA   Dai M., Mao Y.-F., Gao G.-F., Rong R., Ye M., Zhou J., Xu S.-H., Gu J.,
RA   Shi J.-X., Jin W.-R., Zhang C.-K., Wu T.-M., Huang G.-Y., Chen Z.,
RA   Chen M.-D., Chen J.-L.;
RT   "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis
RT   and full-length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7] {ECO:0000312|EMBL:AAH14766.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta {ECO:0000312|EMBL:AAH14766.1}, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8] {ECO:0000312|EMBL:AAF44345.1}
RP   PROTEIN SEQUENCE OF 2-11; 108-131; 148-157; 172-191; 210-216; 225-236 AND
RP   271-289, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Lilla S., Zebisch A., Kolch W.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [9] {ECO:0000305}
RP   FUNCTION, INTERACTION WITH PHB, DEVELOPMENTAL STAGE, AND INDUCTION.
RX   PubMed=11302691; DOI=10.1006/excr.2001.5166;
RA   Coates P.J., Nenutil R., McGregor A., Picksley S.M., Crouch D.H.,
RA   Hall P.A., Wright E.G.;
RT   "Mammalian prohibitin proteins respond to mitochondrial stress and decrease
RT   during cellular senescence.";
RL   Exp. Cell Res. 265:262-273(2001).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-128, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   INTERACTION WITH ARFGEF3, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=19496786; DOI=10.1111/j.1349-7006.2009.01209.x;
RA   Kim J.W., Akiyama M., Park J.H., Lin M.L., Shimo A., Ueki T., Daigo Y.,
RA   Tsunoda T., Nishidate T., Nakamura Y., Katagiri T.;
RT   "Activation of an estrogen/estrogen receptor signaling by BIG3 through its
RT   inhibitory effect on nuclear transport of PHB2/REA in breast cancer.";
RL   Cancer Sci. 100:1468-1478(2009).
RN   [14]
RP   INTERACTION WITH SARS-COV NSP2.
RX   PubMed=19640993; DOI=10.1128/jvi.00842-09;
RA   Cornillez-Ty C.T., Liao L., Yates J.R., Kuhn P., Buchmeier M.J.;
RT   "Severe acute respiratory syndrome coronavirus nonstructural protein 2
RT   interacts with a host protein complex involved in mitochondrial biogenesis
RT   and intracellular signaling.";
RL   J. Virol. 83:10314-10318(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-250, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   INTERACTION WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENVELOPE GLYCOPROTEIN
RP   GP160.
RX   PubMed=19906925; DOI=10.1128/jvi.01641-09;
RA   Emerson V., Holtkotte D., Pfeiffer T., Wang I.H., Schnoelzer M., Kempf T.,
RA   Bosch V.;
RT   "Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an
RT   interaction partner of the C-terminal cytoplasmic domain of the HIV-1
RT   glycoprotein.";
RL   J. Virol. 84:1355-1365(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   INTERACTION WITH ZNF703, AND SUBCELLULAR LOCATION.
RX   PubMed=21328542; DOI=10.1002/emmm.201100121;
RA   Sircoulomb F., Nicolas N., Ferrari A., Finetti P., Bekhouche I.,
RA   Rousselet E., Lonigro A., Adelaide J., Baudelet E., Esteyries S.,
RA   Wicinski J., Audebert S., Charafe-Jauffret E., Jacquemier J., Lopez M.,
RA   Borg J.P., Sotiriou C., Popovici C., Bertucci F., Birnbaum D.,
RA   Chaffanet M., Ginestier C.;
RT   "ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.";
RL   EMBO Mol. Med. 3:153-166(2011).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PHB.
RX   PubMed=20959514; DOI=10.1096/fj.10-167502;
RA   Strub G.M., Paillard M., Liang J., Gomez L., Allegood J.C., Hait N.C.,
RA   Maceyka M., Price M.M., Chen Q., Simpson D.C., Kordula T., Milstien S.,
RA   Lesnefsky E.J., Spiegel S.;
RT   "Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria
RT   interacts with prohibitin 2 to regulate complex IV assembly and
RT   respiration.";
RL   FASEB J. 25:600-612(2011).
RN   [20]
RP   INTERACTION WITH STOML2.
RX   PubMed=21746876; DOI=10.1128/mcb.05393-11;
RA   Christie D.A., Lemke C.D., Elias I.M., Chau L.A., Kirchhof M.G., Li B.,
RA   Ball E.H., Dunn S.D., Hatch G.M., Madrenas J.;
RT   "Stomatin-like protein 2 binds cardiolipin and regulates mitochondrial
RT   biogenesis and function.";
RL   Mol. Cell. Biol. 31:3845-3856(2011).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22997079; DOI=10.1002/jmv.23403;
RA   Wintachai P., Wikan N., Kuadkitkan A., Jaimipuk T., Ubol S.,
RA   Pulmanausahakul R., Auewarakul P., Kasinrerk W., Weng W.Y.,
RA   Panyasrivanit M., Paemanee A., Kittisenachai S., Roytrakul S., Smith D.R.;
RT   "Identification of prohibitin as a Chikungunya virus receptor protein.";
RL   J. Med. Virol. 84:1757-1770(2012).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [23]
RP   FUNCTION, INTERACTION WITH IGFBP6, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=24003225; DOI=10.1074/jbc.m113.510826;
RA   Fu P., Yang Z., Bach L.A.;
RT   "Prohibitin-2 binding modulates insulin-like growth factor-binding protein-
RT   6 (IGFBP-6)-induced rhabdomyosarcoma cell migration.";
RL   J. Biol. Chem. 288:29890-29900(2013).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   REVIEW OF FUNCTION.
RX   PubMed=25904163; DOI=10.1002/iub.1366;
RA   Bavelloni A., Piazzi M., Raffini M., Faenza I., Blalock W.L.;
RT   "Prohibitin 2: At a communications crossroads.";
RL   IUBMB Life 67:239-254(2015).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [28]
RP   FUNCTION, INTERACTION WITH PHB AND MAP1LC3B, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF TYR-77; 121-TYR--LEU-124 AND 175-PHE--ILE-178.
RX   PubMed=28017329; DOI=10.1016/j.cell.2016.11.042;
RA   Wei Y., Chiang W.C., Sumpter R. Jr., Mishra P., Levine B.;
RT   "Prohibitin 2 Is an Inner Mitochondrial Membrane Mitophagy Receptor.";
RL   Cell 168:224.e10-238.e10(2017).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH HUMAN ENTEROVIRUS 71
RP   CAPSID PROTEIN VP1, AND SUBCELLULAR LOCATION.
RX   PubMed=32276428; DOI=10.3390/v12040414;
RA   Su W., Huang S., Zhu H., Zhang B., Wu X.;
RT   "Interaction between PHB2 and Enterovirus A71 VP1 Induces Autophagy and
RT   Affects EV-A71 Infection.";
RL   Viruses 12:0-0(2020).
RN   [30] {ECO:0000244|PDB:6IQE}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 188-265, ALTERNATIVE SPLICING,
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, MUTAGENESIS OF ILE-225 AND
RP   229-GLU--GLU-233, AND INTERACTION WITH PHB AND CLPB.
RX   PubMed=31522117; DOI=10.1016/j.isci.2019.08.056;
RA   Yoshinaka T., Kosako H., Yoshizumi T., Furukawa R., Hirano Y., Kuge O.,
RA   Tamada T., Koshiba T.;
RT   "Structural Basis of Mitochondrial Scaffolds by Prohibitin Complexes:
RT   Insight into a Role of the Coiled-Coil Region.";
RL   IScience 19:1065-1078(2019).
CC   -!- FUNCTION: Protein with pleiotropic attributes mediated in a cell-
CC       compartment- and tissue-specific manner, which include the plasma
CC       membrane-associated cell signaling functions, mitochondrial chaperone,
CC       and transcriptional co-regulator of transcription factors and sex
CC       steroid hormones in the nucleus. {ECO:0000269|PubMed:10359819,
CC       ECO:0000269|PubMed:11302691, ECO:0000269|PubMed:20959514,
CC       ECO:0000269|PubMed:24003225, ECO:0000269|PubMed:28017329,
CC       ECO:0000269|PubMed:31522117}.
CC   -!- FUNCTION: In the mitochondria, together with PHB, forms large ring
CC       complexes (prohibitin complexes) in the inner mitochondrial membrane
CC       (IMM) and functions as chaperone protein that stabilizes mitochondrial
CC       respiratory enzymes and maintains mitochondrial integrity in the IMM,
CC       which is required for mitochondrial morphogenesis, neuronal survival,
CC       and normal lifespan (Probable). The prohibitin complex, with DNAJC19,
CC       regulates cardiolipin remodeling and the protein turnover of OMA1 in a
CC       cardiolipin-binding manner (By similarity). Also regulates cytochrome-c
CC       oxidase assembly (COX) and mitochondrial respiration (PubMed:20959514,
CC       PubMed:11302691). Binding to sphingoid 1-phosphate (SPP) modulates its
CC       regulator activity (PubMed:20959514, PubMed:11302691). Has a key role
CC       of mitophagy receptor involved in targeting mitochondria for autophagic
CC       degradation (PubMed:28017329). Involved in mitochondrial-mediated
CC       antiviral innate immunity, activates DDX58/RIG-I-mediated signal
CC       transduction and production of IFNB1 and proinflammatory cytokine IL6
CC       (PubMed:31522117). {ECO:0000250|UniProtKB:O35129,
CC       ECO:0000269|PubMed:11302691, ECO:0000269|PubMed:20959514,
CC       ECO:0000269|PubMed:28017329, ECO:0000269|PubMed:31522117,
CC       ECO:0000305|PubMed:25904163}.
CC   -!- FUNCTION: In the nucleus, serves as transcriptional co-regulator
CC       (Probable). Acts as a mediator of transcriptional repression by nuclear
CC       hormone receptors via recruitment of histone deacetylases. Functions as
CC       an estrogen receptor (ER)-selective coregulator that potentiates the
CC       inhibitory activities of antiestrogens and represses the activity of
CC       estrogens. Competes with NCOA1 for modulation of ER transcriptional
CC       activity (By similarity). {ECO:0000250|UniProtKB:O35129,
CC       ECO:0000305|PubMed:25904163}.
CC   -!- FUNCTION: In the plasma membrane, is involved in IGFBP6-induced cell
CC       migration (PubMed:24003225). Cooperates with CD86 to mediate CD86-
CC       signaling in B lymphocytes that regulates the level of IgG1 produced
CC       through the activation of distal signaling intermediates. Upon CD40
CC       engagement, required to activate NF-kappa-B signaling pathway via
CC       phospholipase C and protein kinase C activation (By similarity).
CC       {ECO:0000250|UniProtKB:O35129, ECO:0000269|PubMed:24003225}.
CC   -!- FUNCTION: (Microbial infection) Involved in human enterovirus 71/EV-71
CC       infection by enhancing the autophagy mechanism during the infection.
CC       {ECO:0000269|PubMed:32276428}.
CC   -!- SUBUNIT: The mitochondrial prohibitin complex consists of two subunits
CC       (PHB and PHB2), assembled into a membrane-associated ring-shaped
CC       supercomplex of approximately 1 mDa (PubMed:20959514, PubMed:28017329,
CC       PubMed:31522117). Interacts with ESR1, HDAC1 and HDAC5 (By similarity).
CC       Interacts with ZNF703 (PubMed:21328542). Interacts with STOML2
CC       (PubMed:21746876). Interacts with ARFGEF3 (PubMed:19496786). Interacts
CC       with SPHK2. Interacts with COX4I1; the interaction associates PHB2 with
CC       COX (By similarity). Interacts with MAP1LC3B (membrane-bound form LC3-
CC       II); the interaction is direct and upon mitochondrial depolarization
CC       and proteasome-dependent outer membrane rupture (PubMed:28017329).
CC       Interacts with IGFBP6 (via C-terminal domain) (PubMed:24003225).
CC       Interacts with CLPB (PubMed:31522117). Interacts with CD86 (via
CC       cytoplasmic domain); the interactions increases after priming with CD40
CC       (By similarity). Interacts with AFG3L2 (By similarity). Interacts with
CC       DNAJC19 (By similarity). {ECO:0000250|UniProtKB:O35129,
CC       ECO:0000269|PubMed:10359819, ECO:0000269|PubMed:11302691,
CC       ECO:0000269|PubMed:19496786, ECO:0000269|PubMed:20959514,
CC       ECO:0000269|PubMed:21328542, ECO:0000269|PubMed:21746876,
CC       ECO:0000269|PubMed:24003225, ECO:0000269|PubMed:28017329,
CC       ECO:0000269|PubMed:31522117}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS coronavirus/SARS-CoV
CC       nsp2 protein. {ECO:0000269|PubMed:19640993}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human enterovirus 71/EV-
CC       71 capsid protein VP1; the interaction is required for induction of
CC       autophagy and the infectivity of EV-71. {ECO:0000269|PubMed:32276428}.
CC   -!- SUBUNIT: (Microbial infection) Interaction with human immunodeficiency
CC       virus type 1/HIV-1 envelope glycoprotein GP160.
CC       {ECO:0000269|PubMed:19906925}.
CC   -!- INTERACTION:
CC       Q99623; P03372: ESR1; NbExp=4; IntAct=EBI-358348, EBI-78473;
CC       Q99623; P35232: PHB; NbExp=3; IntAct=EBI-358348, EBI-354213;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane
CC       {ECO:0000269|PubMed:20959514, ECO:0000269|PubMed:28017329}. Cytoplasm
CC       {ECO:0000269|PubMed:19496786, ECO:0000269|PubMed:32276428}. Nucleus
CC       {ECO:0000269|PubMed:19496786, ECO:0000269|PubMed:20959514}. Cell
CC       membrane {ECO:0000269|PubMed:22997079, ECO:0000269|PubMed:24003225}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Mitochondrion inner membrane
CC       {ECO:0000305|PubMed:31522117}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Mitochondrion inner membrane
CC       {ECO:0000305|PubMed:31522117}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=V1 {ECO:0000303|PubMed:31522117};
CC         IsoId=Q99623-1; Sequence=Displayed;
CC       Name=2; Synonyms=V3 {ECO:0000303|PubMed:31522117};
CC         IsoId=Q99623-2; Sequence=VSP_045311;
CC   -!- DEVELOPMENTAL STAGE: Levels of expression in fibroblasts decrease
CC       heterogeneously during cellular aging. {ECO:0000269|PubMed:11302691}.
CC   -!- INDUCTION: Expression increases approximately 3-fold upon entry into G1
CC       phase compared to other phases of the cell cycle. Also induced
CC       following inhibition of mitochondrial protein synthesis by
CC       thiamphenicol. {ECO:0000269|PubMed:11302691}.
CC   -!- DOMAIN: LC3-interaction region (LIR) is required for interaction with
CC       MAP1LC3B/LC3-II and for Parkin-mediated mitophagy.
CC       {ECO:0000269|PubMed:28017329}.
CC   -!- PTM: Phosphorylated. Tyrosine phosphorylation is indirectly stimulated
CC       by IGFBP6. {ECO:0000269|PubMed:24003225}.
CC   -!- SIMILARITY: Belongs to the prohibitin family. {ECO:0000255}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U72511; AAC51639.1; -; mRNA.
DR   EMBL; AF150962; AAD38042.1; -; mRNA.
DR   EMBL; AF178980; AAF44345.1; -; mRNA.
DR   EMBL; AF126021; AAF17231.1; -; mRNA.
DR   EMBL; AK298217; BAG60487.1; -; mRNA.
DR   EMBL; U47924; AAB51324.1; -; Genomic_DNA.
DR   EMBL; BC014766; AAH14766.1; -; mRNA.
DR   EMBL; BC110322; AAI10323.1; -; mRNA.
DR   CCDS; CCDS53741.1; -. [Q99623-1]
DR   CCDS; CCDS58207.1; -. [Q99623-2]
DR   RefSeq; NP_001138303.1; NM_001144831.1. [Q99623-1]
DR   RefSeq; NP_001254629.1; NM_001267700.1. [Q99623-2]
DR   PDB; 6IQE; X-ray; 1.70 A; A=188-265.
DR   PDBsum; 6IQE; -.
DR   SMR; Q99623; -.
DR   BioGRID; 116459; 308.
DR   ComplexPortal; CPX-5741; Prohibitin complex.
DR   CORUM; Q99623; -.
DR   IntAct; Q99623; 120.
DR   MINT; Q99623; -.
DR   STRING; 9606.ENSP00000441875; -.
DR   ChEMBL; CHEMBL4295931; -.
DR   DrugBank; DB06774; Capsaicin.
DR   DrugBank; DB15496; Didesmethylrocaglamide.
DR   DrugBank; DB15495; Rocaglamide.
DR   CarbonylDB; Q99623; -.
DR   iPTMnet; Q99623; -.
DR   MetOSite; Q99623; -.
DR   PhosphoSitePlus; Q99623; -.
DR   SwissPalm; Q99623; -.
DR   BioMuta; PHB2; -.
DR   DMDM; 74752151; -.
DR   OGP; Q99623; -.
DR   EPD; Q99623; -.
DR   jPOST; Q99623; -.
DR   MassIVE; Q99623; -.
DR   MaxQB; Q99623; -.
DR   PaxDb; Q99623; -.
DR   PeptideAtlas; Q99623; -.
DR   PRIDE; Q99623; -.
DR   ProteomicsDB; 4765; -.
DR   ProteomicsDB; 78364; -. [Q99623-1]
DR   TopDownProteomics; Q99623-1; -. [Q99623-1]
DR   TopDownProteomics; Q99623-2; -. [Q99623-2]
DR   Antibodypedia; 4444; 449 antibodies.
DR   DNASU; 11331; -.
DR   Ensembl; ENST00000440277; ENSP00000412856; ENSG00000215021. [Q99623-2]
DR   Ensembl; ENST00000535923; ENSP00000441875; ENSG00000215021. [Q99623-1]
DR   GeneID; 11331; -.
DR   KEGG; hsa:11331; -.
DR   UCSC; uc058kpb.1; human. [Q99623-1]
DR   CTD; 11331; -.
DR   DisGeNET; 11331; -.
DR   EuPathDB; HostDB:ENSG00000215021.8; -.
DR   GeneCards; PHB2; -.
DR   HGNC; HGNC:30306; PHB2.
DR   HPA; ENSG00000215021; Low tissue specificity.
DR   MIM; 610704; gene.
DR   neXtProt; NX_Q99623; -.
DR   OpenTargets; ENSG00000215021; -.
DR   PharmGKB; PA142671181; -.
DR   eggNOG; KOG3090; Eukaryota.
DR   GeneTree; ENSGT00950000183070; -.
DR   InParanoid; Q99623; -.
DR   KO; K17081; -.
DR   OMA; RASRFNI; -.
DR   OrthoDB; 1089994at2759; -.
DR   PhylomeDB; Q99623; -.
DR   TreeFam; TF354230; -.
DR   PathwayCommons; Q99623; -.
DR   Reactome; R-HSA-8949664; Processing of SMDT1.
DR   SIGNOR; Q99623; -.
DR   BioGRID-ORCS; 11331; 762 hits in 880 CRISPR screens.
DR   ChiTaRS; PHB2; human.
DR   GeneWiki; PHB2; -.
DR   GenomeRNAi; 11331; -.
DR   Pharos; Q99623; Tbio.
DR   PRO; PR:Q99623; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q99623; protein.
DR   Bgee; ENSG00000215021; Expressed in caecum and 244 other tissues.
DR   ExpressionAtlas; Q99623; baseline and differential.
DR   Genevisible; Q99623; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0071944; C:cell periphery; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:UniProtKB.
DR   GO; GO:0035632; C:mitochondrial prohibitin complex; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0048786; C:presynaptic active zone; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0033218; F:amide binding; IPI:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; NAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046625; F:sphingolipid binding; IDA:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; ISS:UniProtKB.
DR   GO; GO:1990051; P:activation of protein kinase C activity; ISS:UniProtKB.
DR   GO; GO:0140374; P:antiviral innate immune response; IDA:UniProtKB.
DR   GO; GO:0042113; P:B cell activation; ISS:UniProtKB.
DR   GO; GO:0023035; P:CD40 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0002377; P:immunoglobulin production; ISS:UniProtKB.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IMP:UniProtKB.
DR   GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl.
DR   GO; GO:0060744; P:mammary gland branching involved in thelarche; IEA:Ensembl.
DR   GO; GO:0006851; P:mitochondrial calcium ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0007005; P:mitochondrion organization; IMP:UniProtKB.
DR   GO; GO:0000423; P:mitophagy; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0033600; P:negative regulation of mammary gland epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:1902808; P:positive regulation of cell cycle G1/S phase transition; IMP:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0031536; P:positive regulation of exit from mitosis; IMP:UniProtKB.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0006606; P:protein import into nucleus; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:UniProtKB.
DR   GO; GO:0060762; P:regulation of branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:1900208; P:regulation of cardiolipin metabolic process; ISS:UniProtKB.
DR   GO; GO:1904959; P:regulation of cytochrome-c oxidase activity; IMP:UniProtKB.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0039529; P:RIG-I signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007062; P:sister chromatid cohesion; IDA:UniProtKB.
DR   CDD; cd03401; SPFH_prohibitin; 1.
DR   InterPro; IPR001107; Band_7.
DR   InterPro; IPR036013; Band_7/SPFH_dom_sf.
DR   InterPro; IPR000163; Prohibitin.
DR   PANTHER; PTHR23222; PTHR23222; 1.
DR   Pfam; PF01145; Band_7; 1.
DR   PRINTS; PR00679; PROHIBITIN.
DR   SMART; SM00244; PHB; 1.
DR   SUPFAM; SSF117892; SSF117892; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell membrane;
KW   Coiled coil; Cytoplasm; Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Nucleus; Phosphoprotein; Receptor;
KW   Reference proteome; Repressor; Transcription; Transcription regulation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:22814378, ECO:0000269|Ref.8"
FT   CHAIN           2..299
FT                   /note="Prohibitin-2"
FT                   /id="PRO_0000213884"
FT   REGION          19..49
FT                   /note="Necessary for transcriptional repression"
FT                   /evidence="ECO:0000269|PubMed:10359819"
FT   REGION          121..124
FT                   /note="LC3-interaction region"
FT                   /evidence="ECO:0000269|PubMed:28017329"
FT   REGION          150..174
FT                   /note="Necessary for transcriptional repression"
FT                   /evidence="ECO:0000269|PubMed:10359819"
FT   COILED          190..238
FT                   /evidence="ECO:0000244|PDB:6IQE,
FT                   ECO:0000269|PubMed:28017329"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:22814378, ECO:0000269|Ref.8"
FT   MOD_RES         128
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000244|PubMed:15592455"
FT   MOD_RES         147
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O35129"
FT   MOD_RES         151
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         200
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O35129"
FT   MOD_RES         236
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O35129"
FT   MOD_RES         250
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         262
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O35129"
FT   VAR_SEQ         203..240
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045311"
FT   MUTAGEN         77
FT                   /note="Y->K: No effect on interaction wiht MAP1LC3B."
FT                   /evidence="ECO:0000269|PubMed:28017329"
FT   MUTAGEN         121..124
FT                   /note="YQRL->AQRA: Abolishes interaction with MAP1LC3B. No
FT                   effect on interaction with PHB. No effect on mitochondrial
FT                   location. Abolishes rescue of Parkin-mediated mitophagy."
FT                   /evidence="ECO:0000269|PubMed:28017329"
FT   MUTAGEN         175..178
FT                   /note="FSLI->ASLA: Decreases interaction with MAP1LC3B."
FT                   /evidence="ECO:0000269|PubMed:28017329"
FT   MUTAGEN         225
FT                   /note="I->P: Reduces helicity. Decreases homodimerization
FT                   and interaction with PHB. Disrupts mitochondrial dynamics.
FT                   Disrupts mitochondrial-mediated antiviral innate immune
FT                   response."
FT                   /evidence="ECO:0000269|PubMed:31522117"
FT   MUTAGEN         229..233
FT                   /note="EGEAE->KGKAK: No effect on homodimerization or
FT                   interaction with PHB. Decreases mitochondrial dynamics.
FT                   Disrupts mitochondrial-mediated antiviral innate immune
FT                   response."
FT                   /evidence="ECO:0000269|PubMed:31522117"
FT   HELIX           188..244
FT                   /evidence="ECO:0000244|PDB:6IQE"
SQ   SEQUENCE   299 AA;  33296 MW;  A887CC982BF85C80 CRC64;
     MAQNLKDLAG RLPAGPRGMG TALKLLLGAG AVAYGVRESV FTVEGGHRAI FFNRIGGVQQ
     DTILAEGLHF RIPWFQYPII YDIRARPRKI SSPTGSKDLQ MVNISLRVLS RPNAQELPSM
     YQRLGLDYEE RVLPSIVNEV LKSVVAKFNA SQLITQRAQV SLLIRRELTE RAKDFSLILD
     DVAITELSFS REYTAAVEAK QVAQQEAQRA QFLVEKAKQE QRQKIVQAEG EAEAAKMLGE
     ALSKNPGYIK LRKIRAAQNI SKTIATSQNR IYLTADNLVL NLQDESFTRG SDSLIKGKK
//
ID   ACE2_HUMAN              Reviewed;         805 AA.
AC   Q9BYF1; C7ECU1; Q6UWP0; Q86WT0; Q9NRA7; Q9UFZ6;
DT   02-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   02-AUG-2005, sequence version 2.
DT   12-AUG-2020, entry version 181.
DE   RecName: Full=Angiotensin-converting enzyme 2;
DE            EC=3.4.17.23 {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:11815627, ECO:0000269|PubMed:19021774};
DE   AltName: Full=Angiotensin-converting enzyme homolog {ECO:0000303|PubMed:10924499};
DE            Short=ACEH {ECO:0000303|PubMed:10924499};
DE   AltName: Full=Angiotensin-converting enzyme-related carboxypeptidase {ECO:0000303|PubMed:10969042};
DE            Short=ACE-related carboxypeptidase;
DE            EC=3.4.17.- {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:10969042, ECO:0000269|PubMed:11815627, ECO:0000269|PubMed:19021774, ECO:0000269|PubMed:27217402, ECO:0000269|PubMed:28293165};
DE   AltName: Full=Metalloprotease MPROT15 {ECO:0000303|Ref.6};
DE   Contains:
DE     RecName: Full=Processed angiotensin-converting enzyme 2 {ECO:0000303|PubMed:24227843};
DE   Flags: Precursor;
GN   Name=ACE2 {ECO:0000312|HGNC:HGNC:13557}; ORFNames=UNQ868/PRO1885;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, FUNCTION, ACTIVITY
RP   REGULATION, CATALYTIC ACTIVITY, AND SUBSTRATE SPECIFICITY.
RC   TISSUE=Heart;
RX   PubMed=10969042; DOI=10.1161/01.res.87.5.e1;
RA   Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N.,
RA   Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S.;
RT   "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2)
RT   converts angiotensin I to angiotensin 1-9.";
RL   Circ. Res. 87:E1-E9(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, GLYCOSYLATION, FUNCTION,
RP   ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RC   TISSUE=Lymphoma;
RX   PubMed=10924499; DOI=10.1074/jbc.m002615200;
RA   Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J.;
RT   "A human homolog of angiotensin-converting enzyme. Cloning and functional
RT   expression as a captopril-insensitive carboxypeptidase.";
RL   J. Biol. Chem. 275:33238-33243(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=15231706; DOI=10.1210/en.2004-0443;
RA   Douglas G.C., O'Bryan M.K., Hedger M.P., Lee D.K.L., Yarski M.A.,
RA   Smith A.I., Lew R.A.;
RT   "The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is
RT   selectively expressed by adult Leydig cells of the testis.";
RL   Endocrinology 145:4703-4711(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-638.
RC   TISSUE=Lung, and Testis;
RX   PubMed=15937940; DOI=10.1002/ajmg.a.30779;
RA   Itoyama S., Keicho N., Hijikata M., Quy T., Phi N.C., Long H.T., Ha L.D.,
RA   Ban V.V., Matsushita I., Yanai H., Kirikae F., Kirikae T., Kuratsuji T.,
RA   Sasazuki T.;
RT   "Identification of an alternative 5'-untranslated exon and new
RT   polymorphisms of angiotensin-converting enzyme 2 gene: lack of association
RT   with SARS in the Vietnamese population.";
RL   Am. J. Med. Genet. A 136:52-57(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Suzuki Y., Watanabe M., Sugano S.;
RT   "Cloning, expression analysis and chromosomal localization of a novel ACE
RT   like enzyme.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Southan C., Burgess N.;
RT   "MPROT15 polypeptide and MPROT15 polynucleotide.";
RL   Patent number CA2248987, 13-NOV-1999.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Li K.K.B., Yip C.W., Hon C.C., Lam C.Y., Leung F.C.C.;
RT   "Comparative susceptibility to SARS-CoV mediated by ACE2 protein of 15
RT   different species.";
RL   Submitted (JUN-2009) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-26.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-805.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [13]
RP   PROTEIN SEQUENCE OF 679-689, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   INTERACTION WITH ITGB1.
RX   PubMed=15276642; DOI=10.1016/j.bbadis.2004.05.005;
RA   Lin Q., Keller R.S., Weaver B., Zisman L.S.;
RT   "Interaction of ACE2 and integrin beta1 in failing human heart.";
RL   Biochim. Biophys. Acta 1689:175-178(2004).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=12459472; DOI=10.1016/s0014-5793(02)03640-2;
RA   Harmer D., Gilbert M., Borman R., Clark K.L.;
RT   "Quantitative mRNA expression profiling of ACE 2, a novel homologue of
RT   angiotensin converting enzyme.";
RL   FEBS Lett. 532:107-110(2002).
RN   [15]
RP   ACTIVITY REGULATION.
RX   PubMed=12358520; DOI=10.1021/ja0277226;
RA   Dales N.A., Gould A.E., Brown J.A., Calderwood E.F., Guan B., Minor C.A.,
RA   Gavin J.M., Hales P., Kaushik V.K., Stewart M., Tummino P.J., Vickers C.S.,
RA   Ocain T.D., Patane M.A.;
RT   "Substrate-based design of the first class of angiotensin-converting
RT   enzyme-related carboxypeptidase (ACE2) inhibitors.";
RL   J. Am. Chem. Soc. 124:11852-11853(2002).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE
RP   SPECIFICITY, ACTIVITY REGULATION, AND COFACTOR.
RX   PubMed=11815627; DOI=10.1074/jbc.m200581200;
RA   Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K.,
RA   Parsons T., Baronas E., Hsieh F., Acton S., Patane M.A., Nichols A.,
RA   Tummino P.;
RT   "Hydrolysis of biological peptides by human angiotensin-converting enzyme-
RT   related carboxypeptidase.";
RL   J. Biol. Chem. 277:14838-14843(2002).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INDUCTION.
RX   PubMed=14504186; DOI=10.1161/01.cir.0000094734.67990.99;
RA   Zisman L.S., Keller R.S., Weaver B., Lin Q., Speth R., Bristow M.R.,
RA   Canver C.C.;
RT   "Increased angiotensin-(1-7)-forming activity in failing human heart
RT   ventricles: evidence for upregulation of the angiotensin-converting enzyme
RT   Homologue ACE2.";
RL   Circulation 108:1707-1712(2003).
RN   [18]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN (MICROBIAL INFECTION), GLYCOSYLATION, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=14647384; DOI=10.1038/nature02145;
RA   Li W., Moore M.J., Vasilieva N., Sui J., Wong S.-K., Berne M.A.,
RA   Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H.,
RA   Farzan M.;
RT   "Angiotensin-converting enzyme 2 is a functional receptor for the SARS
RT   coronavirus.";
RL   Nature 426:450-454(2003).
RN   [19]
RP   INDUCTION.
RX   PubMed=15151696; DOI=10.1186/1741-7015-2-19;
RA   Goulter A.B., Goddard M.J., Allen J.C., Clark K.L.;
RT   "ACE2 gene expression is up-regulated in the human failing heart.";
RL   BMC Med. 2:19-19(2004).
RN   [20]
RP   TISSUE SPECIFICITY.
RX   PubMed=15141377; DOI=10.1002/path.1570;
RA   Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J., van Goor H.;
RT   "Tissue distribution of ACE2 protein, the functional receptor for SARS
RT   coronavirus. A first step in understanding SARS pathogenesis.";
RL   J. Pathol. 203:631-637(2004).
RN   [21]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=15452268; DOI=10.1128/jvi.78.20.11429-11433.2004;
RA   Li W., Greenough T.C., Moore M.J., Vasilieva N., Somasundaran M.,
RA   Sullivan J.L., Farzan M., Choe H.;
RT   "Efficient replication of severe acute respiratory syndrome coronavirus in
RT   mouse cells is limited by murine angiotensin-converting enzyme 2.";
RL   J. Virol. 78:11429-11433(2004).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-90.
RC   TISSUE=Bile;
RX   PubMed=15084671; DOI=10.1074/mcp.m400015-mcp200;
RA   Kristiansen T.Z., Bunkenborg J., Gronborg M., Molina H., Thuluvath P.J.,
RA   Argani P., Goggins M.G., Maitra A., Pandey A.;
RT   "A proteomic analysis of human bile.";
RL   Mol. Cell. Proteomics 3:715-728(2004).
RN   [23]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=15671045; DOI=10.1093/eurheartj/ehi114;
RA   Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S., Lu S.,
RA   Tikellis C., Grant S.L., Lew R.A., Smith A.I., Cooper M.E., Johnston C.I.;
RT   "Myocardial infarction increases ACE2 expression in rat and humans.";
RL   Eur. Heart J. 26:369-375(2005).
RN   [24]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN (MICROBIAL INFECTION), AND MUTAGENESIS.
RX   PubMed=15791205; DOI=10.1038/sj.emboj.7600640;
RA   Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., Wong S.-K.,
RA   Huang I.-C., Xu K., Vasilieva N., Murakami A., He Y., Marasco W.A.,
RA   Guan Y., Choe H., Farzan M.;
RT   "Receptor and viral determinants of SARS-coronavirus adaptation to human
RT   ACE2.";
RL   EMBO J. 24:1634-1643(2005).
RN   [25]
RP   PROTEOLYTIC CLEAVAGE, AND SUBCELLULAR LOCATION.
RX   PubMed=15983030; DOI=10.1074/jbc.m505111200;
RA   Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T.,
RA   Smith A.I., Hooper N.M., Turner A.J.;
RT   "Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated
RT   ectodomain shedding of the severe-acute respiratory syndrome-coronavirus
RT   (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2).";
RL   J. Biol. Chem. 280:30113-30119(2005).
RN   [26]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HCOV-NL63 SPIKE
RP   GLYCOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=15897467; DOI=10.1073/pnas.0409465102;
RA   Hofmann H., Pyrc K., van der Hoek L., Geier M., Berkhout B., Poehlmann S.;
RT   "Human coronavirus NL63 employs the severe acute respiratory syndrome
RT   coronavirus receptor for cellular entry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:7988-7993(2005).
RN   [27]
RP   FUNCTION, ACTIVE SITE, AND MUTAGENESIS OF ARG-273; HIS-345 AND HIS-505.
RX   PubMed=16008552; DOI=10.1111/j.1742-4658.2005.04756.x;
RA   Guy J.L., Jackson R.M., Jensen H.A., Hooper N.M., Turner A.J.;
RT   "Identification of critical active-site residues in angiotensin-converting
RT   enzyme-2 (ACE2) by site-directed mutagenesis.";
RL   FEBS J. 272:3512-3520(2005).
RN   [28]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY
RP   REGULATION, AND MUTAGENESIS OF ARG-169; TRP-271; LYS-481 AND ARG-514.
RX   PubMed=19021774; DOI=10.1111/j.1742-4658.2008.06733.x;
RA   Rushworth C.A., Guy J.L., Turner A.J.;
RT   "Residues affecting the chloride regulation and substrate selectivity of
RT   the angiotensin-converting enzymes (ACE and ACE2) identified by site-
RT   directed mutagenesis.";
RL   FEBS J. 275:6033-6042(2008).
RN   [29]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18424768; DOI=10.1096/fj.08-107300;
RA   Kowalczuk S., Broeer A., Tietze N., Vanslambrouck J.M., Rasko J.E.,
RA   Broeer S.;
RT   "A protein complex in the brush-border membrane explains a Hartnup disorder
RT   allele.";
RL   FASEB J. 22:2880-2887(2008).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-546.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [31]
RP   FUNCTION, AND MUTAGENESIS OF ARG-273.
RX   PubMed=19185582; DOI=10.1053/j.gastro.2008.10.055;
RA   Camargo S.M., Singer D., Makrides V., Huggel K., Pos K.M., Wagner C.A.,
RA   Kuba K., Danilczyk U., Skovby F., Kleta R., Penninger J.M., Verrey F.;
RT   "Tissue-specific amino acid transporter partners ACE2 and collectrin
RT   differentially interact with hartnup mutations.";
RL   Gastroenterology 136:872-882(2009).
RN   [32]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=21563828; DOI=10.1021/bi200525y;
RA   Lai Z.W., Hanchapola I., Steer D.L., Smith A.I.;
RT   "Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site
RT   identification: determinants and constraints.";
RL   Biochemistry 50:5182-5194(2011).
RN   [33]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC CLEAVAGE, AND INTERACTION WITH TMPRSS2.
RX   PubMed=21068237; DOI=10.1128/jvi.02062-10;
RA   Shulla A., Heald-Sargent T., Subramanya G., Zhao J., Perlman S.,
RA   Gallagher T.;
RT   "A transmembrane serine protease is linked to the severe acute respiratory
RT   syndrome coronavirus receptor and activates virus entry.";
RL   J. Virol. 85:873-882(2011).
RN   [34]
RP   FUNCTION (MICROBIAL INFECTION), SUBCELLULAR LOCATION, AND PROTEOLYTIC
RP   CLEAVAGE.
RX   PubMed=24227843; DOI=10.1128/jvi.02202-13;
RA   Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O.,
RA   Poehlmann S.;
RT   "TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by
RT   TMPRSS2 augments entry driven by the severe acute respiratory syndrome
RT   coronavirus spike protein.";
RL   J. Virol. 88:1293-1307(2014).
RN   [35]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, 3D-STRUCTURE
RP   MODELING, AND ACTIVE SITE.
RX   PubMed=27217402; DOI=10.1161/hypertensionaha.115.06892;
RA   Wang W., McKinnie S.M., Farhan M., Paul M., McDonald T., McLean B.,
RA   Llorens-Cortes C., Hazra S., Murray A.G., Vederas J.C., Oudit G.Y.;
RT   "Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-
RT   Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular
RT   System.";
RL   Hypertension 68:365-377(2016).
RN   [36]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=28293165; DOI=10.3389/fnins.2017.00092;
RA   Yang P., Kuc R.E., Brame A.L., Dyson A., Singer M., Glen R.C., Cheriyan J.,
RA   Wilkinson I.B., Davenport A.P., Maguire J.J.;
RT   "[Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the
RT   Endogenous Cardiovascular Peptide [Pyr1]Apelin-13.";
RL   Front. Neurosci. 11:92-92(2017).
RN   [37]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor.";
RL   Cell 181:1-10(2020).
RN   [38]
RP   INTERACTION WITH SARS-COV-2 SPIKE GLYCOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.";
RL   Science 367:1260-1263(2020).
RN   [39]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH SARS-COV-2 SPIKE
RP   GLYCOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   "Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein.";
RL   Cell 180:1-12(2020).
RN   [40]
RP   TISSUE SPECIFICITY, AND INDUCTION BY ISR.
RX   DOI=10.1016/j.cell.2020.04.035;
RA   Ziegler C.G.K., Allon S.J., Nyquist S.K., Mbano I.M., Miao V.N.,
RA   Tzouanas C.N., Cao Y., Yousif A.S., Bals J., Hauser B.M., Feldman J.,
RA   Muus C., Wadsworth M.H., Kazer S.W., Hughes T.K., Doran B., Gatter G.J.,
RA   Vukovic M., Taliaferro F., Mead B.E., Guo Z., Wang J.P., Gras D.,
RA   Plaisant M., Ansari M., Angelidis I., Adler H., Sucre J.M.S., Taylor C.J.,
RA   Lin B., Waghray A., Mitsialis V., Dwyer D.F., Buchheit K.M., Boyce J.A.,
RA   Barrett N.A., Laidlaw T.M., Carroll S.L., Colonna L., Tkachev V.,
RA   Peterson C.W., Yu A., Zheng H.B., Gideon H.P., Winchell C.G., Lin P.L.,
RA   Bingle C.D., Snapper S.B., Kropski J.A., Theis F.J., Schiller H.B.,
RA   Zaragosi L.E., Barbry P., Leslie A., Kiem H.P., Flynn J.L., Fortune S.M.,
RA   Berger B., Finberg R.W., Kean L.S., Garber M., Schmidt A.G., Lingwood D.,
RA   Shalek A.K., Ordovas-Montanes J.;
RT   "SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway
RT   epithelial cells and is detected in specific cell subsets across tissues.";
RL   Cell 0:0-0(2020).
RN   [41]
RP   TISSUE SPECIFICITY, AND INDUCTION BY CIGARETTE SMOKE.
RX   PubMed=32425701; DOI=10.1016/j.devcel.2020.05.012;
RA   Smith J.C., Sausville E.L., Girish V., Yuan M.L., Vasudevan A., John K.M.,
RA   Sheltzer J.M.;
RT   "Cigarette smoke exposure and inflammatory signaling increase the
RT   expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract.";
RL   Dev. Cell 0:0-0(2020).
RN   [42]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV.";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [43]
RP   TISSUE SPECIFICITY.
RX   PubMed=32327758; DOI=10.1038/s41591-020-0868-6;
RG   HCA Lung Biological Network;
RA   Sungnak W., Huang N., Becavin C., Berg M., Queen R., Litvinukova M.,
RA   Talavera-Lopez C., Maatz H., Reichart D., Sampaziotis F., Worlock K.B.,
RA   Yoshida M., Barnes J.L.;
RT   "SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells
RT   together with innate immune genes.";
RL   Nat. Med. 0:0-0(2020).
RN   [44]
RP   TISSUE SPECIFICITY.
RX   PubMed=32358202; DOI=10.1126/science.abc1669;
RA   Lamers M.M., Beumer J., van der Vaart J., Knoops K., Puschhof J.,
RA   Breugem T.I., Ravelli R.B.G., Paul van Schayck J., Mykytyn A.Z.,
RA   Duimel H.Q., van Donselaar E., Riesebosch S., Kuijpers H.J.H.,
RA   Schippers D., van de Wetering W.J., de Graaf M., Koopmans M., Cuppen E.,
RA   Peters P.J., Haagmans B.L., Clevers H.;
RT   "SARS-CoV-2 productively infects human gut enterocytes.";
RL   Science 0:0-0(2020).
RN   [45] {ECO:0000244|PDB:1R42, ECO:0000244|PDB:1R4L}
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-615 IN COMPLEXES WITH ZINC;
RP   CHLORIDE AND MLN-4760 INHIBITOR, DOMAIN, REACTION MECHANISM, ACTIVE SITE,
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-53; ASN-90; ASN-103; ASN-322;
RP   ASN-432 AND ASN-546.
RX   PubMed=14754895; DOI=10.1074/jbc.m311191200;
RA   Towler P., Staker B., Prasad S.G., Menon S., Tang J., Parsons T., Ryan D.,
RA   Fisher M., Williams D., Dales N.A., Patane M.A., Pantoliano M.W.;
RT   "ACE2 X-ray structures reveal a large hinge-bending motion important for
RT   inhibitor binding and catalysis.";
RL   J. Biol. Chem. 279:17996-18007(2004).
RN   [46] {ECO:0000244|PDB:2AJF}
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 19-615 IN COMPLEX WITH ZINC, AND
RP   GLYCOSYLATION AT ASN-53; ASN-90; ASN-322 AND ASN-546.
RX   PubMed=16166518; DOI=10.1126/science.1116480;
RA   Li F., Li W., Farzan M., Harrison S.C.;
RT   "Structure of SARS coronavirus spike receptor-binding domain complexed with
RT   receptor.";
RL   Science 309:1864-1868(2005).
RN   [47] {ECO:0000244|PDB:6ACG, ECO:0000244|PDB:6ACJ, ECO:0000244|PDB:6ACK}
RP   STRUCTURE BY ELECTRON MICROSCOPY (4.20 ANGSTROMS) OF 19-615.
RX   PubMed=30102747; DOI=10.1371/journal.ppat.1007236;
RA   Song W., Gui M., Wang X., Xiang Y.;
RT   "Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex
RT   with its host cell receptor ACE2.";
RL   PLoS Pathog. 14:e1007236-e1007236(2018).
RN   [48] {ECO:0000244|PDB:6CS2}
RP   STRUCTURE BY ELECTRON MICROSCOPY (4.40 ANGSTROMS) OF 19-615.
RX   PubMed=30356097; DOI=10.1038/s41598-018-34171-7;
RA   Kirchdoerfer R.N., Wang N., Pallesen J., Wrapp D., Turner H.L.,
RA   Cottrell C.A., Corbett K.S., Graham B.S., McLellan J.S., Ward A.B.;
RT   "Stabilized coronavirus spikes are resistant to conformational changes
RT   induced by receptor recognition or proteolysis.";
RL   Sci. Rep. 8:15701-15701(2018).
RN   [49] {ECO:0000244|PDB:6M0J}
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 19-615 IN COMPLEX WITH SARS-COV-2
RP   SPIKE GLYCOPROTEIN.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor.";
RL   Nature 0:0-0(2020).
RN   [50] {ECO:0000244|PDB:6VW1}
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF 19-615 AND IN COMPLEX WITH
RP   SARS-COV-2 SPIKE GLYCOPROTEIN, INTERACTION WITH SARS-COV-2 SPIKE
RP   GLYCOPROTEIN (MICROBIAL INFECTION), INTERACTION WITH SARS-COV SPIKE
RP   GLYCOPROTEIN (MICROBIAL INFECTION), AND FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   "Structural basis of receptor recognition by SARS-CoV-2.";
RL   Nature 0:0-0(2020).
RN   [51] {ECO:0000244|PDB:6M17, ECO:0000244|PDB:6M18, ECO:0000244|PDB:6M1D}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS) OF 18-805, INTERACTION
RP   WITH SARS-COV-2 SPIKE GLYCOPROTEIN (MICROBIAL INFECTION), INTERACTION WITH
RP   SLC6A19, SUBUNIT, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   "Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2.";
RL   Science 0:0-0(2020).
RN   [52]
RP   VARIANTS ARG-26; VAL-468; SER-638 AND ASP-720.
RX   PubMed=32558308; DOI=10.1002/mgg3.1344;
RA   Li Q., Cao Z., Rahman P.;
RT   "Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among
RT   various ethnic populations.";
RL   Mol. Genet. Genomic Med. 0:0-0(2020).
CC   -!- FUNCTION: Essential counter-regulatory carboxypeptidase of the renin-
CC       angiotensin hormone system that is a critical regulator of blood
CC       volume, systemic vascular resistance, and thus cardiovascular
CC       homeostasis (PubMed:27217402). Converts angiotensin I to angiotensin 1-
CC       9, a nine-amino acid peptide with anti-hypertrophic effects in
CC       cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts
CC       as a beneficial vasodilator and anti-proliferation agent,
CC       counterbalancing the actions of the vasoconstrictor angiotensin II
CC       (PubMed:10969042, PubMed:10924499, PubMed:11815627, PubMed:19021774,
CC       PubMed:14504186). Also removes the C-terminal residue from three other
CC       vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin,
CC       but is not active on bradykinin (PubMed:10969042, PubMed:11815627).
CC       Also cleaves other biological peptides, such as apelins (apelin-13,
CC       [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin-
CC       7, neocasomorphin) and dynorphin A with high efficiency
CC       (PubMed:11815627, PubMed:27217402, PubMed:28293165). In addition, ACE2
CC       C-terminus is homologous to collectrin and is responsible for the
CC       trafficking of the neutral amino acid transporter SL6A19 to the plasma
CC       membrane of gut epithelial cells via direct interaction, regulating its
CC       expression on the cell surface and its catalytic activity
CC       (PubMed:18424768, PubMed:19185582). {ECO:0000269|PubMed:10924499,
CC       ECO:0000269|PubMed:10969042, ECO:0000269|PubMed:11815627,
CC       ECO:0000269|PubMed:14504186, ECO:0000269|PubMed:18424768,
CC       ECO:0000269|PubMed:19021774, ECO:0000269|PubMed:19185582,
CC       ECO:0000269|PubMed:27217402}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for human
CC       coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus
CC       NL63/HCoV-NL63. {ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:15452268, ECO:0000269|PubMed:15791205,
CC       ECO:0000269|PubMed:15897467, ECO:0000269|PubMed:24227843,
CC       ECO:0000269|PubMed:32142651, ECO:0000269|PubMed:32155444,
CC       ECO:0000269|PubMed:32221306, ECO:0000269|PubMed:32225175}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=angiotensin II + H2O = angiotensin-(1-7) + L-phenylalanine;
CC         Xref=Rhea:RHEA:26554, ChEBI:CHEBI:15377, ChEBI:CHEBI:58095,
CC         ChEBI:CHEBI:58506, ChEBI:CHEBI:58922; EC=3.4.17.23;
CC         Evidence={ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:11815627,
CC         ECO:0000269|PubMed:19021774, ECO:0000305|PubMed:14504186};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:26555;
CC         Evidence={ECO:0000269|PubMed:14504186};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=angiotensin I + H2O = angiotensin-(1-9) + L-leucine;
CC         Xref=Rhea:RHEA:63532, ChEBI:CHEBI:15377, ChEBI:CHEBI:57427,
CC         ChEBI:CHEBI:147350, ChEBI:CHEBI:147351;
CC         Evidence={ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:10969042,
CC         ECO:0000269|PubMed:11815627, ECO:0000269|PubMed:19021774};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63533;
CC         Evidence={ECO:0000305|PubMed:10924499, ECO:0000305|PubMed:10969042,
CC         ECO:0000305|PubMed:11815627, ECO:0000305|PubMed:19021774};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[des-Arg(9)]-bradykinin + H2O = [des-Phe(8), des-Arg(9)]-
CC         bradykinin + L-phenylalanine; Xref=Rhea:RHEA:63536,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:58095, ChEBI:CHEBI:133069,
CC         ChEBI:CHEBI:147352; Evidence={ECO:0000269|PubMed:10969042,
CC         ECO:0000269|PubMed:11815627};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63537;
CC         Evidence={ECO:0000305|PubMed:10969042, ECO:0000305|PubMed:11815627};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + neurotensin = L-leucine + neurotensin-(1-12);
CC         Xref=Rhea:RHEA:63540, ChEBI:CHEBI:15377, ChEBI:CHEBI:57427,
CC         ChEBI:CHEBI:147362, ChEBI:CHEBI:147363;
CC         Evidence={ECO:0000269|PubMed:10969042};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63541;
CC         Evidence={ECO:0000305|PubMed:10969042};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + neurotensin-(1-8) = L-arginine + neurotensin-(1-7);
CC         Xref=Rhea:RHEA:63572, ChEBI:CHEBI:15377, ChEBI:CHEBI:32682,
CC         ChEBI:CHEBI:147393, ChEBI:CHEBI:147394;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63573;
CC         Evidence={ECO:0000305|PubMed:11815627};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + kinetensin = kinetensin-(1-8) + L-leucine;
CC         Xref=Rhea:RHEA:63544, ChEBI:CHEBI:15377, ChEBI:CHEBI:57427,
CC         ChEBI:CHEBI:147364, ChEBI:CHEBI:147365;
CC         Evidence={ECO:0000269|PubMed:10969042};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63545;
CC         Evidence={ECO:0000305|PubMed:10969042};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dynorphin A-(1-13) + H2O = dynorphin A-(1-12) + L-lysine;
CC         Xref=Rhea:RHEA:63556, ChEBI:CHEBI:15377, ChEBI:CHEBI:32551,
CC         ChEBI:CHEBI:147381, ChEBI:CHEBI:147383;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63557;
CC         Evidence={ECO:0000305|PubMed:11815627};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=apelin-13 + H2O = apelin-12 + L-phenylalanine;
CC         Xref=Rhea:RHEA:63564, ChEBI:CHEBI:15377, ChEBI:CHEBI:58095,
CC         ChEBI:CHEBI:147395, ChEBI:CHEBI:147396;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63565;
CC         Evidence={ECO:0000305|PubMed:11815627};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[Pyr1]apelin-13 + H2O = [Pyr1]apelin-12 + L-phenylalanine;
CC         Xref=Rhea:RHEA:63604, ChEBI:CHEBI:15377, ChEBI:CHEBI:58095,
CC         ChEBI:CHEBI:147415, ChEBI:CHEBI:147416;
CC         Evidence={ECO:0000269|PubMed:27217402, ECO:0000269|PubMed:28293165};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63605;
CC         Evidence={ECO:0000269|PubMed:27217402};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=apelin-17 + H2O = apelin-16 + L-phenylalanine;
CC         Xref=Rhea:RHEA:63608, ChEBI:CHEBI:15377, ChEBI:CHEBI:58095,
CC         ChEBI:CHEBI:147421, ChEBI:CHEBI:147422;
CC         Evidence={ECO:0000269|PubMed:27217402};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63609;
CC         Evidence={ECO:0000269|PubMed:27217402};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=beta-casomorphin-7 + H2O = beta-casomorphin-6 + L-isoleucine;
CC         Xref=Rhea:RHEA:63568, ChEBI:CHEBI:15377, ChEBI:CHEBI:58045,
CC         ChEBI:CHEBI:147390, ChEBI:CHEBI:147391;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63569;
CC         Evidence={ECO:0000305|PubMed:11815627};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + neocasomorphin = L-isoleucine + neocasomorphin-(1-5);
CC         Xref=Rhea:RHEA:63600, ChEBI:CHEBI:15377, ChEBI:CHEBI:58045,
CC         ChEBI:CHEBI:147417, ChEBI:CHEBI:147418;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63601;
CC         Evidence={ECO:0000305|PubMed:11815627};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:11815627};
CC   -!- COFACTOR:
CC       Name=chloride; Xref=ChEBI:CHEBI:17996;
CC         Evidence={ECO:0000269|PubMed:11815627};
CC       Note=Binds 1 Cl(-) ion per subunit. {ECO:0000269|PubMed:11815627};
CC   -!- ACTIVITY REGULATION: Regulated by chloride and fluoride, but not
CC       bromide (PubMed:11815627). Chloride increases angiotensin I and
CC       decreases angiotensin II cleavage (PubMed:19021774). Inhibited by MLN-
CC       4760, cFP_Leu, and EDTA (PubMed:15231706, PubMed:10924499), but not by
CC       the ACE inhibitors lisinopril, captopril and enalaprilat
CC       (PubMed:10969042, PubMed:10924499). Highly potent and selective in
CC       vitro ACE2 inhibitors were identified (PubMed:12358520).
CC       {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:10969042,
CC       ECO:0000269|PubMed:11815627, ECO:0000269|PubMed:12358520,
CC       ECO:0000269|PubMed:15231706, ECO:0000269|PubMed:19021774}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.9 uM for angiotensin I {ECO:0000269|PubMed:11815627};
CC         KM=2 uM for angiotensin II {ECO:0000269|PubMed:11815627};
CC         KM=6.8 uM for apelin-13 {ECO:0000269|PubMed:11815627};
CC         KM=290 uM for [des-Arg(9)]-bradykinin {ECO:0000269|PubMed:11815627};
CC         KM=130 uM for Lys-[des-Arg(9)]-bradykinin
CC         {ECO:0000269|PubMed:11815627};
CC         KM=31 uM for beta-casomorphin {ECO:0000269|PubMed:11815627};
CC         KM=5.5 uM for dynorphin A-(1-13) {ECO:0000269|PubMed:11815627};
CC         KM=300 uM for neurotensin-(1-8) {ECO:0000269|PubMed:11815627};
CC         KM=58.6 uM for angiotensin II {ECO:0000269|PubMed:19021774};
CC         KM=12 uM for [Pyr1]apelin-13 {ECO:0000269|PubMed:27217402};
CC         KM=19 uM for apelin-17 {ECO:0000269|PubMed:27217402};
CC         Vmax=28.7 nmol/min/mg enzyme with angiotensin II as substrate
CC         {ECO:0000269|PubMed:19021774};
CC         Note=kcat is 0.034 sec(-1) with angiotensin I as substrate. kcat is
CC         3.5 sec(-1) with angiotensin II as substrate. kcat is 13 sec(-1) with
CC         apelin-13 as substrate. kcat is 62 sec(-1) with
CC         [des-Arg(9)]-bradykinin as substrate. kcat is 26 sec(-1) with
CC         Lys-[des-Arg(9)]-bradykinin as substrate. kcat is 6.8 sec(-1) with
CC         beta-casomorphin as substrate. kcat is 16 sec(-1) with dynorphin
CC         A-(1-13) as substrate. kcat is 57 sec(-1) with neurotensin-(1-8) as
CC         substrate (PubMed:11815627). kcat is 19.1 sec(-1) with
CC         [Pyr1]apelin-13 as substrate. kcat is 7.7 sec(-1) with apelin-17 as
CC         substrate (PubMed:27217402). {ECO:0000269|PubMed:11815627,
CC         ECO:0000269|PubMed:27217402};
CC       pH dependence:
CC         Optimum pH is 6.5 in the presence of 1 M NaCl. Active from pH 6 to 9.
CC         {ECO:0000269|PubMed:11815627};
CC   -!- SUBUNIT: Homodimer (PubMed:32132184). Interacts with ITGB1
CC       (PubMed:15276642). Interacts with the catalytically active form of
CC       TMPRSS2 (PubMed:21068237). Interacts with SLC6A19; this interaction is
CC       essential for expression and function of SLC6A19 in intestine (By
CC       similarity). {ECO:0000250|UniProtKB:Q8R0I0,
CC       ECO:0000269|PubMed:15276642, ECO:0000269|PubMed:21068237,
CC       ECO:0000269|PubMed:32132184}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS coronavirus/SARS-CoV
CC       spike protein. {ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:15452268, ECO:0000269|PubMed:15791205,
CC       ECO:0000269|PubMed:32225175}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS coronavirus-2/SARS-
CC       CoV-2 spike protein. {ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32132184, ECO:0000269|PubMed:32155444,
CC       ECO:0000269|PubMed:32225175}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human coronavirus
CC       NL63/HCoV-NL63 spike glycoprotein. {ECO:0000269|PubMed:15897467}.
CC   -!- INTERACTION:
CC       Q9BYF1; PRO_0000032457 [P01019]: AGT; NbExp=2; IntAct=EBI-7730807, EBI-25493366;
CC       Q9BYF1; P05556: ITGB1; NbExp=4; IntAct=EBI-7730807, EBI-703066;
CC       Q9BYF1; PRO_0000006688 [P01042]: KNG1; NbExp=2; IntAct=EBI-7730807, EBI-6623273;
CC       Q9BYF1; PRO_0000019524 [P30990]: NTS; NbExp=2; IntAct=EBI-7730807, EBI-6655817;
CC       Q9BYF1; Q695T7: SLC6A19; NbExp=3; IntAct=EBI-7730807, EBI-25475705;
CC       Q9BYF1; O15393: TMPRSS2; NbExp=3; IntAct=EBI-7730807, EBI-12549863;
CC       Q9BYF1; P0DTC2: S; Xeno; NbExp=23; IntAct=EBI-7730807, EBI-25474821;
CC       Q9BYF1; P59594: S; Xeno; NbExp=29; IntAct=EBI-7730807, EBI-15582614;
CC       Q9BYF1; PRO_0000037209 [P59594]: S; Xeno; NbExp=3; IntAct=EBI-7730807, EBI-25475261;
CC       Q9BYF1; Q5GDB5: S; Xeno; NbExp=2; IntAct=EBI-7730807, EBI-25566398;
CC       Q9BYF1; Q6Q1S2: S; Xeno; NbExp=3; IntAct=EBI-7730807, EBI-15814420;
CC       Q9BYF1-1; P59594: S; Xeno; NbExp=2; IntAct=EBI-15814450, EBI-15582614;
CC       Q9BYF1-1; Q6Q1S2: S; Xeno; NbExp=3; IntAct=EBI-15814450, EBI-15814420;
CC   -!- SUBCELLULAR LOCATION: [Processed angiotensin-converting enzyme 2]:
CC       Secreted {ECO:0000269|PubMed:15983030}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18424768};
CC       Single-pass type I membrane protein {ECO:0000255}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q8R0I0}. Note=Detected in both cell membrane and
CC       cytoplasm in neurons. {ECO:0000250|UniProtKB:Q8R0I0}.
CC   -!- TISSUE SPECIFICITY: Expressed in endothelial cells from small and large
CC       arteries, and in arterial smooth muscle cells (at protein level)
CC       (PubMed:15141377). Expressed in lung alveolar epithelial cells,
CC       enterocytes of the small intestine, Leydig cells and Sertoli cells (at
CC       protein level) (PubMed:15141377). Expressed in the renal proximal
CC       tubule and the small intestine (at protein level) (PubMed:18424768).
CC       Expressed in heart, kidney, testis, and gastrointestinal system
CC       (PubMed:10969042, PubMed:10924499, PubMed:15231706, PubMed:12459472,
CC       PubMed:15671045). In lung, expressed at high levels in secretory club
CC       and goblet cells as well as in alveolar type 2 cells (PubMed:32425701).
CC       Coexpressed with TMPRSS2 within lung alveolar type 2 cells, ileal
CC       absorptive enterocytes, intestinal epithelial cells, cornea,
CC       gallbladder and nasal goblet secretory cells (Ref.40, PubMed:32327758,
CC       PubMed:32358202). {ECO:0000269|PubMed:10924499,
CC       ECO:0000269|PubMed:10969042, ECO:0000269|PubMed:12459472,
CC       ECO:0000269|PubMed:15141377, ECO:0000269|PubMed:15231706,
CC       ECO:0000269|PubMed:15671045, ECO:0000269|PubMed:18424768,
CC       ECO:0000269|PubMed:32327758, ECO:0000269|PubMed:32358202,
CC       ECO:0000269|PubMed:32425701, ECO:0000269|Ref.40}.
CC   -!- INDUCTION: Up-regulated in failing heart (PubMed:14504186,
CC       PubMed:15151696, PubMed:15671045). Expression is induced by IFNA and
CC       IFNG (Ref.40, PubMed:32425701). Exposure to cigarette smoke strongly
CC       increases expression in lungs (PubMed:32425701).
CC       {ECO:0000269|PubMed:14504186, ECO:0000269|PubMed:15151696,
CC       ECO:0000269|PubMed:15671045, ECO:0000269|PubMed:32425701,
CC       ECO:0000269|Ref.40}.
CC   -!- INDUCTION: (Microbial infection) In airway epithelial cells, expression
CC       is increased upon influenza A virus infection (Ref.40).
CC       {ECO:0000269|Ref.40}.
CC   -!- DOMAIN: The extracellular region of the ACE2 enzyme is composed of two
CC       domains. The first is a zinc metallopeptidase domain (residues 19-611).
CC       The second domain is located at the C-terminus (residues 612-740) and
CC       is 48% identical to human collectrin. {ECO:0000269|PubMed:14754895}.
CC   -!- PTM: N-glycosylation on Asn-90 may limit SARS infectivity.
CC       {ECO:0000269|PubMed:10924499, ECO:0000269|PubMed:14647384,
CC       ECO:0000269|PubMed:14754895, ECO:0000269|PubMed:15084671,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- PTM: Proteolytic cleavage by ADAM17 generates a secreted form
CC       (PubMed:15983030). Also cleaved by serine proteases: TMPRSS2, TMPRSS11D
CC       and HPN/TMPRSS1. {ECO:0000269|PubMed:15983030,
CC       ECO:0000269|PubMed:21068237, ECO:0000269|PubMed:21563828,
CC       ECO:0000269|PubMed:24227843, ECO:0000269|PubMed:32132184}.
CC   -!- SIMILARITY: Belongs to the peptidase M2 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ89076.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ace2/";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=A way in - Issue 223 of
CC       March 2020;
CC       URL="https://web.expasy.org/spotlight/back_issues/223/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF291820; AAF99721.1; -; mRNA.
DR   EMBL; AF241254; AAF78220.1; -; mRNA.
DR   EMBL; AY623811; AAT45083.1; -; mRNA.
DR   EMBL; AB193259; BAD99266.1; -; mRNA.
DR   EMBL; AB193260; BAD99267.1; -; mRNA.
DR   EMBL; AB046569; BAB40370.1; -; mRNA.
DR   EMBL; E39033; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; GQ262784; ACT66268.1; -; mRNA.
DR   EMBL; AY358714; AAQ89076.1; ALT_SEQ; mRNA.
DR   EMBL; AY217547; AAO25651.1; -; Genomic_DNA.
DR   EMBL; CH471074; EAW98892.1; -; Genomic_DNA.
DR   EMBL; BC039902; AAH39902.1; -; mRNA.
DR   EMBL; BC048094; AAH48094.2; -; mRNA.
DR   EMBL; AL110224; CAB53682.1; -; mRNA.
DR   CCDS; CCDS14169.1; -.
DR   PIR; T14762; T14762.
DR   RefSeq; NP_068576.1; NM_021804.2.
DR   PDB; 1R42; X-ray; 2.20 A; A=1-615.
DR   PDB; 1R4L; X-ray; 3.00 A; A=1-615.
DR   PDB; 1XJP; Model; -; B=19-615.
DR   PDB; 2AJF; X-ray; 2.90 A; A/B=19-615.
DR   PDB; 3D0G; X-ray; 2.80 A; A/B=56-615.
DR   PDB; 3D0H; X-ray; 3.10 A; A/B=56-615.
DR   PDB; 3D0I; X-ray; 2.90 A; A/B=56-615.
DR   PDB; 3KBH; X-ray; 3.31 A; A/B/C/D=19-615.
DR   PDB; 3SCI; X-ray; 2.90 A; A/B=19-615.
DR   PDB; 3SCJ; X-ray; 3.00 A; A/B=19-615.
DR   PDB; 3SCK; X-ray; 3.00 A; A/B=83-615.
DR   PDB; 3SCL; X-ray; 3.00 A; A/B=83-615.
DR   PDB; 6ACG; EM; 5.40 A; D=19-615.
DR   PDB; 6ACJ; EM; 4.20 A; D=19-615.
DR   PDB; 6ACK; EM; 4.50 A; D=19-615.
DR   PDB; 6CS2; EM; 4.40 A; D=19-615.
DR   PDB; 6LZG; X-ray; 2.50 A; A=19-614.
DR   PDB; 6M0J; X-ray; 2.45 A; A=19-615.
DR   PDB; 6M17; EM; 2.90 A; B/D=18-805.
DR   PDB; 6M18; EM; 2.90 A; B/D=18-805.
DR   PDB; 6M1D; EM; 4.50 A; B/D=18-805.
DR   PDB; 6VW1; X-ray; 2.68 A; A/B=19-615.
DR   PDBsum; 1R42; -.
DR   PDBsum; 1R4L; -.
DR   PDBsum; 1XJP; -.
DR   PDBsum; 2AJF; -.
DR   PDBsum; 3D0G; -.
DR   PDBsum; 3D0H; -.
DR   PDBsum; 3D0I; -.
DR   PDBsum; 3KBH; -.
DR   PDBsum; 3SCI; -.
DR   PDBsum; 3SCJ; -.
DR   PDBsum; 3SCK; -.
DR   PDBsum; 3SCL; -.
DR   PDBsum; 6ACG; -.
DR   PDBsum; 6ACJ; -.
DR   PDBsum; 6ACK; -.
DR   PDBsum; 6CS2; -.
DR   PDBsum; 6LZG; -.
DR   PDBsum; 6M0J; -.
DR   PDBsum; 6M17; -.
DR   PDBsum; 6M18; -.
DR   PDBsum; 6M1D; -.
DR   PDBsum; 6VW1; -.
DR   SMR; Q9BYF1; -.
DR   BioGRID; 121864; 12.
DR   ComplexPortal; CPX-5683; SARS-CoV-2 Spike - human ACE2 receptor complex.
DR   ComplexPortal; CPX-5684; SARS-CoV-2 Spike - human ACE2-SLC6A19 complex.
DR   ComplexPortal; CPX-5695; SARS-CoV Spike - human ACE2 receptor complex.
DR   DIP; DIP-44689N; -.
DR   IntAct; Q9BYF1; 20.
DR   MINT; Q9BYF1; -.
DR   STRING; 9606.ENSP00000389326; -.
DR   BindingDB; Q9BYF1; -.
DR   ChEMBL; CHEMBL3736; -.
DR   DrugBank; DB00608; Chloroquine.
DR   DrugBank; DB01611; Hydroxychloroquine.
DR   DrugBank; DB15643; N-(2-Aminoethyl)-1-aziridineethanamine.
DR   DrugBank; DB05203; SPP1148.
DR   GuidetoPHARMACOLOGY; 1614; -.
DR   MEROPS; M02.006; -.
DR   TCDB; 2.A.22.6.3; the neurotransmitter:sodium symporter (nss) family.
DR   GlyConnect; 1012; 4 N-Linked glycans (3 sites).
DR   GlyConnect; 2841; 134 N-Linked glycans (7 sites), 6 O-Linked glycans (56 sites).
DR   GlyGen; Q9BYF1; 7 sites.
DR   iPTMnet; Q9BYF1; -.
DR   PhosphoSitePlus; Q9BYF1; -.
DR   BioMuta; ACE2; -.
DR   DMDM; 71658783; -.
DR   jPOST; Q9BYF1; -.
DR   MassIVE; Q9BYF1; -.
DR   PaxDb; Q9BYF1; -.
DR   PeptideAtlas; Q9BYF1; -.
DR   PRIDE; Q9BYF1; -.
DR   ProteomicsDB; 79634; -.
DR   Antibodypedia; 344; 915 antibodies.
DR   Ensembl; ENST00000252519; ENSP00000252519; ENSG00000130234.
DR   Ensembl; ENST00000427411; ENSP00000389326; ENSG00000130234.
DR   GeneID; 59272; -.
DR   KEGG; hsa:59272; -.
DR   UCSC; uc004cxa.2; human.
DR   CTD; 59272; -.
DR   DisGeNET; 59272; -.
DR   EuPathDB; HostDB:ENSG00000130234.10; -.
DR   GeneCards; ACE2; -.
DR   HGNC; HGNC:13557; ACE2.
DR   HPA; ENSG00000130234; Tissue enriched (intestine).
DR   MIM; 300335; gene.
DR   neXtProt; NX_Q9BYF1; -.
DR   OpenTargets; ENSG00000130234; -.
DR   PharmGKB; PA425; -.
DR   eggNOG; KOG3690; Eukaryota.
DR   GeneTree; ENSGT00940000158077; -.
DR   HOGENOM; CLU_014364_3_0_1; -.
DR   InParanoid; Q9BYF1; -.
DR   KO; K09708; -.
DR   OMA; RWWEMKR; -.
DR   OrthoDB; 422699at2759; -.
DR   PhylomeDB; Q9BYF1; -.
DR   TreeFam; TF312861; -.
DR   BRENDA; 3.4.15.1; 2681.
DR   BRENDA; 3.4.17.23; 2681.
DR   PathwayCommons; Q9BYF1; -.
DR   Reactome; R-HSA-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   SABIO-RK; Q9BYF1; -.
DR   SIGNOR; Q9BYF1; -.
DR   BioGRID-ORCS; 59272; 2 hits in 501 CRISPR screens.
DR   ChiTaRS; ACE2; human.
DR   EvolutionaryTrace; Q9BYF1; -.
DR   GeneWiki; Angiotensin-converting_enzyme_2; -.
DR   GenomeRNAi; 59272; -.
DR   Pharos; Q9BYF1; Tchem.
DR   PRO; PR:Q9BYF1; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9BYF1; protein.
DR   Bgee; ENSG00000130234; Expressed in jejunal mucosa and 142 other tissues.
DR   Genevisible; Q9BYF1; HS.
DR   GO; GO:0031526; C:brush border membrane; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045121; C:membrane raft; TAS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004180; F:carboxypeptidase activity; IDA:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0004181; F:metallocarboxypeptidase activity; EXP:Reactome.
DR   GO; GO:0008237; F:metallopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008241; F:peptidyl-dipeptidase activity; IDA:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; TAS:BHF-UCL.
DR   GO; GO:0002003; P:angiotensin maturation; TAS:Reactome.
DR   GO; GO:0003051; P:angiotensin-mediated drinking behavior; IMP:BHF-UCL.
DR   GO; GO:0051957; P:positive regulation of amino acid transport; IMP:UniProtKB.
DR   GO; GO:0060452; P:positive regulation of cardiac muscle contraction; IEA:Ensembl.
DR   GO; GO:1903598; P:positive regulation of gap junction assembly; IMP:BHF-UCL.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IC:BHF-UCL.
DR   GO; GO:0032800; P:receptor biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0046813; P:receptor-mediated virion attachment to host cell; IDA:BHF-UCL.
DR   GO; GO:0097746; P:regulation of blood vessel diameter; IC:BHF-UCL.
DR   GO; GO:1903779; P:regulation of cardiac conduction; IMP:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell population proliferation; TAS:BHF-UCL.
DR   GO; GO:0001817; P:regulation of cytokine production; IC:BHF-UCL.
DR   GO; GO:0050727; P:regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0003081; P:regulation of systemic arterial blood pressure by renin-angiotensin; IMP:BHF-UCL.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IC:BHF-UCL.
DR   GO; GO:0015827; P:tryptophan transport; IEA:Ensembl.
DR   GO; GO:0046718; P:viral entry into host cell; TAS:UniProtKB.
DR   CDD; cd06461; M2_ACE; 1.
DR   InterPro; IPR031588; Collectrin_dom.
DR   InterPro; IPR001548; Peptidase_M2.
DR   PANTHER; PTHR10514; PTHR10514; 1.
DR   Pfam; PF16959; Collectrin; 1.
DR   Pfam; PF01401; Peptidase_M2; 1.
DR   PRINTS; PR00791; PEPDIPTASEA.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Carboxypeptidase; Cell membrane; Chloride; Cytoplasm;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Hydrolase;
KW   Membrane; Metal-binding; Metalloprotease; Polymorphism; Protease; Receptor;
KW   Reference proteome; Secreted; Signal; Transmembrane; Transmembrane helix;
KW   Zinc.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000255"
FT   CHAIN           18..805
FT                   /note="Angiotensin-converting enzyme 2"
FT                   /id="PRO_0000028570"
FT   CHAIN           18..708
FT                   /note="Processed angiotensin-converting enzyme 2"
FT                   /id="PRO_0000292268"
FT   TOPO_DOM        18..740
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        741..761
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        762..805
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          30..41
FT                   /note="Interaction with SARS-CoV spike glycoprotein"
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   REGION          82..84
FT                   /note="Interaction with SARS-CoV spike glycoprotein"
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   REGION          345..346
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000305|PubMed:14754895"
FT   REGION          353..357
FT                   /note="Interaction with SARS-CoV spike glycoprotein"
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   REGION          652..659
FT                   /note="Essential for cleavage by ADAM17"
FT                   /evidence="ECO:0000269|PubMed:24227843"
FT   REGION          697..716
FT                   /note="Essential for cleavage by TMPRSS11D and TMPRSS2"
FT                   /evidence="ECO:0000269|PubMed:24227843"
FT   ACT_SITE        375
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:14754895,
FT                   ECO:0000305|PubMed:27217402"
FT   ACT_SITE        505
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000305|PubMed:14754895"
FT   METAL           374
FT                   /note="Zinc; catalytic"
FT                   /evidence="ECO:0000269|PubMed:14754895"
FT   METAL           378
FT                   /note="Zinc; catalytic"
FT                   /evidence="ECO:0000269|PubMed:14754895"
FT   METAL           402
FT                   /note="Zinc; catalytic"
FT                   /evidence="ECO:0000269|PubMed:14754895"
FT   BINDING         169
FT                   /note="Chloride"
FT                   /evidence="ECO:0000269|PubMed:14754895,
FT                   ECO:0000305|PubMed:19021774"
FT   BINDING         273
FT                   /note="Substrate"
FT                   /evidence="ECO:0000305|PubMed:14754895"
FT   BINDING         477
FT                   /note="Chloride"
FT                   /evidence="ECO:0000269|PubMed:14754895,
FT                   ECO:0000305|PubMed:19021774"
FT   BINDING         481
FT                   /note="Chloride"
FT                   /evidence="ECO:0000269|PubMed:14754895,
FT                   ECO:0000305|PubMed:19021774"
FT   BINDING         515
FT                   /note="Substrate"
FT                   /evidence="ECO:0000305|PubMed:14754895"
FT   CARBOHYD        53
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305|PubMed:14754895"
FT   CARBOHYD        90
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14754895,
FT                   ECO:0000269|PubMed:15084671"
FT   CARBOHYD        103
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14754895"
FT   CARBOHYD        322
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305|PubMed:14754895"
FT   CARBOHYD        432
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14754895"
FT   CARBOHYD        546
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14754895,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        690
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        133..141
FT                   /evidence="ECO:0000269|PubMed:14754895"
FT   DISULFID        344..361
FT                   /evidence="ECO:0000269|PubMed:14754895"
FT   DISULFID        530..542
FT                   /evidence="ECO:0000269|PubMed:14754895"
FT   VARIANT         26
FT                   /note="K -> R (polymorphism; dbSNP:rs4646116)"
FT                   /evidence="ECO:0000269|PubMed:32558308, ECO:0000269|Ref.9"
FT                   /id="VAR_023082"
FT   VARIANT         468
FT                   /note="I -> V (polymorphism)"
FT                   /evidence="ECO:0000269|PubMed:32558308"
FT                   /id="VAR_083726"
FT   VARIANT         638
FT                   /note="N -> S (polymorphism; dbSNP:rs183135788)"
FT                   /evidence="ECO:0000269|PubMed:15937940,
FT                   ECO:0000269|PubMed:32558308"
FT                   /id="VAR_023083"
FT   VARIANT         720
FT                   /note="N -> D (polymorphism)"
FT                   /evidence="ECO:0000269|PubMed:32558308"
FT                   /id="VAR_083727"
FT   MUTAGEN         24..26
FT                   /note="QAK->KAE: Slightly inhibits interaction with
FT                   SARS-CoV spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         31
FT                   /note="K->D: Abolishes interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         37
FT                   /note="E->A: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         38
FT                   /note="D->A: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         41
FT                   /note="Y->A: Strongly inhibits interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         68
FT                   /note="K->D: Slightly inhibits interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         82..84
FT                   /note="MYP->NFS: Inhibits interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         110
FT                   /note="E->P: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         135..136
FT                   /note="PD->SM: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         160
FT                   /note="E->R: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         169
FT                   /note="R->Q: About 95% loss of angiotensin I cleavage."
FT                   /evidence="ECO:0000269|PubMed:19021774"
FT   MUTAGEN         192
FT                   /note="R->D: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         219
FT                   /note="R->D: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         239
FT                   /note="H->Q: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         271
FT                   /note="W->Q: About 95% loss of angiotensin I cleavage."
FT                   /evidence="ECO:0000269|PubMed:19021774"
FT   MUTAGEN         273
FT                   /note="R->Q: Complete loss of enzyme activity. Does not
FT                   affect amino acid transport activity of SLC6A19."
FT                   /evidence="ECO:0000269|PubMed:16008552,
FT                   ECO:0000269|PubMed:19185582"
FT   MUTAGEN         309
FT                   /note="K->D: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         312
FT                   /note="E->A: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         324
FT                   /note="T->A: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         338..340
FT                   /note="NVQ->DDR: No effect on interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         345
FT                   /note="H->A: Complete loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:16008552"
FT   MUTAGEN         350
FT                   /note="D->A: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         353
FT                   /note="K->H,A,D: Abolishes interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         355
FT                   /note="D->A: Strongly inhibits interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         357
FT                   /note="R->A: Strongly inhibits interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         359
FT                   /note="L->K,A: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         383
FT                   /note="M->A: Slightly inhibits interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         389
FT                   /note="P->A: Slightly inhibits interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         393
FT                   /note="R->A: Slightly inhibits interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         425..427
FT                   /note="SPD->PSN: Slightly inhibits interaction with
FT                   SARS-CoV spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         465..467
FT                   /note="KGE->QDK: No effect on interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         481
FT                   /note="K->Q: About 80% loss of angiotensin I cleavage."
FT                   /evidence="ECO:0000269|PubMed:19021774"
FT   MUTAGEN         505
FT                   /note="H->A: Complete loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:16008552"
FT   MUTAGEN         514
FT                   /note="R->Q: About 50% loss of angiotensin I cleavage but
FT                   two-fold greater activity with angiotensin II."
FT                   /evidence="ECO:0000269|PubMed:19021774"
FT   MUTAGEN         559
FT                   /note="R->S: Slightly inhibits interaction with SARS-CoV
FT                   spike glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   MUTAGEN         603
FT                   /note="F->T: No effect on interaction with SARS-CoV spike
FT                   glycoprotein."
FT                   /evidence="ECO:0000269|PubMed:15791205"
FT   CONFLICT        18
FT                   /note="Q -> H (in Ref. 12; CAB53682)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        508
FT                   /note="N -> D (in Ref. 8; AAQ89076)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        631
FT                   /note="K -> R (in Ref. 5; BAB40370)"
FT                   /evidence="ECO:0000305"
FT   HELIX           23..52
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           56..77
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            78..82
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           85..87
FT                   /evidence="ECO:0000244|PDB:6M0J"
FT   HELIX           91..100
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           104..107
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           110..129
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          131..134
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          137..143
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            144..146
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           148..154
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           158..171
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           173..193
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          196..198
FT                   /evidence="ECO:0000244|PDB:1R4L"
FT   HELIX           199..204
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            205..207
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            213..215
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           220..251
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            253..255
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          258..260
FT                   /evidence="ECO:0000244|PDB:6LZG"
FT   HELIX           264..266
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          267..271
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           276..278
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           279..282
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            284..287
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            294..297
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           298..300
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           304..316
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            317..319
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           327..330
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            337..339
FT                   /evidence="ECO:0000244|PDB:6M0J"
FT   STRAND          347..352
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          355..359
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           366..384
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            385..387
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           390..392
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          396..399
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   HELIX           400..413
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           415..420
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            422..426
FT                   /evidence="ECO:0000244|PDB:1R4L"
FT   HELIX           432..446
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           449..465
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          466..468
FT                   /evidence="ECO:0000244|PDB:1R4L"
FT   HELIX           470..472
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           473..483
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          486..488
FT                   /evidence="ECO:0000244|PDB:3D0G"
FT   HELIX           499..502
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           504..507
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           514..531
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            532..534
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           539..541
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           548..558
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            559..562
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           566..574
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          575..578
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   HELIX           582..598
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          600..602
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   STRAND          607..609
FT                   /evidence="ECO:0000244|PDB:1R42"
FT   TURN            612..615
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   STRAND          618..622
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   HELIX           624..627
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   STRAND          629..631
FT                   /evidence="ECO:0000244|PDB:6M18"
FT   HELIX           637..657
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   HELIX           667..669
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   STRAND          670..673
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   STRAND          677..686
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   STRAND          690..694
FT                   /evidence="ECO:0000244|PDB:6M18"
FT   HELIX           697..706
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   HELIX           708..715
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   STRAND          719..724
FT                   /evidence="ECO:0000244|PDB:6M17"
FT   HELIX           741..766
FT                   /evidence="ECO:0000244|PDB:6M17"
SQ   SEQUENCE   805 AA;  92463 MW;  8EE6EB0A931550E8 CRC64;
     MSSSSWLLLS LVAVTAAQST IEEQAKTFLD KFNHEAEDLF YQSSLASWNY NTNITEENVQ
     NMNNAGDKWS AFLKEQSTLA QMYPLQEIQN LTVKLQLQAL QQNGSSVLSE DKSKRLNTIL
     NTMSTIYSTG KVCNPDNPQE CLLLEPGLNE IMANSLDYNE RLWAWESWRS EVGKQLRPLY
     EEYVVLKNEM ARANHYEDYG DYWRGDYEVN GVDGYDYSRG QLIEDVEHTF EEIKPLYEHL
     HAYVRAKLMN AYPSYISPIG CLPAHLLGDM WGRFWTNLYS LTVPFGQKPN IDVTDAMVDQ
     AWDAQRIFKE AEKFFVSVGL PNMTQGFWEN SMLTDPGNVQ KAVCHPTAWD LGKGDFRILM
     CTKVTMDDFL TAHHEMGHIQ YDMAYAAQPF LLRNGANEGF HEAVGEIMSL SAATPKHLKS
     IGLLSPDFQE DNETEINFLL KQALTIVGTL PFTYMLEKWR WMVFKGEIPK DQWMKKWWEM
     KREIVGVVEP VPHDETYCDP ASLFHVSNDY SFIRYYTRTL YQFQFQEALC QAAKHEGPLH
     KCDISNSTEA GQKLFNMLRL GKSEPWTLAL ENVVGAKNMN VRPLLNYFEP LFTWLKDQNK
     NSFVGWSTDW SPYADQSIKV RISLKSALGD KAYEWNDNEM YLFRSSVAYA MRQYFLKVKN
     QMILFGEEDV RVANLKPRIS FNFFVTAPKN VSDIIPRTEV EKAIRMSRSR INDAFRLNDN
     SLEFLGIQPT LGPPNQPPVS IWLIVFGVVM GVIVVGIVIL IFTGIRDRKK KNKARSGENP
     YASIDISKGE NNPGFQNTDD VQTSF
//
ID   FYV1_HUMAN              Reviewed;        2098 AA.
AC   Q9Y2I7; Q08AR7; Q08AR8; Q53ST3; Q53T36; Q8N5H0; Q8NB67;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 3.
DT   12-AUG-2020, entry version 197.
DE   RecName: Full=1-phosphatidylinositol 3-phosphate 5-kinase {ECO:0000305};
DE            Short=Phosphatidylinositol 3-phosphate 5-kinase;
DE            EC=2.7.1.150 {ECO:0000269|PubMed:17556371};
DE   AltName: Full=FYVE finger-containing phosphoinositide kinase;
DE   AltName: Full=PIKfyve;
DE   AltName: Full=Phosphatidylinositol 3-phosphate 5-kinase type III;
DE            Short=PIPkin-III;
DE            Short=Type III PIP kinase;
DE   AltName: Full=Serine-protein kinase PIKFYVE;
DE            EC=2.7.11.1 {ECO:0000250|UniProtKB:Q9Z1T6};
GN   Name=PIKFYVE {ECO:0000312|HGNC:HGNC:23785}; Synonyms=KIAA0981, PIP5K3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ASN-696; SER-932;
RP   LEU-995; SER-998 AND LYS-1183.
RC   TISSUE=Brain;
RA   Cabezas A., Pattni K., Stenmark H.;
RT   "Human PIKfyve, a PI3P 5-kinase that regulates endocytic trafficking.";
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS ASN-696;
RP   SER-932; LEU-995; SER-998 AND LYS-1183.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3 AND 4).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1037-2098 (ISOFORM 1), AND
RP   VARIANT LYS-1183.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1521-2098 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11706043; DOI=10.1074/jbc.m110194200;
RA   Sbrissa D., Ikonomov O.C., Shisheva A.;
RT   "Phosphatidylinositol 3-phosphate-interacting domains in PIKfyve. Binding
RT   specificity and role in PIKfyve endomembrane localization.";
RL   J. Biol. Chem. 277:6073-6079(2002).
RN   [8]
RP   INTERACTION WITH RABEPK.
RX   PubMed=14530284; DOI=10.1074/jbc.m307260200;
RA   Ikonomov O.C., Sbrissa D., Mlak K., Deeb R., Fligger J., Soans A.,
RA   Finley R.L. Jr., Shisheva A.;
RT   "Active PIKfyve associates with and promotes the membrane attachment of the
RT   late endosome-to-trans-Golgi network transport factor Rab9 effector p40.";
RL   J. Biol. Chem. 278:50863-50871(2003).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH EGFR.
RX   PubMed=17909029; DOI=10.1158/0008-5472.can-07-1333;
RA   Kim J., Jahng W.J., Di Vizio D., Lee J.S., Jhaveri R., Rubin M.A.,
RA   Shisheva A., Freeman M.R.;
RT   "The phosphoinositide kinase PIKfyve mediates epidermal growth factor
RT   receptor trafficking to the nucleus.";
RL   Cancer Res. 67:9229-9237(2007).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND IDENTIFICATION IN THE PI(3,5)P2
RP   REGULATORY COMPLEX.
RX   PubMed=17556371; DOI=10.1074/jbc.m611678200;
RA   Sbrissa D., Ikonomov O.C., Fu Z., Ijuin T., Gruenberg J., Takenawa T.,
RA   Shisheva A.;
RT   "Core protein machinery for mammalian phosphatidylinositol 3,5-bisphosphate
RT   synthesis and turnover that regulates the progression of endosomal
RT   transport. Novel Sac phosphatase joins the ArPIKfyve-PIKfyve complex.";
RL   J. Biol. Chem. 282:23878-23891(2007).
RN   [13]
RP   IDENTIFICATION IN THE PI(3,5)P2 REGULATORY COMPLEX.
RX   PubMed=18950639; DOI=10.1016/j.jmb.2008.10.009;
RA   Sbrissa D., Ikonomov O.C., Fenner H., Shisheva A.;
RT   "ArPIKfyve homomeric and heteromeric interactions scaffold PIKfyve and Sac3
RT   in a complex to promote PIKfyve activity and functionality.";
RL   J. Mol. Biol. 384:766-779(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-299 AND SER-1544, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-329, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-299; SER-1544; SER-1549 AND SER-1754, CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   PHOSPHORYLATION AT SER-318.
RX   PubMed=20513353; DOI=10.1016/j.bbrc.2010.05.134;
RA   Hill E.V., Hudson C.A., Vertommen D., Rider M.H., Tavare J.M.;
RT   "Regulation of PIKfyve phosphorylation by insulin and osmotic stress.";
RL   Biochem. Biophys. Res. Commun. 397:650-655(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=22621786; DOI=10.1152/ajpcell.00105.2012;
RA   Sbrissa D., Ikonomov O.C., Filios C., Delvecchio K., Shisheva A.;
RT   "Functional dissociation between PIKfyve-synthesized PtdIns5P and
RT   PtdIns(3,5)P2 by means of the PIKfyve inhibitor YM201636.";
RL   Am. J. Physiol. 303:C436-C446(2012).
RN   [20]
RP   REVIEW.
RX   PubMed=23086417; DOI=10.1007/978-94-007-5025-8_7;
RA   Shisheva A.;
RT   "PIKfyve and its Lipid products in health and in sickness.";
RL   Curr. Top. Microbiol. Immunol. 362:127-162(2012).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-48; SER-88; SER-299; SER-307;
RP   SER-1544 AND SER-1549, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   FUNCTION.
RX   PubMed=27623384; DOI=10.1016/j.devcel.2016.08.001;
RA   Krishna S., Palm W., Lee Y., Yang W., Bandyopadhyay U., Xu H., Florey O.,
RA   Thompson C.B., Overholtzer M.;
RT   "PIKfyve Regulates Vacuole Maturation and Nutrient Recovery following
RT   Engulfment.";
RL   Dev. Cell 38:536-547(2016).
RN   [24]
RP   FUNCTION.
RX   PubMed=28779020; DOI=10.4049/jimmunol.1601466;
RA   Dayam R.M., Sun C.X., Choy C.H., Mancuso G., Glogauer M., Botelho R.J.;
RT   "The Lipid Kinase PIKfyve Coordinates the Neutrophil Immune Response
RT   through the Activation of the Rac GTPase.";
RL   J. Immunol. 199:2096-2105(2017).
RN   [25]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=29584722; DOI=10.1371/journal.pgen.1007290;
RA   Liggins M.C., Flesher J.L., Jahid S., Vasudeva P., Eby V., Takasuga S.,
RA   Sasaki J., Sasaki T., Boissy R.E., Ganesan A.K.;
RT   "PIKfyve regulates melanosome biogenesis.";
RL   PLoS Genet. 14:e1007290-e1007290(2018).
RN   [26]
RP   FUNCTION, SUBCELLULAR LOCATION, AND ACTIVITY REGULATION.
RX   PubMed=30612035; DOI=10.1016/j.isci.2018.12.015;
RA   Baranov M.V., Bianchi F., Schirmacher A., van Aart M.A.C., Maassen S.,
RA   Muntjewerff E.M., Dingjan I., Ter Beest M., Verdoes M., Keyser S.G.L.,
RA   Bertozzi C.R., Diederichsen U., van den Bogaart G.;
RT   "The Phosphoinositide Kinase PIKfyve Promotes Cathepsin-S-Mediated Major
RT   Histocompatibility Complex Class II Antigen Presentation.";
RL   IScience 11:160-177(2019).
RN   [27]
RP   FUNCTION (MICROBIAL INFECTION), AND ACTIVITY REGULATION.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV.";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [28]
RP   VARIANTS CFD 988-GLN--CYS-2098 DEL AND ARG-1103.
RX   PubMed=15902656; DOI=10.1086/431346;
RA   Li S., Tiab L., Jiao X., Munier F.L., Zografos L., Frueh B.E., Sergeev Y.,
RA   Smith J., Rubin B., Meallet M.A., Forster R.K., Hejtmancik J.F.,
RA   Schorderet D.F.;
RT   "Mutations in PIP5K3 are associated with Francois-Neetens mouchetee fleck
RT   corneal dystrophy.";
RL   Am. J. Hum. Genet. 77:54-63(2005).
CC   -!- FUNCTION: Dual specificity kinase implicated in myriad essential
CC       cellular processes such as maintenance of endomembrane homeostasis, and
CC       endocytic-vacuolar pathway, lysosomal trafficking, nuclear transport,
CC       stress- or hormone-induced signaling and cell cycle progression
CC       (PubMed:23086417). The PI(3,5)P2 regulatory complex regulates both the
CC       synthesis and turnover of phosphatidylinositol 3,5-bisphosphate
CC       (PtdIns(3,5)P2). Sole enzyme to catalyze the phosphorylation of
CC       phosphatidylinositol 3-phosphate on the fifth hydroxyl of the myo-
CC       inositol ring, to form (PtdIns(3,5)P2) (PubMed:17556371). Also
CC       catalyzes the phosphorylation of phosphatidylinositol on the fifth
CC       hydroxyl of the myo-inositol ring, to form phosphatidylinositol 5-
CC       phosphate (PtdIns(5)P) (PubMed:22621786). Has serine-protein kinase
CC       activity and is able to autophosphorylate and transphosphorylate.
CC       Autophosphorylation downregulates lipid product formation (By
CC       similarity). Involved in key endosome operations such as fission and
CC       fusion in the course of endosomal cargo transport (PubMed:22621786).
CC       Required for the maturation of early into late endosomes, phagosomes
CC       and lysosomes (PubMed:30612035). Regulates vacuole maturation and
CC       nutrient recovery following engulfment of macromolecules, initiates the
CC       redistribution of accumulated lysosomal contents back into the endosome
CC       network (PubMed:27623384). Critical regulator of the morphology,
CC       degradative activity, and protein turnover of the endolysosomal system
CC       in macrophages and platelets (By similarity). In neutrophils, critical
CC       to perform chemotaxis, generate ROS, and undertake phagosome fusion
CC       with lysosomes (PubMed:28779020). Plays a key role in the processing
CC       and presentation of antigens by major histocompatibility complex class
CC       II (MHC class II) mediated by CTSS (PubMed:30612035). Regulates
CC       melanosome biogenesis by controlling the delivery of proteins from the
CC       endosomal compartment to the melanosome (PubMed:29584722). Essential
CC       for systemic glucose homeostasis, mediates insulin-induced signals for
CC       endosome/actin remodeling in the course of GLUT4 translocation/glucose
CC       uptake activation (By similarity). Supports microtubule-based endosome-
CC       to-trans-Golgi network cargo transport, trhough association with SPAG9
CC       and RABEPK (By similarity). Mediates EGFR trafficking to the nucleus
CC       (PubMed:17909029). {ECO:0000250|UniProtKB:Q9Z1T6,
CC       ECO:0000269|PubMed:17556371, ECO:0000269|PubMed:17909029,
CC       ECO:0000269|PubMed:22621786, ECO:0000269|PubMed:27623384,
CC       ECO:0000269|PubMed:28779020, ECO:0000269|PubMed:29584722,
CC       ECO:0000269|PubMed:30612035, ECO:0000303|PubMed:23086417}.
CC   -!- FUNCTION: (Microbial infection) Required for cell entry of
CC       coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus EMC
CC       (HCoV-EMC) by endocytosis. {ECO:0000269|PubMed:32221306}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-
CC         phosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,5-bisphosphate) + ADP + H(+); Xref=Rhea:RHEA:13609,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57923,
CC         ChEBI:CHEBI:58088, ChEBI:CHEBI:456216; EC=2.7.1.150;
CC         Evidence={ECO:0000305|PubMed:17556371};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13610;
CC         Evidence={ECO:0000305};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a
CC         1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate) + ADP +
CC         H(+); Xref=Rhea:RHEA:44680, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:57795, ChEBI:CHEBI:57880, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:22621786};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44681;
CC         Evidence={ECO:0000305|PubMed:22621786};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000250|UniProtKB:Q9Z1T6};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000250|UniProtKB:Q9Z1T6};
CC   -!- ACTIVITY REGULATION: Inhibited by apilimod and YM201636.
CC       {ECO:0000269|PubMed:22621786, ECO:0000269|PubMed:29584722,
CC       ECO:0000269|PubMed:30612035, ECO:0000269|PubMed:32221306}.
CC   -!- SUBUNIT: Component of the PI(3,5)P2 regulatory complex/PAS complex, at
CC       least composed of PIKFYVE, FIG4 and VAC14. VAC14 nucleates the assembly
CC       of the complex and serves as a scaffold (PubMed:17556371,
CC       PubMed:18950639). Interacts (via chaperonin-like domain) with RABEPK;
CC       the interaction recruits RABEPK to the endosomal membrane
CC       (PubMed:14530284). Interacts with SPAG9 (By similarity). Interacts with
CC       EGFR (PubMed:17909029). {ECO:0000250|UniProtKB:Q9Z1T6,
CC       ECO:0000269|PubMed:14530284, ECO:0000269|PubMed:17556371,
CC       ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:18950639}.
CC   -!- INTERACTION:
CC       Q9Y2I7; Q08AM6: VAC14; NbExp=5; IntAct=EBI-6138650, EBI-2107455;
CC   -!- SUBCELLULAR LOCATION: Endosome membrane {ECO:0000269|PubMed:11706043,
CC       ECO:0000269|PubMed:17556371}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q9Z1T6}. Early endosome membrane
CC       {ECO:0000269|PubMed:30612035}; Peripheral membrane protein. Cytoplasmic
CC       vesicle, phagosome membrane {ECO:0000269|PubMed:30612035}; Peripheral
CC       membrane protein {ECO:0000305}. Late endosome membrane
CC       {ECO:0000269|PubMed:11706043}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q9Z1T6}. Note=Mainly associated with membranes
CC       of the late endocytic pathway. {ECO:0000269|PubMed:11706043}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9Y2I7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y2I7-2; Sequence=VSP_040108, VSP_040110, VSP_040111;
CC       Name=3;
CC         IsoId=Q9Y2I7-3; Sequence=VSP_040109, VSP_040110, VSP_040111;
CC       Name=4;
CC         IsoId=Q9Y2I7-4; Sequence=VSP_040110, VSP_040111;
CC   -!- DOMAIN: Interaction of FYVE-type domain with phosphatidylinositol 3-
CC       phosphate (PtdIns(3)P) is necessary for targeting to the membranes of
CC       the late endocytic pathway. {ECO:0000269|PubMed:11706043}.
CC   -!- PTM: Phosphorylated in response to insulin at Ser-318 in a protein
CC       kinase B (PKB)-dependent manner (PubMed:20513353). Autophosphorylates
CC       which downregulates lipid product formation (By similarity).
CC       {ECO:0000250|UniProtKB:Q9Z1T6, ECO:0000269|PubMed:20513353}.
CC   -!- DISEASE: Corneal dystrophy, fleck (CFD) [MIM:121850]: A form of stromal
CC       corneal dystrophy characterized by numerous small white flecks
CC       scattered in all levels of the stroma, with configurations varying from
CC       semicircular to wreath-like, curvilinear, or punctate. Although CFD may
CC       occasionally cause mild photophobia, patients are typically
CC       asymptomatic and have normal vision. {ECO:0000269|PubMed:15902656}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC03674.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY457063; AAR19397.1; -; mRNA.
DR   EMBL; AC012362; AAY14870.1; -; Genomic_DNA.
DR   EMBL; AC016697; AAX93222.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70444.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70445.1; -; Genomic_DNA.
DR   EMBL; BC032389; AAH32389.1; -; mRNA.
DR   EMBL; BC125052; AAI25053.1; -; mRNA.
DR   EMBL; BC125053; AAI25054.1; -; mRNA.
DR   EMBL; AK091482; BAC03674.1; ALT_INIT; mRNA.
DR   EMBL; AB023198; BAA76825.1; -; mRNA.
DR   CCDS; CCDS2382.1; -. [Q9Y2I7-1]
DR   CCDS; CCDS33368.1; -. [Q9Y2I7-2]
DR   CCDS; CCDS54431.1; -. [Q9Y2I7-4]
DR   RefSeq; NP_001171471.1; NM_001178000.1. [Q9Y2I7-4]
DR   RefSeq; NP_055855.2; NM_015040.3. [Q9Y2I7-1]
DR   RefSeq; NP_689884.1; NM_152671.3. [Q9Y2I7-2]
DR   SMR; Q9Y2I7; -.
DR   BioGRID; 128336; 20.
DR   CORUM; Q9Y2I7; -.
DR   IntAct; Q9Y2I7; 7.
DR   MINT; Q9Y2I7; -.
DR   STRING; 9606.ENSP00000264380; -.
DR   ChEMBL; CHEMBL1938222; -.
DR   GuidetoPHARMACOLOGY; 2857; -.
DR   iPTMnet; Q9Y2I7; -.
DR   MetOSite; Q9Y2I7; -.
DR   PhosphoSitePlus; Q9Y2I7; -.
DR   BioMuta; PIKFYVE; -.
DR   DMDM; 300669693; -.
DR   EPD; Q9Y2I7; -.
DR   jPOST; Q9Y2I7; -.
DR   MassIVE; Q9Y2I7; -.
DR   PaxDb; Q9Y2I7; -.
DR   PeptideAtlas; Q9Y2I7; -.
DR   PRIDE; Q9Y2I7; -.
DR   ProteomicsDB; 85801; -. [Q9Y2I7-1]
DR   ProteomicsDB; 85802; -. [Q9Y2I7-2]
DR   ProteomicsDB; 85803; -. [Q9Y2I7-3]
DR   ProteomicsDB; 85804; -. [Q9Y2I7-4]
DR   ABCD; Q9Y2I7; 1 sequenced antibody.
DR   Antibodypedia; 34200; 331 antibodies.
DR   DNASU; 200576; -.
DR   Ensembl; ENST00000264380; ENSP00000264380; ENSG00000115020. [Q9Y2I7-1]
DR   Ensembl; ENST00000308862; ENSP00000308715; ENSG00000115020. [Q9Y2I7-3]
DR   Ensembl; ENST00000392202; ENSP00000376038; ENSG00000115020. [Q9Y2I7-2]
DR   Ensembl; ENST00000407449; ENSP00000384356; ENSG00000115020. [Q9Y2I7-4]
DR   GeneID; 200576; -.
DR   KEGG; hsa:200576; -.
DR   UCSC; uc002vcv.4; human. [Q9Y2I7-1]
DR   CTD; 200576; -.
DR   DisGeNET; 200576; -.
DR   EuPathDB; HostDB:ENSG00000115020.16; -.
DR   GeneCards; PIKFYVE; -.
DR   HGNC; HGNC:23785; PIKFYVE.
DR   HPA; ENSG00000115020; Low tissue specificity.
DR   MalaCards; PIKFYVE; -.
DR   MIM; 121850; phenotype.
DR   MIM; 609414; gene.
DR   neXtProt; NX_Q9Y2I7; -.
DR   OpenTargets; ENSG00000115020; -.
DR   Orphanet; 98970; Fleck corneal dystrophy.
DR   PharmGKB; PA165697116; -.
DR   eggNOG; KOG0230; Eukaryota.
DR   GeneTree; ENSGT00940000156307; -.
DR   HOGENOM; CLU_000480_2_1_1; -.
DR   InParanoid; Q9Y2I7; -.
DR   KO; K00921; -.
DR   OMA; TCGQIFD; -.
DR   PhylomeDB; Q9Y2I7; -.
DR   TreeFam; TF321717; -.
DR   BioCyc; MetaCyc:HS03825-MONOMER; -.
DR   BRENDA; 2.7.1.150; 2681.
DR   BRENDA; 2.7.1.68; 2681.
DR   PathwayCommons; Q9Y2I7; -.
DR   Reactome; R-HSA-1660514; Synthesis of PIPs at the Golgi membrane.
DR   Reactome; R-HSA-1660516; Synthesis of PIPs at the early endosome membrane.
DR   Reactome; R-HSA-1660517; Synthesis of PIPs at the late endosome membrane.
DR   SIGNOR; Q9Y2I7; -.
DR   BioGRID-ORCS; 200576; 3 hits in 872 CRISPR screens.
DR   ChiTaRS; PIKFYVE; human.
DR   GeneWiki; PIKFYVE; -.
DR   GenomeRNAi; 200576; -.
DR   Pharos; Q9Y2I7; Tchem.
DR   PRO; PR:Q9Y2I7; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9Y2I7; protein.
DR   Bgee; ENSG00000115020; Expressed in secondary oocyte and 242 other tissues.
DR   ExpressionAtlas; Q9Y2I7; baseline and differential.
DR   Genevisible; Q9Y2I7; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0031902; C:late endosome membrane; TAS:Reactome.
DR   GO; GO:0045121; C:membrane raft; IDA:HGNC-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0012506; C:vesicle membrane; IEA:Ensembl.
DR   GO; GO:0000285; F:1-phosphatidylinositol-3-phosphate 5-kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016308; F:1-phosphatidylinositol-4-phosphate 5-kinase activity; TAS:HGNC-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043813; F:phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:Ensembl.
DR   GO; GO:0032288; P:myelin assembly; IEA:Ensembl.
DR   GO; GO:1904562; P:phosphatidylinositol 5-phosphate metabolic process; IC:ParkinsonsUK-UCL.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0034504; P:protein localization to nucleus; IMP:UniProtKB.
DR   GO; GO:2000785; P:regulation of autophagosome assembly; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0042147; P:retrograde transport, endosome to Golgi; IMP:UniProtKB.
DR   CDD; cd04448; DEP_PIKfyve; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.30.800.10; -; 1.
DR   Gene3D; 3.50.7.10; -; 1.
DR   InterPro; IPR002423; Cpn60/TCP-1.
DR   InterPro; IPR000591; DEP_dom.
DR   InterPro; IPR027409; GroEL-like_apical_dom_sf.
DR   InterPro; IPR037378; PIKfyve_DEP.
DR   InterPro; IPR002498; PInositol-4-P-5-kinase_core.
DR   InterPro; IPR027484; PInositol-4-P-5-kinase_N.
DR   InterPro; IPR027410; TCP-1-like_intermed_sf.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   InterPro; IPR000306; Znf_FYVE.
DR   InterPro; IPR017455; Znf_FYVE-rel.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF00118; Cpn60_TCP1; 1.
DR   Pfam; PF00610; DEP; 1.
DR   Pfam; PF01363; FYVE; 1.
DR   Pfam; PF01504; PIP5K; 2.
DR   SMART; SM00049; DEP; 1.
DR   SMART; SM00064; FYVE; 1.
DR   SMART; SM00330; PIPKc; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   SUPFAM; SSF52029; SSF52029; 1.
DR   SUPFAM; SSF54849; SSF54849; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS50186; DEP; 1.
DR   PROSITE; PS51455; PIPK; 1.
DR   PROSITE; PS50178; ZF_FYVE; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Corneal dystrophy;
KW   Cytoplasmic vesicle; Disease mutation; Endosome; Kinase; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transferase; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:19369195,
FT                   ECO:0000244|PubMed:22814378"
FT   CHAIN           2..2098
FT                   /note="1-phosphatidylinositol 3-phosphate 5-kinase"
FT                   /id="PRO_0000185452"
FT   DOMAIN          365..440
FT                   /note="DEP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00066"
FT   DOMAIN          1758..2084
FT                   /note="PIPK"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00781"
FT   ZN_FING         158..218
FT                   /note="FYVE-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00091"
FT   REGION          616..868
FT                   /note="Chaperonin-like domain"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z1T6"
FT   REGION          1842..2098
FT                   /note="Catalytic"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:19369195,
FT                   ECO:0000244|PubMed:22814378"
FT   MOD_RES         48
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         88
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         299
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18691976,
FT                   ECO:0000244|PubMed:19369195, ECO:0000244|PubMed:23186163"
FT   MOD_RES         307
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         312
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z1T6"
FT   MOD_RES         318
FT                   /note="Phosphoserine; by PKB/AKT1 or PKB/AKT2"
FT                   /evidence="ECO:0000269|PubMed:20513353"
FT   MOD_RES         329
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         475
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z1T6"
FT   MOD_RES         1544
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18691976,
FT                   ECO:0000244|PubMed:19369195, ECO:0000244|PubMed:23186163"
FT   MOD_RES         1549
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19369195,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         1754
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   VAR_SEQ         108..204
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_040108"
FT   VAR_SEQ         109..203
FT                   /note="TRRKAEPTFGGHDPRTAVQLRSLSTVLKRLKEIMEGKSQDSDLKQYWMPDSQ
FT                   CKECYDCSEKFTTFRRRHHCRLCGQIFCSRCCNQEIPGKFMGY -> NSLQHPQEN
FT                   (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_040109"
FT   VAR_SEQ         546..548
FT                   /note="EYL -> GRR (in isoform 2, isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_040110"
FT   VAR_SEQ         549..2098
FT                   /note="Missing (in isoform 2, isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_040111"
FT   VARIANT         617
FT                   /note="M -> V (in dbSNP:rs16840913)"
FT                   /id="VAR_057097"
FT   VARIANT         696
FT                   /note="S -> N (in dbSNP:rs10932258)"
FT                   /evidence="ECO:0000269|Ref.1, ECO:0000269|Ref.3"
FT                   /id="VAR_063406"
FT   VARIANT         932
FT                   /note="L -> S (in dbSNP:rs2363468)"
FT                   /evidence="ECO:0000269|Ref.1, ECO:0000269|Ref.3"
FT                   /id="VAR_063407"
FT   VARIANT         988..2098
FT                   /note="Missing (in CFD)"
FT                   /evidence="ECO:0000269|PubMed:15902656"
FT                   /id="VAR_083736"
FT   VARIANT         995
FT                   /note="Q -> L (in dbSNP:rs893254)"
FT                   /evidence="ECO:0000269|Ref.1, ECO:0000269|Ref.3"
FT                   /id="VAR_063408"
FT   VARIANT         998
FT                   /note="T -> S (in dbSNP:rs893253)"
FT                   /evidence="ECO:0000269|Ref.1, ECO:0000269|Ref.3"
FT                   /id="VAR_063409"
FT   VARIANT         1033
FT                   /note="S -> A (in dbSNP:rs999890)"
FT                   /id="VAR_057098"
FT   VARIANT         1103
FT                   /note="K -> R (in CFD; dbSNP:rs121918336)"
FT                   /evidence="ECO:0000269|PubMed:15902656"
FT                   /id="VAR_025309"
FT   VARIANT         1183
FT                   /note="Q -> K (in dbSNP:rs1529979)"
FT                   /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.1,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_063410"
FT   VARIANT         1858
FT                   /note="R -> Q (in dbSNP:rs2289170)"
FT                   /id="VAR_057099"
FT   CONFLICT        1335
FT                   /note="M -> I (in Ref. 5; BAC03674)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2019
FT                   /note="L -> S (in Ref. 5; BAC03674)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   2098 AA;  237136 MW;  390C43530D3B1E81 CRC64;
     MATDDKTSPT LDSANDLPRS PTSPSHLTHF KPLTPDQDEP PFKSAYSSFV NLFRFNKERA
     EGGQGEQQPL SGSWTSPQLP SRTQSVRSPT PYKKQLNEEL QRRSSALDTR RKAEPTFGGH
     DPRTAVQLRS LSTVLKRLKE IMEGKSQDSD LKQYWMPDSQ CKECYDCSEK FTTFRRRHHC
     RLCGQIFCSR CCNQEIPGKF MGYTGDLRAC TYCRKIALSY AHSTDSNSIG EDLNALSDSA
     CSVSVLDPSE PRTPVGSRKA SRNIFLEDDL AWQSLIHPDS SNTPLSTRLV SVQEDAGKSP
     ARNRSASITN LSLDRSGSPM VPSYETSVSP QANRTYVRTE TTEDERKILL DSVQLKDLWK
     KICHHSSGME FQDHRYWLRT HPNCIVGKEL VNWLIRNGHI ATRAQAIAIG QAMVDGRWLD
     CVSHHDQLFR DEYALYRPLQ STEFSETPSP DSDSVNSVEG HSEPSWFKDI KFDDSDTEQI
     AEEGDDNLAN SASPSKRTSV SSFQSTVDSD SAASISLNVE LDNVNFHIKK PSKYPHVPPH
     PADQKEYLIS DTGGQQLSIS DAFIKESLFN RRVEEKSKEL PFTPLGWHHN NLELLREENG
     EKQAMERLLS ANHNHMMALL QQLLHSDSLS SSWRDIIVSL VCQVVQTVRP DVKNQDDDMD
     IRQFVHIKKI PGGKKFDSVV VNGFVCTKNI AHKKMSSCIK NPKILLLKCS IEYLYREETK
     FTCIDPIVLQ EREFLKNYVQ RIVDVRPTLV LVEKTVSRIA QDMLLEHGIT LVINVKSQVL
     ERISRMTQGD LVMSMDQLLT KPHLGTCHKF YMQIFQLPNE QTKTLMFFEG CPQHLGCTIK
     LRGGSDYELA RVKEILIFMI CVAYHSQLEI SFLMDEFAMP PTLMQNPSFH SLIEGRGHEG
     AVQEQYGGGS IPWDPDIPPE SLPCDDSSLL ELRIVFEKGE QENKNLPQAV ASVKHQEHST
     TACPAGLPCA FFAPVPESLL PLPVDDQQDA LGSEQPETLQ QTVVLQDPKS QIRAFRDPLQ
     DDTGLYVTEE VTSSEDKRKT YSLAFKQELK DVILCISPVI TFREPFLLTE KGMRCSTRDY
     FAEQVYWSPL LNKEFKEMEN RRKKQLLRDL SGLQGMNGSI QAKSIQVLPS HELVSTRIAE
     HLGDSQSLGR MLADYRARGG RIQPKNSDPF AHSKDASSTS SGQSGSKNEG DEERGLILSD
     AVWSTKVDCL NPINHQRLCV LFSSSSAQSS NAPSACVSPW IVTMEFYGKN DLTLGIFLER
     YCFRPSYQCP SMFCDTPMVH HIRRFVHGQG CVQIILKELD SPVPGYQHTI LTYSWCRICK
     QVTPVVALSN ESWSMSFAKY LELRFYGHQY TRRANAEPCG HSIHHDYHQY FSYNQMVASF
     SYSPIRLLEV CVPLPKIFIK RQAPLKVSLL QDLKDFFQKV SQVYVAIDER LASLKTDTFS
     KTREEKMEDI FAQKEMEEGE FKNWIEKMQA RLMSSSVDTP QQLQSVFESL IAKKQSLCEV
     LQAWNNRLQD LFQQEKGRKR PSVPPSPGRL RQGEESKISA MDASPRNISP GLQNGEKEDR
     FLTTLSSQSS TSSTHLQLPT PPEVMSEQSV GGPPELDTAS SSEDVFDGHL LGSTDSQVKE
     KSTMKAIFAN LLPGNSYNPI PFPFDPDKHY LMYEHERVPI AVCEKEPSSI IAFALSCKEY
     RNALEELSKA TQWNSAEEGL PTNSTSDSRP KSSSPIRLPE MSGGQTNRTT ETEPQPTKKA
     SGMLSFFRGT AGKSPDLSSQ KRETLRGADS AYYQVGQTGK EGTENQGVEP QDEVDGGDTQ
     KKQLINPHVE LQFSDANAKF YCRLYYAGEF HKMREVILDS SEEDFIRSLS HSSPWQARGG
     KSGAAFYATE DDRFILKQMP RLEVQSFLDF APHYFNYITN AVQQKRPTAL AKILGVYRIG
     YKNSQNNTEK KLDLLVMENL FYGRKMAQVF DLKGSLRNRN VKTDTGKESC DVVLLDENLL
     KMVRDNPLYI RSHSKAVLRT SIHSDSHFLS SHLIIDYSLL VGRDDTSNEL VVGIIDYIRT
     FTWDKKLEMV VKSTGILGGQ GKMPTVVSPE LYRTRFCEAM DKYFLMVPDH WTGLGLNC
//
ID   VME1_SARS               Reviewed;         221 AA.
AC   P59596; Q6S8E5; Q7T6Q8; Q7T6R1; Q7T6R5; Q7T6S0; Q7T6S3; Q7T726; Q7T7P6;
AC   Q7T7S6; Q7TA12;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 1.
DT   12-AUG-2020, entry version 88.
DE   RecName: Full=Membrane protein {ECO:0000255|HAMAP-Rule:MF_04202};
DE            Short=M protein {ECO:0000255|HAMAP-Rule:MF_04202};
DE   AltName: Full=E1 glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
DE   AltName: Full=Matrix glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
DE   AltName: Full=Membrane glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
GN   Name=M {ECO:0000255|HAMAP-Rule:MF_04202}; ORFNames=5;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, and Isolate HKU-36871;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   "Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China.";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   "Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection.";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   "Mechanisms and enzymes involved in SARS coronavirus genome expression.";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   "Analysis of SARS coronavirus genome in Shanghai isolates.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Isolate ZJ01;
RA   Cong L.-M., Ding G.-Q., Lu Y.-Y., Yan J.-Q., Weng J.-Q., Cheng S.-Y.,
RA   Zhang Y.-J., Mei L.-L., Wang Z.-G., Hu N., Wo J., Yao J., Zhu H.-P.,
RA   Lu Q.-Y., Li M.-H., Gong L.-M., Shi W.;
RT   "SARS coronavirus ZJ01 isolate membrane glycoprotein.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   "Genomic sequence of SARS isolate from the first fatal case in Taiwan.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC2, and Isolate TWC3;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee H.-C., Lin Y.-C.,
RA   Yao C.-W., Chiueh T.-S., Lu J.-J., Chen A., Hsu C.-K., Chen H.-Y.,
RA   Chen P.-J., Su I.-J.;
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   INTERACTION WITH ACCESSORY PROTEIN 3A.
RX   PubMed=15194747; DOI=10.1128/jvi.78.13.6723-6734.2004;
RA   Tan Y.-J., Teng E., Shen S., Tan T.H.P., Goh P.-Y., Fielding B.C.,
RA   Ooi E.-E., Tan H.-C., Lim S.G., Hong W.;
RT   "A novel severe acute respiratory syndrome coronavirus protein, U274, is
RT   transported to the cell surface and undergoes endocytosis.";
RL   J. Virol. 78:6723-6734(2004).
RN   [21]
RP   INTERACTION WITH ACCESSORY PROTEIN 3A.
RX   PubMed=15763150; DOI=10.1016/j.virusres.2005.01.001;
RA   Yuan X., Li J., Shan Y., Yang Z., Zhao Z., Chen B., Yao Z., Dong B.,
RA   Wang S., Chen J., Cong Y.;
RT   "Subcellular localization and membrane association of SARS-CoV 3a
RT   protein.";
RL   Virus Res. 109:191-202(2005).
RN   [22]
RP   INTERACTION WITH ACCESSORY PROTEIN 7A.
RX   PubMed=16580632; DOI=10.1016/j.bbrc.2006.03.091;
RA   Fielding B.C., Gunalan V., Tan T.H.P., Chou C.-F., Shen S., Khan S.,
RA   Lim S.G., Hong W., Tan Y.-J.;
RT   "Severe acute respiratory syndrome coronavirus protein 7a interacts with
RT   hSGT.";
RL   Biochem. Biophys. Res. Commun. 343:1201-1208(2006).
CC   -!- FUNCTION: Component of the viral envelope that plays a central role in
CC       virus morphogenesis and assembly via its interactions with other viral
CC       proteins. {ECO:0000255|HAMAP-Rule:MF_04202, ECO:0000255|PROSITE-
CC       ProRule:PRU01275}.
CC   -!- SUBUNIT: Homomultimer. Interacts with envelope E protein in the budding
CC       compartment of the host cell, which is located between endoplasmic
CC       reticulum and the Golgi complex. Forms a complex with HE and S
CC       proteins. Interacts with nucleocapsid N protein. This interaction
CC       probably participates in RNA packaging into the virus (By similarity).
CC       Interacts with the accessory proteins 3a and 7a. {ECO:0000255|HAMAP-
CC       Rule:MF_04202, ECO:0000269|PubMed:15194747,
CC       ECO:0000269|PubMed:15763150, ECO:0000269|PubMed:16580632}.
CC   -!- INTERACTION:
CC       P59596; P59595: N; NbExp=2; IntAct=EBI-25487824, EBI-7602718;
CC   -!- SUBCELLULAR LOCATION: Virion membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04202}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_04202}. Host Golgi apparatus membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04202}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_04202}. Note=Largely embedded in the lipid bilayer.
CC       {ECO:0000255|HAMAP-Rule:MF_04202}.
CC   -!- SIMILARITY: Belongs to the betacoronaviruses M protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04202}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13444.1; -; Genomic_RNA.
DR   EMBL; AY274119; AAP41041.1; -; Genomic_RNA.
DR   EMBL; AY278554; AAP13571.1; -; Genomic_RNA.
DR   EMBL; AY282752; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY304492; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY304495; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283794; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283795; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283796; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283797; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY283798; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; AAP30034.1; -; Genomic_RNA.
DR   EMBL; AY278489; AAP51231.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37021.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50489.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33701.1; -; Genomic_RNA.
DR   EMBL; AY463059; AAR86790.1; -; Genomic_RNA.
DR   EMBL; AY323974; AAP73415.1; -; mRNA.
DR   EMBL; AY321118; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY338174; AAQ01601.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01613.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97886.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81352.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81366.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81380.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81394.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81408.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72978.1; -; Genomic_RNA.
DR   EMBL; AY362698; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY362699; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY427439; AAQ94064.1; -; Genomic_RNA.
DR   RefSeq; NP_828855.1; NC_004718.3.
DR   PDB; 3I6G; X-ray; 2.20 A; C/F=88-96.
DR   PDBsum; 3I6G; -.
DR   SMR; P59596; -.
DR   BioGRID; 4383913; 5.
DR   ELM; P59596; -.
DR   IntAct; P59596; 4.
DR   PRIDE; P59596; -.
DR   GeneID; 1489672; -.
DR   KEGG; vg:1489672; -.
DR   KO; K24150; -.
DR   SIGNOR; P59596; -.
DR   EvolutionaryTrace; P59596; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000164441; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-UniRule.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-UniRule.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0039660; F:structural constituent of virion; IEA:UniProtKB-UniRule.
DR   GO; GO:0030683; P:mitigation of host immune response by virus; IEA:UniProtKB-KW.
DR   GO; GO:0019058; P:viral life cycle; IEA:InterPro.
DR   HAMAP; MF_04202; BETA_CORONA_M; 1.
DR   InterPro; IPR002574; M_CoV.
DR   Pfam; PF01635; Corona_M; 1.
DR   PROSITE; PS51927; COV_M; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Glycoprotein; Host Golgi apparatus; Host membrane;
KW   Host-virus interaction; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix; Viral envelope protein; Viral immunoevasion;
KW   Viral matrix protein; Virion.
FT   CHAIN           1..221
FT                   /note="Membrane protein"
FT                   /id="PRO_0000106035"
FT   TOPO_DOM        1..18
FT                   /note="Virion surface"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TRANSMEM        19..39
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TOPO_DOM        40..49
FT                   /note="Intravirion"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TRANSMEM        50..70
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TOPO_DOM        71..78
FT                   /note="Virion surface"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TRANSMEM        79..99
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TOPO_DOM        100..221
FT                   /note="Intravirion"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   VARIANT         11
FT                   /note="E -> K (in strain: Isolate Sin2500)"
FT   VARIANT         27
FT                   /note="F -> C (in strain: Isolate CUHK-Su10, Isolate TWC2,
FT                   Isolate TWC3, Isolate TWH, Isolate TWJ, Isolate TWK,
FT                   Isolate TWS, Isolate TWY, Isolate Taiwan TC1, Isolate
FT                   Taiwan TC2 and Isolate Taiwan TC3)"
FT   VARIANT         68
FT                   /note="A -> V (in strain: Isolate HKU-39849, Isolate FRA
FT                   and Isolate Frankfurt 1)"
FT   VARIANT         73
FT                   /note="N -> T (in strain: Isolate TC3)"
FT   VARIANT         119
FT                   /note="L -> P (in strain: Isolate Shanghai QXC1)"
FT   VARIANT         154
FT                   /note="S -> P (in strain: Isolate Urbani)"
SQ   SEQUENCE   221 AA;  25061 MW;  275C37085A0215A8 CRC64;
     MADNGTITVE ELKQLLEQWN LVIGFLFLAW IMLLQFAYSN RNRFLYIIKL VFLWLLWPVT
     LACFVLAAVY RINWVTGGIA IAMACIVGLM WLSYFVASFR LFARTRSMWS FNPETNILLN
     VPLRGTIVTR PLMESELVIG AVIIRGHLRM AGHSLGRCDI KDLPKEITVA TSRTLSYYKL
     GASQRVGTDS GFAAYNRYRI GNYKLNTDHA GSNDNIALLV Q
//
ID   NS3B_SARS               Reviewed;         154 AA.
AC   P59633; Q7TFA9; Q80BV4;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 1.
DT   12-AUG-2020, entry version 75.
DE   RecName: Full=ORF3b protein;
DE   AltName: Full=Accessory protein 3b;
DE   AltName: Full=Non-structural protein 3b;
DE            Short=ns3b;
DE   AltName: Full=Protein X2;
GN   ORFNames=3b;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   "Analysis of SARS coronavirus genome in Shanghai isolates.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RT   "The complete genome of SARS coronavirus TWH.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   FUNCTION.
RX   PubMed=16107218; DOI=10.1186/1743-422x-2-66;
RA   Yuan X., Shan Y., Zhao Z., Chen J., Cong Y.;
RT   "G0/G1 arrest and apoptosis induced by SARS-CoV 3b protein in transfected
RT   cells.";
RL   Virol. J. 2:66-66(2005).
RN   [15]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16046244; DOI=10.1016/j.virusres.2005.06.001;
RA   Yuan X., Yao Z., Shan Y., Chen B., Yang Z., Wu J., Zhao Z., Chen J.,
RA   Cong Y.;
RT   "Nucleolar localization of non-structural protein 3b, a protein
RT   specifically encoded by the severe acute respiratory syndrome
RT   coronavirus.";
RL   Virus Res. 114:70-79(2005).
RN   [16]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16682811;
RA   Yuan X., Shan Y., Yao Z., Li J., Zhao Z., Chen J., Cong Y.;
RT   "Mitochondrial location of severe acute respiratory syndrome coronavirus 3b
RT   protein.";
RL   Mol. Cells 21:186-191(2006).
RN   [17]
RP   INTERACTION WITH HOST RUNX1.
RX   PubMed=22253733; DOI=10.1371/journal.pone.0029542;
RA   Varshney B., Agnihothram S., Agnihotram S., Tan Y.J., Baric R., Lal S.K.;
RT   "SARS coronavirus 3b accessory protein modulates transcriptional activity
RT   of RUNX1b.";
RL   PLoS ONE 7:E29542-E29542(2012).
CC   -!- FUNCTION: Induces host cell G0/G1 arrest and apoptosis.
CC       {ECO:0000269|PubMed:16107218, ECO:0000269|PubMed:16682811}.
CC   -!- SUBUNIT: Interacts with host RUNX1 isoform b.
CC       {ECO:0000269|PubMed:22253733}.
CC   -!- SUBCELLULAR LOCATION: Host nucleus, host nucleolus
CC       {ECO:0000269|PubMed:16046244}. Host mitochondrion
CC       {ECO:0000269|PubMed:16682811}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13447.1; -; Genomic_RNA.
DR   EMBL; AY274119; AAP41039.1; -; Genomic_RNA.
DR   EMBL; AY282752; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278554; AAP13569.1; -; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; AAP30032.1; -; Genomic_RNA.
DR   EMBL; AY278489; AAP51229.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37019.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50487.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33699.1; -; Genomic_RNA.
DR   EMBL; AY463059; AAR86789.1; -; Genomic_RNA.
DR   EMBL; AY338174; AAQ01599.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01611.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97884.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81350.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81364.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81378.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81392.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81406.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72976.1; -; Genomic_RNA.
DR   EMBL; AY427439; AAQ94062.1; -; Genomic_RNA.
DR   RefSeq; NP_828853.1; NC_004718.3.
DR   SMR; P59633; -.
DR   BioGRID; 4383918; 9.
DR   IntAct; P59633; 4.
DR   PRIDE; P59633; -.
DR   GeneID; 1489670; -.
DR   KEGG; vg:1489670; -.
DR   SIGNOR; P59633; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000164441; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0033650; C:host cell mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0044196; C:host cell nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0039526; P:modulation by virus of host apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0039646; P:modulation by virus of host G0/G1 transition checkpoint; IEA:UniProtKB-KW.
DR   GO; GO:0001817; P:regulation of cytokine production; IEP:CACAO.
DR   InterPro; IPR022117; SARS_3b.
DR   Pfam; PF12383; SARS_3b; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; G0/G1 host cell cycle checkpoint dysregulation by virus;
KW   Host mitochondrion; Host nucleus; Host-virus interaction;
KW   Modulation of host cell apoptosis by virus;
KW   Modulation of host cell cycle by virus; Reference proteome.
FT   CHAIN           1..154
FT                   /note="ORF3b protein"
FT                   /id="PRO_0000106132"
FT   REGION          80..138
FT                   /note="Mitochondrial targeting signal"
FT   REGION          134..154
FT                   /note="Nucleolar targeting"
FT   MOTIF           135..153
FT                   /note="Bipartite nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   VARIANT         31
FT                   /note="K -> Q (in strain: Isolate GD01)"
FT   VARIANT         99
FT                   /note="T -> I (in strain: Isolate BJ02)"
FT   VARIANT         115
FT                   /note="L -> Q (in strain: Isolate GD01)"
FT   VARIANT         121
FT                   /note="Q -> P (in strain: Isolate BJ01 and Isolate BJ04)"
SQ   SEQUENCE   154 AA;  17750 MW;  82AB0B68F11060A8 CRC64;
     MMPTTLFAGT HITMTTVYHI TVSQIQLSLL KVTAFQHQNS KKTTKLVVIL RIGTQVLKTM
     SLYMAISPKF TTSLSLHKLL QTLVLKMLHS SSLTSLLKTH RMCKYTQSTA LQELLIQQWI
     QFMMSRRRLL ACLCKHKKVS TNLCTHSFRK KQVR
//
ID   NS6_SARS                Reviewed;          63 AA.
AC   P59634; Q7T6R9; Q7TA25; Q7TFA7; Q80BV3;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-APR-2003, sequence version 1.
DT   12-AUG-2020, entry version 72.
DE   RecName: Full=ORF6 protein;
DE   AltName: Full=Accessory protein 6;
DE   AltName: Full=Non-structural protein 6;
DE            Short=ns6;
DE   AltName: Full=Protein X3;
GN   ORFNames=6;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   "Analysis of SARS coronavirus genome in Shanghai isolates.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RT   "The complete genome of SARS coronavirus TWH.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16103185; DOI=10.1128/jvi.79.17.11335-11342.2005;
RA   Pewe L., Zhou H., Netland J., Tangudu C., Olivares H., Shi L., Look D.,
RA   Gallagher T., Perlman S.;
RT   "A severe acute respiratory syndrome-associated coronavirus-specific
RT   protein enhances virulence of an attenuated murine coronavirus.";
RL   J. Virol. 79:11335-11342(2005).
RN   [15]
RP   SUBCELLULAR LOCATION.
RC   STRAIN=Isolate CUHK-W1;
RX   PubMed=16310783; DOI=10.1016/j.febslet.2005.11.007;
RA   Geng H., Liu Y.-M., Chan W.S., Lo A.W.-I., Au D.M.-Y., Waye M.M.-Y.,
RA   Ho Y.-Y.;
RT   "The putative protein 6 of the severe acute respiratory syndrome-associated
RT   coronavirus: expression and functional characterization.";
RL   FEBS Lett. 579:6763-6768(2005).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17108045; DOI=10.1128/jvi.01515-06;
RA   Tangudu C., Olivares H., Netland J., Perlman S., Gallagher T.;
RT   "Severe acute respiratory syndrome coronavirus protein 6 accelerates murine
RT   coronavirus infections.";
RL   J. Virol. 81:1220-1229(2007).
RN   [17]
RP   INTERACTION WITH NSP8, AND SUBCELLULAR LOCATION.
RX   PubMed=17532020; DOI=10.1016/j.virol.2007.04.029;
RA   Kumar P., Gunalan V., Liu B., Chow V.T., Druce J., Birch C., Catton M.,
RA   Fielding B.C., Tan Y.J., Lal S.K.;
RT   "The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with
RT   its ORF6 accessory protein.";
RL   Virology 366:293-303(2007).
RN   [18]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17596301; DOI=10.1128/jvi.01012-07;
RA   Frieman M., Yount B., Heise M., Kopecky-Bromberg S.A., Palese P.,
RA   Baric R.S.;
RT   "Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1
RT   function by sequestering nuclear import factors on the rough endoplasmic
RT   reticulum/Golgi membrane.";
RL   J. Virol. 81:9812-9824(2007).
RN   [19]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF 49-TYR--LEU-52 AND 53-ASP--GLU-56.
RX   PubMed=22026976; DOI=10.1186/1756-0500-4-446;
RA   Gunalan V., Mirazimi A., Tan Y.J.;
RT   "A putative diacidic motif in the SARS-CoV ORF6 protein influences its
RT   subcellular localization and suppression of expression of co-transfected
RT   expression constructs.";
RL   BMC Res. Notes 4:446-446(2011).
RN   [20]
RP   INTERACTION WITH PROTEIN ORF9B, AND SUBCELLULAR LOCATION.
RX   PubMed=22820404; DOI=10.1016/j.virusres.2012.07.012;
RA   Calvo E., DeDiego M.L., Garcia P., Lopez J.A., Perez-Brena P., Falcon A.;
RT   "Severe acute respiratory syndrome coronavirus accessory proteins 6 and 9b
RT   interact in vivo.";
RL   Virus Res. 169:282-288(2012).
CC   -!- FUNCTION: Disrupts cell nuclear import complex formation by tethering
CC       karyopherin alpha 2 and karyopherin beta 1 to the membrane. Retention
CC       of import factors at the ER/Golgi membrane leads to a loss of transport
CC       into the nucleus. Thereby prevents STAT1 nuclear translocation in
CC       response to interferon signaling, thus blocking the expression of
CC       interferon stimulated genes (ISGs) that display multiple antiviral
CC       activities. {ECO:0000269|PubMed:17596301}.
CC   -!- SUBUNIT: Interacts with host KPNA2 (PubMed:17596301). May interact with
CC       nsp8 (PubMed:17532020). Interacts with protein ORF9b (PubMed:22820404).
CC       {ECO:0000269|PubMed:17532020, ECO:0000269|PubMed:17596301,
CC       ECO:0000269|PubMed:22820404}.
CC   -!- INTERACTION:
CC       P59634; Q13561: DCTN2; Xeno; NbExp=2; IntAct=EBI-25489038, EBI-715074;
CC   -!- SUBCELLULAR LOCATION: Host endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:17108045, ECO:0000269|PubMed:17532020,
CC       ECO:0000269|PubMed:17596301}. Host Golgi apparatus membrane
CC       {ECO:0000269|PubMed:17108045, ECO:0000269|PubMed:17596301}. Host
CC       cytoplasm {ECO:0000269|PubMed:22820404}. Note=Localizes to virus-
CC       induced vesicular structures called double membrane vesicles.
CC       {ECO:0000269|PubMed:17108045, ECO:0000269|PubMed:17596301,
CC       ECO:0000269|PubMed:22026976}.
CC   -!- SIMILARITY: Belongs to the coronaviruses accessory protein 6 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13448.1; -; Genomic_RNA.
DR   EMBL; AY274119; AAP41042.1; -; Genomic_RNA.
DR   EMBL; AY282752; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278554; AAP13572.1; -; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; AAP30035.1; -; Genomic_RNA.
DR   EMBL; AY278489; AAP51232.1; -; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY291451; AAP37022.1; -; Genomic_RNA.
DR   EMBL; AY310120; AAP50490.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33702.1; -; Genomic_RNA.
DR   EMBL; AY463059; AAR86791.1; -; Genomic_RNA.
DR   EMBL; AY338174; AAQ01602.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01614.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97887.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81353.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81367.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81381.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81395.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81409.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72979.1; -; Genomic_RNA.
DR   EMBL; AY427439; AAQ94065.1; -; Genomic_RNA.
DR   RefSeq; NP_828856.1; NC_004718.3.
DR   BioGRID; 4383919; 13.
DR   IntAct; P59634; 2.
DR   GeneID; 1489673; -.
DR   KEGG; vg:1489673; -.
DR   SIGNOR; P59634; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000145651; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000164441; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0009405; P:pathogenesis; IEA:UniProtKB-KW.
DR   InterPro; IPR022736; NS6_bCoV.
DR   Pfam; PF12133; Sars6; 1.
PE   1: Evidence at protein level;
KW   Host cytoplasm; Host endoplasmic reticulum; Host Golgi apparatus;
KW   Host membrane; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host STAT1 by virus; Interferon antiviral system evasion;
KW   Membrane; Reference proteome; Viral immunoevasion; Virulence.
FT   CHAIN           1..63
FT                   /note="ORF6 protein"
FT                   /id="PRO_0000106134"
FT   REGION          54..63
FT                   /note="Critical for disrupting nuclear import"
FT                   /evidence="ECO:0000269|PubMed:17596301"
FT   VARIANT         32..63
FT                   /note="IISSIVRQLFKPLTKKNYSELDDEEPMELDYP -> NKFNSETII (in
FT                   strain: Isolate TWJ)"
FT   VARIANT         57
FT                   /note="P -> L (in strain: Isolate GD01, Isolate BJ01,
FT                   Isolate BJ02, Isolate BJ03 and Isolate BJ04)"
FT   MUTAGEN         49..52
FT                   /note="YSEL->AAAA: No effect in the suppression of nuclear
FT                   gene expression."
FT                   /evidence="ECO:0000269|PubMed:22026976"
FT   MUTAGEN         53..56
FT                   /note="DDEE->AAAA: Reduction in the suppression of nuclear
FT                   gene expression."
FT                   /evidence="ECO:0000269|PubMed:22026976"
SQ   SEQUENCE   63 AA;  7527 MW;  70C9150941C759BF CRC64;
     MFHLVDFQVT IAEILIIIMR TFRIAIWNLD VIISSIVRQL FKPLTKKNYS ELDDEEPMEL
     DYP
//
ID   AP3A_SARS2              Reviewed;         275 AA.
AC   P0DTC3;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=ORF3a protein;
DE            Short=ORF3a;
DE   AltName: Full=Accessory protein 3a;
DE   AltName: Full=Protein 3a;
DE   AltName: Full=Protein U274;
DE   AltName: Full=Protein X1;
GN   ORFNames=3a;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
CC   -!- FUNCTION: Forms homotetrameric potassium sensitive ion channels
CC       (viroporin) and may modulate virus release. Up-regulates expression of
CC       fibrinogen subunits FGA, FGB and FGG in host lung epithelial cells.
CC       Induces apoptosis in cell culture. Downregulates the type 1 interferon
CC       receptor by inducing serine phosphorylation within the IFN alpha-
CC       receptor subunit 1 (IFNAR1) degradation motif and increasing IFNAR1
CC       ubiquitination. {ECO:0000250|UniProtKB:P59632}.
CC   -!- SUBUNIT: Homotetramer composed of two homodimers linked non covalently.
CC       Interacts with M, S and E proteins. Also interacts with the accessory
CC       protein 7a. {ECO:0000250|UniProtKB:P59632}.
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000250|UniProtKB:P59632}. Host Golgi
CC       apparatus membrane {ECO:0000250|UniProtKB:P59632}; Multi-pass membrane
CC       protein {ECO:0000250|UniProtKB:P59632}. Host cell membrane
CC       {ECO:0000250|UniProtKB:P59632}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P59632}. Secreted
CC       {ECO:0000250|UniProtKB:P59632}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P59632}. Note=The cell surface expressed protein
CC       can undergo endocytosis. The protein is secreted in association with
CC       membranous structures. {ECO:0000250|UniProtKB:P59632}.
CC   -!- DOMAIN: The second or the third transmembrane region are responsible
CC       for Golgi localization. {ECO:0000250|UniProtKB:P59632}.
CC   -!- PTM: Exists in both O-glycosylated and non-glycosylated forms. The
CC       glycosylated form is associated with the virion.
CC       {ECO:0000250|UniProtKB:P59632}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43417.1; -; Genomic_RNA.
DR   RefSeq; YP_009724391.1; NC_045512.2.
DR   SMR; P0DTC3; -.
DR   BioGRID; 4383868; 8.
DR   IntAct; P0DTC3; 38.
DR   GlyGen; P0DTC3; 2 sites.
DR   GeneID; 43740569; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019012; C:virion; IEA:UniProtKB-SubCell.
DR   InterPro; IPR024407; Protein_3a_bCoV.
DR   Pfam; PF11289; APA3_viroporin; 1.
PE   3: Inferred from homology;
KW   Glycoprotein; Host cell membrane; Host cytoplasm; Host Golgi apparatus;
KW   Host membrane; Membrane; Reference proteome; Secreted; Transmembrane;
KW   Transmembrane helix; Virion.
FT   CHAIN           1..275
FT                   /note="ORF3a protein"
FT                   /id="PRO_0000449650"
FT   TRANSMEM        35..55
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        71..91
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        94..114
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   SITE            133
FT                   /note="Involved in polymerization"
FT                   /evidence="ECO:0000250|UniProtKB:P59632"
FT   CARBOHYD        32
FT                   /note="O-linked (GalNAc...) threonine; by host"
FT                   /evidence="ECO:0000250|UniProtKB:P59632"
FT   CARBOHYD        34
FT                   /note="O-linked (GalNAc...) threonine; by host"
FT                   /evidence="ECO:0000255"
SQ   SEQUENCE   275 AA;  31123 MW;  4688E6D477E031C4 CRC64;
     MDLFMRIFTI GTVTLKQGEI KDATPSDFVR ATATIPIQAS LPFGWLIVGV ALLAVFQSAS
     KIITLKKRWQ LALSKGVHFV CNLLLLFVTV YSHLLLVAAG LEAPFLYLYA LVYFLQSINF
     VRIIMRLWLC WKCRSKNPLL YDANYFLCWH TNCYDYCIPY NSVTSSIVIT SGDGTTSPIS
     EHDYQIGGYT EKWESGVKDC VVLHSYFTSD YYQLYSTQLS TDTGVEHVTF FIYNKIVDEP
     EEHVQIHTID GSSGVVNPVM EPIYDEPTTT TSVPL
//
ID   VME1_SARS2              Reviewed;         222 AA.
AC   P0DTC5;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=Membrane protein {ECO:0000255|HAMAP-Rule:MF_04202};
DE            Short=M;
DE   AltName: Full=E1 glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
DE   AltName: Full=Matrix glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
DE   AltName: Full=Membrane glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
GN   ORFNames=M;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
CC   -!- FUNCTION: Component of the viral envelope that plays a central role in
CC       virus morphogenesis and assembly via its interactions with other viral
CC       proteins. {ECO:0000255|HAMAP-Rule:MF_04202, ECO:0000255|PROSITE-
CC       ProRule:PRU01275}.
CC   -!- SUBUNIT: Homomultimer. Interacts with envelope E protein in the budding
CC       compartment of the host cell, which is located between endoplasmic
CC       reticulum and the Golgi complex. Forms a complex with HE and S
CC       proteins. Interacts with nucleocapsid N protein. This interaction
CC       probably participates in RNA packaging into the virus (By similarity).
CC       Interacts with the accessory proteins 3a and 7a (By similarity).
CC       {ECO:0000250|UniProtKB:P59596, ECO:0000255|HAMAP-Rule:MF_04202}.
CC   -!- SUBCELLULAR LOCATION: Virion membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04202}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_04202}. Host Golgi apparatus membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04202}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_04202}. Note=Largely embedded in the lipid bilayer.
CC       {ECO:0000255|HAMAP-Rule:MF_04202}.
CC   -!- SIMILARITY: Belongs to the betacoronaviruses M protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04202}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43419.1; -; Genomic_RNA.
DR   RefSeq; YP_009724393.1; NC_045512.2.
DR   BioGRID; 4383846; 30.
DR   IntAct; P0DTC5; 85.
DR   GeneID; 43740571; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0039660; F:structural constituent of virion; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:mitigation of host immune response by virus; IEA:UniProtKB-KW.
DR   GO; GO:0019058; P:viral life cycle; IEA:InterPro.
DR   HAMAP; MF_04202; BETA_CORONA_M; 1.
DR   InterPro; IPR002574; M_CoV.
DR   Pfam; PF01635; Corona_M; 1.
DR   PROSITE; PS51927; COV_M; 1.
PE   3: Inferred from homology;
KW   Glycoprotein; Host Golgi apparatus; Host membrane; Host-virus interaction;
KW   Membrane; Reference proteome; Transmembrane; Transmembrane helix;
KW   Viral envelope protein; Viral immunoevasion; Viral matrix protein; Virion.
FT   CHAIN           1..222
FT                   /note="Membrane protein"
FT                   /id="PRO_0000449652"
FT   TOPO_DOM        2..19
FT                   /note="Virion surface"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TRANSMEM        20..40
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TOPO_DOM        41..50
FT                   /note="Intravirion"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TRANSMEM        51..71
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TOPO_DOM        72..79
FT                   /note="Virion surface"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TRANSMEM        80..100
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
FT   TOPO_DOM        101..222
FT                   /note="Intravirion"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04202"
SQ   SEQUENCE   222 AA;  25147 MW;  ED44D84C3BB9A6DB CRC64;
     MADSNGTITV EELKKLLEQW NLVIGFLFLT WICLLQFAYA NRNRFLYIIK LIFLWLLWPV
     TLACFVLAAV YRINWITGGI AIAMACLVGL MWLSYFIASF RLFARTRSMW SFNPETNILL
     NVPLHGTILT RPLLESELVI GAVILRGHLR IAGHHLGRCD IKDLPKEITV ATSRTLSYYK
     LGASQRVAGD SGFAAYSRYR IGNYKLNTDH SSSSDNIALL VQ
//
ID   NS7A_SARS2              Reviewed;         121 AA.
AC   P0DTC7;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=ORF7a protein;
DE            Short=ORF7a;
DE   AltName: Full=Accessory protein 7a;
DE   AltName: Full=Protein U122;
DE   AltName: Full=Protein X4;
DE   Flags: Precursor;
GN   ORFNames=7a;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
CC   -!- FUNCTION: Plays a role as antagonist of host tetherin (BST2),
CC       disrupting its antiviral effect. Acts by binding to BST2 thereby
CC       interfering with its glycosylation. May suppress small interfering RNA
CC       (siRNA). May bind to host ITGAL, thereby playing a role in attachment
CC       or modulation of leukocytes. {ECO:0000250|UniProtKB:P59635}.
CC   -!- SUBUNIT: Interacts with the spike glycoprotein. Interacts with M
CC       protein. Interacts with E protein. Interacts with the ORF3a protein.
CC       Interacts with human SGT. Interacts with host ITGAL. Interacts with
CC       host BST2. {ECO:0000250|UniProtKB:P59635}.
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000250|UniProtKB:P59635}. Host
CC       endoplasmic reticulum membrane {ECO:0000250|UniProtKB:P59635}; Single-
CC       pass membrane protein {ECO:0000250|UniProtKB:P59635}. Host endoplasmic
CC       reticulum-Golgi intermediate compartment membrane
CC       {ECO:0000250|UniProtKB:P59635}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P59635}. Host Golgi apparatus membrane
CC       {ECO:0000250|UniProtKB:P59635}; Single-pass membrane protein
CC       {ECO:0000250|UniProtKB:P59635}.
CC   -!- DOMAIN: The di-lysine motif confers endoplasmic reticulum localization
CC       for type I membrane proteins. {ECO:0000250|UniProtKB:P59635}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43421.1; -; Genomic_RNA.
DR   RefSeq; YP_009724395.1; NC_045512.2.
DR   PDB; 6W37; X-ray; 2.90 A; A=16-82.
DR   PDBsum; 6W37; -.
DR   SMR; P0DTC7; -.
DR   BioGRID; 4383872; 2.
DR   IntAct; P0DTC7; 48.
DR   GeneID; 43740573; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044173; C:host cell endoplasmic reticulum-Golgi intermediate compartment membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019012; C:virion; IEA:UniProtKB-SubCell.
DR   GO; GO:0039646; P:modulation by virus of host G0/G1 transition checkpoint; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.1550; -; 1.
DR   InterPro; IPR014888; NS7A_CoV.
DR   InterPro; IPR036495; NS7A_sf_CoV.
DR   Pfam; PF08779; SARS_X4; 1.
DR   SUPFAM; SSF117066; SSF117066; 1.
DR   PROSITE; PS51919; X4E; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disulfide bond;
KW   G0/G1 host cell cycle checkpoint dysregulation by virus;
KW   Host endoplasmic reticulum; Host Golgi apparatus; Host membrane;
KW   Host-virus interaction; Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host tetherin by virus; Membrane;
KW   Modulation of host cell cycle by virus; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Viral immunoevasion; Virion.
FT   SIGNAL          1..15
FT                   /evidence="ECO:0000255"
FT   CHAIN           16..121
FT                   /note="ORF7a protein"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000449654"
FT   TRANSMEM        96..116
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          16..81
FT                   /note="X4e"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01267"
FT   MOTIF           117..121
FT                   /note="Di-lysine motif"
FT                   /evidence="ECO:0000250|UniProtKB:P59635"
FT   DISULFID        23..58
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01267"
FT   DISULFID        35..67
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01267"
FT   STRAND          21..24
FT                   /evidence="ECO:0000244|PDB:6W37"
FT   STRAND          27..32
FT                   /evidence="ECO:0000244|PDB:6W37"
FT   STRAND          34..37
FT                   /evidence="ECO:0000244|PDB:6W37"
FT   STRAND          39..41
FT                   /evidence="ECO:0000244|PDB:6W37"
FT   STRAND          47..49
FT                   /evidence="ECO:0000244|PDB:6W37"
FT   TURN            50..52
FT                   /evidence="ECO:0000244|PDB:6W37"
FT   STRAND          53..57
FT                   /evidence="ECO:0000244|PDB:6W37"
FT   STRAND          60..66
FT                   /evidence="ECO:0000244|PDB:6W37"
FT   STRAND          72..80
FT                   /evidence="ECO:0000244|PDB:6W37"
SQ   SEQUENCE   121 AA;  13744 MW;  891E7EAB9E8A5BA9 CRC64;
     MKIILFLALI TLATCELYHY QECVRGTTVL LKEPCSSGTY EGNSPFHPLA DNKFALTCFS
     TQFAFACPDG VKHVYQLRAR SVSPKLFIRQ EEVQELYSPI FLIVAAIVFI TLCFTLKRKT
     E
//
ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M. Plays an important role in enhancing the efficiency of
CC       subgenomic viral RNA transcription as well as viral replication (By
CC       similarity). May modulate transforming growth factor-beta signaling by
CC       binding host smad3 (By similarity). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- SUBUNIT: Homooligomer. Both monomeric and oligomeric forms interact
CC       with RNA. Interacts with protein M. Interacts with protein E. May bind
CC       to host HNRNPA1. Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (By similarity). May interact with host
CC       SMAD3 (By similarity). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       endoplasmic reticulum-Golgi intermediate compartment
CC       {ECO:0000255|HAMAP-Rule:MF_04096}. Host Golgi apparatus
CC       {ECO:0000255|HAMAP-Rule:MF_04096}. Note=Located inside the virion,
CC       complexed with the viral RNA. Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine and threonine residues.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   RefSeq; YP_009724397.2; NC_045512.2.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 7C22; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 16.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 22.
DR   GeneID; 43740575; -.
DR   SIGNOR; P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0044177; C:host cell Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0019013; C:viral nucleocapsid; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; Corona_nucleoca; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF103068; SSF103068; 1.
DR   SUPFAM; SSF110304; SSF110304; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host Golgi apparatus; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Transcription;
KW   Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note="Nucleoprotein"
FT                   /id="PRO_0000449656"
FT   DOMAIN          48..175
FT                   /note="CoV N NTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01276"
FT   DOMAIN          247..364
FT                   /note="CoV N CTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01277"
FT   REGION          41..186
FT                   /note="RNA-binding"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04096"
FT   REGION          258..361
FT                   /note="Dimerization"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04096"
FT   MOD_RES         176
FT                   /note="Phosphoserine; by host"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04096"
FT   STRAND          56..58
FT                   /evidence="ECO:0000244|PDB:6M3M"
FT   STRAND          60..62
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   STRAND          76..78
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   HELIX           80..82
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   STRAND          84..90
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   STRAND          93..95
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   STRAND          99..103
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   STRAND          107..112
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   TURN            117..120
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   STRAND          130..134
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   TURN            144..146
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   TURN            151..153
FT                   /evidence="ECO:0000244|PDB:6VYO"
FT   STRAND          171..173
FT                   /evidence="ECO:0000244|PDB:6YI3"
FT   HELIX           251..254
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   HELIX           259..261
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   STRAND          266..268
FT                   /evidence="ECO:0000244|PDB:6WJI"
FT   HELIX           270..274
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   HELIX           289..294
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   HELIX           295..297
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   HELIX           301..305
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   HELIX           311..317
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   STRAND          318..325
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   STRAND          328..338
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   HELIX           346..356
FT                   /evidence="ECO:0000244|PDB:6YUN"
FT   HELIX           359..362
FT                   /evidence="ECO:0000244|PDB:6YUN"
SQ   SEQUENCE   419 AA;  45626 MW;  56688DB785414E81 CRC64;
     MSDNGPQNQR NAPRITFGGP SDSTGSNQNG ERSGARSKQR RPQGLPNNTA SWFTALTQHG
     KEDLKFPRGQ GVPINTNSSP DDQIGYYRRA TRRIRGGDGK MKDLSPRWYF YYLGTGPEAG
     LPYGANKDGI IWVATEGALN TPKDHIGTRN PANNAAIVLQ LPQGTTLPKG FYAEGSRGGS
     QASSRSSSRS RNSSRNSTPG SSRGTSPARM AGNGGDAALA LLLLDRLNQL ESKMSGKGQQ
     QQGQTVTKKS AAEASKKPRQ KRTATKAYNV TQAFGRRGPE QTQGNFGDQE LIRQGTDYKH
     WPQIAQFAPS ASAFFGMSRI GMEVTPSGTW LTYTGAIKLD DKDPNFKDQV ILLNKHIDAY
     KTFPPTEPKK DKKKKADETQ ALPQRQKKQQ TVTLLPAADL DDFSKQLQQS MSSADSTQA
//
ID   VEMP_SARS2              Reviewed;          75 AA.
AC   P0DTC4;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=Envelope small membrane protein {ECO:0000255|HAMAP-Rule:MF_04204};
DE            Short=E;
DE            Short=sM protein {ECO:0000255|HAMAP-Rule:MF_04204};
GN   Name=E {ECO:0000255|HAMAP-Rule:MF_04204}; ORFNames=4;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
CC   -!- FUNCTION: Plays a central role in virus morphogenesis and assembly.
CC       Acts as a viroporin and self-assembles in host membranes forming
CC       pentameric protein-lipid pores that allow ion transport. Also plays a
CC       role in the induction of apoptosis. {ECO:0000255|HAMAP-Rule:MF_04204}.
CC   -!- SUBUNIT: Homopentamer. Interacts with membrane protein M in the budding
CC       compartment of the host cell, which is located between endoplasmic
CC       reticulum and the Golgi complex. Interacts with Nucleoprotein (By
CC       similarity). Interacts with the accessory proteins 3a and 7a. Interacts
CC       (via C-terminus) with human MPP5 (via PDZ domain); this inhibits the
CC       interaction between human MPP5 and human CRB3, and causes delayed tight
CC       junction formation and defective cell polarity (By similarity).
CC       {ECO:0000250|UniProtKB:P59637, ECO:0000255|HAMAP-Rule:MF_04204}.
CC   -!- SUBCELLULAR LOCATION: Host Golgi apparatus membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04204}; Single-pass type III membrane protein
CC       {ECO:0000255|HAMAP-Rule:MF_04204}. Note=The cytoplasmic tail functions
CC       as a Golgi complex-targeting signal. {ECO:0000255|HAMAP-Rule:MF_04204}.
CC   -!- SIMILARITY: Belongs to the betacoronaviruses E protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04204}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43418.1; -; Genomic_RNA.
DR   RefSeq; YP_009724392.1; NC_045512.2.
DR   SMR; P0DTC4; -.
DR   BioGRID; 4383845; 6.
DR   IntAct; P0DTC4; 17.
DR   GeneID; 43740570; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0039707; P:pore formation by virus in membrane of host cell; IEA:InterPro.
DR   HAMAP; MF_04204; BETA_CORONA_E; 1.
DR   InterPro; IPR003873; E_protein_CoV.
DR   Pfam; PF02723; NS3_envE; 1.
DR   PROSITE; PS51926; COV_E; 1.
PE   3: Inferred from homology;
KW   Apoptosis; Host Golgi apparatus; Host membrane; Membrane;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..75
FT                   /note="Envelope small membrane protein"
FT                   /id="PRO_0000449651"
FT   TOPO_DOM        1..16
FT                   /note="Virion surface"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04204"
FT   TRANSMEM        17..37
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04204"
FT   TOPO_DOM        38..75
FT                   /note="Intravirion"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_04204"
FT   MOTIF           72..75
FT                   /note="PDZ-binding; required for interaction with human
FT                   MPP5"
FT                   /evidence="ECO:0000250|UniProtKB:P59637"
SQ   SEQUENCE   75 AA;  8365 MW;  5C431BD2AA1B6B99 CRC64;
     MYSFVSEETG TLIVNSVLLF LAFVVFLLVT LAILTALRLC AYCCNIVNVS LVKPSFYVYS
     RVKNLNSSRV PDLLV
//
ID   NS6_SARS2               Reviewed;          61 AA.
AC   P0DTC6;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=ORF6 protein;
DE            Short=ORF6;
DE   AltName: Full=Accessory protein 6;
DE   AltName: Full=Non-structural protein 6;
DE            Short=ns6;
DE   AltName: Full=Protein X3;
GN   ORFNames=6;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
CC   -!- FUNCTION: Disrupts cell nuclear import complex formation by tethering
CC       karyopherin alpha 2 and karyopherin beta 1 to the membrane. Retention
CC       of import factors at the ER/Golgi membrane leads to a loss of transport
CC       into the nucleus. Thereby prevents STAT1 nuclear translocation in
CC       response to interferon signaling, thus blocking the expression of
CC       interferon stimulated genes (ISGs) that display multiple antiviral
CC       activities. {ECO:0000250|UniProtKB:P59634}.
CC   -!- SUBUNIT: Interacts with host KPNA2. May interact with nsp8. Interacts
CC       with protein ORF9b. {ECO:0000250|UniProtKB:P59634}.
CC   -!- SUBCELLULAR LOCATION: Host endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:P59634}. Host Golgi apparatus membrane
CC       {ECO:0000250|UniProtKB:P59634}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P59634}. Note=Localizes to virus-induced
CC       vesicular structures called double membrane vesicles.
CC       {ECO:0000250|UniProtKB:P59634}.
CC   -!- SIMILARITY: Belongs to the coronaviruses accessory protein 6 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43420.1; -; Genomic_RNA.
DR   RefSeq; YP_009724394.1; NC_045512.2.
DR   BioGRID; 4383870; 3.
DR   IntAct; P0DTC6; 21.
DR   GeneID; 43740572; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0009405; P:pathogenesis; IEA:UniProtKB-KW.
DR   InterPro; IPR022736; NS6_bCoV.
DR   Pfam; PF12133; Sars6; 1.
PE   3: Inferred from homology;
KW   Host cytoplasm; Host endoplasmic reticulum; Host Golgi apparatus;
KW   Host membrane; Membrane; Reference proteome; Virulence.
FT   CHAIN           1..61
FT                   /note="ORF6 protein"
FT                   /id="PRO_0000449653"
SQ   SEQUENCE   61 AA;  7273 MW;  B21BD303F59A1D0A CRC64;
     MFHLVDFQVT IAEILLIIMR TFKVSIWNLD YIINLIIKNL SKSLTENKYS QLDEEQPMEI
     D
//
ID   ORF9B_SARS2             Reviewed;          97 AA.
AC   P0DTD2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=ORF9b protein;
DE            Short=ORF9b;
DE   AltName: Full=Accessory protein 9b;
DE   AltName: Full=ORF-9b;
DE   AltName: Full=Protein 9b;
GN   ORFNames=9b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
CC   -!- FUNCTION: Plays a role in the inhibition of host innate immune response
CC       by targeting the mitochondrial-associated adapter MAVS.
CC       Mechanistically, usurps the E3 ligase ITCH to trigger the degradation
CC       of MAVS, TRAF3, and TRAF6. In addition, causes mitochondrial elongation
CC       by triggering ubiquitination and proteasomal degradation of dynamin-
CC       like protein 1/DNM1L. {ECO:0000250|UniProtKB:P59636}.
CC   -!- SUBUNIT: Homodimer. Interacts with host XPO1; this interaction mediates
CC       protein ORF9b export out of the nucleus. Interacts with host MAVS.
CC       Interacts with protein ORF6. {ECO:0000250|UniProtKB:P59636}.
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000250|UniProtKB:P59636}. Host
CC       cytoplasmic vesicle membrane {ECO:0000250|UniProtKB:P59636}; Peripheral
CC       membrane protein {ECO:0000250|UniProtKB:P59636}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P59636}. Host endoplasmic reticulum
CC       {ECO:0000250|UniProtKB:P59636}. Host nucleus
CC       {ECO:0000250|UniProtKB:P59636}. Host mitochondrion
CC       {ECO:0000250|UniProtKB:P59636}. Note=Binds non-covalently to
CC       intracellular lipid bilayers. {ECO:0000250|UniProtKB:P59636}.
CC   -!- MISCELLANEOUS: The gene encoding this protein is included within the N
CC       gene (alternative ORF). {ECO:0000250|UniProtKB:P59636}.
CC   -!- SIMILARITY: Belongs to the coronavirus group 2 protein 9b family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   SMR; P0DTD2; -.
DR   BioGRID; 4383874; 11.
DR   IntAct; P0DTD2; 24.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044162; C:host cell cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   InterPro; IPR037223; Protein_9b_SARS.
DR   InterPro; IPR018542; Protein_9b_SARS-like.
DR   Pfam; PF09399; SARS_lipid_bind; 1.
DR   SUPFAM; SSF141666; SSF141666; 1.
DR   PROSITE; PS51920; SARS_9B; 1.
PE   3: Inferred from homology;
KW   Host cytoplasm; Host cytoplasmic vesicle; Host endoplasmic reticulum;
KW   Host membrane; Host mitochondrion; Host nucleus; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host MAVS by virus; Inhibition of host RLR pathway by virus;
KW   Membrane; Reference proteome; Viral immunoevasion; Virion.
FT   CHAIN           1..97
FT                   /note="ORF9b protein"
FT                   /evidence="ECO:0000250|UniProtKB:P59636"
FT                   /id="PRO_0000449657"
FT   DOMAIN          8..97
FT                   /note="9b"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01268"
FT   MOTIF           45..53
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250|UniProtKB:P59636"
SQ   SEQUENCE   97 AA;  10797 MW;  62CFB65C1804545E CRC64;
     MDPKISEMHP ALRLVDPQIQ LAVTRMENAV GRDQNNVGPK VYPIILRLGS PLSLNMARKT
     LNSLEDKAFQ LTPIAVQMTK LATTEELPDE FVVVTVK
//
ID   NS7B_SARS               Reviewed;          44 AA.
AC   Q7TFA1; Q7TLC9;
DT   17-APR-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2003, sequence version 1.
DT   12-AUG-2020, entry version 47.
DE   RecName: Full=Protein non-structural 7b;
DE            Short=ns7b;
DE   AltName: Full=Accessory protein 7b;
GN   ORFNames=7b;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   "Mechanisms and enzymes involved in SARS coronavirus genome expression.";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [4]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17037516; DOI=10.1007/978-0-387-33012-9_20;
RA   Pekosz A., Schaecher S.R., Diamond M.S., Fremont D.H., Sims A.C.,
RA   Baric R.S.;
RT   "Structure, expression, and intracellular localization of the SARS-CoV
RT   accessory proteins 7a and 7b.";
RL   Adv. Exp. Med. Biol. 581:115-120(2006).
CC   -!- INTERACTION:
CC       Q7TFA1; P59637: E; NbExp=2; IntAct=EBI-25492846, EBI-25487741;
CC       Q7TFA1; Q19QW5: ORF6; NbExp=2; IntAct=EBI-25492846, EBI-25493595;
CC   -!- SUBCELLULAR LOCATION: Host membrane {ECO:0000305}; Single-pass membrane
CC       protein {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY274119; AAP41044.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33704.1; -; Genomic_RNA.
DR   RefSeq; NP_849175.1; NC_004718.3.
DR   BioGRID; 4383921; 8.
DR   IntAct; Q7TFA1; 4.
DR   GeneID; 1489675; -.
DR   KEGG; vg:1489675; -.
DR   SIGNOR; Q7TFA1; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000137377; Genome.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   InterPro; IPR021532; NS7B_SARS-like.
DR   Pfam; PF11395; DUF2873; 1.
PE   1: Evidence at protein level;
KW   Host membrane; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..44
FT                   /note="Protein non-structural 7b"
FT                   /id="PRO_0000283857"
FT   TRANSMEM        9..29
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
SQ   SEQUENCE   44 AA;  5302 MW;  7AD647C9E311E04F CRC64;
     MNELTLIDFY LCFLAFLLFL VLIMLIIFWF SLEIQDLEEP CTKV
//
ID   Y14_SARS                Reviewed;          70 AA.
AC   Q7TLC7;
DT   29-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2003, sequence version 1.
DT   12-AUG-2020, entry version 32.
DE   RecName: Full=Uncharacterized protein 14;
GN   ORFNames=ORF14;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
CC   -!- INTERACTION:
CC       Q7TLC7; P59636: 9b; NbExp=3; IntAct=EBI-25488942, EBI-9021274;
CC       Q7TLC7; Q7TLC7: ORF14; NbExp=3; IntAct=EBI-25488942, EBI-25488942;
CC       Q7TLC7; Q13561: DCTN2; Xeno; NbExp=2; IntAct=EBI-25488942, EBI-715074;
CC       Q7TLC7; O14964: HGS; Xeno; NbExp=2; IntAct=EBI-25488942, EBI-740220;
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY274119; AAP41049.1; -; Genomic_RNA.
DR   BioGRID; 4383925; 8.
DR   IntAct; Q7TLC7; 7.
DR   Proteomes; UP000000354; Genome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   InterPro; IPR035113; Protein_14_SARS-like.
DR   Pfam; PF17635; DUF5515; 1.
PE   1: Evidence at protein level;
KW   Reference proteome.
FT   CHAIN           1..70
FT                   /note="Uncharacterized protein 14"
FT                   /id="PRO_0000289937"
SQ   SEQUENCE   70 AA;  7852 MW;  9FCDB5ADCD6CF79A CRC64;
     MLPPCYNFLK EQHCQKASTQ REAEAAVKPL LAPHHVVAVI QEIQLLAAVG EILLLEWLAE
     VVKLPSRYCC
//
ID   NS8B_SARS               Reviewed;          84 AA.
AC   Q80H93; Q7TFA6;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   12-AUG-2020, entry version 58.
DE   RecName: Full=ORF8b protein;
DE   AltName: Full=Accessory protein 8b;
DE   AltName: Full=Non-structural protein 8b;
DE            Short=ns8b;
GN   ORFNames=8b;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   "Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome.";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   "The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39).";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   "The complete genome of SARS coronavirus clone TW1.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   "SARS virus is a close relative of type II coronaviruses.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RT   "The complete genome of SARS coronavirus TWH.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   SUBCELLULAR LOCATION.
RC   STRAIN=Isolate CUHK-Su10;
RX   PubMed=16753150; DOI=10.1016/j.febslet.2006.05.051;
RA   Law P.Y.P., Liu Y.-M., Geng H., Kwan K.H., Waye M.M.-Y., Ho Y.-Y.;
RT   "Expression and functional characterization of the putative protein 8b of
RT   the severe acute respiratory syndrome-associated coronavirus.";
RL   FEBS Lett. 580:3643-3648(2006).
CC   -!- FUNCTION: Non-structural protein which is dispensable for virus
CC       replication in cell culture.
CC   -!- SUBCELLULAR LOCATION: Host cytoplasm {ECO:0000269|PubMed:16753150}.
CC       Host nucleus {ECO:0000269|PubMed:16753150}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; AAP13450.1; -; Genomic_RNA.
DR   EMBL; AY274119; AAP41046.1; -; Genomic_RNA.
DR   EMBL; AY282752; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278554; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278491; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278487; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278488; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY278489; AAP51236.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; AY278490; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY279354; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY310120; AAP50494.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33706.1; -; Genomic_RNA.
DR   EMBL; AY348314; AAP97889.1; -; Genomic_RNA.
DR   EMBL; AY338174; AAQ01604.1; -; Genomic_RNA.
DR   EMBL; AY338175; AAQ01616.1; -; Genomic_RNA.
DR   EMBL; AP006557; BAC81357.1; -; Genomic_RNA.
DR   EMBL; AP006558; BAC81371.1; -; Genomic_RNA.
DR   EMBL; AP006559; BAC81385.1; -; Genomic_RNA.
DR   EMBL; AP006560; BAC81399.1; -; Genomic_RNA.
DR   EMBL; AP006561; BAC81413.1; -; Genomic_RNA.
DR   EMBL; AY323977; AAP72983.1; -; Genomic_RNA.
DR   EMBL; AY427439; AAQ94069.1; -; Genomic_RNA.
DR   EMBL; AY322208; AAP82973.1; -; Genomic_RNA.
DR   RefSeq; NP_849177.1; NC_004718.3.
DR   BioGRID; 4383923; 13.
DR   IntAct; Q80H93; 6.
DR   PRIDE; Q80H93; -.
DR   GeneID; 1489677; -.
DR   KEGG; vg:1489677; -.
DR   SIGNOR; Q80H93; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000103670; Genome.
DR   Proteomes; UP000109640; Genome.
DR   Proteomes; UP000116947; Genome.
DR   Proteomes; UP000121636; Genome.
DR   Proteomes; UP000131569; Genome.
DR   Proteomes; UP000131955; Genome.
DR   Proteomes; UP000137377; Genome.
DR   Proteomes; UP000138690; Genome.
DR   Proteomes; UP000143093; Genome.
DR   Proteomes; UP000146108; Genome.
DR   Proteomes; UP000146181; Genome.
DR   Proteomes; UP000146296; Genome.
DR   Proteomes; UP000148194; Genome.
DR   Proteomes; UP000153467; Genome.
DR   Proteomes; UP000160648; Genome.
DR   Proteomes; UP000172416; Genome.
DR   GO; GO:0030430; C:host cell cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   InterPro; IPR022722; NS8_bCoV.
DR   Pfam; PF12093; Corona_NS8; 1.
PE   4: Predicted;
KW   Host cytoplasm; Host nucleus; Reference proteome.
FT   CHAIN           1..84
FT                   /note="ORF8b protein"
FT                   /id="PRO_0000106135"
FT   VARIANT         76
FT                   /note="L -> F (in strain: Isolate GD01)"
SQ   SEQUENCE   84 AA;  9560 MW;  510EEE64470C3B1E CRC64;
     MCLKILVRYN TRGNTYSTAW LCALGKVLPF HRWHTMVQTC TPNVTINCQD PAGGALIARC
     WYLHEGHQTA AFRDVLVVLN KRTN
//
ID   A0A663DJA2_SARS2        Unreviewed;        38 AA.
AC   A0A663DJA2;
DT   22-APR-2020, integrated into UniProtKB/TrEMBL.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   SubName: Full=ORF10 proteiin {ECO:0000313|EMBL:QHZ00366.1};
DE   SubName: Full=ORF10 protein {ECO:0000313|EMBL:QHI42199.1, ECO:0000313|EMBL:QHS34554.1};
GN   Name=ORF10 {ECO:0000313|EMBL:QHI42199.1};
GN   Synonyms=orf10 {ECO:0000313|EMBL:QHS34554.1};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Nidovirales; Cornidovirineae; Coronaviridae;
OC   Orthocoronavirinae; Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049 {ECO:0000313|EMBL:QHI42199.1, ECO:0000313|Proteomes:UP000464024};
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1] {ECO:0000313|EMBL:QIA98562.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/ITA/INMI1/2020 {ECO:0000313|EMBL:QIA98562.1};
RX   PubMed=32229288;
RA   Capobianchi M.R., Rueca M., Messina F., Giombini E., Carletti F.,
RA   Colavita F., Castilletti C., Lalle E., Bordi L., Vairo F., Nicastri E.,
RA   Ippolito G., Maria Gruber C.E., Bartolini B.;
RT   "Molecular characterization of SARS-CoV-2 from the first case of COVID-19
RT   in Italy.";
RL   Clin. Microbiol. Infect. 0:0-0(2020).
RN   [2] {ECO:0000313|EMBL:QIB84681.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/NPL/61-TW/2020 {ECO:0000313|EMBL:QIB84681.1};
RX   PubMed=32057299;
RA   Bastola A., Sah R., Rodriguez-Morales A.J., Lal B.K., Jha R., Ojha H.C.,
RA   Shrestha B., Chu D.K.W., Poon L.L.M., Costello A., Morita K., Pandey B.D.;
RT   "The first 2019 novel coronavirus case in Nepal.";
RL   Lancet Infect. Dis. 0:0-0(2020).
RN   [3] {ECO:0000313|EMBL:QHI42199.1, ECO:0000313|Proteomes:UP000464024}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Wuhan-Hu-1 {ECO:0000313|EMBL:QHI42199.1};
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W.,
RA   Tian J.H., Pei Y.Y., Yuan M.L., Zhang Y.L., Dai F.H., Liu Y., Wang Q.M.,
RA   Zheng J.J., Xu L., Holmes E.C., Zhang Y.Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
RN   [4] {ECO:0000313|EMBL:QIX14045.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/IME-HZ01/2020
RC   {ECO:0000313|EMBL:QIX14045.1};
RX   PubMed=32222421;
RA   Zhang X.A., Fan H., Qi R.Z., Zheng W., Zheng K., Gong J.H., Fang L.Q.,
RA   Liu W.;
RT   "Importing coronavirus disease 2019 (COVID-19) into China after
RT   international air travel.";
RL   Travel Med Infect Dis 101620:0-0(2020).
RN   [5] {ECO:0000313|EMBL:QHR84457.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Australia/VIC01/2020 {ECO:0000313|EMBL:QHR84457.1};
RA   Caly L., Seemann T., Schultz M., Druce J., Taiaroa G.;
RT   "Complete genome sequence of first Australian case of the 2019-nCoV corona
RT   virus, Australia/VIC01/2020.";
RL   Submitted (JAN-2020) to the EMBL/GenBank/DDBJ databases.
RN   [6] {ECO:0000313|EMBL:QHU79182.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=NCoV-FIN-29-Jan-2020 {ECO:0000313|EMBL:QHU79182.1};
RA   Smura T., Kuivanen S., Broas M., Peltola J., Kallio-Kokko H., Vapalahti O.;
RT   "2019-nCoV Finland.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [7] {ECO:0000313|EMBL:QHZ00407.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-MA1/2020 {ECO:0000313|EMBL:QHZ00407.1};
RA   Paden C.R., Zhang J., Queen K., Li Y., Tao Y., Uehara A., Lu X., Lynch B.,
RA   Sakthivel S.K.K., Whitaker B.L., Kamili S., Wang L., Murray J.R.,
RA   Gerber S.I., Lindstrom S., Tong S.;
RT   "2019-nCoV Massachusetts.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [8] {ECO:0000313|EMBL:QHU79202.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-WA1-A12/2020 {ECO:0000313|EMBL:QHU79202.1}, and
RC   2019-nCoV/USA-WA1-F6/2020 {ECO:0000313|EMBL:QHU79212.1};
RA   Queen K., Tamin A., Harcourt J., Tao Y., Paden C.R., Zhang J., Li Y.,
RA   Uehara A., Lu X., Kamili S., Gautam R., Wang H., Murray J.R., Gerber S.I.,
RA   Lindstrom S., Thornburg N., Tong S.;
RT   "2019-NCoV WA1 culture isolates.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [9] {ECO:0000313|EMBL:QIA20053.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/Yunnan-01/2020
RC   {ECO:0000313|EMBL:QIA20053.1};
RA   Fu X., Li D., Sun Y.;
RT   "A novel coronavirus associated with a respiratory disease in Kunming of
RT   Yunnan province, China.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [10] {ECO:0000313|EMBL:BCA25652.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/Japan/KY/V-029/2020 {ECO:0000313|EMBL:BCA25652.1};
RA   Sekizuka T., Matsuyama S., Shirato K., Nao N., Itokawa K., Hashino M.,
RA   Tanaka R., Yatsu K., Suzuki T., Suzuki M., Hasegawa H., Wakita T.,
RA   Takeda M., Kuroda M.;
RT   "Complete genome sequence of Wuhan seafood market pneumonia virus 2019-
RT   nCoV/Japan/KY/V-029/2020 isolated from a patient in Japan.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [11] {ECO:0000313|EMBL:BCA25662.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/Japan/TY/WK-012/2020 {ECO:0000313|EMBL:BCA25662.1};
RA   Sekizuka T., Matsuyama S., Shirato K., Nao N., Itokawa K., Hashino M.,
RA   Tanaka R., Yatsu K., Suzuki T., Suzuki M., Hasegawa H., Wakita T.,
RA   Takeda M., Kuroda M.;
RT   "Complete genome sequence of Wuhan seafood market pneumonia virus 2019-
RT   nCoV/Japan/TY/WK-012/2020 isolated from a patient in Japan.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [12] {ECO:0000313|EMBL:BCA25672.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/Japan/TY/WK-501/2020 {ECO:0000313|EMBL:BCA25672.1};
RA   Sekizuka T., Matsuyama S., Shirato K., Nao N., Itokawa K., Hashino M.,
RA   Tanaka R., Yatsu K., Suzuki T., Suzuki M., Hasegawa H., Wakita T.,
RA   Takeda M., Kuroda M.;
RT   "Complete genome sequence of Wuhan seafood market pneumonia virus 2019-
RT   nCoV/Japan/TY/WK-501/2020 isolated from a patient in Japan.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [13] {ECO:0000313|EMBL:BCA25682.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/Japan/TY/WK-521/2020 {ECO:0000313|EMBL:BCA25682.1};
RA   Sekizuka T., Matsuyama S., Shirato K., Nao N., Itokawa K., Hashino M.,
RA   Tanaka R., Yatsu K., Suzuki T., Suzuki M., Hasegawa H., Wakita T.,
RA   Takeda M., Kuroda M.;
RT   "Complete genome sequence of Wuhan seafood market pneumonia virus 2019-
RT   nCoV/Japan/TY/WK-521/2020 isolated from a patient in Japan.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [14] {ECO:0000313|EMBL:BCA87369.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/Hu/DP/Kng/19-020 {ECO:0000313|EMBL:BCA87369.1}, and
RC   SARS-CoV-2/Hu/DP/Kng/19-027 {ECO:0000313|EMBL:BCA87379.1};
RA   Hishiki T., Suzuki R., Sakuragi J., Usui K., Tanaka Y., Kawai J., Kogo Y.,
RA   Matsuki Y., An T., Hayashizaki Y., Takasaki T.;
RT   "Development of SmartAmp system for SARS-CoV-2 using viruses isolated from
RT   patients in a Cruse Ship.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [15] {ECO:0000313|EMBL:QHZ00366.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=HZ-1 {ECO:0000313|EMBL:QHZ00366.1};
RA   Yu H., Li J., Yu X., Wang H., Pan J.;
RT   "Genomic Analysis of First Case of 2019-ncov in Hangzhou, Zhejiang China.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [16] {ECO:0000313|EMBL:QHZ00387.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SNU01 {ECO:0000313|EMBL:QHZ00387.1};
RA   Park W.B., Kwon N.-J., Choi S.-J., Kang C.K., Choe P.G., Kim J.Y., Yun J.,
RA   Lee G.-W., Seong M.-W., Kim N., Seo J.-S., Oh M.-D.;
RT   "Isolation of 2019 novel coronavirus from a patient imported into Korea
RT   from Wuhan, China.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [17] {ECO:0000313|EMBL:QHZ87600.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CA6/2020 {ECO:0000313|EMBL:QHZ87600.1};
RA   Zhang J., Queen K., Li Y., Tao Y., Uehara A., Paden C.R., Lu X., Lynch B.,
RA   Sakthivel S.K.K., Whitaker B.L., Kamili S., Wang L., Murray J.R.,
RA   Gerber S.I., Lindstrom S., Tong S.;
RT   "nCoV-2019 California.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [18] {ECO:0000313|EMBL:QHZ87590.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-IL2/2020 {ECO:0000313|EMBL:QHZ87590.1};
RA   Li Y., Zhang J., Queen K., Tao Y., Uehara A., Paden C.R., Lu X., Lynch B.,
RA   Sakthivel S.K.K., Whitaker B.L., Kamili S., Wang L., Murray J.R.,
RA   Gerber S.I., Lindstrom S., Tong S.;
RT   "nCoV-2019 Illinois case.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [19] {ECO:0000313|EMBL:QHW06067.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CA5/2020 {ECO:0000313|EMBL:QHW06067.1};
RA   Tao Y., Queen K., Zhang J., Li Y., Uehara A., Paden C.R., Lu X., Lynch B.,
RA   Sakthivel S.K.K., Whitaker B.L., Kamili S., Wang L., Murray J.R.,
RA   Gerber S.I., Lindstrom S., Tong S.;
RT   "Novel coronavirus 2019 California sequence.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [20] {ECO:0000313|EMBL:QHW06047.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CA3/2020 {ECO:0000313|EMBL:QHW06047.1}, and
RC   2019-nCoV/USA-CA4/2020 {ECO:0000313|EMBL:QHW06057.1};
RA   Queen K., Zhang J., Li Y., Tao Y., Uehara A., Paden C.R., Lu X., Lynch B.,
RA   Sakthivel S.K.K., Whitaker B.L., Kamili S., Wang L., Murray J.R.,
RA   Gerber S.I., Lindstrom S., Tong S.;
RT   "Novel coronavirus 2019 sequences from California.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [21] {ECO:0000313|EMBL:QHZ00397.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-WI1/2020 {ECO:0000313|EMBL:QHZ00397.1};
RA   Zhang J., Uehara A., Queen K., Li Y., Tao Y., Paden C.R., Lu X., Lynch B.,
RA   Sakthivel S.K.K., Whitaker B.L., Kamili S., Wang L., Murray J.R.,
RA   Gerber S.I., Lindstrom S., Tong S.;
RT   "Novel coronavirus sequence Wisconsin.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [22] {ECO:0000313|EMBL:QID98802.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CA9/2020 {ECO:0000313|EMBL:QID98802.1};
RA   Queen K., Uehara A., Zhang J., Li Y., Tao Y., Paden C.R., Wang H.,
RA   Kamili S., Lu X., Lynch B., Sakthivel S.K.K., Whitaker B.L., Wang L.,
RA   Murray J.R., Padilla J., Lee J., Gerber S.I., Lindstrom S., Tong S.;
RT   "US case California.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [23] {ECO:0000313|EMBL:QID21056.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CA7/2020 {ECO:0000313|EMBL:QID21056.1},
RC   2019-nCoV/USA-CA8/2020 {ECO:0000313|EMBL:QID21066.1}, and
RC   2019-nCoV/USA-TX1/2020 {ECO:0000313|EMBL:QID21076.1};
RA   Queen K., Uehara A., Zhang J., Li Y., Tao Y., Paden C.R., Wang H.,
RA   Kamili S., Lu X., Lynch B., Sakthivel S.K.K., Whitaker B.L., Wang L.,
RA   Murray J.R., Gerber S.I., Lindstrom S., Tong S.;
RT   "US cases.";
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [24] {ECO:0000313|EMBL:QHS34554.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/IND/29/2020 {ECO:0000313|EMBL:QHS34554.1};
RA   Yadav P.D., Potdar V., Abraham P.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [25] {ECO:0000313|EMBL:QIG55873.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/HKG/HKU-902a/2020
RC   {ECO:0000313|EMBL:QIG55873.1}, SARS-CoV-2/human/HKG/HKU-902b/2020
RC   {ECO:0000313|EMBL:QIG55883.1}, SARS-CoV-2/human/HKG/HKU-903a/2020
RC   {ECO:0000313|EMBL:QIG55893.1}, SARS-CoV-2/human/HKG/HKU-903b/2020
RC   {ECO:0000313|EMBL:QIG55903.1}, SARS-CoV-2/human/HKG/HKU-907a/2020
RC   {ECO:0000313|EMBL:QIG55913.1}, SARS-CoV-2/human/HKG/HKU-907b/2020
RC   {ECO:0000313|EMBL:QIG55923.1}, SARS-CoV-2/human/HKG/HKU-908a/2020
RC   {ECO:0000313|EMBL:QIG55933.1}, and SARS-CoV-2/human/HKG/HKU-908b/2020
RC   {ECO:0000313|EMBL:QIG55943.1};
RA   To K.K.W., Yuen K.-Y.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [26] {ECO:0000313|EMBL:QIE07469.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/IQTC02/2020 {ECO:0000313|EMBL:QIE07469.1};
RA   Shi Y., Zheng K., Sun J., Huang J., Zhu A., Zhuang Z., Dai J., Chen Z.,
RA   Sun F., Zhang Z., Li X., Wang Y.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [27] {ECO:0000313|EMBL:QIE07479.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/IQTC04/2020 {ECO:0000313|EMBL:QIE07479.1};
RA   Huang J., Shi Y., Sun J., Zheng K., Zhu A., Sun F., Zhuang Z., Dai J.,
RA   Zhang Z., Huang S., Wang Y., Li X.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [28] {ECO:0000313|EMBL:QIE07459.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/IQTC01/2020 {ECO:0000313|EMBL:QIE07459.1};
RA   Shi Y., Sun J., Zheng K., Huang J., Zhao J.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [29] {ECO:0000313|EMBL:QIA98603.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/NTU01/TWN/human/2020 {ECO:0000313|EMBL:QIA98603.1},
RC   and SARS-CoV-2/NTU02/TWN/human/2020 {ECO:0000313|EMBL:QIA98614.1};
RA   Yeh S.-H., Lin Y.-Y., Lai Y.-Y., Li C.-L., Chang S.-C., Chen P.-J.,
RA   Chang S.-Y.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [30] {ECO:0000313|EMBL:QIX14045.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/IME-HZ01/2020
RC   {ECO:0000313|EMBL:QIX14045.1};
RA   Zhang X., Fan H., Liu W.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [31] {ECO:0000313|EMBL:QIA98591.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/IND/166/2020 {ECO:0000313|EMBL:QIA98591.1};
RA   Potdar V., Choudhary M., Yadav P.D., Shete-Aich A.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [32] {ECO:0000313|EMBL:QIE07489.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/IQTC03/2020 {ECO:0000313|EMBL:QIE07489.1};
RA   Zheng K., Shi Y., Sun J., Huang J., Zhu A., Sun F., Zhuang Z., Dai J.,
RA   Chen Z., Huang S., Zhang Z., Li X., Wang Y.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [33] {ECO:0000313|EMBL:QIC53212.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/SWE/01/2020 {ECO:0000313|EMBL:QIC53212.1};
RA   Bengner M., Palmerus M., Lindsjo O., Lind Karlberg M., Monteil V.,
RA   Appelberg S., Brave A., Muradrasoli S., Tegmark-Wisell K.;
RL   Submitted (FEB-2020) to the EMBL/GenBank/DDBJ databases.
RN   [34] {ECO:0000313|EMBL:QIQ68562.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/HZ-162/2020 {ECO:0000313|EMBL:QIQ68562.1},
RC   SARS-CoV-2/human/CHN/HZ-178/2020 {ECO:0000313|EMBL:QIQ68572.1},
RC   SARS-CoV-2/human/CHN/HZ-185/2020 {ECO:0000313|EMBL:QIQ68582.1},
RC   SARS-CoV-2/human/CHN/HZ-477/2020 {ECO:0000313|EMBL:QIQ68592.1},
RC   SARS-CoV-2/human/CHN/HZ-48/2020 {ECO:0000313|EMBL:QIQ68612.1},
RC   SARS-CoV-2/human/CHN/HZ-481/2020 {ECO:0000313|EMBL:QIQ68602.1},
RC   SARS-CoV-2/human/CHN/HZ-49/2020 {ECO:0000313|EMBL:QIQ68622.1},
RC   SARS-CoV-2/human/CHN/HZ-551/2020 {ECO:0000313|EMBL:QIQ68632.1},
RC   SARS-CoV-2/human/CHN/HZ-576/2020 {ECO:0000313|EMBL:QIQ68642.1},
RC   SARS-CoV-2/human/CHN/HZ-60/2020 {ECO:0000313|EMBL:QIQ68652.1},
RC   SARS-CoV-2/human/CHN/HZ-62/2020 {ECO:0000313|EMBL:QIQ68662.1},
RC   SARS-CoV-2/human/CHN/HZ-638/2020 {ECO:0000313|EMBL:QIQ68672.1},
RC   SARS-CoV-2/human/CHN/HZ-79/2020 {ECO:0000313|EMBL:QIQ68682.1},
RC   SARS-CoV-2/human/CHN/HZ-90/2020 {ECO:0000313|EMBL:QIQ68692.1}, and
RC   SARS-CoV-2/human/CHN/HZ-91/2020 {ECO:0000313|EMBL:QIQ68702.1};
RA   Liu Y., Sun Z., Chen J., Wang X.;
RT   "A cluster of cases infected with 2019 novel coronavirus during a meeting
RT   in Hangzhou, China: epidemiological evidence for person to person
RT   transmission.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [35] {ECO:0000313|EMBL:QIJ96501.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CruiseA-23/2020 {ECO:0000313|EMBL:QIJ96501.1},
RC   2019-nCoV/USA-CruiseA-24/2020 {ECO:0000313|EMBL:QIJ96511.1},
RC   2019-nCoV/USA-CruiseA-25/2020 {ECO:0000313|EMBL:QIJ96521.1}, and
RC   2019-nCoV/USA-CruiseA-26/2020 {ECO:0000313|EMBL:QIJ96531.1};
RA   Queen K., Uehara A., Tao Y., Paden C.R., Zhang J., Li Y., Wang H.,
RA   Kamili S., Lu X., Lynch B., Sakthivel S.K.K., Whitaker B.L., Wang L.,
RA   Murray J.R., Padilla J., Lee J., Gerber S.I., Lindstrom S., Tong S.;
RT   "additional Cruise A sequences.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [36] {ECO:0000313|EMBL:QIJ96471.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CruiseA-19/2020 {ECO:0000313|EMBL:QIJ96471.1},
RC   2019-nCoV/USA-CruiseA-21/2020 {ECO:0000313|EMBL:QIJ96481.1}, and
RC   2019-nCoV/USA-CruiseA-22/2020 {ECO:0000313|EMBL:QIJ96491.1};
RA   Tao Y., Queen K., Paden C.R., Uehara A., Zhang J., Li Y., Keckler M.S.,
RA   Laufer Halpin A.S., Wang H., Padilla J., Lee J., Elkins C.A., Gerber S.I.,
RA   Tong S.;
RT   "Additional Cruise A sequences.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [37] {ECO:0000313|EMBL:QIQ68704.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/ESP/Valencia003/2020
RC   {ECO:0000313|EMBL:QIQ68704.1}, SARS-CoV-2/human/ESP/Valencia10/2020
RC   {ECO:0000313|EMBL:QIS30153.1}, and SARS-CoV-2/human/ESP/Valencia9/2020
RC   {ECO:0000313|EMBL:QIS30143.1};
RA   Bracho M.A., D'Auria G., Navarro D., de Marco G., Garcia-Gonzalez N.,
RA   Beamud B., Gonzalez-Candelas F.;
RT   "Analysis of SARS-CoV-2 genome sequences from Comunitat Valenciana (Spain),
RT   March 2020.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [38] {ECO:0000313|EMBL:QIQ08798.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/ESP/Valencia4/2020
RC   {ECO:0000313|EMBL:QIQ08808.1}, SARS-CoV-2/human/ESP/Valencia5/2020
RC   {ECO:0000313|EMBL:QIQ08798.1}, SARS-CoV-2/human/ESP/Valencia6/2020
RC   {ECO:0000313|EMBL:QIQ08818.1}, SARS-CoV-2/human/ESP/Valencia7/2020
RC   {ECO:0000313|EMBL:QIQ08828.1}, and SARS-CoV-2/human/ESP/Valencia8/2020
RC   {ECO:0000313|EMBL:QIQ08838.1};
RA   Bracho M.A., D'Auria G., Gimeno C., Ocete M.D., De Marco G.,
RA   Garcia-Gonzalez N., Beamud B., Gonzalez-Candelas F.;
RT   "Analysis of SARS-CoV-2 genome sequences from Comunitat Valenciana (Spain),
RT   March 2020.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [39] {ECO:0000313|EMBL:QIG56002.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/BRA/SP02/2020 {ECO:0000313|EMBL:QIG56002.1};
RA   Amgarten D., Malta F., Ruiz R.M., Petroni R., Santana R.A.F.,
RA   de Menezes F.G., Mangueira C.L.P., Pinho J.R.R.;
RT   "Complete genome sequences of SARS-COV-2 isolated in Brazil.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [40] {ECO:0000313|EMBL:QII57176.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CruiseA-10/2020 {ECO:0000313|EMBL:QII57196.1},
RC   2019-nCoV/USA-CruiseA-11/2020 {ECO:0000313|EMBL:QII57206.1},
RC   2019-nCoV/USA-CruiseA-12/2020 {ECO:0000313|EMBL:QII57216.1},
RC   2019-nCoV/USA-CruiseA-7/2020 {ECO:0000313|EMBL:QII57176.1},
RC   2019-nCoV/USA-CruiseA-8/2020 {ECO:0000313|EMBL:QII57186.1}, and
RC   2019-nCoV/USA-CruiseA-9/2020 {ECO:0000313|EMBL:QII57226.1};
RA   Tao Y., Paden C.R., Queen K., Uehara A., Zhang J., Li Y., Wang H.,
RA   Kamili S., Lu X., Lynch B., Sakthivel S.K.K., Whitaker B.L., Wang L.,
RA   Murray J.R., Padilla J., Lee J., Gerber S.I., Lindstrom S., Tong S.;
RT   "Cruise A sequences.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [41] {ECO:0000313|EMBL:QII57296.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CruiseA-1/2020 {ECO:0000313|EMBL:QII57296.1},
RC   2019-nCoV/USA-CruiseA-2/2020 {ECO:0000313|EMBL:QII57306.1},
RC   2019-nCoV/USA-CruiseA-3/2020 {ECO:0000313|EMBL:QII57316.1},
RC   2019-nCoV/USA-CruiseA-4/2020 {ECO:0000313|EMBL:QII57326.1},
RC   2019-nCoV/USA-CruiseA-5/2020 {ECO:0000313|EMBL:QII57336.1}, and
RC   2019-nCoV/USA-CruiseA-6/2020 {ECO:0000313|EMBL:QII57346.1};
RA   Uehara A., Tao Y., Paden C.R., Queen K., Zhang J., Li Y., Keckler M.S.,
RA   Laufer Halpin A.S., Wang H., Padilla J., Lee J., Elkins C.A., Gerber S.I.,
RA   Tong S.;
RT   "Cruise A sequences.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [42] {ECO:0000313|EMBL:QII57236.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=2019-nCoV/USA-CruiseA-13/2020 {ECO:0000313|EMBL:QII57236.1},
RC   2019-nCoV/USA-CruiseA-14/2020 {ECO:0000313|EMBL:QII57246.1},
RC   2019-nCoV/USA-CruiseA-15/2020 {ECO:0000313|EMBL:QII57256.1},
RC   2019-nCoV/USA-CruiseA-16/2020 {ECO:0000313|EMBL:QII57266.1},
RC   2019-nCoV/USA-CruiseA-17/2020 {ECO:0000313|EMBL:QII57276.1}, and
RC   2019-nCoV/USA-CruiseA-18/2020 {ECO:0000313|EMBL:QII57286.1};
RA   Paden C.R., Tao Y., Queen K., Uehara A., Zhang J., Li Y., Wang H.,
RA   Kamili S., Lu X., Lynch B., Sakthivel S.K.K., Whitaker B.L., Wang L.,
RA   Murray J.R., Padilla J., Lee J., Gerber S.I., Lindstrom S., Tong S.;
RT   "Cruise A sequences.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [43] {ECO:0000313|EMBL:QIQ50190.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=FDAARGOS_983 {ECO:0000313|EMBL:QIQ50190.1};
RA   Thornburg N., Bradford R., Rashid S., Flores B., Parker M., Tallon L.,
RA   Sadzewicz L., Ott S., Vavikolanu K., Nadendla S., Sichtig H.;
RT   "FDA dAtabase for Regulatory Grade micrObial Sequences (FDA-ARGOS):
RT   Supporting development and validation of Infectious Disease Dx tests.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [44] {ECO:0000313|EMBL:QIK02952.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=USA/MN1-MDH1/2020 {ECO:0000313|EMBL:QIK02972.1},
RC   USA/MN2-MDH2/2020 {ECO:0000313|EMBL:QIK02962.1}, and USA/MN3-MDH3/2020
RC   {ECO:0000313|EMBL:QIK02952.1};
RA   Plumb M., Garfin J., Wang X.;
RT   "Full genome sequences of first three Minnesota, U.S. COVID-19 cases.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [45] {ECO:0000313|EMBL:QIS60297.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/PER/Peru-10/2020
RC   {ECO:0000313|EMBL:QIS60297.1};
RA   Padilla-Rojas C.P., Lope-Pari P.N., Vega-Chozo K., Balbuena-Torres J.,
RA   Caceres-Rey O.A., Bailon-Calderon H., Huaringa-Nunez M., Rojas-Serrano N.;
RT   "Near-complete genome sequence of 2019 novel coronavirus SARS-CoV-2 causing
RT   a COVID-19 case in Peru.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [46] {ECO:0000313|EMBL:QII87791.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/WA3-UW1/2020
RC   {ECO:0000313|EMBL:QII87791.1}, SARS-CoV-2/human/USA/WA4-UW2/2020
RC   {ECO:0000313|EMBL:QII87803.1}, SARS-CoV-2/human/USA/WA6-UW3/2020
RC   {ECO:0000313|EMBL:QII87815.1}, SARS-CoV-2/human/USA/WA7-UW4/2020
RC   {ECO:0000313|EMBL:QII87827.1}, SARS-CoV-2/human/USA/WA8-UW5/2020
RC   {ECO:0000313|EMBL:QII87839.1}, and SARS-CoV-2/human/USA/WA9-UW6/2020
RC   {ECO:0000313|EMBL:QII87849.1};
RA   Roychoudhury P., Greninger A., Jerome K.;
RT   "SARS-CoV-2 genomes from WA state.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [47] {ECO:0000313|EMBL:BCB97899.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/Hu/DP/Kng/19-031 {ECO:0000313|EMBL:BCB97899.1}, and
RC   SARS-CoV-2/Hu/Kng/19-437 {ECO:0000313|EMBL:BCB97909.1};
RA   Hishiki T., Suzuki R., Sakuragi J., Usui K., Tanaka Y., Kawai J., Kogo Y.,
RA   Matsuki Y., An T., Hayashizaki Y., Takasaki T.;
RT   "SARS-CoV-2 isolation from COVID-19 patients and asymptomatic individual.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [48] {ECO:0000313|EMBL:BCB15099.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=TKYE6182_2020 {ECO:0000313|EMBL:BCB15099.1};
RA   Kumagai R., Yoshida I., Nagashima M., Chiba T., Sadamasu K.;
RT   "The Detection of severe acute respiratory syndrome coronavirus 2 (SARS-
RT   CoV-2) in Tokyo (February, 2020).";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [49] {ECO:0000313|EMBL:QIK50446.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/VNM/nCoV-19-01S/2020
RC   {ECO:0000313|EMBL:QIK50446.1};
RA   Cao T.M., Nguyen H.T., Pham H.T.T., Vu N.P.H., Dao M.H., Huynh L.T.K.,
RA   Nguyen L.T., Nguyen N.T., Nguyen T.T.N., Nguyen A.H., Luong Q.C.,
RA   Nguyen T.V., Tran K.C., Pham Q.D., Tran T., Hoang C.Q., Nguyen T.T.,
RA   Le H.Q., Phung T.M., Vo T.N.A., Nguyen S.N., Pham D.T., Phan L.T.,
RA   Nguyen T.V.;
RT   "The first human to human transmission of CoVid-19 case in Viet Nam.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [50] {ECO:0000313|EMBL:QIK50456.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/VNM/nCoV-19-02S/2020
RC   {ECO:0000313|EMBL:QIK50456.1};
RA   Nguyen H.T., Cao T.M., Pham H.T.T., Vu N.P.H., Dao M.H., Huynh L.T.K.,
RA   Nguyen L.T., Nguyen N.T., Nguyen T.T.N., Nguyen A.H., Luong Q.C.,
RA   Nguyen T.V., Tran K.C., Pham Q.D., Tran T., Hoang C.Q., Nguyen T.T.,
RA   Le H.Q., Phung T.M., Vo T.N.A., Nguyen S.N., Pham D.T., Nguyen T.V.,
RA   Phan L.T.;
RT   "The first imported case of CoVid-19 in Viet Nam.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [51] {ECO:0000313|EMBL:QIS60377.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/WA-NH10/2020
RC   {ECO:0000313|EMBL:QIS60387.1}, SARS-CoV-2/human/USA/WA-NH11/2020
RC   {ECO:0000313|EMBL:QIS60397.1}, SARS-CoV-2/human/USA/WA-NH12/2020
RC   {ECO:0000313|EMBL:QIS60407.1}, SARS-CoV-2/human/USA/WA-NH13/2020
RC   {ECO:0000313|EMBL:QIS60497.1}, SARS-CoV-2/human/USA/WA-NH14/2020
RC   {ECO:0000313|EMBL:QIS60417.1}, SARS-CoV-2/human/USA/WA-NH17/2020
RC   {ECO:0000313|EMBL:QIS60427.1}, SARS-CoV-2/human/USA/WA-NH18/2020
RC   {ECO:0000313|EMBL:QIS60437.1}, SARS-CoV-2/human/USA/WA-NH19/2020
RC   {ECO:0000313|EMBL:QIS60447.1}, SARS-CoV-2/human/USA/WA-NH20/2020
RC   {ECO:0000313|EMBL:QIS60457.1}, SARS-CoV-2/human/USA/WA-NH21/2020
RC   {ECO:0000313|EMBL:QIS60467.1}, SARS-CoV-2/human/USA/WA-NH22/2020
RC   {ECO:0000313|EMBL:QIS60477.1}, SARS-CoV-2/human/USA/WA-NH23/2020
RC   {ECO:0000313|EMBL:QIS60507.1}, SARS-CoV-2/human/USA/WA-NH24/2020
RC   {ECO:0000313|EMBL:QIS60487.1}, and SARS-CoV-2/human/USA/WA-NH9/2020
RC   {ECO:0000313|EMBL:QIS60377.1};
RA   Tao Y., Zhang J., Paden C.R., Queen K., Uehara A., Li Y., Wang H.,
RA   Jacobs J., Russell D., Hiatt B., Gant J., Tong S.;
RT   "WA state nursing home sequences.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [52] {ECO:0000313|EMBL:QIS60307.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/WA-NH2/2020 {ECO:0000313|EMBL:QIS60307.1},
RC   SARS-CoV-2/human/USA/WA-NH3/2020 {ECO:0000313|EMBL:QIS60317.1},
RC   SARS-CoV-2/human/USA/WA-NH4/2020 {ECO:0000313|EMBL:QIS60327.1},
RC   SARS-CoV-2/human/USA/WA-NH5/2020 {ECO:0000313|EMBL:QIS60337.1},
RC   SARS-CoV-2/human/USA/WA-NH6/2020 {ECO:0000313|EMBL:QIS60347.1},
RC   SARS-CoV-2/human/USA/WA-NH7/2020 {ECO:0000313|EMBL:QIS60357.1}, and
RC   SARS-CoV-2/human/USA/WA-NH8/2020 {ECO:0000313|EMBL:QIS60367.1};
RA   Zhang J., Tao Y., Paden C.R., Queen K., Uehara A., Li Y., Wang H.,
RA   Jacobs J., Russell D., Hiatt B., Gant J., Tong S.;
RT   "Washington state nursing home sequences.";
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [53] {ECO:0000313|EMBL:QIK50425.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/TWN/CGMH-CGU-01/2020
RC   {ECO:0000313|EMBL:QIK50425.1};
RA   Tsao K.-C., Gong Y.-N., Yang S.-L., Liu Y.-C., Huang C.-G., Huang Y.-C.,
RA   Chen G.-W., Shih S.-R.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [54] {ECO:0000313|EMBL:QIO04375.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/KMS1/2020 {ECO:0000313|EMBL:QIO04375.1};
RA   Xu X., Liao Y., Wang L., Zhou X., Xie Z., Chen H., Fan S., Liu L.,
RA   Zheng H., Jiang G., Li Q.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [55] {ECO:0000313|EMBL:QIS30073.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/CZB-RR057-005/2020
RC   {ECO:0000313|EMBL:QIS30073.1}, SARS-CoV-2/human/USA/CZB-RR057-006/2020
RC   {ECO:0000313|EMBL:QIS30083.1}, SARS-CoV-2/human/USA/CZB-RR057-007/2020
RC   {ECO:0000313|EMBL:QIS30093.1}, SARS-CoV-2/human/USA/CZB-RR057-011/2020
RC   {ECO:0000313|EMBL:QIS30103.1}, SARS-CoV-2/human/USA/CZB-RR057-013/2020
RC   {ECO:0000313|EMBL:QIS30113.1}, SARS-CoV-2/human/USA/CZB-RR057-014/2020
RC   {ECO:0000313|EMBL:QIS30123.1}, and
RC   SARS-CoV-2/human/USA/CZB-RR057-015/2020 {ECO:0000313|EMBL:QIS30133.1};
RA   Arevalo S., Batson J., Botvinnik O., Castaneda G., Detweiler A.,
RA   Dynerman D., Hao S., Kamm J., Kistler A., Kumar G.R., Langelier C., Li L.,
RA   Miller S., Mwakibete L., Neff N., Pisco A., Phelps M., Tan M., Zhao C.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [56] {ECO:0000313|EMBL:QIS60285.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-Cov-2/human/PAK/Manga1/2020 {ECO:0000313|EMBL:QIS60285.1};
RA   Zainab T., Shamshad S., Noureen A., Malik A., Asad M.J., Rizvi K.A.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [57] {ECO:0000313|EMBL:QIH45031.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/105/2020 {ECO:0000313|EMBL:QIH45031.1},
RC   SARS-CoV-2/human/CHN/231/2020 {ECO:0000313|EMBL:QIH45041.1},
RC   SARS-CoV-2/human/CHN/233/2020 {ECO:0000313|EMBL:QIH45051.1}, and
RC   SARS-CoV-2/human/CHN/235/2020 {ECO:0000313|EMBL:QIH45061.1};
RA   Li J., Li L., Li Z., Qiu S., Song H., Li P., Li P.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [58] {ECO:0000313|EMBL:QIH55229.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/WA2/2020 {ECO:0000313|EMBL:QIH55229.1};
RA   Chu H., Boeckh M., Englund J., Famulare M., Lutz B., Nickerson D.,
RA   Rieder M., Starita L., Thompson M., Shendure J., Bedford T.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [59] {ECO:0000313|EMBL:QIQ68562.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CHN/HZ-162/2020 {ECO:0000313|EMBL:QIQ68562.1},
RC   SARS-CoV-2/human/CHN/HZ-178/2020 {ECO:0000313|EMBL:QIQ68572.1},
RC   SARS-CoV-2/human/CHN/HZ-185/2020 {ECO:0000313|EMBL:QIQ68582.1},
RC   SARS-CoV-2/human/CHN/HZ-477/2020 {ECO:0000313|EMBL:QIQ68592.1},
RC   SARS-CoV-2/human/CHN/HZ-48/2020 {ECO:0000313|EMBL:QIQ68612.1},
RC   SARS-CoV-2/human/CHN/HZ-481/2020 {ECO:0000313|EMBL:QIQ68602.1},
RC   SARS-CoV-2/human/CHN/HZ-49/2020 {ECO:0000313|EMBL:QIQ68622.1},
RC   SARS-CoV-2/human/CHN/HZ-551/2020 {ECO:0000313|EMBL:QIQ68632.1},
RC   SARS-CoV-2/human/CHN/HZ-576/2020 {ECO:0000313|EMBL:QIQ68642.1},
RC   SARS-CoV-2/human/CHN/HZ-60/2020 {ECO:0000313|EMBL:QIQ68652.1},
RC   SARS-CoV-2/human/CHN/HZ-62/2020 {ECO:0000313|EMBL:QIQ68662.1},
RC   SARS-CoV-2/human/CHN/HZ-638/2020 {ECO:0000313|EMBL:QIQ68672.1},
RC   SARS-CoV-2/human/CHN/HZ-79/2020 {ECO:0000313|EMBL:QIQ68682.1},
RC   SARS-CoV-2/human/CHN/HZ-90/2020 {ECO:0000313|EMBL:QIQ68692.1}, and
RC   SARS-CoV-2/human/CHN/HZ-91/2020 {ECO:0000313|EMBL:QIQ68702.1};
RA   Yu H., Li J., Yu X., Wang H., Pan J.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [60] {ECO:0000313|EMBL:QIS30063.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/COL/79256_Antioquia/2020
RC   {ECO:0000313|EMBL:QIS30063.1};
RA   Mercado-Reyes M.M., Laiton-Donato K., Alvarez-Diaz D.A., Usme-Ciro J.A.,
RA   Franco-Munoz C.E., Puerto-Castro G.M., Franco-Sierra N.D., Gonzalez M.A.,
RA   Cucunuba Z.M., Villabona-Arenas C.J., Villabona-Arenas L., Echeverria S.,
RA   Florez A.C., Gomez-Rangel S., Rodriguez L.D., Barbosa J., Ospitia E.,
RA   Ospina-Martinez M.L.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [61] {ECO:0000313|EMBL:QIK50436.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/PC00101P/2020
RC   {ECO:0000313|EMBL:QIK50436.1};
RA   Zeller M., Anderson C., Spencer E., Klitting R., Robles-Sikisaka R.,
RA   Gangavarapu K., Nicholson L., Andersen K.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [62] {ECO:0000313|EMBL:QJC21002.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/HKG/HKU-001a/2020
RC   {ECO:0000313|EMBL:QJC21002.1};
RA   Chan J.F.W., Yuen K.-Y.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [63] {ECO:0000313|EMBL:QIS30003.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/Wuhan_YB012504/human/2020/CHN
RC   {ECO:0000313|EMBL:QIS30051.1},
RC   SARS-CoV-2/Wuhan_YB012506/human/2020/CHN
RC   {ECO:0000313|EMBL:QIS30039.1},
RC   SARS-CoV-2/Wuhan_YB012602/human/2020/CHN
RC   {ECO:0000313|EMBL:QIS30027.1},
RC   SARS-CoV-2/Wuhan_YB012605/human/2020/CHN
RC   {ECO:0000313|EMBL:QIS30015.1}, and
RC   SARS-CoV-2/Wuhan_YB012611/human/2020/CHN
RC   {ECO:0000313|EMBL:QIS30003.1};
RA   Si H., Zhu Y., Lin H., Xie S., Shi Z., Zhou P.;
RL   Submitted (MAR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [64] {ECO:0000313|EMBL:QIU78716.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/ESP/Valencia11/2020
RC   {ECO:0000313|EMBL:QIU78752.1}, SARS-CoV-2/human/ESP/Valencia12/2020
RC   {ECO:0000313|EMBL:QIU78740.1}, SARS-CoV-2/human/ESP/Valencia13/2020
RC   {ECO:0000313|EMBL:QIU78716.1}, SARS-CoV-2/human/ESP/Valencia14/2020
RC   {ECO:0000313|EMBL:QIU78764.1}, SARS-CoV-2/human/ESP/Valencia15/2020
RC   {ECO:0000313|EMBL:QIU78776.1}, SARS-CoV-2/human/ESP/Valencia16/2020
RC   {ECO:0000313|EMBL:QIU78788.1}, SARS-CoV-2/human/ESP/Valencia17/2020
RC   {ECO:0000313|EMBL:QIU78728.1}, SARS-CoV-2/human/ESP/Valencia18/2020
RC   {ECO:0000313|EMBL:QIU78799.1}, SARS-CoV-2/human/ESP/Valencia19/2020
RC   {ECO:0000313|EMBL:QIU78811.1}, SARS-CoV-2/human/ESP/Valencia20/2020
RC   {ECO:0000313|EMBL:QIU78822.1}, SARS-CoV-2/human/ESP/Valencia22/2020
RC   {ECO:0000313|EMBL:QIU78832.1}, SARS-CoV-2/human/ESP/Valencia23/2020
RC   {ECO:0000313|EMBL:QIU78856.1}, SARS-CoV-2/human/ESP/Valencia25/2020
RC   {ECO:0000313|EMBL:QIU78843.1}, and
RC   SARS-CoV-2/human/ESP/Valencia26/2020 {ECO:0000313|EMBL:QIU78864.1};
RA   Bracho M.A., D'Auria G., Ocete M.D., De Marco G., Garcia-Gonzalez N.,
RA   Beamud B., Concepcion G., Gonzalez-Candelas F.;
RT   "Analysis of SARS-CoV-2 genome sequences from Comunitat Valenciana
RT   (Spain).";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [65] {ECO:0000313|EMBL:QIU81907.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS CoV-2/human/USA/UF-1/2020 {ECO:0000313|EMBL:QIU81907.1};
RA   Elbadry M.A., Subramaniam K., Waltzek T.B., Stephenson C.J., Gibson J.C.,
RA   Alam M., Morris J.G.Jr., Lednicky J.A.;
RT   "Genetic analysis of SARS CoV-2 in Gainesville, Florida, 2020.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [66] {ECO:0000313|EMBL:QIZ15006.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/ENV/USA/UF-3/2020 {ECO:0000313|EMBL:QIZ15006.1};
RA   Shankar S.N., Wu C.-Y., Clugston J.R., Elbadry M.A., Morris J.G.Jr.,
RA   Lednicky J.A.;
RT   "Genomic sequence of SARS CoV-2 in breathing air.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [67] {ECO:0000313|EMBL:QJC19500.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/IND/GBRC1/2020 {ECO:0000313|EMBL:QJC19500.1};
RA   Pandit R., Shah T., Hinsu A., Sabara P., Puvar A., Raval J., Gandhi M.,
RA   Trivedi P., Pandya M., Kanani A., Verma A., Savaliya N., Kumar R.,
RA   Kumar D., Saiyed Z., Kinariwala D., Patel D., Aring B., Vaghela G.,
RA   Barve S., Modi B., Joshi K., Sood N., Shah P., Dixit R., Bagatharia S.,
RA   Joshi M., Joshi C.;
RT   "Novel Coronavirus genome sequence and its characterization from the
RT   patient in Gujarat, India during COVID-19 outbreak.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [68] {ECO:0000313|EMBL:QIV64986.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/UNC_200181/2020
RC   {ECO:0000313|EMBL:QIV64986.1}, and
RC   SARS-CoV-2/human/USA/UNC_200189/2020 {ECO:0000313|EMBL:QIV64998.1};
RA   Bailey A.G., Caro-Vegas C.P., Dittmer D., Eason A.B., Juarez A.,
RA   Landis J.T., McNamara R.P., Miller M.B., Moorad R., Pluta L.J.,
RA   Seltzer T.A., Thompson C., Vahrson W., Villamor F.;
RT   "SARS-COV-2 Sequence in North Carolina Covid 19 Outbreak.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [69] {ECO:0000313|EMBL:QIZ97048.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/AZ-ASU2922/2020
RC   {ECO:0000313|EMBL:QIZ97048.1}, SARS-CoV-2/human/USA/AZ-ASU2923/2020
RC   {ECO:0000313|EMBL:QIZ97059.1}, and
RC   SARS-CoV-2/human/USA/AZ-ASU2936/2020 {ECO:0000313|EMBL:QIZ97071.1};
RA   Holland L.A., Kaelin E.A., Maqsood R., Estifanos B., Wu L.I., Varsani A.,
RA   Halden R.U., Hogue B.G., Scotch M., Lim E.S.;
RT   "Sentinel surveillance in Arizona identifies SARS-CoV-2 isolate with 27
RT   amino acid in-frame deletion in accessory protein ORF7a.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [70] {ECO:0000313|EMBL:QIU81919.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/UF-2/2020 {ECO:0000313|EMBL:QIU81919.1};
RA   Elbadry M.A., Subramaniam K., Waltzek T.B., Gibson J.C., Stephenson C.J.,
RA   Morris J.G.Jr., Lednicky J.A.;
RT   "Sequence of SARS CoV-2 determined directly from patient specimen.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [71] {ECO:0000313|EMBL:QIV14981.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/UNC_200173/2020
RC   {ECO:0000313|EMBL:QIV14981.1};
RA   Bailey A.G., Caro-Vegas C., Thompson C., Dittmer D., Eason A.B., Juarez A.,
RA   Landis J.T., McNamara R.P., Miller M.B., Moorad R., Pluta L.J.,
RA   Seltzer T.A., Villamor F., Vahrson W.;
RT   "Severe Acute Respiratory Syndrome Coronavirus 2 sequence in North Carolina
RT   Covid19 Outbreak.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [72] {ECO:0000313|EMBL:BCD58762.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=TKYE6968_2020 {ECO:0000313|EMBL:BCD58762.1};
RA   Kumagai R., Yoshida I., Asakura H., Nagashima M., Chiba T., Sadamasu K.;
RT   "The Detection of severe acute respiratory syndrome coronavirus 2(SARS-CoV-
RT   2) in Tokyo (February, 2020).";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [73] {ECO:0000313|EMBL:BCD57652.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=TKYE6947_2020 {ECO:0000313|EMBL:BCD57652.1};
RA   Kumagai R., Yoshida I., Asakura H., Nagashima M., Chiba T., Sadamasu K.;
RT   "The Detection of severe acute respiratory syndrome coronavirus 2(SARS-CoV-
RT   2) in Tokyo (March, 2020).";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [74] {ECO:0000313|EMBL:QIZ15546.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/ZAF/R03006/2020 {ECO:0000313|EMBL:QIZ15546.1};
RA   Allam M., Ismail A., Khumalo Z.T.H., Kwenda S., van Heusden P., Cloete R.,
RA   Wibmer C.K., Mohale T., Subramoney K., Mtshali P.S., Mnyameni F.,
RA   Walaza S., Ngubane W., Govender N., Motaze N.V., Bhiman J.N.;
RT   "Whole-Genome Sequence of the Severe Acute Respiratory Syndrome Coronavirus
RT   2 (SARS-CoV-2) obtained from a South African Coronavirus Disease 2019
RT   (COVID-19) Patient.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [75] {ECO:0000313|EMBL:QJD23282.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/NY-PV08109/2020
RC   {ECO:0000313|EMBL:QJD23642.1}, SARS-CoV-2/human/USA/NY-PV08120/2020
RC   {ECO:0000313|EMBL:QJD24182.1}, SARS-CoV-2/human/USA/NY-PV08121/2020
RC   {ECO:0000313|EMBL:QJD23426.1}, SARS-CoV-2/human/USA/NY-PV08122/2020
RC   {ECO:0000313|EMBL:QJD24014.1}, SARS-CoV-2/human/USA/NY-PV08123/2020
RC   {ECO:0000313|EMBL:QJD24338.1}, SARS-CoV-2/human/USA/NY-PV08124/2020
RC   {ECO:0000313|EMBL:QJD23378.1}, SARS-CoV-2/human/USA/NY-PV08125/2020
RC   {ECO:0000313|EMBL:QJD24290.1}, SARS-CoV-2/human/USA/NY-PV08127/2020
RC   {ECO:0000313|EMBL:QJD23558.1}, SARS-CoV-2/human/USA/NY-PV08133/2020
RC   {ECO:0000313|EMBL:QJD24228.1}, SARS-CoV-2/human/USA/NY-PV08135/2020
RC   {ECO:0000313|EMBL:QJD23702.1}, SARS-CoV-2/human/USA/NY-PV08136/2020
RC   {ECO:0000313|EMBL:QJD24146.1}, SARS-CoV-2/human/USA/NY-PV08137/2020
RC   {ECO:0000313|EMBL:QJD23533.1}, SARS-CoV-2/human/USA/NY-PV08138/2020
RC   {ECO:0000313|EMBL:QJD23882.1}, SARS-CoV-2/human/USA/NY-PV08139/2020
RC   {ECO:0000313|EMBL:QJD23292.1}, SARS-CoV-2/human/USA/NY-PV08140/2020
RC   {ECO:0000313|EMBL:QJD23388.1}, SARS-CoV-2/human/USA/NY-PV08143/2020
RC   {ECO:0000313|EMBL:QJD24266.1}, SARS-CoV-2/human/USA/NY-PV08146/2020
RC   {ECO:0000313|EMBL:QJD23498.1}, SARS-CoV-2/human/USA/NY-PV08148/2020
RC   {ECO:0000313|EMBL:QJD23594.1}, SARS-CoV-2/human/USA/NY-PV08149/2020
RC   {ECO:0000313|EMBL:QJD23798.1}, SARS-CoV-2/human/USA/NY-PV08150/2020
RC   {ECO:0000313|EMBL:QJD24170.1}, SARS-CoV-2/human/USA/NY-PV08400/2020
RC   {ECO:0000313|EMBL:QJD23713.1}, SARS-CoV-2/human/USA/NY-PV08401/2020
RC   {ECO:0000313|EMBL:QJD23462.1}, SARS-CoV-2/human/USA/NY-PV08402/2020
RC   {ECO:0000313|EMBL:QJD24002.1}, SARS-CoV-2/human/USA/NY-PV08403/2020
RC   {ECO:0000313|EMBL:QJD23618.1}, SARS-CoV-2/human/USA/NY-PV08404/2020
RC   {ECO:0000313|EMBL:QJD23784.1}, SARS-CoV-2/human/USA/NY-PV08405/2020
RC   {ECO:0000313|EMBL:QJD23856.1}, SARS-CoV-2/human/USA/NY-PV08410/2020
RC   {ECO:0000313|EMBL:QJD24108.1}, SARS-CoV-2/human/USA/NY-PV08412/2020
RC   {ECO:0000313|EMBL:QJD23654.1}, SARS-CoV-2/human/USA/NY-PV08413/2020
RC   {ECO:0000313|EMBL:QJD23846.1}, SARS-CoV-2/human/USA/NY-PV08414/2020
RC   {ECO:0000313|EMBL:QJD24324.1}, SARS-CoV-2/human/USA/NY-PV08415/2020
RC   {ECO:0000313|EMBL:QJD24050.1}, SARS-CoV-2/human/USA/NY-PV08416/2020
RC   {ECO:0000313|EMBL:QJD24194.1}, SARS-CoV-2/human/USA/NY-PV08417/2020
RC   {ECO:0000313|EMBL:QJD23916.1}, SARS-CoV-2/human/USA/NY-PV08419/2020
RC   {ECO:0000313|EMBL:QJD24024.1}, SARS-CoV-2/human/USA/NY-PV08420/2020
RC   {ECO:0000313|EMBL:QJD23568.1}, SARS-CoV-2/human/USA/NY-PV08425/2020
RC   {ECO:0000313|EMBL:QJD23906.1}, SARS-CoV-2/human/USA/NY-PV08426/2020
RC   {ECO:0000313|EMBL:QJD23330.1}, SARS-CoV-2/human/USA/NY-PV08427/2020
RC   {ECO:0000313|EMBL:QJD24254.1}, SARS-CoV-2/human/USA/NY-PV08428/2020
RC   {ECO:0000313|EMBL:QJD23870.1}, SARS-CoV-2/human/USA/NY-PV08429/2020
RC   {ECO:0000313|EMBL:QJD24314.1}, SARS-CoV-2/human/USA/NY-PV08432/2020
RC   {ECO:0000313|EMBL:QJD23306.1}, SARS-CoV-2/human/USA/NY-PV08434/2020
RC   {ECO:0000313|EMBL:QJD23630.1}, SARS-CoV-2/human/USA/NY-PV08435/2020
RC   {ECO:0000313|EMBL:QJD24206.1}, SARS-CoV-2/human/USA/NY-PV08436/2020
RC   {ECO:0000313|EMBL:QJD23342.1}, SARS-CoV-2/human/USA/NY-PV08438/2020
RC   {ECO:0000313|EMBL:QJD23471.1}, SARS-CoV-2/human/USA/NY-PV08441/2020
RC   {ECO:0000313|EMBL:QJD23486.1}, SARS-CoV-2/human/USA/NY-PV08443/2020
RC   {ECO:0000313|EMBL:QJD24302.1}, SARS-CoV-2/human/USA/NY-PV08444/2020
RC   {ECO:0000313|EMBL:QJD24122.1}, SARS-CoV-2/human/USA/NY-PV08445/2020
RC   {ECO:0000313|EMBL:QJD23582.1}, SARS-CoV-2/human/USA/NY-PV08446/2020
RC   {ECO:0000313|EMBL:QJD23762.1}, SARS-CoV-2/human/USA/NY-PV08447/2020
RC   {ECO:0000313|EMBL:QJD24278.1}, SARS-CoV-2/human/USA/NY-PV08448/2020
RC   {ECO:0000313|EMBL:QJD23822.1}, SARS-CoV-2/human/USA/NY-PV08449/2020
RC   {ECO:0000313|EMBL:QJD24134.1}, SARS-CoV-2/human/USA/NY-PV08450/2020
RC   {ECO:0000313|EMBL:QJD23942.1}, SARS-CoV-2/human/USA/NY-PV08452/2020
RC   {ECO:0000313|EMBL:QJD24074.1}, SARS-CoV-2/human/USA/NY-PV08453/2020
RC   {ECO:0000313|EMBL:QJD23690.1}, SARS-CoV-2/human/USA/NY-PV08455/2020
RC   {ECO:0000313|EMBL:QJD24098.1}, SARS-CoV-2/human/USA/NY-PV08456/2020
RC   {ECO:0000313|EMBL:QJD23366.1}, SARS-CoV-2/human/USA/NY-PV08459/2020
RC   {ECO:0000313|EMBL:QJD24062.1}, SARS-CoV-2/human/USA/NY-PV08461/2020
RC   {ECO:0000313|EMBL:QJD23930.1}, SARS-CoV-2/human/USA/NY-PV08462/2020
RC   {ECO:0000313|EMBL:QJD23738.1}, SARS-CoV-2/human/USA/NY-PV08463/2020
RC   {ECO:0000313|EMBL:QJD23438.1}, SARS-CoV-2/human/USA/NY-PV08464/2020
RC   {ECO:0000313|EMBL:QJD23282.1}, SARS-CoV-2/human/USA/NY-PV08466/2020
RC   {ECO:0000313|EMBL:QJD24350.1}, SARS-CoV-2/human/USA/NY-PV08468/2020
RC   {ECO:0000313|EMBL:QJD23606.1}, SARS-CoV-2/human/USA/NY-PV08469/2020
RC   {ECO:0000313|EMBL:QJD23750.1}, SARS-CoV-2/human/USA/NY-PV08471/2020
RC   {ECO:0000313|EMBL:QJD23666.1}, SARS-CoV-2/human/USA/NY-PV08472/2020
RC   {ECO:0000313|EMBL:QJD23978.1}, SARS-CoV-2/human/USA/NY-PV08473/2020
RC   {ECO:0000313|EMBL:QJD23810.1}, SARS-CoV-2/human/USA/NY-PV08474/2020
RC   {ECO:0000313|EMBL:QJD23834.1}, SARS-CoV-2/human/USA/NY-PV08476/2020
RC   {ECO:0000313|EMBL:QJD23953.1}, SARS-CoV-2/human/USA/NY-PV08477/2020
RC   {ECO:0000313|EMBL:QJD23990.1}, SARS-CoV-2/human/USA/NY-PV08478/2020
RC   {ECO:0000313|EMBL:QJD23318.1}, SARS-CoV-2/human/USA/NY-PV08481/2020
RC   {ECO:0000313|EMBL:QJD23894.1}, SARS-CoV-2/human/USA/NY-PV08485/2020
RC   {ECO:0000313|EMBL:QJD23726.1}, SARS-CoV-2/human/USA/NY-PV08486/2020
RC   {ECO:0000313|EMBL:QJD23354.1}, SARS-CoV-2/human/USA/NY-PV08487/2020
RC   {ECO:0000313|EMBL:QJD24086.1}, SARS-CoV-2/human/USA/NY-PV08489/2020
RC   {ECO:0000313|EMBL:QJD24218.1}, SARS-CoV-2/human/USA/NY-PV08490/2020
RC   {ECO:0000313|EMBL:QJD23402.1}, SARS-CoV-2/human/USA/NY-PV08491/2020
RC   {ECO:0000313|EMBL:QJD23774.1}, SARS-CoV-2/human/USA/NY-PV08492/2020
RC   {ECO:0000313|EMBL:QJD23450.1}, SARS-CoV-2/human/USA/NY-PV08493/2020
RC   {ECO:0000313|EMBL:QJD24242.1}, SARS-CoV-2/human/USA/NY-PV08494/2020
RC   {ECO:0000313|EMBL:QJD23546.1}, SARS-CoV-2/human/USA/NY-PV08495/2020
RC   {ECO:0000313|EMBL:QJD23678.1}, SARS-CoV-2/human/USA/NY-PV08496/2020
RC   {ECO:0000313|EMBL:QJD24038.1}, SARS-CoV-2/human/USA/NY-PV08498/2020
RC   {ECO:0000313|EMBL:QJD23966.1}, SARS-CoV-2/human/USA/NY-PV08500/2020
RC   {ECO:0000313|EMBL:QJD23510.1}, SARS-CoV-2/human/USA/NY-PV09000/2020
RC   {ECO:0000313|EMBL:QJD23522.1}, SARS-CoV-2/human/USA/NY1-PV08001/2020
RC   {ECO:0000313|EMBL:QJD24158.1}, and
RC   SARS-CoV-2/human/USA/NY2-PV08100/2020 {ECO:0000313|EMBL:QJD23414.1};
RA   Gonzalez-Reiche A.S., Hernandez M., Sullivan M., Ciferri B., Alshammary H.,
RA   Obla A., Fabre S., Kleiner G., Polanco J., Khan Z., Alburquerque B.,
RA   van de Guchte A., Dutta J., Francoeur N., Salom Melo B., Oussenko I.,
RA   Deikus G., Soto J., Sridhar S.H., Wang Y.C., Twyman K., Kasarskis A.,
RA   Altman D.R., Smith M., Sebra R., Aberg J., Krammer F., Garcia-Sastre A.,
RA   Luksza M., Patel G., Paniz-Mondolfi A., Gitman M., Sordillo E.M., Simon V.,
RA   van Bakel H.;
RT   "Whole-genome sequencing of COVID-19 clinical isolates.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [76] {ECO:0000313|EMBL:QJD24362.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/NJ-PV09072/2020
RC   {ECO:0000313|EMBL:QJD24506.1}, SARS-CoV-2/human/USA/NY-PV09006/2020
RC   {ECO:0000313|EMBL:QJD25298.1}, SARS-CoV-2/human/USA/NY-PV09019/2020
RC   {ECO:0000313|EMBL:QJD24386.1}, SARS-CoV-2/human/USA/NY-PV09020/2020
RC   {ECO:0000313|EMBL:QJD25562.1}, SARS-CoV-2/human/USA/NY-PV09021/2020
RC   {ECO:0000313|EMBL:QJD25646.1}, SARS-CoV-2/human/USA/NY-PV09023/2020
RC   {ECO:0000313|EMBL:QJD25034.1}, SARS-CoV-2/human/USA/NY-PV09025/2020
RC   {ECO:0000313|EMBL:QJD25730.1}, SARS-CoV-2/human/USA/NY-PV09028/2020
RC   {ECO:0000313|EMBL:QJD25202.1}, SARS-CoV-2/human/USA/NY-PV09029/2020
RC   {ECO:0000313|EMBL:QJD25538.1}, SARS-CoV-2/human/USA/NY-PV09030/2020
RC   {ECO:0000313|EMBL:QJD25476.1}, SARS-CoV-2/human/USA/NY-PV09032/2020
RC   {ECO:0000313|EMBL:QJD24878.1}, SARS-CoV-2/human/USA/NY-PV09037/2020
RC   {ECO:0000313|EMBL:QJD25106.1}, SARS-CoV-2/human/USA/NY-PV09039/2020
RC   {ECO:0000313|EMBL:QJD24674.1}, SARS-CoV-2/human/USA/NY-PV09041/2020
RC   {ECO:0000313|EMBL:QJD24734.1}, SARS-CoV-2/human/USA/NY-PV09043/2020
RC   {ECO:0000313|EMBL:QJD25118.1}, SARS-CoV-2/human/USA/NY-PV09044/2020
RC   {ECO:0000313|EMBL:QJD25058.1}, SARS-CoV-2/human/USA/NY-PV09045/2020
RC   {ECO:0000313|EMBL:QJD25310.1}, SARS-CoV-2/human/USA/NY-PV09046/2020
RC   {ECO:0000313|EMBL:QJD25586.1}, SARS-CoV-2/human/USA/NY-PV09047/2020
RC   {ECO:0000313|EMBL:QJD25597.1}, SARS-CoV-2/human/USA/NY-PV09050/2020
RC   {ECO:0000313|EMBL:QJD25680.1}, SARS-CoV-2/human/USA/NY-PV09056/2020
RC   {ECO:0000313|EMBL:QJD24854.1}, SARS-CoV-2/human/USA/NY-PV09057/2020
RC   {ECO:0000313|EMBL:QJD25418.1}, SARS-CoV-2/human/USA/NY-PV09060/2020
RC   {ECO:0000313|EMBL:QJD24530.1}, SARS-CoV-2/human/USA/NY-PV09061/2020
RC   {ECO:0000313|EMBL:QJD24962.1}, SARS-CoV-2/human/USA/NY-PV09063/2020
RC   {ECO:0000313|EMBL:QJD24986.1}, SARS-CoV-2/human/USA/NY-PV09064/2020
RC   {ECO:0000313|EMBL:QJD24926.1}, SARS-CoV-2/human/USA/NY-PV09067/2020
RC   {ECO:0000313|EMBL:QJD25070.1}, SARS-CoV-2/human/USA/NY-PV09068/2020
RC   {ECO:0000313|EMBL:QJD25382.1}, SARS-CoV-2/human/USA/NY-PV09069/2020
RC   {ECO:0000313|EMBL:QJD25022.1}, SARS-CoV-2/human/USA/NY-PV09071/2020
RC   {ECO:0000313|EMBL:QJD24602.1}, SARS-CoV-2/human/USA/NY-PV09073/2020
RC   {ECO:0000313|EMBL:QJD25634.1}, SARS-CoV-2/human/USA/NY-PV09075/2020
RC   {ECO:0000313|EMBL:QJD24698.1}, SARS-CoV-2/human/USA/NY-PV09076/2020
RC   {ECO:0000313|EMBL:QJD25344.1}, SARS-CoV-2/human/USA/NY-PV09077/2020
RC   {ECO:0000313|EMBL:QJD24662.1}, SARS-CoV-2/human/USA/NY-PV09079/2020
RC   {ECO:0000313|EMBL:QJD24518.1}, SARS-CoV-2/human/USA/NY-PV09080/2020
RC   {ECO:0000313|EMBL:QJD25212.1}, SARS-CoV-2/human/USA/NY-PV09083/2020
RC   {ECO:0000313|EMBL:QJD25190.1}, SARS-CoV-2/human/USA/NY-PV09087/2020
RC   {ECO:0000313|EMBL:QJD24422.1}, SARS-CoV-2/human/USA/NY-PV09088/2020
RC   {ECO:0000313|EMBL:QJD25274.1}, SARS-CoV-2/human/USA/NY-PV09090/2020
RC   {ECO:0000313|EMBL:QJD25622.1}, SARS-CoV-2/human/USA/NY-PV09092/2020
RC   {ECO:0000313|EMBL:QJD25154.1}, SARS-CoV-2/human/USA/NY-PV09097/2020
RC   {ECO:0000313|EMBL:QJD24830.1}, SARS-CoV-2/human/USA/NY-PV09098/2020
RC   {ECO:0000313|EMBL:QJD25178.1}, SARS-CoV-2/human/USA/NY-PV09099/2020
RC   {ECO:0000313|EMBL:QJD24794.1}, SARS-CoV-2/human/USA/NY-PV09102/2020
RC   {ECO:0000313|EMBL:QJD25466.1}, SARS-CoV-2/human/USA/NY-PV09103/2020
RC   {ECO:0000313|EMBL:QJD24434.1}, SARS-CoV-2/human/USA/NY-PV09115/2020
RC   {ECO:0000313|EMBL:QJD25670.1}, SARS-CoV-2/human/USA/NY-PV09116/2020
RC   {ECO:0000313|EMBL:QJD24890.1}, SARS-CoV-2/human/USA/NY-PV09118/2020
RC   {ECO:0000313|EMBL:QJD24766.1}, SARS-CoV-2/human/USA/NY-PV09119/2020
RC   {ECO:0000313|EMBL:QJD24578.1}, SARS-CoV-2/human/USA/NY-PV09120/2020
RC   {ECO:0000313|EMBL:QJD24638.1}, SARS-CoV-2/human/USA/NY-PV09121/2020
RC   {ECO:0000313|EMBL:QJD24445.1}, SARS-CoV-2/human/USA/NY-PV09122/2020
RC   {ECO:0000313|EMBL:QJD24746.1}, SARS-CoV-2/human/USA/NY-PV09123/2020
RC   {ECO:0000313|EMBL:QJD25082.1}, SARS-CoV-2/human/USA/NY-PV09125/2020
RC   {ECO:0000313|EMBL:QJD25226.1}, SARS-CoV-2/human/USA/NY-PV09126/2020
RC   {ECO:0000313|EMBL:QJD25550.1}, SARS-CoV-2/human/USA/NY-PV09127/2020
RC   {ECO:0000313|EMBL:QJD25694.1}, SARS-CoV-2/human/USA/NY-PV09128/2020
RC   {ECO:0000313|EMBL:QJD24614.1}, SARS-CoV-2/human/USA/NY-PV09129/2020
RC   {ECO:0000313|EMBL:QJD24782.1}, SARS-CoV-2/human/USA/NY-PV09130/2020
RC   {ECO:0000313|EMBL:QJD25430.1}, SARS-CoV-2/human/USA/NY-PV09132/2020
RC   {ECO:0000313|EMBL:QJD24806.1}, SARS-CoV-2/human/USA/NY-PV09134/2020
RC   {ECO:0000313|EMBL:QJD25010.1}, SARS-CoV-2/human/USA/NY-PV09135/2020
RC   {ECO:0000313|EMBL:QJD25250.1}, SARS-CoV-2/human/USA/NY-PV09137/2020
RC   {ECO:0000313|EMBL:QJD25658.1}, SARS-CoV-2/human/USA/NY-PV09138/2020
RC   {ECO:0000313|EMBL:QJD24974.1}, SARS-CoV-2/human/USA/NY-PV09139/2020
RC   {ECO:0000313|EMBL:QJD25358.1}, SARS-CoV-2/human/USA/NY-PV09140/2020
RC   {ECO:0000313|EMBL:QJD24842.1}, SARS-CoV-2/human/USA/NY-PV09141/2020
RC   {ECO:0000313|EMBL:QJD24540.1}, SARS-CoV-2/human/USA/NY-PV09142/2020
RC   {ECO:0000313|EMBL:QJD24554.1}, SARS-CoV-2/human/USA/NY-PV09143/2020
RC   {ECO:0000313|EMBL:QJD24362.1}, SARS-CoV-2/human/USA/NY-PV09144/2020
RC   {ECO:0000313|EMBL:QJD24686.1}, SARS-CoV-2/human/USA/NY-PV09145/2020
RC   {ECO:0000313|EMBL:QJD24410.1}, SARS-CoV-2/human/USA/NY-PV09147/2020
RC   {ECO:0000313|EMBL:QJD25130.1}, SARS-CoV-2/human/USA/NY-PV09149/2020
RC   {ECO:0000313|EMBL:QJD24648.1}, SARS-CoV-2/human/USA/NY-PV09151/2020
RC   {ECO:0000313|EMBL:QJD25574.1}, SARS-CoV-2/human/USA/NY-PV09152/2020
RC   {ECO:0000313|EMBL:QJD24626.1}, SARS-CoV-2/human/USA/NY-PV09153/2020
RC   {ECO:0000313|EMBL:QJD24470.1}, SARS-CoV-2/human/USA/NY-PV09154/2020
RC   {ECO:0000313|EMBL:QJD24374.1}, SARS-CoV-2/human/USA/NY-PV09156/2020
RC   {ECO:0000313|EMBL:QJD24758.1}, SARS-CoV-2/human/USA/NY-PV09157/2020
RC   {ECO:0000313|EMBL:QJD25046.1}, SARS-CoV-2/human/USA/NY-PV09158/2020
RC   {ECO:0000313|EMBL:QJD25718.1}, SARS-CoV-2/human/USA/NY-PV09161/2020
RC   {ECO:0000313|EMBL:QJD25440.1}, SARS-CoV-2/human/USA/NY-PV09163/2020
RC   {ECO:0000313|EMBL:QJD24818.1}, SARS-CoV-2/human/USA/NY-PV09164/2020
RC   {ECO:0000313|EMBL:QJD24482.1}, SARS-CoV-2/human/USA/NY-PV09165/2020
RC   {ECO:0000313|EMBL:QJD25406.1}, SARS-CoV-2/human/USA/NY-PV09168/2020
RC   {ECO:0000313|EMBL:QJD25610.1}, SARS-CoV-2/human/USA/NY-PV09169/2020
RC   {ECO:0000313|EMBL:QJD25454.1}, SARS-CoV-2/human/USA/NY-PV09170/2020
RC   {ECO:0000313|EMBL:QJD25094.1}, SARS-CoV-2/human/USA/NY-PV09171/2020
RC   {ECO:0000313|EMBL:QJD25322.1}, SARS-CoV-2/human/USA/NY-PV09172/2020
RC   {ECO:0000313|EMBL:QJD25370.1}, SARS-CoV-2/human/USA/NY-PV09176/2020
RC   {ECO:0000313|EMBL:QJD24722.1}, SARS-CoV-2/human/USA/NY-PV09177/2020
RC   {ECO:0000313|EMBL:QJD25394.1}, SARS-CoV-2/human/USA/NY-PV09178/2020
RC   {ECO:0000313|EMBL:QJD25754.1}, SARS-CoV-2/human/USA/NY-PV09179/2020
RC   {ECO:0000313|EMBL:QJD24866.1}, SARS-CoV-2/human/USA/NY-PV09180/2020
RC   {ECO:0000313|EMBL:QJD24902.1}, SARS-CoV-2/human/USA/NY-PV09181/2020
RC   {ECO:0000313|EMBL:QJD25262.1}, SARS-CoV-2/human/USA/NY-PV09182/2020
RC   {ECO:0000313|EMBL:QJD24590.1}, SARS-CoV-2/human/USA/NY-PV09183/2020
RC   {ECO:0000313|EMBL:QJD25286.1}, SARS-CoV-2/human/USA/NY-PV09186/2020
RC   {ECO:0000313|EMBL:QJD25526.1}, SARS-CoV-2/human/USA/NY-PV09187/2020
RC   {ECO:0000313|EMBL:QJD25490.1}, SARS-CoV-2/human/USA/NY-PV09188/2020
RC   {ECO:0000313|EMBL:QJD24457.1}, SARS-CoV-2/human/USA/NY-PV09189/2020
RC   {ECO:0000313|EMBL:QJD25766.1}, SARS-CoV-2/human/USA/NY-PV09190/2020
RC   {ECO:0000313|EMBL:QJD25142.1}, SARS-CoV-2/human/USA/NY-PV09192/2020
RC   {ECO:0000313|EMBL:QJD24950.1}, SARS-CoV-2/human/USA/NY-PV09193/2020
RC   {ECO:0000313|EMBL:QJD24710.1}, SARS-CoV-2/human/USA/NY-PV09194/2020
RC   {ECO:0000313|EMBL:QJD25238.1}, SARS-CoV-2/human/USA/NY-PV09195/2020
RC   {ECO:0000313|EMBL:QJD24494.1}, SARS-CoV-2/human/USA/NY-PV09197/2020
RC   {ECO:0000313|EMBL:QJD25166.1}, SARS-CoV-2/human/USA/NY-PV09198/2020
RC   {ECO:0000313|EMBL:QJD25742.1}, SARS-CoV-2/human/USA/NY-PV09199/2020
RC   {ECO:0000313|EMBL:QJD24938.1}, SARS-CoV-2/human/USA/NY-PV09200/2020
RC   {ECO:0000313|EMBL:QJD25334.1}, SARS-CoV-2/human/USA/NY-PV09301/2020
RC   {ECO:0000313|EMBL:QJD24566.1}, SARS-CoV-2/human/USA/NY-PV09303/2020
RC   {ECO:0000313|EMBL:QJD24914.1}, SARS-CoV-2/human/USA/NY-PV09304/2020
RC   {ECO:0000313|EMBL:QJD25706.1}, SARS-CoV-2/human/USA/NY-PV09305/2020
RC   {ECO:0000313|EMBL:QJD24398.1}, SARS-CoV-2/human/USA/NY-PV09307/2020
RC   {ECO:0000313|EMBL:QJD24998.1}, SARS-CoV-2/human/USA/NY-PV09308/2020
RC   {ECO:0000313|EMBL:QJD25502.1}, and
RC   SARS-CoV-2/human/USA/NY-PV09309/2020 {ECO:0000313|EMBL:QJD25514.1};
RA   Gonzalez-Reiche A.S., Sullivan M., Obla A., Patel G., Sordillo E.,
RA   Gitman M., Paniz-Mondolfi A., Hernandez M., Fabre S., Polanco J., Khan Z.,
RA   Albuquerque B., Dutta J., Soto J., Sridhar S.H., Wang Y.C., Smith M.,
RA   Sebra R., Miorin L., Liu W., Albrecht R., Aberg J., Krammer F.,
RA   Garcia-Sastre A., Simon V., van Bakel H.;
RT   "Whole-genome sequencing of COVID-19 clinical isolates.";
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [77] {ECO:0000313|EMBL:QIT06888.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/CA_2602/2020
RC   {ECO:0000313|EMBL:QIT06900.1}, SARS-CoV-2/human/USA/GA_2741/2020
RC   {ECO:0000313|EMBL:QIT06924.1}, SARS-CoV-2/human/USA/GA_2742/2020
RC   {ECO:0000313|EMBL:QIT06936.1}, SARS-CoV-2/human/USA/OR_2656/2020
RC   {ECO:0000313|EMBL:QIT06948.1}, SARS-CoV-2/human/USA/RI_0520/2020
RC   {ECO:0000313|EMBL:QIT06888.1}, and SARS-CoV-2/human/USA/WA_5030/2020
RC   {ECO:0000313|EMBL:QIT06912.1};
RA   Tao Y., Zhang J., Queen K., Uehara A., Paden C.R., Li Y., Wang H.,
RA   Padilla J., Lee J., Tong S.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [78] {ECO:0000313|EMBL:QIZ16518.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/TUR/ERAGEM-001/2020
RC   {ECO:0000313|EMBL:QIZ16518.1};
RA   Pavel S.T.I., Yetiskin H., Aydin G., Holyavkin C., Uygut M.A., Dursun Z.B.,
RA   Celik I., Iseri A., Ozdarendeli A.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [79] {ECO:0000313|EMBL:QIV64974.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/UNC_200191/2020
RC   {ECO:0000313|EMBL:QIV64974.1};
RA   Bailey A.G., Caro-Vegas C., Dittmer D., Eason A.B., Juarez A., Landis J.T.,
RA   McNamara R.P., Miller M.B., Moorad R., Pluta L.J., Seltzer T.A.,
RA   Thompson C., Vahrson W., Villamor F.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [80] {ECO:0000313|EMBL:QIX13684.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/VA-DCLS-0001/2020
RC   {ECO:0000313|EMBL:QIX13684.1}, SARS-CoV-2/human/USA/VA-DCLS-0002/2020
RC   {ECO:0000313|EMBL:QIX13696.1}, SARS-CoV-2/human/USA/VA-DCLS-0003/2020
RC   {ECO:0000313|EMBL:QIX13708.1}, SARS-CoV-2/human/USA/VA-DCLS-0004/2020
RC   {ECO:0000313|EMBL:QIX13720.1}, SARS-CoV-2/human/USA/VA-DCLS-0005/2020
RC   {ECO:0000313|EMBL:QIX13732.1}, SARS-CoV-2/human/USA/VA-DCLS-0006/2020
RC   {ECO:0000313|EMBL:QIX13743.1}, SARS-CoV-2/human/USA/VA-DCLS-0007/2020
RC   {ECO:0000313|EMBL:QIX13756.1}, SARS-CoV-2/human/USA/VA-DCLS-0008/2020
RC   {ECO:0000313|EMBL:QIX13768.1}, SARS-CoV-2/human/USA/VA-DCLS-0009/2020
RC   {ECO:0000313|EMBL:QIX13780.1}, SARS-CoV-2/human/USA/VA-DCLS-0010/2020
RC   {ECO:0000313|EMBL:QIX13792.1}, SARS-CoV-2/human/USA/VA-DCLS-0011/2020
RC   {ECO:0000313|EMBL:QIX13804.1}, SARS-CoV-2/human/USA/VA-DCLS-0012/2020
RC   {ECO:0000313|EMBL:QIX13816.1}, SARS-CoV-2/human/USA/VA-DCLS-0016/2020
RC   {ECO:0000313|EMBL:QIX13828.1}, SARS-CoV-2/human/USA/VA-DCLS-0017/2020
RC   {ECO:0000313|EMBL:QIX13840.1}, SARS-CoV-2/human/USA/VA-DCLS-0018/2020
RC   {ECO:0000313|EMBL:QIX13852.1}, SARS-CoV-2/human/USA/VA-DCLS-0019/2020
RC   {ECO:0000313|EMBL:QIX13864.1}, SARS-CoV-2/human/USA/VA-DCLS-0020/2020
RC   {ECO:0000313|EMBL:QIX13876.1}, SARS-CoV-2/human/USA/VA-DCLS-0021/2020
RC   {ECO:0000313|EMBL:QIX13888.1}, SARS-CoV-2/human/USA/VA-DCLS-0024/2020
RC   {ECO:0000313|EMBL:QIX13900.1}, SARS-CoV-2/human/USA/VA-DCLS-0031/2020
RC   {ECO:0000313|EMBL:QIX13912.1}, SARS-CoV-2/human/USA/VA-DCLS-0033/2020
RC   {ECO:0000313|EMBL:QIX13924.1}, SARS-CoV-2/human/USA/VA-DCLS-0034/2020
RC   {ECO:0000313|EMBL:QIX13936.1}, SARS-CoV-2/human/USA/VA-DCLS-0036/2020
RC   {ECO:0000313|EMBL:QIX13948.1}, SARS-CoV-2/human/USA/VA-DCLS-0038/2020
RC   {ECO:0000313|EMBL:QIX13960.1}, SARS-CoV-2/human/USA/VA-DCLS-0039/2020
RC   {ECO:0000313|EMBL:QIX13972.1}, SARS-CoV-2/human/USA/VA-DCLS-0040/2020
RC   {ECO:0000313|EMBL:QIX13984.1}, SARS-CoV-2/human/USA/VA-DCLS-0041/2020
RC   {ECO:0000313|EMBL:QJA41994.1}, SARS-CoV-2/human/USA/VA-DCLS-0042/2020
RC   {ECO:0000313|EMBL:QIX13996.1}, SARS-CoV-2/human/USA/VA-DCLS-0043/2020
RC   {ECO:0000313|EMBL:QIX14008.1}, SARS-CoV-2/human/USA/VA-DCLS-0044/2020
RC   {ECO:0000313|EMBL:QIX14020.1}, SARS-CoV-2/human/USA/VA-DCLS-0045/2020
RC   {ECO:0000313|EMBL:QIX14032.1}, SARS-CoV-2/human/USA/VA-DCLS-0046/2020
RC   {ECO:0000313|EMBL:QIX14044.1}, SARS-CoV-2/human/USA/VA-DCLS-0047/2020
RC   {ECO:0000313|EMBL:QJA42006.1}, SARS-CoV-2/human/USA/VA-DCLS-0048/2020
RC   {ECO:0000313|EMBL:QJA42018.1}, SARS-CoV-2/human/USA/VA-DCLS-0049/2020
RC   {ECO:0000313|EMBL:QJA42030.1}, SARS-CoV-2/human/USA/VA-DCLS-0050/2020
RC   {ECO:0000313|EMBL:QJA42042.1}, SARS-CoV-2/human/USA/VA-DCLS-0051/2020
RC   {ECO:0000313|EMBL:QJA42054.1}, SARS-CoV-2/human/USA/VA-DCLS-0052/2020
RC   {ECO:0000313|EMBL:QJA42066.1}, SARS-CoV-2/human/USA/VA-DCLS-0053/2020
RC   {ECO:0000313|EMBL:QJA42078.1}, SARS-CoV-2/human/USA/VA-DCLS-0054/2020
RC   {ECO:0000313|EMBL:QJA42090.1}, SARS-CoV-2/human/USA/VA-DCLS-0055/2020
RC   {ECO:0000313|EMBL:QJA42102.1}, SARS-CoV-2/human/USA/VA-DCLS-0056/2020
RC   {ECO:0000313|EMBL:QJA42114.1}, SARS-CoV-2/human/USA/VA-DCLS-0057/2020
RC   {ECO:0000313|EMBL:QJA42126.1}, SARS-CoV-2/human/USA/VA-DCLS-0058/2020
RC   {ECO:0000313|EMBL:QJA42138.1}, SARS-CoV-2/human/USA/VA-DCLS-0059/2020
RC   {ECO:0000313|EMBL:QJA42150.1}, SARS-CoV-2/human/USA/VA-DCLS-0060/2020
RC   {ECO:0000313|EMBL:QJA42162.1}, SARS-CoV-2/human/USA/VA-DCLS-0061/2020
RC   {ECO:0000313|EMBL:QJA42174.1}, SARS-CoV-2/human/USA/VA-DCLS-0063/2020
RC   {ECO:0000313|EMBL:QJA42186.1}, SARS-CoV-2/human/USA/VA-DCLS-0064/2020
RC   {ECO:0000313|EMBL:QJA42198.1}, SARS-CoV-2/human/USA/VA-DCLS-0065/2020
RC   {ECO:0000313|EMBL:QJA42210.1}, SARS-CoV-2/human/USA/VA-DCLS-0066/2020
RC   {ECO:0000313|EMBL:QJA42222.1}, SARS-CoV-2/human/USA/VA-DCLS-0067/2020
RC   {ECO:0000313|EMBL:QJA42234.1}, and
RC   SARS-CoV-2/human/USA/VA-DCLS-0068/2020 {ECO:0000313|EMBL:QJA42246.1};
RA   Fink L.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [81] {ECO:0000313|EMBL:QIX12204.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/IRN/HGRC-1.1-IPI-8206/2020
RC   {ECO:0000313|EMBL:QIX12204.1};
RG   Rapid Response Team of Infection Diseases;
RG   Pasteur Institute of Iran;
RA   Zeinali S., Khosravi M.A., Abbasalipour Bashash M., Mostafavi Jabbari S.,
RA   Firoozi M., Pourtavakoli S., Khateri E., Zeinali R., Hoseini F.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [82] {ECO:0000313|EMBL:QIT06996.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/ISR/ISR_JP0320/2020
RC   {ECO:0000313|EMBL:QIT06996.1};
RA   Cohen-Gihon I., Israeli O., Shifman O., Stein D., Melamed S., Paran N.,
RA   Israely T., Achdout H., Yahalom Ronen Y., Tamir H., Politi B., Cherry L.,
RA   Vitner E., Weiss S., Laskar O., Mandelboim M., Erster O., Regev-Yochay G.,
RA   Segal G., Yitzhaki S., Shapira S.C., Beth-Din A., Zvi A.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [83] {ECO:0000313|EMBL:QJA41662.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/USA-WA_0418/2020
RC   {ECO:0000313|EMBL:QJA41722.1}, SARS-CoV-2/human/USA/USA-WA_0427/2020
RC   {ECO:0000313|EMBL:QJA41686.1}, SARS-CoV-2/human/USA/USA-WA_0428/2020
RC   {ECO:0000313|EMBL:QJA41674.1}, SARS-CoV-2/human/USA/USA-WA_0434/2020
RC   {ECO:0000313|EMBL:QJA41698.1}, SARS-CoV-2/human/USA/USA-WA_0442/2020
RC   {ECO:0000313|EMBL:QJA41710.1}, and
RC   SARS-CoV-2/human/USA/USA-WA_0480/2020 {ECO:0000313|EMBL:QJA41662.1};
RA   Zhang J., Tao Y., Paden C.R., Queen K., Uehara A., Li Y., Wang H.,
RA   Jacobs J., Russell D., Hiatt B., Gant J., Tong S.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [84] {ECO:0000313|EMBL:QIU80934.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/CT-UW-1365/2020
RC   {ECO:0000313|EMBL:QIZ14878.1}, SARS-CoV-2/human/USA/CT-UW-3845/2020
RC   {ECO:0000313|EMBL:QJC20100.1}, SARS-CoV-2/human/USA/CT-UW-4238/2020
RC   {ECO:0000313|EMBL:QJC19596.1}, SARS-CoV-2/human/USA/CT-UW-4244/2020
RC   {ECO:0000313|EMBL:QJC19620.1}, SARS-CoV-2/human/USA/CT-UW-4251/2020
RC   {ECO:0000313|EMBL:QJC19632.1}, SARS-CoV-2/human/USA/CT-UW-4341/2020
RC   {ECO:0000313|EMBL:QJC19860.1}, SARS-CoV-2/human/USA/CT-UW-4344/2020
RC   {ECO:0000313|EMBL:QJA17249.1}, SARS-CoV-2/human/USA/CT-UW-4346/2020
RC   {ECO:0000313|EMBL:QJA17261.1}, SARS-CoV-2/human/USA/CT-UW-4347/2020
RC   {ECO:0000313|EMBL:QJA17273.1}, SARS-CoV-2/human/USA/CT-UW-4366/2020
RC   {ECO:0000313|EMBL:QJA17309.1}, SARS-CoV-2/human/USA/CT-UW-4372/2020
RC   {ECO:0000313|EMBL:QJA17321.1}, SARS-CoV-2/human/USA/CT-UW238/2020
RC   {ECO:0000313|EMBL:QIQ68492.1}, SARS-CoV-2/human/USA/CT-UW250/2020
RC   {ECO:0000313|EMBL:QIS30233.1}, SARS-CoV-2/human/USA/CT-UW256/2020
RC   {ECO:0000313|EMBL:QIS30293.1}, SARS-CoV-2/human/USA/CT-UW303/2020
RC   {ECO:0000313|EMBL:QIS60579.1}, SARS-CoV-2/human/USA/CT-UW327/2020
RC   {ECO:0000313|EMBL:QIS60831.1}, SARS-CoV-2/human/USA/CT-UW329/2020
RC   {ECO:0000313|EMBL:QIS61503.1}, SARS-CoV-2/human/USA/CT-UW331/2020
RC   {ECO:0000313|EMBL:QIS60879.1}, SARS-CoV-2/human/USA/ID-UW-1925/2020
RC   {ECO:0000313|EMBL:QIZ13584.1}, SARS-CoV-2/human/USA/ID-UW-1934/2020
RC   {ECO:0000313|EMBL:QIZ13596.1}, SARS-CoV-2/human/USA/ID-UW-1935/2020
RC   {ECO:0000313|EMBL:QIZ13558.1}, SARS-CoV-2/human/USA/ID-UW-1938/2020
RC   {ECO:0000313|EMBL:QIZ13548.1}, SARS-CoV-2/human/USA/ID-UW-1939/2020
RC   {ECO:0000313|EMBL:QIZ13568.1}, SARS-CoV-2/human/USA/ID-UW-2127/2020
RC   {ECO:0000313|EMBL:QJA16469.1}, SARS-CoV-2/human/USA/ID-UW-2134/2020
RC   {ECO:0000313|EMBL:QJA16637.1}, SARS-CoV-2/human/USA/ID-UW-2159/2020
RC   {ECO:0000313|EMBL:QJA16803.1}, SARS-CoV-2/human/USA/ID-UW-2160/2020
RC   {ECO:0000313|EMBL:QJA16769.1}, SARS-CoV-2/human/USA/ID-UW-2173/2020
RC   {ECO:0000313|EMBL:QJA17189.1}, SARS-CoV-2/human/USA/ID-UW-2174/2020
RC   {ECO:0000313|EMBL:QJA17129.1}, SARS-CoV-2/human/USA/ID-UW-2195/2020
RC   {ECO:0000313|EMBL:QJA17201.1}, SARS-CoV-2/human/USA/ID-UW-2198/2020
RC   {ECO:0000313|EMBL:QJA17117.1}, SARS-CoV-2/human/USA/ID-UW-2255/2020
RC   {ECO:0000313|EMBL:QJA17225.1}, SARS-CoV-2/human/USA/ID-UW-3888/2020
RC   {ECO:0000313|EMBL:QJC20220.1}, SARS-CoV-2/human/USA/ID-UW-3892/2020
RC   {ECO:0000313|EMBL:QJC20292.1}, SARS-CoV-2/human/USA/ID-UW-4100/2020
RC   {ECO:0000313|EMBL:QJC20723.1}, SARS-CoV-2/human/USA/ID-UW-4239/2020
RC   {ECO:0000313|EMBL:QJC19608.1}, SARS-CoV-2/human/USA/ID-UW-4266/2020
RC   {ECO:0000313|EMBL:QJC19644.1}, SARS-CoV-2/human/USA/ID-UW-4355/2020
RC   {ECO:0000313|EMBL:QJA17284.1}, SARS-CoV-2/human/USA/ID-UW-4357/2020
RC   {ECO:0000313|EMBL:QJA17297.1}, SARS-CoV-2/human/USA/ID-UW-4375/2020
RC   {ECO:0000313|EMBL:QJA17333.1}, SARS-CoV-2/human/USA/ID-UW-4378/2020
RC   {ECO:0000313|EMBL:QJA17345.1}, SARS-CoV-2/human/USA/ID-UW-4380/2020
RC   {ECO:0000313|EMBL:QJA17357.1}, SARS-CoV-2/human/USA/ID-UW-4396/2020
RC   {ECO:0000313|EMBL:QJA17381.1}, SARS-CoV-2/human/USA/ID-UW-4400/2020
RC   {ECO:0000313|EMBL:QJA17393.1}, SARS-CoV-2/human/USA/ID-UW-4424/2020
RC   {ECO:0000313|EMBL:QJA17440.1}, SARS-CoV-2/human/USA/ID-UW-4427/2020
RC   {ECO:0000313|EMBL:QJA17453.1}, SARS-CoV-2/human/USA/ID-UW-4433/2020
RC   {ECO:0000313|EMBL:QJA17465.1}, SARS-CoV-2/human/USA/ID-UW-4448/2020
RC   {ECO:0000313|EMBL:QJA17477.1}, SARS-CoV-2/human/USA/ID-UW-4461/2020
RC   {ECO:0000313|EMBL:QJA17489.1}, SARS-CoV-2/human/USA/ID-UW-4462/2020
RC   {ECO:0000313|EMBL:QJC20232.1}, SARS-CoV-2/human/USA/ID-UW-4486/2020
RC   {ECO:0000313|EMBL:QJC20244.1}, SARS-CoV-2/human/USA/IL-UW-1311/2020
RC   {ECO:0000313|EMBL:QIZ14866.1}, SARS-CoV-2/human/USA/IL-UW348/2020
RC   {ECO:0000313|EMBL:QIS61083.1}, SARS-CoV-2/human/USA/IL-UW349/2020
RC   {ECO:0000313|EMBL:QIS61095.1}, SARS-CoV-2/human/USA/IL-UW353/2020
RC   {ECO:0000313|EMBL:QIS61143.1}, SARS-CoV-2/human/USA/IL-UW381/2020
RC   {ECO:0000313|EMBL:QIS61465.1}, SARS-CoV-2/human/USA/MN-UW266/2020
RC   {ECO:0000313|EMBL:QIS30393.1}, SARS-CoV-2/human/USA/MN-UW326/2020
RC   {ECO:0000313|EMBL:QIS60819.1}, SARS-CoV-2/human/USA/MN-UW335/2020
RC   {ECO:0000313|EMBL:QIS60927.1}, SARS-CoV-2/human/USA/OR-UW-1849/2020
RC   {ECO:0000313|EMBL:QIZ13188.1}, SARS-CoV-2/human/USA/OR-UW-1851/2020
RC   {ECO:0000313|EMBL:QIZ13176.1}, SARS-CoV-2/human/USA/OR-UW-1885/2020
RC   {ECO:0000313|EMBL:QIZ13428.1}, SARS-CoV-2/human/USA/OR-UW-1887/2020
RC   {ECO:0000313|EMBL:QIZ13440.1}, SARS-CoV-2/human/USA/OR-UW-1937/2020
RC   {ECO:0000313|EMBL:QIZ13379.1}, SARS-CoV-2/human/USA/OR-UW-4300/2020
RC   {ECO:0000313|EMBL:QJC19716.1}, SARS-CoV-2/human/USA/OR-UW-4388/2020
RC   {ECO:0000313|EMBL:QJA17369.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-1402/2020
RC   {ECO:0000313|EMBL:QIZ14948.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-1403/2020
RC   {ECO:0000313|EMBL:QIU81186.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-1773/2020
RC   {ECO:0000313|EMBL:QIZ14770.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-1791/2020
RC   {ECO:0000313|EMBL:QIZ13714.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-1816/2020
RC   {ECO:0000313|EMBL:QIZ13942.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-1817/2020
RC   {ECO:0000313|EMBL:QIZ13930.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-1818/2020
RC   {ECO:0000313|EMBL:QIZ13918.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-1832/2020
RC   {ECO:0000313|EMBL:QIZ13786.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-1834/2020
RC   {ECO:0000313|EMBL:QIZ13903.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-2069/2020
RC   {ECO:0000313|EMBL:QJA16457.1},
RC   SARS-CoV-2/human/USA/UNKNOWN-UW-2139/2020
RC   {ECO:0000313|EMBL:QJA16625.1}, SARS-CoV-2/human/USA/WA-UW-1268/2020
RC   {ECO:0000313|EMBL:QIU81222.1}, SARS-CoV-2/human/USA/WA-UW-1269/2020
RC   {ECO:0000313|EMBL:QIU81042.1}, SARS-CoV-2/human/USA/WA-UW-1271/2020
RC   {ECO:0000313|EMBL:QIU80958.1}, SARS-CoV-2/human/USA/WA-UW-1279/2020
RC   {ECO:0000313|EMBL:QIU81090.1}, SARS-CoV-2/human/USA/WA-UW-1287/2020
RC   {ECO:0000313|EMBL:QIU81030.1}, SARS-CoV-2/human/USA/WA-UW-1294/2020
RC   {ECO:0000313|EMBL:QIZ14938.1}, SARS-CoV-2/human/USA/WA-UW-1296/2020
RC   {ECO:0000313|EMBL:QIU81258.1}, SARS-CoV-2/human/USA/WA-UW-1297/2020
RC   {ECO:0000313|EMBL:QIU81270.1}, SARS-CoV-2/human/USA/WA-UW-1300/2020
RC   {ECO:0000313|EMBL:QIU81210.1}, SARS-CoV-2/human/USA/WA-UW-1302/2020
RC   {ECO:0000313|EMBL:QIU81006.1}, SARS-CoV-2/human/USA/WA-UW-1304/2020
RC   {ECO:0000313|EMBL:QIU80970.1}, SARS-CoV-2/human/USA/WA-UW-1306/2020
RC   {ECO:0000313|EMBL:QIU81114.1}, SARS-CoV-2/human/USA/WA-UW-1308/2020
RC   {ECO:0000313|EMBL:QIU81078.1}, SARS-CoV-2/human/USA/WA-UW-1309/2020
RC   {ECO:0000313|EMBL:QIU81126.1}, SARS-CoV-2/human/USA/WA-UW-1314/2020
RC   {ECO:0000313|EMBL:QIU81294.1}, SARS-CoV-2/human/USA/WA-UW-1315/2020
RC   {ECO:0000313|EMBL:QIU80982.1}, SARS-CoV-2/human/USA/WA-UW-1319/2020
RC   {ECO:0000313|EMBL:QIU81066.1}, SARS-CoV-2/human/USA/WA-UW-1320/2020
RC   {ECO:0000313|EMBL:QIU81054.1}, SARS-CoV-2/human/USA/WA-UW-1322/2020
RC   {ECO:0000313|EMBL:QIU81330.1}, SARS-CoV-2/human/USA/WA-UW-1327/2020
RC   {ECO:0000313|EMBL:QIU81102.1}, SARS-CoV-2/human/USA/WA-UW-1329/2020
RC   {ECO:0000313|EMBL:QIU80994.1}, SARS-CoV-2/human/USA/WA-UW-1334/2020
RC   {ECO:0000313|EMBL:QIU81342.1}, SARS-CoV-2/human/USA/WA-UW-1338/2020
RC   {ECO:0000313|EMBL:QIU81234.1}, SARS-CoV-2/human/USA/WA-UW-1341/2020
RC   {ECO:0000313|EMBL:QIZ14926.1}, SARS-CoV-2/human/USA/WA-UW-1342/2020
RC   {ECO:0000313|EMBL:QIZ14914.1}, SARS-CoV-2/human/USA/WA-UW-1346/2020
RC   {ECO:0000313|EMBL:QIU81354.1}, SARS-CoV-2/human/USA/WA-UW-1347/2020
RC   {ECO:0000313|EMBL:QIU81306.1}, SARS-CoV-2/human/USA/WA-UW-1349/2020
RC   {ECO:0000313|EMBL:QIU81390.1}, SARS-CoV-2/human/USA/WA-UW-1353/2020
RC   {ECO:0000313|EMBL:QIU81246.1}, SARS-CoV-2/human/USA/WA-UW-1362/2020
RC   {ECO:0000313|EMBL:QIZ14888.1}, SARS-CoV-2/human/USA/WA-UW-1417/2020
RC   {ECO:0000313|EMBL:QIU81174.1}, SARS-CoV-2/human/USA/WA-UW-1422/2020
RC   {ECO:0000313|EMBL:QIZ14986.1}, SARS-CoV-2/human/USA/WA-UW-1425/2020
RC   {ECO:0000313|EMBL:QIU81738.1}, SARS-CoV-2/human/USA/WA-UW-1426/2020
RC   {ECO:0000313|EMBL:QIU81498.1}, SARS-CoV-2/human/USA/WA-UW-1433/2020
RC   {ECO:0000313|EMBL:QIU81726.1}, SARS-CoV-2/human/USA/WA-UW-1435/2020
RC   {ECO:0000313|EMBL:QIU81666.1}, SARS-CoV-2/human/USA/WA-UW-1436/2020
RC   {ECO:0000313|EMBL:QIZ14974.1}, SARS-CoV-2/human/USA/WA-UW-1440/2020
RC   {ECO:0000313|EMBL:QIU81690.1}, SARS-CoV-2/human/USA/WA-UW-1441/2020
RC   {ECO:0000313|EMBL:QIU81678.1}, SARS-CoV-2/human/USA/WA-UW-1446/2020
RC   {ECO:0000313|EMBL:QIU81510.1}, SARS-CoV-2/human/USA/WA-UW-1448/2020
RC   {ECO:0000313|EMBL:QIU81486.1}, SARS-CoV-2/human/USA/WA-UW-1470/2020
RC   {ECO:0000313|EMBL:QIU81702.1}, SARS-CoV-2/human/USA/WA-UW-1471/2020
RC   {ECO:0000313|EMBL:QIU81714.1}, SARS-CoV-2/human/USA/WA-UW-1472/2020
RC   {ECO:0000313|EMBL:QIZ14902.1}, SARS-CoV-2/human/USA/WA-UW-1478/2020
RC   {ECO:0000313|EMBL:QIZ14962.1}, SARS-CoV-2/human/USA/WA-UW-1538/2020
RC   {ECO:0000313|EMBL:QIZ14818.1}, SARS-CoV-2/human/USA/WA-UW-1552/2020
RC   {ECO:0000313|EMBL:QIU81570.1}, SARS-CoV-2/human/USA/WA-UW-1561/2020
RC   {ECO:0000313|EMBL:QIU81522.1}, SARS-CoV-2/human/USA/WA-UW-1562/2020
RC   {ECO:0000313|EMBL:QIU81654.1}, SARS-CoV-2/human/USA/WA-UW-1567/2020
RC   {ECO:0000313|EMBL:QIU81414.1}, SARS-CoV-2/human/USA/WA-UW-1569/2020
RC   {ECO:0000313|EMBL:QIU81642.1}, SARS-CoV-2/human/USA/WA-UW-1570/2020
RC   {ECO:0000313|EMBL:QIU81630.1}, SARS-CoV-2/human/USA/WA-UW-1572/2020
RC   {ECO:0000313|EMBL:QIZ14842.1}, SARS-CoV-2/human/USA/WA-UW-1574/2020
RC   {ECO:0000313|EMBL:QIU81618.1}, SARS-CoV-2/human/USA/WA-UW-1575/2020
RC   {ECO:0000313|EMBL:QIZ14854.1}, SARS-CoV-2/human/USA/WA-UW-1576/2020
RC   {ECO:0000313|EMBL:QIU81606.1}, SARS-CoV-2/human/USA/WA-UW-1578/2020
RC   {ECO:0000313|EMBL:QIU81582.1}, SARS-CoV-2/human/USA/WA-UW-1581/2020
RC   {ECO:0000313|EMBL:QIU81450.1}, SARS-CoV-2/human/USA/WA-UW-1583/2020
RC   {ECO:0000313|EMBL:QIU81438.1}, SARS-CoV-2/human/USA/WA-UW-1586/2020
RC   {ECO:0000313|EMBL:QIU81546.1}, SARS-CoV-2/human/USA/WA-UW-1587/2020
RC   {ECO:0000313|EMBL:QIU81558.1}, SARS-CoV-2/human/USA/WA-UW-1588/2020
RC   {ECO:0000313|EMBL:QIU81534.1}, SARS-CoV-2/human/USA/WA-UW-1591/2020
RC   {ECO:0000313|EMBL:QIU81594.1}, SARS-CoV-2/human/USA/WA-UW-1593/2020
RC   {ECO:0000313|EMBL:QIU81426.1}, SARS-CoV-2/human/USA/WA-UW-1595/2020
RC   {ECO:0000313|EMBL:QIZ14830.1}, SARS-CoV-2/human/USA/WA-UW-1599/2020
RC   {ECO:0000313|EMBL:QIU81762.1}, SARS-CoV-2/human/USA/WA-UW-1603/2020
RC   {ECO:0000313|EMBL:QIU81462.1}, SARS-CoV-2/human/USA/WA-UW-1608/2020
RC   {ECO:0000313|EMBL:QIU81750.1}, SARS-CoV-2/human/USA/WA-UW-1611/2020
RC   {ECO:0000313|EMBL:QIU81474.1}, SARS-CoV-2/human/USA/WA-UW-1616/2020
RC   {ECO:0000313|EMBL:QIZ14794.1}, SARS-CoV-2/human/USA/WA-UW-1620/2020
RC   {ECO:0000313|EMBL:QIZ14782.1}, SARS-CoV-2/human/USA/WA-UW-1638/2020
RC   {ECO:0000313|EMBL:QIZ14805.1}, SARS-CoV-2/human/USA/WA-UW-1640/2020
RC   {ECO:0000313|EMBL:QIZ14158.1}, SARS-CoV-2/human/USA/WA-UW-1644/2020
RC   {ECO:0000313|EMBL:QIZ14038.1}, SARS-CoV-2/human/USA/WA-UW-1645/2020
RC   {ECO:0000313|EMBL:QIZ14062.1}, SARS-CoV-2/human/USA/WA-UW-1646/2020
RC   {ECO:0000313|EMBL:QIZ14050.1}, SARS-CoV-2/human/USA/WA-UW-1651/2020
RC   {ECO:0000313|EMBL:QIZ14218.1}, SARS-CoV-2/human/USA/WA-UW-1652/2020
RC   {ECO:0000313|EMBL:QIZ14230.1}, SARS-CoV-2/human/USA/WA-UW-1656/2020
RC   {ECO:0000313|EMBL:QIZ14170.1}, SARS-CoV-2/human/USA/WA-UW-1659/2020
RC   {ECO:0000313|EMBL:QIZ14204.1}, SARS-CoV-2/human/USA/WA-UW-1661/2020
RC   {ECO:0000313|EMBL:QIZ14122.1}, SARS-CoV-2/human/USA/WA-UW-1666/2020
RC   {ECO:0000313|EMBL:QIZ14146.1}, SARS-CoV-2/human/USA/WA-UW-1670/2020
RC   {ECO:0000313|EMBL:QIZ14350.1}, SARS-CoV-2/human/USA/WA-UW-1672/2020
RC   {ECO:0000313|EMBL:QIZ14182.1}, SARS-CoV-2/human/USA/WA-UW-1673/2020
RC   {ECO:0000313|EMBL:QIZ14266.1}, SARS-CoV-2/human/USA/WA-UW-1675/2020
RC   {ECO:0000313|EMBL:QIZ14073.1}, SARS-CoV-2/human/USA/WA-UW-1677/2020
RC   {ECO:0000313|EMBL:QIZ14362.1}, SARS-CoV-2/human/USA/WA-UW-1680/2020
RC   {ECO:0000313|EMBL:QIZ14374.1}, SARS-CoV-2/human/USA/WA-UW-1682/2020
RC   {ECO:0000313|EMBL:QIZ14410.1}, SARS-CoV-2/human/USA/WA-UW-1683/2020
RC   {ECO:0000313|EMBL:QIZ14086.1}, SARS-CoV-2/human/USA/WA-UW-1684/2020
RC   {ECO:0000313|EMBL:QIZ14393.1}, SARS-CoV-2/human/USA/WA-UW-1688/2020
RC   {ECO:0000313|EMBL:QIZ14098.1}, SARS-CoV-2/human/USA/WA-UW-1689/2020
RC   {ECO:0000313|EMBL:QIZ14326.1}, SARS-CoV-2/human/USA/WA-UW-1690/2020
RC   {ECO:0000313|EMBL:QIZ14386.1}, SARS-CoV-2/human/USA/WA-UW-1695/2020
RC   {ECO:0000313|EMBL:QIZ14422.1}, SARS-CoV-2/human/USA/WA-UW-1697/2020
RC   {ECO:0000313|EMBL:QIZ14254.1}, SARS-CoV-2/human/USA/WA-UW-1698/2020
RC   {ECO:0000313|EMBL:QIZ14242.1}, SARS-CoV-2/human/USA/WA-UW-1700/2020
RC   {ECO:0000313|EMBL:QIZ14458.1}, SARS-CoV-2/human/USA/WA-UW-1702/2020
RC   {ECO:0000313|EMBL:QIZ14530.1}, SARS-CoV-2/human/USA/WA-UW-1705/2020
RC   {ECO:0000313|EMBL:QIZ14506.1}, SARS-CoV-2/human/USA/WA-UW-1706/2020
RC   {ECO:0000313|EMBL:QIZ14518.1}, SARS-CoV-2/human/USA/WA-UW-1707/2020
RC   {ECO:0000313|EMBL:QIZ14494.1}, SARS-CoV-2/human/USA/WA-UW-1708/2020
RC   {ECO:0000313|EMBL:QIZ14578.1}, SARS-CoV-2/human/USA/WA-UW-1709/2020
RC   {ECO:0000313|EMBL:QIZ14552.1}, SARS-CoV-2/human/USA/WA-UW-1712/2020
RC   {ECO:0000313|EMBL:QIZ14290.1}, SARS-CoV-2/human/USA/WA-UW-1715/2020
RC   {ECO:0000313|EMBL:QIZ14338.1}, SARS-CoV-2/human/USA/WA-UW-1716/2020
RC   {ECO:0000313|EMBL:QIZ14278.1}, SARS-CoV-2/human/USA/WA-UW-1718/2020
RC   {ECO:0000313|EMBL:QIZ14314.1}, SARS-CoV-2/human/USA/WA-UW-1722/2020
RC   {ECO:0000313|EMBL:QIZ14602.1}, SARS-CoV-2/human/USA/WA-UW-1723/2020
RC   {ECO:0000313|EMBL:QIZ14194.1}, SARS-CoV-2/human/USA/WA-UW-1724/2020
RC   {ECO:0000313|EMBL:QIZ14542.1}, SARS-CoV-2/human/USA/WA-UW-1726/2020
RC   {ECO:0000313|EMBL:QIZ14134.1}, SARS-CoV-2/human/USA/WA-UW-1728/2020
RC   {ECO:0000313|EMBL:QIZ14110.1}, SARS-CoV-2/human/USA/WA-UW-1729/2020
RC   {ECO:0000313|EMBL:QIZ14434.1}, SARS-CoV-2/human/USA/WA-UW-1730/2020
RC   {ECO:0000313|EMBL:QIZ14672.1}, SARS-CoV-2/human/USA/WA-UW-1731/2020
RC   {ECO:0000313|EMBL:QIZ14566.1}, SARS-CoV-2/human/USA/WA-UW-1732/2020
RC   {ECO:0000313|EMBL:QIZ14626.1}, SARS-CoV-2/human/USA/WA-UW-1733/2020
RC   {ECO:0000313|EMBL:QIZ14614.1}, SARS-CoV-2/human/USA/WA-UW-1735/2020
RC   {ECO:0000313|EMBL:QIZ14686.1}, SARS-CoV-2/human/USA/WA-UW-1739/2020
RC   {ECO:0000313|EMBL:QIZ14638.1}, SARS-CoV-2/human/USA/WA-UW-1741/2020
RC   {ECO:0000313|EMBL:QIZ14650.1}, SARS-CoV-2/human/USA/WA-UW-1744/2020
RC   {ECO:0000313|EMBL:QIZ14470.1}, SARS-CoV-2/human/USA/WA-UW-1745/2020
RC   {ECO:0000313|EMBL:QIZ14482.1}, SARS-CoV-2/human/USA/WA-UW-1748/2020
RC   {ECO:0000313|EMBL:QIZ14446.1}, SARS-CoV-2/human/USA/WA-UW-1750/2020
RC   {ECO:0000313|EMBL:QIZ14662.1}, SARS-CoV-2/human/USA/WA-UW-1753/2020
RC   {ECO:0000313|EMBL:QIZ14698.1}, SARS-CoV-2/human/USA/WA-UW-1756/2020
RC   {ECO:0000313|EMBL:QIZ14710.1}, SARS-CoV-2/human/USA/WA-UW-1758/2020
RC   {ECO:0000313|EMBL:QIZ14746.1}, SARS-CoV-2/human/USA/WA-UW-1760/2020
RC   {ECO:0000313|EMBL:QIZ14758.1}, SARS-CoV-2/human/USA/WA-UW-1762/2020
RC   {ECO:0000313|EMBL:QIZ14734.1}, SARS-CoV-2/human/USA/WA-UW-1765/2020
RC   {ECO:0000313|EMBL:QIZ14302.1}, SARS-CoV-2/human/USA/WA-UW-1770/2020
RC   {ECO:0000313|EMBL:QIZ14722.1}, SARS-CoV-2/human/USA/WA-UW-1772/2020
RC   {ECO:0000313|EMBL:QIZ14590.1}, SARS-CoV-2/human/USA/WA-UW-1774/2020
RC   {ECO:0000313|EMBL:QIZ13798.1}, SARS-CoV-2/human/USA/WA-UW-1775/2020
RC   {ECO:0000313|EMBL:QIZ13810.1}, SARS-CoV-2/human/USA/WA-UW-1778/2020
RC   {ECO:0000313|EMBL:QIZ13822.1}, SARS-CoV-2/human/USA/WA-UW-1779/2020
RC   {ECO:0000313|EMBL:QIZ13846.1}, SARS-CoV-2/human/USA/WA-UW-1782/2020
RC   {ECO:0000313|EMBL:QIZ13870.1}, SARS-CoV-2/human/USA/WA-UW-1784/2020
RC   {ECO:0000313|EMBL:QIZ13858.1}, SARS-CoV-2/human/USA/WA-UW-1785/2020
RC   {ECO:0000313|EMBL:QIZ13726.1}, SARS-CoV-2/human/USA/WA-UW-1792/2020
RC   {ECO:0000313|EMBL:QIZ13762.1}, SARS-CoV-2/human/USA/WA-UW-1796/2020
RC   {ECO:0000313|EMBL:QIZ13774.1}, SARS-CoV-2/human/USA/WA-UW-1797/2020
RC   {ECO:0000313|EMBL:QIZ13834.1}, SARS-CoV-2/human/USA/WA-UW-1799/2020
RC   {ECO:0000313|EMBL:QIZ13882.1}, SARS-CoV-2/human/USA/WA-UW-1801/2020
RC   {ECO:0000313|EMBL:QIZ13738.1}, SARS-CoV-2/human/USA/WA-UW-1805/2020
RC   {ECO:0000313|EMBL:QIZ13894.1}, SARS-CoV-2/human/USA/WA-UW-1821/2020
RC   {ECO:0000313|EMBL:QIZ14012.1}, SARS-CoV-2/human/USA/WA-UW-1822/2020
RC   {ECO:0000313|EMBL:QIZ14026.1}, SARS-CoV-2/human/USA/WA-UW-1825/2020
RC   {ECO:0000313|EMBL:QIZ13989.1}, SARS-CoV-2/human/USA/WA-UW-1826/2020
RC   {ECO:0000313|EMBL:QIZ14002.1}, SARS-CoV-2/human/USA/WA-UW-1827/2020
RC   {ECO:0000313|EMBL:QIZ13978.1}, SARS-CoV-2/human/USA/WA-UW-1828/2020
RC   {ECO:0000313|EMBL:QIZ13954.1}, SARS-CoV-2/human/USA/WA-UW-1831/2020
RC   {ECO:0000313|EMBL:QIZ13966.1}, SARS-CoV-2/human/USA/WA-UW-1835/2020
RC   {ECO:0000313|EMBL:QIZ13140.1}, SARS-CoV-2/human/USA/WA-UW-1840/2020
RC   {ECO:0000313|EMBL:QIZ13750.1}, SARS-CoV-2/human/USA/WA-UW-1843/2020
RC   {ECO:0000313|EMBL:QIZ13200.1}, SARS-CoV-2/human/USA/WA-UW-1846/2020
RC   {ECO:0000313|EMBL:QIZ13212.1}, SARS-CoV-2/human/USA/WA-UW-1850/2020
RC   {ECO:0000313|EMBL:QIZ13104.1}, SARS-CoV-2/human/USA/WA-UW-1853/2020
RC   {ECO:0000313|EMBL:QIZ13236.1}, SARS-CoV-2/human/USA/WA-UW-1854/2020
RC   {ECO:0000313|EMBL:QIZ13248.1}, SARS-CoV-2/human/USA/WA-UW-1855/2020
RC   {ECO:0000313|EMBL:QIZ13260.1}, SARS-CoV-2/human/USA/WA-UW-1858/2020
RC   {ECO:0000313|EMBL:QIZ13078.1}, SARS-CoV-2/human/USA/WA-UW-1860/2020
RC   {ECO:0000313|EMBL:QIZ13224.1}, SARS-CoV-2/human/USA/WA-UW-1863/2020
RC   {ECO:0000313|EMBL:QIZ13164.1}, SARS-CoV-2/human/USA/WA-UW-1864/2020
RC   {ECO:0000313|EMBL:QIZ13128.1}, SARS-CoV-2/human/USA/WA-UW-1865/2020
RC   {ECO:0000313|EMBL:QIZ13678.1}, SARS-CoV-2/human/USA/WA-UW-1866/2020
RC   {ECO:0000313|EMBL:QIZ13092.1}, SARS-CoV-2/human/USA/WA-UW-1868/2020
RC   {ECO:0000313|EMBL:QIZ13116.1}, SARS-CoV-2/human/USA/WA-UW-1870/2020
RC   {ECO:0000313|EMBL:QIZ13272.1}, SARS-CoV-2/human/USA/WA-UW-1872/2020
RC   {ECO:0000313|EMBL:QIZ13284.1}, SARS-CoV-2/human/USA/WA-UW-1874/2020
RC   {ECO:0000313|EMBL:QIZ13414.1}, SARS-CoV-2/human/USA/WA-UW-1877/2020
RC   {ECO:0000313|EMBL:QIZ13404.1}, SARS-CoV-2/human/USA/WA-UW-1878/2020
RC   {ECO:0000313|EMBL:QIZ13368.1}, SARS-CoV-2/human/USA/WA-UW-1879/2020
RC   {ECO:0000313|EMBL:QIZ13356.1}, SARS-CoV-2/human/USA/WA-UW-1880/2020
RC   {ECO:0000313|EMBL:QIZ13476.1}, SARS-CoV-2/human/USA/WA-UW-1881/2020
RC   {ECO:0000313|EMBL:QIZ13452.1}, SARS-CoV-2/human/USA/WA-UW-1888/2020
RC   {ECO:0000313|EMBL:QIZ13464.1}, SARS-CoV-2/human/USA/WA-UW-1890/2020
RC   {ECO:0000313|EMBL:QIZ13524.1}, SARS-CoV-2/human/USA/WA-UW-1904/2020
RC   {ECO:0000313|EMBL:QIZ13344.1}, SARS-CoV-2/human/USA/WA-UW-1905/2020
RC   {ECO:0000313|EMBL:QIZ13295.1}, SARS-CoV-2/human/USA/WA-UW-1907/2020
RC   {ECO:0000313|EMBL:QIZ13690.1}, SARS-CoV-2/human/USA/WA-UW-1913/2020
RC   {ECO:0000313|EMBL:QIZ13320.1}, SARS-CoV-2/human/USA/WA-UW-1917/2020
RC   {ECO:0000313|EMBL:QIZ13702.1}, SARS-CoV-2/human/USA/WA-UW-1919/2020
RC   {ECO:0000313|EMBL:QIZ13308.1}, SARS-CoV-2/human/USA/WA-UW-1920/2020
RC   {ECO:0000313|EMBL:QIZ13332.1}, SARS-CoV-2/human/USA/WA-UW-1921/2020
RC   {ECO:0000313|EMBL:QIZ13512.1}, SARS-CoV-2/human/USA/WA-UW-1928/2020
RC   {ECO:0000313|EMBL:QIZ13536.1}, SARS-CoV-2/human/USA/WA-UW-1930/2020
RC   {ECO:0000313|EMBL:QIZ13392.1}, SARS-CoV-2/human/USA/WA-UW-1944/2020
RC   {ECO:0000313|EMBL:QIZ13608.1}, SARS-CoV-2/human/USA/WA-UW-1946/2020
RC   {ECO:0000313|EMBL:QIZ13151.1}, SARS-CoV-2/human/USA/WA-UW-1954/2020
RC   {ECO:0000313|EMBL:QIZ13632.1}, SARS-CoV-2/human/USA/WA-UW-1955/2020
RC   {ECO:0000313|EMBL:QIZ13488.1}, SARS-CoV-2/human/USA/WA-UW-1956/2020
RC   {ECO:0000313|EMBL:QIZ13500.1}, SARS-CoV-2/human/USA/WA-UW-1963/2020
RC   {ECO:0000313|EMBL:QIZ13654.1}, SARS-CoV-2/human/USA/WA-UW-1965/2020
RC   {ECO:0000313|EMBL:QIZ13620.1}, SARS-CoV-2/human/USA/WA-UW-1968/2020
RC   {ECO:0000313|EMBL:QIZ13641.1}, SARS-CoV-2/human/USA/WA-UW-1977/2020
RC   {ECO:0000313|EMBL:QIZ13020.1}, SARS-CoV-2/human/USA/WA-UW-1984/2020
RC   {ECO:0000313|EMBL:QIZ13666.1}, SARS-CoV-2/human/USA/WA-UW-1986/2020
RC   {ECO:0000313|EMBL:QIZ13032.1}, SARS-CoV-2/human/USA/WA-UW-1988/2020
RC   {ECO:0000313|EMBL:QIZ13008.1}, SARS-CoV-2/human/USA/WA-UW-1994/2020
RC   {ECO:0000313|EMBL:QIZ12984.1}, SARS-CoV-2/human/USA/WA-UW-1998/2020
RC   {ECO:0000313|EMBL:QIZ12996.1}, SARS-CoV-2/human/USA/WA-UW-2006/2020
RC   {ECO:0000313|EMBL:QIZ12972.1}, SARS-CoV-2/human/USA/WA-UW-2008/2020
RC   {ECO:0000313|EMBL:QIZ13068.1}, SARS-CoV-2/human/USA/WA-UW-2009/2020
RC   {ECO:0000313|EMBL:QIZ13056.1}, SARS-CoV-2/human/USA/WA-UW-2016/2020
RC   {ECO:0000313|EMBL:QIZ13044.1}, SARS-CoV-2/human/USA/WA-UW-2072/2020
RC   {ECO:0000313|EMBL:QJA16481.1}, SARS-CoV-2/human/USA/WA-UW-2074/2020
RC   {ECO:0000313|EMBL:QJA16517.1}, SARS-CoV-2/human/USA/WA-UW-2078/2020
RC   {ECO:0000313|EMBL:QJA16493.1}, SARS-CoV-2/human/USA/WA-UW-2082/2020
RC   {ECO:0000313|EMBL:QJA16431.1}, SARS-CoV-2/human/USA/WA-UW-2086/2020
RC   {ECO:0000313|EMBL:QJA16553.1}, SARS-CoV-2/human/USA/WA-UW-2087/2020
RC   {ECO:0000313|EMBL:QJA16505.1}, SARS-CoV-2/human/USA/WA-UW-2091/2020
RC   {ECO:0000313|EMBL:QJA16409.1}, SARS-CoV-2/human/USA/WA-UW-2094/2020
RC   {ECO:0000313|EMBL:QJA16577.1}, SARS-CoV-2/human/USA/WA-UW-2100/2020
RC   {ECO:0000313|EMBL:QJA16685.1}, SARS-CoV-2/human/USA/WA-UW-2104/2020
RC   {ECO:0000313|EMBL:QJA16601.1}, SARS-CoV-2/human/USA/WA-UW-2108/2020
RC   {ECO:0000313|EMBL:QJA16565.1}, SARS-CoV-2/human/USA/WA-UW-2109/2020
RC   {ECO:0000313|EMBL:QJA16649.1}, SARS-CoV-2/human/USA/WA-UW-2112/2020
RC   {ECO:0000313|EMBL:QJA16661.1}, SARS-CoV-2/human/USA/WA-UW-2115/2020
RC   {ECO:0000313|EMBL:QJA16589.1}, SARS-CoV-2/human/USA/WA-UW-2119/2020
RC   {ECO:0000313|EMBL:QJA16541.1}, SARS-CoV-2/human/USA/WA-UW-2129/2020
RC   {ECO:0000313|EMBL:QJA16673.1}, SARS-CoV-2/human/USA/WA-UW-2131/2020
RC   {ECO:0000313|EMBL:QJA16445.1}, SARS-CoV-2/human/USA/WA-UW-2132/2020
RC   {ECO:0000313|EMBL:QJA16529.1}, SARS-CoV-2/human/USA/WA-UW-2137/2020
RC   {ECO:0000313|EMBL:QJA16613.1}, SARS-CoV-2/human/USA/WA-UW-2140/2020
RC   {ECO:0000313|EMBL:QJA16721.1}, SARS-CoV-2/human/USA/WA-UW-2141/2020
RC   {ECO:0000313|EMBL:QJA16697.1}, SARS-CoV-2/human/USA/WA-UW-2142/2020
RC   {ECO:0000313|EMBL:QJA16781.1}, SARS-CoV-2/human/USA/WA-UW-2144/2020
RC   {ECO:0000313|EMBL:QJA16745.1}, SARS-CoV-2/human/USA/WA-UW-2145/2020
RC   {ECO:0000313|EMBL:QJA16733.1}, SARS-CoV-2/human/USA/WA-UW-2146/2020
RC   {ECO:0000313|EMBL:QJA16757.1}, SARS-CoV-2/human/USA/WA-UW-2149/2020
RC   {ECO:0000313|EMBL:QJA16793.1}, SARS-CoV-2/human/USA/WA-UW-2164/2020
RC   {ECO:0000313|EMBL:QJA16709.1}, SARS-CoV-2/human/USA/WA-UW-2169/2020
RC   {ECO:0000313|EMBL:QJA16421.1}, SARS-CoV-2/human/USA/WA-UW-2177/2020
RC   {ECO:0000313|EMBL:QJA16970.1}, SARS-CoV-2/human/USA/WA-UW-2179/2020
RC   {ECO:0000313|EMBL:QJA16949.1}, SARS-CoV-2/human/USA/WA-UW-2180/2020
RC   {ECO:0000313|EMBL:QJA16961.1}, SARS-CoV-2/human/USA/WA-UW-2181/2020
RC   {ECO:0000313|EMBL:QJA16817.1}, SARS-CoV-2/human/USA/WA-UW-2192/2020
RC   {ECO:0000313|EMBL:QJA17057.1}, SARS-CoV-2/human/USA/WA-UW-2193/2020
RC   {ECO:0000313|EMBL:QJA17032.1}, SARS-CoV-2/human/USA/WA-UW-2203/2020
RC   {ECO:0000313|EMBL:QJA16829.1}, SARS-CoV-2/human/USA/WA-UW-2208/2020
RC   {ECO:0000313|EMBL:QJA17213.1}, SARS-CoV-2/human/USA/WA-UW-2212/2020
RC   {ECO:0000313|EMBL:QJA17165.1}, SARS-CoV-2/human/USA/WA-UW-2213/2020
RC   {ECO:0000313|EMBL:QJA17177.1}, SARS-CoV-2/human/USA/WA-UW-2214/2020
RC   {ECO:0000313|EMBL:QJA17153.1}, SARS-CoV-2/human/USA/WA-UW-2215/2020
RC   {ECO:0000313|EMBL:QJA17141.1}, SARS-CoV-2/human/USA/WA-UW-2218/2020
RC   {ECO:0000313|EMBL:QJA17105.1}, SARS-CoV-2/human/USA/WA-UW-2219/2020
RC   {ECO:0000313|EMBL:QJA17081.1}, SARS-CoV-2/human/USA/WA-UW-2220/2020
RC   {ECO:0000313|EMBL:QJA16898.1}, SARS-CoV-2/human/USA/WA-UW-2225/2020
RC   {ECO:0000313|EMBL:QJA16877.1}, SARS-CoV-2/human/USA/WA-UW-2228/2020
RC   {ECO:0000313|EMBL:QJA16865.1}, SARS-CoV-2/human/USA/WA-UW-2230/2020
RC   {ECO:0000313|EMBL:QJA17069.1}, SARS-CoV-2/human/USA/WA-UW-2232/2020
RC   {ECO:0000313|EMBL:QJA17045.1}, SARS-CoV-2/human/USA/WA-UW-2234/2020
RC   {ECO:0000313|EMBL:QJA16985.1}, SARS-CoV-2/human/USA/WA-UW-2235/2020
RC   {ECO:0000313|EMBL:QJA17021.1}, SARS-CoV-2/human/USA/WA-UW-2236/2020
RC   {ECO:0000313|EMBL:QJA16889.1}, SARS-CoV-2/human/USA/WA-UW-2238/2020
RC   {ECO:0000313|EMBL:QJA17009.1}, SARS-CoV-2/human/USA/WA-UW-2240/2020
RC   {ECO:0000313|EMBL:QJA16841.1}, SARS-CoV-2/human/USA/WA-UW-2244/2020
RC   {ECO:0000313|EMBL:QJA16853.1}, SARS-CoV-2/human/USA/WA-UW-2245/2020
RC   {ECO:0000313|EMBL:QJA17093.1}, SARS-CoV-2/human/USA/WA-UW-2247/2020
RC   {ECO:0000313|EMBL:QJA16925.1}, SARS-CoV-2/human/USA/WA-UW-2249/2020
RC   {ECO:0000313|EMBL:QJA16913.1}, SARS-CoV-2/human/USA/WA-UW-2250/2020
RC   {ECO:0000313|EMBL:QJA16937.1}, SARS-CoV-2/human/USA/WA-UW-2253/2020
RC   {ECO:0000313|EMBL:QJA16997.1}, SARS-CoV-2/human/USA/WA-UW-2258/2020
RC   {ECO:0000313|EMBL:QJA17237.1}, SARS-CoV-2/human/USA/WA-UW-3809/2020
RC   {ECO:0000313|EMBL:QJC19872.1}, SARS-CoV-2/human/USA/WA-UW-3810/2020
RC   {ECO:0000313|EMBL:QJC19884.1}, SARS-CoV-2/human/USA/WA-UW-3812/2020
RC   {ECO:0000313|EMBL:QJC19896.1}, SARS-CoV-2/human/USA/WA-UW-3814/2020
RC   {ECO:0000313|EMBL:QJC19908.1}, SARS-CoV-2/human/USA/WA-UW-3815/2020
RC   {ECO:0000313|EMBL:QJC19920.1}, SARS-CoV-2/human/USA/WA-UW-3816/2020
RC   {ECO:0000313|EMBL:QJC19932.1}, SARS-CoV-2/human/USA/WA-UW-3819/2020
RC   {ECO:0000313|EMBL:QJC19944.1}, SARS-CoV-2/human/USA/WA-UW-3826/2020
RC   {ECO:0000313|EMBL:QJC19956.1}, SARS-CoV-2/human/USA/WA-UW-3827/2020
RC   {ECO:0000313|EMBL:QJC19968.1}, SARS-CoV-2/human/USA/WA-UW-3828/2020
RC   {ECO:0000313|EMBL:QJC19980.1}, SARS-CoV-2/human/USA/WA-UW-3829/2020
RC   {ECO:0000313|EMBL:QJC19992.1}, SARS-CoV-2/human/USA/WA-UW-3832/2020
RC   {ECO:0000313|EMBL:QJC20004.1}, SARS-CoV-2/human/USA/WA-UW-3833/2020
RC   {ECO:0000313|EMBL:QJC20016.1}, SARS-CoV-2/human/USA/WA-UW-3834/2020
RC   {ECO:0000313|EMBL:QJC20028.1}, SARS-CoV-2/human/USA/WA-UW-3838/2020
RC   {ECO:0000313|EMBL:QJC20040.1}, SARS-CoV-2/human/USA/WA-UW-3839/2020
RC   {ECO:0000313|EMBL:QJC20052.1}, SARS-CoV-2/human/USA/WA-UW-3841/2020
RC   {ECO:0000313|EMBL:QJC20064.1}, SARS-CoV-2/human/USA/WA-UW-3843/2020
RC   {ECO:0000313|EMBL:QJC20076.1}, SARS-CoV-2/human/USA/WA-UW-3844/2020
RC   {ECO:0000313|EMBL:QJC20088.1}, SARS-CoV-2/human/USA/WA-UW-3850/2020
RC   {ECO:0000313|EMBL:QJC20112.1}, SARS-CoV-2/human/USA/WA-UW-3855/2020
RC   {ECO:0000313|EMBL:QJC20124.1}, SARS-CoV-2/human/USA/WA-UW-3858/2020
RC   {ECO:0000313|EMBL:QJC20136.1}, SARS-CoV-2/human/USA/WA-UW-3862/2020
RC   {ECO:0000313|EMBL:QJC20148.1}, SARS-CoV-2/human/USA/WA-UW-3868/2020
RC   {ECO:0000313|EMBL:QJC20160.1}, SARS-CoV-2/human/USA/WA-UW-3871/2020
RC   {ECO:0000313|EMBL:QJC20172.1}, SARS-CoV-2/human/USA/WA-UW-3880/2020
RC   {ECO:0000313|EMBL:QJC20184.1}, SARS-CoV-2/human/USA/WA-UW-3881/2020
RC   {ECO:0000313|EMBL:QJC20196.1}, SARS-CoV-2/human/USA/WA-UW-3883/2020
RC   {ECO:0000313|EMBL:QJC20208.1}, SARS-CoV-2/human/USA/WA-UW-3889/2020
RC   {ECO:0000313|EMBL:QJC20280.1}, SARS-CoV-2/human/USA/WA-UW-3895/2020
RC   {ECO:0000313|EMBL:QJC20304.1}, SARS-CoV-2/human/USA/WA-UW-3900/2020
RC   {ECO:0000313|EMBL:QJC20316.1}, SARS-CoV-2/human/USA/WA-UW-3903/2020
RC   {ECO:0000313|EMBL:QJC20328.1}, SARS-CoV-2/human/USA/WA-UW-3908/2020
RC   {ECO:0000313|EMBL:QJC20340.1}, SARS-CoV-2/human/USA/WA-UW-3911/2020
RC   {ECO:0000313|EMBL:QJC20352.1}, SARS-CoV-2/human/USA/WA-UW-3918/2020
RC   {ECO:0000313|EMBL:QJC20364.1}, SARS-CoV-2/human/USA/WA-UW-3923/2020
RC   {ECO:0000313|EMBL:QJC20376.1}, SARS-CoV-2/human/USA/WA-UW-3932/2020
RC   {ECO:0000313|EMBL:QJC20388.1}, SARS-CoV-2/human/USA/WA-UW-3935/2020
RC   {ECO:0000313|EMBL:QJC20400.1}, SARS-CoV-2/human/USA/WA-UW-3939/2020
RC   {ECO:0000313|EMBL:QJC20412.1}, SARS-CoV-2/human/USA/WA-UW-3940/2020
RC   {ECO:0000313|EMBL:QJC20424.1}, SARS-CoV-2/human/USA/WA-UW-3941/2020
RC   {ECO:0000313|EMBL:QJC20436.1}, SARS-CoV-2/human/USA/WA-UW-3942/2020
RC   {ECO:0000313|EMBL:QJC20448.1}, SARS-CoV-2/human/USA/WA-UW-3946/2020
RC   {ECO:0000313|EMBL:QJC20460.1}, SARS-CoV-2/human/USA/WA-UW-3950/2020
RC   {ECO:0000313|EMBL:QJC20472.1}, SARS-CoV-2/human/USA/WA-UW-3954/2020
RC   {ECO:0000313|EMBL:QJC20484.1}, SARS-CoV-2/human/USA/WA-UW-3959/2020
RC   {ECO:0000313|EMBL:QJC20496.1}, SARS-CoV-2/human/USA/WA-UW-3963/2020
RC   {ECO:0000313|EMBL:QJC20507.1}, SARS-CoV-2/human/USA/WA-UW-3964/2020
RC   {ECO:0000313|EMBL:QJC20519.1}, SARS-CoV-2/human/USA/WA-UW-3969/2020
RC   {ECO:0000313|EMBL:QJC20531.1}, SARS-CoV-2/human/USA/WA-UW-3983/2020
RC   {ECO:0000313|EMBL:QJC20543.1}, SARS-CoV-2/human/USA/WA-UW-3984/2020
RC   {ECO:0000313|EMBL:QJC20555.1}, SARS-CoV-2/human/USA/WA-UW-3985/2020
RC   {ECO:0000313|EMBL:QJC20567.1}, SARS-CoV-2/human/USA/WA-UW-3986/2020
RC   {ECO:0000313|EMBL:QJC20579.1}, SARS-CoV-2/human/USA/WA-UW-3988/2020
RC   {ECO:0000313|EMBL:QJC20591.1}, SARS-CoV-2/human/USA/WA-UW-3989/2020
RC   {ECO:0000313|EMBL:QJC20603.1}, SARS-CoV-2/human/USA/WA-UW-3990/2020
RC   {ECO:0000313|EMBL:QJC20615.1}, SARS-CoV-2/human/USA/WA-UW-3994/2020
RC   {ECO:0000313|EMBL:QJC20627.1}, SARS-CoV-2/human/USA/WA-UW-3996/2020
RC   {ECO:0000313|EMBL:QJC20639.1}, SARS-CoV-2/human/USA/WA-UW-3997/2020
RC   {ECO:0000313|EMBL:QJC20651.1}, SARS-CoV-2/human/USA/WA-UW-4035/2020
RC   {ECO:0000313|EMBL:QJC20663.1}, SARS-CoV-2/human/USA/WA-UW-4038/2020
RC   {ECO:0000313|EMBL:QJC20675.1}, SARS-CoV-2/human/USA/WA-UW-4039/2020
RC   {ECO:0000313|EMBL:QJC20687.1}, SARS-CoV-2/human/USA/WA-UW-4068/2020
RC   {ECO:0000313|EMBL:QJC20699.1}, SARS-CoV-2/human/USA/WA-UW-4082/2020
RC   {ECO:0000313|EMBL:QJC20711.1}, SARS-CoV-2/human/USA/WA-UW-4105/2020
RC   {ECO:0000313|EMBL:QJC20735.1}, SARS-CoV-2/human/USA/WA-UW-4109/2020
RC   {ECO:0000313|EMBL:QJC20747.1}, SARS-CoV-2/human/USA/WA-UW-4111/2020
RC   {ECO:0000313|EMBL:QJC20759.1}, SARS-CoV-2/human/USA/WA-UW-4180/2020
RC   {ECO:0000313|EMBL:QJC19512.1}, SARS-CoV-2/human/USA/WA-UW-4188/2020
RC   {ECO:0000313|EMBL:QJC19524.1}, SARS-CoV-2/human/USA/WA-UW-4197/2020
RC   {ECO:0000313|EMBL:QJC19536.1}, SARS-CoV-2/human/USA/WA-UW-4213/2020
RC   {ECO:0000313|EMBL:QJC19548.1}, SARS-CoV-2/human/USA/WA-UW-4217/2020
RC   {ECO:0000313|EMBL:QJC19560.1}, SARS-CoV-2/human/USA/WA-UW-4227/2020
RC   {ECO:0000313|EMBL:QJC19572.1}, SARS-CoV-2/human/USA/WA-UW-4228/2020
RC   {ECO:0000313|EMBL:QJC19584.1}, SARS-CoV-2/human/USA/WA-UW-4281/2020
RC   {ECO:0000313|EMBL:QJC19656.1}, SARS-CoV-2/human/USA/WA-UW-4289/2020
RC   {ECO:0000313|EMBL:QJC19668.1}, SARS-CoV-2/human/USA/WA-UW-4290/2020
RC   {ECO:0000313|EMBL:QJC19680.1}, SARS-CoV-2/human/USA/WA-UW-4291/2020
RC   {ECO:0000313|EMBL:QJC19692.1}, SARS-CoV-2/human/USA/WA-UW-4292/2020
RC   {ECO:0000313|EMBL:QJC19704.1}, SARS-CoV-2/human/USA/WA-UW-4315/2020
RC   {ECO:0000313|EMBL:QJC19728.1}, SARS-CoV-2/human/USA/WA-UW-4316/2020
RC   {ECO:0000313|EMBL:QJC19740.1}, SARS-CoV-2/human/USA/WA-UW-4318/2020
RC   {ECO:0000313|EMBL:QJC19752.1}, SARS-CoV-2/human/USA/WA-UW-4321/2020
RC   {ECO:0000313|EMBL:QJC19764.1}, SARS-CoV-2/human/USA/WA-UW-4322/2020
RC   {ECO:0000313|EMBL:QJC19776.1}, SARS-CoV-2/human/USA/WA-UW-4324/2020
RC   {ECO:0000313|EMBL:QJC19788.1}, SARS-CoV-2/human/USA/WA-UW-4326/2020
RC   {ECO:0000313|EMBL:QJC19800.1}, SARS-CoV-2/human/USA/WA-UW-4329/2020
RC   {ECO:0000313|EMBL:QJC19812.1}, SARS-CoV-2/human/USA/WA-UW-4330/2020
RC   {ECO:0000313|EMBL:QJC19824.1}, SARS-CoV-2/human/USA/WA-UW-4335/2020
RC   {ECO:0000313|EMBL:QJC19836.1}, SARS-CoV-2/human/USA/WA-UW-4340/2020
RC   {ECO:0000313|EMBL:QJC19848.1}, SARS-CoV-2/human/USA/WA-UW-4404/2020
RC   {ECO:0000313|EMBL:QJA17405.1}, SARS-CoV-2/human/USA/WA-UW-4406/2020
RC   {ECO:0000313|EMBL:QJA17417.1}, SARS-CoV-2/human/USA/WA-UW-4407/2020
RC   {ECO:0000313|EMBL:QJA17429.1}, SARS-CoV-2/human/USA/WA-UW-4499/2020
RC   {ECO:0000313|EMBL:QJC20256.1}, SARS-CoV-2/human/USA/WA-UW-4500/2020
RC   {ECO:0000313|EMBL:QJC20268.1}, SARS-CoV-2/human/USA/WA-UW192/2020
RC   {ECO:0000313|EMBL:QIQ49770.1}, SARS-CoV-2/human/USA/WA-UW193/2020
RC   {ECO:0000313|EMBL:QIQ49780.1}, SARS-CoV-2/human/USA/WA-UW194/2020
RC   {ECO:0000313|EMBL:QIQ49790.1}, SARS-CoV-2/human/USA/WA-UW195/2020
RC   {ECO:0000313|EMBL:QIQ49800.1}, SARS-CoV-2/human/USA/WA-UW196/2020
RC   {ECO:0000313|EMBL:QIQ49810.1}, SARS-CoV-2/human/USA/WA-UW197/2020
RC   {ECO:0000313|EMBL:QIQ49820.1}, SARS-CoV-2/human/USA/WA-UW198/2020
RC   {ECO:0000313|EMBL:QIQ49830.1}, SARS-CoV-2/human/USA/WA-UW199/2020
RC   {ECO:0000313|EMBL:QIQ49840.1}, SARS-CoV-2/human/USA/WA-UW200/2020
RC   {ECO:0000313|EMBL:QIQ49850.1}, SARS-CoV-2/human/USA/WA-UW201/2020
RC   {ECO:0000313|EMBL:QIQ49860.1}, SARS-CoV-2/human/USA/WA-UW202/2020
RC   {ECO:0000313|EMBL:QIQ49870.1}, SARS-CoV-2/human/USA/WA-UW203/2020
RC   {ECO:0000313|EMBL:QIQ49880.1}, SARS-CoV-2/human/USA/WA-UW204/2020
RC   {ECO:0000313|EMBL:QIQ49890.1}, SARS-CoV-2/human/USA/WA-UW205/2020
RC   {ECO:0000313|EMBL:QIQ49900.1}, SARS-CoV-2/human/USA/WA-UW206/2020
RC   {ECO:0000313|EMBL:QIQ49910.1}, SARS-CoV-2/human/USA/WA-UW207/2020
RC   {ECO:0000313|EMBL:QIQ49920.1}, SARS-CoV-2/human/USA/WA-UW208/2020
RC   {ECO:0000313|EMBL:QIQ49930.1}, SARS-CoV-2/human/USA/WA-UW209/2020
RC   {ECO:0000313|EMBL:QIQ49940.1}, SARS-CoV-2/human/USA/WA-UW210/2020
RC   {ECO:0000313|EMBL:QIQ49950.1}, SARS-CoV-2/human/USA/WA-UW211/2020
RC   {ECO:0000313|EMBL:QIQ49960.1}, SARS-CoV-2/human/USA/WA-UW212/2020
RC   {ECO:0000313|EMBL:QIQ49970.1}, SARS-CoV-2/human/USA/WA-UW213/2020
RC   {ECO:0000313|EMBL:QIQ49980.1}, SARS-CoV-2/human/USA/WA-UW214/2020
RC   {ECO:0000313|EMBL:QIQ49990.1}, SARS-CoV-2/human/USA/WA-UW215/2020
RC   {ECO:0000313|EMBL:QIQ50000.1}, SARS-CoV-2/human/USA/WA-UW216/2020
RC   {ECO:0000313|EMBL:QIQ50010.1}, SARS-CoV-2/human/USA/WA-UW217/2020
RC   {ECO:0000313|EMBL:QIQ50020.1}, SARS-CoV-2/human/USA/WA-UW218/2020
RC   {ECO:0000313|EMBL:QIQ50030.1}, SARS-CoV-2/human/USA/WA-UW219/2020
RC   {ECO:0000313|EMBL:QIQ50040.1}, SARS-CoV-2/human/USA/WA-UW220/2020
RC   {ECO:0000313|EMBL:QIQ50050.1}, SARS-CoV-2/human/USA/WA-UW221/2020
RC   {ECO:0000313|EMBL:QIQ50060.1}, SARS-CoV-2/human/USA/WA-UW222/2020
RC   {ECO:0000313|EMBL:QIQ50070.1}, SARS-CoV-2/human/USA/WA-UW223/2020
RC   {ECO:0000313|EMBL:QIQ50080.1}, SARS-CoV-2/human/USA/WA-UW224/2020
RC   {ECO:0000313|EMBL:QIQ50090.1}, SARS-CoV-2/human/USA/WA-UW225/2020
RC   {ECO:0000313|EMBL:QIQ50100.1}, SARS-CoV-2/human/USA/WA-UW226/2020
RC   {ECO:0000313|EMBL:QIQ50110.1}, SARS-CoV-2/human/USA/WA-UW227/2020
RC   {ECO:0000313|EMBL:QIQ50120.1}, SARS-CoV-2/human/USA/WA-UW228/2020
RC   {ECO:0000313|EMBL:QIQ50130.1}, SARS-CoV-2/human/USA/WA-UW229/2020
RC   {ECO:0000313|EMBL:QIQ50140.1}, SARS-CoV-2/human/USA/WA-UW230/2020
RC   {ECO:0000313|EMBL:QIQ50150.1}, SARS-CoV-2/human/USA/WA-UW231/2020
RC   {ECO:0000313|EMBL:QIQ50160.1}, SARS-CoV-2/human/USA/WA-UW232/2020
RC   {ECO:0000313|EMBL:QIQ50170.1}, SARS-CoV-2/human/USA/WA-UW233/2020
RC   {ECO:0000313|EMBL:QIQ50180.1}, SARS-CoV-2/human/USA/WA-UW234/2020
RC   {ECO:0000313|EMBL:QIQ68522.1}, SARS-CoV-2/human/USA/WA-UW235/2020
RC   {ECO:0000313|EMBL:QIQ68532.1}, SARS-CoV-2/human/USA/WA-UW236/2020
RC   {ECO:0000313|EMBL:QIQ68472.1}, SARS-CoV-2/human/USA/WA-UW237/2020
RC   {ECO:0000313|EMBL:QIQ68482.1}, SARS-CoV-2/human/USA/WA-UW239/2020
RC   {ECO:0000313|EMBL:QIQ68502.1}, SARS-CoV-2/human/USA/WA-UW240/2020
RC   {ECO:0000313|EMBL:QIQ68512.1}, SARS-CoV-2/human/USA/WA-UW241/2020
RC   {ECO:0000313|EMBL:QIQ68542.1}, SARS-CoV-2/human/USA/WA-UW242/2020
RC   {ECO:0000313|EMBL:QIQ68552.1}, SARS-CoV-2/human/USA/WA-UW243/2020
RC   {ECO:0000313|EMBL:QIS30163.1}, SARS-CoV-2/human/USA/WA-UW244/2020
RC   {ECO:0000313|EMBL:QIS30173.1}, SARS-CoV-2/human/USA/WA-UW245/2020
RC   {ECO:0000313|EMBL:QIS30183.1}, SARS-CoV-2/human/USA/WA-UW246/2020
RC   {ECO:0000313|EMBL:QIS30193.1}, SARS-CoV-2/human/USA/WA-UW247/2020
RC   {ECO:0000313|EMBL:QIS30203.1}, SARS-CoV-2/human/USA/WA-UW248/2020
RC   {ECO:0000313|EMBL:QIS30213.1}, SARS-CoV-2/human/USA/WA-UW249/2020
RC   {ECO:0000313|EMBL:QIS30223.1}, SARS-CoV-2/human/USA/WA-UW251/2020
RC   {ECO:0000313|EMBL:QIS30243.1}, SARS-CoV-2/human/USA/WA-UW252/2020
RC   {ECO:0000313|EMBL:QIS30253.1}, SARS-CoV-2/human/USA/WA-UW253/2020
RC   {ECO:0000313|EMBL:QIS30263.1}, SARS-CoV-2/human/USA/WA-UW254/2020
RC   {ECO:0000313|EMBL:QIS30273.1}, SARS-CoV-2/human/USA/WA-UW255/2020
RC   {ECO:0000313|EMBL:QIS30283.1}, SARS-CoV-2/human/USA/WA-UW257/2020
RC   {ECO:0000313|EMBL:QIS30303.1}, SARS-CoV-2/human/USA/WA-UW258/2020
RC   {ECO:0000313|EMBL:QIS30313.1}, SARS-CoV-2/human/USA/WA-UW259/2020
RC   {ECO:0000313|EMBL:QIS30323.1}, SARS-CoV-2/human/USA/WA-UW260/2020
RC   {ECO:0000313|EMBL:QIS30333.1}, SARS-CoV-2/human/USA/WA-UW261/2020
RC   {ECO:0000313|EMBL:QIS30343.1}, SARS-CoV-2/human/USA/WA-UW262/2020
RC   {ECO:0000313|EMBL:QIS30353.1}, SARS-CoV-2/human/USA/WA-UW263/2020
RC   {ECO:0000313|EMBL:QIS30363.1}, SARS-CoV-2/human/USA/WA-UW264/2020
RC   {ECO:0000313|EMBL:QIS30373.1}, SARS-CoV-2/human/USA/WA-UW265/2020
RC   {ECO:0000313|EMBL:QIS30383.1}, SARS-CoV-2/human/USA/WA-UW267/2020
RC   {ECO:0000313|EMBL:QIS30403.1}, SARS-CoV-2/human/USA/WA-UW268/2020
RC   {ECO:0000313|EMBL:QIS30413.1}, SARS-CoV-2/human/USA/WA-UW269/2020
RC   {ECO:0000313|EMBL:QIS30423.1}, SARS-CoV-2/human/USA/WA-UW270/2020
RC   {ECO:0000313|EMBL:QIS30433.1}, SARS-CoV-2/human/USA/WA-UW271/2020
RC   {ECO:0000313|EMBL:QIS30443.1}, SARS-CoV-2/human/USA/WA-UW272/2020
RC   {ECO:0000313|EMBL:QIS30453.1}, SARS-CoV-2/human/USA/WA-UW273/2020
RC   {ECO:0000313|EMBL:QIS30463.1}, SARS-CoV-2/human/USA/WA-UW274/2020
RC   {ECO:0000313|EMBL:QIS30473.1}, SARS-CoV-2/human/USA/WA-UW275/2020
RC   {ECO:0000313|EMBL:QIS30483.1}, SARS-CoV-2/human/USA/WA-UW276/2020
RC   {ECO:0000313|EMBL:QIS30493.1}, SARS-CoV-2/human/USA/WA-UW277/2020
RC   {ECO:0000313|EMBL:QIS30503.1}, SARS-CoV-2/human/USA/WA-UW278/2020
RC   {ECO:0000313|EMBL:QIS30512.1}, SARS-CoV-2/human/USA/WA-UW279/2020
RC   {ECO:0000313|EMBL:QIS30523.1}, SARS-CoV-2/human/USA/WA-UW280/2020
RC   {ECO:0000313|EMBL:QIS30533.1}, SARS-CoV-2/human/USA/WA-UW282/2020
RC   {ECO:0000313|EMBL:QIS30543.1}, SARS-CoV-2/human/USA/WA-UW284/2020
RC   {ECO:0000313|EMBL:QIS30553.1}, SARS-CoV-2/human/USA/WA-UW285/2020
RC   {ECO:0000313|EMBL:QIS30563.1}, SARS-CoV-2/human/USA/WA-UW286/2020
RC   {ECO:0000313|EMBL:QIS30573.1}, SARS-CoV-2/human/USA/WA-UW287/2020
RC   {ECO:0000313|EMBL:QIS30583.1}, SARS-CoV-2/human/USA/WA-UW288/2020
RC   {ECO:0000313|EMBL:QIS30593.1}, SARS-CoV-2/human/USA/WA-UW289/2020
RC   {ECO:0000313|EMBL:QIS30603.1}, SARS-CoV-2/human/USA/WA-UW290/2020
RC   {ECO:0000313|EMBL:QIS30613.1}, SARS-CoV-2/human/USA/WA-UW291/2020
RC   {ECO:0000313|EMBL:QIS30623.1}, SARS-CoV-2/human/USA/WA-UW292/2020
RC   {ECO:0000313|EMBL:QIS30633.1}, SARS-CoV-2/human/USA/WA-UW293/2020
RC   {ECO:0000313|EMBL:QIS30643.1}, SARS-CoV-2/human/USA/WA-UW294/2020
RC   {ECO:0000313|EMBL:QIS30653.1}, SARS-CoV-2/human/USA/WA-UW295/2020
RC   {ECO:0000313|EMBL:QIS30663.1}, SARS-CoV-2/human/USA/WA-UW296/2020
RC   {ECO:0000313|EMBL:QIS30673.1}, SARS-CoV-2/human/USA/WA-UW297/2020
RC   {ECO:0000313|EMBL:QIS30683.1}, SARS-CoV-2/human/USA/WA-UW298/2020
RC   {ECO:0000313|EMBL:QIS60519.1}, SARS-CoV-2/human/USA/WA-UW299/2020
RC   {ECO:0000313|EMBL:QIS60531.1}, SARS-CoV-2/human/USA/WA-UW300/2020
RC   {ECO:0000313|EMBL:QIS60543.1}, SARS-CoV-2/human/USA/WA-UW302/2020
RC   {ECO:0000313|EMBL:QIS60567.1}, SARS-CoV-2/human/USA/WA-UW304/2020
RC   {ECO:0000313|EMBL:QIS60591.1}, SARS-CoV-2/human/USA/WA-UW305/2020
RC   {ECO:0000313|EMBL:QIS60603.1}, SARS-CoV-2/human/USA/WA-UW307/2020
RC   {ECO:0000313|EMBL:QIS60627.1}, SARS-CoV-2/human/USA/WA-UW308/2020
RC   {ECO:0000313|EMBL:QIS60639.1}, SARS-CoV-2/human/USA/WA-UW310/2020
RC   {ECO:0000313|EMBL:QIS60651.1}, SARS-CoV-2/human/USA/WA-UW312/2020
RC   {ECO:0000313|EMBL:QIS60663.1}, SARS-CoV-2/human/USA/WA-UW313/2020
RC   {ECO:0000313|EMBL:QIS60675.1}, SARS-CoV-2/human/USA/WA-UW314/2020
RC   {ECO:0000313|EMBL:QIS60687.1}, SARS-CoV-2/human/USA/WA-UW315/2020
RC   {ECO:0000313|EMBL:QIS60699.1}, SARS-CoV-2/human/USA/WA-UW316/2020
RC   {ECO:0000313|EMBL:QIS60711.1}, SARS-CoV-2/human/USA/WA-UW317/2020
RC   {ECO:0000313|EMBL:QIS60723.1}, SARS-CoV-2/human/USA/WA-UW319/2020
RC   {ECO:0000313|EMBL:QIS60735.1}, SARS-CoV-2/human/USA/WA-UW320/2020
RC   {ECO:0000313|EMBL:QIS60747.1}, SARS-CoV-2/human/USA/WA-UW321/2020
RC   {ECO:0000313|EMBL:QIS60759.1}, SARS-CoV-2/human/USA/WA-UW322/2020
RC   {ECO:0000313|EMBL:QIS60771.1}, SARS-CoV-2/human/USA/WA-UW323/2020
RC   {ECO:0000313|EMBL:QIS60783.1}, SARS-CoV-2/human/USA/WA-UW324/2020
RC   {ECO:0000313|EMBL:QIS60795.1}, SARS-CoV-2/human/USA/WA-UW325/2020
RC   {ECO:0000313|EMBL:QIS60807.1}, SARS-CoV-2/human/USA/WA-UW328/2020
RC   {ECO:0000313|EMBL:QIS60843.1}, SARS-CoV-2/human/USA/WA-UW330/2020
RC   {ECO:0000313|EMBL:QIS60867.1}, SARS-CoV-2/human/USA/WA-UW332/2020
RC   {ECO:0000313|EMBL:QIS60891.1}, SARS-CoV-2/human/USA/WA-UW333/2020
RC   {ECO:0000313|EMBL:QIS60903.1}, SARS-CoV-2/human/USA/WA-UW334/2020
RC   {ECO:0000313|EMBL:QIS60915.1}, SARS-CoV-2/human/USA/WA-UW336/2020
RC   {ECO:0000313|EMBL:QIS60939.1}, SARS-CoV-2/human/USA/WA-UW337/2020
RC   {ECO:0000313|EMBL:QIS60951.1}, SARS-CoV-2/human/USA/WA-UW338/2020
RC   {ECO:0000313|EMBL:QIS60963.1}, SARS-CoV-2/human/USA/WA-UW339/2020
RC   {ECO:0000313|EMBL:QIS60975.1}, SARS-CoV-2/human/USA/WA-UW340/2020
RC   {ECO:0000313|EMBL:QIS60987.1}, SARS-CoV-2/human/USA/WA-UW341/2020
RC   {ECO:0000313|EMBL:QIS60999.1}, SARS-CoV-2/human/USA/WA-UW342/2020
RC   {ECO:0000313|EMBL:QIS61011.1}, SARS-CoV-2/human/USA/WA-UW343/2020
RC   {ECO:0000313|EMBL:QIS61023.1}, SARS-CoV-2/human/USA/WA-UW344/2020
RC   {ECO:0000313|EMBL:QIS61035.1}, SARS-CoV-2/human/USA/WA-UW345/2020
RC   {ECO:0000313|EMBL:QIS61047.1}, SARS-CoV-2/human/USA/WA-UW346/2020
RC   {ECO:0000313|EMBL:QIS61059.1}, SARS-CoV-2/human/USA/WA-UW347/2020
RC   {ECO:0000313|EMBL:QIS61069.1}, SARS-CoV-2/human/USA/WA-UW350/2020
RC   {ECO:0000313|EMBL:QIS61107.1}, SARS-CoV-2/human/USA/WA-UW351/2020
RC   {ECO:0000313|EMBL:QIS61119.1}, SARS-CoV-2/human/USA/WA-UW352/2020
RC   {ECO:0000313|EMBL:QIS61131.1}, SARS-CoV-2/human/USA/WA-UW354/2020
RC   {ECO:0000313|EMBL:QIS61155.1}, SARS-CoV-2/human/USA/WA-UW355/2020
RC   {ECO:0000313|EMBL:QIS61167.1}, SARS-CoV-2/human/USA/WA-UW356/2020
RC   {ECO:0000313|EMBL:QIS61179.1}, SARS-CoV-2/human/USA/WA-UW357/2020
RC   {ECO:0000313|EMBL:QIS61191.1}, SARS-CoV-2/human/USA/WA-UW358/2020
RC   {ECO:0000313|EMBL:QIS61203.1}, SARS-CoV-2/human/USA/WA-UW359/2020
RC   {ECO:0000313|EMBL:QIS61215.1}, SARS-CoV-2/human/USA/WA-UW360/2020
RC   {ECO:0000313|EMBL:QIS61227.1}, SARS-CoV-2/human/USA/WA-UW361/2020
RC   {ECO:0000313|EMBL:QIS61239.1}, SARS-CoV-2/human/USA/WA-UW362/2020
RC   {ECO:0000313|EMBL:QIS61251.1}, SARS-CoV-2/human/USA/WA-UW363/2020
RC   {ECO:0000313|EMBL:QIS61263.1}, SARS-CoV-2/human/USA/WA-UW364/2020
RC   {ECO:0000313|EMBL:QIS61275.1}, SARS-CoV-2/human/USA/WA-UW365/2020
RC   {ECO:0000313|EMBL:QIS61287.1}, SARS-CoV-2/human/USA/WA-UW366/2020
RC   {ECO:0000313|EMBL:QIS61299.1}, SARS-CoV-2/human/USA/WA-UW367/2020
RC   {ECO:0000313|EMBL:QIS61311.1}, SARS-CoV-2/human/USA/WA-UW368/2020
RC   {ECO:0000313|EMBL:QIS61323.1}, SARS-CoV-2/human/USA/WA-UW369/2020
RC   {ECO:0000313|EMBL:QIS61335.1}, SARS-CoV-2/human/USA/WA-UW370/2020
RC   {ECO:0000313|EMBL:QIS61347.1}, SARS-CoV-2/human/USA/WA-UW371/2020
RC   {ECO:0000313|EMBL:QIS61359.1}, SARS-CoV-2/human/USA/WA-UW372/2020
RC   {ECO:0000313|EMBL:QIS61371.1}, SARS-CoV-2/human/USA/WA-UW373/2020
RC   {ECO:0000313|EMBL:QIS61383.1}, SARS-CoV-2/human/USA/WA-UW374/2020
RC   {ECO:0000313|EMBL:QIS61395.1}, SARS-CoV-2/human/USA/WA-UW375/2020
RC   {ECO:0000313|EMBL:QIS61407.1}, SARS-CoV-2/human/USA/WA-UW376/2020
RC   {ECO:0000313|EMBL:QIS61419.1}, SARS-CoV-2/human/USA/WA-UW378/2020
RC   {ECO:0000313|EMBL:QIS61443.1}, SARS-CoV-2/human/USA/WA-UW379/2020
RC   {ECO:0000313|EMBL:QIS60855.1}, SARS-CoV-2/human/USA/WA-UW380/2020
RC   {ECO:0000313|EMBL:QIS61455.1}, SARS-CoV-2/human/USA/WA-UW382/2020
RC   {ECO:0000313|EMBL:QIS61477.1}, SARS-CoV-2/human/USA/WA-UW383/2020
RC   {ECO:0000313|EMBL:QIS61491.1}, SARS-CoV-2/human/USA/WA-UW384/2020
RC   {ECO:0000313|EMBL:QIS61515.1}, SARS-CoV-2/human/USA/WA-UW385/2020
RC   {ECO:0000313|EMBL:QIS61527.1}, SARS-CoV-2/human/USA/WA-UW386/2020
RC   {ECO:0000313|EMBL:QIS61537.1}, SARS-CoV-2/human/USA/WA-UW387/2020
RC   {ECO:0000313|EMBL:QIS61551.1}, SARS-CoV-2/human/USA/WA-UW388/2020
RC   {ECO:0000313|EMBL:QIS61563.1}, SARS-CoV-2/human/USA/WA-UW389/2020
RC   {ECO:0000313|EMBL:QIS61575.1}, SARS-CoV-2/human/USA/WA-UW390/2020
RC   {ECO:0000313|EMBL:QIS61431.1}, SARS-CoV-2/human/USACT-UW420/2020
RC   {ECO:0000313|EMBL:QIU81282.1}, SARS-CoV-2/human/USACT-UW423/2020
RC   {ECO:0000313|EMBL:QIU81318.1}, SARS-CoV-2/human/USACT-UW427/2020
RC   {ECO:0000313|EMBL:QIU81366.1}, SARS-CoV-2/human/USACT-UW428/2020
RC   {ECO:0000313|EMBL:QIU81378.1}, SARS-CoV-2/human/USACT-UW430/2020
RC   {ECO:0000313|EMBL:QIU81402.1}, SARS-CoV-2/human/USAOR-UW409/2020
RC   {ECO:0000313|EMBL:QIU81150.1}, SARS-CoV-2/human/USAUNKNOWN-UW398/2020
RC   {ECO:0000313|EMBL:QIU81018.1}, SARS-CoV-2/human/USAWA-UW391/2020
RC   {ECO:0000313|EMBL:QIU80934.1}, SARS-CoV-2/human/USAWA-UW392/2020
RC   {ECO:0000313|EMBL:QIU80946.1}, SARS-CoV-2/human/USAWA-UW408/2020
RC   {ECO:0000313|EMBL:QIU81138.1}, SARS-CoV-2/human/USAWA-UW410/2020
RC   {ECO:0000313|EMBL:QIU81162.1}, and SARS-CoV-2/human/USAWA-UW413/2020
RC   {ECO:0000313|EMBL:QIU81198.1};
RA   Roychoudhury P., Greninger A., Jerome K.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [85] {ECO:0000313|EMBL:QIZ15558.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/AZ_8132/2020
RC   {ECO:0000313|EMBL:QIZ15558.1}, SARS-CoV-2/human/USA/AZ_8135/2020
RC   {ECO:0000313|EMBL:QIZ15570.1}, SARS-CoV-2/human/USA/DC_0004/2020
RC   {ECO:0000313|EMBL:QIZ15582.1}, SARS-CoV-2/human/USA/FL_1177/2020
RC   {ECO:0000313|EMBL:QIZ15594.1}, SARS-CoV-2/human/USA/FL_7169/2020
RC   {ECO:0000313|EMBL:QIZ15606.1}, SARS-CoV-2/human/USA/FL_9590/2020
RC   {ECO:0000313|EMBL:QIZ15618.1}, SARS-CoV-2/human/USA/FL_9655/2020
RC   {ECO:0000313|EMBL:QIZ15630.1}, SARS-CoV-2/human/USA/FL_9656/2020
RC   {ECO:0000313|EMBL:QIZ15642.1}, SARS-CoV-2/human/USA/GA_1621/2020
RC   {ECO:0000313|EMBL:QIZ15654.1}, SARS-CoV-2/human/USA/GA_1847/2020
RC   {ECO:0000313|EMBL:QIZ15666.1}, SARS-CoV-2/human/USA/GA_2055/2020
RC   {ECO:0000313|EMBL:QIZ15678.1}, SARS-CoV-2/human/USA/GA_2118/2020
RC   {ECO:0000313|EMBL:QIZ15690.1}, SARS-CoV-2/human/USA/GA_2120/2020
RC   {ECO:0000313|EMBL:QIZ15702.1}, SARS-CoV-2/human/USA/GA_2185/2020
RC   {ECO:0000313|EMBL:QIZ15714.1}, SARS-CoV-2/human/USA/GA_2343/2020
RC   {ECO:0000313|EMBL:QIZ15726.1}, SARS-CoV-2/human/USA/IA_6394/2020
RC   {ECO:0000313|EMBL:QIZ15738.1}, SARS-CoV-2/human/USA/IL_0087/2020
RC   {ECO:0000313|EMBL:QIZ15750.1}, SARS-CoV-2/human/USA/IL_0089/2020
RC   {ECO:0000313|EMBL:QIZ15762.1}, SARS-CoV-2/human/USA/IN_2001/2020
RC   {ECO:0000313|EMBL:QIZ15774.1}, SARS-CoV-2/human/USA/KS_4126/2020
RC   {ECO:0000313|EMBL:QIZ15786.1}, SARS-CoV-2/human/USA/LA_0842/2020
RC   {ECO:0000313|EMBL:QIZ15798.1}, SARS-CoV-2/human/USA/MA_0020/2020
RC   {ECO:0000313|EMBL:QIZ15810.1}, SARS-CoV-2/human/USA/MA_3672/2020
RC   {ECO:0000313|EMBL:QIZ15822.1}, SARS-CoV-2/human/USA/MA_3699/2020
RC   {ECO:0000313|EMBL:QIZ15834.1}, SARS-CoV-2/human/USA/MA_3878/2020
RC   {ECO:0000313|EMBL:QIZ15846.1}, SARS-CoV-2/human/USA/MA_4811/2020
RC   {ECO:0000313|EMBL:QIZ15858.1}, SARS-CoV-2/human/USA/MD_0026/2020
RC   {ECO:0000313|EMBL:QIZ15870.1}, SARS-CoV-2/human/USA/MO_4470/2020
RC   {ECO:0000313|EMBL:QIZ15882.1}, SARS-CoV-2/human/USA/NC_0024/2020
RC   {ECO:0000313|EMBL:QIZ15894.1}, SARS-CoV-2/human/USA/NC_0031/2020
RC   {ECO:0000313|EMBL:QIZ15906.1}, SARS-CoV-2/human/USA/NC_6999/2020
RC   {ECO:0000313|EMBL:QIZ15918.1}, SARS-CoV-2/human/USA/NE_6605/2020
RC   {ECO:0000313|EMBL:QIZ15930.1}, SARS-CoV-2/human/USA/NE_7025/2020
RC   {ECO:0000313|EMBL:QIZ15942.1}, SARS-CoV-2/human/USA/NH_0029/2020
RC   {ECO:0000313|EMBL:QIZ15954.1}, SARS-CoV-2/human/USA/NH_0033/2020
RC   {ECO:0000313|EMBL:QIZ15966.1}, SARS-CoV-2/human/USA/NJ_3592/2020
RC   {ECO:0000313|EMBL:QIZ15978.1}, SARS-CoV-2/human/USA/NV_0052/2020
RC   {ECO:0000313|EMBL:QIZ15990.1}, SARS-CoV-2/human/USA/OH_0023/2020
RC   {ECO:0000313|EMBL:QIZ16002.1}, SARS-CoV-2/human/USA/PA_1802/2020
RC   {ECO:0000313|EMBL:QIZ16014.1}, SARS-CoV-2/human/USA/PA_1881/2020
RC   {ECO:0000313|EMBL:QIZ16026.1}, SARS-CoV-2/human/USA/PA_2317/2020
RC   {ECO:0000313|EMBL:QIZ16038.1}, SARS-CoV-2/human/USA/PA_2937/2020
RC   {ECO:0000313|EMBL:QIZ16050.1}, SARS-CoV-2/human/USA/PA_4395/2020
RC   {ECO:0000313|EMBL:QIZ16062.1}, SARS-CoV-2/human/USA/PA_4405/2020
RC   {ECO:0000313|EMBL:QIZ16074.1}, SARS-CoV-2/human/USA/RI_0702/2020
RC   {ECO:0000313|EMBL:QIZ16086.1}, SARS-CoV-2/human/USA/SC_3569/2020
RC   {ECO:0000313|EMBL:QIZ16098.1}, SARS-CoV-2/human/USA/SC_3575/2020
RC   {ECO:0000313|EMBL:QIZ16110.1}, SARS-CoV-2/human/USA/SC_6370/2020
RC   {ECO:0000313|EMBL:QIZ16122.1}, SARS-CoV-2/human/USA/UT_8199/2020
RC   {ECO:0000313|EMBL:QIZ16134.1}, SARS-CoV-2/human/USA/UT_8906/2020
RC   {ECO:0000313|EMBL:QIZ16146.1}, SARS-CoV-2/human/USA/VA_6352/2020
RC   {ECO:0000313|EMBL:QIZ16158.1}, SARS-CoV-2/human/USA/VA_6377/2020
RC   {ECO:0000313|EMBL:QIZ16170.1}, SARS-CoV-2/human/USA/VA_6382/2020
RC   {ECO:0000313|EMBL:QIZ16182.1}, and SARS-CoV-2/human/USA/VA_6389/2020
RC   {ECO:0000313|EMBL:QIZ16194.1};
RA   Li Y., Queen K., Paden C.R., Marine R., Uehara A., Tao Y., Zhang J.,
RA   Wang H., Keckler M.S., Laufer Halpin A.S., Elkins C.A., Tong S.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [86] {ECO:0000313|EMBL:QJD23282.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/NJ-PV09072/2020
RC   {ECO:0000313|EMBL:QJD24506.1}, SARS-CoV-2/human/USA/NY-PV08109/2020
RC   {ECO:0000313|EMBL:QJD23642.1}, SARS-CoV-2/human/USA/NY-PV08120/2020
RC   {ECO:0000313|EMBL:QJD24182.1}, SARS-CoV-2/human/USA/NY-PV08121/2020
RC   {ECO:0000313|EMBL:QJD23426.1}, SARS-CoV-2/human/USA/NY-PV08122/2020
RC   {ECO:0000313|EMBL:QJD24014.1}, SARS-CoV-2/human/USA/NY-PV08123/2020
RC   {ECO:0000313|EMBL:QJD24338.1}, SARS-CoV-2/human/USA/NY-PV08124/2020
RC   {ECO:0000313|EMBL:QJD23378.1}, SARS-CoV-2/human/USA/NY-PV08125/2020
RC   {ECO:0000313|EMBL:QJD24290.1}, SARS-CoV-2/human/USA/NY-PV08127/2020
RC   {ECO:0000313|EMBL:QJD23558.1}, SARS-CoV-2/human/USA/NY-PV08133/2020
RC   {ECO:0000313|EMBL:QJD24228.1}, SARS-CoV-2/human/USA/NY-PV08135/2020
RC   {ECO:0000313|EMBL:QJD23702.1}, SARS-CoV-2/human/USA/NY-PV08136/2020
RC   {ECO:0000313|EMBL:QJD24146.1}, SARS-CoV-2/human/USA/NY-PV08137/2020
RC   {ECO:0000313|EMBL:QJD23533.1}, SARS-CoV-2/human/USA/NY-PV08138/2020
RC   {ECO:0000313|EMBL:QJD23882.1}, SARS-CoV-2/human/USA/NY-PV08139/2020
RC   {ECO:0000313|EMBL:QJD23292.1}, SARS-CoV-2/human/USA/NY-PV08140/2020
RC   {ECO:0000313|EMBL:QJD23388.1}, SARS-CoV-2/human/USA/NY-PV08143/2020
RC   {ECO:0000313|EMBL:QJD24266.1}, SARS-CoV-2/human/USA/NY-PV08146/2020
RC   {ECO:0000313|EMBL:QJD23498.1}, SARS-CoV-2/human/USA/NY-PV08148/2020
RC   {ECO:0000313|EMBL:QJD23594.1}, SARS-CoV-2/human/USA/NY-PV08149/2020
RC   {ECO:0000313|EMBL:QJD23798.1}, SARS-CoV-2/human/USA/NY-PV08150/2020
RC   {ECO:0000313|EMBL:QJD24170.1}, SARS-CoV-2/human/USA/NY-PV08400/2020
RC   {ECO:0000313|EMBL:QJD23713.1}, SARS-CoV-2/human/USA/NY-PV08401/2020
RC   {ECO:0000313|EMBL:QJD23462.1}, SARS-CoV-2/human/USA/NY-PV08402/2020
RC   {ECO:0000313|EMBL:QJD24002.1}, SARS-CoV-2/human/USA/NY-PV08403/2020
RC   {ECO:0000313|EMBL:QJD23618.1}, SARS-CoV-2/human/USA/NY-PV08404/2020
RC   {ECO:0000313|EMBL:QJD23784.1}, SARS-CoV-2/human/USA/NY-PV08405/2020
RC   {ECO:0000313|EMBL:QJD23856.1}, SARS-CoV-2/human/USA/NY-PV08410/2020
RC   {ECO:0000313|EMBL:QJD24108.1}, SARS-CoV-2/human/USA/NY-PV08412/2020
RC   {ECO:0000313|EMBL:QJD23654.1}, SARS-CoV-2/human/USA/NY-PV08413/2020
RC   {ECO:0000313|EMBL:QJD23846.1}, SARS-CoV-2/human/USA/NY-PV08414/2020
RC   {ECO:0000313|EMBL:QJD24324.1}, SARS-CoV-2/human/USA/NY-PV08415/2020
RC   {ECO:0000313|EMBL:QJD24050.1}, SARS-CoV-2/human/USA/NY-PV08416/2020
RC   {ECO:0000313|EMBL:QJD24194.1}, SARS-CoV-2/human/USA/NY-PV08417/2020
RC   {ECO:0000313|EMBL:QJD23916.1}, SARS-CoV-2/human/USA/NY-PV08419/2020
RC   {ECO:0000313|EMBL:QJD24024.1}, SARS-CoV-2/human/USA/NY-PV08420/2020
RC   {ECO:0000313|EMBL:QJD23568.1}, SARS-CoV-2/human/USA/NY-PV08425/2020
RC   {ECO:0000313|EMBL:QJD23906.1}, SARS-CoV-2/human/USA/NY-PV08426/2020
RC   {ECO:0000313|EMBL:QJD23330.1}, SARS-CoV-2/human/USA/NY-PV08427/2020
RC   {ECO:0000313|EMBL:QJD24254.1}, SARS-CoV-2/human/USA/NY-PV08428/2020
RC   {ECO:0000313|EMBL:QJD23870.1}, SARS-CoV-2/human/USA/NY-PV08429/2020
RC   {ECO:0000313|EMBL:QJD24314.1}, SARS-CoV-2/human/USA/NY-PV08432/2020
RC   {ECO:0000313|EMBL:QJD23306.1}, SARS-CoV-2/human/USA/NY-PV08434/2020
RC   {ECO:0000313|EMBL:QJD23630.1}, SARS-CoV-2/human/USA/NY-PV08435/2020
RC   {ECO:0000313|EMBL:QJD24206.1}, SARS-CoV-2/human/USA/NY-PV08436/2020
RC   {ECO:0000313|EMBL:QJD23342.1}, SARS-CoV-2/human/USA/NY-PV08438/2020
RC   {ECO:0000313|EMBL:QJD23471.1}, SARS-CoV-2/human/USA/NY-PV08441/2020
RC   {ECO:0000313|EMBL:QJD23486.1}, SARS-CoV-2/human/USA/NY-PV08443/2020
RC   {ECO:0000313|EMBL:QJD24302.1}, SARS-CoV-2/human/USA/NY-PV08444/2020
RC   {ECO:0000313|EMBL:QJD24122.1}, SARS-CoV-2/human/USA/NY-PV08445/2020
RC   {ECO:0000313|EMBL:QJD23582.1}, SARS-CoV-2/human/USA/NY-PV08446/2020
RC   {ECO:0000313|EMBL:QJD23762.1}, SARS-CoV-2/human/USA/NY-PV08447/2020
RC   {ECO:0000313|EMBL:QJD24278.1}, SARS-CoV-2/human/USA/NY-PV08448/2020
RC   {ECO:0000313|EMBL:QJD23822.1}, SARS-CoV-2/human/USA/NY-PV08449/2020
RC   {ECO:0000313|EMBL:QJD24134.1}, SARS-CoV-2/human/USA/NY-PV08450/2020
RC   {ECO:0000313|EMBL:QJD23942.1}, SARS-CoV-2/human/USA/NY-PV08452/2020
RC   {ECO:0000313|EMBL:QJD24074.1}, SARS-CoV-2/human/USA/NY-PV08453/2020
RC   {ECO:0000313|EMBL:QJD23690.1}, SARS-CoV-2/human/USA/NY-PV08455/2020
RC   {ECO:0000313|EMBL:QJD24098.1}, SARS-CoV-2/human/USA/NY-PV08456/2020
RC   {ECO:0000313|EMBL:QJD23366.1}, SARS-CoV-2/human/USA/NY-PV08459/2020
RC   {ECO:0000313|EMBL:QJD24062.1}, SARS-CoV-2/human/USA/NY-PV08461/2020
RC   {ECO:0000313|EMBL:QJD23930.1}, SARS-CoV-2/human/USA/NY-PV08462/2020
RC   {ECO:0000313|EMBL:QJD23738.1}, SARS-CoV-2/human/USA/NY-PV08463/2020
RC   {ECO:0000313|EMBL:QJD23438.1}, SARS-CoV-2/human/USA/NY-PV08464/2020
RC   {ECO:0000313|EMBL:QJD23282.1}, SARS-CoV-2/human/USA/NY-PV08466/2020
RC   {ECO:0000313|EMBL:QJD24350.1}, SARS-CoV-2/human/USA/NY-PV08468/2020
RC   {ECO:0000313|EMBL:QJD23606.1}, SARS-CoV-2/human/USA/NY-PV08469/2020
RC   {ECO:0000313|EMBL:QJD23750.1}, SARS-CoV-2/human/USA/NY-PV08471/2020
RC   {ECO:0000313|EMBL:QJD23666.1}, SARS-CoV-2/human/USA/NY-PV08472/2020
RC   {ECO:0000313|EMBL:QJD23978.1}, SARS-CoV-2/human/USA/NY-PV08473/2020
RC   {ECO:0000313|EMBL:QJD23810.1}, SARS-CoV-2/human/USA/NY-PV08474/2020
RC   {ECO:0000313|EMBL:QJD23834.1}, SARS-CoV-2/human/USA/NY-PV08476/2020
RC   {ECO:0000313|EMBL:QJD23953.1}, SARS-CoV-2/human/USA/NY-PV08477/2020
RC   {ECO:0000313|EMBL:QJD23990.1}, SARS-CoV-2/human/USA/NY-PV08478/2020
RC   {ECO:0000313|EMBL:QJD23318.1}, SARS-CoV-2/human/USA/NY-PV08481/2020
RC   {ECO:0000313|EMBL:QJD23894.1}, SARS-CoV-2/human/USA/NY-PV08485/2020
RC   {ECO:0000313|EMBL:QJD23726.1}, SARS-CoV-2/human/USA/NY-PV08486/2020
RC   {ECO:0000313|EMBL:QJD23354.1}, SARS-CoV-2/human/USA/NY-PV08487/2020
RC   {ECO:0000313|EMBL:QJD24086.1}, SARS-CoV-2/human/USA/NY-PV08489/2020
RC   {ECO:0000313|EMBL:QJD24218.1}, SARS-CoV-2/human/USA/NY-PV08490/2020
RC   {ECO:0000313|EMBL:QJD23402.1}, SARS-CoV-2/human/USA/NY-PV08491/2020
RC   {ECO:0000313|EMBL:QJD23774.1}, SARS-CoV-2/human/USA/NY-PV08492/2020
RC   {ECO:0000313|EMBL:QJD23450.1}, SARS-CoV-2/human/USA/NY-PV08493/2020
RC   {ECO:0000313|EMBL:QJD24242.1}, SARS-CoV-2/human/USA/NY-PV08494/2020
RC   {ECO:0000313|EMBL:QJD23546.1}, SARS-CoV-2/human/USA/NY-PV08495/2020
RC   {ECO:0000313|EMBL:QJD23678.1}, SARS-CoV-2/human/USA/NY-PV08496/2020
RC   {ECO:0000313|EMBL:QJD24038.1}, SARS-CoV-2/human/USA/NY-PV08498/2020
RC   {ECO:0000313|EMBL:QJD23966.1}, SARS-CoV-2/human/USA/NY-PV08500/2020
RC   {ECO:0000313|EMBL:QJD23510.1}, SARS-CoV-2/human/USA/NY-PV09000/2020
RC   {ECO:0000313|EMBL:QJD23522.1}, SARS-CoV-2/human/USA/NY-PV09006/2020
RC   {ECO:0000313|EMBL:QJD25298.1}, SARS-CoV-2/human/USA/NY-PV09019/2020
RC   {ECO:0000313|EMBL:QJD24386.1}, SARS-CoV-2/human/USA/NY-PV09020/2020
RC   {ECO:0000313|EMBL:QJD25562.1}, SARS-CoV-2/human/USA/NY-PV09021/2020
RC   {ECO:0000313|EMBL:QJD25646.1}, SARS-CoV-2/human/USA/NY-PV09023/2020
RC   {ECO:0000313|EMBL:QJD25034.1}, SARS-CoV-2/human/USA/NY-PV09025/2020
RC   {ECO:0000313|EMBL:QJD25730.1}, SARS-CoV-2/human/USA/NY-PV09028/2020
RC   {ECO:0000313|EMBL:QJD25202.1}, SARS-CoV-2/human/USA/NY-PV09029/2020
RC   {ECO:0000313|EMBL:QJD25538.1}, SARS-CoV-2/human/USA/NY-PV09030/2020
RC   {ECO:0000313|EMBL:QJD25476.1}, SARS-CoV-2/human/USA/NY-PV09032/2020
RC   {ECO:0000313|EMBL:QJD24878.1}, SARS-CoV-2/human/USA/NY-PV09037/2020
RC   {ECO:0000313|EMBL:QJD25106.1}, SARS-CoV-2/human/USA/NY-PV09039/2020
RC   {ECO:0000313|EMBL:QJD24674.1}, SARS-CoV-2/human/USA/NY-PV09041/2020
RC   {ECO:0000313|EMBL:QJD24734.1}, SARS-CoV-2/human/USA/NY-PV09043/2020
RC   {ECO:0000313|EMBL:QJD25118.1}, SARS-CoV-2/human/USA/NY-PV09044/2020
RC   {ECO:0000313|EMBL:QJD25058.1}, SARS-CoV-2/human/USA/NY-PV09045/2020
RC   {ECO:0000313|EMBL:QJD25310.1}, SARS-CoV-2/human/USA/NY-PV09046/2020
RC   {ECO:0000313|EMBL:QJD25586.1}, SARS-CoV-2/human/USA/NY-PV09047/2020
RC   {ECO:0000313|EMBL:QJD25597.1}, SARS-CoV-2/human/USA/NY-PV09050/2020
RC   {ECO:0000313|EMBL:QJD25680.1}, SARS-CoV-2/human/USA/NY-PV09056/2020
RC   {ECO:0000313|EMBL:QJD24854.1}, SARS-CoV-2/human/USA/NY-PV09057/2020
RC   {ECO:0000313|EMBL:QJD25418.1}, SARS-CoV-2/human/USA/NY-PV09060/2020
RC   {ECO:0000313|EMBL:QJD24530.1}, SARS-CoV-2/human/USA/NY-PV09061/2020
RC   {ECO:0000313|EMBL:QJD24962.1}, SARS-CoV-2/human/USA/NY-PV09063/2020
RC   {ECO:0000313|EMBL:QJD24986.1}, SARS-CoV-2/human/USA/NY-PV09064/2020
RC   {ECO:0000313|EMBL:QJD24926.1}, SARS-CoV-2/human/USA/NY-PV09067/2020
RC   {ECO:0000313|EMBL:QJD25070.1}, SARS-CoV-2/human/USA/NY-PV09068/2020
RC   {ECO:0000313|EMBL:QJD25382.1}, SARS-CoV-2/human/USA/NY-PV09069/2020
RC   {ECO:0000313|EMBL:QJD25022.1}, SARS-CoV-2/human/USA/NY-PV09071/2020
RC   {ECO:0000313|EMBL:QJD24602.1}, SARS-CoV-2/human/USA/NY-PV09073/2020
RC   {ECO:0000313|EMBL:QJD25634.1}, SARS-CoV-2/human/USA/NY-PV09075/2020
RC   {ECO:0000313|EMBL:QJD24698.1}, SARS-CoV-2/human/USA/NY-PV09076/2020
RC   {ECO:0000313|EMBL:QJD25344.1}, SARS-CoV-2/human/USA/NY-PV09077/2020
RC   {ECO:0000313|EMBL:QJD24662.1}, SARS-CoV-2/human/USA/NY-PV09079/2020
RC   {ECO:0000313|EMBL:QJD24518.1}, SARS-CoV-2/human/USA/NY-PV09080/2020
RC   {ECO:0000313|EMBL:QJD25212.1}, SARS-CoV-2/human/USA/NY-PV09083/2020
RC   {ECO:0000313|EMBL:QJD25190.1}, SARS-CoV-2/human/USA/NY-PV09087/2020
RC   {ECO:0000313|EMBL:QJD24422.1}, SARS-CoV-2/human/USA/NY-PV09088/2020
RC   {ECO:0000313|EMBL:QJD25274.1}, SARS-CoV-2/human/USA/NY-PV09090/2020
RC   {ECO:0000313|EMBL:QJD25622.1}, SARS-CoV-2/human/USA/NY-PV09092/2020
RC   {ECO:0000313|EMBL:QJD25154.1}, SARS-CoV-2/human/USA/NY-PV09097/2020
RC   {ECO:0000313|EMBL:QJD24830.1}, SARS-CoV-2/human/USA/NY-PV09098/2020
RC   {ECO:0000313|EMBL:QJD25178.1}, SARS-CoV-2/human/USA/NY-PV09099/2020
RC   {ECO:0000313|EMBL:QJD24794.1}, SARS-CoV-2/human/USA/NY-PV09102/2020
RC   {ECO:0000313|EMBL:QJD25466.1}, SARS-CoV-2/human/USA/NY-PV09103/2020
RC   {ECO:0000313|EMBL:QJD24434.1}, SARS-CoV-2/human/USA/NY-PV09115/2020
RC   {ECO:0000313|EMBL:QJD25670.1}, SARS-CoV-2/human/USA/NY-PV09116/2020
RC   {ECO:0000313|EMBL:QJD24890.1}, SARS-CoV-2/human/USA/NY-PV09118/2020
RC   {ECO:0000313|EMBL:QJD24766.1}, SARS-CoV-2/human/USA/NY-PV09119/2020
RC   {ECO:0000313|EMBL:QJD24578.1}, SARS-CoV-2/human/USA/NY-PV09120/2020
RC   {ECO:0000313|EMBL:QJD24638.1}, SARS-CoV-2/human/USA/NY-PV09121/2020
RC   {ECO:0000313|EMBL:QJD24445.1}, SARS-CoV-2/human/USA/NY-PV09122/2020
RC   {ECO:0000313|EMBL:QJD24746.1}, SARS-CoV-2/human/USA/NY-PV09123/2020
RC   {ECO:0000313|EMBL:QJD25082.1}, SARS-CoV-2/human/USA/NY-PV09125/2020
RC   {ECO:0000313|EMBL:QJD25226.1}, SARS-CoV-2/human/USA/NY-PV09126/2020
RC   {ECO:0000313|EMBL:QJD25550.1}, SARS-CoV-2/human/USA/NY-PV09127/2020
RC   {ECO:0000313|EMBL:QJD25694.1}, SARS-CoV-2/human/USA/NY-PV09128/2020
RC   {ECO:0000313|EMBL:QJD24614.1}, SARS-CoV-2/human/USA/NY-PV09129/2020
RC   {ECO:0000313|EMBL:QJD24782.1}, SARS-CoV-2/human/USA/NY-PV09130/2020
RC   {ECO:0000313|EMBL:QJD25430.1}, SARS-CoV-2/human/USA/NY-PV09132/2020
RC   {ECO:0000313|EMBL:QJD24806.1}, SARS-CoV-2/human/USA/NY-PV09134/2020
RC   {ECO:0000313|EMBL:QJD25010.1}, SARS-CoV-2/human/USA/NY-PV09135/2020
RC   {ECO:0000313|EMBL:QJD25250.1}, SARS-CoV-2/human/USA/NY-PV09137/2020
RC   {ECO:0000313|EMBL:QJD25658.1}, SARS-CoV-2/human/USA/NY-PV09138/2020
RC   {ECO:0000313|EMBL:QJD24974.1}, SARS-CoV-2/human/USA/NY-PV09139/2020
RC   {ECO:0000313|EMBL:QJD25358.1}, SARS-CoV-2/human/USA/NY-PV09140/2020
RC   {ECO:0000313|EMBL:QJD24842.1}, SARS-CoV-2/human/USA/NY-PV09141/2020
RC   {ECO:0000313|EMBL:QJD24540.1}, SARS-CoV-2/human/USA/NY-PV09142/2020
RC   {ECO:0000313|EMBL:QJD24554.1}, SARS-CoV-2/human/USA/NY-PV09143/2020
RC   {ECO:0000313|EMBL:QJD24362.1}, SARS-CoV-2/human/USA/NY-PV09144/2020
RC   {ECO:0000313|EMBL:QJD24686.1}, SARS-CoV-2/human/USA/NY-PV09145/2020
RC   {ECO:0000313|EMBL:QJD24410.1}, SARS-CoV-2/human/USA/NY-PV09147/2020
RC   {ECO:0000313|EMBL:QJD25130.1}, SARS-CoV-2/human/USA/NY-PV09149/2020
RC   {ECO:0000313|EMBL:QJD24648.1}, SARS-CoV-2/human/USA/NY-PV09151/2020
RC   {ECO:0000313|EMBL:QJD25574.1}, SARS-CoV-2/human/USA/NY-PV09152/2020
RC   {ECO:0000313|EMBL:QJD24626.1}, SARS-CoV-2/human/USA/NY-PV09153/2020
RC   {ECO:0000313|EMBL:QJD24470.1}, SARS-CoV-2/human/USA/NY-PV09154/2020
RC   {ECO:0000313|EMBL:QJD24374.1}, SARS-CoV-2/human/USA/NY-PV09156/2020
RC   {ECO:0000313|EMBL:QJD24758.1}, SARS-CoV-2/human/USA/NY-PV09157/2020
RC   {ECO:0000313|EMBL:QJD25046.1}, SARS-CoV-2/human/USA/NY-PV09158/2020
RC   {ECO:0000313|EMBL:QJD25718.1}, SARS-CoV-2/human/USA/NY-PV09161/2020
RC   {ECO:0000313|EMBL:QJD25440.1}, SARS-CoV-2/human/USA/NY-PV09163/2020
RC   {ECO:0000313|EMBL:QJD24818.1}, SARS-CoV-2/human/USA/NY-PV09164/2020
RC   {ECO:0000313|EMBL:QJD24482.1}, SARS-CoV-2/human/USA/NY-PV09165/2020
RC   {ECO:0000313|EMBL:QJD25406.1}, SARS-CoV-2/human/USA/NY-PV09168/2020
RC   {ECO:0000313|EMBL:QJD25610.1}, SARS-CoV-2/human/USA/NY-PV09169/2020
RC   {ECO:0000313|EMBL:QJD25454.1}, SARS-CoV-2/human/USA/NY-PV09170/2020
RC   {ECO:0000313|EMBL:QJD25094.1}, SARS-CoV-2/human/USA/NY-PV09171/2020
RC   {ECO:0000313|EMBL:QJD25322.1}, SARS-CoV-2/human/USA/NY-PV09172/2020
RC   {ECO:0000313|EMBL:QJD25370.1}, SARS-CoV-2/human/USA/NY-PV09176/2020
RC   {ECO:0000313|EMBL:QJD24722.1}, SARS-CoV-2/human/USA/NY-PV09177/2020
RC   {ECO:0000313|EMBL:QJD25394.1}, SARS-CoV-2/human/USA/NY-PV09178/2020
RC   {ECO:0000313|EMBL:QJD25754.1}, SARS-CoV-2/human/USA/NY-PV09179/2020
RC   {ECO:0000313|EMBL:QJD24866.1}, SARS-CoV-2/human/USA/NY-PV09180/2020
RC   {ECO:0000313|EMBL:QJD24902.1}, SARS-CoV-2/human/USA/NY-PV09181/2020
RC   {ECO:0000313|EMBL:QJD25262.1}, SARS-CoV-2/human/USA/NY-PV09182/2020
RC   {ECO:0000313|EMBL:QJD24590.1}, SARS-CoV-2/human/USA/NY-PV09183/2020
RC   {ECO:0000313|EMBL:QJD25286.1}, SARS-CoV-2/human/USA/NY-PV09186/2020
RC   {ECO:0000313|EMBL:QJD25526.1}, SARS-CoV-2/human/USA/NY-PV09187/2020
RC   {ECO:0000313|EMBL:QJD25490.1}, SARS-CoV-2/human/USA/NY-PV09188/2020
RC   {ECO:0000313|EMBL:QJD24457.1}, SARS-CoV-2/human/USA/NY-PV09189/2020
RC   {ECO:0000313|EMBL:QJD25766.1}, SARS-CoV-2/human/USA/NY-PV09190/2020
RC   {ECO:0000313|EMBL:QJD25142.1}, SARS-CoV-2/human/USA/NY-PV09192/2020
RC   {ECO:0000313|EMBL:QJD24950.1}, SARS-CoV-2/human/USA/NY-PV09193/2020
RC   {ECO:0000313|EMBL:QJD24710.1}, SARS-CoV-2/human/USA/NY-PV09194/2020
RC   {ECO:0000313|EMBL:QJD25238.1}, SARS-CoV-2/human/USA/NY-PV09195/2020
RC   {ECO:0000313|EMBL:QJD24494.1}, SARS-CoV-2/human/USA/NY-PV09197/2020
RC   {ECO:0000313|EMBL:QJD25166.1}, SARS-CoV-2/human/USA/NY-PV09198/2020
RC   {ECO:0000313|EMBL:QJD25742.1}, SARS-CoV-2/human/USA/NY-PV09199/2020
RC   {ECO:0000313|EMBL:QJD24938.1}, SARS-CoV-2/human/USA/NY-PV09200/2020
RC   {ECO:0000313|EMBL:QJD25334.1}, SARS-CoV-2/human/USA/NY-PV09301/2020
RC   {ECO:0000313|EMBL:QJD24566.1}, SARS-CoV-2/human/USA/NY-PV09303/2020
RC   {ECO:0000313|EMBL:QJD24914.1}, SARS-CoV-2/human/USA/NY-PV09304/2020
RC   {ECO:0000313|EMBL:QJD25706.1}, SARS-CoV-2/human/USA/NY-PV09305/2020
RC   {ECO:0000313|EMBL:QJD24398.1}, SARS-CoV-2/human/USA/NY-PV09307/2020
RC   {ECO:0000313|EMBL:QJD24998.1}, SARS-CoV-2/human/USA/NY-PV09308/2020
RC   {ECO:0000313|EMBL:QJD25502.1}, SARS-CoV-2/human/USA/NY-PV09309/2020
RC   {ECO:0000313|EMBL:QJD25514.1}, SARS-CoV-2/human/USA/NY1-PV08001/2020
RC   {ECO:0000313|EMBL:QJD24158.1}, and
RC   SARS-CoV-2/human/USA/NY2-PV08100/2020 {ECO:0000313|EMBL:QJD23414.1};
RG   NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS);
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [87] {ECO:0000313|EMBL:QJD20846.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/LKA/COV38/2020 {ECO:0000313|EMBL:QJD20846.1},
RC   SARS-CoV-2/human/LKA/COV486/2020 {ECO:0000313|EMBL:QJD20882.1},
RC   SARS-CoV-2/human/LKA/COV53/2020 {ECO:0000313|EMBL:QJD20858.1}, and
RC   SARS-CoV-2/human/LKA/COV91/2020 {ECO:0000313|EMBL:QJD20870.1};
RA   Jeewandara C., Ariyaratne D., Gomes L., Jayathilaka D., Ranasinghe D.,
RA   Wijewickrama A., Narangoda E., Idampitiya D., Malavige G.N.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [88] {ECO:0000313|EMBL:QJD23150.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/CZE/2256/2020 {ECO:0000313|EMBL:QJD23150.1},
RC   SARS-CoV-2/human/CZE/CzechiaMotol_1899/2020
RC   {ECO:0000313|EMBL:QJD23210.1},
RC   SARS-CoV-2/human/CZE/CzechiaMotol_1967/2020
RC   {ECO:0000313|EMBL:QJD23222.1},
RC   SARS-CoV-2/human/CZE/CzechiaMotol_1968/2020
RC   {ECO:0000313|EMBL:QJD23186.1},
RC   SARS-CoV-2/human/CZE/CzechiaMotol_2122/2020
RC   {ECO:0000313|EMBL:QJD23162.1},
RC   SARS-CoV-2/human/CZE/CzechiaMotol_2174/2020
RC   {ECO:0000313|EMBL:QJD23198.1}, and
RC   SARS-CoV-2/human/CZE/CzechiaMotol_2448/2020
RC   {ECO:0000313|EMBL:QJD23174.1};
RA   Kramna L., Polackova K., Cinek O.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [89] {ECO:0000313|EMBL:QJA17533.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/CT_9849/2020
RC   {ECO:0000313|EMBL:QJA17533.1}, SARS-CoV-2/human/USA/GA_2070/2020
RC   {ECO:0000313|EMBL:QJA17545.1}, SARS-CoV-2/human/USA/GA_2147/2020
RC   {ECO:0000313|EMBL:QJA17557.1}, SARS-CoV-2/human/USA/GA_2275/2020
RC   {ECO:0000313|EMBL:QJA17569.1}, SARS-CoV-2/human/USA/HI_4970/2020
RC   {ECO:0000313|EMBL:QJA17581.1}, SARS-CoV-2/human/USA/HI_7881/2020
RC   {ECO:0000313|EMBL:QJA17593.1}, and SARS-CoV-2/human/USA/IN_72003/2020
RC   {ECO:0000313|EMBL:QJA17605.1};
RA   Uehara A., Li Y., Queen K., Paden C.R., Marine R., Tao Y., Zhang J.,
RA   Wang H., Keckler M.S., Laufer Halpin A.S., Elkins C.A., Tong S.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [90] {ECO:0000313|EMBL:QJC21050.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/LA097/2020 {ECO:0000313|EMBL:QJC21050.1};
RA   Rose R., Nolan D., Garcia-Diaz J., Yang T., Caruso L., Navia W.,
RA   Von Borstel L., Zhou X., Cross S., Moraga D., Lamers S., Feehan A.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [91] {ECO:0000313|EMBL:QJA17617.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/IN_82003/2020
RC   {ECO:0000313|EMBL:QJA17617.1}, SARS-CoV-2/human/USA/IN_92003/2020
RC   {ECO:0000313|EMBL:QJA17629.1}, SARS-CoV-2/human/USA/MD_0027/2020
RC   {ECO:0000313|EMBL:QJA17641.1}, SARS-CoV-2/human/USA/MN_0100/2020
RC   {ECO:0000313|EMBL:QJA17653.1}, SARS-CoV-2/human/USA/MN_0101/2020
RC   {ECO:0000313|EMBL:QJA17749.1}, SARS-CoV-2/human/USA/NC_0025/2020
RC   {ECO:0000313|EMBL:QJA17761.1}, SARS-CoV-2/human/USA/NV_0016/2020
RC   {ECO:0000313|EMBL:QJA17737.1}, SARS-CoV-2/human/USA/OH_0019/2020
RC   {ECO:0000313|EMBL:QJA17665.1}, SARS-CoV-2/human/USA/OH_0020/2020
RC   {ECO:0000313|EMBL:QJA17677.1}, SARS-CoV-2/human/USA/PA_2734/2020
RC   {ECO:0000313|EMBL:QJA17689.1}, SARS-CoV-2/human/USA/PA_2735/2020
RC   {ECO:0000313|EMBL:QJA17701.1}, SARS-CoV-2/human/USA/PA_2887/2020
RC   {ECO:0000313|EMBL:QJA17713.1}, and SARS-CoV-2/human/USA/RI_0882/2020
RC   {ECO:0000313|EMBL:QJA17725.1};
RA   Queen K., Li Y., Uehara A., Paden C.R., Marine R., Tao Y., Zhang J.,
RA   Wang H., Keckler M.S., Laufer Halpin A.S., Elkins C.A., Tong S.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [92] {ECO:0000313|EMBL:QIZ64274.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/UT-00001/2020
RC   {ECO:0000313|EMBL:QIZ64274.1}, SARS-CoV-2/human/USA/UT-00003/2020
RC   {ECO:0000313|EMBL:QIZ64287.1}, SARS-CoV-2/human/USA/UT-00004/2020
RC   {ECO:0000313|EMBL:QIZ64298.1}, SARS-CoV-2/human/USA/UT-00005/2020
RC   {ECO:0000313|EMBL:QIZ64310.1}, SARS-CoV-2/human/USA/UT-00006/2020
RC   {ECO:0000313|EMBL:QIZ64323.1}, SARS-CoV-2/human/USA/UT-00008/2020
RC   {ECO:0000313|EMBL:QIZ64335.1}, SARS-CoV-2/human/USA/UT-00009/2020
RC   {ECO:0000313|EMBL:QIZ64344.1}, SARS-CoV-2/human/USA/UT-00010/2020
RC   {ECO:0000313|EMBL:QIZ64359.1}, SARS-CoV-2/human/USA/UT-00011/2020
RC   {ECO:0000313|EMBL:QIZ64370.1}, SARS-CoV-2/human/USA/UT-00012/2020
RC   {ECO:0000313|EMBL:QIZ64383.1}, SARS-CoV-2/human/USA/UT-00013/2020
RC   {ECO:0000313|EMBL:QIZ64394.1}, SARS-CoV-2/human/USA/UT-00014/2020
RC   {ECO:0000313|EMBL:QIZ64407.1}, SARS-CoV-2/human/USA/UT-00015/2020
RC   {ECO:0000313|EMBL:QIZ64419.1}, SARS-CoV-2/human/USA/UT-00016/2020
RC   {ECO:0000313|EMBL:QIZ64431.1}, SARS-CoV-2/human/USA/UT-00017/2020
RC   {ECO:0000313|EMBL:QIZ64443.1}, SARS-CoV-2/human/USA/UT-00019/2020
RC   {ECO:0000313|EMBL:QIZ64455.1}, SARS-CoV-2/human/USA/UT-00020/2020
RC   {ECO:0000313|EMBL:QIZ64467.1}, SARS-CoV-2/human/USA/UT-00021/2020
RC   {ECO:0000313|EMBL:QIZ64479.1}, SARS-CoV-2/human/USA/UT-00022/2020
RC   {ECO:0000313|EMBL:QIZ64491.1}, SARS-CoV-2/human/USA/UT-00023/2020
RC   {ECO:0000313|EMBL:QIZ64503.1}, SARS-CoV-2/human/USA/UT-00025/2020
RC   {ECO:0000313|EMBL:QIZ64515.1}, SARS-CoV-2/human/USA/UT-00027/2020
RC   {ECO:0000313|EMBL:QIZ64526.1}, SARS-CoV-2/human/USA/UT-00028/2020
RC   {ECO:0000313|EMBL:QIZ64539.1}, SARS-CoV-2/human/USA/UT-00031/2020
RC   {ECO:0000313|EMBL:QIZ64550.1}, SARS-CoV-2/human/USA/UT-00032/2020
RC   {ECO:0000313|EMBL:QIZ64563.1}, SARS-CoV-2/human/USA/UT-00033/2020
RC   {ECO:0000313|EMBL:QIZ64575.1}, SARS-CoV-2/human/USA/UT-00034/2020
RC   {ECO:0000313|EMBL:QIZ64587.1}, SARS-CoV-2/human/USA/UT-00087/2020
RC   {ECO:0000313|EMBL:QIZ64589.1}, SARS-CoV-2/human/USA/UT-00089/2020
RC   {ECO:0000313|EMBL:QIZ64609.1}, SARS-CoV-2/human/USA/UT-00090/2020
RC   {ECO:0000313|EMBL:QIZ64619.1}, SARS-CoV-2/human/USA/UT-00159/2020
RC   {ECO:0000313|EMBL:QIZ64633.1}, SARS-CoV-2/human/USA/UT-00284/2020
RC   {ECO:0000313|EMBL:QIZ64643.1}, SARS-CoV-2/human/USA/UT-00287/2020
RC   {ECO:0000313|EMBL:QIZ64657.1}, SARS-CoV-2/human/USA/UT-00288/2020
RC   {ECO:0000313|EMBL:QIZ64667.1}, SARS-CoV-2/human/USA/UT-00289/2020
RC   {ECO:0000313|EMBL:QIZ64681.1}, SARS-CoV-2/human/USA/UT-00290/2020
RC   {ECO:0000313|EMBL:QIZ64694.1}, SARS-CoV-2/human/USA/UT-00291/2020
RC   {ECO:0000313|EMBL:QIZ64703.1}, SARS-CoV-2/human/USA/UT-00297/2020
RC   {ECO:0000313|EMBL:QIZ64717.1}, SARS-CoV-2/human/USA/UT-00300/2020
RC   {ECO:0000313|EMBL:QIZ64728.1}, SARS-CoV-2/human/USA/UT-00301/2020
RC   {ECO:0000313|EMBL:QIZ64741.1}, SARS-CoV-2/human/USA/UT-00303/2020
RC   {ECO:0000313|EMBL:QIZ64763.1}, SARS-CoV-2/human/USA/UT-00342/2020
RC   {ECO:0000313|EMBL:QIZ64773.1}, SARS-CoV-2/human/USA/UT-00344/2020
RC   {ECO:0000313|EMBL:QIZ64785.1}, SARS-CoV-2/human/USA/UT-00345/2020
RC   {ECO:0000313|EMBL:QIZ64797.1}, SARS-CoV-2/human/USA/UT-00346/2020
RC   {ECO:0000313|EMBL:QIZ64809.1}, SARS-CoV-2/human/USA/UT-00347/2020
RC   {ECO:0000313|EMBL:QIZ64821.1}, SARS-CoV-2/human/USA/UT-00348/2020
RC   {ECO:0000313|EMBL:QIZ64835.1}, SARS-CoV-2/human/USA/UT-00349/2020
RC   {ECO:0000313|EMBL:QIZ64847.1}, SARS-CoV-2/human/USA/UT-00350/2020
RC   {ECO:0000313|EMBL:QIZ64857.1}, SARS-CoV-2/human/USA/UT-00352/2020
RC   {ECO:0000313|EMBL:QIZ64871.1}, and SARS-CoV-2/human/USA/UT-00361/2020
RC   {ECO:0000313|EMBL:QIZ64883.1};
RA   Young E., Oakeson K.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [93] {ECO:0000313|EMBL:QJD23234.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/MYS/186197/2020 {ECO:0000313|EMBL:QJD23267.1},
RC   SARS-CoV-2/human/MYS/188407/2020 {ECO:0000313|EMBL:QJD23234.1},
RC   SARS-CoV-2/human/MYS/189332/2020 {ECO:0000313|EMBL:QJD23246.1}, and
RC   SARS-CoV-2/human/MYS/190300/2020 {ECO:0000313|EMBL:QJD23258.1};
RA   Chan Y.F.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [94] {ECO:0000313|EMBL:QIU80906.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/IRN/HGRC-01-IPI-8206/2020
RC   {ECO:0000313|EMBL:QIU80906.1};
RG   Rapid Response Team from Pasteur Institute of Iran;
RA   Zeinali S., Khosravi M.A., Abbasalipour Bashash M., Mostafavi Jabbari S.,
RA   Firoozi M., Pourtavakoli S., Khateri E., Zeinali R., Hoseini F.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [95] {ECO:0000313|EMBL:QJA41650.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/BRA/SP02cc/2020 {ECO:0000313|EMBL:QJA41650.1};
RA   Malta F., Amgarten D., de Oliveira D.B.L., Araujo D.B., Machado R.R.G.,
RA   Santana R.A.F., Mangueira C.L.P., Durigon E.L., Pinho J.R.R.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [96] {ECO:0000313|EMBL:QIT07008.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/ISR/ISR_IT0320/2020
RC   {ECO:0000313|EMBL:QIT07008.1};
RA   Cohen-Gihon I., Israeli O., Shifman O., Stein D., Melamed S., Paran N.,
RA   Israely T., Achdout H., Yahalom Ronen Y., Tamir H., Politi B., Cherry L.,
RA   Vitner E., Laskar O., Weiss S., Mandelboim M., Erster O., Regev-Yochay G.,
RA   Segal G., Yitzhaki S., Shapira S.C., Beth-Din A., Zvi A.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [97] {ECO:0000313|EMBL:QIT06960.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/FL_5091/2020
RC   {ECO:0000313|EMBL:QIT06972.1}, SARS-CoV-2/human/USA/FL_5125/2020
RC   {ECO:0000313|EMBL:QIT06960.1}, and SARS-CoV-2/human/USA/TX_2020/2020
RC   {ECO:0000313|EMBL:QIT06984.1};
RA   Uehara A., Tao Y., Zhang J., Queen K., Paden C.R., Li Y., Wang H.,
RA   Padilla J., Lee J., Tong S.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [98] {ECO:0000313|EMBL:QJD20641.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/TWN/CGMH-CGU-03/2020
RC   {ECO:0000313|EMBL:QJD20641.1}, SARS-CoV-2/human/TWN/CGMH-CGU-04/2020
RC   {ECO:0000313|EMBL:QJD20653.1}, and
RC   SARS-CoV-2/human/TWN/CGMH-CGU-05/2020 {ECO:0000313|EMBL:QJD20665.1};
RA   Tsao K.-C., Gong Y.-N., Yang S.-L., Liu Y.-C., Huang C.-G., Hsiao M.-J.,
RA   Huang P.-W., Yang C.-T., Chiu C.-H., Huang C.-H., Le K.-T., Lin S.-M.,
RA   Huang P.-N., Lee K.-M., Chen G.-W., Shih S.-R.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [99] {ECO:0000313|EMBL:QIZ16206.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/IA_6390/2020
RC   {ECO:0000313|EMBL:QIZ16278.1}, SARS-CoV-2/human/USA/IA_6391/2020
RC   {ECO:0000313|EMBL:QIZ16206.1}, SARS-CoV-2/human/USA/IA_6395/2020
RC   {ECO:0000313|EMBL:QIZ16242.1}, SARS-CoV-2/human/USA/IA_6396/2020
RC   {ECO:0000313|EMBL:QIZ16230.1}, SARS-CoV-2/human/USA/IA_6399/2020
RC   {ECO:0000313|EMBL:QIZ16266.1}, SARS-CoV-2/human/USA/IA_6401/2020
RC   {ECO:0000313|EMBL:QIZ16254.1}, SARS-CoV-2/human/USA/MA_1355/2020
RC   {ECO:0000313|EMBL:QIZ16434.1}, SARS-CoV-2/human/USA/MA_2652/2020
RC   {ECO:0000313|EMBL:QIZ16446.1}, SARS-CoV-2/human/USA/MA_3614/2020
RC   {ECO:0000313|EMBL:QIZ16458.1}, SARS-CoV-2/human/USA/MA_3616/2020
RC   {ECO:0000313|EMBL:QIZ16470.1}, SARS-CoV-2/human/USA/MA_3623/2020
RC   {ECO:0000313|EMBL:QIZ16218.1}, SARS-CoV-2/human/USA/MA_3626/2020
RC   {ECO:0000313|EMBL:QIZ16482.1}, SARS-CoV-2/human/USA/MA_3642/2020
RC   {ECO:0000313|EMBL:QIZ16494.1}, SARS-CoV-2/human/USA/MA_3653/2020
RC   {ECO:0000313|EMBL:QIZ16506.1}, SARS-CoV-2/human/USA/MA_8932/2020
RC   {ECO:0000313|EMBL:QIZ16374.1}, SARS-CoV-2/human/USA/MA_8933/2020
RC   {ECO:0000313|EMBL:QIZ16386.1}, SARS-CoV-2/human/USA/MA_9703/2020
RC   {ECO:0000313|EMBL:QIZ16398.1}, SARS-CoV-2/human/USA/MA_9704/2020
RC   {ECO:0000313|EMBL:QIZ16410.1}, SARS-CoV-2/human/USA/MA_9889/2020
RC   {ECO:0000313|EMBL:QIZ16422.1}, SARS-CoV-2/human/USA/NJ_3201/2020
RC   {ECO:0000313|EMBL:QIZ16290.1}, SARS-CoV-2/human/USA/NY_1922/2020
RC   {ECO:0000313|EMBL:QIZ16350.1}, SARS-CoV-2/human/USA/SC_3520/2020
RC   {ECO:0000313|EMBL:QIZ16302.1}, SARS-CoV-2/human/USA/SC_3570/2020
RC   {ECO:0000313|EMBL:QIZ16314.1}, SARS-CoV-2/human/USA/SC_3571/2020
RC   {ECO:0000313|EMBL:QIZ16326.1}, SARS-CoV-2/human/USA/SC_3572/2020
RC   {ECO:0000313|EMBL:QIZ16338.1}, and SARS-CoV-2/human/USA/VA_6171/2020
RC   {ECO:0000313|EMBL:QIZ16362.1};
RA   Tao Y., Paden C.R., Zhang J., Queen K., Uehara A., Li Y., Wang H.,
RA   Keckler M.S., Laufer Halpin A.S., Elkins C.A., Tong S.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [100] {ECO:0000313|EMBL:QJC21014.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/ESP/VH000001133/2020
RC   {ECO:0000313|EMBL:QJC21014.1}, and
RC   SARS-CoV-2/human/ESP/VH198152683/2020 {ECO:0000313|EMBL:QJC21026.1};
RA   Andres C., Garcia-Cehic D., Pinana M., Guerrero-Murillo M., Rando A.,
RA   Pumarola T., Codina M.G., Anton A., Quer J.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [101] {ECO:0000313|EMBL:QJA41734.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/USA-WA_0422/2020
RC   {ECO:0000313|EMBL:QJA41794.1}, SARS-CoV-2/human/USA/USA-WA_0429/2020
RC   {ECO:0000313|EMBL:QJA41818.1}, SARS-CoV-2/human/USA/USA-WA_0432/2020
RC   {ECO:0000313|EMBL:QJA41746.1}, SARS-CoV-2/human/USA/USA-WA_0440/2020
RC   {ECO:0000313|EMBL:QJA41842.1}, SARS-CoV-2/human/USA/USA-WA_0441/2020
RC   {ECO:0000313|EMBL:QJA41830.1}, SARS-CoV-2/human/USA/USA-WA_0447/2020
RC   {ECO:0000313|EMBL:QJA41866.1}, SARS-CoV-2/human/USA/USA-WA_0448/2020
RC   {ECO:0000313|EMBL:QJA41770.1}, SARS-CoV-2/human/USA/USA-WA_0457/2020
RC   {ECO:0000313|EMBL:QJA41758.1}, SARS-CoV-2/human/USA/USA-WA_0478/2020
RC   {ECO:0000313|EMBL:QJA41782.1}, SARS-CoV-2/human/USA/USA-WA_0484/2020
RC   {ECO:0000313|EMBL:QJA41806.1}, SARS-CoV-2/human/USA/USA-WA_0711/2020
RC   {ECO:0000313|EMBL:QJA41854.1}, and
RC   SARS-CoV-2/human/USA/USA-WA_0797/2020 {ECO:0000313|EMBL:QJA41734.1};
RA   Tao Y., Zhang J., Paden C.R., Queen K., Uehara A., Li Y., Wang H.,
RA   Jacobs J., Russell D., Hiatt B., Gant J., Tong S.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [102] {ECO:0000313|EMBL:QIZ16544.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/GRC/10/2020 {ECO:0000313|EMBL:QIZ16544.1},
RC   SARS-CoV-2/human/GRC/12/2020 {ECO:0000313|EMBL:QIZ16556.1},
RC   SARS-CoV-2/human/GRC/13/2020 {ECO:0000313|EMBL:QIZ16580.1}, and
RC   SARS-CoV-2/human/GRC/16/2020 {ECO:0000313|EMBL:QIZ16568.1};
RA   Bampali M., Dovrolis N., Gatzidou E., Froukala E., Stavropoulou A.,
RA   Veletza S., Tsakris A., Spanakis N., Karakasiliotis I.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [103] {ECO:0000313|EMBL:QIV14993.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/KOR/BA-ACH_2604/2020
RC   {ECO:0000313|EMBL:QIV14993.1}, SARS-CoV-2/human/KOR/BA-ACH_2718/2020
RC   {ECO:0000313|EMBL:QIV15005.1}, SARS-CoV-2/human/KOR/BA-ACH_2719/2020
RC   {ECO:0000313|EMBL:QIV15017.1}, SARS-CoV-2/human/USA/AZ_4811/2020
RC   {ECO:0000313|EMBL:QIV15029.1}, SARS-CoV-2/human/USA/FL_6318/2020
RC   {ECO:0000313|EMBL:QIV15041.1}, SARS-CoV-2/human/USA/GA_1299/2020
RC   {ECO:0000313|EMBL:QIV15053.1}, SARS-CoV-2/human/USA/GA_1320/2020
RC   {ECO:0000313|EMBL:QIV15065.1}, SARS-CoV-2/human/USA/GA_1445/2020
RC   {ECO:0000313|EMBL:QIV15077.1}, SARS-CoV-2/human/USA/IL_1293/2020
RC   {ECO:0000313|EMBL:QIV15089.1}, SARS-CoV-2/human/USA/IL_1375/2020
RC   {ECO:0000313|EMBL:QIV15101.1}, SARS-CoV-2/human/USA/NH_0004/2020
RC   {ECO:0000313|EMBL:QIV15113.1}, SARS-CoV-2/human/USA/NH_0008/2020
RC   {ECO:0000313|EMBL:QIV15125.1}, SARS-CoV-2/human/USA/NY_2929/2020
RC   {ECO:0000313|EMBL:QIV15137.1}, SARS-CoV-2/human/USA/OR_5430/2020
RC   {ECO:0000313|EMBL:QIV15149.1}, SARS-CoV-2/human/USA/RI_0556/2020
RC   {ECO:0000313|EMBL:QIV15161.1}, SARS-CoV-2/human/USA/TX_2039/2020
RC   {ECO:0000313|EMBL:QIV15173.1}, SARS-CoV-2/human/USA/TX_2817/2020
RC   {ECO:0000313|EMBL:QIV15185.1}, and SARS-CoV-2/human/USA/TX_2967/2020
RC   {ECO:0000313|EMBL:QIV15197.1};
RA   Queen K., Li Y., Tao Y., Zhang J., Uehara A., Paden C.R., Wang H.,
RA   Marine R., Keckler M.S., Laufer Halpin A.S., Padilla J., Lee J.,
RA   Elkins C.A., Tong S.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [104] {ECO:0000313|EMBL:QIV65008.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/MI-SC2-0001/2020
RC   {ECO:0000313|EMBL:QIV65008.1}, SARS-CoV-2/human/USA/MI-SC2-0002/2020
RC   {ECO:0000313|EMBL:QIV65019.1}, SARS-CoV-2/human/USA/MI-SC2-0003/2020
RC   {ECO:0000313|EMBL:QIV65030.1}, SARS-CoV-2/human/USA/MI-SC2-0004/2020
RC   {ECO:0000313|EMBL:QIV65041.1}, SARS-CoV-2/human/USA/MI-SC2-0005/2020
RC   {ECO:0000313|EMBL:QIV65052.1}, SARS-CoV-2/human/USA/MI-SC2-0006/2020
RC   {ECO:0000313|EMBL:QIV65063.1}, SARS-CoV-2/human/USA/MI-SC2-0007/2020
RC   {ECO:0000313|EMBL:QIV65074.1}, SARS-CoV-2/human/USA/MI-SC2-0008/2020
RC   {ECO:0000313|EMBL:QIV65085.1}, and
RC   SARS-CoV-2/human/USA/MI-SC2-0009/2020 {ECO:0000313|EMBL:QIV65096.1};
RA   Blankenship H.M., Riner D., Soehnlen M.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
RN   [105] {ECO:0000313|EMBL:QJC21038.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=SARS-CoV-2/human/USA/LA096/2020 {ECO:0000313|EMBL:QJC21038.1};
RA   Rose R., Nolan D., Garcia-Diaz J., Yang T., Caruso L., Navia W.,
RA   Von Borstel L., Zhou X., Cross S., Lamers S., Feehan A.;
RL   Submitted (APR-2020) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; LC522972; BCA25652.1; -; Genomic_RNA.
DR   EMBL; LC522973; BCA25662.1; -; Genomic_RNA.
DR   EMBL; LC522974; BCA25672.1; -; Genomic_RNA.
DR   EMBL; LC522975; BCA25682.1; -; Genomic_RNA.
DR   EMBL; LC528232; BCA87369.1; -; Genomic_RNA.
DR   EMBL; LC528233; BCA87379.1; -; Genomic_RNA.
DR   EMBL; LC529905; BCB15099.1; -; Genomic_RNA.
DR   EMBL; LC534418; BCB97899.1; -; Genomic_RNA.
DR   EMBL; LC534419; BCB97909.1; -; Genomic_RNA.
DR   EMBL; LC542809; BCD57652.1; -; Genomic_RNA.
DR   EMBL; LC542976; BCD58762.1; -; Genomic_RNA.
DR   EMBL; MN908947; QHI42199.1; -; Genomic_RNA.
DR   EMBL; MT007544; QHR84457.1; -; Genomic_RNA.
DR   EMBL; MT012098; QHS34554.1; -; Genomic_RNA.
DR   EMBL; MT020781; QHU79182.1; -; Genomic_RNA.
DR   EMBL; MT020880; QHU79202.1; -; Genomic_RNA.
DR   EMBL; MT020881; QHU79212.1; -; Genomic_RNA.
DR   EMBL; MT027062; QHW06047.1; -; Genomic_RNA.
DR   EMBL; MT027063; QHW06057.1; -; Genomic_RNA.
DR   EMBL; MT027064; QHW06067.1; -; Genomic_RNA.
DR   EMBL; MT039873; QHZ00366.1; -; Genomic_RNA.
DR   EMBL; MT039890; QHZ00387.1; -; Genomic_RNA.
DR   EMBL; MT039887; QHZ00397.1; -; Genomic_RNA.
DR   EMBL; MT039888; QHZ00407.1; -; Genomic_RNA.
DR   EMBL; MT044257; QHZ87590.1; -; Genomic_RNA.
DR   EMBL; MT044258; QHZ87600.1; -; Genomic_RNA.
DR   EMBL; MT049951; QIA20053.1; -; Genomic_RNA.
DR   EMBL; MT066156; QIA98562.1; -; Genomic_RNA.
DR   EMBL; MT050493; QIA98591.1; -; Genomic_RNA.
DR   EMBL; MT066175; QIA98603.1; -; Genomic_RNA.
DR   EMBL; MT066176; QIA98614.1; -; Genomic_RNA.
DR   EMBL; MT072688; QIB84681.1; -; Genomic_RNA.
DR   EMBL; MT077125; QIC50506.1; -; Genomic_RNA.
DR   EMBL; MT093571; QIC53212.1; -; Genomic_RNA.
DR   EMBL; MT106052; QID21056.1; -; Genomic_RNA.
DR   EMBL; MT106053; QID21066.1; -; Genomic_RNA.
DR   EMBL; MT106054; QID21076.1; -; Genomic_RNA.
DR   EMBL; MT118835; QID98802.1; -; Genomic_RNA.
DR   EMBL; MT123290; QIE07459.1; -; Genomic_RNA.
DR   EMBL; MT123291; QIE07469.1; -; Genomic_RNA.
DR   EMBL; MT123292; QIE07479.1; -; Genomic_RNA.
DR   EMBL; MT123293; QIE07489.1; -; Genomic_RNA.
DR   EMBL; MT114412; QIG55873.1; -; Genomic_RNA.
DR   EMBL; MT114413; QIG55883.1; -; Genomic_RNA.
DR   EMBL; MT114414; QIG55893.1; -; Genomic_RNA.
DR   EMBL; MT114415; QIG55903.1; -; Genomic_RNA.
DR   EMBL; MT114416; QIG55913.1; -; Genomic_RNA.
DR   EMBL; MT114417; QIG55923.1; -; Genomic_RNA.
DR   EMBL; MT114418; QIG55933.1; -; Genomic_RNA.
DR   EMBL; MT114419; QIG55943.1; -; Genomic_RNA.
DR   EMBL; MT126808; QIG56002.1; -; Genomic_RNA.
DR   EMBL; MT135041; QIH45031.1; -; Genomic_RNA.
DR   EMBL; MT135042; QIH45041.1; -; Genomic_RNA.
DR   EMBL; MT135043; QIH45051.1; -; Genomic_RNA.
DR   EMBL; MT135044; QIH45061.1; -; Genomic_RNA.
DR   EMBL; MT152824; QIH55229.1; -; Genomic_RNA.
DR   EMBL; MT159705; QII57176.1; -; Genomic_RNA.
DR   EMBL; MT159706; QII57186.1; -; Genomic_RNA.
DR   EMBL; MT159707; QII57196.1; -; Genomic_RNA.
DR   EMBL; MT159708; QII57206.1; -; Genomic_RNA.
DR   EMBL; MT159709; QII57216.1; -; Genomic_RNA.
DR   EMBL; MT159710; QII57226.1; -; Genomic_RNA.
DR   EMBL; MT159711; QII57236.1; -; Genomic_RNA.
DR   EMBL; MT159712; QII57246.1; -; Genomic_RNA.
DR   EMBL; MT159713; QII57256.1; -; Genomic_RNA.
DR   EMBL; MT159714; QII57266.1; -; Genomic_RNA.
DR   EMBL; MT159715; QII57276.1; -; Genomic_RNA.
DR   EMBL; MT159716; QII57286.1; -; Genomic_RNA.
DR   EMBL; MT159717; QII57296.1; -; Genomic_RNA.
DR   EMBL; MT159718; QII57306.1; -; Genomic_RNA.
DR   EMBL; MT159719; QII57316.1; -; Genomic_RNA.
DR   EMBL; MT159720; QII57326.1; -; Genomic_RNA.
DR   EMBL; MT159721; QII57336.1; -; Genomic_RNA.
DR   EMBL; MT159722; QII57346.1; -; Genomic_RNA.
DR   EMBL; MT163716; QII87791.1; -; Genomic_RNA.
DR   EMBL; MT163717; QII87803.1; -; Genomic_RNA.
DR   EMBL; MT163718; QII87815.1; -; Genomic_RNA.
DR   EMBL; MT163719; QII87827.1; -; Genomic_RNA.
DR   EMBL; MT163720; QII87839.1; -; Genomic_RNA.
DR   EMBL; MT163721; QII87849.1; -; Genomic_RNA.
DR   EMBL; MT184907; QIJ96471.1; -; Genomic_RNA.
DR   EMBL; MT184908; QIJ96481.1; -; Genomic_RNA.
DR   EMBL; MT184909; QIJ96491.1; -; Genomic_RNA.
DR   EMBL; MT184910; QIJ96501.1; -; Genomic_RNA.
DR   EMBL; MT184911; QIJ96511.1; -; Genomic_RNA.
DR   EMBL; MT184912; QIJ96521.1; -; Genomic_RNA.
DR   EMBL; MT184913; QIJ96531.1; -; Genomic_RNA.
DR   EMBL; MT188339; QIK02952.1; -; Genomic_RNA.
DR   EMBL; MT188340; QIK02962.1; -; Genomic_RNA.
DR   EMBL; MT188341; QIK02972.1; -; Genomic_RNA.
DR   EMBL; MT192759; QIK50425.1; -; Genomic_RNA.
DR   EMBL; MT192765; QIK50436.1; -; Genomic_RNA.
DR   EMBL; MT192772; QIK50446.1; -; Genomic_RNA.
DR   EMBL; MT192773; QIK50456.1; -; Genomic_RNA.
DR   EMBL; MT226610; QIO04375.1; -; Genomic_RNA.
DR   EMBL; MT233519; QIQ08798.1; -; Genomic_RNA.
DR   EMBL; MT233520; QIQ08808.1; -; Genomic_RNA.
DR   EMBL; MT233521; QIQ08818.1; -; Genomic_RNA.
DR   EMBL; MT233522; QIQ08828.1; -; Genomic_RNA.
DR   EMBL; MT233523; QIQ08838.1; -; Genomic_RNA.
DR   EMBL; MT246449; QIQ49770.1; -; Genomic_RNA.
DR   EMBL; MT246450; QIQ49780.1; -; Genomic_RNA.
DR   EMBL; MT246451; QIQ49790.1; -; Genomic_RNA.
DR   EMBL; MT246452; QIQ49800.1; -; Genomic_RNA.
DR   EMBL; MT246453; QIQ49810.1; -; Genomic_RNA.
DR   EMBL; MT246454; QIQ49820.1; -; Genomic_RNA.
DR   EMBL; MT246455; QIQ49830.1; -; Genomic_RNA.
DR   EMBL; MT246456; QIQ49840.1; -; Genomic_RNA.
DR   EMBL; MT246457; QIQ49850.1; -; Genomic_RNA.
DR   EMBL; MT246458; QIQ49860.1; -; Genomic_RNA.
DR   EMBL; MT246459; QIQ49870.1; -; Genomic_RNA.
DR   EMBL; MT246460; QIQ49880.1; -; Genomic_RNA.
DR   EMBL; MT246461; QIQ49890.1; -; Genomic_RNA.
DR   EMBL; MT246462; QIQ49900.1; -; Genomic_RNA.
DR   EMBL; MT246463; QIQ49910.1; -; Genomic_RNA.
DR   EMBL; MT246464; QIQ49920.1; -; Genomic_RNA.
DR   EMBL; MT246465; QIQ49930.1; -; Genomic_RNA.
DR   EMBL; MT246466; QIQ49940.1; -; Genomic_RNA.
DR   EMBL; MT246467; QIQ49950.1; -; Genomic_RNA.
DR   EMBL; MT246468; QIQ49960.1; -; Genomic_RNA.
DR   EMBL; MT246469; QIQ49970.1; -; Genomic_RNA.
DR   EMBL; MT246470; QIQ49980.1; -; Genomic_RNA.
DR   EMBL; MT246471; QIQ49990.1; -; Genomic_RNA.
DR   EMBL; MT246472; QIQ50000.1; -; Genomic_RNA.
DR   EMBL; MT246473; QIQ50010.1; -; Genomic_RNA.
DR   EMBL; MT246474; QIQ50020.1; -; Genomic_RNA.
DR   EMBL; MT246475; QIQ50030.1; -; Genomic_RNA.
DR   EMBL; MT246476; QIQ50040.1; -; Genomic_RNA.
DR   EMBL; MT246477; QIQ50050.1; -; Genomic_RNA.
DR   EMBL; MT246478; QIQ50060.1; -; Genomic_RNA.
DR   EMBL; MT246479; QIQ50070.1; -; Genomic_RNA.
DR   EMBL; MT246480; QIQ50080.1; -; Genomic_RNA.
DR   EMBL; MT246481; QIQ50090.1; -; Genomic_RNA.
DR   EMBL; MT246482; QIQ50100.1; -; Genomic_RNA.
DR   EMBL; MT246483; QIQ50110.1; -; Genomic_RNA.
DR   EMBL; MT246484; QIQ50120.1; -; Genomic_RNA.
DR   EMBL; MT246485; QIQ50130.1; -; Genomic_RNA.
DR   EMBL; MT246486; QIQ50140.1; -; Genomic_RNA.
DR   EMBL; MT246487; QIQ50150.1; -; Genomic_RNA.
DR   EMBL; MT246488; QIQ50160.1; -; Genomic_RNA.
DR   EMBL; MT246489; QIQ50170.1; -; Genomic_RNA.
DR   EMBL; MT246490; QIQ50180.1; -; Genomic_RNA.
DR   EMBL; MT233526; QIQ50190.1; -; Genomic_RNA.
DR   EMBL; MT246667; QIQ50200.1; -; Genomic_RNA.
DR   EMBL; MT251972; QIQ68472.1; -; Genomic_RNA.
DR   EMBL; MT251973; QIQ68482.1; -; Genomic_RNA.
DR   EMBL; MT251974; QIQ68492.1; -; Genomic_RNA.
DR   EMBL; MT251975; QIQ68502.1; -; Genomic_RNA.
DR   EMBL; MT251976; QIQ68512.1; -; Genomic_RNA.
DR   EMBL; MT251977; QIQ68522.1; -; Genomic_RNA.
DR   EMBL; MT251978; QIQ68532.1; -; Genomic_RNA.
DR   EMBL; MT251979; QIQ68542.1; -; Genomic_RNA.
DR   EMBL; MT251980; QIQ68552.1; -; Genomic_RNA.
DR   EMBL; MT253696; QIQ68562.1; -; Genomic_RNA.
DR   EMBL; MT253697; QIQ68572.1; -; Genomic_RNA.
DR   EMBL; MT253698; QIQ68582.1; -; Genomic_RNA.
DR   EMBL; MT253699; QIQ68592.1; -; Genomic_RNA.
DR   EMBL; MT253700; QIQ68602.1; -; Genomic_RNA.
DR   EMBL; MT253701; QIQ68612.1; -; Genomic_RNA.
DR   EMBL; MT253702; QIQ68622.1; -; Genomic_RNA.
DR   EMBL; MT253703; QIQ68632.1; -; Genomic_RNA.
DR   EMBL; MT253704; QIQ68642.1; -; Genomic_RNA.
DR   EMBL; MT253705; QIQ68652.1; -; Genomic_RNA.
DR   EMBL; MT253706; QIQ68662.1; -; Genomic_RNA.
DR   EMBL; MT253707; QIQ68672.1; -; Genomic_RNA.
DR   EMBL; MT253708; QIQ68682.1; -; Genomic_RNA.
DR   EMBL; MT253709; QIQ68692.1; -; Genomic_RNA.
DR   EMBL; MT253710; QIQ68702.1; -; Genomic_RNA.
DR   EMBL; MT198652; QIQ68704.1; -; Genomic_RNA.
DR   EMBL; MT259227; QIS30003.1; -; Genomic_RNA.
DR   EMBL; MT259228; QIS30015.1; -; Genomic_RNA.
DR   EMBL; MT259229; QIS30027.1; -; Genomic_RNA.
DR   EMBL; MT259230; QIS30039.1; -; Genomic_RNA.
DR   EMBL; MT259231; QIS30051.1; -; Genomic_RNA.
DR   EMBL; MT256924; QIS30063.1; -; Genomic_RNA.
DR   EMBL; MT258377; QIS30073.1; -; Genomic_RNA.
DR   EMBL; MT258378; QIS30083.1; -; Genomic_RNA.
DR   EMBL; MT258379; QIS30093.1; -; Genomic_RNA.
DR   EMBL; MT258380; QIS30103.1; -; Genomic_RNA.
DR   EMBL; MT258381; QIS30113.1; -; Genomic_RNA.
DR   EMBL; MT258382; QIS30123.1; -; Genomic_RNA.
DR   EMBL; MT258383; QIS30133.1; -; Genomic_RNA.
DR   EMBL; MT256917; QIS30143.1; -; Genomic_RNA.
DR   EMBL; MT256918; QIS30153.1; -; Genomic_RNA.
DR   EMBL; MT259235; QIS30163.1; -; Genomic_RNA.
DR   EMBL; MT259236; QIS30173.1; -; Genomic_RNA.
DR   EMBL; MT259237; QIS30183.1; -; Genomic_RNA.
DR   EMBL; MT259238; QIS30193.1; -; Genomic_RNA.
DR   EMBL; MT259239; QIS30203.1; -; Genomic_RNA.
DR   EMBL; MT259240; QIS30213.1; -; Genomic_RNA.
DR   EMBL; MT259241; QIS30223.1; -; Genomic_RNA.
DR   EMBL; MT259242; QIS30233.1; -; Genomic_RNA.
DR   EMBL; MT259243; QIS30243.1; -; Genomic_RNA.
DR   EMBL; MT259244; QIS30253.1; -; Genomic_RNA.
DR   EMBL; MT259245; QIS30263.1; -; Genomic_RNA.
DR   EMBL; MT259246; QIS30273.1; -; Genomic_RNA.
DR   EMBL; MT259247; QIS30283.1; -; Genomic_RNA.
DR   EMBL; MT259248; QIS30293.1; -; Genomic_RNA.
DR   EMBL; MT259249; QIS30303.1; -; Genomic_RNA.
DR   EMBL; MT259250; QIS30313.1; -; Genomic_RNA.
DR   EMBL; MT259251; QIS30323.1; -; Genomic_RNA.
DR   EMBL; MT259252; QIS30333.1; -; Genomic_RNA.
DR   EMBL; MT259253; QIS30343.1; -; Genomic_RNA.
DR   EMBL; MT259254; QIS30353.1; -; Genomic_RNA.
DR   EMBL; MT259255; QIS30363.1; -; Genomic_RNA.
DR   EMBL; MT259256; QIS30373.1; -; Genomic_RNA.
DR   EMBL; MT259257; QIS30383.1; -; Genomic_RNA.
DR   EMBL; MT259258; QIS30393.1; -; Genomic_RNA.
DR   EMBL; MT259259; QIS30403.1; -; Genomic_RNA.
DR   EMBL; MT259260; QIS30413.1; -; Genomic_RNA.
DR   EMBL; MT259261; QIS30423.1; -; Genomic_RNA.
DR   EMBL; MT259262; QIS30433.1; -; Genomic_RNA.
DR   EMBL; MT259263; QIS30443.1; -; Genomic_RNA.
DR   EMBL; MT259264; QIS30453.1; -; Genomic_RNA.
DR   EMBL; MT259265; QIS30463.1; -; Genomic_RNA.
DR   EMBL; MT259266; QIS30473.1; -; Genomic_RNA.
DR   EMBL; MT259267; QIS30483.1; -; Genomic_RNA.
DR   EMBL; MT259268; QIS30493.1; -; Genomic_RNA.
DR   EMBL; MT259269; QIS30503.1; -; Genomic_RNA.
DR   EMBL; MT259270; QIS30512.1; -; Genomic_RNA.
DR   EMBL; MT259271; QIS30523.1; -; Genomic_RNA.
DR   EMBL; MT259272; QIS30533.1; -; Genomic_RNA.
DR   EMBL; MT259273; QIS30543.1; -; Genomic_RNA.
DR   EMBL; MT259274; QIS30553.1; -; Genomic_RNA.
DR   EMBL; MT259275; QIS30563.1; -; Genomic_RNA.
DR   EMBL; MT259276; QIS30573.1; -; Genomic_RNA.
DR   EMBL; MT259277; QIS30583.1; -; Genomic_RNA.
DR   EMBL; MT259278; QIS30593.1; -; Genomic_RNA.
DR   EMBL; MT259279; QIS30603.1; -; Genomic_RNA.
DR   EMBL; MT259280; QIS30613.1; -; Genomic_RNA.
DR   EMBL; MT259281; QIS30623.1; -; Genomic_RNA.
DR   EMBL; MT259282; QIS30633.1; -; Genomic_RNA.
DR   EMBL; MT259283; QIS30643.1; -; Genomic_RNA.
DR   EMBL; MT259284; QIS30653.1; -; Genomic_RNA.
DR   EMBL; MT259285; QIS30663.1; -; Genomic_RNA.
DR   EMBL; MT259286; QIS30673.1; -; Genomic_RNA.
DR   EMBL; MT259287; QIS30683.1; -; Genomic_RNA.
DR   EMBL; MT262993; QIS60285.1; -; Genomic_RNA.
DR   EMBL; MT263074; QIS60297.1; -; Genomic_RNA.
DR   EMBL; MT262896; QIS60307.1; -; Genomic_RNA.
DR   EMBL; MT262897; QIS60317.1; -; Genomic_RNA.
DR   EMBL; MT262898; QIS60327.1; -; Genomic_RNA.
DR   EMBL; MT262899; QIS60337.1; -; Genomic_RNA.
DR   EMBL; MT262900; QIS60347.1; -; Genomic_RNA.
DR   EMBL; MT262901; QIS60357.1; -; Genomic_RNA.
DR   EMBL; MT262902; QIS60367.1; -; Genomic_RNA.
DR   EMBL; MT262903; QIS60377.1; -; Genomic_RNA.
DR   EMBL; MT262904; QIS60387.1; -; Genomic_RNA.
DR   EMBL; MT262905; QIS60397.1; -; Genomic_RNA.
DR   EMBL; MT262906; QIS60407.1; -; Genomic_RNA.
DR   EMBL; MT262907; QIS60417.1; -; Genomic_RNA.
DR   EMBL; MT262908; QIS60427.1; -; Genomic_RNA.
DR   EMBL; MT262909; QIS60437.1; -; Genomic_RNA.
DR   EMBL; MT262910; QIS60447.1; -; Genomic_RNA.
DR   EMBL; MT262911; QIS60457.1; -; Genomic_RNA.
DR   EMBL; MT262912; QIS60467.1; -; Genomic_RNA.
DR   EMBL; MT262913; QIS60477.1; -; Genomic_RNA.
DR   EMBL; MT262914; QIS60487.1; -; Genomic_RNA.
DR   EMBL; MT262915; QIS60497.1; -; Genomic_RNA.
DR   EMBL; MT262916; QIS60507.1; -; Genomic_RNA.
DR   EMBL; MT263381; QIS60519.1; -; Genomic_RNA.
DR   EMBL; MT263382; QIS60531.1; -; Genomic_RNA.
DR   EMBL; MT263383; QIS60543.1; -; Genomic_RNA.
DR   EMBL; MT263385; QIS60567.1; -; Genomic_RNA.
DR   EMBL; MT263386; QIS60579.1; -; Genomic_RNA.
DR   EMBL; MT263387; QIS60591.1; -; Genomic_RNA.
DR   EMBL; MT263388; QIS60603.1; -; Genomic_RNA.
DR   EMBL; MT263390; QIS60627.1; -; Genomic_RNA.
DR   EMBL; MT263391; QIS60639.1; -; Genomic_RNA.
DR   EMBL; MT263392; QIS60651.1; -; Genomic_RNA.
DR   EMBL; MT263393; QIS60663.1; -; Genomic_RNA.
DR   EMBL; MT263394; QIS60675.1; -; Genomic_RNA.
DR   EMBL; MT263395; QIS60687.1; -; Genomic_RNA.
DR   EMBL; MT263396; QIS60699.1; -; Genomic_RNA.
DR   EMBL; MT263397; QIS60711.1; -; Genomic_RNA.
DR   EMBL; MT263398; QIS60723.1; -; Genomic_RNA.
DR   EMBL; MT263399; QIS60735.1; -; Genomic_RNA.
DR   EMBL; MT263400; QIS60747.1; -; Genomic_RNA.
DR   EMBL; MT263401; QIS60759.1; -; Genomic_RNA.
DR   EMBL; MT263402; QIS60771.1; -; Genomic_RNA.
DR   EMBL; MT263403; QIS60783.1; -; Genomic_RNA.
DR   EMBL; MT263404; QIS60795.1; -; Genomic_RNA.
DR   EMBL; MT263405; QIS60807.1; -; Genomic_RNA.
DR   EMBL; MT263406; QIS60819.1; -; Genomic_RNA.
DR   EMBL; MT263407; QIS60831.1; -; Genomic_RNA.
DR   EMBL; MT263408; QIS60843.1; -; Genomic_RNA.
DR   EMBL; MT263409; QIS60855.1; -; Genomic_RNA.
DR   EMBL; MT263410; QIS60867.1; -; Genomic_RNA.
DR   EMBL; MT263411; QIS60879.1; -; Genomic_RNA.
DR   EMBL; MT263412; QIS60891.1; -; Genomic_RNA.
DR   EMBL; MT263413; QIS60903.1; -; Genomic_RNA.
DR   EMBL; MT263414; QIS60915.1; -; Genomic_RNA.
DR   EMBL; MT263415; QIS60927.1; -; Genomic_RNA.
DR   EMBL; MT263416; QIS60939.1; -; Genomic_RNA.
DR   EMBL; MT263417; QIS60951.1; -; Genomic_RNA.
DR   EMBL; MT263418; QIS60963.1; -; Genomic_RNA.
DR   EMBL; MT263419; QIS60975.1; -; Genomic_RNA.
DR   EMBL; MT263420; QIS60987.1; -; Genomic_RNA.
DR   EMBL; MT263421; QIS60999.1; -; Genomic_RNA.
DR   EMBL; MT263422; QIS61011.1; -; Genomic_RNA.
DR   EMBL; MT263423; QIS61023.1; -; Genomic_RNA.
DR   EMBL; MT263424; QIS61035.1; -; Genomic_RNA.
DR   EMBL; MT263425; QIS61047.1; -; Genomic_RNA.
DR   EMBL; MT263426; QIS61059.1; -; Genomic_RNA.
DR   EMBL; MT263427; QIS61069.1; -; Genomic_RNA.
DR   EMBL; MT263428; QIS61083.1; -; Genomic_RNA.
DR   EMBL; MT263429; QIS61095.1; -; Genomic_RNA.
DR   EMBL; MT263430; QIS61107.1; -; Genomic_RNA.
DR   EMBL; MT263431; QIS61119.1; -; Genomic_RNA.
DR   EMBL; MT263432; QIS61131.1; -; Genomic_RNA.
DR   EMBL; MT263433; QIS61143.1; -; Genomic_RNA.
DR   EMBL; MT263434; QIS61155.1; -; Genomic_RNA.
DR   EMBL; MT263435; QIS61167.1; -; Genomic_RNA.
DR   EMBL; MT263436; QIS61179.1; -; Genomic_RNA.
DR   EMBL; MT263437; QIS61191.1; -; Genomic_RNA.
DR   EMBL; MT263438; QIS61203.1; -; Genomic_RNA.
DR   EMBL; MT263439; QIS61215.1; -; Genomic_RNA.
DR   EMBL; MT263440; QIS61227.1; -; Genomic_RNA.
DR   EMBL; MT263441; QIS61239.1; -; Genomic_RNA.
DR   EMBL; MT263442; QIS61251.1; -; Genomic_RNA.
DR   EMBL; MT263443; QIS61263.1; -; Genomic_RNA.
DR   EMBL; MT263444; QIS61275.1; -; Genomic_RNA.
DR   EMBL; MT263445; QIS61287.1; -; Genomic_RNA.
DR   EMBL; MT263446; QIS61299.1; -; Genomic_RNA.
DR   EMBL; MT263447; QIS61311.1; -; Genomic_RNA.
DR   EMBL; MT263448; QIS61323.1; -; Genomic_RNA.
DR   EMBL; MT263449; QIS61335.1; -; Genomic_RNA.
DR   EMBL; MT263450; QIS61347.1; -; Genomic_RNA.
DR   EMBL; MT263451; QIS61359.1; -; Genomic_RNA.
DR   EMBL; MT263452; QIS61371.1; -; Genomic_RNA.
DR   EMBL; MT263453; QIS61383.1; -; Genomic_RNA.
DR   EMBL; MT263454; QIS61395.1; -; Genomic_RNA.
DR   EMBL; MT263455; QIS61407.1; -; Genomic_RNA.
DR   EMBL; MT263456; QIS61419.1; -; Genomic_RNA.
DR   EMBL; MT263457; QIS61431.1; -; Genomic_RNA.
DR   EMBL; MT263458; QIS61443.1; -; Genomic_RNA.
DR   EMBL; MT263459; QIS61455.1; -; Genomic_RNA.
DR   EMBL; MT263460; QIS61465.1; -; Genomic_RNA.
DR   EMBL; MT263461; QIS61477.1; -; Genomic_RNA.
DR   EMBL; MT263462; QIS61491.1; -; Genomic_RNA.
DR   EMBL; MT263463; QIS61503.1; -; Genomic_RNA.
DR   EMBL; MT263464; QIS61515.1; -; Genomic_RNA.
DR   EMBL; MT263465; QIS61527.1; -; Genomic_RNA.
DR   EMBL; MT263466; QIS61537.1; -; Genomic_RNA.
DR   EMBL; MT263467; QIS61551.1; -; Genomic_RNA.
DR   EMBL; MT263468; QIS61563.1; -; Genomic_RNA.
DR   EMBL; MT263469; QIS61575.1; -; Genomic_RNA.
DR   EMBL; MT276323; QIT06888.1; -; Genomic_RNA.
DR   EMBL; MT276324; QIT06900.1; -; Genomic_RNA.
DR   EMBL; MT276325; QIT06912.1; -; Genomic_RNA.
DR   EMBL; MT276326; QIT06924.1; -; Genomic_RNA.
DR   EMBL; MT276327; QIT06936.1; -; Genomic_RNA.
DR   EMBL; MT276328; QIT06948.1; -; Genomic_RNA.
DR   EMBL; MT276329; QIT06960.1; -; Genomic_RNA.
DR   EMBL; MT276330; QIT06972.1; -; Genomic_RNA.
DR   EMBL; MT276331; QIT06984.1; -; Genomic_RNA.
DR   EMBL; MT276597; QIT06996.1; -; Genomic_RNA.
DR   EMBL; MT276598; QIT07008.1; -; Genomic_RNA.
DR   EMBL; MT292569; QIU78716.1; -; Genomic_RNA.
DR   EMBL; MT292570; QIU78728.1; -; Genomic_RNA.
DR   EMBL; MT292571; QIU78740.1; -; Genomic_RNA.
DR   EMBL; MT292572; QIU78752.1; -; Genomic_RNA.
DR   EMBL; MT292573; QIU78764.1; -; Genomic_RNA.
DR   EMBL; MT292574; QIU78776.1; -; Genomic_RNA.
DR   EMBL; MT292575; QIU78788.1; -; Genomic_RNA.
DR   EMBL; MT292576; QIU78799.1; -; Genomic_RNA.
DR   EMBL; MT292577; QIU78811.1; -; Genomic_RNA.
DR   EMBL; MT292578; QIU78822.1; -; Genomic_RNA.
DR   EMBL; MT292579; QIU78832.1; -; Genomic_RNA.
DR   EMBL; MT292580; QIU78843.1; -; Genomic_RNA.
DR   EMBL; MT292581; QIU78856.1; -; Genomic_RNA.
DR   EMBL; MT292582; QIU78864.1; -; Genomic_RNA.
DR   EMBL; MT281530; QIU80906.1; -; Genomic_RNA.
DR   EMBL; MT293156; QIU80934.1; -; Genomic_RNA.
DR   EMBL; MT293157; QIU80946.1; -; Genomic_RNA.
DR   EMBL; MT293158; QIU80958.1; -; Genomic_RNA.
DR   EMBL; MT293159; QIU80970.1; -; Genomic_RNA.
DR   EMBL; MT293160; QIU80982.1; -; Genomic_RNA.
DR   EMBL; MT293161; QIU80994.1; -; Genomic_RNA.
DR   EMBL; MT293162; QIU81006.1; -; Genomic_RNA.
DR   EMBL; MT293163; QIU81018.1; -; Genomic_RNA.
DR   EMBL; MT293164; QIU81030.1; -; Genomic_RNA.
DR   EMBL; MT293165; QIU81042.1; -; Genomic_RNA.
DR   EMBL; MT293166; QIU81054.1; -; Genomic_RNA.
DR   EMBL; MT293167; QIU81066.1; -; Genomic_RNA.
DR   EMBL; MT293168; QIU81078.1; -; Genomic_RNA.
DR   EMBL; MT293169; QIU81090.1; -; Genomic_RNA.
DR   EMBL; MT293170; QIU81102.1; -; Genomic_RNA.
DR   EMBL; MT293171; QIU81114.1; -; Genomic_RNA.
DR   EMBL; MT293172; QIU81126.1; -; Genomic_RNA.
DR   EMBL; MT293173; QIU81138.1; -; Genomic_RNA.
DR   EMBL; MT293174; QIU81150.1; -; Genomic_RNA.
DR   EMBL; MT293175; QIU81162.1; -; Genomic_RNA.
DR   EMBL; MT293176; QIU81174.1; -; Genomic_RNA.
DR   EMBL; MT293177; QIU81186.1; -; Genomic_RNA.
DR   EMBL; MT293178; QIU81198.1; -; Genomic_RNA.
DR   EMBL; MT293179; QIU81210.1; -; Genomic_RNA.
DR   EMBL; MT293180; QIU81222.1; -; Genomic_RNA.
DR   EMBL; MT293181; QIU81234.1; -; Genomic_RNA.
DR   EMBL; MT293182; QIU81246.1; -; Genomic_RNA.
DR   EMBL; MT293183; QIU81258.1; -; Genomic_RNA.
DR   EMBL; MT293184; QIU81270.1; -; Genomic_RNA.
DR   EMBL; MT293185; QIU81282.1; -; Genomic_RNA.
DR   EMBL; MT293186; QIU81294.1; -; Genomic_RNA.
DR   EMBL; MT293187; QIU81306.1; -; Genomic_RNA.
DR   EMBL; MT293188; QIU81318.1; -; Genomic_RNA.
DR   EMBL; MT293189; QIU81330.1; -; Genomic_RNA.
DR   EMBL; MT293190; QIU81342.1; -; Genomic_RNA.
DR   EMBL; MT293191; QIU81354.1; -; Genomic_RNA.
DR   EMBL; MT293192; QIU81366.1; -; Genomic_RNA.
DR   EMBL; MT293193; QIU81378.1; -; Genomic_RNA.
DR   EMBL; MT293194; QIU81390.1; -; Genomic_RNA.
DR   EMBL; MT293195; QIU81402.1; -; Genomic_RNA.
DR   EMBL; MT293196; QIU81414.1; -; Genomic_RNA.
DR   EMBL; MT293197; QIU81426.1; -; Genomic_RNA.
DR   EMBL; MT293198; QIU81438.1; -; Genomic_RNA.
DR   EMBL; MT293199; QIU81450.1; -; Genomic_RNA.
DR   EMBL; MT293200; QIU81462.1; -; Genomic_RNA.
DR   EMBL; MT293201; QIU81474.1; -; Genomic_RNA.
DR   EMBL; MT293202; QIU81486.1; -; Genomic_RNA.
DR   EMBL; MT293203; QIU81498.1; -; Genomic_RNA.
DR   EMBL; MT293204; QIU81510.1; -; Genomic_RNA.
DR   EMBL; MT293205; QIU81522.1; -; Genomic_RNA.
DR   EMBL; MT293206; QIU81534.1; -; Genomic_RNA.
DR   EMBL; MT293207; QIU81546.1; -; Genomic_RNA.
DR   EMBL; MT293208; QIU81558.1; -; Genomic_RNA.
DR   EMBL; MT293209; QIU81570.1; -; Genomic_RNA.
DR   EMBL; MT293210; QIU81582.1; -; Genomic_RNA.
DR   EMBL; MT293211; QIU81594.1; -; Genomic_RNA.
DR   EMBL; MT293212; QIU81606.1; -; Genomic_RNA.
DR   EMBL; MT293213; QIU81618.1; -; Genomic_RNA.
DR   EMBL; MT293214; QIU81630.1; -; Genomic_RNA.
DR   EMBL; MT293215; QIU81642.1; -; Genomic_RNA.
DR   EMBL; MT293216; QIU81654.1; -; Genomic_RNA.
DR   EMBL; MT293217; QIU81666.1; -; Genomic_RNA.
DR   EMBL; MT293218; QIU81678.1; -; Genomic_RNA.
DR   EMBL; MT293219; QIU81690.1; -; Genomic_RNA.
DR   EMBL; MT293220; QIU81702.1; -; Genomic_RNA.
DR   EMBL; MT293221; QIU81714.1; -; Genomic_RNA.
DR   EMBL; MT293222; QIU81726.1; -; Genomic_RNA.
DR   EMBL; MT293223; QIU81738.1; -; Genomic_RNA.
DR   EMBL; MT293224; QIU81750.1; -; Genomic_RNA.
DR   EMBL; MT293225; QIU81762.1; -; Genomic_RNA.
DR   EMBL; MT295464; QIU81907.1; -; Genomic_RNA.
DR   EMBL; MT295465; QIU81919.1; -; Genomic_RNA.
DR   EMBL; MT300186; QIV14981.1; -; Genomic_RNA.
DR   EMBL; MT304474; QIV14993.1; -; Genomic_RNA.
DR   EMBL; MT304475; QIV15005.1; -; Genomic_RNA.
DR   EMBL; MT304476; QIV15017.1; -; Genomic_RNA.
DR   EMBL; MT304477; QIV15029.1; -; Genomic_RNA.
DR   EMBL; MT304478; QIV15041.1; -; Genomic_RNA.
DR   EMBL; MT304479; QIV15053.1; -; Genomic_RNA.
DR   EMBL; MT304480; QIV15065.1; -; Genomic_RNA.
DR   EMBL; MT304481; QIV15077.1; -; Genomic_RNA.
DR   EMBL; MT304482; QIV15089.1; -; Genomic_RNA.
DR   EMBL; MT304483; QIV15101.1; -; Genomic_RNA.
DR   EMBL; MT304484; QIV15113.1; -; Genomic_RNA.
DR   EMBL; MT304485; QIV15125.1; -; Genomic_RNA.
DR   EMBL; MT304486; QIV15137.1; -; Genomic_RNA.
DR   EMBL; MT304487; QIV15149.1; -; Genomic_RNA.
DR   EMBL; MT304488; QIV15161.1; -; Genomic_RNA.
DR   EMBL; MT304489; QIV15173.1; -; Genomic_RNA.
DR   EMBL; MT304490; QIV15185.1; -; Genomic_RNA.
DR   EMBL; MT304491; QIV15197.1; -; Genomic_RNA.
DR   EMBL; MT308702; QIV64974.1; -; Genomic_RNA.
DR   EMBL; MT308703; QIV64986.1; -; Genomic_RNA.
DR   EMBL; MT308704; QIV64998.1; -; Genomic_RNA.
DR   EMBL; MT308692; QIV65008.1; -; Genomic_RNA.
DR   EMBL; MT308693; QIV65019.1; -; Genomic_RNA.
DR   EMBL; MT308694; QIV65030.1; -; Genomic_RNA.
DR   EMBL; MT308695; QIV65041.1; -; Genomic_RNA.
DR   EMBL; MT308696; QIV65052.1; -; Genomic_RNA.
DR   EMBL; MT308697; QIV65063.1; -; Genomic_RNA.
DR   EMBL; MT308698; QIV65074.1; -; Genomic_RNA.
DR   EMBL; MT308699; QIV65085.1; -; Genomic_RNA.
DR   EMBL; MT308700; QIV65096.1; -; Genomic_RNA.
DR   EMBL; MT320891; QIX12204.1; -; Genomic_RNA.
DR   EMBL; MT322394; QIX13684.1; -; Genomic_RNA.
DR   EMBL; MT322395; QIX13696.1; -; Genomic_RNA.
DR   EMBL; MT322396; QIX13708.1; -; Genomic_RNA.
DR   EMBL; MT322397; QIX13720.1; -; Genomic_RNA.
DR   EMBL; MT322398; QIX13732.1; -; Genomic_RNA.
DR   EMBL; MT322399; QIX13743.1; -; Genomic_RNA.
DR   EMBL; MT322400; QIX13756.1; -; Genomic_RNA.
DR   EMBL; MT322401; QIX13768.1; -; Genomic_RNA.
DR   EMBL; MT322402; QIX13780.1; -; Genomic_RNA.
DR   EMBL; MT322403; QIX13792.1; -; Genomic_RNA.
DR   EMBL; MT322404; QIX13804.1; -; Genomic_RNA.
DR   EMBL; MT322405; QIX13816.1; -; Genomic_RNA.
DR   EMBL; MT322406; QIX13828.1; -; Genomic_RNA.
DR   EMBL; MT322407; QIX13840.1; -; Genomic_RNA.
DR   EMBL; MT322408; QIX13852.1; -; Genomic_RNA.
DR   EMBL; MT322409; QIX13864.1; -; Genomic_RNA.
DR   EMBL; MT322410; QIX13876.1; -; Genomic_RNA.
DR   EMBL; MT322411; QIX13888.1; -; Genomic_RNA.
DR   EMBL; MT322412; QIX13900.1; -; Genomic_RNA.
DR   EMBL; MT322413; QIX13912.1; -; Genomic_RNA.
DR   EMBL; MT322414; QIX13924.1; -; Genomic_RNA.
DR   EMBL; MT322415; QIX13936.1; -; Genomic_RNA.
DR   EMBL; MT322416; QIX13948.1; -; Genomic_RNA.
DR   EMBL; MT322417; QIX13960.1; -; Genomic_RNA.
DR   EMBL; MT322418; QIX13972.1; -; Genomic_RNA.
DR   EMBL; MT322419; QIX13984.1; -; Genomic_RNA.
DR   EMBL; MT322420; QIX13996.1; -; Genomic_RNA.
DR   EMBL; MT322421; QIX14008.1; -; Genomic_RNA.
DR   EMBL; MT322422; QIX14020.1; -; Genomic_RNA.
DR   EMBL; MT322423; QIX14032.1; -; Genomic_RNA.
DR   EMBL; MT322424; QIX14044.1; -; Genomic_RNA.
DR   EMBL; MT039874; QIX14045.1; -; Genomic_RNA.
DR   EMBL; MT326023; QIZ12972.1; -; Genomic_RNA.
DR   EMBL; MT326024; QIZ12984.1; -; Genomic_RNA.
DR   EMBL; MT326025; QIZ12996.1; -; Genomic_RNA.
DR   EMBL; MT326026; QIZ13008.1; -; Genomic_RNA.
DR   EMBL; MT326027; QIZ13020.1; -; Genomic_RNA.
DR   EMBL; MT326028; QIZ13032.1; -; Genomic_RNA.
DR   EMBL; MT326029; QIZ13044.1; -; Genomic_RNA.
DR   EMBL; MT326030; QIZ13056.1; -; Genomic_RNA.
DR   EMBL; MT326031; QIZ13068.1; -; Genomic_RNA.
DR   EMBL; MT326032; QIZ13078.1; -; Genomic_RNA.
DR   EMBL; MT326033; QIZ13092.1; -; Genomic_RNA.
DR   EMBL; MT326034; QIZ13104.1; -; Genomic_RNA.
DR   EMBL; MT326035; QIZ13116.1; -; Genomic_RNA.
DR   EMBL; MT326036; QIZ13128.1; -; Genomic_RNA.
DR   EMBL; MT326037; QIZ13140.1; -; Genomic_RNA.
DR   EMBL; MT326038; QIZ13151.1; -; Genomic_RNA.
DR   EMBL; MT326039; QIZ13164.1; -; Genomic_RNA.
DR   EMBL; MT326040; QIZ13176.1; -; Genomic_RNA.
DR   EMBL; MT326041; QIZ13188.1; -; Genomic_RNA.
DR   EMBL; MT326042; QIZ13200.1; -; Genomic_RNA.
DR   EMBL; MT326043; QIZ13212.1; -; Genomic_RNA.
DR   EMBL; MT326044; QIZ13224.1; -; Genomic_RNA.
DR   EMBL; MT326045; QIZ13236.1; -; Genomic_RNA.
DR   EMBL; MT326046; QIZ13248.1; -; Genomic_RNA.
DR   EMBL; MT326047; QIZ13260.1; -; Genomic_RNA.
DR   EMBL; MT326048; QIZ13272.1; -; Genomic_RNA.
DR   EMBL; MT326049; QIZ13284.1; -; Genomic_RNA.
DR   EMBL; MT326050; QIZ13295.1; -; Genomic_RNA.
DR   EMBL; MT326051; QIZ13308.1; -; Genomic_RNA.
DR   EMBL; MT326052; QIZ13320.1; -; Genomic_RNA.
DR   EMBL; MT326053; QIZ13332.1; -; Genomic_RNA.
DR   EMBL; MT326054; QIZ13344.1; -; Genomic_RNA.
DR   EMBL; MT326055; QIZ13356.1; -; Genomic_RNA.
DR   EMBL; MT326056; QIZ13368.1; -; Genomic_RNA.
DR   EMBL; MT326057; QIZ13379.1; -; Genomic_RNA.
DR   EMBL; MT326058; QIZ13392.1; -; Genomic_RNA.
DR   EMBL; MT326059; QIZ13404.1; -; Genomic_RNA.
DR   EMBL; MT326060; QIZ13414.1; -; Genomic_RNA.
DR   EMBL; MT326061; QIZ13428.1; -; Genomic_RNA.
DR   EMBL; MT326062; QIZ13440.1; -; Genomic_RNA.
DR   EMBL; MT326063; QIZ13452.1; -; Genomic_RNA.
DR   EMBL; MT326064; QIZ13464.1; -; Genomic_RNA.
DR   EMBL; MT326065; QIZ13476.1; -; Genomic_RNA.
DR   EMBL; MT326066; QIZ13488.1; -; Genomic_RNA.
DR   EMBL; MT326067; QIZ13500.1; -; Genomic_RNA.
DR   EMBL; MT326068; QIZ13512.1; -; Genomic_RNA.
DR   EMBL; MT326069; QIZ13524.1; -; Genomic_RNA.
DR   EMBL; MT326070; QIZ13536.1; -; Genomic_RNA.
DR   EMBL; MT326071; QIZ13548.1; -; Genomic_RNA.
DR   EMBL; MT326072; QIZ13558.1; -; Genomic_RNA.
DR   EMBL; MT326073; QIZ13568.1; -; Genomic_RNA.
DR   EMBL; MT326074; QIZ13584.1; -; Genomic_RNA.
DR   EMBL; MT326075; QIZ13596.1; -; Genomic_RNA.
DR   EMBL; MT326076; QIZ13608.1; -; Genomic_RNA.
DR   EMBL; MT326077; QIZ13620.1; -; Genomic_RNA.
DR   EMBL; MT326078; QIZ13632.1; -; Genomic_RNA.
DR   EMBL; MT326079; QIZ13641.1; -; Genomic_RNA.
DR   EMBL; MT326080; QIZ13654.1; -; Genomic_RNA.
DR   EMBL; MT326081; QIZ13666.1; -; Genomic_RNA.
DR   EMBL; MT326082; QIZ13678.1; -; Genomic_RNA.
DR   EMBL; MT326083; QIZ13690.1; -; Genomic_RNA.
DR   EMBL; MT326084; QIZ13702.1; -; Genomic_RNA.
DR   EMBL; MT326085; QIZ13714.1; -; Genomic_RNA.
DR   EMBL; MT326086; QIZ13726.1; -; Genomic_RNA.
DR   EMBL; MT326087; QIZ13738.1; -; Genomic_RNA.
DR   EMBL; MT326088; QIZ13750.1; -; Genomic_RNA.
DR   EMBL; MT326089; QIZ13762.1; -; Genomic_RNA.
DR   EMBL; MT326090; QIZ13774.1; -; Genomic_RNA.
DR   EMBL; MT326091; QIZ13786.1; -; Genomic_RNA.
DR   EMBL; MT326092; QIZ13798.1; -; Genomic_RNA.
DR   EMBL; MT326093; QIZ13810.1; -; Genomic_RNA.
DR   EMBL; MT326094; QIZ13822.1; -; Genomic_RNA.
DR   EMBL; MT326095; QIZ13834.1; -; Genomic_RNA.
DR   EMBL; MT326096; QIZ13846.1; -; Genomic_RNA.
DR   EMBL; MT326097; QIZ13858.1; -; Genomic_RNA.
DR   EMBL; MT326098; QIZ13870.1; -; Genomic_RNA.
DR   EMBL; MT326099; QIZ13882.1; -; Genomic_RNA.
DR   EMBL; MT326100; QIZ13894.1; -; Genomic_RNA.
DR   EMBL; MT326101; QIZ13903.1; -; Genomic_RNA.
DR   EMBL; MT326102; QIZ13918.1; -; Genomic_RNA.
DR   EMBL; MT326103; QIZ13930.1; -; Genomic_RNA.
DR   EMBL; MT326104; QIZ13942.1; -; Genomic_RNA.
DR   EMBL; MT326105; QIZ13954.1; -; Genomic_RNA.
DR   EMBL; MT326106; QIZ13966.1; -; Genomic_RNA.
DR   EMBL; MT326107; QIZ13978.1; -; Genomic_RNA.
DR   EMBL; MT326108; QIZ13989.1; -; Genomic_RNA.
DR   EMBL; MT326109; QIZ14002.1; -; Genomic_RNA.
DR   EMBL; MT326110; QIZ14012.1; -; Genomic_RNA.
DR   EMBL; MT326111; QIZ14026.1; -; Genomic_RNA.
DR   EMBL; MT326112; QIZ14038.1; -; Genomic_RNA.
DR   EMBL; MT326113; QIZ14050.1; -; Genomic_RNA.
DR   EMBL; MT326114; QIZ14062.1; -; Genomic_RNA.
DR   EMBL; MT326115; QIZ14073.1; -; Genomic_RNA.
DR   EMBL; MT326116; QIZ14086.1; -; Genomic_RNA.
DR   EMBL; MT326117; QIZ14098.1; -; Genomic_RNA.
DR   EMBL; MT326118; QIZ14110.1; -; Genomic_RNA.
DR   EMBL; MT326119; QIZ14122.1; -; Genomic_RNA.
DR   EMBL; MT326120; QIZ14134.1; -; Genomic_RNA.
DR   EMBL; MT326121; QIZ14146.1; -; Genomic_RNA.
DR   EMBL; MT326122; QIZ14158.1; -; Genomic_RNA.
DR   EMBL; MT326123; QIZ14170.1; -; Genomic_RNA.
DR   EMBL; MT326124; QIZ14182.1; -; Genomic_RNA.
DR   EMBL; MT326125; QIZ14194.1; -; Genomic_RNA.
DR   EMBL; MT326126; QIZ14204.1; -; Genomic_RNA.
DR   EMBL; MT326127; QIZ14218.1; -; Genomic_RNA.
DR   EMBL; MT326128; QIZ14230.1; -; Genomic_RNA.
DR   EMBL; MT326129; QIZ14242.1; -; Genomic_RNA.
DR   EMBL; MT326130; QIZ14254.1; -; Genomic_RNA.
DR   EMBL; MT326131; QIZ14266.1; -; Genomic_RNA.
DR   EMBL; MT326132; QIZ14278.1; -; Genomic_RNA.
DR   EMBL; MT326133; QIZ14290.1; -; Genomic_RNA.
DR   EMBL; MT326134; QIZ14302.1; -; Genomic_RNA.
DR   EMBL; MT326135; QIZ14314.1; -; Genomic_RNA.
DR   EMBL; MT326136; QIZ14326.1; -; Genomic_RNA.
DR   EMBL; MT326137; QIZ14338.1; -; Genomic_RNA.
DR   EMBL; MT326138; QIZ14350.1; -; Genomic_RNA.
DR   EMBL; MT326139; QIZ14362.1; -; Genomic_RNA.
DR   EMBL; MT326140; QIZ14374.1; -; Genomic_RNA.
DR   EMBL; MT326141; QIZ14386.1; -; Genomic_RNA.
DR   EMBL; MT326142; QIZ14393.1; -; Genomic_RNA.
DR   EMBL; MT326143; QIZ14410.1; -; Genomic_RNA.
DR   EMBL; MT326144; QIZ14422.1; -; Genomic_RNA.
DR   EMBL; MT326145; QIZ14434.1; -; Genomic_RNA.
DR   EMBL; MT326146; QIZ14446.1; -; Genomic_RNA.
DR   EMBL; MT326147; QIZ14458.1; -; Genomic_RNA.
DR   EMBL; MT326148; QIZ14470.1; -; Genomic_RNA.
DR   EMBL; MT326149; QIZ14482.1; -; Genomic_RNA.
DR   EMBL; MT326150; QIZ14494.1; -; Genomic_RNA.
DR   EMBL; MT326151; QIZ14506.1; -; Genomic_RNA.
DR   EMBL; MT326152; QIZ14518.1; -; Genomic_RNA.
DR   EMBL; MT326153; QIZ14530.1; -; Genomic_RNA.
DR   EMBL; MT326154; QIZ14542.1; -; Genomic_RNA.
DR   EMBL; MT326155; QIZ14552.1; -; Genomic_RNA.
DR   EMBL; MT326156; QIZ14566.1; -; Genomic_RNA.
DR   EMBL; MT326157; QIZ14578.1; -; Genomic_RNA.
DR   EMBL; MT326158; QIZ14590.1; -; Genomic_RNA.
DR   EMBL; MT326159; QIZ14602.1; -; Genomic_RNA.
DR   EMBL; MT326160; QIZ14614.1; -; Genomic_RNA.
DR   EMBL; MT326161; QIZ14626.1; -; Genomic_RNA.
DR   EMBL; MT326162; QIZ14638.1; -; Genomic_RNA.
DR   EMBL; MT326163; QIZ14650.1; -; Genomic_RNA.
DR   EMBL; MT326164; QIZ14662.1; -; Genomic_RNA.
DR   EMBL; MT326165; QIZ14672.1; -; Genomic_RNA.
DR   EMBL; MT326166; QIZ14686.1; -; Genomic_RNA.
DR   EMBL; MT326167; QIZ14698.1; -; Genomic_RNA.
DR   EMBL; MT326168; QIZ14710.1; -; Genomic_RNA.
DR   EMBL; MT326169; QIZ14722.1; -; Genomic_RNA.
DR   EMBL; MT326170; QIZ14734.1; -; Genomic_RNA.
DR   EMBL; MT326171; QIZ14746.1; -; Genomic_RNA.
DR   EMBL; MT326172; QIZ14758.1; -; Genomic_RNA.
DR   EMBL; MT326173; QIZ14770.1; -; Genomic_RNA.
DR   EMBL; MT326174; QIZ14782.1; -; Genomic_RNA.
DR   EMBL; MT326175; QIZ14794.1; -; Genomic_RNA.
DR   EMBL; MT326176; QIZ14805.1; -; Genomic_RNA.
DR   EMBL; MT326177; QIZ14818.1; -; Genomic_RNA.
DR   EMBL; MT326178; QIZ14830.1; -; Genomic_RNA.
DR   EMBL; MT326179; QIZ14842.1; -; Genomic_RNA.
DR   EMBL; MT326180; QIZ14854.1; -; Genomic_RNA.
DR   EMBL; MT326181; QIZ14866.1; -; Genomic_RNA.
DR   EMBL; MT326182; QIZ14878.1; -; Genomic_RNA.
DR   EMBL; MT326183; QIZ14888.1; -; Genomic_RNA.
DR   EMBL; MT326184; QIZ14902.1; -; Genomic_RNA.
DR   EMBL; MT326185; QIZ14914.1; -; Genomic_RNA.
DR   EMBL; MT326186; QIZ14926.1; -; Genomic_RNA.
DR   EMBL; MT326187; QIZ14938.1; -; Genomic_RNA.
DR   EMBL; MT326188; QIZ14948.1; -; Genomic_RNA.
DR   EMBL; MT326189; QIZ14962.1; -; Genomic_RNA.
DR   EMBL; MT326190; QIZ14974.1; -; Genomic_RNA.
DR   EMBL; MT326191; QIZ14986.1; -; Genomic_RNA.
DR   EMBL; MT324684; QIZ15006.1; -; Genomic_RNA.
DR   EMBL; MT324062; QIZ15546.1; -; Genomic_RNA.
DR   EMBL; MT325561; QIZ15558.1; -; Genomic_RNA.
DR   EMBL; MT325562; QIZ15570.1; -; Genomic_RNA.
DR   EMBL; MT325563; QIZ15582.1; -; Genomic_RNA.
DR   EMBL; MT325564; QIZ15594.1; -; Genomic_RNA.
DR   EMBL; MT325565; QIZ15606.1; -; Genomic_RNA.
DR   EMBL; MT325566; QIZ15618.1; -; Genomic_RNA.
DR   EMBL; MT325567; QIZ15630.1; -; Genomic_RNA.
DR   EMBL; MT325568; QIZ15642.1; -; Genomic_RNA.
DR   EMBL; MT325569; QIZ15654.1; -; Genomic_RNA.
DR   EMBL; MT325570; QIZ15666.1; -; Genomic_RNA.
DR   EMBL; MT325571; QIZ15678.1; -; Genomic_RNA.
DR   EMBL; MT325572; QIZ15690.1; -; Genomic_RNA.
DR   EMBL; MT325573; QIZ15702.1; -; Genomic_RNA.
DR   EMBL; MT325574; QIZ15714.1; -; Genomic_RNA.
DR   EMBL; MT325575; QIZ15726.1; -; Genomic_RNA.
DR   EMBL; MT325576; QIZ15738.1; -; Genomic_RNA.
DR   EMBL; MT325577; QIZ15750.1; -; Genomic_RNA.
DR   EMBL; MT325578; QIZ15762.1; -; Genomic_RNA.
DR   EMBL; MT325579; QIZ15774.1; -; Genomic_RNA.
DR   EMBL; MT325580; QIZ15786.1; -; Genomic_RNA.
DR   EMBL; MT325581; QIZ15798.1; -; Genomic_RNA.
DR   EMBL; MT325582; QIZ15810.1; -; Genomic_RNA.
DR   EMBL; MT325583; QIZ15822.1; -; Genomic_RNA.
DR   EMBL; MT325584; QIZ15834.1; -; Genomic_RNA.
DR   EMBL; MT325585; QIZ15846.1; -; Genomic_RNA.
DR   EMBL; MT325586; QIZ15858.1; -; Genomic_RNA.
DR   EMBL; MT325587; QIZ15870.1; -; Genomic_RNA.
DR   EMBL; MT325588; QIZ15882.1; -; Genomic_RNA.
DR   EMBL; MT325589; QIZ15894.1; -; Genomic_RNA.
DR   EMBL; MT325590; QIZ15906.1; -; Genomic_RNA.
DR   EMBL; MT325591; QIZ15918.1; -; Genomic_RNA.
DR   EMBL; MT325592; QIZ15930.1; -; Genomic_RNA.
DR   EMBL; MT325593; QIZ15942.1; -; Genomic_RNA.
DR   EMBL; MT325594; QIZ15954.1; -; Genomic_RNA.
DR   EMBL; MT325595; QIZ15966.1; -; Genomic_RNA.
DR   EMBL; MT325596; QIZ15978.1; -; Genomic_RNA.
DR   EMBL; MT325597; QIZ15990.1; -; Genomic_RNA.
DR   EMBL; MT325598; QIZ16002.1; -; Genomic_RNA.
DR   EMBL; MT325599; QIZ16014.1; -; Genomic_RNA.
DR   EMBL; MT325600; QIZ16026.1; -; Genomic_RNA.
DR   EMBL; MT325601; QIZ16038.1; -; Genomic_RNA.
DR   EMBL; MT325602; QIZ16050.1; -; Genomic_RNA.
DR   EMBL; MT325603; QIZ16062.1; -; Genomic_RNA.
DR   EMBL; MT325604; QIZ16074.1; -; Genomic_RNA.
DR   EMBL; MT325605; QIZ16086.1; -; Genomic_RNA.
DR   EMBL; MT325606; QIZ16098.1; -; Genomic_RNA.
DR   EMBL; MT325607; QIZ16110.1; -; Genomic_RNA.
DR   EMBL; MT325608; QIZ16122.1; -; Genomic_RNA.
DR   EMBL; MT325609; QIZ16134.1; -; Genomic_RNA.
DR   EMBL; MT325610; QIZ16146.1; -; Genomic_RNA.
DR   EMBL; MT325611; QIZ16158.1; -; Genomic_RNA.
DR   EMBL; MT325612; QIZ16170.1; -; Genomic_RNA.
DR   EMBL; MT325613; QIZ16182.1; -; Genomic_RNA.
DR   EMBL; MT325614; QIZ16194.1; -; Genomic_RNA.
DR   EMBL; MT325615; QIZ16206.1; -; Genomic_RNA.
DR   EMBL; MT325616; QIZ16218.1; -; Genomic_RNA.
DR   EMBL; MT325617; QIZ16230.1; -; Genomic_RNA.
DR   EMBL; MT325618; QIZ16242.1; -; Genomic_RNA.
DR   EMBL; MT325619; QIZ16254.1; -; Genomic_RNA.
DR   EMBL; MT325620; QIZ16266.1; -; Genomic_RNA.
DR   EMBL; MT325621; QIZ16278.1; -; Genomic_RNA.
DR   EMBL; MT325622; QIZ16290.1; -; Genomic_RNA.
DR   EMBL; MT325623; QIZ16302.1; -; Genomic_RNA.
DR   EMBL; MT325624; QIZ16314.1; -; Genomic_RNA.
DR   EMBL; MT325625; QIZ16326.1; -; Genomic_RNA.
DR   EMBL; MT325626; QIZ16338.1; -; Genomic_RNA.
DR   EMBL; MT325627; QIZ16350.1; -; Genomic_RNA.
DR   EMBL; MT325628; QIZ16362.1; -; Genomic_RNA.
DR   EMBL; MT325629; QIZ16374.1; -; Genomic_RNA.
DR   EMBL; MT325630; QIZ16386.1; -; Genomic_RNA.
DR   EMBL; MT325631; QIZ16398.1; -; Genomic_RNA.
DR   EMBL; MT325632; QIZ16410.1; -; Genomic_RNA.
DR   EMBL; MT325633; QIZ16422.1; -; Genomic_RNA.
DR   EMBL; MT325634; QIZ16434.1; -; Genomic_RNA.
DR   EMBL; MT325635; QIZ16446.1; -; Genomic_RNA.
DR   EMBL; MT325636; QIZ16458.1; -; Genomic_RNA.
DR   EMBL; MT325637; QIZ16470.1; -; Genomic_RNA.
DR   EMBL; MT325638; QIZ16482.1; -; Genomic_RNA.
DR   EMBL; MT325639; QIZ16494.1; -; Genomic_RNA.
DR   EMBL; MT325640; QIZ16506.1; -; Genomic_RNA.
DR   EMBL; MT327745; QIZ16518.1; -; Genomic_RNA.
DR   EMBL; MT328032; QIZ16544.1; -; Genomic_RNA.
DR   EMBL; MT328033; QIZ16556.1; -; Genomic_RNA.
DR   EMBL; MT328034; QIZ16568.1; -; Genomic_RNA.
DR   EMBL; MT328035; QIZ16580.1; -; Genomic_RNA.
DR   EMBL; MT334522; QIZ64274.1; -; Genomic_RNA.
DR   EMBL; MT334523; QIZ64287.1; -; Genomic_RNA.
DR   EMBL; MT334524; QIZ64298.1; -; Genomic_RNA.
DR   EMBL; MT334525; QIZ64310.1; -; Genomic_RNA.
DR   EMBL; MT334526; QIZ64323.1; -; Genomic_RNA.
DR   EMBL; MT334527; QIZ64335.1; -; Genomic_RNA.
DR   EMBL; MT334528; QIZ64344.1; -; Genomic_RNA.
DR   EMBL; MT334529; QIZ64359.1; -; Genomic_RNA.
DR   EMBL; MT334530; QIZ64370.1; -; Genomic_RNA.
DR   EMBL; MT334531; QIZ64383.1; -; Genomic_RNA.
DR   EMBL; MT334532; QIZ64394.1; -; Genomic_RNA.
DR   EMBL; MT334533; QIZ64407.1; -; Genomic_RNA.
DR   EMBL; MT334534; QIZ64419.1; -; Genomic_RNA.
DR   EMBL; MT334535; QIZ64431.1; -; Genomic_RNA.
DR   EMBL; MT334536; QIZ64443.1; -; Genomic_RNA.
DR   EMBL; MT334537; QIZ64455.1; -; Genomic_RNA.
DR   EMBL; MT334538; QIZ64467.1; -; Genomic_RNA.
DR   EMBL; MT334539; QIZ64479.1; -; Genomic_RNA.
DR   EMBL; MT334540; QIZ64491.1; -; Genomic_RNA.
DR   EMBL; MT334541; QIZ64503.1; -; Genomic_RNA.
DR   EMBL; MT334542; QIZ64515.1; -; Genomic_RNA.
DR   EMBL; MT334543; QIZ64526.1; -; Genomic_RNA.
DR   EMBL; MT334544; QIZ64539.1; -; Genomic_RNA.
DR   EMBL; MT334545; QIZ64550.1; -; Genomic_RNA.
DR   EMBL; MT334546; QIZ64563.1; -; Genomic_RNA.
DR   EMBL; MT334547; QIZ64575.1; -; Genomic_RNA.
DR   EMBL; MT334548; QIZ64587.1; -; Genomic_RNA.
DR   EMBL; MT334549; QIZ64589.1; -; Genomic_RNA.
DR   EMBL; MT334550; QIZ64609.1; -; Genomic_RNA.
DR   EMBL; MT334551; QIZ64619.1; -; Genomic_RNA.
DR   EMBL; MT334552; QIZ64633.1; -; Genomic_RNA.
DR   EMBL; MT334553; QIZ64643.1; -; Genomic_RNA.
DR   EMBL; MT334554; QIZ64657.1; -; Genomic_RNA.
DR   EMBL; MT334555; QIZ64667.1; -; Genomic_RNA.
DR   EMBL; MT334556; QIZ64681.1; -; Genomic_RNA.
DR   EMBL; MT334557; QIZ64694.1; -; Genomic_RNA.
DR   EMBL; MT334558; QIZ64703.1; -; Genomic_RNA.
DR   EMBL; MT334559; QIZ64717.1; -; Genomic_RNA.
DR   EMBL; MT334560; QIZ64728.1; -; Genomic_RNA.
DR   EMBL; MT334561; QIZ64741.1; -; Genomic_RNA.
DR   EMBL; MT334563; QIZ64763.1; -; Genomic_RNA.
DR   EMBL; MT334564; QIZ64773.1; -; Genomic_RNA.
DR   EMBL; MT334565; QIZ64785.1; -; Genomic_RNA.
DR   EMBL; MT334566; QIZ64797.1; -; Genomic_RNA.
DR   EMBL; MT334567; QIZ64809.1; -; Genomic_RNA.
DR   EMBL; MT334568; QIZ64821.1; -; Genomic_RNA.
DR   EMBL; MT334569; QIZ64835.1; -; Genomic_RNA.
DR   EMBL; MT334570; QIZ64847.1; -; Genomic_RNA.
DR   EMBL; MT334571; QIZ64857.1; -; Genomic_RNA.
DR   EMBL; MT334572; QIZ64871.1; -; Genomic_RNA.
DR   EMBL; MT334573; QIZ64883.1; -; Genomic_RNA.
DR   EMBL; MT339039; QIZ97048.1; -; Genomic_RNA.
DR   EMBL; MT339040; QIZ97059.1; -; Genomic_RNA.
DR   EMBL; MT339041; QIZ97071.1; -; Genomic_RNA.
DR   EMBL; MT345798; QJA16409.1; -; Genomic_RNA.
DR   EMBL; MT345799; QJA16421.1; -; Genomic_RNA.
DR   EMBL; MT345800; QJA16431.1; -; Genomic_RNA.
DR   EMBL; MT345801; QJA16445.1; -; Genomic_RNA.
DR   EMBL; MT345802; QJA16457.1; -; Genomic_RNA.
DR   EMBL; MT345803; QJA16469.1; -; Genomic_RNA.
DR   EMBL; MT345804; QJA16481.1; -; Genomic_RNA.
DR   EMBL; MT345805; QJA16493.1; -; Genomic_RNA.
DR   EMBL; MT345806; QJA16505.1; -; Genomic_RNA.
DR   EMBL; MT345807; QJA16517.1; -; Genomic_RNA.
DR   EMBL; MT345808; QJA16529.1; -; Genomic_RNA.
DR   EMBL; MT345809; QJA16541.1; -; Genomic_RNA.
DR   EMBL; MT345810; QJA16553.1; -; Genomic_RNA.
DR   EMBL; MT345811; QJA16565.1; -; Genomic_RNA.
DR   EMBL; MT345812; QJA16577.1; -; Genomic_RNA.
DR   EMBL; MT345813; QJA16589.1; -; Genomic_RNA.
DR   EMBL; MT345814; QJA16601.1; -; Genomic_RNA.
DR   EMBL; MT345815; QJA16613.1; -; Genomic_RNA.
DR   EMBL; MT345816; QJA16625.1; -; Genomic_RNA.
DR   EMBL; MT345817; QJA16637.1; -; Genomic_RNA.
DR   EMBL; MT345818; QJA16649.1; -; Genomic_RNA.
DR   EMBL; MT345819; QJA16661.1; -; Genomic_RNA.
DR   EMBL; MT345820; QJA16673.1; -; Genomic_RNA.
DR   EMBL; MT345821; QJA16685.1; -; Genomic_RNA.
DR   EMBL; MT345822; QJA16697.1; -; Genomic_RNA.
DR   EMBL; MT345823; QJA16709.1; -; Genomic_RNA.
DR   EMBL; MT345824; QJA16721.1; -; Genomic_RNA.
DR   EMBL; MT345825; QJA16733.1; -; Genomic_RNA.
DR   EMBL; MT345826; QJA16745.1; -; Genomic_RNA.
DR   EMBL; MT345827; QJA16757.1; -; Genomic_RNA.
DR   EMBL; MT345828; QJA16769.1; -; Genomic_RNA.
DR   EMBL; MT345829; QJA16781.1; -; Genomic_RNA.
DR   EMBL; MT345830; QJA16793.1; -; Genomic_RNA.
DR   EMBL; MT345831; QJA16803.1; -; Genomic_RNA.
DR   EMBL; MT345832; QJA16817.1; -; Genomic_RNA.
DR   EMBL; MT345833; QJA16829.1; -; Genomic_RNA.
DR   EMBL; MT345834; QJA16841.1; -; Genomic_RNA.
DR   EMBL; MT345835; QJA16853.1; -; Genomic_RNA.
DR   EMBL; MT345836; QJA16865.1; -; Genomic_RNA.
DR   EMBL; MT345837; QJA16877.1; -; Genomic_RNA.
DR   EMBL; MT345838; QJA16889.1; -; Genomic_RNA.
DR   EMBL; MT345839; QJA16898.1; -; Genomic_RNA.
DR   EMBL; MT345840; QJA16913.1; -; Genomic_RNA.
DR   EMBL; MT345841; QJA16925.1; -; Genomic_RNA.
DR   EMBL; MT345842; QJA16937.1; -; Genomic_RNA.
DR   EMBL; MT345843; QJA16949.1; -; Genomic_RNA.
DR   EMBL; MT345844; QJA16961.1; -; Genomic_RNA.
DR   EMBL; MT345845; QJA16970.1; -; Genomic_RNA.
DR   EMBL; MT345846; QJA16985.1; -; Genomic_RNA.
DR   EMBL; MT345847; QJA16997.1; -; Genomic_RNA.
DR   EMBL; MT345848; QJA17009.1; -; Genomic_RNA.
DR   EMBL; MT345849; QJA17021.1; -; Genomic_RNA.
DR   EMBL; MT345850; QJA17032.1; -; Genomic_RNA.
DR   EMBL; MT345851; QJA17045.1; -; Genomic_RNA.
DR   EMBL; MT345852; QJA17057.1; -; Genomic_RNA.
DR   EMBL; MT345853; QJA17069.1; -; Genomic_RNA.
DR   EMBL; MT345854; QJA17081.1; -; Genomic_RNA.
DR   EMBL; MT345855; QJA17093.1; -; Genomic_RNA.
DR   EMBL; MT345856; QJA17105.1; -; Genomic_RNA.
DR   EMBL; MT345857; QJA17117.1; -; Genomic_RNA.
DR   EMBL; MT345858; QJA17129.1; -; Genomic_RNA.
DR   EMBL; MT345859; QJA17141.1; -; Genomic_RNA.
DR   EMBL; MT345860; QJA17153.1; -; Genomic_RNA.
DR   EMBL; MT345861; QJA17165.1; -; Genomic_RNA.
DR   EMBL; MT345862; QJA17177.1; -; Genomic_RNA.
DR   EMBL; MT345863; QJA17189.1; -; Genomic_RNA.
DR   EMBL; MT345864; QJA17201.1; -; Genomic_RNA.
DR   EMBL; MT345865; QJA17213.1; -; Genomic_RNA.
DR   EMBL; MT345866; QJA17225.1; -; Genomic_RNA.
DR   EMBL; MT345867; QJA17237.1; -; Genomic_RNA.
DR   EMBL; MT345868; QJA17249.1; -; Genomic_RNA.
DR   EMBL; MT345869; QJA17261.1; -; Genomic_RNA.
DR   EMBL; MT345870; QJA17273.1; -; Genomic_RNA.
DR   EMBL; MT345871; QJA17284.1; -; Genomic_RNA.
DR   EMBL; MT345872; QJA17297.1; -; Genomic_RNA.
DR   EMBL; MT345873; QJA17309.1; -; Genomic_RNA.
DR   EMBL; MT345874; QJA17321.1; -; Genomic_RNA.
DR   EMBL; MT345875; QJA17333.1; -; Genomic_RNA.
DR   EMBL; MT345876; QJA17345.1; -; Genomic_RNA.
DR   EMBL; MT345877; QJA17357.1; -; Genomic_RNA.
DR   EMBL; MT345878; QJA17369.1; -; Genomic_RNA.
DR   EMBL; MT345879; QJA17381.1; -; Genomic_RNA.
DR   EMBL; MT345880; QJA17393.1; -; Genomic_RNA.
DR   EMBL; MT345881; QJA17405.1; -; Genomic_RNA.
DR   EMBL; MT345882; QJA17417.1; -; Genomic_RNA.
DR   EMBL; MT345883; QJA17429.1; -; Genomic_RNA.
DR   EMBL; MT345884; QJA17440.1; -; Genomic_RNA.
DR   EMBL; MT345885; QJA17453.1; -; Genomic_RNA.
DR   EMBL; MT345886; QJA17465.1; -; Genomic_RNA.
DR   EMBL; MT345887; QJA17477.1; -; Genomic_RNA.
DR   EMBL; MT345888; QJA17489.1; -; Genomic_RNA.
DR   EMBL; MT344944; QJA17533.1; -; Genomic_RNA.
DR   EMBL; MT344945; QJA17545.1; -; Genomic_RNA.
DR   EMBL; MT344946; QJA17557.1; -; Genomic_RNA.
DR   EMBL; MT344947; QJA17569.1; -; Genomic_RNA.
DR   EMBL; MT344948; QJA17581.1; -; Genomic_RNA.
DR   EMBL; MT344949; QJA17593.1; -; Genomic_RNA.
DR   EMBL; MT344950; QJA17605.1; -; Genomic_RNA.
DR   EMBL; MT344951; QJA17617.1; -; Genomic_RNA.
DR   EMBL; MT344952; QJA17629.1; -; Genomic_RNA.
DR   EMBL; MT344953; QJA17641.1; -; Genomic_RNA.
DR   EMBL; MT344954; QJA17653.1; -; Genomic_RNA.
DR   EMBL; MT344955; QJA17665.1; -; Genomic_RNA.
DR   EMBL; MT344956; QJA17677.1; -; Genomic_RNA.
DR   EMBL; MT344957; QJA17689.1; -; Genomic_RNA.
DR   EMBL; MT344958; QJA17701.1; -; Genomic_RNA.
DR   EMBL; MT344959; QJA17713.1; -; Genomic_RNA.
DR   EMBL; MT344960; QJA17725.1; -; Genomic_RNA.
DR   EMBL; MT344961; QJA17737.1; -; Genomic_RNA.
DR   EMBL; MT344962; QJA17749.1; -; Genomic_RNA.
DR   EMBL; MT344963; QJA17761.1; -; Genomic_RNA.
DR   EMBL; MT350282; QJA41650.1; -; Genomic_RNA.
DR   EMBL; MT350263; QJA41662.1; -; Genomic_RNA.
DR   EMBL; MT350264; QJA41674.1; -; Genomic_RNA.
DR   EMBL; MT350265; QJA41686.1; -; Genomic_RNA.
DR   EMBL; MT350266; QJA41698.1; -; Genomic_RNA.
DR   EMBL; MT350267; QJA41710.1; -; Genomic_RNA.
DR   EMBL; MT350268; QJA41722.1; -; Genomic_RNA.
DR   EMBL; MT350269; QJA41734.1; -; Genomic_RNA.
DR   EMBL; MT350270; QJA41746.1; -; Genomic_RNA.
DR   EMBL; MT350271; QJA41758.1; -; Genomic_RNA.
DR   EMBL; MT350272; QJA41770.1; -; Genomic_RNA.
DR   EMBL; MT350273; QJA41782.1; -; Genomic_RNA.
DR   EMBL; MT350274; QJA41794.1; -; Genomic_RNA.
DR   EMBL; MT350275; QJA41806.1; -; Genomic_RNA.
DR   EMBL; MT350276; QJA41818.1; -; Genomic_RNA.
DR   EMBL; MT350277; QJA41830.1; -; Genomic_RNA.
DR   EMBL; MT350278; QJA41842.1; -; Genomic_RNA.
DR   EMBL; MT350279; QJA41854.1; -; Genomic_RNA.
DR   EMBL; MT350280; QJA41866.1; -; Genomic_RNA.
DR   EMBL; MT350236; QJA41994.1; -; Genomic_RNA.
DR   EMBL; MT350237; QJA42006.1; -; Genomic_RNA.
DR   EMBL; MT350238; QJA42018.1; -; Genomic_RNA.
DR   EMBL; MT350239; QJA42030.1; -; Genomic_RNA.
DR   EMBL; MT350240; QJA42042.1; -; Genomic_RNA.
DR   EMBL; MT350241; QJA42054.1; -; Genomic_RNA.
DR   EMBL; MT350242; QJA42066.1; -; Genomic_RNA.
DR   EMBL; MT350243; QJA42078.1; -; Genomic_RNA.
DR   EMBL; MT350244; QJA42090.1; -; Genomic_RNA.
DR   EMBL; MT350245; QJA42102.1; -; Genomic_RNA.
DR   EMBL; MT350246; QJA42114.1; -; Genomic_RNA.
DR   EMBL; MT350247; QJA42126.1; -; Genomic_RNA.
DR   EMBL; MT350248; QJA42138.1; -; Genomic_RNA.
DR   EMBL; MT350249; QJA42150.1; -; Genomic_RNA.
DR   EMBL; MT350250; QJA42162.1; -; Genomic_RNA.
DR   EMBL; MT350251; QJA42174.1; -; Genomic_RNA.
DR   EMBL; MT350252; QJA42186.1; -; Genomic_RNA.
DR   EMBL; MT350253; QJA42198.1; -; Genomic_RNA.
DR   EMBL; MT350254; QJA42210.1; -; Genomic_RNA.
DR   EMBL; MT350255; QJA42222.1; -; Genomic_RNA.
DR   EMBL; MT350256; QJA42234.1; -; Genomic_RNA.
DR   EMBL; MT350257; QJA42246.1; -; Genomic_RNA.
DR   EMBL; MT358637; QJC19500.1; -; Genomic_RNA.
DR   EMBL; MT358644; QJC19512.1; -; Genomic_RNA.
DR   EMBL; MT358645; QJC19524.1; -; Genomic_RNA.
DR   EMBL; MT358646; QJC19536.1; -; Genomic_RNA.
DR   EMBL; MT358647; QJC19548.1; -; Genomic_RNA.
DR   EMBL; MT358648; QJC19560.1; -; Genomic_RNA.
DR   EMBL; MT358649; QJC19572.1; -; Genomic_RNA.
DR   EMBL; MT358650; QJC19584.1; -; Genomic_RNA.
DR   EMBL; MT358651; QJC19596.1; -; Genomic_RNA.
DR   EMBL; MT358652; QJC19608.1; -; Genomic_RNA.
DR   EMBL; MT358653; QJC19620.1; -; Genomic_RNA.
DR   EMBL; MT358654; QJC19632.1; -; Genomic_RNA.
DR   EMBL; MT358655; QJC19644.1; -; Genomic_RNA.
DR   EMBL; MT358656; QJC19656.1; -; Genomic_RNA.
DR   EMBL; MT358657; QJC19668.1; -; Genomic_RNA.
DR   EMBL; MT358658; QJC19680.1; -; Genomic_RNA.
DR   EMBL; MT358659; QJC19692.1; -; Genomic_RNA.
DR   EMBL; MT358660; QJC19704.1; -; Genomic_RNA.
DR   EMBL; MT358661; QJC19716.1; -; Genomic_RNA.
DR   EMBL; MT358662; QJC19728.1; -; Genomic_RNA.
DR   EMBL; MT358663; QJC19740.1; -; Genomic_RNA.
DR   EMBL; MT358664; QJC19752.1; -; Genomic_RNA.
DR   EMBL; MT358665; QJC19764.1; -; Genomic_RNA.
DR   EMBL; MT358666; QJC19776.1; -; Genomic_RNA.
DR   EMBL; MT358667; QJC19788.1; -; Genomic_RNA.
DR   EMBL; MT358668; QJC19800.1; -; Genomic_RNA.
DR   EMBL; MT358669; QJC19812.1; -; Genomic_RNA.
DR   EMBL; MT358670; QJC19824.1; -; Genomic_RNA.
DR   EMBL; MT358671; QJC19836.1; -; Genomic_RNA.
DR   EMBL; MT358672; QJC19848.1; -; Genomic_RNA.
DR   EMBL; MT358673; QJC19860.1; -; Genomic_RNA.
DR   EMBL; MT358674; QJC19872.1; -; Genomic_RNA.
DR   EMBL; MT358675; QJC19884.1; -; Genomic_RNA.
DR   EMBL; MT358676; QJC19896.1; -; Genomic_RNA.
DR   EMBL; MT358677; QJC19908.1; -; Genomic_RNA.
DR   EMBL; MT358678; QJC19920.1; -; Genomic_RNA.
DR   EMBL; MT358679; QJC19932.1; -; Genomic_RNA.
DR   EMBL; MT358680; QJC19944.1; -; Genomic_RNA.
DR   EMBL; MT358681; QJC19956.1; -; Genomic_RNA.
DR   EMBL; MT358682; QJC19968.1; -; Genomic_RNA.
DR   EMBL; MT358683; QJC19980.1; -; Genomic_RNA.
DR   EMBL; MT358684; QJC19992.1; -; Genomic_RNA.
DR   EMBL; MT358685; QJC20004.1; -; Genomic_RNA.
DR   EMBL; MT358686; QJC20016.1; -; Genomic_RNA.
DR   EMBL; MT358687; QJC20028.1; -; Genomic_RNA.
DR   EMBL; MT358688; QJC20040.1; -; Genomic_RNA.
DR   EMBL; MT358689; QJC20052.1; -; Genomic_RNA.
DR   EMBL; MT358690; QJC20064.1; -; Genomic_RNA.
DR   EMBL; MT358691; QJC20076.1; -; Genomic_RNA.
DR   EMBL; MT358692; QJC20088.1; -; Genomic_RNA.
DR   EMBL; MT358693; QJC20100.1; -; Genomic_RNA.
DR   EMBL; MT358694; QJC20112.1; -; Genomic_RNA.
DR   EMBL; MT358695; QJC20124.1; -; Genomic_RNA.
DR   EMBL; MT358696; QJC20136.1; -; Genomic_RNA.
DR   EMBL; MT358697; QJC20148.1; -; Genomic_RNA.
DR   EMBL; MT358698; QJC20160.1; -; Genomic_RNA.
DR   EMBL; MT358699; QJC20172.1; -; Genomic_RNA.
DR   EMBL; MT358700; QJC20184.1; -; Genomic_RNA.
DR   EMBL; MT358701; QJC20196.1; -; Genomic_RNA.
DR   EMBL; MT358702; QJC20208.1; -; Genomic_RNA.
DR   EMBL; MT358703; QJC20220.1; -; Genomic_RNA.
DR   EMBL; MT358704; QJC20232.1; -; Genomic_RNA.
DR   EMBL; MT358705; QJC20244.1; -; Genomic_RNA.
DR   EMBL; MT358706; QJC20256.1; -; Genomic_RNA.
DR   EMBL; MT358707; QJC20268.1; -; Genomic_RNA.
DR   EMBL; MT358708; QJC20280.1; -; Genomic_RNA.
DR   EMBL; MT358709; QJC20292.1; -; Genomic_RNA.
DR   EMBL; MT358710; QJC20304.1; -; Genomic_RNA.
DR   EMBL; MT358711; QJC20316.1; -; Genomic_RNA.
DR   EMBL; MT358712; QJC20328.1; -; Genomic_RNA.
DR   EMBL; MT358713; QJC20340.1; -; Genomic_RNA.
DR   EMBL; MT358714; QJC20352.1; -; Genomic_RNA.
DR   EMBL; MT358715; QJC20364.1; -; Genomic_RNA.
DR   EMBL; MT358716; QJC20376.1; -; Genomic_RNA.
DR   EMBL; MT358717; QJC20388.1; -; Genomic_RNA.
DR   EMBL; MT358718; QJC20400.1; -; Genomic_RNA.
DR   EMBL; MT358719; QJC20412.1; -; Genomic_RNA.
DR   EMBL; MT358720; QJC20424.1; -; Genomic_RNA.
DR   EMBL; MT358721; QJC20436.1; -; Genomic_RNA.
DR   EMBL; MT358722; QJC20448.1; -; Genomic_RNA.
DR   EMBL; MT358723; QJC20460.1; -; Genomic_RNA.
DR   EMBL; MT358724; QJC20472.1; -; Genomic_RNA.
DR   EMBL; MT358725; QJC20484.1; -; Genomic_RNA.
DR   EMBL; MT358726; QJC20496.1; -; Genomic_RNA.
DR   EMBL; MT358727; QJC20507.1; -; Genomic_RNA.
DR   EMBL; MT358728; QJC20519.1; -; Genomic_RNA.
DR   EMBL; MT358729; QJC20531.1; -; Genomic_RNA.
DR   EMBL; MT358730; QJC20543.1; -; Genomic_RNA.
DR   EMBL; MT358731; QJC20555.1; -; Genomic_RNA.
DR   EMBL; MT358732; QJC20567.1; -; Genomic_RNA.
DR   EMBL; MT358733; QJC20579.1; -; Genomic_RNA.
DR   EMBL; MT358734; QJC20591.1; -; Genomic_RNA.
DR   EMBL; MT358735; QJC20603.1; -; Genomic_RNA.
DR   EMBL; MT358736; QJC20615.1; -; Genomic_RNA.
DR   EMBL; MT358737; QJC20627.1; -; Genomic_RNA.
DR   EMBL; MT358738; QJC20639.1; -; Genomic_RNA.
DR   EMBL; MT358739; QJC20651.1; -; Genomic_RNA.
DR   EMBL; MT358740; QJC20663.1; -; Genomic_RNA.
DR   EMBL; MT358741; QJC20675.1; -; Genomic_RNA.
DR   EMBL; MT358742; QJC20687.1; -; Genomic_RNA.
DR   EMBL; MT358743; QJC20699.1; -; Genomic_RNA.
DR   EMBL; MT358744; QJC20711.1; -; Genomic_RNA.
DR   EMBL; MT358745; QJC20723.1; -; Genomic_RNA.
DR   EMBL; MT358746; QJC20735.1; -; Genomic_RNA.
DR   EMBL; MT358747; QJC20747.1; -; Genomic_RNA.
DR   EMBL; MT358748; QJC20759.1; -; Genomic_RNA.
DR   EMBL; MT230904; QJC21002.1; -; Genomic_RNA.
DR   EMBL; MT359865; QJC21014.1; -; Genomic_RNA.
DR   EMBL; MT359866; QJC21026.1; -; Genomic_RNA.
DR   EMBL; MT358401; QJC21038.1; -; Genomic_RNA.
DR   EMBL; MT358402; QJC21050.1; -; Genomic_RNA.
DR   EMBL; MT370516; QJD20641.1; -; Genomic_RNA.
DR   EMBL; MT370517; QJD20653.1; -; Genomic_RNA.
DR   EMBL; MT370518; QJD20665.1; -; Genomic_RNA.
DR   EMBL; MT371047; QJD20846.1; -; Genomic_RNA.
DR   EMBL; MT371048; QJD20858.1; -; Genomic_RNA.
DR   EMBL; MT371049; QJD20870.1; -; Genomic_RNA.
DR   EMBL; MT371050; QJD20882.1; -; Genomic_RNA.
DR   EMBL; MT371568; QJD23150.1; -; Genomic_RNA.
DR   EMBL; MT371569; QJD23162.1; -; Genomic_RNA.
DR   EMBL; MT371570; QJD23174.1; -; Genomic_RNA.
DR   EMBL; MT371571; QJD23186.1; -; Genomic_RNA.
DR   EMBL; MT371572; QJD23198.1; -; Genomic_RNA.
DR   EMBL; MT371573; QJD23210.1; -; Genomic_RNA.
DR   EMBL; MT371574; QJD23222.1; -; Genomic_RNA.
DR   EMBL; MT372480; QJD23234.1; -; Genomic_RNA.
DR   EMBL; MT372481; QJD23246.1; -; Genomic_RNA.
DR   EMBL; MT372482; QJD23258.1; -; Genomic_RNA.
DR   EMBL; MT372483; QJD23267.1; -; Genomic_RNA.
DR   EMBL; MT370831; QJD23282.1; -; Genomic_RNA.
DR   EMBL; MT370832; QJD23292.1; -; Genomic_RNA.
DR   EMBL; MT370833; QJD23306.1; -; Genomic_RNA.
DR   EMBL; MT370834; QJD23318.1; -; Genomic_RNA.
DR   EMBL; MT370835; QJD23330.1; -; Genomic_RNA.
DR   EMBL; MT370836; QJD23342.1; -; Genomic_RNA.
DR   EMBL; MT370837; QJD23354.1; -; Genomic_RNA.
DR   EMBL; MT370838; QJD23366.1; -; Genomic_RNA.
DR   EMBL; MT370839; QJD23378.1; -; Genomic_RNA.
DR   EMBL; MT370840; QJD23388.1; -; Genomic_RNA.
DR   EMBL; MT370841; QJD23402.1; -; Genomic_RNA.
DR   EMBL; MT370842; QJD23414.1; -; Genomic_RNA.
DR   EMBL; MT370843; QJD23426.1; -; Genomic_RNA.
DR   EMBL; MT370844; QJD23438.1; -; Genomic_RNA.
DR   EMBL; MT370845; QJD23450.1; -; Genomic_RNA.
DR   EMBL; MT370846; QJD23462.1; -; Genomic_RNA.
DR   EMBL; MT370847; QJD23471.1; -; Genomic_RNA.
DR   EMBL; MT370848; QJD23486.1; -; Genomic_RNA.
DR   EMBL; MT370849; QJD23498.1; -; Genomic_RNA.
DR   EMBL; MT370850; QJD23510.1; -; Genomic_RNA.
DR   EMBL; MT370851; QJD23522.1; -; Genomic_RNA.
DR   EMBL; MT370852; QJD23533.1; -; Genomic_RNA.
DR   EMBL; MT370853; QJD23546.1; -; Genomic_RNA.
DR   EMBL; MT370854; QJD23558.1; -; Genomic_RNA.
DR   EMBL; MT370855; QJD23568.1; -; Genomic_RNA.
DR   EMBL; MT370856; QJD23582.1; -; Genomic_RNA.
DR   EMBL; MT370857; QJD23594.1; -; Genomic_RNA.
DR   EMBL; MT370858; QJD23606.1; -; Genomic_RNA.
DR   EMBL; MT370859; QJD23618.1; -; Genomic_RNA.
DR   EMBL; MT370860; QJD23630.1; -; Genomic_RNA.
DR   EMBL; MT370861; QJD23642.1; -; Genomic_RNA.
DR   EMBL; MT370862; QJD23654.1; -; Genomic_RNA.
DR   EMBL; MT370863; QJD23666.1; -; Genomic_RNA.
DR   EMBL; MT370864; QJD23678.1; -; Genomic_RNA.
DR   EMBL; MT370865; QJD23690.1; -; Genomic_RNA.
DR   EMBL; MT370866; QJD23702.1; -; Genomic_RNA.
DR   EMBL; MT370867; QJD23713.1; -; Genomic_RNA.
DR   EMBL; MT370868; QJD23726.1; -; Genomic_RNA.
DR   EMBL; MT370869; QJD23738.1; -; Genomic_RNA.
DR   EMBL; MT370870; QJD23750.1; -; Genomic_RNA.
DR   EMBL; MT370871; QJD23762.1; -; Genomic_RNA.
DR   EMBL; MT370872; QJD23774.1; -; Genomic_RNA.
DR   EMBL; MT370873; QJD23784.1; -; Genomic_RNA.
DR   EMBL; MT370874; QJD23798.1; -; Genomic_RNA.
DR   EMBL; MT370875; QJD23810.1; -; Genomic_RNA.
DR   EMBL; MT370876; QJD23822.1; -; Genomic_RNA.
DR   EMBL; MT370877; QJD23834.1; -; Genomic_RNA.
DR   EMBL; MT370878; QJD23846.1; -; Genomic_RNA.
DR   EMBL; MT370879; QJD23856.1; -; Genomic_RNA.
DR   EMBL; MT370880; QJD23870.1; -; Genomic_RNA.
DR   EMBL; MT370881; QJD23882.1; -; Genomic_RNA.
DR   EMBL; MT370882; QJD23894.1; -; Genomic_RNA.
DR   EMBL; MT370883; QJD23906.1; -; Genomic_RNA.
DR   EMBL; MT370884; QJD23916.1; -; Genomic_RNA.
DR   EMBL; MT370885; QJD23930.1; -; Genomic_RNA.
DR   EMBL; MT370886; QJD23942.1; -; Genomic_RNA.
DR   EMBL; MT370887; QJD23953.1; -; Genomic_RNA.
DR   EMBL; MT370888; QJD23966.1; -; Genomic_RNA.
DR   EMBL; MT370889; QJD23978.1; -; Genomic_RNA.
DR   EMBL; MT370890; QJD23990.1; -; Genomic_RNA.
DR   EMBL; MT370891; QJD24002.1; -; Genomic_RNA.
DR   EMBL; MT370892; QJD24014.1; -; Genomic_RNA.
DR   EMBL; MT370893; QJD24024.1; -; Genomic_RNA.
DR   EMBL; MT370894; QJD24038.1; -; Genomic_RNA.
DR   EMBL; MT370895; QJD24050.1; -; Genomic_RNA.
DR   EMBL; MT370896; QJD24062.1; -; Genomic_RNA.
DR   EMBL; MT370897; QJD24074.1; -; Genomic_RNA.
DR   EMBL; MT370898; QJD24086.1; -; Genomic_RNA.
DR   EMBL; MT370899; QJD24098.1; -; Genomic_RNA.
DR   EMBL; MT370900; QJD24108.1; -; Genomic_RNA.
DR   EMBL; MT370901; QJD24122.1; -; Genomic_RNA.
DR   EMBL; MT370902; QJD24134.1; -; Genomic_RNA.
DR   EMBL; MT370903; QJD24146.1; -; Genomic_RNA.
DR   EMBL; MT370904; QJD24158.1; -; Genomic_RNA.
DR   EMBL; MT370905; QJD24170.1; -; Genomic_RNA.
DR   EMBL; MT370906; QJD24182.1; -; Genomic_RNA.
DR   EMBL; MT370907; QJD24194.1; -; Genomic_RNA.
DR   EMBL; MT370908; QJD24206.1; -; Genomic_RNA.
DR   EMBL; MT370909; QJD24218.1; -; Genomic_RNA.
DR   EMBL; MT370910; QJD24228.1; -; Genomic_RNA.
DR   EMBL; MT370911; QJD24242.1; -; Genomic_RNA.
DR   EMBL; MT370912; QJD24254.1; -; Genomic_RNA.
DR   EMBL; MT370913; QJD24266.1; -; Genomic_RNA.
DR   EMBL; MT370914; QJD24278.1; -; Genomic_RNA.
DR   EMBL; MT370915; QJD24290.1; -; Genomic_RNA.
DR   EMBL; MT370916; QJD24302.1; -; Genomic_RNA.
DR   EMBL; MT370917; QJD24314.1; -; Genomic_RNA.
DR   EMBL; MT370918; QJD24324.1; -; Genomic_RNA.
DR   EMBL; MT370919; QJD24338.1; -; Genomic_RNA.
DR   EMBL; MT370920; QJD24350.1; -; Genomic_RNA.
DR   EMBL; MT370921; QJD24362.1; -; Genomic_RNA.
DR   EMBL; MT370922; QJD24374.1; -; Genomic_RNA.
DR   EMBL; MT370923; QJD24386.1; -; Genomic_RNA.
DR   EMBL; MT370924; QJD24398.1; -; Genomic_RNA.
DR   EMBL; MT370925; QJD24410.1; -; Genomic_RNA.
DR   EMBL; MT370926; QJD24422.1; -; Genomic_RNA.
DR   EMBL; MT370927; QJD24434.1; -; Genomic_RNA.
DR   EMBL; MT370928; QJD24445.1; -; Genomic_RNA.
DR   EMBL; MT370929; QJD24457.1; -; Genomic_RNA.
DR   EMBL; MT370930; QJD24470.1; -; Genomic_RNA.
DR   EMBL; MT370931; QJD24482.1; -; Genomic_RNA.
DR   EMBL; MT370932; QJD24494.1; -; Genomic_RNA.
DR   EMBL; MT370933; QJD24506.1; -; Genomic_RNA.
DR   EMBL; MT370934; QJD24518.1; -; Genomic_RNA.
DR   EMBL; MT370935; QJD24530.1; -; Genomic_RNA.
DR   EMBL; MT370936; QJD24540.1; -; Genomic_RNA.
DR   EMBL; MT370937; QJD24554.1; -; Genomic_RNA.
DR   EMBL; MT370938; QJD24566.1; -; Genomic_RNA.
DR   EMBL; MT370939; QJD24578.1; -; Genomic_RNA.
DR   EMBL; MT370940; QJD24590.1; -; Genomic_RNA.
DR   EMBL; MT370941; QJD24602.1; -; Genomic_RNA.
DR   EMBL; MT370942; QJD24614.1; -; Genomic_RNA.
DR   EMBL; MT370943; QJD24626.1; -; Genomic_RNA.
DR   EMBL; MT370944; QJD24638.1; -; Genomic_RNA.
DR   EMBL; MT370945; QJD24648.1; -; Genomic_RNA.
DR   EMBL; MT370946; QJD24662.1; -; Genomic_RNA.
DR   EMBL; MT370947; QJD24674.1; -; Genomic_RNA.
DR   EMBL; MT370948; QJD24686.1; -; Genomic_RNA.
DR   EMBL; MT370949; QJD24698.1; -; Genomic_RNA.
DR   EMBL; MT370950; QJD24710.1; -; Genomic_RNA.
DR   EMBL; MT370951; QJD24722.1; -; Genomic_RNA.
DR   EMBL; MT370952; QJD24734.1; -; Genomic_RNA.
DR   EMBL; MT370953; QJD24746.1; -; Genomic_RNA.
DR   EMBL; MT370954; QJD24758.1; -; Genomic_RNA.
DR   EMBL; MT370955; QJD24766.1; -; Genomic_RNA.
DR   EMBL; MT370956; QJD24782.1; -; Genomic_RNA.
DR   EMBL; MT370957; QJD24794.1; -; Genomic_RNA.
DR   EMBL; MT370958; QJD24806.1; -; Genomic_RNA.
DR   EMBL; MT370959; QJD24818.1; -; Genomic_RNA.
DR   EMBL; MT370960; QJD24830.1; -; Genomic_RNA.
DR   EMBL; MT370961; QJD24842.1; -; Genomic_RNA.
DR   EMBL; MT370962; QJD24854.1; -; Genomic_RNA.
DR   EMBL; MT370963; QJD24866.1; -; Genomic_RNA.
DR   EMBL; MT370964; QJD24878.1; -; Genomic_RNA.
DR   EMBL; MT370965; QJD24890.1; -; Genomic_RNA.
DR   EMBL; MT370966; QJD24902.1; -; Genomic_RNA.
DR   EMBL; MT370967; QJD24914.1; -; Genomic_RNA.
DR   EMBL; MT370968; QJD24926.1; -; Genomic_RNA.
DR   EMBL; MT370969; QJD24938.1; -; Genomic_RNA.
DR   EMBL; MT370970; QJD24950.1; -; Genomic_RNA.
DR   EMBL; MT370971; QJD24962.1; -; Genomic_RNA.
DR   EMBL; MT370972; QJD24974.1; -; Genomic_RNA.
DR   EMBL; MT370973; QJD24986.1; -; Genomic_RNA.
DR   EMBL; MT370974; QJD24998.1; -; Genomic_RNA.
DR   EMBL; MT370975; QJD25010.1; -; Genomic_RNA.
DR   EMBL; MT370976; QJD25022.1; -; Genomic_RNA.
DR   EMBL; MT370977; QJD25034.1; -; Genomic_RNA.
DR   EMBL; MT370978; QJD25046.1; -; Genomic_RNA.
DR   EMBL; MT370979; QJD25058.1; -; Genomic_RNA.
DR   EMBL; MT370980; QJD25070.1; -; Genomic_RNA.
DR   EMBL; MT370981; QJD25082.1; -; Genomic_RNA.
DR   EMBL; MT370982; QJD25094.1; -; Genomic_RNA.
DR   EMBL; MT370983; QJD25106.1; -; Genomic_RNA.
DR   EMBL; MT370984; QJD25118.1; -; Genomic_RNA.
DR   EMBL; MT370985; QJD25130.1; -; Genomic_RNA.
DR   EMBL; MT370986; QJD25142.1; -; Genomic_RNA.
DR   EMBL; MT370987; QJD25154.1; -; Genomic_RNA.
DR   EMBL; MT370988; QJD25166.1; -; Genomic_RNA.
DR   EMBL; MT370989; QJD25178.1; -; Genomic_RNA.
DR   EMBL; MT370990; QJD25190.1; -; Genomic_RNA.
DR   EMBL; MT370991; QJD25202.1; -; Genomic_RNA.
DR   EMBL; MT370992; QJD25212.1; -; Genomic_RNA.
DR   EMBL; MT370993; QJD25226.1; -; Genomic_RNA.
DR   EMBL; MT370994; QJD25238.1; -; Genomic_RNA.
DR   EMBL; MT370995; QJD25250.1; -; Genomic_RNA.
DR   EMBL; MT370996; QJD25262.1; -; Genomic_RNA.
DR   EMBL; MT370997; QJD25274.1; -; Genomic_RNA.
DR   EMBL; MT370998; QJD25286.1; -; Genomic_RNA.
DR   EMBL; MT370999; QJD25298.1; -; Genomic_RNA.
DR   EMBL; MT371000; QJD25310.1; -; Genomic_RNA.
DR   EMBL; MT371001; QJD25322.1; -; Genomic_RNA.
DR   EMBL; MT371002; QJD25334.1; -; Genomic_RNA.
DR   EMBL; MT371003; QJD25344.1; -; Genomic_RNA.
DR   EMBL; MT371004; QJD25358.1; -; Genomic_RNA.
DR   EMBL; MT371005; QJD25370.1; -; Genomic_RNA.
DR   EMBL; MT371006; QJD25382.1; -; Genomic_RNA.
DR   EMBL; MT371007; QJD25394.1; -; Genomic_RNA.
DR   EMBL; MT371008; QJD25406.1; -; Genomic_RNA.
DR   EMBL; MT371009; QJD25418.1; -; Genomic_RNA.
DR   EMBL; MT371010; QJD25430.1; -; Genomic_RNA.
DR   EMBL; MT371011; QJD25440.1; -; Genomic_RNA.
DR   EMBL; MT371012; QJD25454.1; -; Genomic_RNA.
DR   EMBL; MT371013; QJD25466.1; -; Genomic_RNA.
DR   EMBL; MT371014; QJD25476.1; -; Genomic_RNA.
DR   EMBL; MT371015; QJD25490.1; -; Genomic_RNA.
DR   EMBL; MT371016; QJD25502.1; -; Genomic_RNA.
DR   EMBL; MT371017; QJD25514.1; -; Genomic_RNA.
DR   EMBL; MT371018; QJD25526.1; -; Genomic_RNA.
DR   EMBL; MT371019; QJD25538.1; -; Genomic_RNA.
DR   EMBL; MT371020; QJD25550.1; -; Genomic_RNA.
DR   EMBL; MT371021; QJD25562.1; -; Genomic_RNA.
DR   EMBL; MT371022; QJD25574.1; -; Genomic_RNA.
DR   EMBL; MT371023; QJD25586.1; -; Genomic_RNA.
DR   EMBL; MT371024; QJD25597.1; -; Genomic_RNA.
DR   EMBL; MT371025; QJD25610.1; -; Genomic_RNA.
DR   EMBL; MT371026; QJD25622.1; -; Genomic_RNA.
DR   EMBL; MT371027; QJD25634.1; -; Genomic_RNA.
DR   EMBL; MT371028; QJD25646.1; -; Genomic_RNA.
DR   EMBL; MT371029; QJD25658.1; -; Genomic_RNA.
DR   EMBL; MT371030; QJD25670.1; -; Genomic_RNA.
DR   EMBL; MT371031; QJD25680.1; -; Genomic_RNA.
DR   EMBL; MT371032; QJD25694.1; -; Genomic_RNA.
DR   EMBL; MT371033; QJD25706.1; -; Genomic_RNA.
DR   EMBL; MT371034; QJD25718.1; -; Genomic_RNA.
DR   EMBL; MT371035; QJD25730.1; -; Genomic_RNA.
DR   EMBL; MT371036; QJD25742.1; -; Genomic_RNA.
DR   EMBL; MT371037; QJD25754.1; -; Genomic_RNA.
DR   EMBL; MT371038; QJD25766.1; -; Genomic_RNA.
DR   RefSeq; YP_009725255.1; NC_045512.2.
DR   BioGRID; 4383867; 9.
DR   IntAct; A0A663DJA2; 29.
DR   GeneID; 43740576; -.
DR   Proteomes; UP000464024; Genome.
PE   4: Predicted;
KW   Reference proteome {ECO:0000313|Proteomes:UP000464024}.
SQ   SEQUENCE   38 AA;  4449 MW;  AE48AE9E0598073C CRC64;
     MGYINVFAFP FTIYSLLLCR MNSRNYIAQV DVVNFNLT
//
ID   NS8_SARS2               Reviewed;         121 AA.
AC   P0DTC8;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=ORF8 protein;
DE            Short=ORF8;
DE   AltName: Full=Non-structural protein 8;
DE            Short=ns8;
DE   Flags: Precursor;
GN   ORFNames=8;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=isolate 2019-nCoV_HKU-SZ-002a_2020;
RX   PubMed=31986261; DOI=10.1016/s0140-6736(20)30154-9;
RA   Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J.,
RA   Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M.,
RA   Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y.;
RT   "A familial cluster of pneumonia associated with the 2019 novel coronavirus
RT   indicating person-to-person transmission: a study of a family cluster.";
RL   Lancet 395:514-523(2020).
CC   -!- FUNCTION: May play a role in host-virus interaction. {ECO:0000305}.
CC   -!- MISCELLANEOUS: Similar to some Bat coronavirus ns8 genes, but is
CC       entirely different from SARS ns8a or Ns8b. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43422.1; -; Genomic_RNA.
DR   EMBL; MN938384; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   RefSeq; YP_009724396.1; NC_045512.2.
DR   BioGRID; 4383873; 47.
DR   IntAct; P0DTC8; 89.
DR   GeneID; 43740577; -.
DR   Proteomes; UP000464024; Genome.
DR   InterPro; IPR022722; NS8_bCoV.
DR   Pfam; PF12093; Corona_NS8; 1.
PE   3: Inferred from homology;
KW   Reference proteome; Signal.
FT   SIGNAL          1..15
FT                   /evidence="ECO:0000255"
FT   CHAIN           16..121
FT                   /note="ORF8 protein"
FT                   /id="PRO_0000449655"
FT   VARIANT         84
FT                   /note="L -> S (in isolate 2019-nCoV_HKU-SZ-002a_2020)"
SQ   SEQUENCE   121 AA;  13831 MW;  912AD9E147A64907 CRC64;
     MKFLVFLGII TTVAAFHQEC SLQSCTQHQP YVVDDPCPIH FYSKWYIRVG ARKSAPLIEL
     CVDEAGSKSP IQYIDIGNYT VSCLPFTINC QEPKLGSLVV RCSFYEDFLE YHDVRVVLDF
     I
//
ID   Y14_SARS2               Reviewed;          73 AA.
AC   P0DTD3;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=Uncharacterized protein 14;
DE            Short=ORF14;
GN   ORFNames=ORF14;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
CC   -!- FUNCTION: May play a role in host-virus interaction. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000255}; Single-pass membrane
CC       protein {ECO:0000255}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   IntAct; P0DTD3; 86.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   InterPro; IPR035113; Protein_14_SARS-like.
DR   Pfam; PF17635; DUF5515; 1.
PE   3: Inferred from homology;
KW   Membrane; Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..73
FT                   /note="Uncharacterized protein 14"
FT                   /id="PRO_0000449658"
FT   TRANSMEM        47..67
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
SQ   SEQUENCE   73 AA;  8050 MW;  8CCDEF1C0EA37D06 CRC64;
     MLQSCYNFLK EQHCQKASTQ KGAEAAVKPL LVPHHVVATV QEIQLQAAVG ELLLLEWLAM
     AVMLLLLCCC LTD
//
ID   NS7B_SARS2              Reviewed;          43 AA.
AC   P0DTD8;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   12-AUG-2020, entry version 3.
DE   RecName: Full=ORF7b protein;
DE            Short=ORF7b;
DE   AltName: Full=Accessory protein 7b;
GN   ORFNames=7b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   "A new coronavirus associated with human respiratory disease in China.";
RL   Nature 579:265-269(2020).
CC   -!- SUBCELLULAR LOCATION: Host membrane {ECO:0000250|UniProtKB:Q7TFA1};
CC       Single-pass membrane protein {ECO:0000250|UniProtKB:Q7TFA1}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   RefSeq; YP_009725318.1; NC_045512.2.
DR   IntAct; P0DTD8; 29.
DR   GeneID; 43740574; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   InterPro; IPR021532; NS7B_SARS-like.
DR   Pfam; PF11395; DUF2873; 1.
PE   3: Inferred from homology;
KW   Host membrane; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..43
FT                   /note="ORF7b protein"
FT                   /id="PRO_0000449799"
FT   TRANSMEM        9..29
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
SQ   SEQUENCE   43 AA;  5180 MW;  33DE6E3EBAEF1D9F CRC64;
     MIELSLIDFY LCFLAFLLFL VLIMLIIFWF SLELQDHNET CHA
//
ID   NS8A_SARS               Reviewed;          39 AA.
AC   Q7TFA0; Q7TLC8;
DT   17-APR-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2003, sequence version 1.
DT   12-AUG-2020, entry version 37.
DE   RecName: Full=ORF8a protein;
DE   AltName: Full=Accessory protein 8a;
DE   AltName: Full=Protein non-structural 8a;
DE            Short=ns8a;
DE   Flags: Precursor;
GN   ORFNames=8a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   "Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome.";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   "The genome sequence of the SARS-associated coronavirus.";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt 1;
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   "Mechanisms and enzymes involved in SARS coronavirus genome expression.";
RL   J. Gen. Virol. 84:2305-2315(2003).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY278741; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; AY274119; AAP41045.1; -; Genomic_RNA.
DR   EMBL; AY291315; AAP33705.1; -; Genomic_RNA.
DR   RefSeq; NP_849176.1; NC_004718.3.
DR   BioGRID; 4383922; 5.
DR   IntAct; Q7TFA0; 3.
DR   GeneID; 1489676; -.
DR   KEGG; vg:1489676; -.
DR   SIGNOR; Q7TFA0; -.
DR   Proteomes; UP000000354; Genome.
DR   Proteomes; UP000137377; Genome.
DR   InterPro; IPR022722; NS8_bCoV.
DR   Pfam; PF12093; Corona_NS8; 1.
PE   3: Inferred from homology;
KW   Reference proteome; Signal.
FT   SIGNAL          1..15
FT                   /evidence="ECO:0000255"
FT   CHAIN           16..39
FT                   /note="ORF8a protein"
FT                   /id="PRO_0000283858"
SQ   SEQUENCE   39 AA;  4327 MW;  1F890982A820681F CRC64;
     MKLLIVLTCI SLCSCICTVV QRCASNKPHV LEDPCKVQH
//
